<SEC-DOCUMENT>0001213900-21-020392.txt : 20210406
<SEC-HEADER>0001213900-21-020392.hdr.sgml : 20210406
<ACCEPTANCE-DATETIME>20210406160557
ACCESSION NUMBER:		0001213900-21-020392
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210406
DATE AS OF CHANGE:		20210406

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nano-X Imaging Ltd.
		CENTRAL INDEX KEY:			0001795251
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39461
		FILM NUMBER:		21809264

	BUSINESS ADDRESS:	
		STREET 1:		COMMUNICATIONS CENTER
		CITY:			NEVE ILAN
		STATE:			L3
		ZIP:			9085000
		BUSINESS PHONE:		972 02 995 0506

	MAIL ADDRESS:	
		STREET 1:		COMMUNICATIONS CENTER
		CITY:			NEVE ILAN
		STATE:			L3
		ZIP:			9085000
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2020_nanoximaging.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, D.C. 20549</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 16pt Times New Roman, Times, Serif; margin: 0; text-align: center">FORM 20-F</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">(Mark One)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#9744; <B>REGISTRATION
STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">OR</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#9746; <B>ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the fiscal year ended December 31,
2020</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">OR</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#9744; <B>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">OR</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#9744; <B>SHELL
COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Date of event requiring this shell company
report</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the transition period from&nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; to&nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Commission file number 001-38024</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">NANO-X IMAGING LTD</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Exact name of Registrant as specified
in its charter)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">N/A<BR>
(Translation of Registrant&rsquo;s name into English)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">State of Israel<BR>
(Jurisdiction of incorporation or organization)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Communication Center,<BR>
Neve Ilan, Israel 9085000<BR>
(Address of principal executive offices)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Ran Poliakine, Chairman
of the Board and Chief Executive Officer<BR>
Telephone: +972 02 995 0506<BR>
Facsimile: +972 02 544 5214<BR>
Communication Center,<BR>
Neve Ilan, Israel 9085000<BR>
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Securities registered or to be registered
pursuant to Section 12(b) of the Act.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Title of
        each class</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Trading
        Symbol</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Name of
        each exchange on which registered</B></P></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Ordinary Shares, par value NIS 0.01 per share</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><B>NNOX</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><B>The <FONT>NASDAQ
Stock Market LLC</FONT></B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act: None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate the number of outstanding shares of each of the issuer&rsquo;s
classes of capital or common stock as of the close of the period covered by the annual report: 46,100,173 Ordinary Shares as of
December 31, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. Yes &#9744;
No &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If this report is an annual or transition report, indicate by check
mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Yes &#9744; No &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Note&mdash;Checking the box above will not relieve any registrant
required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those
sections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes &#9746; No &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes &#9746;
No &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &ldquo;large accelerated
filer,&rdquo; &ldquo;accelerated filer,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">Large accelerated filer</TD>
    <TD STYLE="width: 30%">&#9744;</TD>
    <TD STYLE="width: 25%">Accelerated filer</TD>
    <TD STYLE="width: 25%">&#9744;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Non-accelerated filer</TD>
    <TD>&#9744;</TD>
    <TD>Emerging growth company</TD>
    <TD>&#9746;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company that prepares its financial statements
in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards&dagger; provided pursuant to Section 13(a) of the Exchange Act.
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&dagger; The term &ldquo;new or revised financial accounting standard&rdquo;
refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5,
2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has filed a report
on and attestation to its management&rsquo;s assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued
its audit report. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark which basis of accounting the registrant
has used to prepare the financial statements included in this annual report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">U.S. GAAP &#9746;</TD>
    <TD STYLE="width: 70%">International Financial Reporting Standards as issued by the International Accounting Standards Board &#9744;</TD>
    <TD STYLE="width: 15%; text-align: center">Other &#9744;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If &ldquo;Other&rdquo; has been checked in response to the previous
question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 &#9744;
Item 18 &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If this is an annual report, indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744;
No &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING
THE PAST FIVE YEARS)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by checkmark whether the registrant has filed all documents
and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution
of securities under a plan confirmed by a court. Yes &#9744; No &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1.25in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 6%; text-align: center"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001">PART I</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 1.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_002">Identity of Directors, Senior Management and Advisors</A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 2.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_003">Offer Statistics and Expected Timetable</A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 3.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_004">Key Information</A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 4.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_005">Information on the Company</A></TD>
    <TD STYLE="text-align: center">54</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 5.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_006">Operating and Financial Review and Prospects</A></TD>
    <TD STYLE="text-align: center">84</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 6.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_007">Directors, Senior Management and Employees</A></TD>
    <TD STYLE="text-align: center">98</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 7.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_008">Major Shareholders and Related Party Transactions</A></TD>
    <TD STYLE="text-align: center">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 8.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_009">Financial Information</A></TD>
    <TD STYLE="text-align: center">117</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 9.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_010">Offer and Listing</A></TD>
    <TD STYLE="text-align: center">118</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 10.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_011">Additional Information</A></TD>
    <TD STYLE="text-align: center">118</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 11.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_012">Qualitative and Quantitative Disclosures About Market Risk</A></TD>
    <TD STYLE="text-align: center">133</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 12.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_013">Description of Securities Other than Equity Securities</A></TD>
    <TD STYLE="text-align: center">133</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_014">PART II</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">134</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 13.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_015">Defaults, Dividend Arrearages and Delinquencies</A></TD>
    <TD STYLE="text-align: center">134</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 14.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_016">Material Modifications to the Rights of Security Holders and Use of Proceeds</A></TD>
    <TD STYLE="text-align: center">134</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 15.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_017">Controls and Procedures</A></TD>
    <TD STYLE="text-align: center">134</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 16.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_018">[Reserved]</A></TD>
    <TD STYLE="text-align: center">135</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 16D.</TD>
    <TD STYLE="text-indent: 0pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_019">Exemptions from the Listing Standards for Audit Committees</A></P></TD>
    <TD STYLE="text-align: center">136</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 16E.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_020">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</A></TD>
    <TD STYLE="text-align: center">136</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 16F.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_021">Change in Registrant&rsquo;s Certifying Accountant</A></TD>
    <TD STYLE="text-align: center">136</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 16G.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_022">Corporate Governance</A></TD>
    <TD STYLE="text-align: center">136</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 16H.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_023">Mine Safety Disclosure</A></TD>
    <TD STYLE="text-align: center">137</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_027">PART III</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">138</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 17.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_024">Financial Statements</A></TD>
    <TD STYLE="text-align: center">138</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 35pt">Item 18.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_025">Financial Statements</A></TD>
    <TD STYLE="text-align: center">138</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 35pt">Item 19.</TD>
    <TD STYLE="text-indent: 0pt"><A HREF="#a_026">Exhibits</A></TD>
    <TD STYLE="text-align: center">138</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">INTRODUCTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NANO-X IMAGING LTD was incorporated under
the laws of the State of Israel on December&nbsp;20, 2018 and commenced operations on September&nbsp;3, 2019. Unless the context
otherwise requires, all references to &ldquo;Nanox,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo;
and similar designations refer to NANO-X IMAGING LTD, an Israeli company, its wholly-owned Japanese subsidiary and its wholly-owned
Korean subsidiary, or, where applicable, its predecessor company, Nanox Imaging PLC, a Gibraltar public limited company, and its
wholly-owned Japanese subsidiary. Unless derived from our financial statements or otherwise noted, the terms &ldquo;shekels&rdquo;
and &ldquo;NIS&rdquo; refer to New&nbsp;Israeli Shekels, the lawful currency of the State of Israel, the terms &ldquo;dollar&rdquo;
or &ldquo;$&rdquo; refer to U.S. dollars, the lawful currency of the United States, &ldquo;Yen&rdquo; refers to Japanese Yen, the
lawful currency of Japan, and &ldquo;KRW&rdquo; refers to Korean Won, the lawful currency of South Korea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">FORWARD-LOOKING
STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This annual report on Form 20-F contains
forward-looking statements that are based on our management&rsquo;s belief and assumptions and on information currently available
to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these
statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from
any future results, levels of activity, performance or achievements stated in or implied by these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All statements that are not historical facts
contained in this annual report on Form 20-F are forward-looking statements. These forward-looking statements include information
about possible or assumed future results of our business, financial condition, results of operations, prospects, liquidity, plans
and objectives. In some cases, you can identify forward-looking statements by terminology such as &ldquo;can,&rdquo; &ldquo;might,&rdquo;
&ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
&ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;predict,&rdquo;
&ldquo;potential,&rdquo; or the negative of these terms or other similar expressions. Forward-looking statements are based on information
we have when those statements are made or our management&rsquo;s good faith belief as of that time with respect to future events,
and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in or suggested by the forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The initiation, timing, progress and results of our research and development, manufacturing and commercialization activities
with respect to our X-ray source technology, the Nanox.ARC, the Nanox.CLOUD and the Nanox System;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to successfully demonstrate the feasibility of our technology for commercial applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our expectations regarding the necessity of, timing of filing for, and receipt of, regulatory clearances or approvals regarding
our technology, the Nanox.ARC and the Nanox.CLOUD;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to secure and maintain required U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) clearance and similar approvals from regulatory agencies worldwide and comply
with applicable quality standards and regulatory requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to manufacture the Nanox.ARC, if cleared, at substantially lower costs compared to medical imaging systems that
use a legacy analog X-ray source;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our expectations regarding the planned deployment schedule to meet our target minimum installed base of 1,000 Nanox Systems
and final deployment of 15,000 Nanox Systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the pricing structure of our products and services, if such products and services receive regulatory clearance or approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the implementation of our business models;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our expectations regarding collaborations with third-parties and their potential benefits;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to enter into and maintain our arrangements with third-party manufacturers and suppliers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to conduct business globally;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our expectations regarding when certain patents may be issued and the protection and enforcement of our intellectual property
rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to operate our business without infringing the intellectual property rights and proprietary technology of third
parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>regulatory developments in the United States and other jurisdictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the rate and degree of market acceptance of our technology and our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>development relating to our competitors and the medical imaging industry;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our estimates of the adoption of the MSaaS-based model by market participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our estimates regarding the market opportunities for our technology and our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to attract, motivate and retain key executive managers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to comply with data protection laws, regulations and similar rules and to establish and maintain adequate cyber-security
and data protection;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to obtain third-party payor coverage or reimbursement of our Nanox System;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our expectation regarding the maintenance of our foreign private issuer and emerging growth company status;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects
of our business operations, including but not limited to the development, deployment and regulatory clearance of the Nanox Systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the costs incurred with respect to and the outcome of the securities class-action litigation we are currently subject to and
any similar or other claims and litigation we may be subject to in the future; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our success at managing other risks and uncertainties, including those listed under &ldquo;Item 3. Key Information&mdash;D.
Risk Factors.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many important factors, in addition to the
factors described above and in other sections of this annual report on Form 20-F, could adversely impact our business and financial
performance. The forward-looking statements contained in this annual report on Form 20-F speak only as of the date of this annual
report on Form 20-F and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described
under the sections in this annual report on Form 20-F entitled &ldquo;Item 3. Key Information&mdash;D. Risk Factors&rdquo; and
&ldquo;Item 5. Operating and Financial Review and Prospects&rdquo; and elsewhere in this annual report on Form 20-F. Because forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which
are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Moreover, we operate
in an evolving environment. New risks and uncertainties emerge from time to time, and it is not possible for our management to
predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor,
or combination of factors, may cause actual results to differ materially from estimates or forward-looking statements. We qualify
all of our forward-looking statements by these cautionary statements. Except as required by law, we undertake no obligation to
update publicly any forward-looking statements after the date of this annual report on Form 20-F to conform these statements to
actual results or to changes in our expectations.<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A>PART I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_002"></A>Item 1.</TD><TD>Identity of Directors, Senior Management and Advisors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_003"></A>Item 2.</TD><TD>Offer Statistics and Expected Timetable</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_004"></A>Item 3.</TD><TD>Key Information</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. Selected Financial
Data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following tables set forth our selected
consolidated historical financial data which is derived from our audited financial statements, which have been prepared in accordance
with generally accepted accounting principles in the United States (&ldquo;U.S. GAAP&rdquo;). The selected statement of operations
for each of the years in the three-year period ended December 31, 2020 and the consolidated balance sheet data as of December&nbsp;31,
2020 and 2019 have been derived from our audited consolidated financial statements included elsewhere in this annual report on
Form 20-F. You should read this data together with our audited consolidated financial statements and related notes included elsewhere
in this annual report on Form 20-F and the information under the caption &ldquo;Item 5. Operating and Financial Review and Prospects.&rdquo;
Our historical results are not necessarily indicative of our future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($ in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9,210</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,717</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">672</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">209</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">22,268</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,298</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,023</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">TOTAL OPERATING EXPENSES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,923</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">22,571</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">OPERATING LOSS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(43,923</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,571</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: normal; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">FINANCIAL
    (INCOME) EXPENSES, <FONT STYLE="font-style: normal; font-weight: normal">net</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(108</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">NET LOSS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(43,815</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(22,563</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,909</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">BASIC AND DILUTED LOSS PER SHARE</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.23</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.90</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">THE WEIGHTED AVERAGE OF THE NUMBER OF ORDINARY SHARES (in thousands)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">35,654</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">25,181</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,793</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($ in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">213,468</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,072</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,325</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,564</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">TOTAL CURRENT ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">219,793</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,636</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">NON-CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">228</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Operating lease right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">526</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Other non-current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">661</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">TOTAL NON- CURRENT ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,356</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,235</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">236,149</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,871</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: -0.625in">Liabilities and Shareholders&rsquo; Equity (Capital Deficiency)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">435</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Accrued expenses and other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Related party liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,748</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Related party accrued liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Current maturities of operating leases</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">519</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">140</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">TOTAL CURRENT LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,480</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,263</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">NON-CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Non-current operating leases</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">923</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">386</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">TOTAL NON-CURRENT LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">923</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">386</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><P STYLE="text-indent: -0.25in; margin-left: 0in; padding-left: 0.125in; font-weight: bold; text-align: left"><B>TOTAL
LIABILITIES</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,403</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,649</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">COMMITMENTS AND CONTINGENCIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">SHAREHOLDERS&rsquo; EQUITY (CAPITAL DEFICIENCY):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Ordinary Shares, par value NIS 0.01 per share, 100,000,000
    and 40,000,000 shares authorized at December 31, 2020 and 2019, respectively; 46,100,173 and 27,150,080 issued and outstanding at
    December 31, 2020 and 2019, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,031</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,748</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(84,416</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,601</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">TOTAL SHAREHOLDERS&rsquo; EQUITY (CAPITAL DEFICIENCY)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">230,746</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,778</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">TOTAL LIABILITIES AND SHAREHOLDERS&rsquo; &nbsp;EQUITY (CAPITAL DEFICIENCY)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">236,149</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,871</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">B. Capitalization
and Indebtedness</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">C. Reasons for
the Offer and Use of Proceeds</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">D. Risk Factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risk Factors Summary</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Risks Related to Our Business</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We are a development-stage company with limited operating history. We may never be able to effectuate our business plan or
achieve any revenue or reach profitability. Therefore, at this stage of our business, potential investors have a high probability
of losing their entire investment. </TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our efforts may never demonstrate the feasibility of our digital X-ray source technology, including both the MEMs X-ray chips
and tubes, for commercial applications.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Two of our business models depend on the successful commercial application of the Nanox.CLOUD, which is subject to numerous
risks and uncertainties.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We are highly dependent on the successful development, marketing and sale of our X-ray source technology and the related products
and services.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Products utilizing our technology may need to be approved or cleared by the FDA and similar regulatory agencies worldwide.
We may not receive, or may be delayed in receiving, the necessary approval or clearance for our future products, which would adversely
affect business, financial condition, results of operations and prospects.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We may need to obtain additional financing to fund our future operations. If we are unable to obtain such financing, we may
be unable to complete the development and commercialization of our technology and our products and services.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The success of our primary business model, the Subscription Model, is subject to numerous risks and uncertainties.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We may not be successful in tailoring our X-ray source to the specific systems of other medical imaging companies under our
Licensing Model, and/or entering into licensing agreements on terms favorable to us.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>To the extent that we license our X-ray source technology to other medical imaging companies, the products integrating our
technology may need to be approved or cleared by the FDA or similar regulatory agencies.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business
and our financial results and could cause a disruption to the development or deployment of the Nanox System.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our industry is highly competitive and is subject to technological change, which may result in new products or solutions that
are superior to our technology or other future products we may bring to market from time to time. If we are unable to anticipate
or keep pace with changes in the marketplace and the direction of technological innovation and customer demands, our technology
may become less useful or obsolete and our operating results will suffer.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We expect to depend on third parties to manufacture the Nanox.ARC and to supply certain component parts. Our reliance on third-party
manufacturers and suppliers involve certain risks that may result in, among others, increased costs, quality or compliance issues,
or failure to timely manufacture the Nanox.ARC, any of which could materially harm our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We may experience development or manufacturing problems and higher costs, or delays that could limit our revenue, if any, or
increase our losses.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We may not be able to successfully execute our business models.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We have a limited operating history. If we successfully commercially launch the Nanox.ARC or the Nanox.CLOUD, and they do not
achieve widespread market acceptance, we will not be able to generate the revenue necessary to support our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We plan to do business globally, including in certain countries where we might have limited resources and would be subject
to additional regulatory burdens and other risks and uncertainties.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Because the Nanox System is still in the development stage, it is not yet approved for third-party payor coverage or reimbursement.
If in the future we are approved for and are otherwise able to commercialize it, but are unable to obtain adequate reimbursement
or insurance coverage from third-party payors, we may not be able to generate significant revenue, in which case we may need to
obtain additional financing.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Recent changes in the United States related to payment policies for imaging procedures could have a negative impact on the
utilization of our imaging services.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Billing complexities associated with obtaining payment or reimbursement may negatively affect our revenue, cash flow and profitability.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Any collaborative and MSaaS arrangements that we have established or may establish in the future may not be successful or we
may otherwise not realize the anticipated benefits from these collaborations. We do not control third parties with whom we have
or may have collaborative or MSaaS arrangements, and we will rely on them to achieve results which may be significant to us. In
addition, any current or future collaborative and MSaaS arrangements may place the development and commercialization of our technology
outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We could become subject to product liability claims, product recalls, and warranty claims that could be expensive, divert management&rsquo;s
attention and harm our business reputation and financial results.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We are highly dependent on key members of our executive management team. Our inability to retain these individuals could impede
our business plan and growth strategies, which could have a negative impact on our business and the value of your investment.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The mishandling or the perceived mishandling of sensitive information, or the occurrence of data security breaches, could harm
our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Exchange rate fluctuations between the U.S. dollar, Japanese Yen, the New Israeli Shekel and the South Korean Won and inflation
may negatively affect our results of operations, and we may not be able to hedge our currency exchange risks successfully.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>If significant tariffs or other restrictions related to &ldquo;trade wars&rdquo; are placed on Chinese imports or any related
counter-measures are taken by China, our revenue and results of operations may be materially harmed.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our business may be impacted by changes in general economic conditions.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We are currently subject to securities class-action litigation and may be subject to similar or other claims and litigation
in the future, all of which will require significant management attention, could result in significant legal expenses and may result
in unfavorable outcomes, all or any of which could have a material adverse impact on our financial condition and results of operations,
harm our reputation or otherwise negatively impact our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We do not expect to carry any business interruption insurance or any other insurance (except for director and officer, property
and product liability insurance). As a result, we may incur uninsured losses, increasing the possibility that you would lose your
entire investment in our company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Certain of our directors and/or officers may have interests that compete with ours.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our management team has limited experience managing a public company.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Our Intellectual Property</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to
ensure their protection.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Patent terms may be inadequate to protect our competitive position on our future products for an adequate amount of time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Claims that our technology or our future products or the sale or use of our future products infringe the patents or other intellectual
property rights of third parties could result in costly litigation or could require substantial time and money to resolve, even
if litigation is avoided.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment
and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we
or our future licensors do not comply with these requirements.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We may be subject to claims that our employees, consultants or advisers have wrongfully used or disclosed alleged trade secrets
of their former employers or claims asserting ownership of what we regard as our own intellectual property.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets
of interest and our business may be adversely affected.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our rights to develop and commercialize our products may be subject to the terms and conditions of licenses and sublicenses
granted to us by third parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We may be required to pay certain milestones and royalties and fulfill other obligations under our license agreements with
third-party licensors.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>If we choose to license our technology to third parties, this could result in disputes or otherwise limit our future operations.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Government Regulation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our product candidates and operations are subject to extensive government regulation and oversight both in the United States
and abroad, and our failure to comply with applicable requirements could harm our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We may not receive, or may be delayed in receiving, the necessary clearances or approvals for our future products, and failure
to timely obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial
penalties, and might require us to recall or withdraw a product from the market.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our products must be manufactured in accordance with federal, state and foreign regulations, and we could be forced to recall
our devices or terminate production if we fail to comply with these regulations.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product
liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in
the promotion of these uses, any of which could be costly to our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required
to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial
condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either
voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other
healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational
harm and diminished profits and future earnings.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Changes in laws or regulations relating to data protection, or any actual or perceived failure by us to comply with such laws
and regulations or our privacy policies, could materially and adversely affect our business or could lead to government enforcement
actions and significant penalties against us, and adversely impact our operating results.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>If we do not obtain and maintain international regulatory registrations, clearances or approvals for our products, we will
be unable to market and sell our products outside of the United States.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly for us to obtain regulatory
clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Healthcare reform laws could adversely affect our products and financial condition.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their
ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being
developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Employee Matters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent
our competitors from benefiting from the expertise of some of our former employees.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We may not be able to attract and retain the highly skilled employees we need to support our planned growth.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Owning Our Ordinary
Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our share price may be volatile, and you may lose all or part of your investment.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We are an &ldquo;emerging growth company&rdquo; under the JOBS Act and we cannot be certain if the reduced disclosure requirements
applicable to emerging growth companies will make our ordinary shares less attractive to investors.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our status as an &ldquo;emerging growth company&rdquo; under the JOBS Act may make it more difficult to raise capital as and
when we need it.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>As a foreign private issuer, we are exempt from certain requirements that apply to domestic issuers and we are permitted to
follow certain home country corporate governance practices instead of applicable SEC and Nasdaq requirements, which may result
in less protection than is accorded to shareholders under rules applicable to domestic issuers.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We may lose our foreign private issuer status which would then require us to comply with the Exchange Act&rsquo;s domestic
reporting regime and cause us to incur significant legal, accounting and other expenses.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We have not paid dividends in the past and have no immediate plans to pay dividends.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We incur significant increased costs as a result of operating as a public company that reports to the SEC and our management
may be required to devote substantial time to meet compliance obligations.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Shares eligible for future sale may adversely affect the market for our ordinary shares and the issuance of additional ordinary
shares as a result of the exercise of our outstanding warrants and options will dilute the percentage ownership of our other shareholders.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The purchase price of the ordinary shares may not reflect our actual value.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>We have identified material weaknesses in our internal control over financial reporting that could, if not remediated, result
in material misstatements in our financial statements. If we fail to maintain an effective system of internal control over financial
reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose
confidence in our financial and other public reporting, which would harm our business and the trading price of our ordinary shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>It is likely that we will be classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes
for our taxable year ended December 31, 2020, for the current taxable year and possibly for future taxable years, which could result
in adverse U.S. federal income tax consequences to U.S. Holders of our ordinary shares.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Our Operations in Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Conditions in Israel could materially and adversely affect our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The termination or reduction of tax and other incentives that the Israeli government provides to Israeli companies may increase
our costs and taxes.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>It may be difficult to enforce a U.S. judgment against us, our officers and directors named in this annual report on Form 20-F
in Israel or the United States, or to assert U.S. securities laws claims in Israel or serve process on our officers and directors.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Your rights and responsibilities as our shareholder will be governed by Israeli law, which may differ in some respects from
the rights and responsibilities of shareholders of U.S. corporations.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Our amended and restated articles of association contains exclusive forum provisions for certain claims, which could limit
our shareholders&rsquo; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Provisions of our amended and restated articles of association and Israeli law and tax considerations may delay, prevent or
make difficult an acquisition of us, which could prevent a change of control and negatively affect the price of our ordinary shares.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Our Business</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We are a development-stage company
with limited operating history. We may never be able to effectuate our business plan or achieve any revenue or reach profitability.
Therefore, at this stage of our business, potential investors have a high probability of losing their entire investment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a development-stage company, and
are subject to all of the risks inherent in the establishment of a new business enterprise. We have a limited operating history
and only a preliminary and unproven business plan upon which investors may evaluate our prospects. We have not yet demonstrated
the feasibility of our digital X-ray source technology for commercial applications. Although we have produced a working prototype
of the Nanox.ARC and developed a prototype of the Nanox.CLOUD, we have not produced any of the approximately 15,000&nbsp;Nanox.ARC&nbsp;units
planned for the initial global deployment under the contract manufacturing agreement with FoxSemicon Integrated Technology, Inc.,
a subsidiary of Foxconn (&ldquo;FITI&rdquo;). <FONT STYLE="font-family: Times New Roman, Times, Serif">Due, in part, to travel
restrictions as a result of the COVID-19 pandemic, we engaged Dagesh P.K. Ltd. (&ldquo;Dagesh&rdquo;) to manufacture a small number
of Nanox.ARC units in Israel on a purchase order basis that we expect will be used for the acceptance tests under our MSaaS agreements,
demonstrations, regulatory approvals and for the initial global deployment, among other purposes. </FONT>Even if we are able to
manufacture the Nanox.ARC, we may not be able to do so at the low costs needed to support our business models, including the Subscription
Model, which is our primary business model. We may not receive, or may be delayed in receiving, the necessary approval or clearance
for the Nanox.ARC or our future products. We also have not entered into any commercial arrangement for the licensing of our X-ray
source under the Licensing Model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, even if our technology becomes
commercially viable, our business models may not generate sufficient revenue necessary to support our business. We estimate that
effectively stimulating market interest in our Nanox System will require deploying at least 5,000 to 10,000 Nanox.ARC units. In
addition, we estimate that a minimum installed base of at least 1,000 Nanox.ARC units will be needed to support our business during
the initial deployment, assuming we enter into at least one licensing agreement on commercially reasonable terms. We may never
achieve any of these thresholds for units deployed in the near-to-mid-term at any level or at all, which may cause our business
to fail. The Subscription Model is based on selling the Nanox System at low cost or no cost using a pay-per-scan pricing structure,
which is pioneering for medical imaging companies and is subject to numerous risks. The medical imaging industry is also highly
competitive and our technology, products, services or business models may not achieve widespread market acceptance. If we are unable
to address any issues mentioned above, or encounter other problems, expenses, difficulties, complications, and delays in connection
with the starting and expansion of our business, our entire business may fail, in which case you may lose your entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have a history of net losses and negative
cash flow from operations since inception and we expect such losses and negative cash flows from operations to continue in the
foreseeable future. As of December 31, 2020 and 2019, we had working capital (deficiency) of approximately $215.3&nbsp;million
and $(10.6) million, respectively, and shareholders&rsquo; equity (deficit) of approximately $230.7&nbsp;million and $(8.8) million,
respectively. For the years ended December&nbsp;31, 2020, 2019 and 2018, we incurred net losses of approximately $43.8&nbsp;million,
$22.6&nbsp;million and $1.9 million, respectively. As of December 31, 2020 and 2019, we had an accumulated deficit of approximately
$84.4&nbsp;million and $40.6&nbsp;million, respectively, and negative cash flow from operations of $21.5&nbsp;million, $5.5&nbsp;million
and $3.7 million for the years ended December&nbsp;31, 2020, 2019 and 2018, respectively. We anticipate our losses will continue
to increase from current levels because we expect to incur additional costs related to developing our business, including research
and development costs, manufacturing costs, employee-related costs, costs of complying with government regulations, intellectual
property development and prosecution costs, marketing and promotion costs, capital expenditures, general and administrative expenses,
and costs associated with operating as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ability to generate revenue from our
operations and, ultimately, achieve profitability will depend on, among others, whether we can complete the development and commercialization
of our technology, our future products and our services, including our X-ray source technology, the Nanox.ARC and the Nanox.CLOUD,
whether we can manufacture the Nanox.ARC on a commercial scale in such amounts and at such costs as we anticipate, and whether
we can achieve market acceptance of our products, services and business models. We may never generate any revenue or operate on
a profitable basis. Even if we achieve profitability, we may not be able to sustain it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our efforts may never demonstrate
the feasibility of our digital X-ray source technology, including both the MEMs X-ray chips and tubes, for commercial applications.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have developed our X-ray source technology,
including both the MEMs X-ray chips and tubes, and a working prototype of the Nanox.ARC. Even though we believe our X-ray source
has achieved commercial applicability, our technology has not been tested over extended periods of time and therefore no meaningful
data exists regarding the durability, safety and effectiveness of our X-ray source over extended periods. Although we have produced
a working prototype of the Nanox.ARC, we may not be able to successfully integrate our X-ray source into the Nanox.ARC or any medical
imaging system. In addition, there is no precedent for commercialization of technology like ours. Even with a fully functional
prototype, the commercial scale production and deployment of Nanox.ARC will require significant additional development, sales and
marketing efforts, and we may not be able to ensure the effectiveness, accuracy, consistency and safety of the Nanox.ARC in commercial
settings. Any unanticipated technical or other problems and the possible insufficiency of funds and other resources needed to complete
the development and commercialization of our X-ray source, the Nanox.ARC or the Nanox.CLOUD may result in delays and cause us to
incur additional expenses that would increase our losses. If our X-ray source is not commercially feasible now or in the long term,
our business may fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Two of our business models depend
on the successful commercial application of the Nanox.CLOUD, which is subject to numerous risks and uncertainties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the Nanox.ARC, we are also
developing the Nanox.CLOUD, a companion cloud software designed to deliver MSaaS. We have developed a prototype of the Nanox.CLOUD.
The development and commercialization of the Nanox.CLOUD has a number of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the Nanox.CLOUD requires a considerable investment of technical, financial, and legal resources, which may not be available
to us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>it may require separate regulatory clearances or approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>it may not be technically viable to integrate the Nanox.CLOUD with the businesses of our potential customers and collaborators,
such as local operators, radiologists, cloud storage providers, medical AI&nbsp;software providers and others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>market acceptance of the MSaaS model is affected by a variety of factors, including security, reliability, scalability, customization,
performance, customer preference, patients&rsquo; concerns with entrusting a third party to store and manage their health data,
public concerns regarding privacy and compliance with restrictive laws or regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our cloud-based service may raise concerns among our customer base, including concerns regarding changes to pricing over time,
service availability, information security of a cloud-based solution and access to medical images while offline;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the Nanox.CLOUD may be subject to computer system failures, cyber-attacks or other security breaches;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>incorrect or improper implementation or use of the Nanox.CLOUD by third-party cloud-service providers under our Sales Model
could result in customer dissatisfaction and harm our business and reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>undetected software errors or flaws in the Nanox.CLOUD could harm our reputation or decrease market acceptance of the MSaaS
model; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>we may incur higher costs than we expected as we expand our cloud-based services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are unable to successfully develop
and commercialize the Nanox.CLOUD, our business, financial condition, results of operations and prospects could be negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We are highly dependent on the successful
development, marketing and sale of our X-ray source technology and the related products and services.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our core digital X-ray source technology
is the basis of our business. The Nanox.ARC currently under development is being designed to integrate our X-ray source technology
into a medical imaging device for commercial use. As a result, the success of our business plan is highly dependent on our ability
to develop, manufacture and commercialize our X-ray source technology and related products and services, such as the Nanox.ARC
and the Nanox.CLOUD, and our failure to do so could cause our business to fail. Successful commercialization of medical imaging
devices is a complex and uncertain process, dependent on the efforts of management, manufacturers, local operators, integrators,
medical professionals, third-party payors, as well as general economic conditions, among other factors. Any factor that adversely
impacts the development and commercialization of our X-ray source technology or related products and services, including the Nanox.ARC,
the Nanox.CLOUD and the Nanox System, will have a negative impact on our business, financial condition, results of operations and
prospects. Some potential factors include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to achieve sufficient market acceptance by hospitals and clinics, providers of medical imaging services, medical
professionals such as radiologists, third-party payors and others in the medical community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to compete with existing medical imaging technology companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to establish, maintain and expand our sales, marketing and distribution networks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to obtain and/or maintain necessary regulatory approvals; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to effectively protect our intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our inability to successfully obtain clearance
or approval for and subsequently commercialize our X-ray source technology or related products and services, and/or successfully
develop and commercialize additional products or any enhancements to the products which we may develop would have a material adverse
effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Products utilizing our technology
may need to be approved or cleared by the FDA and similar regulatory agencies worldwide. We may not receive, or may be delayed
in receiving, the necessary approval or clearance for our future products, which would adversely affect business, financial condition,
results of operations and prospects.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are taking a multi-step approach to the regulatory
clearance process. As a first step, we submitted a 510(k)&nbsp;premarket notification to an accredited Review Organization under the FDA&rsquo;s
510(k) Third&nbsp;Party Review Program (the &ldquo;Third Party Review Program&rdquo;) for the Nanox Cart X-Ray System, which is a single-source
version of the Nanox.ARC (the &ldquo;Nanox Cart X-Ray System&rdquo;), in January 2020. As part of the review process, in March 2020, we
received an information request, referred to as a major deficiency letter, from the Review Organization, which among other things, required
us to provide additional data and other information to complete the application and to address certain deficiencies highlighted by the
reviewer, including the results of certain performance tests. On September&nbsp;3, 2020, we submitted our response to the Review Organization.
The response included additional data and other information to complete the application and to address certain deficiencies identified
by the reviewer, including the results of certain performance tests. On September&nbsp;10, 2020, the Review Organization requested that
we include a second predicate device in our 510(k) premarket notification. On September&nbsp;26, 2020, we submitted our revised 510(k)
premarket notification to the Review Organization, which the Review Organization subsequently recommended to the FDA for clearance on
December 28, 2020. On January&nbsp;1, 2021, we received an informational request from the FDA through the Review Organization regarding
our submission, which we responded to on January&nbsp;4, 2021. On January 30, 2021, we received additional information requests from the
FDA which, among other things, require us to address certain deficiencies and questions, including requests that we provide additional
support regarding the intended use of the Nanox.ARC and the comparability of the Nanox.ARC to the predicate device. We submitted our response
to these requests on March 1, 2021. On April 1, 2021, we received clearance from the FDA to market our Nanox Cart X-Ray System. We will
continue to optimize and develop features of the Nanox.ARC, and plan to submit an additional 510(k) premarket notification to the FDA
with respect to the multi-source Nanox.ARC and the Nanox.CLOUD during 2021. If cleared by the FDA, we expect to commercialize the multi-source
Nanox.ARC and we may seek alternatives for commercialization of our Nanox Cart X-Ray System. The review process may be more costly and
time consuming than we expect and we may not ultimately be successful in completing the review process and our 510(k) premarket notification
for the multi-source Nanox.ARC may not be cleared by the FDA in a timely manner or at all. We may also need to seek approval from foreign
regulatory authorities. With respect to our X-ray source technology, although we believe that it does not require FDA approval or clearance,
regulatory agencies may not agree. To date, we have not had any discussion with the FDA or other regulatory authorities regarding the
regulatory pathways for the novel digital X-ray source. Efforts to achieve required governmental clearances and approvals could be costly
and time consuming, and we may not be able to obtain any such required clearances or approvals in accordance with our anticipated timeline
or in a cost-efficient manner. Any delay or failure to obtain necessary regulatory clearances or approvals could have a material negative
impact on our ability to generate revenues. Even if the products containing our technology receive the required regulatory clearance or
approval, such products will remain subject to extensive regulatory requirements. If we fail to comply with the regulatory requirements
of the FDA and other applicable U.S. and foreign regulatory authorities, or previously unknown problems with any approved commercial products,
manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the cost of compliance with
new laws or regulations governing our technology or future products could adversely affect our business, financial condition, results
of operations and prospects. New laws or regulations may impose restrictions or obligations on us that could force us to redesign
our technology or other future products or services, and may impose restrictions that are not possible or practicable to comply
with, which could cause our business to fail. See &ldquo;&mdash;Risks Related to Government Regulation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We may need to obtain additional
financing to fund our future operations. If we are unable to obtain such financing, we may be unable to complete the development
and commercialization of our technology and our products and services.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our operations have consumed substantial
amounts of cash since inception. Our net losses were $43.8&nbsp;million, $22.6&nbsp;million and $1.9 million for the years ended
December&nbsp;31, 2020, 2019 and 2018, respectively. In addition, significant resources were invested in the development of our
X-ray source technology prior to us acquiring the technology. We anticipate that our future cash requirements will continue to
be significant. We may need to obtain additional financing to implement our business plan as described in this annual report on
Form 20-F. Specifically, although we believe our cash on hand is sufficient to complete the manufacture, shipping, installation
and deployment of the initial wave of approximately 15,000 Nanox.ARC units, as well as to support the continued research and development
of the Nanox.ARC and the development of the Nanox.CLOUD, we may need to raise additional funds for such purposes, including in
the case of unforeseen events. Such financings could include equity financing, which may be dilutive to shareholders, or debt financing,
which would likely restrict our ability to borrow from other sources. In addition, such securities may contain rights, preferences
or privileges senior to those of the rights of our current shareholders. Additional funds may not be available when we need them,
on terms attractive to us, or at all. If adequate funds are not available on a timely basis, we may be required to curtail the
development of our technology, products or services, or materially delay, curtail, reduce or terminate our research and development
and commercialization activities. We could be forced to sell or dispose of our rights or assets. Any inability to raise adequate
funds on commercially reasonable terms could have a material adverse effect on our business, financial condition, results of operation
and prospects, including the possibility that a lack of funds could cause our business to fail and liquidate with little or no
return to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>The success of our primary business
model, the Subscription Model, is subject to numerous risks and uncertainties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect the Subscription Model to be our
primary business model and the key to achieving our vision of increasing early-detection of medical conditions that are discoverable
by X-ray. Even if we are able to successfully implement our Sales Model and/or our Licensing Model, the sustainability of our general
business plan depends substantially on the sustainability of our Subscription Model. We believe that effectively stimulating market
interest in our Nanox System will require deploying 5,000 to 10,000 Nanox.ARC units. In addition, we estimate that a minimum installed
base of at least 1,000 Nanox.ARC units will be needed to support our business during the initial deployment, assuming we enter
into at least one licensing agreement on commercially reasonable terms. The success of our Subscription Model will also depend
on each device, once deployed, performing a sufficient number of scans per day to be fully utilized. We may not be successful in
achieving these goals for various reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the process of manufacturing and deploying the Nanox System is a complex, multi-step process that depends on factors outside
our control, and could cause us to expend significant time and resources prior to earning associated revenues;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the manufacturing cost of the Nanox.ARC may be higher than we expect, may increase significantly, or may increase at a higher
rate than anticipated, and we may not be able to set or timely adjust our pay-per-scan pricing to compensate for any increased
costs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the manufacturing of the Nanox.ARC may take longer than we expected, and we may have insufficient manufacturing capacity and
experience delays in the manufacturing and deployment of the Nanox System, which would have a negative impact on the timing of
our revenues;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>deployment and full utilization of the Nanox System may not be achieved or may take substantially longer than we expect, and
we may not be able to deploy a sufficient number of units of the Nanox System to support our business or to effectively stimulate
market interest;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>a Nanox System may perform fewer scans per day than our estimates due to a number of factors, including low market acceptance
rate, technical failures and downtime, service disruptions, outages or other performance problems, which would have a negative
impact on our revenues and our ability to recover costs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the implementation, integration and testing of the Nanox.CLOUD with our potential customers and collaborators can be complex,
time-consuming and expensive for them, which may have a negative impact on the timing of our revenues;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the inability or unwillingness of potential customers to invest in the required safety infrastructure, including customary
X-ray shielding, to allow the Nanox.ARC to be safety operated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>as part of the Subscription Model, we will be responsible for maintenance of the Nanox System units we deploy, which may be
more costly and time-consuming than we expect;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our customers may not be able to find or retain a sufficient number of radiologists to review the images generated by the Nanox
System, especially as we deploy additional Nanox Systems and the volume of scans increases;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the portion of our pay-per-scan pricing allocated to our collaborators may not be acceptable to them, either now or in the
future, and pricing negotiations with such collaborators may be a complex and time-consuming process;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the availability of insurance coverage and the level of reimbursement for the Nanox.ARC provided by third-party payors may
not be sufficient for our customers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our pay-per-scan pricing may not be sufficient to recover our costs and may not be adjusted in a timely manner, which could
negatively affect our revenues or cause our revenues and results of operations to vary significantly from period to period;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>we may be unsuccessful in maintaining our target price per scan because we do not control the price charged by local operators
and higher prices may adversely affect market acceptance of the Nanox System; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>regulatory authorities may challenge our Subscription Model altogether, and impose significant civil, criminal, and administrative
penalties, damages, fines, and/or exclusion from government funded healthcare programs, which could adversely affect our revenues
and results of operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of the above factors may negatively
affect the implementation of our Subscription Model, or cause our Subscription Model to fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We may not be successful in tailoring
our X-ray source to the specific systems of other medical imaging companies under our Licensing Model, and/or entering into licensing
agreements on terms favorable to us.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under our proposed Licensing Model, we expect
to be engaged to tailor our X-ray source to other medical imaging companies&rsquo; specific systems to replace the legacy X-ray
source or to license our X-ray source technology to them to develop new types of imaging systems, and we expect to receive a one-time,
non-recurring licensing fee upfront, as well as recurring royalty payments for each imaging system sold by such companies. We expect
customization to be a complex and multi-step process that varies for each project, which will require significant research and
testing activities. We may also not be able to demonstrate the feasibility, functionality or safety of our technology in other
medical imaging systems, meet the potential licensees&rsquo; design and manufacturing requirements, or satisfy their marketing
and product needs. In addition, we may not be successful in entering into licensing agreements with favorable terms as a result
of a numbers of factors, many of which are outside of our control, including willingness of, and the resources available to, other
medical imaging companies to in-license our novel X-ray source technology, our ability to agree with a potential partner on the
value of our technology, or on the related terms, as well as the availability of other technologies at lower cost or other alternative
technologies at the time. We have not entered into any licensing agreements; however, we expect to enter into negotiations regarding
a commercial arrangement with FUJIFILM Corporation for the licensing of our Nanox System. Any of the above factors may negatively
affect the implementation of our Licensing Model, or cause our Licensing Model to fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>To the extent that we license our
X-ray source technology to other medical imaging companies, the products integrating our technology may need to be approved or
cleared by the FDA or similar regulatory agencies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA may require products developed by
other medical imaging companies under the Licensing Model to go through lengthier or more rigorous processes than we expected.
These products may also be subject to regulations by governmental agencies in other jurisdictions, or regulation by other federal,
state and local agencies. In addition, we may not have control with respect to any such further regulatory approval strategies
or process. If such products do not receive, or are delayed in receiving, the necessary clearances or approvals, or if the performance
of one or more clinical trials are required in connection with such clearances or approvals, the prospects of our Licensing Model
may be materially affected, which could have a material adverse impact on our business and our revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>A pandemic, epidemic or outbreak
of an infectious disease, such as COVID-19, may materially and adversely affect our business and our financial results and could
cause a disruption to the development or deployment of the Nanox System.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Public health crises such as pandemics or
similar outbreaks could adversely impact our business. Beginning in 2019, a novel strain of a virus named SARS-CoV-2 (severe acute
respiratory syndrome coronavirus 2), or coronavirus, which causes COVID-19, has spread to most countries across the world, including
Israel, Japan and all 50 states within the U.S. The COVID-19 pandemic is evolving, and to date has led to the implementation of
various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The COVID-19
pandemic has adversely impacted our operations in various ways. For example, our engineers have limited ability to make work-related
trips to Korea or Israel to test and optimize the Nanox.ARC or to begin development of MEMs X-ray chip manufacturing in Korea.
Our potential business partners have limited ability to make on-site visits to our facilities or attend industry conferences and
meetings in person to experience the Nanox.ARC, which has negatively impacted our business development and deployment activities.
Due, in part, to travel restrictions as a result of the COVID-19 pandemic, we expect to manufacture a small number of Nanox.ARC
units in Israel on a purchase order basis that will be used for the acceptance tests under our MSaaS agreements, demonstrations,
regulatory approvals and for the initial global deployment, among other purposes. The external labs we work with have been affected
by COVID-19, resulting in delays in our timeline for obtaining regulatory clearance and approval. Our FDA and other regulatory
approvals and clearances may be delayed due to prioritization of vaccines for COVID-19. COVID-19 has also caused shutdowns or disruptions
of business for our manufactures and suppliers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The extent to which the COVID-19 pandemic
impacts our operations or those of our third-party partners will depend on future developments, which are highly uncertain and
cannot be predicted with confidence, including the duration of the pandemic, new information that will emerge concerning the severity
of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In addition, if any treatment
or vaccine for COVID-19 is ineffective or underutilized, any impact on our business may be prolonged. The continued spread of COVID-19
globally could adversely impact our development, manufacture or deployment of the Nanox System, which could adversely affect our
ability to obtain regulatory clearance and approval for and to commercialize the Nanox System, increase our operating expenses
and have a material adverse effect on our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These and other factors arising from the
COVID-19 pandemic could worsen in countries that are afflicted with the coronavirus. Any of these factors, and other factors related
to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operations
and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the
United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize
the Nanox System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our industry is highly competitive
and is subject to technological change, which may result in new products or solutions that are superior to our technology or other
future products we may bring to market from time to time. If we are unable to anticipate or keep pace with changes in the marketplace
and the direction of technological innovation and customer demands, our technology may become less useful or obsolete and our operating
results will suffer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The medical imaging industry is rapidly evolving and subject to intense
and increasing competition. To compete successfully and to be able to establish and maintain a competitive position in current and future
technologies, we will need to demonstrate the advantages of our technology over well-established alternative solutions, products and technologies,
such as computed tomography (&ldquo;CT&rdquo;), as well as newer methods of medical imaging and early detection. We believe that effectively
stimulating market interest for the Nanox System will require deploying 5,000 to 10,000 Nanox.ARC units. To achieve this, we will need
to raise or develop financial resources, technical expertise, marketing, distribution or support capabilities and we may not be successful
in doing so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Also, companies offering traditional medical
imaging systems, such as General Electric, Siemens, Philips, Hologic, Varian, Fuji, Toshiba and Hitachi, may be better established
in the market than we are, have greater corporate, financial, operational, sales and marketing resources than we do, or have more
experience in research and development than we have. In particular, the field emission technology has been used by a wide range
of leading market players in an attempt to create an alternative digital source of X-ray, the most well-known attempt being the
use of carbon nano tubes as the base materials for a potential field emission-based solution. In addition, early-detection technologies
developed by other companies, such as blood testing and DNA screening, may also reduce the attractiveness of our technology for
early detection or render it obsolete. Successful developments of these or other technologies by competitors resulting in new approaches
for medical imaging, including technologies, products or services that are more effective or commercially attractive, could make
our technology less useful or obsolete. We may also face opposition from certain industry leaders, who may have political influence
and the ability to delay deployment of the Nanox System in certain geographical areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, as the market expands, we expect
the entry of additional competitors, such as cloud computing companies or leading IT companies, who may have longer operating histories,
more extensive international operations, greater name recognition, and/or substantially greater technical, marketing and financial
resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our competitive position also depends on
our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>generate widespread awareness, acceptance and adoption of our technology and future products or services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>develop new or enhanced technologies or features that improve the convenience, efficiency, safety or perceived safety, and
productivity of our technology and future products or services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>properly identify customer needs and deliver new products or services or product enhancements to address those needs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>limit the time required from prototype development to commercial production;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>limit the timing and cost of regulatory approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>attract and retain qualified personnel and collaborators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>protect our inventions with patents or otherwise develop proprietary products and processes; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>secure sufficient capital resources to expand both our continued research and development, and sales and marketing efforts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our technology is not, or our future
products or services are not, competitive based on these or other factors, our business would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We expect to depend on third parties
to manufacture the Nanox.ARC and to supply certain component parts. Our reliance on third-party manufacturers and suppliers involve
certain risks that may result in, among others, increased costs, quality or compliance issues, or failure to timely manufacture
the Nanox.ARC, any of which could materially harm our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If cleared, we expect to rely on third-party manufacturers
and suppliers for the commercial production of the multi-source Nanox.ARC. We have entered into direct arrangements on a purchase order
basis with a manufacturer for the production of our X-ray tubes. We are evaluating, subject to completion of testing, a transition from
glass-based X-ray tubes to ceramics-based tubes for cost efficiency purposes, which are the tubes to be used in the multi-source version
of the Nanox.ARC, and we intend to enter into an agreement for such ceramics-based tubes with a new manufacturer in the future. In addition,
we have entered into a contract manufacturing agreement with FITI to manufacture the multi-source Nanox.ARC, with a goal to enable the
commercial production of the initial approximately 15,000 units planned for global deployment by the end of 2024. Under the contract manufacturing
agreement with FITI, FITI will negotiate and contract with other parties for the supply of the various other components of the Nanox.ARC
in accordance with the pre-approved supplier list and on the terms to be agreed upon by both parties. Our dependence on such third-party
manufacturers and suppliers involves a number of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>insufficient capacity or delays in meeting our demand;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>inadequate manufacturing yields, inferior quality and excessive costs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>inability to manufacture products that meet the agreed upon specifications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>inability to obtain an adequate supply of materials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>inability to comply with the relevant regulatory requirements for the manufacturing process;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>limited warranties on products supplied to us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>inability or failure to comply with our contractual obligations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>potential increases in prices; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>increased exposure to potential misappropriation of our intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Due, in part, to travel restrictions as
a result of the COVID-19 pandemic, we expect to manufacture a small number of Nanox.ARC units in Israel on a purchase order basis
that will be used for the acceptance tests under our MSaaS agreements, demonstrations, regulatory approvals and for the initial
global deployment, among other purposes. Although we expect to formalize our arrangement in writing, we have not yet done so, and
we may not establish a formal agreement or be able to enforce the obligations under such arrangements. Furthermore, we currently
expect to engage only one general manufacturer for the mass production of the Nanox.ARC. As we further expand our business in connection
with the commercialization of our technology, we expect to seek to engage alternative manufacturers of the Nanox.ARC. If any of
our manufacturers or suppliers breach their agreements, are unable to meet their contractual or quality requirements, or become
unwilling to perform for any reason, we may be unable, or may be unable in a timely manner, to locate alternative acceptable manufacturers
or suppliers and enter into favorable agreements with them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As mentioned above, we currently manufacture
the MEMs X-ray chips in the clean rooms located in Tokyo, Japan. While we intend to expand our manufacturing capacity, including
through the establishment of the Korean Subsidiary, to meet our currently anticipated needs, we may not have sufficient capacity
to manufacture the MEMs X-ray chips as our business expands. In addition, we rely on third parties to supply the raw materials
and certain component parts. Disruptions of our relationships with such suppliers could negatively impact our production for an
extended period of time. Any inability to acquire sufficient quantities of any raw materials or components in a timely manner from
these third-party suppliers could have a material negative impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, if we change the manufacturer
of a critical component of our products, such as our proposed transition from using glass-based tubes to ceramics-based tubes,
we will be required to verify that the new manufacturer maintains facilities, procedures and operations that comply with our quality
and applicable regulatory requirements, which could further impede our ability to manufacture our products in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Transitioning to a new supplier could be
time-consuming and expensive, may result in interruptions in our operations and product delivery, could affect the performance
specifications of our products or could require that we modify the design of those systems. If the change in manufacturer results
in a significant change to any product, a new 510(k) clearance or approval from the FDA or similar international regulatory authorization
may be necessary before we implement the change, which could cause substantial delays. The occurrence of any of these events could
harm our ability to meet the demand for our products in a timely or cost-effective manner. See &ldquo;&mdash;Risks Related to Government
Regulation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We may experience development or
manufacturing problems and higher costs, or delays that could limit our revenue, if any, or increase our losses.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Developing manufacturing procedures for
new products requires developing specific production processes for those products. Developing such processes could be time consuming,
and any unexpected difficulty in doing so can delay the introduction of the Nanox.ARC. Moreover, difficulties associated with adapting
our technology and product design to the proprietary process technology and design rules of outside manufacturers can lead to reduced
yields. Since low yields may result from either design or process technology failures, yield problems may not be effectively determined
or resolved until an actual product exists that can be analyzed and tested to identify process sensitivities relating to the design
rules that are used. As a result, yield problems may not be identified until well into the production process, and resolution of
yield problems may require cooperation between our manufacturers and us. This risk could be compounded by the offshore location
of our manufacturers, increasing the effort and time required to identify, communicate and resolve manufacturing yield problems.
Manufacturing defects that we do not discover during the manufacturing or testing process may lead to costly product recalls. These
risks may lead to increased costs or delayed product delivery, which would harm our profitability and customer relationships. Furthermore,
our, our manufacturers&rsquo; or our suppliers&rsquo; production processes and assembly methods may have to change to accommodate
any significant, future expansion of our manufacturing capacity, which may increase the manufacturing costs, delay production of
our products, reduce our product margin, require supplemental filings with the FDA or other regulatory authorities, any of which
may adversely impact our business. If we are unable to keep up with demand for our products by successfully manufacturing and shipping
our products in a timely manner, our revenue could be impaired, and market acceptance for our products could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We may not be able to successfully
execute our business models.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are pursuing three simultaneous business
models to maximize the commercial potential of our X-ray source technology, each of which requires significant time and resources,
in particular, our primary business model, the Subscription Model. We are a company with limited operating history and we may not
have the necessary resources, expertise and experience to successfully execute any of our business models on a global scale, such
as obtaining the necessary approvals or clearances from the regulatory agencies of our target markets. Our ability to execute our
models is dependent on a number of factors, including the ability of our senior management team to execute our models, our ability
to engage local operators and integrators in different geographic regions, our ability to begin or maintain our pace of product
development, manufacturing and commercialization, our ability to meet the changing needs of the medical imaging market, and the
ability of our employees to perform at a high-level. If we are unable to execute our models, if our models do not drive the growth
that we anticipate, or if our market opportunity is not as large as we have estimated, it could adversely affect our business and
our prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We have a limited operating history.
If we successfully commercially launch the Nanox.ARC or the Nanox.CLOUD, and they do not achieve widespread market acceptance,
we will not be able to generate the revenue necessary to support our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have a limited operating history and
have no history of marketing our X-ray source technology, the Nanox.ARC, the Nanox.CLOUD or any other product using our technology.
We may fail to generate significant interest in our X-ray source technology, the Nanox.ARC, the Nanox.CLOUD or the imaging products
using our technology, or any other product we may develop. These and other factors, including the following, may affect the rate
and level of market acceptance:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>effectiveness of the sales and marketing efforts of us, and our partners such as the local partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>perception by medical professionals and patients of the convenience, safety, efficiency and benefits of the Nanox.ARC, the
Nanox.CLOUD or products using our technology, compared to competing methods of medical imaging, such as the time and skill required
to read the tomographic images produced by the Nanox.ARC and our X-ray source;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>opposition from certain industry leaders, which may limit our ability to promote the Nanox.ARC or the Nanox.CLOUD and to penetrate
into the medical imaging market in certain geographical areas;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the existence of established medical imaging technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>willingness of market participants to accept the MSaaS model;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the changing and volatile U.S. and global economic environments, including as a result of the COVID-19 pandemic;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>timing of market introduction of competing products, and the sales and marketing initiatives of such products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>press and blog coverage, social media coverage, and other publicity and public relations factors by others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>lack of financing or other resources to successfully develop and commercialize our technology and implement our business plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the level of commitment and support that we receive from our partners, such as local operators, cloud storage providers and
medical AI software providers, as well as medical professionals such as radiologists; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>coverage determinations and reimbursement levels of third party payors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If cleared or approved for marketing by the FDA
or other regulatory agencies, depending on the approved clinical indication, the multi-source Nanox.ARC will be competing with existing
and future imaging products and similar offerings. The technology underlying our X-ray source and the Nanox.ARC may be perceived as inferior
or inaccurate and patients may be unwilling to undergo medical screening using the Nanox.ARC or other products using our technology. Moreover,
patients and medical professionals may be unwilling to depart from the current medical imaging technology. Medical professionals tend
to be slow to change their medical diagnostic practices because of perceived liability risks arising from the use of new technology or
products, and they may not recommend medical imaging using the Nanox.ARC or other products using our technology until there is long-term
clinical evidence to convince them to alter or modify their existing imaging methods. Our efforts to educate patients, radiologists and
other members of the medical community on the benefits of our products require significant resources and may not be successful. Our efforts
to educate the marketplace may require more resources than are required by conventional technologies marketed by our competitors. In particular,
gaining market acceptance for our products in nascent markets, such as China, India, and certain countries in Latin America, could be
challenging. Moreover, in the event that the Nanox.ARC or other products using our technology are the subject of guidelines, clinical
studies or scientific publications that are unfavorable or damaging, or otherwise call into question their benefits, we may have difficulty
in convincing market participants to adopt our products. In addition, medical professionals, patients, providers of medical imaging services
and third-party payors may not adopt or reimburse the use of the Nanox.ARC in the near term or at all. If we are unable to achieve or
maintain an adequate level of market acceptance, we may not generate significant revenue or become profitable and our business, financial
condition, results of operations and prospects would be significantly harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We plan to do business globally,
including in certain countries where we might have limited resources and would be subject to additional regulatory burdens and
other risks and uncertainties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect to do business globally, including
in North America and certain countries in Asia, Europe, Africa, Latin America and Australia. Commercialization of our X-ray source
technology, the Nanox.ARC or the Nanox System in foreign markets, either directly or through third parties, is subject to additional
risks and uncertainties, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reimbursement and insurance coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our inability to find agencies, dealers or distributors in specific countries or regions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our inability to directly control commercial activities of third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>limited resources to be deployed to a specific jurisdiction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the burden of complying with complex and changing regulatory, tax, accounting and legal requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>different medical imaging practice and customs in foreign countries affecting acceptance in the marketplace;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>import or export licensing and other requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>longer accounts receivable collection times;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>longer lead times for shipping;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>language barriers for technical training;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reduced protection of intellectual property rights in some foreign countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>foreign currency exchange rate fluctuations; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>interpretations of contractual provisions governed by foreign laws in the event of a contract dispute.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Specifically, we are subject to the U.S.
Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C.
&sect; 201, the U.S. Travel Act, the USA PATRIOT Act, the United Kingdom Bribery Act 2010, the Proceeds of Crime Act 2002, Chapter
9 (sub-chapter 5) of the Israeli Penal Law, 1977, the Israeli Prohibition on Money Laundering Law&ndash;2000 and possibly other
anti-bribery and anti-money laundering laws in countries outside of the United States in which we conduct our activities. As we
engage finders to obtain MSaaS agreements in certain countries, we and our finders may have direct or indirect interactions with
officials and employees of government agencies or state-owned or affiliated entities. We may be held liable for the corrupt or
other illegal activities of these third-party business partners and intermediaries, our employees, representatives, contractors,
partners and agents, even if we do not explicitly authorize such activities. As we expand our international business, our risks
under these laws may increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also may sell the Nanox.ARC, the Nanox.CLOUD
or the Nanox System to government entities, which are subject to a number of challenges and risks. Any actual or perceived privacy,
data protection, or data security incident, or even any perceived defect with regard to our practices or measures in these areas,
may negatively impact public sector demand for our products. Government entities may also have statutory, contractual or other
legal rights to terminate contracts with us for convenience or due to a default, and any such termination may adversely affect
our future results of operations. Governments routinely investigate and audit government contractors&rsquo; administrative processes,
and any unfavorable audit could result in the government refusing to continue buying our subscriptions, a reduction of revenue,
or fines or civil or criminal liability if the audit uncovers improper or illegal activities. In addition, sales of the Nanox.ARC,
the Nanox.CLOUD or the Nanox System in foreign markets could also be adversely affected by the imposition of governmental controls,
political and economic instability, trade restrictions and changes in tariffs, any of which may adversely affect our business,
financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Because the Nanox System is still
in the development stage, it is not yet approved for third-party payor coverage or reimbursement. If in the future we are approved
for and are otherwise able to commercialize it, but are unable to obtain adequate reimbursement or insurance coverage from third-party
payors, we may not be able to generate significant revenue, in which case we may need to obtain additional financing.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because the Nanox System is still in the
development stage, it is not yet approved for third-party payor coverage or reimbursement. Coding and coverage determinations as
well as reimbursement levels and conditions are important to the commercial success of an imaging product or offering. The future
availability of insurance coverage and reimbursement for newly approved medical devices is highly uncertain, and our future business
will be greatly impacted by the level of reimbursement provided by third-party payors. In the United States, third-party payors
decide which imaging products and services they will cover, how much they will pay and whether they will continue reimbursement.
Third-party payors may not cover or provide adequate reimbursement for the Nanox System or the imaging services using the Nanox
System, assuming we are able to fully develop and obtain all regulatory approvals and clearances to market it in the United States
or other geographies. To date, we have not had any discussions with any third-party payors, including any regulatory agencies administering
any government funded healthcare programs, regarding the coding, coverage or reimbursement for imaging services using the Nanox
System. Accordingly, unless government and other third-party payors provide coverage and reimbursement for our services, patients
and healthcare providers may choose not to use them, which would cause investors to lose their entire investment. A primary trend
in the United States healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors
have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Reimbursement
may not be available, or continue to be available, for the Nanox System or the imaging services using the Nanox System, other products
or systems using our X-ray source technology or any other products we may develop in the future, or even if reimbursement is available,
such reimbursement may not be adequate. We also will be subject to foreign reimbursement policies in the international markets
we expect to enter. Decisions by health insurers or other third-party payors in these markets not to cover, or to discontinue reimbursing,
our products could materially and adversely affect our business. If such decisions are made, they could also have a negative impact
on our ability to generate revenues, in which case we may need to obtain additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Recent changes in the United States
related to payment policies for imaging procedures could have a negative impact on the utilization of our imaging services.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, over the past several
years, the Centers for Medicare &amp; Medicaid Services (&ldquo;CMS&rdquo;), the federal agency responsible for administering the
Medicare program, has implemented numerous changes to payment policies for imaging procedures in both the hospital setting and
non-hospital settings, which include physician offices and freestanding imaging facilities. Some of these changes have had a negative
impact on utilization of imaging services. Examples of these changes include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>limiting payments for imaging services in physician offices and free-standing imaging facility settings based upon rates paid
to hospital outpatient departments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reducing payments for certain imaging procedures when performed together with other imaging procedures in the same family of
procedures on the same patient on the same day in the physician office and free-standing imaging facility setting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>making significant revisions to the methodology for determining the practice expense component of the Medicare payment applicable
to the physician office and free-standing imaging facility setting which results in a reduction in payment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>revising payment policies and reducing payment amounts for imaging procedures performed in the hospital outpatient setting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also expect increased regulation and
oversight of advanced diagnostic testing. One provision in the Protecting Access to Medicare Act requires CMS to develop appropriate
use criteria (&ldquo;AUC&rdquo;) that professionals must consult when ordering advanced diagnostic imaging services (which include
magnetic resonance imaging (&ldquo;MRI&rdquo;), CT, nuclear medicine (including position emission tomography) and other advanced
diagnostic imaging services that the Secretary of the Department of Health and Human Services (&ldquo;HHS&rdquo;) may specify).
Under this provision, which is currently set to be fully implemented on January&nbsp;1, 2022, payment is to be made to the furnishing
professional for an applicable advanced diagnostic imaging service only if the claim indicates that the ordering professional consulted
a qualified clinical decision support mechanism, as identified by HHS, as to whether the ordered service adheres to the applicable
AUC. To the extent that these types of changes have the effect of reducing the aggregate number of diagnostic medical imaging procedures
performed in the United States, our business, results of operations, financial condition and cash flows would be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Billing complexities associated
with obtaining payment or reimbursement may negatively affect our revenue, cash flow and profitability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Billing for imaging services is complex.
Payment is provided by individual patients and from a variety of payors, such as commercial insurance carriers, managed care organizations
and governmental programs. Each payor typically has different billing requirements, and the billing requirements of many payors
have become increasingly stringent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Among the factors complicating our customers&rsquo;
ability to bill and receive reimbursement from third-party payors are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>disputes among payors as to which party is responsible for payment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>disparity in coverage among various payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>disparity in information and billing requirements among payors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>incorrect or missing billing information, which is required to be provided by the ordering physician.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we may be required to seek
new billing codes for imaging services using the Nanox System, and regulatory authorities may not approve the creation of separate
codes. Additionally, even if we are successful, these billing codes or the payment amounts associated with such codes may change
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The impact of these factors may be compounded
by our use of the novel Subscription Model. These billing complexities, and the related uncertainty in obtaining payment for our
products, could negatively affect our revenue, cash flow and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Any collaborative and MSaaS arrangements
that we have established or may establish in the future may not be successful or we may otherwise not realize the anticipated benefits
from these collaborations. We do not control third parties with whom we have or may have collaborative or MSaaS arrangements, and
we will rely on them to achieve results which may be significant to us. In addition, any current or future collaborative and MSaaS
arrangements may place the development and commercialization of our technology outside our control, may require us to relinquish
important rights or may otherwise be on terms unfavorable to us.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into certain, and expect
to enter into additional, collaborative arrangements and MSaaS agreements with respect to the research, development, manufacture
and commercialization of our technology with different relevant industry participants, including, among others, local operators,
integrators, radiologists, cloud storage providers and medical AI software providers and third-party payors. See &ldquo;Item 4.
Information on the Company&mdash;B. Business Overview&mdash;Commercial Agreements.&rdquo; Any future potential collaborative or
MSaaS arrangements may require us to rely on external consultants, advisors and experts for assistance in several key functions,
including research and development, manufacturing, regulatory, intellectual property, commercialization and distribution. We cannot
and will not control these third parties, but we may rely on them to achieve results, which may be significant to us. Relying upon
these collaborative arrangements subjects us to a number of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>we may not be able to control the amount and timing of resources that our collaborators may devote to our technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>should a collaborator fail to comply with applicable laws, rules or regulations when performing services for us, we could be
held liable for such violations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our collaborators may have a shortage of qualified personnel, particularly radiologists who can review the medical images generated
by the Nanox System, especially as we deploy additional Nanox Systems and the volume of scans increases;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>we may be required to relinquish important rights, such as marketing and distribution rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>business combinations or significant changes in a collaborator&rsquo;s business strategy may adversely affect a collaborator&rsquo;s
willingness or ability to complete its obligations under any arrangement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our collaborators may default on their payments to us or fail to deliver standby letters of credit or financial guarantees,
and it may be time consuming and difficult to enforce such payment obligations and obligations to provide standby letters of credit
and financial guarantees in various jurisdictions, and we may be unsuccessful in enforcing such obligations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our collaborative arrangements are subject to conditionality, including receipt of regulatory clearance and material compliance
with acceptance test protocol, among other things, for the Nanox.ARC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>under certain circumstances, a collaborator could move forward with a competing product developed either independently or in
collaboration with others, including our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our current or future collaborators may utilize our proprietary information in a way that could expose us to competitive harm;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our collaborators could obtain ownership or other control over intellectual property that is material to our business; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>collaborative arrangements are often terminated or allowed to expire or remain unformalized by a written agreement, which could
delay the ability to commercialize our technology.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, if disputes arise between us
and any of our collaborators, it could result in the delay or termination of the development, manufacturing or commercialization
of products containing our technology, lead to protracted and costly legal proceedings, or cause collaborators to act in their
own interest, which may not be in our interest. As a result, the collaborative arrangements that we may enter into, may not achieve
their intended goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any of these scenarios materialize, they
could have a material adverse effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also may have other future products where
it is desirable or essential to enter into agreements with a collaborator who has greater financial resources or different expertise
than us, but for which we are unable to find an appropriate collaborator or are unable to do so on favorable terms. If we fail
to enter into such collaborative agreements on favorable terms, it could materially delay or impair our ability to develop and
commercialize, and increase the costs of development and commercialization of, our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We could become subject to product
liability claims, product recalls, and warranty claims that could be expensive, divert management&rsquo;s attention and harm our
business reputation and financial results.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business exposes us to potential liability
risks that are inherent in the marketing and sale of products used in patient care. We may be held liable if the Nanox System or
if any other product that integrates our X-ray source technology causes injury or death or is found otherwise unsuitable during
usage. The Nanox System currently under development incorporates sophisticated components and computer software. Complex software
can contain errors, particularly when first introduced. In addition, new products or enhancements may contain undetected errors
or performance problems that, despite testing, are discovered only after installation. Patients could allege or possibly prove
defects of our products or other products that integrate our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A product liability claim, regardless of
its merit or eventual outcome, could result in significant legal defense costs and divert management&rsquo;s attention. Regardless
of merit or eventual outcome, liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>decreased demand for the Nanox System;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>injury to our reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>costs of related litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>substantial monetary awards to patients and others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>loss of revenue; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the inability to commercialize future products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these outcomes may have an adverse
effect on our business, financial condition and results of operations, and may increase the volatility of our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The coverage limits of our insurance policies
we may choose to purchase to cover related risks may not be sufficient to cover future claims. If sales of the Nanox System or
other products integrating our technology increase or we suffer future product liability claims, we may be unable to maintain product
liability insurance at satisfactory rates or with adequate amounts or at all. A product liability claim, any product recalls or
excessive warranty claims, whether arising from defects in design or manufacture or otherwise, could negatively affect our sales
or require a change in the design or manufacturing process, any of which could harm our relationship with our customers and partners,
and have a material adverse impact on our reputation and business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, if the Nanox System or other
products integrating our technology are defective, we, our future customers or partners may be required to notify regulatory authorities
and/or to recall the products. See &ldquo;&mdash;Risks Related to Government Regulation&mdash;Our products may cause or contribute
to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to
do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations.
The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of
the FDA or another governmental authority, could have a negative impact on us.&rdquo; Any recall would divert management&rsquo;s
attention and financial resources and harm our reputation with customers, patients, medical professionals and third-party payors.
A recall involving the Nanox System would be particularly harmful to our business. The adverse publicity resulting from any of
these actions could adversely affect the perception of our customers or partners. These investigations or recalls, especially if
accompanied by unfavorable publicity, could result in our incurring substantial costs, losing revenues and damaging our reputation,
each of which would harm our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We are highly dependent on key members
of our executive management team. Our inability to retain these individuals could impede our business plan and growth strategies,
which could have a negative impact on our business and the value of your investment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ability to implement our business plan
depends on the continued services of key members of our senior management. In particular, and to a critical extent, we are dependent
on the continued efforts and services of the members of management named under &ldquo;Item 6. Directors, Senior Management and
Employees.&rdquo; If we lose the services of such key members of our management team, we would likely be forced to expend significant
time and money in the pursuit of replacement individuals, which may result in a delay in the implementation of our business plan
and plan of operations. We may not be able to find satisfactory replacements on terms that would not be unduly expensive or burdensome
to us. We do not currently carry a key-man life insurance policy that would assist us in recouping our costs in the event of the
death or disability of a member of our management team. The loss of members of our management team, or our inability to attract
or retain other qualified individuals, could have a material adverse effect on our business, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>The mishandling or the perceived
mishandling of sensitive information, or the occurrence of data security breaches, could harm our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect that the Nanox System will enable
us to accumulate a significant amount of highly sensitive and/or confidential information, including medical images and other medical
information. These images could be received by our customers or collaborators, such as medical AI-analytics companies, to increase
the probability of early disease detection. While employee contracts generally contain standard confidentiality provisions, our
employees, customers or collaborators may not properly handle or process sensitive or confidential data. The improper handling
of sensitive or confidential data, or even the perception of such mishandling (whether or not valid), or other security lapses
by us, our customers or collaborators, could reduce demand for such products or otherwise expose us to financial or reputational
harm or legal liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, any security breach, including
personal data breaches, or incident, including cybersecurity incidents, that we experience could result in unauthorized access
to, misuse of, or unauthorized acquisition of the sensitive or confidential information and data (including medical information),
the loss, corruption, or alteration of this data, interruptions in our operations, or damage to our systems. Any such incidents
could expose us to claims, litigation, regulatory or other governmental investigations, administrative fines and potential liability.
An increasing number of digital platforms have disclosed breaches of their security, some of which have involved sophisticated
and highly targeted attacks on portions of their services. Because the techniques used to obtain unauthorized access, disable or
degrade service, or sabotage systems change frequently and often are not foreseeable or recognized until launched against a target,
we may be unable to anticipate these techniques or to implement adequate preventative measures. If an actual or perceived breach
of our security occurs, public perception of the effectiveness of our security measures and brand could be harmed and our results
of operations could be negatively affected. Data security breaches and other incidents may also result from non-technical means
(e.g., actions by employees or contractors). Any compromise of our security could result in a violation of applicable security,
privacy or data protection, consumer and other laws, regulatory or other governmental investigations, enforcement actions, and
legal and financial exposure, including potential contractual liability. Any such compromise could also result in damage to our
reputation and a loss of confidence in our security and privacy or data protection measures. Any of these effects could materially
and adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our business and operations would
suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ability to execute our business strategy
depends, in part, on the continued and uninterrupted performance of our IT systems, which support our operations. Despite the implementation
of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from,
among others, computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks
or cyber-intrusions over the internet, attachments to emails, persons inside our organization, or persons with access to systems
inside our organization or similar disruptive problems. The risk of a security breach or disruption, particularly through cyber-attacks
or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number,
intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to
occur and cause interruptions in our operations, it could result in a material disruption of our product development programs.
Any such security breach may compromise information stored on our networks and may result in significant data losses or theft of
personally identifiable information. A cybersecurity breach could also hurt our reputation by adversely affecting the patients&rsquo;
perception of the security of their information. A number of proposed and enacted federal, state and international laws and regulations
obligate companies to notify individuals of security breaches involving particular personally identifiable information, which could
result from breaches experienced by us or by third parties, including collaborators, vendors, contractors or other organizations
with which we expect to form strategic relationships. In addition, a cybersecurity attack could result in other negative consequences,
including disruption of our internal operations, increased cyber security protection costs, lost revenue, regulatory actions or
litigations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Exchange rate fluctuations between
the U.S. dollar, Japanese Yen, the New Israeli Shekel and the South Korean Won and inflation may negatively affect our results
of operations, and we may not be able to hedge our currency exchange risks successfully.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The U.S. dollar is our functional and reporting
currency. However, a portion of our operating expenses, including personnel and facilities related expenses, are incurred in NIS,
Yen and KRW. As a result, we are exposed to the risks that the NIS, Yen and KRW may appreciate relative to the U.S. dollar, or,
if the NIS, Yen and KRW instead devalues relative to the U.S. dollar, that the inflation rate in Israel may exceed such rate of
devaluation of the NIS, Yen or KRW, or that the timing of such devaluation may lag behind inflation in Israel. In any such event,
the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely
affected. Given our general lack of currency hedging arrangements to protect us from fluctuations in the exchange rates of the
NIS, Yen and KRW and other foreign currencies in relation to the U.S. dollar (and/or from inflation of such foreign currencies),
we may be exposed to material adverse effects from such movements. Our exchange rate exposure may change over time as our business
evolves and could result in increased costs or reduced revenue and could affect our actual cash flow. Changes in the relative values
of currencies occur regularly and, in some instances, may have a significant impact on our operating results. The rate of inflation
in Israel or in currency exchange rates may materially change and we might not be able to effectively mitigate these risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>If significant tariffs or other
restrictions related to &ldquo;trade wars&rdquo; are placed on Chinese imports or any related counter-measures are taken by China,
our revenue and results of operations may be materially harmed.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have, and expect to enter into, agreements
with manufacturers and/or suppliers in China for the production of our X-ray tube, the Nanox.ARC and some of their respective components.
If significant tariffs or other restrictions are placed by the United States government on Chinese imports or any related counter-measures
are taken by China, our business, financial condition and results of operations may be materially harmed. In July 2018, the Trump
Administration announced a list of thousands of categories of goods that could face tariffs. If these duties or any other forms
of duties or tariffs are imposed on the Nanox.ARC, our X-ray tube or their components, we may be required to charge higher prices
in the United States than we expect, which may result in fewer customers and harm our operating performance. Alternatively, we
may seek to shift production outside of China, resulting in significant costs and disruption to our operations and business. Our
business could also be impacted by retaliatory trade measures taken by China or other countries in response to existing or future
tariffs, causing us to raise prices or make changes to our operations, any of which could materially harm our business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our business may be impacted by
changes in general economic conditions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business is subject to risks arising
from changes in domestic and global economic conditions, including adverse economic conditions in markets in which we operate,
which may harm our business. For example, the current COVID-19 pandemic has caused significant volatility and uncertainty in U.S.
and international markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our future customers significantly reduce
spending in areas in which our technology and products are utilized, or prioritize other expenditures over our technology and products,
our business, financial condition, results of operations and prospects would be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Disruption to the global economy could also
result in a number of follow-on effects on our business, including a possible slow-down resulting from lower customer expenditures;
inability of customers to pay for products, solutions or services on time, if at all; more restrictive export regulations which
could limit our potential customer base; negative impact on our liquidity, financial condition and share price, which may impact
our ability to raise capital in the market, obtain financing and secure other sources of funding in the future on terms favorable
to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the occurrence of catastrophic
events, such as hurricanes, storms, earthquakes, tsunamis, floods, medical epidemics and other catastrophes that adversely affect
the business climate in any of our markets could have a material adverse effect on our business, financial condition and results
of operations. Some of our operations are located in areas that have been in the past, and may be in the future, susceptible to
such occurrences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We are currently subject to securities
class-action litigation and may be subject to similar or other claims and litigation in the future, all of which will require significant
management attention, could result in significant legal expenses and may result in unfavorable outcomes, all or any of which could
have a material adverse impact on our financial condition and results of operations, harm our reputation or otherwise negatively
impact our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are, and may in the future become, subject
to litigation or claims arising in or outside the ordinary course of business that could negatively affect our business operations
and financial condition, including securities class actions and shareholder derivative actions, both of which are typically expensive
to defend. Such claims and litigation proceedings may be brought by third parties, including our customers, competitors, advisors,
service providers, partners or collaborators, employees, and governmental or regulatory bodies. For example, we currently have
a securities class-action complaint pending against us and certain current officers and a director, asserting violations of federal
securities laws and seeking unspecified damages. We believe this lawsuit is without merit and intend to defend this case vigorously.
See &ldquo;Item 4. Information on the Company&mdash;B. Business Overview&mdash;Legal Proceedings.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The outcome of any litigation, regardless
of its merits, is inherently uncertain and may differ substantially from our expectations. Any claims and lawsuits, and the disposition
of such claims and lawsuits, could be time-consuming and expensive to resolve, divert management attention and resources, and lead
to attempts on the part of other parties to pursue similar claims. We may not be able to determine the amount of any potential
losses and other costs we may incur due to the inherent uncertainties of litigation and settlement negotiations. In the event we
are required or decide to pay amounts in connection with any claims or lawsuits, such amounts could be significant and could have
a material adverse impact on our liquidity, business, financial condition and results of operations. In addition, depending on
the nature and timing of any such dispute, a resolution of a legal matter could materially affect our future operating results,
our cash flows or both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We do not expect to carry any business
interruption insurance or any other insurance (except for director and officer, property and product liability insurance). As a
result, we may incur uninsured losses, increasing the possibility that you would lose your entire investment in our company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our products and services are in the medical
imaging field and so may be subject to claims. We are not immune from product liability or other product claim risks, and we may
not be able to maintain insurance on acceptable terms against such risks or that such insurance will be sufficient to protect us
against potential claims or that insurance will be available in the future in amounts sufficient to protect us. A product liability
claim or other claim, as well as any claims for uninsured liabilities or in excess of insured liabilities, could have a material
adverse effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Certain of our directors and/or
officers may have interests that compete with ours.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain of our directors currently own,
operate and manage other entities, which may have similar or different objectives than ours. Such activities could detract from
the time these people have to allocate to our affairs. We had previously entered into a consulting agreement and a service agreement
with an entity owned by Ran Poliakine, and we are currently party to a service agreement with an entity of which Onn Fenig and
Ran Poliakine each serves as a director and Ran Poliakine is a significant shareholder. Furthermore, Ran Poliakine is a director
and Onn Fenig manages the operations of such entity&rsquo;s controlled subsidiary. See &ldquo;Item 7. Major Shareholders and Related
Party Transactions&mdash;B. Related Party Transactions&mdash;Agreements With Directors and Officers&mdash;Relationship With Six-Eye
Interactive Ltd.&rdquo; and &ldquo;&mdash;Relationship with SixAI Ltd.&rdquo; Additionally, we lease office space to an entity
of which Ran Poliakine serves as a member of senior management, Richard Stone serves as a director and Anat Kaphan serves as a
consultant. Each of Ran Poliakine and Richard Stone is also a significant shareholder. See &ldquo;Item 7. Major Shareholders and
Related Party Transactions&mdash;B. Related Party Transactions&mdash;Agreements with Directors and Officers&mdash;Relationship
with Illumigyn, Ltd.&rdquo; Additionally, we lease office space to an entity of which each of Ran Poliakine and Richard Stone is
a shareholder of its parent company. See &ldquo;Item 7. Major Shareholders and Related Party Transactions&mdash;B. Related Party
Transactions&mdash;Agreements With Directors and Officers&mdash;Relationship with Wellsense Technologies, Ltd.&rdquo; The terms
of such agreements may not be as favorable to us as those that could be obtained from a third party. Moreover, certain of our directors
and officers are affiliated with our current shareholders, and may have different interests than other shareholders. For additional
information regarding related party transactions and potential conflicts of interest, see &ldquo;Item 7. Major Shareholders and
Related Party Transactions&mdash;B. Related Party Transactions.&rdquo; Under the Israeli Companies Law, 5759-1999 (the&nbsp;&ldquo;Companies
Law&rdquo;), office holders must promptly disclose to us any direct or indirect personal interest that he or she may have and all
related material information or documents known to him or her relating to any existing or proposed transaction by us. In addition,
we have adopted a code of ethics and conduct that requires our employees, officers and directors to disclose any situation that
reasonably would be expected to give rise to a conflict of interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our management team has limited
experience managing a public company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Most members of our management team have
limited experience managing a publicly traded company, interacting with public company investors and complying with the increasingly
complex laws pertaining to public companies in the United States. Our management team may not successfully or efficiently manage
our operations a public company subject to significant regulatory oversight and reporting obligations under the U.S. federal securities
laws and the continuous scrutiny of securities analysts and investors. These obligations and constituents require significant attention
from our senior management and could divert their attention away from the day-to-day management of our business, which could adversely
affect our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Our Intellectual Property</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>It is difficult and costly to protect
our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We rely upon a combination of patents and
trade secrets to protect the intellectual property related to our proprietary technologies. Our success depends significantly on
our ability to obtain and maintain intellectual property protection with respect to our technology and products. Patents and other
proprietary rights provide uncertain protections, and we may be unable to protect our intellectual property for reasons including
those that result from complex factual and legal issues such as those that create uncertainty as to the validity, scope and enforceability
of any particular patent that we hold or for which we have applied. As a result, we may be unsuccessful in defending our patents
and other proprietary rights against third-party challenges, which could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although we are attempting to obtain patent
coverage for our technology where available and where we believe appropriate, there are aspects of the technology for which patent
coverage may never be sought or received. Additionally, we have obtained, and may in the future obtain, certain intellectual property
related to our technology from third parties, and we cannot be certain that such third parties took the necessary actions to maintain
such rights or that the transfer of such rights to us was proper and effective. We may, as a result, be subject to claims challenging
the ownership or enforceability of such rights. Furthermore, we may not possess the resources to, or for other reasons may not
choose to, pursue patent protection on every invention or in any or every country where we may eventually decide to sell our future
products. Our ability to prevent others from making or selling duplicate or similar technologies will be impaired for those technologies
with respect to which, and in those countries where, we have no patent protection. In addition, there is no assurance that all
potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from
issuing from a pending patent application or later invalidate or narrow the scope of an issued patent. Even if patents do successfully
issue and even if such patents cover our technology, third parties may challenge their validity, enforceability or scope, which
may result in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to these patents or any
other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, for patents that do issue based
on our applications or future applications, any issued patents may not provide us with any competitive advantages. Competitors
may be able to design around our patents and develop products that provide outcomes comparable or superior to ours. Any changes
we make to our product or any future products, including designs that may be required for commercialization or that cause them
to have what we view as more advantageous properties, may not be covered by patents and patent applications we have licensed or
own, and we may be required to file new applications and/or seek other forms of protection for any such altered products if any
such protection is available. In addition, the patent prosecution process is expensive, time-consuming and complicated, and we
and our current or future licensors, licensees or collaborators may not be able to prepare, file, prosecute and maintain all necessary
or desirable patents or patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current
or future licensors, licensees or collaborators will fail to identify patentable aspects of inventions before it is too late to
obtain patent protection for them. In addition, if we choose to and are able to secure patent protection in countries outside the
U.S., the laws of some foreign countries may not protect our intellectual property rights to the same extent as do the laws of
the United States. For instance, the legal systems of some countries, including India, China and other developing countries, do
not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement
of our patents or the misappropriation of our other intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in">Some countries also have compulsory licensing
laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability
of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies,
which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties
with respect to any patents relevant to our business, our competitive position may be impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Changes in either the patent laws or their
interpretation in the United States and other countries may diminish our ability to protect our inventions and enforce our intellectual
property rights, and more generally could affect the value of our intellectual property. Our efforts to seek patent protection
for our technology could be negatively impacted by any such changes, which could have a material adverse effect on our existing
patent rights and our ability to protect and enforce our intellectual property in the future. In particular, our ability to stop
third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will
depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may come to believe that third parties
are infringing on, or otherwise violating, our patents or other proprietary rights. To prevent infringement or unauthorized use,
we may need to file infringement and/or misappropriation suits, which are very expensive and time-consuming, could result in meritorious
counterclaims against us and would distract management&rsquo;s attention. Also, in an infringement or misappropriation proceeding,
a court may decide that one or more of our patents is invalid, unenforceable, or both, in which case third parties may be able
to use our technology without paying license fees or royalties. Even if the validity of our patents is upheld, a court may refuse
to stop the other party from using the technology at issue on the grounds that the other party&rsquo;s activities are not covered
by our patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to patents, we rely on trade
secrets to protect our technology; however, the policies we use to protect our trade secrets may not be effective in preventing
misappropriation of our trade secrets by others. In addition, confidentiality agreements executed by our employees, consultants
and advisors may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information
in the event of unauthorized use or disclosure. Litigating a trade secret claim is expensive and time consuming, and the outcome
may be unexpected. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover,
our competitors may independently develop knowledge, methods and know-how that allow them to create substantially similar products
or services without misappropriating our trade secrets. If we are unable to protect our trade secrets, we may be unable to prevent
competitors from using our own inventions and intellectual property to compete against us, and our business may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Patent terms may be inadequate to
protect our competitive position on our future products for an adequate amount of time.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Patents have a limited lifespan. In the
United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&nbsp;years from its
earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it
affords, is limited. Even if patents covering our future products are obtained, once the patent life has expired, we may be open
to competition from competitive products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Given the amount of time required for the
development, testing and regulatory review of new products, patents protecting our future products might expire before or shortly
after we or our future partners commercialize those products. As a result, our owned and licensed patent portfolio may not provide
us with sufficient rights to exclude others from commercializing products similar or identical to ours for a sufficient amount
of time, and, as a result, we may not be able to obtain adequate protection from our patent portfolio against competition, in spite
of the time and effort invested in the commercialization of our future products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Claims that our technology or our
future products or the sale or use of our future products infringe the patents or other intellectual property rights of third parties
could result in costly litigation or could require substantial time and money to resolve, even if litigation is avoided.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because our industry is characterized by
competing intellectual property, we may be subject to legal actions for violating the intellectual property rights of others, including
claims that former employees, collaborators or third parties have an interest in our patents, trade secrets or other intellectual
property. For example, we may have inventorship or ownership disputes arising from conflicting obligations of employees, consultants
or others who are involved in developing our technology or our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also may be required to participate in
interference, derivation or opposition proceedings that concern disputes regarding priority of inventions disclosed in our patents.
Determining whether a product infringes a patent, as well as priority of inventions and other patent-related disputes, involves
complex legal and factual issues and the outcome is often uncertain. We have not conducted any significant search of patents issued
to third parties, and third-party patents containing claims covering our technology or methods that predate our patents may exist.
Because of the number of patents issued and patent applications filed in our technical areas or fields (including some pertaining
specifically to medical imaging technologies), our competitors or other third parties may assert that our technology and the methods
we employ in the use of products incorporating our technology are covered by United States or foreign patents held by them. In
addition, because patent applications can take many years to issue and because publication schedules for pending applications vary
by jurisdiction, there may be applications now pending of which we are unaware, and which may result in issued patents that our
technology or other future products would infringe. Also, because the claims of published patent applications can change between
publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As the number of competitors in the market
for medical imaging technologies increases, and as the number of patents issued in this area grows, the possibility of patent infringement
claims against us increases. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively
than we can, including if they have substantially greater resources. Defending against such litigation is costly and time consuming,
and would distract our management from our business. In addition, any uncertainties resulting from the initiation and continuation
of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event that we become subject to a
patent infringement or other intellectual property lawsuit and if the relevant patents or other intellectual property were upheld
as valid and enforceable and we were found to infringe or violate those rights or the terms of a license to which we are a party,
we could be prevented from selling any infringing products of ours unless we could obtain a license or were able to redesign the
product to avoid infringement. If we were unable to obtain a license or successfully redesign, we might be prevented from selling
our technology or other future products. If we are able to redesign, we may need to invest substantial resources in the redesign
process. If there is an allegation or determination that we have infringed the intellectual property rights of a competitor or
other person, we may be required to pay damages, or a settlement or ongoing royalties, or we may be required to enter into cross-licenses
with our competitors. In any of these circumstances, we may be unable to sell our products at competitive prices or at all, and
our business, financial condition, results of operations and prospects could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we may be required to indemnify
our customers and distributors against claims relating to the infringement of intellectual property rights of third parties related
to our products. Third parties may assert infringement claims against our customers or distributors. These claims may require us
to initiate or defend protracted and costly litigation on behalf of our customers or distributors, regardless of the merits of
these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers or distributors, or may
be required to obtain licenses for the products or services they use. If we cannot obtain all necessary licenses on commercially
reasonable terms, our distributors may be forced to stop distributing our products or services, and our customers may be forced
to stop using our products or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during discovery. There could also be public announcements of the results of hearings,
motions or other interim proceedings or developments, which could have a material adverse effect on the price of our ordinary shares.
If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price
of our ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Obtaining and maintaining patent
protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental
patent agencies, and our patent protection could be reduced or eliminated if we or our future licensors do not comply with these
requirements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Periodic maintenance fees, renewal fees,
annuity fees and various other government fees on a patent and patent application are due to be paid to the patent offices and
agencies in several stages over the lifetime of the patent and patent application. The U.S. Patent and Trademark Office and various
foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar
provisions during the patent application process. In certain circumstances, we may be required to rely on our licensing partners
to take the necessary action to comply with these requirements with respect to patents or other intellectual property they have
licensed to us. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance
with the applicable rules, there are situations in which noncompliance, which could include failure to respond to official actions
within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents, can result in
abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant
jurisdiction. In such an event, our competitors may be able to enter the market and compete with our products, which would have
a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We may be subject to claims that
our employees, consultants or advisers have wrongfully used or disclosed alleged trade secrets of their former employers or claims
asserting ownership of what we regard as our own intellectual property</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many of our employees, consultants and advisers,
including our senior management, were previously employed at other companies that may have proprietary rights related to our business.
Some of these employees, consultants and advisers, including members of our senior management, executed proprietary rights, non-disclosure
and non-competition agreements in connection with such previous employment. Although we try to ensure that such individuals do
not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees
have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&rsquo;s
former employer. We are not aware of any such disclosures, or threatened or pending claims related to these matters, but in the
future, litigation may be necessary to defend against such claims. If we fail in defending any such claims, we may lose valuable
intellectual property rights or personnel, in addition to possibly paying monetary damages and being enjoined from conducting our
business as contemplated. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, a licensor, collaborator,
employee, consultant, adviser or other third party may dispute our or our licensor&rsquo;s ownership of certain intellectual property
rights. We seek to address these concerns in our contractual agreements; however, we may not have contractual arrangements with
the party in question and/or such provisions may not be effective. If these provisions prove to be ineffective, we may not be able
to achieve our business objectives. If we or our licensors fail in defending any such claims, we may have to pay monetary damages
and may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property, which
could adversely impact our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>If our trademarks and trade names
are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may
be adversely affected.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our unregistered trademarks or trade names
are valuable assets and may be challenged, infringed, circumvented or declared generic or determined to infringe third party&rsquo;s
marks. We may not be able to protect our rights to these trademarks and trade names, which may be necessary to build name recognition
among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks
similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there
could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate
variations of our unregistered trademarks or trade names. We have not conducted any registrability studies for possible future
trademarks to assess whether such marks would be successfully registered. Over the long term, if we are unable to establish name
recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely
affected. In addition, we may license our trademarks and trade names to third parties, such as distributors. Though these license
agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of
our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks
and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain
names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources
and adversely affect our competitive position, business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our rights to develop and commercialize
our products may be subject to the terms and conditions of licenses and sublicenses granted to us by third parties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We rely on licenses and sublicenses to certain
patent rights and other intellectual property from third parties that are important or necessary to the development of our products,
including the software modules that we expect to integrate into the Nanox.CLOUD. These and other licenses may not provide exclusive
rights to use such intellectual property in all relevant fields of use and in all territories in which we may wish to develop or
commercialize our products and the underlying patents may fail to provide the intended exclusivity. As a result, we may not be
able to prevent competitors from developing and commercializing competitive products in the markets that we hope to address. Moreover,
we would not own at least some of the underlying intellectual property rights related to these products, and as a result our rights
would be subject to the continuation and compliance with the terms of those agreements. If such in-licenses were terminated, competitors
would have the freedom to develop, seek regulatory approval of, and to market, products similar or identical to ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, these license agreements may
not grant us the right to control the preparation, filing, prosecution or maintenance of patents and patent applications covering
our products. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted or
maintained in a manner consistent with the best interests of our business. If our current or future licensing partners fail to
file, prosecute or maintain such patents, including the payment of applicable fees, or otherwise lose rights to those patents or
patent applications, the intellectual property we have licensed or exclusivity we have been granted may be reduced or eliminated,
and our right to develop and commercialize any of our future products that are subject of such licensed rights, and our ability
to prevent competitors from developing or commercializing such products, could be adversely affected. In addition, even where we
have the right to control patent prosecution and maintenance of patents and patent applications we have licensed from third parties,
we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that
took place prior to the date upon which we assumed control over patent prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the terms of such license agreements,
the licensors may also have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity
or unenforceability of these patents. Even if we are permitted to pursue the enforcement or defense of our licensed patents, we
may require the cooperation of our future licensors or collaboration partners and any other applicable patent owners and we cannot
be certain that such cooperation will be provided to us. We also cannot be certain that our licensors will allocate sufficient
resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed
patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent
us from continuing to license intellectual property that we may need to operate our business. If we lose any of our licensed intellectual
property, our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, our future licensors may rely
on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive
owners of the patents we in-license. If other third parties have ownership rights to our in-licensed patents, they may be able
to license such patents to our competitors, and our competitors could market competing products and technologies. In addition,
if our licensors have not obtained adequate rights from these third parties, we may need to obtain additional rights from these
third parties or we could be prevented from developing and commercializing the related products. This could have a material adverse
effect on our competitive position, business, financial conditions, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In spite of our best efforts, our licensors
might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, in
which event we may have to cease developing, manufacturing or marketing any product covered by these agreements and we may face
other additional penalties or be required to grant our licensors additional rights. In addition, we may seek to obtain additional
licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner
that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including
our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. Any of
these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We may be required to pay certain
milestones and royalties and fulfill other obligations under our license agreements with third-party licensors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may be required to pay milestones and
royalties related to our development or commercialization activities of our products utilizing the technologies licensed or sublicensed
from third parties under license agreements we may enter into with them. These payments could adversely affect our overall profitability
related to any future products that we may seek to develop or commercialize. In order to maintain our license rights under our
license agreements, we may need to meet certain specified milestones or fulfill certain obligations, including to devote a certain
amount of resources, in the development of our products. Failure to satisfy such obligations could result in the termination of
our rights under such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>If we choose to license our technology
to third parties, this could result in disputes or otherwise limit our future operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may also in the future, as one of our
strategies, deploy our technology into the market and license patents and other intellectual proprietary rights to third parties.
Disputes with our licensees may arise, including regarding the scope and content of these licenses. Additionally, a licensee may
use our intellectual property without our permission, dispute our ownership of certain intellectual property rights or argue that
our intellectual property does not cover our product. Regardless of whether we pursue legal action to enforce any such dispute,
a dispute with a licensee or customer over intellectual property rights may damage our relationship with that licensee or customer
and may also harm our reputation in the industry. Our ability to expand into additional fields with our technologies also may be
restricted by licenses or other rights we may grant to third parties in the future, including if the licenses are exclusive, the
licensee is assigned ownership of intellectual property that we develop or rights of first negotiation or refusal are granted.
For instance, pursuant to the Right of First Negotiation Agreement with FUJIFILM Corporation, dated May&nbsp;21, 2019, we granted
FUJIFILM Corporation a right of first negotiation to obtain an exclusive license to certain of our intellectual property for use
in the field of mammography. See &ldquo;Item 4. Information on the Company&mdash;B. Business Overview&mdash;Our Business Model&mdash;The
Licensing Model&rdquo; for a description of the terms of such agreement. If we choose to use this intellectual property in the
field of mammography in the future, our ability would be limited by these rights and any related rights granted in the future to
FUJIFILM Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Government Regulation</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our product candidates and operations
are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to comply with
applicable requirements could harm our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect the Nanox.ARC and other future
products we develop to be regulated by the FDA as medical devices. Our product candidate is subject to extensive regulation in
the United States and elsewhere, including by the FDA and its foreign counterparts, the U.S. Department of Justice (the &ldquo;DOJ&rdquo;)
and the U.S. Department of Health and Human Services-Office of the Inspector General. The FDA and foreign
regulatory agencies regulate, among other things, with respect to medical devices: design, development and manufacturing; testing,
labeling, content and language of instructions for use and storage; clinical trials; product safety; establishment registration
and device listing; marketing, sales and distribution; pre-market clearance and approval; conformity assessment procedures; record
keeping procedures; advertising and promotion; recalls and field safety corrective actions; post-market surveillance, including
reporting of deaths or serious injuries and malfunctions that, if they were to occur, could lead to death or serious injury; post-market
approval studies; and product import and export.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The regulations our product candidate is
subject to are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our
ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales for any approved product.
Failure to comply with applicable regulations could jeopardize our ability to sell our future products, if cleared or approved,
and result in enforcement actions such as: warning or untitled letters; fines; injunctions; consent decrees; civil penalties; customer
notifications; termination of distribution; recalls or seizures of products; administrative detention of medical devices believed
to be adulterated or misbranded; delays in the introduction of products into the market; operating restrictions; total or partial
suspension of production; refusal to grant future clearances or approvals for new products, new intended uses or modifications
to our products; withdrawals or suspensions of current approvals, resulting in prohibitions on sales of our products; and in the
most serious cases, criminal prosecution or penalties. The occurrence of any of these events would have a material adverse effect
on our business, financial condition and results of operations and could result in shareholders losing their entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We may not receive, or may be delayed
in receiving, the necessary clearances or approvals for our future products, and failure to timely obtain necessary clearances
or approvals for our future products would adversely affect our ability to grow our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, before we can market
a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive
either clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (the &ldquo;FDCA&rdquo;) or approval of a pre-market
approval application (a &ldquo;PMA&rdquo;) from the FDA, unless an exemption applies. In the 510(k) clearance process, before a
device may be marketed, the FDA must determine that a proposed device is &ldquo;substantially equivalent&rdquo; to a legally-marketed
&ldquo;predicate&rdquo; device, which includes a device that has been previously cleared through the 510(k) process, a device that
was legally marketed prior to May&nbsp;28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant
to an approved PMA and later down-classified, or a 510(k)-exempt device. To be &ldquo;substantially equivalent,&rdquo; the proposed
device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate
device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate
device. Clinical data are sometimes required to support substantial equivalence. In the process of obtaining PMA approval, the
FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including,
but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required
for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Modifications to products that are approved
through a PMA application generally require FDA approval. Similarly, certain modifications made to products cleared through a 510(k)
may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy and uncertain.
The FDA&rsquo;s 510(k) clearance process usually takes from three to 12 months, but can last longer. The process of obtaining a
PMA is generally much more costly and uncertain than the 510(k) clearance process and generally takes from one to three&nbsp;years,
or even longer, from the time the application is submitted to the FDA. In addition, a PMA generally requires the performance of
one or more clinical trials. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or
failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory
clearances or approvals, they may include significant limitations on the indicated uses for the device or other restrictions or
requirements, which may limit the market for the device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, we are taking a multi-step approach to the regulatory
clearance process. As a first step, we submitted a 510(k) premarket notification for the Nanox Cart X-Ray System to an accredited Review
Organization under the Third Party Review Program in January 2020. As part of the review process, in March 2020, we received an information
request, referred to as a major deficiency letter, from the Review Organization, which among other things, required us to provide additional
data and other information to complete the application and to address certain deficiencies highlighted by the reviewer, including the
results of certain performance tests. On September&nbsp;3, 2020, we submitted our response to the Review Organization. The response included
additional data and other information to complete the application and to address certain deficiencies identified by the reviewer, including
the results of certain performance tests. On September&nbsp;10, 2020, the Review Organization requested that we include a second predicate
device in our 510(k) premarket notification. On September&nbsp;26, 2020, we submitted our revised 510(k) premarket notification to the
Review Organization, which the Review Organization subsequently recommended to the FDA for clearance on December&nbsp;28, 2020. On January&nbsp;1,
2021, we received an information request from the FDA through the Review Organization regarding our submission, which we responded to
on January&nbsp;4, 2021. On January 30, 2021, we received additional information requests from the FDA which, among other things, require
us to address certain deficiencies and questions, including requests that we provide additional support regarding the intended use of
the Nanox.ARC and the comparability of the Nanox.ARC to the predicate device. We submitted our response to these requests on March 1,
2021. On April 1, 2021, we received clearance from the FDA to market our Nanox Cart X-Ray System. We will continue to optimize and develop
features of the Nanox.ARC, and plan to submit an additional 510(k) premarket notification to the FDA with respect to the multi-source
Nanox.ARC and the Nanox.CLOUD during 2021. If cleared by the FDA, we expect to commercialize the multi-source Nanox.ARC and we may seek
alternatives for commercialization of our Nanox Cart X-Ray System. The review process may be more costly and time consuming than we expect
and we may not ultimately be successful in completing the review process and our 510(k) premarket notification may not be cleared by the
FDA in a timely manner or at all. If cleared, any modification to these systems that has not been previously cleared may require us to
submit a new 510(k) premarket notification and obtain clearance, or submit a PMA and obtain FDA approval prior to implementing the change.
Specifically, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute
a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires
every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&rsquo;s decision. The FDA
may not agree with our decisions regarding whether new clearances or approvals are necessary. We may make modifications or add additional
features in the future that we believe do not require a new 510(k) clearance or approval of a PMA. If the FDA disagrees with our determination
and requires us to submit new 510(k) notifications or PMA applications for modifications to our previously cleared products for which
we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product
until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. If the FDA requires us to go
through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, product
introductions or modifications could be delayed or canceled, which could adversely affect our ability to grow our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA can delay, limit or deny clearance
or approval of a medical device for many reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our product
candidates are safe or effective for their intended uses or are substantially equivalent to a predicate device;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the disagreement of the FDA or the applicable foreign regulatory body with the design or implementation of our clinical trials
or the interpretation of data from pre-clinical studies or clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>serious and unexpected adverse effects experienced by participants in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the manufacturing process or facilities we use may not meet applicable requirements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly
in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to sell our products in member
countries of the European Economic Area (&ldquo;EEA&rdquo;), our products must comply with the essential requirements of the EU
Medical Devices Directive (Council Directive 93/42/EEC). Compliance with these requirements is a prerequisite to be able to affix
the Conformit&eacute; Europ&eacute;ene (&ldquo;CE&rdquo;) mark to our products, without which they cannot be sold or marketed in
the EEA. To demonstrate compliance with the essential requirements we must undergo a conformity assessment procedure, which varies
according to the type of medical device and its classification. Except for low-risk medical devices (Class&nbsp;I non-sterile,
non-measuring devices), where the manufacturer can issue a European Community (&ldquo;EC&rdquo;) Declaration of Conformity based
on a self-assessment of the conformity of its products with the essential requirements of the EU Medical Devices Directive, a conformity
assessment procedure requires the intervention of an organization accredited by a member state of the EEA to conduct conformity
assessments, or a Notified Body. Depending on the relevant conformity assessment procedure, the Notified Body would typically audit
and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. The Notified
Body issues a certificate of conformity following successful completion of a conformity assessment procedure conducted in relation
to the medical device and its manufacturer and their conformity with the essential requirements. This certificate entitles the
manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a general rule, demonstration of conformity
of medical devices and their manufacturers with the essential requirements must be based, among other things, on the evaluation
of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer
must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable
risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and
that any claims made about the performance and safety of the device are supported by suitable evidence. If we fail to remain in
compliance with applicable European laws and directives, we would be unable to continue to affix the CE mark to our products, which
would prevent us from selling them within the EEA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Failure to comply with post-marketing
regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall
or withdraw a product from the market.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we receive regulatory clearance or approval
of the Nanox.ARC or other future products, we will remain subject to ongoing and pervasive regulatory requirements governing, among
other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, import, export, registration,
and listing of devices. For example, we will be required to submit periodic reports to the FDA as a condition of 510(k) clearance.
These reports include information about failures and certain adverse events associated with the device after its clearance. Failure
to submit such reports, or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following
its review of the periodic reports, the FDA might ask for additional information or initiate further investigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The regulations to which we are subject
are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue
or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have obtained the proper
regulatory clearance or approval to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign
laws and regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with
applicable regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities, which
may include any of the following sanctions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>untitled letters or warning letters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>fines, injunctions, consent decrees and civil penalties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>recalls, termination of distribution, administrative detention, or seizure of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>customer notifications or repair, replacement or refunds;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>operating restrictions or partial suspension or total shutdown of production;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>delays in or refusal to grant our requests for future clearances or approvals or foreign marketing authorizations of new products,
new intended uses, or modifications to existing products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>withdrawals or suspensions of product clearances or approvals, resulting in prohibitions on sales of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>criminal prosecution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these sanctions could result in higher
than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the FDA or state or foreign
authorities may change their clearance and approval policies, adopt additional regulations or revise existing regulations, or take
other actions, which may prevent or delay clearance or approval of our future products under development on a timely basis. Such
policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new clearances
or approvals, increase the costs of compliance or restrict our ability to maintain any approvals we are able to obtain. For example,
the FDA has announced steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of
the FDCA. For more information, see &ldquo;&mdash;Legislative or regulatory reforms in the United States or the EU may make it
more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute
our products after clearance or approval is obtained.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our products must be manufactured
in accordance with federal, state and foreign regulations, and we could be forced to recall our devices or terminate production
if we fail to comply with these regulations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The methods used in, and the facilities
used for, the manufacture of our products must comply with the Quality System Regulation (&ldquo;QSR&rdquo;), which is a complex
regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance,
labeling, packaging, handling, storage, distribution, installation, servicing and shipping of medical devices. As manufacturers
of electron radiation-emitting products, we are also responsible for compliance with the radiological health regulations and certain
radiation safety performance standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, we are required to verify that
our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory requirements.
The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which
may include the facilities of subcontractors. Our products are also subject to similar state regulations and various laws and regulations
of foreign countries governing manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our third-party manufacturers may not take
the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. In addition,
failure to comply with applicable FDA or state or foreign requirements or later discovery of previously unknown problems with our
products or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions
or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension of
production or distribution; administrative or judicially imposed sanctions; the FDA&rsquo;s refusal to grant pending or future
clearances or approvals for our products; clinical holds; refusal to permit the import or export of our products; and criminal
prosecution of us, our suppliers or our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these actions could significantly
and negatively affect supply of our products. If any of these events occurs, our reputation could be harmed, we could be exposed
to product liability claims and we could lose customers and experience reduced sales and increased costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>The misuse or off-label use of our
products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly
investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of
which could be costly to our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Advertising and promotion of our future
products that obtains approval in the United States may be heavily scrutinized by the FDA, the DOJ, HHS, state attorneys general,
members of Congress, and the public. In addition, advertising and promotion of any future product that obtains approval outside
of the United States will be heavily scrutinized by comparable foreign regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect that, if cleared or approved, our
products, including the multi-source Nanox.ARC, will be cleared by the requisite regulatory authorities for specific indications. We
expect to train our marketing personnel and direct sales force to not promote our devices for uses outside of the FDA-approved
indications for use, known as &ldquo;off-label uses.&rdquo; We cannot, however, prevent a physician from using our devices
off-label, when in the physician&rsquo;s independent professional medical judgment he or she deems it appropriate. There may be
increased risk of injury to patients if physicians attempt to use our devices off-label. Furthermore, the use of our devices for
indications other than those approved by the FDA or approved by any foreign regulatory body may not effectively treat such
conditions, which could harm our reputation in the marketplace among healthcare providers and patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the FDA or any state or foreign regulatory
body determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify
our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition
of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or
criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other
regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label
use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties,
damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations.
We may become subject to such actions and, if we are not successful in defending against such actions, those actions may have a
material adverse effect on our business, financial condition and results of operations. Equivalent laws and potential consequences
exist in foreign jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, if our products are cleared
or approved, healthcare providers may misuse our products or use improper techniques if they are not adequately trained, potentially
leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may
become subject to costly litigation by our customers or their patients. As described above, product liability claims could divert
management&rsquo;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that
may not be covered by insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0in"><B>Our products may cause or contribute
to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to
do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations.
The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of
the FDA or another governmental authority, could have a negative impact on us.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Nanox.ARC or our other future products
receive clearance or approval, we will be subject to the FDA&rsquo;s medical device reporting regulations and similar foreign regulations,
which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more
of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction
were to recur, could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the
date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we
become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event,
especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from
the use of the product. If we fail to comply with our reporting obligations, the FDA or other regulatory bodies could take action,
including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties,
revocation of our device clearance or approval, seizure of our products or delay in clearance or approval of future products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA and foreign regulatory bodies have
the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture
of a product or in the event that a product poses an unacceptable risk to health. The FDA&rsquo;s authority to require a recall
must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also
choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could
occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design
deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other
errors may occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Depending on the corrective action we take
to redress a product&rsquo;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new clearances
or approvals for the device before we may market or distribute the corrected device. Seeking such clearances or approvals may delay
our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with
our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions,
administrative penalties or civil or criminal fines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Companies are required to maintain certain
records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections
for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations,
it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement
could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales.
Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication
of our time and capital, distract management from operating our business and may harm our reputation and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our relationships with customers
and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations,
which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and
future earnings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Physicians, other healthcare providers,
and third-party payors will play a primary role with respect to any future products for which we obtain marketing approval. Our
arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws
and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute
our product. Restrictions under applicable federal and state healthcare laws and regulations include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The U.S. federal healthcare program Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either
the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made,
in whole or in part, under federal healthcare programs such as Medicare and Medicaid. Although there are a number of statutory
exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are
drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend medical devices, including
certain discounts, or engaging consultants as speakers or consultants, may be subject to scrutiny if they do not fit squarely within
the exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback
liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants. Liability may
be established without a person or entity having actual knowledge of the federal Anti-Kickback Statute or specific intent to violate
it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Due to the breadth of these laws, the
narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject,
it is possible that some of our current or future practices might be challenged under one or more of these laws, including, without
limitation, our proposed Subscription Model, and our advisory, consulting and royalty agreements with certain physicians who receive
compensation, in part, in the form of stock or stock options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The federal civil False Claims Act prohibits, among other things, any person from knowingly presenting, or causing to be presented,
a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used, a false
record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly
avoiding, decreasing, or concealing an obligation to pay money to the federal government. In recent years, several healthcare companies
have faced enforcement actions under the federal False Claims Act for, among other things, allegedly providing free product to
customers with the expectation that the customers would bill federal programs for the product or causing false claims to be submitted
because of the company&rsquo;s marketing the product for unapproved, and thus non-reimbursable, uses. False Claims Act liability
is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of
tens of thousands of dollars per false claim or statement. Healthcare companies also are subject to other federal false claims
laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health
benefit programs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The Health Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;), as amended by the Health Information
Technology for Economic and Clinical Health Act of 2009 (&ldquo;HITECH&rdquo;), imposes criminal and civil liability for knowingly
and willfully executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or
covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare
benefits, items or services. In addition, HIPAA, as amended by HITECH, and their respective implementing regulations impose obligations,
including mandatory contractual terms, on covered healthcare providers, health plans, as well as their business associates, with
respect to safeguarding the privacy, security and transmission of individually identifiable health information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The Physician Payment Sunshine Act, implemented as the Open Payments program, requires manufacturers of certain products reimbursed
by Medicare, Medicaid, or the Children&rsquo;s Health Insurance Program to track and report to the federal government payments
and transfers of value that they make to physicians and teaching hospitals, certain other healthcare professionals beginning in
2022, group purchasing organizations, and ownership interests held by physicians and their families, and provides for public disclosures
of these data. Manufacturers are required to submit annual reports to the government and failure to do so may result in civil monetary
penalties for all payments, transfers of value and ownership or investment interests not reported in an annual submission, and
may result in liability under other federal laws and regulations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Many states have adopted laws and regulations analogous to the federal laws cited above, including state anti-kickback and
false claims laws, which may apply to items or services reimbursed under Medicaid and other state programs or, in several states,
regardless of the payer. Several states have enacted legislation requiring medical device companies to, among other things, establish
marketing compliance programs; file periodic reports with the state, including reports on gifts and payments to individual health
care providers; make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities; and/or register
their sales representatives. Some states prohibit specified sales and marketing practices, including the provision of gifts, meals,
or other items to certain health care providers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Efforts to ensure that our business arrangements
with third parties will comply with applicable healthcare laws and regulations involve substantial costs. Additionally, it is possible
that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations
or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in
violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil,
criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and
Medicaid, and the curtailment or restructuring of our operations. Exclusion, suspension and debarment from government funded healthcare
programs would significantly impact our ability to commercialize, sell or distribute any product. If any of the physicians or other
providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject
to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Changes in laws or regulations relating
to data protection, or any actual or perceived failure by us to comply with such laws and regulations or our privacy policies,
could materially and adversely affect our business or could lead to government enforcement actions and significant penalties against
us, and adversely impact our operating results.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect to receive health information
and other highly sensitive or confidential information and data of patients and other third parties (e.g., healthcare providers
who refer patients for scans), which we expect to compile and analyze. Collection and use of this data might raise privacy and
data protection concerns, which could negatively impact our business. There are numerous federal, state and international laws
and regulations regarding privacy, data protection, information security, and the collection, storing, sharing, use, processing,
transfer, disclosure, and protection of personal information and other data, and the scope of such laws and regulations may change,
be subject to differing interpretations, and may be inconsistent among countries and regions we intend to operate in (e.g., the
United States, the European Union and Israel), or conflict with other laws and regulations. The regulatory framework for privacy
and data protection worldwide is, and is likely to remain for the foreseeable future, uncertain and complex, and this or other
actual or alleged obligations may be interpreted and applied in a manner that we may not anticipate or that is inconsistent from
one jurisdiction to another and may conflict with other rules or practices including ours. Further, any significant change to applicable
laws, regulations, or industry practices regarding the collection, use, retention, security, or disclosure of data, or their interpretation,
or any changes regarding the manner in which the consent of relevant users for the collection, use, retention, or disclosure of
such data must be obtained, could increase our costs and require us to modify our services and candidate products, possibly in
a material manner, which we may be unable to complete, and may limit our ability to store and process patients&rsquo; data or develop
new services and features.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In particular, we will be subject to U.S. data
protection laws and regulations (i.e., laws and regulations that address privacy and data security) at both the federal and state levels.
The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus
on privacy and data security issues. Numerous federal and state laws, including state data breach notification laws, state health information
privacy laws, and federal and state consumer protection laws, govern the collection, use, and disclosure of health-related and other personal
information. Failure to comply with such laws and regulations could result in government enforcement actions and create liability for
us (including the imposition of significant civil or criminal penalties), private litigation and/or adverse publicity that could negatively
affect our business. For instance, California enacted the California Consumer Privacy Act (&ldquo;CCPA&rdquo;) on June&nbsp;28, 2018,
which took effect on January&nbsp;1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy
and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as
a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights
Act (&ldquo;CPRA&rdquo;), recently passed in California. The CPRA will impose additional data protection obligations on covered businesses,
including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for
certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations
and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January
1, 2023, and additional compliance investment and potential business process changes may be required. The CCPA and the CPRA may increase
our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we expect to obtain health
information that is subject to privacy and security requirements under HITECH and its implementing regulations. The Privacy Standards
and Security Standards under HIPAA establish a set of standards for the protection of individually identifiable health information
by health plans, health care clearinghouses and certain health care providers, referred to as Covered Entities, and the business
associates with whom Covered Entities enter into service relationships pursuant to which individually identifiable health information
may be exchanged. Notably, whereas HIPAA previously directly regulated only Covered Entities, HITECH makes certain of HIPAA&rsquo;s
privacy and security standards also directly applicable to Covered Entities&rsquo; business associates. As a result, both Covered
Entities and business associates are now subject to significant civil and criminal penalties for failure to comply with Privacy
Standards and Security Standards. As part of our normal operations, we expect to collect, process and retain personal identifying
information regarding patients, including as a business associate of Covered Entities, so we expect to be subject to HIPAA, including
changes implemented through HITECH, and we could be subject to criminal penalties if we knowingly obtain or disclose individually
identifiable health information in a manner that is not authorized or permitted by HIPAA. A data breach affecting sensitive personal
information, including health information, also could result in significant legal and financial exposure and reputational damages
that could potentially have an adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">HIPAA requires Covered Entities (like many
of our potential customers) and business associates, like us, to develop and maintain policies and procedures with respect to protected
health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect
such information. HITECH expands the notification requirement for breaches of patient-identifiable health information, restricts
certain disclosures and sales of patient-identifiable health information and provides for civil monetary penalties for HIPAA violations.
HITECH also increased the civil and criminal penalties that may be imposed against Covered Entities and business associates and
gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA
and its implementing regulations and seek attorney&rsquo;s fees and costs associated with pursuing federal civil actions. Additionally,
certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent or broader
in scope than HIPAA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Internationally, many jurisdictions have
or are considering enacting privacy or data protection laws or regulations relating to the collection, use, storage, transfer,
disclosure and/or other processing of personal data, as well as certification requirements for the hosting of health data specifically.
Such laws and regulations may include data hosting, data residency or data localization requirements (which generally require that
certain types of data collected within a certain country be stored and processed within that country), data export restrictions,
international transfer laws (which prohibit or impose conditions upon the transfer of such data from one country to another), or
may require companies to implement privacy or data protection and security policies, enable users to access, correct and delete
personal data stored or maintained by such companies, inform individuals of security breaches that affect their personal data or
obtain individuals&rsquo; consent to use their personal data. For example, European legislators adopted the European Union&rsquo;s
General Data Protection Regulation (2016/679) (&ldquo;GDPR&rdquo;), which became effective on May&nbsp;25, 2018, and are now in
the process of finalizing the ePrivacy Regulation to replace the European ePrivacy Directive (Directive 2002/58/EC as amended by
Directive 2009/136/EC). The GDPR, supplemented by national laws and further implemented through binding guidance from the European
Data Protection Board, imposes more stringent European Union data protection requirements and provides for significant penalties
for noncompliance. Further, following the United Kingdom&rsquo;s withdrawal from the European Economic Area and the European Union,
and the expiry of the transition period, companies have to comply with both the GDPR and the GDPR as incorporated into United Kingdom
national law, the latter regime having the ability to separately fine up to the greater of &pound;17.5 million or 4% of global
turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection
law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which may expose us to
further compliance risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Virtually every jurisdiction in which we
expect to operate has established its own data security and privacy legal framework with which we must, and our target customers
will need to, comply, including the rules and regulation mentioned above. We may also need to comply with varying and possibly
conflicting privacy laws and regulations in other jurisdictions. As a result, we could face regulatory actions, including significant
fines or penalties, adverse publicity and possible loss of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While we are preparing to implement various
measures intended to enable us to comply with applicable privacy or data protection laws, regulations and contractual obligations,
these measures may not always be effective and do not guarantee compliance. Any failure or perceived failure by us to comply with
our contractual or legal obligations or regulatory requirements relating to privacy, data protection, or information security may
result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer advocacy
groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and
otherwise materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens
imposed by, the laws, regulations, and policies that are applicable to the businesses of our customers or partners may limit the
adoption and use of, and reduce the overall demand for, our products and services. Additionally, if third parties we work with
violate applicable laws, regulations, or agreements, such violations may put the data we have received at risk, could result in
governmental investigations or enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy
groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and
otherwise materially and adversely affect our reputation and business. Further, public scrutiny of, or complaints about, technology
companies or their data handling or data protection practices, even if unrelated to our business, industry or operations, may lead
to increased scrutiny of technology companies, including us, and may cause government agencies to enact additional regulatory requirements,
or to modify their enforcement or investigation activities, which may increase our costs and risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>If we do not obtain and maintain
international regulatory registrations, clearances or approvals for our products, we will be unable to market and sell our products
outside of the United States.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sales of our products outside of the United
States are subject to foreign regulatory requirements that vary widely from country to country. Approval procedures vary among
countries and can involve additional testing. The time required to obtain approval outside of the United States may differ substantially
from that required to obtain FDA approval. In addition, the FDA regulates exports of medical devices from the United States. While
the regulations of some countries may not impose barriers to marketing and selling our products or only require notification, others
require that we obtain the clearance or approval of a specified regulatory body. Complying with foreign regulatory requirements,
including obtaining registrations, clearances or approvals, can be expensive and time-consuming, and we may not receive regulatory
clearances or approvals in each country in which we plan to market our products or we may be unable to do so on a timely basis.
The time required to obtain registrations, clearances or approvals, if required by other countries, may be longer than that required
for FDA clearance or approval, and requirements for such registrations, clearances or approvals may significantly differ from FDA
requirements. If we modify our products, we may need to apply for additional regulatory clearances or approvals before we are permitted
to sell the modified product. In addition, we may not continue to meet the quality and safety standards required to maintain the
authorizations that we have received. If we are unable to maintain our authorizations in a particular country, we will no longer
be able to sell the applicable product in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regulatory clearance or approval by the
FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, and registration, clearance
or approval by one or more foreign regulatory authorities does not ensure registration, clearance or approval by regulatory authorities
in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance or approval
in one country may have a negative effect on the regulatory process in others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Legislative or regulatory reforms
in the United States or the EU may make it more difficult and costly for us to obtain regulatory clearances or approvals for our
products or to manufacture, market or distribute our products after clearance or approval is obtained.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, legislation is drafted
and introduced in Congress that could significantly change the statutory provisions governing the regulation of medical devices.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations,
or take other actions, which may prevent or delay approval or clearance of our future products under development or impact our
ability to modify our currently cleared products on a timely basis. Over the last several years, the FDA has proposed reforms to
its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period,
or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November
2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under
Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing
the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices
that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared
on the basis of demonstrated substantial equivalence to predicate devices that are more than 10&nbsp;years old. In May 2019, the
FDA solicited public feedback on these proposals. The FDA requested public feedback on whether it should consider certain actions
that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k)
clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such
proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional
regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance, or
restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">More recently, in September 2019, the FDA
finalized guidance describing an optional &ldquo;safety and performance based&rdquo; premarket review pathway for manufacturers
of &ldquo;certain, well-understood device types&rdquo; to demonstrate substantial equivalence under the 510(k) clearance pathway
by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need,
in the case of applicable products, for manufacturers to compare the safety and performance of their medical devices to specific
predicate devices in the clearance process. The FDA intends to develop and maintain a list device types appropriate for the &ldquo;safety
and performance based&rdquo; pathway and will continue to develop product-specific guidance documents that identify the performance
criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible. The FDA
may establish performance criteria for classes of devices for which we or our competitors seek or currently have received clearance,
and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain new 510(k)
clearances or otherwise create competition that may negatively affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, FDA regulations and guidance
are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new statutes,
regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any
future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute our products.
We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted
or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to
obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional
record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA&rsquo;s and other regulatory authorities&rsquo;
policies may change and additional government regulations may be promulgated that could prevent, limit or delay regulatory clearance
or approval of our future products. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance,
we may lose any marketing approval or clearance that we may have obtained and we may not achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April&nbsp;5, 2017, the European Parliament
passed the Medical Devices Regulation (Regulation 2017/745), which repeals and replaces the EU Medical Devices Directive. Unlike
directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable,
i.e., without the need for adoption of EEA member state laws implementing them, in all EEA member states and are intended to eliminate
current differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation, among other things,
is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices
and ensure a high level of safety and health while supporting innovation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Medical Devices Regulation will, however,
only become applicable three years after publication (in 2020). Once applicable, the new regulations will, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>strengthen the rules on placing devices on the market and reinforce surveillance once they are available;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>establish explicit provisions on manufacturers&rsquo; responsibilities for follow-up regarding the quality, performance and
safety of devices placed on the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification
number;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products
available in the EU; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>strengthened rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts
before they are placed on the market.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These modifications may have an effect on
the way we conduct our business in the EEA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Healthcare reform laws could adversely
affect our products and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the past several years, the U.S.
healthcare industry has been subject to an increase in governmental regulation at both the federal and state levels. Efforts to
control healthcare costs, including limiting access to care, alternative delivery models and changes in the methods used to determine
reimbursement scenarios and rates, are ongoing at the federal and state government levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2010, former President Obama signed
into law the Patient Protection and Affordable Care Act, and the Health Care and Education Reconciliation Act of 2010 (collectively,
the &ldquo;ACA&rdquo;), which included measures that significantly changed the way healthcare is financed by both governmental
and private insurers. While a primary goal of these healthcare reform efforts was to expand coverage to more individuals, it also
involved additional regulatory mandates and other measures designed to constrain medical costs. The ACA significantly impacts the
medical device industry. Among other things, the ACA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Imposes an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United
States, which, through a series of legislative amendments, was suspended, effective January&nbsp;1, 2016 and subsequently repealed
altogether on December&nbsp;20, 2019;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Establishes a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness
research in an effort to coordinate and develop such research; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Implements Medicare payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians
and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment
models.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the ACA and related healthcare
reform laws, regulations and initiatives have significantly increased regulation of managed care plans and decreased reimbursement
under Medicare managed care. Moreover, to alleviate budget shortfalls, states have reduced or frozen payments to Medicaid managed
care plans. We cannot accurately predict the complete impact of these healthcare reform initiatives, but they could lead to a decreased
demand for medical devices and other outcomes that could adversely impact our business and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some of the provisions of the ACA have yet
to be fully implemented, and certain provisions have been subject to judicial and Congressional challenges. In addition, there
have been efforts by the Trump administration to repeal or replace certain aspects of the ACA and to alter the implementation of
the ACA and related laws. For example, the Tax Cuts and Jobs Act enacted on December&nbsp;22, 2017, or TCJA, eliminated the shared
responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue
Code of 1986, commonly referred to as the &ldquo;individual mandate,&rdquo; effective January&nbsp;1, 2019. On December&nbsp;14,
2018, a U.S.&nbsp;District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual
mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs
Act, the remaining provisions of the ACA are invalid as well. This decision was subsequently appealed, and on December&nbsp;18,
2019, the U.S. Court of Appeals for the Fifth Circuit affirmed the decision of the district court that the individual mandate,
as amended by the TCJA, was unconstitutional. The Fifth Circuit remanded the case to the district court to consider a remedy, including
to consider and explain which provisions of the ACA are inseverable and invalid. The U.S. Supreme Court is currently reviewing
the case. A decision is expected during the current Supreme Court term in 2021, and the ACA remains in effect while judicial review
of the decision is pending. It is unclear how this litigation, including all future hearings and appeals, and other efforts to
challenge, repeal or replace the ACA, or portions thereof, will affect our future products or our business. It is possible that
the ACA, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in
the future, could have an adverse effect on our industry generally and on our ability to commercialize our future products and
achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Disruptions at the FDA and other
government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy
key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or
commercialized in a timely manner or at all, which could negatively impact our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ability of the FDA to review and clear
or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory,
and policy changes, the FDA&rsquo;s ability to hire and retain key personnel and accept the payment of user fees, and other events
that may otherwise affect the FDA&rsquo;s ability to perform routine functions. Average review times at the FDA have fluctuated
in recent years as a result. In addition, government funding of other government agencies that fund research and development activities
is subject to the political process, which is inherently fluid and unpredictable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Disruptions at the FDA and other agencies
may also slow the time necessary for new medical devices or modifications to cleared or approved medical devices to be reviewed
and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several
years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory
agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Separately, in response to the COVID-19
pandemic, on March&nbsp;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities,
and on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities.
Subsequently, on July&nbsp;10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing
facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify
the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections
to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or
other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns
continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory
activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our
regulatory submissions, which could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Employee Matters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Under applicable employment laws,
we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from
the expertise of some of our former employees.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our employment agreements generally include
covenants not to compete. These agreements prohibit our employees, if they cease working for us, from competing directly with us
or working for our competitors for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions
in which our employees work at all or for a sufficient duration of time to prevent members of our management team from competing
with us. For example, Israeli courts have required employers seeking to enforce covenants not to compete to demonstrate that the
competitive activities of a former employee will harm one of a limited number of material interests of the employer, such as the
secrecy of a company&rsquo;s confidential commercial information or the protection of its intellectual property. In Israel, if
we cannot demonstrate that such an interest will be harmed, we may be unable to prevent our competitors from benefiting from the
expertise of our former employees or consultants and our competitiveness may be diminished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We may not be able to attract and
retain the highly skilled employees we need to support our planned growth.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To continue to execute our business and
our growth plan, we must attract and retain highly qualified personnel. Competition for these personnel is intense. We may not
be successful in attracting and retaining qualified personnel. If we fail to attract new personnel or fail to retain and motivate
our current personnel, our business, financial condition, results of operations and future growth prospects could be severely harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Owning Our Ordinary
Shares</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our share price may be volatile,
and you may lose all or part of your investment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market price for our shares may be volatile
and subject to wide fluctuations in response to factors including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>actual or anticipated fluctuations in results of operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>actual or anticipated changes in our growth rate relative to our competitors, as well as announcements by us or our competitors
of significant business developments, changes in relationships with our target customers, manufacturers or suppliers, acquisitions
or expansion plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public,
as well as variance in our financial performance from the expectations of market analysts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>issuance of new or updated research reports or short reports by securities analysts or other market participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>additions or departures of key management or other personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our involvement in litigation, including the securities class-action;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain
patent protection for our technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>announcement or expectation of additional debt or equity financing efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>sales of our ordinary shares or other securities by us, our insiders or our other shareholders, or the perception that these
sales may occur in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the trading volume of our ordinary shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>market conditions in our industry;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>changes in the estimation of the future size and growth rate of our markets; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>general economic, market or political conditions in the United States or elsewhere.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In particular, the market prices of pre-commercial-stage
companies like ours have been highly volatile due to factors, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to develop and commercialize our technology and future products or services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>developments or disputes concerning our product&rsquo;s intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our or our competitors&rsquo; technological innovations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>fluctuations in the valuation of companies perceived by investors to be comparable to us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital
commitments, new technologies or patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>failure to complete significant transactions or collaborate with vendors in manufacturing our product; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>proposals for legislation that would place restrictions on the price of medical therapies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These and other market and industry factors
may cause the market price and demand for our ordinary shares to fluctuate substantially, regardless of our actual operating performance,
which may limit or prevent investors from readily selling their ordinary shares and may otherwise negatively affect the liquidity
of our ordinary shares. In addition, the stock market in general, and Nasdaq Global Market and emerging growth companies in particular,
have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance
of these companies. Such broad market fluctuations, and other factors (such as variations in quarterly and yearly operating results,
general trends in the medical imaging industry, and changes in state, federal or other applicable regulations affecting us and
our industry) may adversely affect the market price of our ordinary shares, if a market for them develops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the past, when the market price of shares
has been volatile, holders of those shares have instituted securities class action litigation against the company that issued the
shares. If any of our shareholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a
lawsuit could also divert resources and the time and attention of our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We are an &ldquo;emerging growth
company&rdquo; under the JOBS Act and we cannot be certain if the reduced disclosure requirements applicable to emerging growth
companies will make our ordinary shares less attractive to investors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an &ldquo;emerging growth company,&rdquo;
as defined in the JOBS Act, and for so long as we continue to be an &ldquo;emerging growth company&rdquo; we may take advantage
of certain exemptions from various reporting requirements that are applicable to other public companies that are not &ldquo;emerging
growth companies&rdquo; including, but not limited to, not being required to comply with the auditor attestation requirements of
section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports
and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and
shareholder approval of any golden parachute payments not previously approved. In addition, under the JOBS Act, emerging growth
companies can delay adopting new or revised financial accounting standards until such time as those standards apply to private
companies. We have elected to &ldquo;opt out&rdquo; of this provision and, as a result, we will comply with new or revised accounting
standards as required when they are adopted for public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our status as an &ldquo;emerging
growth company&rdquo; under the JOBS Act may make it more difficult to raise capital as and when we need it.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because of the exemptions from various reporting
requirements provided to us as an &ldquo;emerging growth company,&rdquo; we may be less attractive to investors and it may be difficult
for us to raise additional capital as and when we need it. Investors may be unable to compare our business with other companies
in our industry if they believe that our reporting is not as transparent as the reporting of other companies in our industry. If
we are unable to raise additional capital as and when we need it, our financial condition and results of operations may be materially
and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will remain an emerging growth company
until the earliest of: (i)&nbsp;the last day of our fiscal year during which we have total annual gross revenue of at least $1.07&nbsp;billion;
(ii)&nbsp;December 31, 2025; (iii)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion
in non-convertible debt; or (iv)&nbsp;the date on which we are deemed to be a &ldquo;large accelerated filer&rdquo; under the Exchange
Act. Once we cease to be an emerging growth company, we will not be entitled to the exemptions provided to emerging growth companies
under the JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>As a foreign private issuer, we
are exempt from certain requirements that apply to domestic issuers and we are permitted to follow certain home country corporate
governance practices instead of applicable SEC and Nasdaq requirements, which may result in less protection than is accorded to
shareholders under rules applicable to domestic issuers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We report under the Exchange Act as a non-U.S.
company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act, we are exempt
from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (1) the sections of
the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the
Exchange Act, (2) the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading
activities and liability for insiders who profit from trades made in a short period of time and (3) the rules under the Exchange
Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information,
although we intend to furnish comparable quarterly information on Form 6-K. In addition, foreign private issuers are not required
to file their annual report on Form 20-F until 120 days after the end of each fiscal year, while U.S. domestic issuers that are
accelerated filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year and U.S.
domestic issuers that are large accelerated filers are required to file their annual report on Form 10-K within 60 days after the
end of each fiscal year. Foreign private issuers are also exempt from Regulation FD, which is intended to prevent issuers from
making selective disclosures of material information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, as a foreign private issuer,
we will be permitted to follow certain home country corporate governance practices instead of those otherwise required under the
listing rules of the Nasdaq Stock Market for domestic issuers. For instance, we may follow home country practice in Israel with
regard to, among other things, composition of the board of directors, director nomination procedure, approval of compensation of
officers, and quorum at shareholder meetings. For example, under Israeli law, as currently applicable to us, there is no requirement
for a majority of our directors to be independent. In addition, we may follow our home country law, instead of the listing rules
of the Nasdaq Stock Market, which require that we obtain shareholder approval for certain dilutive events, such as for the establishment
or amendment of certain equity based compensation plans, an issuance that will result in a change of control of the company, certain
transactions other than a public offering involving issuances of a 20% or more interest in the company and certain acquisitions
of the stock or assets of another company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result of all of the above, you may
not have the same protections afforded to shareholders of a company that is not a foreign private issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We may lose our foreign private
issuer status which would then require us to comply with the Exchange Act&rsquo;s domestic reporting regime and cause us to incur
significant legal, accounting and other expenses.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As discussed above, we are a foreign private
issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the
Exchange Act applicable to U.S. domestic issuers. We will remain a foreign private issuer until our board determines that we no
longer meet the qualification set forth in Securities Act Rule 405 and Exchange Act Rule 3b-4, with such determinations to be made
on an annual basis as of the end of our second fiscal quarter. In order to maintain our current status as a foreign private issuer,
either (a) a majority of our ordinary shares must be either directly or indirectly owned of record by non-residents of the United
States or (b)(i)&nbsp;a majority of our executive officers or directors must not be U.S. citizens or residents, (ii)&nbsp;more
than 50 percent of our assets cannot be located in the United States and (iii)&nbsp;our business must be administered principally
outside the United States. If we lose this status, we would be required to comply with the Exchange Act reporting and other requirements
applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We
may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The
regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable
to a U.S. domestic issuer may be significantly higher than the costs we would incur as a foreign private issuer. As a result, we
expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some
activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable
to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance,
and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations
could also make it more difficult for us to attract and retain qualified members of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We have not paid dividends in the
past and have no immediate plans to pay dividends.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to reinvest all of our future earnings,
to the extent we have earnings, in order to develop and commercialize our technology and products and to cover operating costs,
finance operations and to otherwise become and remain competitive. We have never declared or paid any dividends on our ordinary
shares and we do not plan to pay any cash dividends with respect to our securities in the foreseeable future. As we are a development-stage
company with limited operating history, we may not be able to generate, at any time, sufficient surplus cash that would be available
for distribution to the holders of our ordinary shares as a dividend. Therefore, you should not expect to receive cash dividends
on the ordinary shares we are offering. Consequently, investors may need to rely on sales of their ordinary shares after price
appreciation, which may never occur, as the only way to realize any future gains on their investment. In addition, the Companies
Law imposes restrictions on our ability to declare and pay dividends. See &ldquo;Item 8. Financial Information&mdash;A. Consolidated
Statements and Other Financial Information&mdash;Dividend Policy&rdquo; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We incur significant increased costs
as a result of operating as a public company that reports to the SEC and our management may be required to devote substantial time
to meet compliance obligations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a public company reporting to the SEC,
we incur significant legal, insurance, director compensation, accounting and other expenses that we did not incur as a private
company. We are subject to reporting requirements of the Exchange Act and the Sarbanes-Oxley Act, as well as rules subsequently
implemented by the SEC that impose significant requirements on public companies, including requiring establishment and maintenance
of effective disclosure and financial controls and changes in corporate governance practices. In addition, the Dodd-Frank Wall
Street Reform and Consumer Protection Act (the &ldquo;Dodd-Frank Act&rdquo;) imposes various other requirements on public companies.
There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that may increase
our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue
strain on our personnel, systems and resources. Our management and other personnel may need to devote a substantial amount of time
to these compliance initiatives. In addition, we expect these rules and regulations to make it more difficult and more expensive
for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage
or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult and expensive
for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also incur costs associated with corporate
governance requirements, including requirements under rules implemented by the SEC and the Nasdaq Global Market, and provisions
of Israeli corporate law applicable to public companies. These rules and regulations will increase our legal and financial compliance
costs, introduce costs such as investor relations and stock exchange listing fees, and make some activities more time-consuming
and costly. Our board and other personnel may need to devote a substantial amount of time to these initiatives. For example, if
required by the Companies Law, our board of directors must include at least two external directors who must be nominated within
three months of the closing of the initial public offering, and our audit committee and compensation committee must consist of
a majority of independent directors. We exceeded this three-month period. However, our shareholders approved the appointment of
two external directors during the shareholder meeting in February 2021 and as a result we are now in compliance with the Companies
Law. To the extent we are not in compliance with the Companies Law or Nasdaq Global Market rules, we may be subject to additional
costs or delisting. We are continuously evaluating and monitoring developments with respect to these rules, and we cannot estimate
the amount of additional costs we may incur or the timing of such costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As an &ldquo;emerging growth company,&rdquo;
as defined in the JOBS Act, we may take advantage of certain temporary exemptions from various reporting requirements, including,
but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act (and the rules and regulations of the SEC thereunder). When these exemptions cease to apply, we expect to incur additional
expenses and devote increased management effort toward ensuring compliance with them. We cannot estimate the amount of additional
costs we may incur as a result of being a public company or the timing of such costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to Section 404 of the Sarbanes-Oxley
Act and the related rules adopted by the SEC and the Public Company Accounting Oversight Board, starting with the second annual
report that we file with the SEC, our management will be required to report on the effectiveness of our internal control over financial
reporting. In addition, once we no longer qualify as an &ldquo;emerging growth company&rdquo; under the JOBS Act and lose the ability
to rely on the exemptions related thereto discussed above and depending on our status as per Rule 12b-2 of the Exchange Act, our
independent registered public accounting firm may also need to attest to the effectiveness of our internal control over financial
reporting under Section 404. Irrespective of compliance with Section 404, any failure of our internal controls could have a material
adverse effect on our stated results of operations and harm our reputation. As a result, we may experience higher than anticipated
operating expenses, as well as higher independent auditor fees during and after the implementation of these changes. If we are
unable to implement any of the required changes to our internal control over financial reporting effectively or efficiently or
are required to do so earlier than anticipated, it could adversely affect our operations, financial reporting and/or results of
operations and could result in an adverse opinion on internal controls from our independent auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Shares eligible for future sale
may adversely affect the market for our ordinary shares and the issuance of additional ordinary shares as a result of the exercise
of our outstanding warrants and options will dilute the percentage ownership of our other shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, certain of our shareholders
are eligible to sell all or some of their ordinary shares by means of ordinary brokerage transactions in the open market pursuant
to Rule 144, promulgated under the Securities Act, subject to certain limitations. In general, pursuant to Rule 144, non-affiliate
shareholders may sell freely after six&nbsp;months subject only to the current public information requirement (which disappears
after one year). Of the 47,378,183 ordinary shares outstanding as of March 20, 2021, approximately 33,546,098 ordinary shares have
been registered under the Securities Act and are freely transferable by persons other than our &ldquo;affiliates&rdquo; without
restriction or additional registration; the remaining shares outstanding have not been registered under the Securities Act and
may be offered or sold only pursuant to an effective registration statement or pursuant to an available exemption from the registration
requirements. As of March 20, 2021, approximately 4,585,726 of our ordinary&nbsp;shares are held by &ldquo;non-affiliates&rdquo;
and are freely tradable without restriction pursuant to Rule 144, although the shareholders who participated in our secondary offering
consummated in February 2021 are subject to the lock-up agreements entered into in connection with such offering. In addition,
certain shareholders have the ability to cause us to register the resale of their shares under the Registration Rights Agreement
(as defined below) or the terms of certain warrants. See &ldquo;Item 10. Additional Information&mdash;C. Material Contracts&rdquo;
for a description of the registration rights. Any substantial sale of our ordinary shares pursuant to Rule 144 or pursuant to any
resale prospectus may have a material adverse effect on the market price of our ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, as of March 20, 2021, there were 13
outstanding warrants to purchase a total of 2,838,496 ordinary shares with exercise prices ranging from $0.01 per share to $20.87 per
share. As of December 31, 2020, there were 4,689,800 ordinary shares issuable upon the exercise of options to purchase ordinary shares
outstanding under our 2019 Equity Incentive Plan (as defined below), at a weighted average exercise price of $5.73 per share, and 2,978,247
additional ordinary shares reserved for future issuance under our 2019 Equity Incentive Plan. The warrants are exercisable immediately
and expire on various dates. More convertible securities may be granted in the future to the Company&rsquo;s officers, directors, employees
or consultants or as part of future financings. The exercise of outstanding stock options and warrants and conversion of notes and debentures
will dilute the percentage ownership of the Company&rsquo;s other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>The purchase price of the ordinary
shares may not reflect our actual value.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The price of our ordinary shares may not
be indicative of our actual value or any future market price for our securities. This price may not accurately reflect the value
of the ordinary shares or the value that potential investors will realize upon their disposition of ordinary shares. The price
does not necessarily bear any relationship to our assets, earnings, book value per share or other generally accepted criteria of
value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If equity research analysts discontinue
research or reports about us or our business or if they issue unfavorable commentary or downgrade our ordinary shares, or if other
market participants such as short sellers issue unfavorable reports about us, the price of our ordinary shares could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The trading market for our ordinary shares
relies in part on the research and reports that equity research analysts publish about us and our business. The analysts&rsquo;
estimates are based upon their own opinions and are often different from our estimates or expectations. If our results of operations
are below the estimates or expectations of public market analysts and investors, the price of our ordinary shares could decline.
Moreover, the price of our ordinary shares could decline if one or more securities analysts downgrade our ordinary shares or if
those analysts issue other unfavorable commentary or cease publishing reports about us or our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We have identified material weaknesses
in our internal control over financial reporting that could, if not remediated, result in material misstatements in our financial
statements. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately
report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public
reporting, which would harm our business and the trading price of our ordinary shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective internal controls over financial
reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures
are designed to prevent fraud. Our management will be required to assess the effectiveness of our internal controls and procedures
and disclose changes in these controls on an annual basis. However, for as long as we are an &ldquo;emerging growth company&rdquo;
under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our
internal controls over financial reporting pursuant to Section 404.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any failure to implement required new or
improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations.
In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered
public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material
weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further
attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information,
which could have a negative effect on the trading price of our ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have identified a material weakness in
our internal control over financial reporting in connection with the audit of our financial statements as of and for the years
ended December&nbsp;31, 2019 and 2020. As defined in Regulation&nbsp;12b-2 under the Exchange Act, a &ldquo;material weakness&rdquo;
is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of our annual financial statements will not be prevented, or detected on a timely basis.
Specifically, we determined that the material weakness is related to having an insufficient number of financial reporting personnel
with an appropriate level of knowledge, experience and training in application of U.S. GAAP and SEC rules and regulations commensurate
with our reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have taken action toward remediating this material
weakness by hiring additional qualified personnel with U.S. GAAP accounting and reporting experience in order to improve our ability to
have effective internal control over financial reporting, and we intend to provide enhanced training to existing financial and accounting
employees on related U.S. GAAP issues. In addition, to remediate this material weakness, we are implementing measures including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>we have hired a corporate controller with U.S. GAAP and SEC reporting experience, an internal auditor (part-time) and a financial
planning and analysis professional and are continuing to seek additional financial professionals to increase the number of qualified
financial reporting personnel and to strengthen our finance department;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>we are selecting and implementing a new enterprise resource planning system;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>we are developing, communicating and implementing an accounting policy manual for our financial reporting personnel for recurring
transactions and period-end closing processes; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>we are establishing monitoring and oversight controls for non-recurring and complex transactions to ensure the accuracy and
completeness of our consolidated financial statements and related disclosures.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">However, the material weakness will not be considered
remediated until our applicable controls will have been implemented and operating for a sufficient period of time and our management,
including the Chief Financial Officer and Chief Executive Officer, have assessed and concluded, through testing, that these controls are
operating effectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These controls and other procedures are designed
to ensure that information required to be disclosed by us in the reports that we file with the SEC is disclosed accurately and is recorded,
processed, summarized and reported within the time periods specified in SEC rules and forms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even if we develop effective internal control over
financial reporting, these controls may become inadequate because of changes in conditions or the degree of compliance with these policies
or procedures may deteriorate, and material weaknesses and deficiencies may be discovered in them. We are working with our legal and financial
advisors to identify those areas in which changes should be made to our financial and management control systems to manage our growth
and our obligations as a public company. These areas include corporate governance, corporate control, disclosure controls and procedures
and financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have made, and will continue to make,
changes in these and other areas. In any event, the process of determining whether our existing internal controls are compliant
with Section 404 and sufficiently effective will require the investment of substantial time and resources, including by our chief
financial officer and other members of our senior management. As a result, this process may divert internal resources and take
a significant amount of time and effort to complete, even more so after we are no longer an &ldquo;Emerging Growth Company.&rdquo;
In addition, we cannot predict the outcome of this process and whether we will need to implement remedial actions in order to implement
effective controls over financial reporting. The determination of whether or not our internal controls are sufficient and any remedial
actions required could result in us incurring additional costs that we did not anticipate, including the hiring of outside consultants.
We may also fail to complete our evaluation, testing and any required remediation needed to comply with Section 404 in a timely
fashion. Irrespective of compliance with Section 404, any additional failure of our internal controls could have a material adverse
effect on our stated results of operations and harm our reputation. As a result, we may experience higher than anticipated operating
expenses, as well as higher independent auditor fees during and after the implementation of these changes. If we are unable to
implement any of the required changes to our internal control over financial reporting effectively or efficiently or are required
to do so earlier than anticipated, it could adversely affect our operations, financial reporting or results of operations and could
result in an adverse opinion on internal controls from our independent auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, if we are unable to certify
that our internal control over financial reporting is effective and in compliance with Section 404, we may be subject to sanctions
or investigations by regulatory authorities, such as the SEC or stock exchanges, and we could lose investor confidence in the accuracy
and completeness of our financial reports, which could hurt our business, the price of our ordinary shares and our ability to access
the capital markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>We believe that we will technically
be classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for our taxable year ended
December 31, 2020, for the current taxable year and possibly for future taxable years, which could result in adverse U.S. federal
income tax consequences to U.S. Holders of our ordinary shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A non-U.S. corporation will be a PFIC for
any taxable year if either (1) at least 75% of its gross income for such year consists of certain types of passive income; or (2)
at least 50% of the value of its assets (generally determined based on an average of the quarterly values of the assets) during
such year is attributable to assets that produce passive income or are held for the production of passive income. For this purpose,
cash and assets readily convertible into cash are categorized as passive assets and our goodwill and other unbooked intangibles
will generally be taken into account in determining our asset value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A non-U.S. corporation&rsquo;s PFIC status
is a factual determination made annually after the close of each taxable year. Prior to the commercialization of our medical imaging
technology, passive income could constitute more than 75% of gross income for any taxable year. Consequently, we believe that we
will technically be classified as a PFIC for the taxable year ended December&nbsp;31, 2020. Depending upon the composition of our
income and assets and the market price of our ordinary shares during 2021 and subsequent taxable years and whether we start generating
a substantial amount of active revenue, we could continue to be classified as a PFIC for 2021 and subsequent taxable years if we
are classified as a PFIC for 2020. In addition, it is possible that any subsidiary that we own would also be classified as a PFIC
for such taxable years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we were classified as a PFIC for any
taxable year during which a U.S. Holder (as defined below) holds our ordinary shares, certain adverse U.S. federal income tax consequences
could apply to such U.S. Holder. See &ldquo;Item 10. Additional Information&mdash;E. Taxation&mdash;U.S. Federal Income Tax Considerations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Our Operations in Israel</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Conditions in Israel could materially
and adversely affect our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our executive offices are located in Neve
Ilan, Israel. In addition, a number of our officers and directors are residents of Israel. Accordingly, political, economic and
military conditions in Israel and the surrounding region may directly affect our business and operations. Since the establishment
of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries, as well
as terrorist acts committed within Israel by hostile elements. During the last decade, there have been extended hostilities in
2009, 2012 through 2014, with additional small flare-ups as recently as 2018 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since February 2011, Egypt has experienced
political turbulence and an increase in terrorist activity in the Sinai Peninsula. Such political turbulence and violence may damage
peaceful and diplomatic relations between Israel and Egypt, and could affect the region as a whole. Similar civil unrest and political
turbulence has occurred in other countries in the region, including Syria, which shares a common border with Israel, and is affecting
the political stability of those countries. Since April 2011, internal conflict in Syria has escalated and chemical weapons have
been used in the region. Foreign actors have intervened and may continue to intervene in Syria. This instability and any intervention
may lead to deterioration of the political and economic relationships that exist between the State of Israel and some of these
countries and may lead to additional conflicts in the region. In addition, Iran has threatened to attack Israel and may be developing
nuclear weapons. Iran also has a strong influence among extremist groups in the region, including Hamas in Gaza, Hezbollah in Lebanon
and various rebel militia groups in Syria. These situations have escalated at various points in recent years and may escalate in
the future to more violent events, which may affect Israel and us. Any armed conflicts, terrorist activities or political instability
in the region could adversely affect business conditions and could harm our results of operations and could make it more difficult
for us to raise capital. In addition, the political and security situation in Israel may result in parties with whom we have agreements
involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant
to force majeure provisions in such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently do not, and we do not expect
to, carry any commercial insurance that covers losses resulting from events associated with war and terrorism. Although the Israeli
government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot
be assured that this government coverage will be maintained or, if maintained, that it will be sufficient to compensate us fully
for damages incurred and the government may cease providing such coverage or the coverage might not suffice to cover potential
damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political
instability in the region would likely negatively affect business conditions and could harm our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, in the past, the State of Israel
and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel
and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial
condition or the expansion of our business. A campaign of boycotts, divestment and sanctions has been undertaken against Israel,
which could also adversely impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, many Israeli citizens are obligated
to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age of 40 (or older
for certain reservists) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist
activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve
duty call-ups in the future. Our operations could be disrupted by such call-ups, which may include the call-up of members of our
management. Such disruption could materially adversely affect our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>The termination or reduction of
tax and other incentives that the Israeli government provides to Israeli companies may increase our costs and taxes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Israeli government currently provides
tax and capital investment incentives to Israeli companies, as well as grant and loan programs relating to research and development
and marketing and export activities (see &ldquo;Item 10. Additional Information&mdash;E. Taxation&mdash;Israeli Tax Considerations
and Government Programs&rdquo;). In recent years, the Israeli government has reduced the benefits available under these programs
and the Israeli governmental authorities may in the future further reduce or eliminate the benefits of these programs. We may take
advantage of these benefits and programs in the future; however, there can be no assurance that such benefits and programs will
be available to us. If we qualify for such benefits and programs and fail to meet the conditions thereof, the benefits could be
canceled and we could be required to refund any benefits we might already have enjoyed and become subject to penalties. Additionally,
if we qualify for such benefits and programs and they are subsequently terminated or reduced, it could have an adverse effect on
our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>It may be difficult to enforce a
U.S. judgment against us, our officers and directors named in this annual report on Form 20-F in Israel or the United States, or
to assert U.S. securities laws claims in Israel or serve process on our officers and directors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many of our directors and officers are not
residents of the United States and a significant portion of their and our assets are located outside the United States. Service
of process upon us or our non-U.S. resident directors and officers may be difficult to obtain within the United States. We have
been informed by our legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original actions
instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts
may refuse to hear a claim based on a violation of U.S. securities laws against us or our directors and officers because Israel
may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may
determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable
U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be
governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Additionally, Israeli
courts might not enforce judgments obtained in the United States against us or our directors and officers, which may make it difficult
to collect on judgments rendered against us or our directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moreover, an Israeli court will not enforce
a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts
(subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of the State of Israel, if
it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that was given in the
same matter between the same parties, or if a suit in the same matter between the same parties was pending before a court or tribunal
in Israel at the time the foreign action was brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Your rights and responsibilities
as our shareholder will be governed by Israeli law, which may differ in some respects from the rights and responsibilities of shareholders
of U.S. corporations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are incorporated under Israeli law. The
rights and responsibilities of holders of our ordinary shares are governed by our amended and restated articles of association
and the Companies Law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders
in typical U.S. corporations. In particular, pursuant to the Companies Law, each shareholder of an Israeli company has to act in
good faith and in a customary manner in exercising his or her rights and fulfilling his or her obligations toward the company and
other shareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at the
general meeting of shareholders on amendments to a company&rsquo;s articles of association, increases in a company&rsquo;s authorized
share capital, mergers and certain transactions requiring shareholders&rsquo; approval under the Companies Law. In addition, under
Israeli law, a controlling shareholder of an Israeli company or a shareholder who knows that it possesses the power to determine
the outcome of a shareholder vote or who has the power to appoint or prevent the appointment of a director or officer in the company
or has other powers toward the company has a duty of fairness toward the company. However, Israeli law does not define the substance
of this duty of fairness. There is little case law available in Israel to assist in understanding the implications of these provisions
that govern shareholder behavior.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our amended and restated articles
of association contains exclusive forum provisions for certain claims, which could limit our shareholders&rsquo; ability to obtain
a favorable judicial forum for disputes with us or our directors, officers or employees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended and restated articles of association
provides that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the
exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the &ldquo;Federal Forum
Provision&rdquo;). Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware
holding that such provisions are facially valid under Delaware law. While there can be no assurance that U.S. federal or state
courts or Israeli courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should
be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our shareholders to enforce
any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. Section
27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created
by the Exchange Act or the rules and regulations thereunder and the Federal Forum Provision does not apply to suits brought to
enforce any duty or liability created by the Exchange Act. Accordingly, actions by our shareholders to enforce any duty or liability
created by the Exchange Act or the rules and regulations thereunder must also be brought in federal court. Our shareholders will
not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any person or entity purchasing or otherwise
acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to the Federal Forum
Provision. This provision may limit our shareholders&rsquo; ability to bring a claim in a judicial forum they find favorable for
disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers
and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated
articles of association to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving
such action in other jurisdictions, which could harm our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Provisions of our amended and restated
articles of association and Israeli law and tax considerations may delay, prevent or make difficult an acquisition of us, which
could prevent a change of control and negatively affect the price of our ordinary shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Israeli corporate law regulates mergers,
requires tender offers for acquisitions of shares if such acquisitions cause the acquirer to hold more than specified thresholds,
requires special approvals for certain transactions involving directors, officers or significant shareholders and regulates other
matters that may be relevant to these types of transactions. For example, under Israeli law, a merger may not be consummated unless
at least 50 days have passed from the date that a merger proposal was filed by each merging company with the Israel Registrar of
Companies and at least 30 days have passed from the date that the shareholders of both merging companies approved the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to our shareholders, especially for those shareholders whose country of residence
for tax purposes does not have a tax treaty with Israel which exempts such shareholders from Israeli tax. For example, Israeli
tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law
allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions,
including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of
shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions,
the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has
occurred. In order to benefit from the tax deferral, a pre-ruling from the Israeli Tax Authority may be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These provisions of Israeli law and Israeli
tax laws may delay, prevent or make difficult a merger with, or an acquisition of us, or all or a significant portion of our assets,
which could prevent a change of control and may make it more difficult for a third party to acquire us, even if doing so would
be beneficial to our shareholders. These provisions may limit the price that investors may be willing to pay in the future for
our ordinary shares and therefore depress the price of our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended and restated articles of association
provide that our directors (other than external directors) are elected on a staggered basis, such that a potential acquirer cannot
readily replace our entire board of directors at a single annual general shareholder meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_005"></A>Item 4.</TD><TD><A NAME="c_001"></A>Information on the Company</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. History and
Development of the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NANO-X IMAGING LTD was incorporated under
the laws of the State of Israel on December&nbsp;20, 2018 and commenced operations on September&nbsp;3, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Substantially all of our assets at the time
of commencement of our operations were acquired or assigned (the &ldquo;Asset Purchase&rdquo;) from our predecessor company, Nanox
Imaging PLC (&ldquo;Nanox Gibraltar&rdquo;), a Gibraltar public company, under an Asset Purchase Agreement, dated as of September&nbsp;3,
2019 and as amended on December&nbsp;3, 2019 and December&nbsp;31, 2019, between Nanox Gibraltar and us. Pursuant to the Asset
Purchase Agreement, substantially all of the assets of Nanox Gibraltar, including all patents, patent applications and all other
intellectual property rights, but not including the shares of Nanox Japan, Inc., a wholly owned subsidiary of Nanox Gibraltar (&ldquo;Nanox
Japan (predecessor)&rdquo;), were sold to the Company for an aggregate consideration of $13.3 million, reflecting the fair market
value of the transferred assets, which was estimated to be $6.1 million (excluding cash) based on an independent valuation report,
plus the cash balance less $200,000, which cash amount totaled $7.2 million as of the date of the Asset Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Asset Purchase Agreement,
the consideration for the transferred assets will be paid only on the occurrence of one of the following events: (a) the closing
of a transaction involving the sale of all or substantially all of the Company&rsquo;s assets; (b) the acquisition of the Company
by, or the merger of the Company with, another entity, consolidation, reorganization, recapitalization, sale, assignment or disposal
by the Company of all or substantially all of the issued and outstanding shares of the Company; (c) the transfer, sale, lease,
grant or other disposition of or the grant of an exclusive license over all or substantially all of Company&rsquo;s assets, including,
but not limited to, intellectual property, with the same economic effect to that of a sale and/or cessation of its business; (d)
any other transaction, except for a financing round, following which the shareholders of the Company prior to the closing of such
transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity; (e) the closing of the first
underwritten public offering of the Company pursuant to a registration statement under the Securities Act or the Securities Law
(or under equivalent securities law of another jurisdiction) or any other securities laws world-wide with the same effects and
results; and (f) an equity financing of the Company at a minimum pre-money valuation of $100.0 million, with proceeds to the Company
of at least $30.0 million. In the events of (e) or (f) above, the Company will have the option to pay the consideration in cash
or by the issuance to Nanox Gibraltar of the Company&rsquo;s securities of the same series to be issued upon such event, in an
amount reflecting a 25% discount on the price per share to be determined in connection with (e) and (f) above. If the Company elects
to pay such consideration in cash, Nanox Gibraltar will have the right, at its sole discretion and in good faith, to reject such
payment in cash, and require that the Company pay such consideration in the form of the Company&rsquo;s securities in such amount
and with such discount described above. In connection with this, the Company recorded a related party liability in an amount of
$17.8 million in its financial statements as of and for the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In January 2020, the board of directors
of the Company and the board of directors and shareholders of Nanox Gibraltar approved the issuance of shares in accordance with
the terms of the Asset Purchase Agreement described above. As a result, 1,109,245 of the Company&rsquo;s ordinary shares were issued
to Nanox Gibraltar, representing an aggregate consideration of approximately $17.8 million, and the Company has no further obligations
to Nanox Gibraltar under the Asset Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located
at Communications Center, Neve Ilan, Israel 9085000, and our telephone number is +972 02 995 0506. Our website address is <U>http://www.nanox.vision</U>.
The information contained therein or connected thereto shall not be deemed to be incorporated into this annual report on Form 20-F.
Our agent for service of process in the United States is CT Corporation System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Private Placement and Public Offerings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From December 2019 through August 2020, we entered
into share purchase agreements with certain investors (together, the &ldquo;Investors&rdquo;), under which we sold an aggregate of 4,937,000
ordinary shares to the Investors, at a price per share of $16.00, for an aggregate purchase price, before fees and expenses, of approximately
$79&nbsp;million (the &ldquo;Private Placement&rdquo;). As part of the Private Placement, we sold 312,500&nbsp;ordinary shares to Foxconn
Singapore Pte Ltd. for an aggregate purchase price of approximately $5&nbsp;million, 1,250,000 ordinary shares to SK Telecom TMT Investment
Corp. (&ldquo;SKT&rdquo;) for an aggregate purchase price of $20 million, 375,000 ordinary shares to certain funds affiliated with Industrial
Alliance Investment Management Inc., a Canadian-based financial institution, for an aggregate purchase price of approximately $6 million,
and 2,512,000 ordinary shares to Yozma for an aggregate purchase price of $40.2 million, in each case before fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 25, 2020, we completed our initial
public offering of 10,555,556 ordinary shares at a public offering price of $18 per share, including 1,376,812 additional ordinary
shares purchased by the underwriters at the public offering price, less the underwriting discount, pursuant to the exercise in
full of their option to purchase additional ordinary shares. Our ordinary shares are listed on the NASDAQ Global Market under the
symbol &ldquo;NNOX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 10, 2021, certain of our shareholders
sold an aggregate of 3,091,635 ordinary shares in a public offering pursuant to an Underwriting Agreement by and among us, Cantor
Fitzgerald &amp; Co., acting as representative of the underwriters, and the selling shareholders named therein (the &ldquo;Selling
Shareholders&rdquo;). We did not receive any of the proceeds from the sale of ordinary shares offered by the Selling Shareholders.
The Selling Shareholders entered into new lock-up agreements with Cantor Fitzgerald &amp; Co. pursuant to which, subject to certain
exceptions, the Selling Shareholders agreed not to sell or otherwise dispose of ordinary shares or any securities convertible into
or exchangeable for ordinary shares for a period of 90 days after February 16, 2021 without the prior written consent of Cantor
Fitzgerald &amp; Co. In addition, the Selling Shareholders agreed not to sell or otherwise dispose of ordinary shares or any securities
convertible into or exchangeable for ordinary shares in an amount that exceeds one third of the remaining ordinary shares or any
securities convertible into or exchangeable for ordinary shares such persons hold during each of the subsequent 30-day periods
for a total of 90 days without the prior written consent of Cantor Fitzgerald &amp; Co. None of our directors and officers entered
into lockup agreements in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">B. Business Overview</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Early detection saves lives&mdash;and we
at Nanox are focused on applying our proprietary medical imaging technology to make diagnostic medicine more accessible and affordable
across the globe. Our vision is to increase early detection of medical conditions that are discoverable by X-ray, which we believe
is key to increasing early treatment, improving health outcomes and, ultimately, saving lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a first step to producing a new class
of affordable medical imaging systems, we have focused on identifying and developing a novel X-ray source. Our X-ray source is
based on a novel digital MEMs semiconductor cathode that we believe can achieve the same functionalities as legacy X-ray analog
cathodes, while allowing for lower-cost production than existing medical imaging systems. We developed this technology over eight
years to reach commercial applicability. This novel digital X-ray source is the basis of core technology in the Nanox.ARC, the
imaging system we are developing, and we believe it also has the potential to replace the legacy X-ray source in other existing
imaging systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our solution, which we refer to as the Nanox
System, has two integrated components&mdash;hardware (Nanox.ARC) and software (Nanox.CLOUD). We have developed a working prototype
of the Nanox.ARC, a medical imaging system incorporating our novel digital X-ray source. Subject to receiving regulatory clearance,
the first version of the Nanox.ARC that we expect to introduce to the market will be a 3D tomosynthesis imaging system. Tomosynthesis
is an imaging technique widely used for early detection, that is designed to produce a high-resolution, 3D X-ray image reconstruction
of the scanned human body part for review by a professional diagnostics expert. In parallel, we have developed a prototype of the
Nanox.CLOUD, a companion cloud-based software that is designed to provide an end-to-end medical imaging service, including services
such as image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic
assistive AI systems, billing and reporting. The Nanox System is designed to enable MSaaS to improve accessibility and affordability
of early-detection services worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If cleared, we plan to market and deploy
the Nanox System globally at a substantially lower cost than currently available medical imaging systems, such as CT, because our
digital X-ray source will allow the Nanox.ARC to have a simpler structure without the costly cooling equipment or the complex rotating
mechanism used in legacy CT devices. See &ldquo;&mdash;Our Technology&mdash;The Nanox System.&rdquo; We believe that the Nanox
System could increase the accessibility and affordability of early-detection medical imaging systems worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As we continue to develop the Nanox.ARC, we are taking a multi-step
approach to the regulatory clearance process. As a first step, we submitted a 510(k) premarket notification for the Nanox Cart X-Ray System
to an accredited Review Organization under the Third Party Review Program in January 2020. As part of the review process, in March 2020,
we received an information request, referred to as a major deficiency letter, from the Review Organization which, among other things,
required us to provide additional data and other information to complete the application and to address certain deficiencies highlighted
by the reviewer, including the results of certain performance tests. On September&nbsp;3, 2020, we submitted our response to the Review
Organization. The response included additional data and other information to complete the application and to address certain deficiencies
identified by the reviewer, including the results of certain performance tests. On September&nbsp;10, 2020, the Review Organization requested
that we include a second predicate device in our 510(k) premarket notification. On September&nbsp;26, 2020, we submitted our revised 510(k)
premarket notification to the Review Organization, which the Review Organization subsequently recommended to the FDA for clearance on
December 28, 2020. On January&nbsp;1, 2021, we received an information request from the FDA through the Review Organization regarding
our submission, which we responded to on January&nbsp;4, 2021. On January 30, 2021, we received additional information requests from the
FDA which, among other things, require us to address certain deficiencies and questions, including requests that we provide additional
support regarding the intended use of the Nanox.ARC and the comparability of the Nanox.ARC to the predicate device. We submitted our response
to these requests on March 1, 2021. On April 1, 2021, we received clearance from the FDA to market our Nanox Cart X-Ray System. We will
continue to optimize and develop features of the Nanox.ARC, and plan to submit an additional 510(k) premarket notification to the FDA
with respect to the multi-source Nanox.ARC and the Nanox.CLOUD during 2021. If cleared by the FDA, we expect to commercialize the multi-source
Nanox.ARC and we may seek alternatives for commercialization of our Nanox Cart X-Ray System. We believe that our novel digital X-ray source
will not require FDA approval or clearance. However, to date, we have not obtained feedback from the FDA regarding our regulatory strategy
with respect to our digital X-ray source. We first demonstrated a working prototype of the Nanox.ARC in February 2020 and, if the multi-source
Nanox.ARC is cleared by the FDA and authorized by similar regulatory agencies in other jurisdictions, we are targeting shipment of 1,000
Nanox Systems by the first quarter of 2022, with the goal to finalize deployment of the initial 15,000 Nanox Systems by the end of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Limitation of Current Medical Imaging
Systems and Our Market Opportunity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The main categories of current medical imaging
systems that use X-ray sources include CT, mammography, fluoroscopy, angiogram and dental. The analog X-ray source used by these
systems produces X-rays by accelerating electrons to high energies, causing them to hit a metal target from which the X-rays are
emitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This requires a significant amount of electrical
energy to be transferred to the X-ray tube. Due to the heat generated by this process, one of the most complex mechanical challenges
is cooling the analog X-ray source. In addition, for CTs, the mechanical structure is even more complex because the analog X-ray
source needs to rotate in a heavy gantry at high speed. We believe these are key factors leading to the high cost and complexity
of existing medical imaging systems, which in turn significantly limits the availability of medical imaging for early detection
globally. According to a report from the Pan-American Health Organization and WHO in 2012, approximately two-thirds of the world
population did not have access to medical imaging, while many people with access to medical imaging face substantial wait times
for scanning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, most market participants, including
medical imaging manufacturing companies, medical imaging providers and radiologists, among others, have not provided the same level
of end-to-end medical imaging services. One of the reasons is that the scanning process is currently not integrated with the diagnostics
process, which contributes to extended wait times for image diagnostics by experts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We estimate that the total annual capital
expenditures on existing X-ray-based medical imaging systems, not including support, maintenance, insurance and ancillary services,
will reach approximately $21&nbsp;billion by 2021, which we believe represents a significant market opportunity for the Nanox System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Solution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe the Nanox System addresses the
limitations of existing medical imaging systems on three levels:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>Digital X-ray source with the potential to significantly reduce the costs of medical imaging systems</B>. We believe our
digital X-ray source technology will allow us to manufacture the Nanox.ARC, if cleared, at substantially lower costs compared to
medical imaging systems that use a legacy analog X-ray source without sacrificing imaging quality. A lower cost device has the
potential to substantially increase medical imaging availability and improve accessibility of early-detection services broadly
across the globe.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>Technology designed to improve upon the industry standard with integrated radiology diagnostics via a cloud-based MSaaS
platform</B>. The Nanox.ARC employs our novel digital X-ray source that is designed to be energy-efficient, smaller and can be
more precisely controlled compared to existing X-ray source. By integrating the Nanox.CLOUD, we believe the Nanox System could
provide a streamlined process where each scanned image is uploaded automatically to the cloud system and matched to a human radiology
expert and decision assistive AI algorithms to provide scan reviews and diagnostics in a significantly shorter time frame than
current diagnostics, which could substantially reduce wait-times for imaging results and increase early detection rates compared
to currently employed imaging process protocols.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>Business model designed to increase the availability of medical imaging</B>. Our primary business model is based on a pay-per-scan
pricing structure as opposed to the capital expenditure-based business model currently used by medical imaging manufacturing companies.
We believe our business model will significantly reduce the price per scan compared to the current global average cost of $300
per scan, and has the potential to commoditize medical imaging services at prices that are affordable to a greater number of people.
We believe our MSaaS business model has the potential to expand the total size of the X-ray-based medical imaging market.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Strategy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">&nbsp;</TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>Secure regulatory clearance for our medical imaging system.</B> We are taking a multi-step approach
                              to the regulatory clearance process. As a first step, we submitted a 510(k) premarket notification for
                              the Nanox Cart X-Ray System to an accredited Review Organization under the Third Party Review Program in
                              January 2020. As part of the review process, in March 2020, we received an information request, referred
                              to as a major deficiency letter, from the Review Organization which, among other things, required us to
                              provide additional data and other information to complete the application and to address certain deficiencies
                              highlighted by the reviewer, including the results of certain performance tests. On September&nbsp;3, 2020,
                              we submitted our response to the Review Organization. The response included additional data and other information
                              to complete the application and to address certain deficiencies identified by the reviewer, including the
                              results of certain performance tests. On September&nbsp;10, 2020, the Review Organization requested that
                              we include a second predicate device in our 510(k) premarket notification. On September&nbsp;26, 2020,
                              we submitted our revised 510(k) premarket notification to the Review Organization, which the Review Organization
                              subsequently recommended to the FDA for clearance on December 28, 2020. On January&nbsp;1, 2021, we received
                              an information request from the FDA through the Review Organization regarding our submission, which we
                              responded to on January&nbsp;4, 2021. On January 30, 2021, we received additional information requests
                              from the FDA which, among other things, require us to address certain deficiencies and questions, including
                              requests that we provide additional support regarding the intended use of the Nanox.ARC and the comparability
                              of the Nanox.ARC to the predicate device. We submitted our response to these requests on March 1, 2021.
                              On April 1, 2021, we received clearance from the FDA to market our Nanox Cart X-Ray System. We will continue
                              to optimize and develop features of the Nanox.ARC, and plan to submit an additional 510(k) premarket notification
                              to the FDA with respect to the multi-source Nanox.ARC and the Nanox.CLOUD during 2021. If cleared by the
                              FDA, we expect to commercialize the multi-source Nanox.ARC and we may seek alternatives for commercialization
                              of our Nanox Cart X-Ray System.</TD></TR>
                                                                                                                                          </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>Jumpstart the MSaaS-based medical imaging market with strategic partnerships</B>. We plan to produce and deploy an initial
wave of approximately 15,000 Nanox.ARC units over the next three to four years to jumpstart the MSaaS-based medical imaging market.
We have entered into a contract manufacturing agreement with FITI, a subsidiary of Foxconn for the commercial production and assembly
of the Nanox.ARC and we have entered into commercial agreements with strategic regional partners for the deployment, operation
and marketing of the Nanox System broadly across the globe, including in the United States and certain countries in Asia, Europe,
Africa, Latin America and Australia. Specifically, we have entered into nine multi-year MSaaS agreements with partners for the
deployment of Nanox Systems in various regions that obligate the counterparty to obtain standby letters of credit for the amount
of the agreed minimum annual fee. See &ldquo;&mdash;Commercial Agreements&mdash;MSaaS Agreements&rdquo; and &ldquo;Item 3. Key
Information&mdash;D. Risk Factors&mdash;Risk Related to our Business&mdash;Any collaborative and MSaaS arrangements that we have
established or may establish in the future may not be successful or we may otherwise not realize the anticipated benefits from
these collaborations.&rdquo; In addition, we have entered into a collaboration agreement with USARAD for deploying and operating
the Nanox System and establishing connections with the radiologist community in the United States. We plan to work with these partners
to achieve local integrations into health maintenance organizations, electronic health record systems, payment methods and insurance
coverage companies. In addition, we have entered into collaboration agreements with AI partners and image-transfer partners and
are actively seeking collaboration opportunities, as we anticipate an industry shift to a digital and cloud-based subscription
model will bring more digital healthcare disruptors into the market. See &ldquo;&mdash;Commercial Agreements&mdash;Collaboration
Agreements&mdash;Collaboration Agreements with our AI Partners&rdquo; and &ldquo;&mdash;Collaboration Agreement with our Image-Transfer
Partner.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>Maximize the commercial potential of our technology with simultaneous business models</B>. We plan to commercialize our
novel X-ray source technology by pursuing three simultaneous business models, which we believe will provide us the flexibility
and long-term sustainability to monetize our technology.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><I>Subscription Model</I>: In certain countries, if permitted by the laws in the applicable jurisdiction, our primary sales
strategy will be based on a pay-per-scan pricing structure, where we expect to sell the Nanox System at low cost or at no cost,
with a suggested retail price per scan that is substantially lower than the current global average charge, and receive a portion
of the proceeds from each scan as the right-to-use licensing fee and fees for usage of the Nanox.CLOUD, artificial intelligence
capability and maintenance support.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><I>Sales Model</I>: In certain countries, to accommodate specific local regulatory requirements, we expect to sell the Nanox.ARC
for a one-time charge at a price that is substantially less than current market offerings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><I>Licensing Model</I>: For certain medical imaging market participants, we plan to tailor our X-ray source technology to their
specific imaging systems to replace the legacy X-ray source or to license our X-ray source technology to them to develop new types
of imaging systems. We expect to charge a one-time licensing fee upfront and receive recurring royalty payments for each system
sold.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><B>Leverage the Nanox System to bring added value to our collaborators</B>. We expect that the Nanox System will enable us
to accumulate a significant number of medical images, which have the potential to be used by collaborators, such as medical AI-analytics
companies, through machine learning algorithms to increase the probability of early disease detection.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Technology</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Legacy Analog X-ray Source and Limitations
of Existing Medical Imaging Systems</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The X-ray tube technology has essentially
remained unchanged since its inception in 1895. For any type of imaging system to generate X-rays, the system must use X-ray tubes
as a source for the X-rays. The X-ray tube converts electrical power into X-rays by accelerating electrons to high energies, causing
them to hit a metal target from which the X-rays are emitted. X-rays can only be produced if the X-ray tube is energized, which
has historically required a significant amount of electrical energy to be transferred to the X-ray tube. However, only a small
amount of the energy deposited into the X-ray tube is actually converted into X-rays; the majority of the energy turns into heat.
This is called a thermionic (heat-based) mode of operation where a metal filament needs to be heated up to approximately 2,000&deg;C
to generate the electron stream (a &ldquo;cathode&rdquo;) that will hit a metal target (an &ldquo;anode&rdquo;) to generate the
photon-based X-ray stream resulting from that high-energy impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Heating the filament to approximately 2,000&deg;C
requires the mechanical cathode support systems to withstand high temperatures within a high vacuum, high voltage environment.
Tungsten was introduced into the X-ray tube in 1903 for its properties of a high melting point and ductility. The tungsten filaments
still used today are critical components of X-ray tubes, but they limit the lifetime of the X-ray tube due to the progressive evaporation
of filament material under these high temperatures. At temperatures of up to 2,000&deg;C, the filament evaporates in a hot spot
close to the peak temperature location which over time can cause a catastrophic failure of the filament.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that the use of the legacy analog
X-ray source is one of the key factors for the high cost of existing medical imaging systems. The main categories of medical imaging
systems that use X-ray sources include CT (3D&nbsp;cross-sectional 360&deg; &ldquo;slicing&rdquo; X-ray imaging), mammography (2D
and 3D breast X-ray imaging), fluoroscopy (real-time X-ray video imaging), angiogram (blood vessels, contrast X-ray imaging) and
dental (2D and panoramic X-ray imaging). CT scanners, for example, are complex diagnostic imaging systems that use X-rays to take
pictures of a patient&rsquo;s internal structures and organs. Due to the limitations of the analog X-ray source described above,
general radiographic X-ray tubes are not well suited for use in a CT scanner. CT scanners instead use a specialized X-ray tube
designed to withstand the excessive amount of heat produced by continuous energization. This X-ray tube is located in the gantry,
which is the largest part of a CT scanner and consists of the X-ray detectors, the mechanical supports and the scanner housing.
Due to the heat generated by this process, one of the most complex mechanical challenges is cooling the analog X-ray source while
rotating it in a heavy gantry at high-speed. One solution used is the rotating anode, where a tungsten metal disk rotates at high
revolutions per minute so the electron beam hits a different spot on the disk on a continuous basis to prevent the concentration
of heat in one spot on the disk and reduce the likelihood of overheating or burning. In addition, CT scanners require a long continuous
exposure time to create 3D photographs of the patient&rsquo;s body using multiple X-ray images, which means that the X-ray tube
must be continually energized and that patients are continuously exposed to radiation throughout that period. As a result of these
complexities, most high-quality X-ray tubes for a CT scanner weigh between approximately 50 and 100 kilograms with the cooling
mechanism and generally cost over $150,000 each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Our Novel Digital X-ray Source</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Realizing that the X-ray tube technology
has essentially not changed in more than 100&nbsp;years and remains a significant source of complexity and cost-driver of existing
X-ray-based medical imaging systems, we developed a novel digital X-ray source that we believe addresses these drawbacks and will
enable a new class of medical imaging systems that can be produced at a significantly lower cost than the existing systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our technology has its roots in field emission
display (&ldquo;FED&rdquo;) technology. FED technology was originally developed by Sony with other technology partners, for television
screens and monitors, offering a novel way of lighting screen pixels compared to traditional cathode-ray tubes that were based
on a one-source electron gun beam. The field emission display innovation used multiple nano-scale electron guns to achieve a much
higher quality image with significantly reduced motion blur effects. In 2009, after having invested substantial resources in the
development of this technology for over a decade including through a joint venture called Field Emission Technologies, Inc. (&ldquo;FET&rdquo;),
Sony ceased development of the project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2009, FET dissolved and transferred certain
assets to FET Japan Inc. (&ldquo;FETJ&rdquo;). Scientists on our team, who worked at FETJ, applied their expertise to develop non-display
related applications, including our X-ray source technology. In 2011, our predecessor company acquired certain non-display related
know-how from FETJ and certain members of the FETJ technical team joined us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After acquiring the technology, we spent
over eight years developing a digital X-ray source for the medical imaging industry that could be produced on a commercial scale.
Our X-ray source is a MEMs-based semiconductor cathode that achieves electron emission by a non-thermionic low-voltage trigger
to approximately 100&nbsp;million nano-scale molybdenum cones that act as multiple electron &ldquo;guns,&rdquo; instead of a single
heated filament. The cathode is housed in a customized X-ray tube.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe our X-ray source has the following
technological advantages over the analog X-ray source:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Reduced duration of radiation exposure</I>.
Our X-ray source uses a digital chip that is designed to provide better control and enables near-instantaneous on/off toggling
of the electron beam. This source control also enables a precise &ldquo;stop and start&rdquo; operation, which we believe can potentially
result in significantly reduced duration of radiation exposure compared to an analog X-ray source that exposes patients to continuous
radiation exposure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Multi-spectral imaging capacity using
one X-ray source</I>. Our X-ray source is designed to create multi-spectral imaging using one X-ray source chip because there is
complete independence and separation between the strength of X-ray penetration and the amount of photons for illumination (referred
to as &ldquo;KvP / mA&rdquo;). KvP represents the speed of electrons that gives the X-ray its penetrating power, and higher KvP
means the X-rays can penetrate higher density materials such as bones. mA represents the amount of photons or brightness levels
of the X-ray image. For legacy X-ray sources, KvP / mA ratios were codependent in a linear relationship and each X-ray source could
only produce one set of KvP / mA combinations dedicated for a particular use (for example, either tissue images or bone images,
but not both simultaneously). We believe our X-ray source technology can produce multi-spectral imaging from one X-ray source,
which allows for variable energy levels to be controlled during one scan. With multi-spectral imaging, one source chip can be used
for multiple types of scans, such as head-scans, abdomen, mammography and angiograms, involving both soft and hard tissues at variable
densities, simultaneously. We believe this multi-spectral imaging could also be applied to real-time video imaging. The image below
is a general illustration of the functionality and capability of multi-spectral imaging. Our working prototype uses 60 KvP / mA,
and we intend to commercialize the multi-source Nanox.ARC with a range of 60 - 120 KvP / mA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Higher frequency use over a longer lifetime</I>.
Our X-ray source is based on a field of multiple electron guns on our MEMs-based cathode that spread the load of electron generation
among many &ldquo;producers&rdquo; compared to a single filament that heats to a high temperature in the analog X-ray tube. As
a result, our digital X-ray source is designed to shoot an electron beam at different locations on a stationary anode during each
duty cycle without the need for the complex, high precision rotating mechanism. In addition, the near instant on/off toggling feature
of our digital X-ray source is designed to allow us to reduce the duration of each operation. As a result, we believe our medical
imaging system will have higher stability and a longer lifetime, with a longer mean time between failures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Simplified hardware structure</I>. Because
our X-ray source is designed to direct an electron beam at different locations for each duty-cycle as described above, we are able
to have multiple stationary tubes arranged around the patient as opposed to one tube that rotates around the patient. We believe
this could reduce the complexity and cost of the Nanox.ARC compared to legacy CT devices. In addition, the current approach to
increase durability of the tungsten anode in CT devices, the rotating anode mechanism discussed above, requires both a significant
increase in tube size and cost to allow for the complex movements of the components. In contrast, we believe by using our X-ray
source we will be able to significantly reduce the size of X-ray tubes and simplify the structure of our medical imaging system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe our X-ray source has the potential
to replace the legacy X-ray source in other existing imaging systems, as well as the X-ray source in systems used in other industries,
such as security scanners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Comparative Images from the Nanox.ARC
and a Commercial Alternative</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have generated the images below with
the Nanox.ARC using a single X-ray tube on an imaging phantom. An imaging phantom is a specially designed object that is scanned
or imaged to evaluate and analyze the performance of an imaging device. The comparisons below show the X-ray images taken by our
novel X-ray source (single tube) that is expected to be used in the Nanox.ARC and a commercial alternative, the DigitalDiagnost
Rel. 3.x by Philips, Germany, each at the same source-to-image distance (100 cm), at the same source-detector angle (90<SUP>&#9702;</SUP>) and with
the same detector. &ldquo;KvP&rdquo; represents the penetrating power of the X-ray generated by the device. &ldquo;mAs&rdquo;
represents the quantity of X-rays used during a given exposure time. The KvP and mAs numbers shown in the images below are based
on the machine reading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="width: 352px; height: 700px"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>The Nanox System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nanox System has two integrated components
&mdash; hardware (Nanox.ARC) and software (Nanox.CLOUD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have developed a working prototype of the
Nanox.ARC, a medical device that integrates our proprietary and novel X-ray source. Subject to receiving regulatory clearance, the
first version of the multi-source Nanox.ARC that we expect to introduce to the market is expected to be a 3D tomosynthesis imaging
system that produces a 3D reconstruction of the scanned human body part, as illustrated in the image below. The Nanox.ARC, using our
X-ray source, is being designed to produce partial and full-body scans, with remote operation capability, and to have a full kVp/mA
energy throughout range as per industry standards, multi-spectral imaging range, as well as quiet operation, cloud connectivity and
standard compliance safety mechanisms. It is being designed for easy setup and operation with multiple stationary X-ray tubes
arranged around the patient. The substantial majority of operational software that we anticipate will be used to run the Nanox.ARC
will be cloud-computing based and integrated with the Nanox.CLOUD, as further explained below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="image_003.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the Nanox.ARC, we
have developed a working prototype of the Nanox.CLOUD, a companion cloud software that will allow for the delivery of medical screening
as a service. With the Nanox.CLOUD, we anticipate that the high-cost components of existing medical imaging systems, such as analytics
and computing software that are traditionally installed via multiple licenses on-premise and on a per-system basis, will become
centralized through the cloud. We believe this will significantly reduce on-going software and IT licensing costs and enable a
wide range of functionalities, such as per-body-part vertical analysis, multiple AI diagnostics and remote support. The Nanox.CLOUD
is also expected to be able to provide an end-to-end medical imaging service, including services such as image repository, radiologist
matching, online and offline diagnostics review and annotation, connectivity to medical imaging AI systems and billing and reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A reliable and streamlined, post-scan imaging
service is central to the delivery of effective clinical services. Today, even patients in developed countries experience delays
of weeks and sometimes months for medical imaging and subsequent diagnostics results. For example, in Canada, access to medical
imaging procedures is a growing problem with months of reported wait times for magnetic resonance imaging (&ldquo;MRI&rdquo;) and
CT screening. Long wait times not only negatively impact patient outcomes but also add significant costs to the Canadian healthcare
system each year due to delays in detection and treatment. Wait times for a CT scan can be longer than six weeks in Scotland, over
12 months in Ireland, and in the UK, tens of thousands of suspected cancer patients face month-long wait times to discover whether
they have a particular illness due to delays in analyzing scans and X-rays. The Nanox System is designed to address such gaps and
inefficiencies between completion of the scan and follow-on diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe the Nanox System, if successfully
developed, will streamline the entire medical screening process ranging from scanning to support diagnostics, and solve the bottleneck
of imaging-to-diagnostics. The image below illustrates the potential interplay among the Nanox.ARC, the Nanox.CLOUD and third-party
participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also expect to be able to offer
the Nanox System for a substantially lower cost than existing medical imaging systems, which we believe is key to achieving our
goal of making early-detection medical imaging systems more accessible globally. We believe our novel X-ray source is crucial to
our ability to substantially reduce the manufacturing cost of the Nanox.ARC. Our digital X-ray source generates X-ray radiation
that is measurably identical in all key metrics to the X-ray radiation generated by existing analog X-ray sources, but without
creating the high temperature that results from the filament used in the analog X-ray tube, thereby eliminating the need for the
costly cooling equipment. In addition, our digital X-ray source is designed to enable the Nanox.ARC to have multiple stationary
tubes arranged around the patient, which allows for a more simplified structure, as opposed to requiring the heavy, complex, high-precision
rotating mechanisms used in legacy CT devices. We currently estimate the aggregate cost of purchasing and assembling the components
of the Nanox.ARC will be approximately $8,000 to $12,000 per unit, assuming at least 15,000 Nanox.ARC units will be manufactured.
We believe this will enable us to offer the Nanox System at a substantially lower cost than the cost of existing medical imaging
systems based on analog X-ray sources. For example, a new high-end CT scanner sells for $1,350,000 to $2,100,000, with an additional
$35,000 to $100,000 for cardiac software, $15,500 to $35,000 for lung software and approximately 10% to 14% of the capital expenditure
cost for annual support and maintenance services, reaching a total cost of ownership in the millions of dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our estimated manufacturing costs of the
Nanox.ARC are subject to a number of assumptions and uncertainties and the actual cost per unit could vary significantly from our
estimate, which would have a negative impact on our business. See &ldquo;Item 3. Key Information&mdash;D. Risk Factors&mdash;Risks
Related to Our Business&mdash;We are a development-stage company with limited operating history. We may never be able to effectuate
our business plan or achieve any revenue or reach profitability. Therefore, at this stage of our business, potential investors
have a high probability of losing their entire investment,&rdquo; &ldquo;&mdash;The success of our primary business model, the
Subscription Model, is subject to numerous risks and uncertainties,&rdquo; &ldquo;&mdash;We may experience development or manufacturing
problems and higher costs, or delays that could limit our revenue, if any, or increase our losses&rdquo; and &ldquo;&mdash;We may
not be able to successfully execute our business models.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not believe that our novel digital X-ray source will require
FDA approval or clearance because we believe it falls within a category of radiology vacuum tubes converting electrical input power into
X-rays that utilize the same energy levels, radiation types and throughputs as already existing and approved X-ray tubes applied in a
wide range of radiology medical procedures. As a result, we expect that there will be no novel claim or methodology related to the X-ray
radiation produced by the digital X-ray source. As we continue to develop the Nanox.ARC, we are taking a multi-step approach to the regulatory
clearance process. As a first step, we submitted a 510(k) premarket notification to an accredited Review Organization under the Third
Party Review Program in January 2020 to seek clearance of a medical imaging system that incorporates a single digital X-ray source. The
submission was based on a predicate filing for an equivalence claim to an existing FDA-approved X-ray imaging system by another market
participant. Because our novel digital X-ray source incorporated into this system generates X-ray radiation that is measurably identical
in all key characteristics to the X-ray radiation generated by the analog X-ray source incorporated into existing FDA-cleared X-ray imaging
systems, we made no new claims as to the operation, image quality or functionality of this system versus the predicate device. As part
of the review process, in March 2020, we received an information request, referred to as a major deficiency letter, from the Review Organization
which, among other things, required us to provide additional data and other information to complete the application and to address certain
deficiencies highlighted by the reviewer, including the results of certain performance tests. On September&nbsp;3, 2020, we submitted
our response to the Review Organization. The response included additional data and other information to complete the application and to
address certain deficiencies identified by the reviewer, including the results of certain performance tests. On September&nbsp;10, 2020,
the Review Organization requested that we include a second predicate device in our 510(k) premarket notification. On September&nbsp;26,
2020, we submitted our revised 510(k) premarket notification to the Review Organization, which the Review Organization subsequently recommended
to the FDA for clearance on December 28, 2020. On January&nbsp;1, 2021, we received an information request from the FDA through the Review
Organization regarding our submission, which we responded to on January&nbsp;4, 2021. On January 30, 2021, we received additional information
requests from the FDA which, among other things, require us to address certain deficiencies and questions, including requests that we
provide additional support regarding the intended use of the Nanox.ARC and the comparability of the Nanox.ARC to the predicate device.
We submitted our response to these requests on March 1, 2021. On April 1, 2021, we received clearance from the FDA to market our Nanox
Cart X-Ray System. We will continue to optimize and develop features of the Nanox.ARC, and plan to submit an additional 510(k) premarket
notification to the FDA with respect to the multi-source Nanox.ARC and the Nanox.CLOUD during 2021. If cleared by the FDA, we expect to
commercialize the multi-source Nanox.ARC and we may seek alternatives for commercialization of our Nanox Cart X-Ray System. To date, we
have not obtained feedback from the FDA regarding the regulatory pathways for the novel digital X-ray source.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-style: normal"><B>Our
Business Model</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to commercialize our X-ray source
technology through three simultaneous business models: (i)&nbsp;the Subscription Model, (ii)&nbsp;the Sales Model and (iii)&nbsp;the
Licensing Model. The chart below illustrates the various revenue streams we expect to derive from these three business models.
We expect the Subscription Model to be our primary business model and the key vehicle to achieving our vision of increasing early-detection
of medical conditions that are discoverable by X-ray.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_005.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&thinsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">We expect to contract with third parties to provide maintenance
and support services.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>The Subscription Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foundation of the Subscription Model
is our integrated offering of the Nanox.ARC and the Nanox.CLOUD, which we refer to as the &ldquo;Nanox System.&rdquo; Under the
Subscription Model, we expect to sell the Nanox System, if cleared or approved by the requisite regulatory authorities, either
at low cost or at no cost, and to receive a portion of the proceeds from each scan as the right-to-use licensing fee, and fees
for usage of the Nanox.CLOUD, artificial intelligence capability and maintenance support, with the remaining amount allocated among
our partners, including the local operators, radiologists, cloud storage providers, medical AI software providers and others, on
a case by case basis. While the actual pricing charged by local operators may be greater than our suggested retail price, the retail
price per scan in all markets other than the United States is still expected to be substantially less than the global average of
approximately $300. In the United States, we expect the retail price to represent a significant reduction compared to the $3,275
average cost of a CT scan. We expect the Nanox System will be operated by local operators independent from us, but we would contract
with third parties to provide the day-to-day maintenance of the Nanox System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While we believe our novel X-ray source
could provide existing market participants with the paradigm shift needed for preventive healthcare disruption, we also believe
existing market participants are not likely to undertake the change-leadership route and will be slow to adopt the MSaaS model.
Accordingly, we plan to produce and deploy approximately 15,000 Nanox.ARC units broadly across the globe over three to four years
to jumpstart the MSaaS-based medical imaging market, including in the United States and certain countries in Asia, Europe, Africa,
Latin America and Australia. We estimate that effectively stimulating market interest in our Nanox System will require deploying
5,000 to 10,000 Nanox.ARC units. We believe that this strategy will help initiate market disruption and accelerate the adoption
of our novel X-ray source technology by traditional industry leaders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>The Sales Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In certain countries, such as China, we
intend to commercialize our technology using the Sales Model to accommodate specific local regulatory requirements. Under this
model, we expect to sell the Nanox System, if cleared or approved by the requisite regulatory authorities, for a one-time charge.
We expect this retail price to be higher than the upfront sales price under the Subscription Model but still substantially lower
than the cost of existing medical imaging systems. We expect to enter into arrangements with third-party cloud vendors which will
be responsible for providing the Nanox.CLOUD services, and be paid separately by the owner-operators of the Nanox Systems. In addition,
we expect to contract with third-party service providers to provide maintenance services for the Nanox Systems at the owner-operators&rsquo;
own costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>The Licensing Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While we believe the medical imaging industry
will eventually migrate towards the recurring revenue-based MSaaS model, we expect certain leading market participants will be
slower to adopt this model. For these market participants, we expect to provide an intermediate solution through which they will
adopt our X-ray source technology for their existing systems. Under the Licensing Model, we would be engaged to tailor our X-ray
source to the specific systems of medical imaging device manufacturers or to license our X-ray source technology to them to develop
new types of imaging systems for a one-time licensing fee upfront for the X-ray source, as well as recurring royalty payments for
each system sold. The licensees would be responsible for the operation of the medical imaging systems integrating our X-ray source.
Although we expect to initially rely on the Licensing Model, in part, we view the Licensing Model as a transitional phase, aimed
at maximizing the commercial value of our technology and strategic buy-in from market participants to our vision through partnership
and commercial relationships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FUJIFILM Corporation was the first medical
imaging device manufacturer to participate in our licensing model. On May&nbsp;21, 2019, Nanox Gibraltar, our predecessor company,
entered into a Right of First Negotiation Agreement with FUJIFILM Corporation. Under the terms of such agreement, the parties agreed
to exclusively negotiate in good faith the terms and conditions of a potential commercial agreement until December&nbsp;31, 2019.
The terms of the commercial agreement are intended to cover the exclusive, worldwide licensing of certain patents and know-hows
related to mammography medical devices and solutions owned by us to FUJIFILM Corporation to develop, manufacture, market, distribute,
operate and use mammography equipment and services (the &ldquo;field of use&rdquo;). Under the Right of First Negotiation Agreement,
if such commercial agreement was not entered into by December&nbsp;31, 2019, and if we later become involved in any negotiation
to enter into an agreement for the grant of license of the patents covered by the agreement in the field of use to any third party,
FUJIFILM Corporation would have a right of first negotiation for six months with respect to such proposed transaction under terms
and conditions no less favorable to us than those proposed or offered by or to such third party. In accordance with the terms of
the Right of First Negotiation Agreement, we assumed all of Nanox Gibraltar&rsquo;s obligations under such agreement upon the transfer
of Nanox Gibraltar&rsquo;s assets to us. We expect to enter into negotiations regarding the terms of a potential commercial agreement
with FUJIFILM Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Sales and Marketing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to commercialize our technology
using the three simultaneous business models described above broadly across the globe by the end of 2024, including in the United
States and certain countries in Asia, Europe, Africa, Latin America and Australia. Our sales and marketing strategy varies depending
on specific geographical regions, as different regions generally require different marketing approaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In most countries, other than the United
States, we expect to primarily market through local partnerships with strong national branding and operational market participants
in the target region. These local partners would be engaged in deploying and operating our medical imaging systems, training and
recruiting a local medical professional workforce to operate the systems and providing medical imaging diagnostics for the systems&rsquo;
scan results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, because we expect
our systems will be relatively simple and cost effective to deploy compared to existing medical imaging systems, many urgent care
units, outpatient clinics and retail locations could potentially become medical imaging service providers with the support of the
appropriate partners and radiologists. We have already initiated discussions with some of the largest urgent care units, private
clinic chains and retail locations for the potential deployment of thousands of units in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we also expect to engage local
value-added resellers or integrators in different geographic regions to facilitate the local integration of our systems with health
maintenance organizations, electronic health record systems, payment methods and insurance coverage companies. We estimate that
it will take approximately three to six months of integration and localization efforts before we can generate sales in a given
region.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Manufacturing and Supply</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have optimized the MEMs proprietary manufacturing
process and currently use our own equipment in the clean rooms located at the University of Tokyo to manufacture the MEMs X-ray
chip, as shown in the picture below. As we further expand our business in connection with the commercialization of our technology,
we expect to obtain access to other clean rooms provided by third parties. We plan to retain our core X-ray source technology production
activities for the foreseeable future, and we intend to expand our manufacturing capacity, including through the establishment
of the Korean Subsidiary, to meet our currently anticipated needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into direct arrangements
on a purchase order basis with a manufacturer for the production of our X-ray tubes. In addition, we are evaluating, subject to
completion of testing, a transition from glass-based X-ray tubes to ceramics-based tubes for cost efficiency purposes, which are
the tubes to be used in the multi-source version of the Nanox.ARC, and we intend to enter into an agreement for such ceramics-based
tubes with a new manufacturer in the future. We also expect to rely on third-party manufacturers for the commercial production
of the other components of the Nanox.ARC, if cleared or approved by the requisite regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Due, in part, to travel restrictions as a
result of the COVID-19 pandemic, we engaged Dagesh to manufacture a small number of Nanox.ARC units in Israel on a purchase order
basis that we expect will be used for the acceptance tests under our MSaaS agreements, demonstrations, regulatory approvals and for
the initial global deployment, among other purposes. We expect to enter into a formal agreement for the manufacture of these
Nanox.ARC units. Furthermore, we have entered into a contract manufacturing agreement with FITI, as further described below, for
mass production of the multi-source Nanox.ARC, with a goal to enable the commercial production of approximately 15,000 Nanox.ARC
units that we plan to deploy by the end of 2024. Under the contract manufacturing agreement, FITI will negotiate and subcontract
with other third parties for the commercial supply of the components of the Nanox.ARC in accordance with the pre-approved supplier
list and on the terms to be agreed upon by both parties, except for the MEMs X-ray chip and the X-ray tube. As we further expand our
business in connection with the commercialization of our technology, we also expect to seek to engage alternative manufacturers of
the Nanox.ARC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May&nbsp;26, 2020, we entered into a
Contract Manufacturing Agreement with FITI. Under the terms of the agreement, FITI agrees to manufacture, package, distribute and
ship, and we agree to purchase, certain products and procurement and assembly services, including a minimum of 1,000 Nanox Systems
per year. We agree to provide FITI with a rolling forecast of our estimated monthly purchases, which FITI will use to prepare its
supply chain to cover the material and manufacturing needs. Subsequently, we will send purchase orders to FITI for certain products
and services. Prices for the products will be agreed by the parties at least 90 days prior to the first expected delivery date.
FITI will be entitled to order materials in accordance with an approved supplier list and on the terms that the parties agree upon
on a quarterly basis, and FITI must obtain our prior written consent if it procures materials from other suppliers. FITI may also
purchase materials from us to support orders pursuant to our requests. The parties also agree to enter into a quality agreement,
which will set forth the manufacturing standards applicable to FITI. The agreement will be in effect for three years from the date
of the agreement and is renewable for successive terms of one year unless or until either party notifies the other in writing of
its intention not to renew with 90 days&rsquo; prior notice. The agreement may be terminated by notice of the non-breaching party
in case of a material breach of a party&rsquo;s material obligations, or by either party in case of the bankruptcy or insolvency
of the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have worked with a third party to develop
the initial prototype of the Nanox.CLOUD and we plan to continue to develop the Nanox.CLOUD internally.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Commercial Agreements</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>MSaaS Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into nine MSaaS agreements
to deploy 5,150 Nanox Systems in 13 regions as described in the table below. Under the terms of each agreement, we grant the other
party a limited, non-transferable, exclusive, sub-licensable right to access and operate the Nanox System in the region indicated
for such party. We undertake to provide the specified number of Nanox Systems to each entity as indicated in the table below based
on agreed shipment schedules, subject to local regulatory approval and material compliance with acceptance test protocol (the &ldquo;conditions
precedent&rdquo;). The other party undertakes to deploy the systems to provide a minimum number of scans per year (based on 7 scans
per day and 23 days per month) on a pay-per-scan basis at a minimum of $14 per scan, and to pay a minimum annual fee (including
payments to our partners) in the amount indicated in the table below. The MSaaS agreements require each of our counterparties to
deliver to us a standby letter of credit or financial guarantee in the amount equal to the minimum annual fee in favor of us after
receipt of the conditions precedent. However, there can be no guaranty that our counterparties will be able to obtain such letters
of credit or financial guarantees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nanox Systems provided under each agreement
will remain our property, and the other party will only have a limited license to use the Nanox Systems. In addition, we must approve
in writing any sublicense granted under this agreement. We undertake to provide billing, radiology and maintenance services and
to provide training for a local medical professional workforce to operate the Nanox.ARC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each agreement will be in effect for multiple
years, ranging from three to seven years from the date of the applicable agreement, and is renewable for an additional multi-year
term with both parties&rsquo; mutual consent as indicated in the table below. Each agreement may be terminated by notice of the
non-breaching party in case of a material breach of a party&rsquo;s material obligations, or by either party in case of the bankruptcy
or insolvency of the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; text-align: center"><DIV STYLE="padding: 0in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P><P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Entity</B></P> </DIV></TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">Date of MsaaS<BR>
 Agreement</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">Region</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">Number of<BR>
 Nanox<BR>
 Systems to<BR>
 be Provided</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">Minimum Annual <BR>
Fee and Amount of<BR>
 Letter of Credit or<BR>
 Financial Guarantee <BR>
(approximate)</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">Initial<BR>
 Term</TD><TD STYLE="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">Renewal <BR>
Term</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 34%; text-align: left">The Gateway Group, Ltd.</TD><TD STYLE="text-align: left; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; width: 10%; vertical-align: top">February 11, 2020</TD><TD STYLE="text-align: left; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: left">Australia, New Zealand and Norway</TD><TD STYLE="text-align: left; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: right">&nbsp;</TD><TD STYLE="vertical-align: top; width: 8%; text-align: right">1,000</TD><TD STYLE="vertical-align: top; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; width: 8%; text-align: left"><FONT STYLE="font-size: 10pt">$58 million</FONT></TD><TD STYLE="vertical-align: top; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 10%; vertical-align: top">3 years</TD><TD STYLE="text-align: left; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 10%; vertical-align: top">3 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Golden Vine International Company, Ltd.</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">May 28, 2020</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Taiwan and Singapore</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">500</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Up to $29 million</FONT></TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">5 years</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">5 years*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Promedica Bioelectronics s.r.l</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">May 29, 2020</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Italy</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">500</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">$29 million</FONT></TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">4 years</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">3 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">JSC Roel Group</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">May 29, 2020</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Russian Federation</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">500</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">$12.6 million</FONT></TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">5 years</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">5 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Clarity Medical Solution, a division of &ldquo;Grodnobioproduct&rdquo; LLC</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">June 4, 2020</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Belarus</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">100</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">$3.7 million</FONT></TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">3 years</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">4 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Gold Rush</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">June 16, 2020</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">South Africa</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">500</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">$15.5 million</FONT></TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">3 years</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">3 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">LATAM Business Development Group Ltd.</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">July 6, 2020</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Brazil</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">1,000</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">$4.8 million (9 million Letter of Credit) in Year 1 $14.5 million in Year 2 $24.2 million in Year 3***</FONT></TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">6 years</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">3 years</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">APR 1998 S.L</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">July 25, 2020</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Spain</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">420</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">$11.4 million</FONT></TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">5 years</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">5 years**</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">SPI Medical</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">August 23, 2020</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Mexico and Guatemala</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">630</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">$17.1 million****</FONT></TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">7 years</TD><TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">N/A</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>TOTAL</TD><TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: right">5,150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">$180.9 million*****</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">*</TD><TD>The MSaaS Agreement with Golden Vine International Company, Ltd. may also be terminated by either party upon notice stipulating
that the notifying party has come to the conclusion, based on market evidence, that there is no business merit for the Nanox.ARC
in Taiwan or Singapore.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">**</TD><TD>The MSaaS Agreement with APR 1998 S.L. may also be terminated by the service provider at the end of a six-month trial period
by sending within five days a formal notice to the Company if trial results are not satisfactory.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">***</TD><TD>The enforceability of the standby letter of credit from LATAM Business Development Group Ltd. in our favor is also conditioned
upon the parties finalizing within 90 days of the date of the agreement or prior to receipt of regulatory approval, in mutually
agreed form, the terms and conditions of the statement of work, the system requirement specifications and the service level agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">****</TD><TD>According to the agreement, SPI issued a performance bond purchased from Aseguradora Aserta, S.A. de C.V., Grupo Financiero
Aserta, a top financial institution of Mexico, in favor of us in the amount of approximately $17.1&nbsp;million, effective through
October&nbsp;31, 2021, which guarantees the exclusivity of the MSaaS agreement between SPI and us prior to the satisfaction of
certain conditions, including receipt of regulatory approval and compliance with acceptance test protocol, and upon satisfaction
of those conditions, will be converted into a financial guarantee that guarantees the minimum annual service fee to us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">*****</TD><TD>The total amount includes payments to be received by our partners. The total amount payable to us would be approximately $139&nbsp;million
excluding the payments to our partners.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into certain business development
agreements with finders to obtain MSaaS agreements in specified countries. Once the standby letter of credit or financial guarantee
has been issued in connection with each MSaaS agreement above, we will grant warrants to purchase our ordinary shares to the finder
who caused such MSaaS agreement to be signed between the Company and the entity. The warrants will be granted in an amount equal
to 30% of the amount of the standby letter of credit or financial guarantee divided by 35.36 and have an exercise price equal to
the fair market value of our ordinary shares at the time of the grant. The finder will also be entitled to 5% of the gross amount
that we receive from scans made by the Nanox Systems under the MSaaS agreement. If a finder causes an MSaaS agreement to be signed
between us and an entity with a minimum of 23 scans per day at a minimum of $30 per scan, once the standby letter of credit or
financial guarantee has been issued, we will grant the finder warrants to purchase our ordinary shares in an amount equal to 5%
of the amount of the standby letter of credit or financial guarantee divided by the fair market value of the ordinary shares at
the time of issuance of the warrant. If a finder causes a letter of intent to be signed with an entity that will cooperate to deploy
Nanox Systems, we will grant the finder warrants to purchase our ordinary shares in an amount equal to $300,000 divided by $18,
the market price of our ordinary shares at the time of the closing of our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October&nbsp;26, 2020, we entered into
an amendment to a certain business development agreement with certain finders in Russia, Belarus, South Africa, Brazil, Mexico
and Guatemala, pursuant to which the Company paid the finders an aggregate one-time payment of $400,000, plus value-added tax and
issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share, with graded
vesting ending ten weeks following the grant date, which may be exercised on a cashless basis. As a result, we recorded an expense
of $6.1 million for the warrants granted. The finders waived any and all past, present and future compensation to which they are
or may be entitled pursuant to the agreements and all activities undertaken on our behalf, including the right to a percentage
of future revenues we receive from scans made by the Nanox Systems and the issuance of warrants. These finders and their assigns
also agree not to sell the shares underlying the warrants in excess of 10% of the daily average trading volume of our shares during
the five trading days preceding such sale. In addition, these finders became party to the Registration Rights Agreement with respect
to the ordinary shares underlying their warrants. In December 2020, 390,000 of such warrants were exercised for a net of 271,630
ordinary shares and in February 2021, 260,000 of such warrants were exercised for a net of 200,283 ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe our MSaaS business model has
the potential to expand the total size of the X-ray-based medical imaging market. We plan to measure the success of our MSaaS business
model by annual capacity for Above-the-Line (&ldquo;ATL&rdquo;) scans which represent the increased capacity of imaging care we
can provide to people that originally had no meaningful access to medical imaging. As we expand our operations and deploy more
units of the Nanox Systems in an increasing number of countries using the MSaaS model, we expect our ATL scans metric to increase
accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Collaboration Agreements</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Collaboration Agreement with Hadasit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into a Collaboration Agreement,
dated September&nbsp;8, 2019, with Hadasit Medical Research Services and Development Ltd. (&ldquo;Hadasit&rdquo;), a wholly owned
subsidiary of the Hadassah Medical Organization (&ldquo;HMO&rdquo;). Under the terms of the agreement, the parties agreed to collaborate
with respect to our medical imaging technology and resulting medical images devices (the &ldquo;Company Products&rdquo;), by way
of (a) joint research and development projects (each, a &ldquo;Research Project&rdquo;); and (b) the provision by Hadasit of services
in connection with Company Products, such as testing and consulting work, where no innovative research will be carried out (each,
a &ldquo;Service&rdquo;). Each Research Project and Service will be rendered under a separate project agreement to be entered into
between the parties in writing from time to time (collectively, the &ldquo;Project Agreements&rdquo;). Prior to entering into any
Project Agreement, a joint steering committee to be established shall be responsible for determining whether such Project Agreement
constitutes a Research Project or a Service. The parties envisage the collaboration to continue over a period of five years, unless
extended in writing. Under this agreement, Hadasit has agreed to extend competitive prices comparable to prices that it offers
to other commercial entities with respect to the Research Projects and Services. We made a non-refundable payment to Hadasit as
an advance on account of the Research Projects and Services in the amount of $250,000, plus value-added tax, which amount will
be credited against payments due from time to time to Hadasit under the Project Agreements. We have no obligation to enter into
any Project Agreements with Hadasit that will cause us to pay Hadasit any payments in excess of the amount advanced, and we are
not permitted to use funding from the Israel Innovation Authority for any Research Projects or Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under this agreement, Hadasit has granted
us an exclusive, worldwide license, with the right to sublicense, under Hadasit&rsquo;s rights in proprietary information created
within the framework of a Research Project (collectively, the &ldquo;Collaboration Intellectual Property&rdquo;), to develop, have
developed, manufacture, have manufactured, use, market, offer for sale, sell, have sold, distribute, export and import Company
Products. Notwithstanding the foregoing, Hadasit reserves for itself, HMO and other non-commercial third parties, rights to Collaboration
Intellectual Property for teaching or academic research purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In consideration for Hadasit&rsquo;s license
to us, Hadasit is entitled to compensation, on a country-by-country basis, for all commercial scans (each, a &ldquo;Scan&rdquo;)
carried out with the use of Covered Products (as defined below) throughout the applicable revenue sharing period at the rate of
ten cents per Scan, which period commences upon the first Scan conducted in a country and ending on the later of: (i)&nbsp;the
expiration of the last to expire valid claim of the applicable jointly owned patent; and (ii) 15&nbsp;years from the date of the
first Scan conducted in such country with a Covered Product after receipt of required regulatory approvals in such country. No
royalty is due for Scans that are carried out with the use of Covered Products without consideration for internal, testing, training
or demonstration purposes. &ldquo;Covered Products&rdquo; are those Company Products which (i)&nbsp;comprise, contain or incorporate,
and/or use, in whole or in part, Collaboration Intellectual Property; (ii)&nbsp;the development, production and/or sale of which,
is based on, or involves, in whole or in part, the use of the Collaboration Intellectual Property; or (iii)&nbsp;are produced or
manufactured in whole or in part, using a process, method or system covered by, or included within the Collaboration Intellectual
Property. If we, our affiliate or sublicensee challenges the validity, enforceability or scope of any patents jointly owned by
us and Hadasit, Hadasit may terminate such license with respect to Covered Products covered by such patents and double the revenue
sharing rate owed Hadasit under the agreement as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, under this agreement, we have
granted Hadasit a royalty-free, worldwide, non-exclusive license, with the right to sublicense only to permitted contractors, to
use, copy, maintain, modify and prepare derivative works of our intellectual property as necessary to conduct the Research Projects
and Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term of the agreement will continue
until the expiration of all payment obligations thereunder. The agreement may be terminated by mutual consent, by the non-breaching
party in case of a material breach of a party&rsquo;s material obligations, or by either party in case of the bankruptcy or insolvency
of the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We also granted Hadasit a warrant to purchase
23,957 of our ordinary shares at a price of $20.87 per share with a total exercise price of $500,000. The warrant was exercised
on a cashless basis in September 2020 <FONT STYLE="background-color: white">for a net of 9,163 ordinary shares</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Collaboration Agreement with USARAD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We entered into a Non-Exclusive Collaboration
Agreement, dated January&nbsp;22, 2020, with USARAD. Under the terms of the agreement, USARAD will use best efforts to contact
official public health authorities of governments and/or medical center operators in the United States (&ldquo;Medical System Operators&rdquo;),
to facilitate the closing of commercial agreements between us and the Medical System Operator for the deployment of 3,000 Nanox
Systems and to promote the Nanox.CLOUD services with radiologists for joining the Nanox diagnostics services platform. We must
approve any engagement of a Medical System Operator that USARAD contacts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We undertake to provide the deployed Nanox
Systems on a pay-per-scan subscription basis using the Nanox.CLOUD. Subject to FDA clearance and a satisfactory Nanox System pilot
testing by the Medical System Operator, USARAD undertakes to use best efforts to engage Medical System Operators that will undertake
an annual subscription to a minimum number of scans per year. USARAD also undertakes to establish connections with the radiologist
community in the United States. USARAD will receive a fee-per-scan, which will be subject to an upfront subscription commitment
and fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We undertake to fully finance the cost of
the Nanox Systems to be deployed in accordance with any commercial agreements between us and a Medical System Operator and their
ongoing maintenance, as well as to provide training for the Nanox System operations. USARAD undertakes to make introductions to
local maintenance contractors that are qualified to maintain medical equipment for the purpose of providing ongoing maintenance
services for the Nanox Systems on our behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The agreement will be in effect for 12 months
from the date of the agreement and will be automatically renewed for additional 12-month periods. The agreement may be terminated
by 90 days&rsquo; advance written notice by either party, by notice of the non-breaching party in case of a material breach of
a party&rsquo;s material obligations, or by either party in case of the bankruptcy or insolvency of the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January&nbsp;5, 2021, we announced the
extension of our collaboration with USARAD, under which we intend to launch, jointly with USARAD pursuant to an oral agreement,
an advanced radiology diagnostics service, combining over 300 expert radiologists and AI decision support algorithms and solutions.
We plan to use X-ray based algorithms, including 2D and 3D tomosynthesis, to provide analysis of large datasets combined with expert
radiologists&rsquo; interpretations through a unique proprietary workflow that prioritizes urgent cases. The service is planned
to be launched after strategically partnering with several leading AI companies. We plan to target insurance companies and other
key constituents within the healthcare ecosystem, including outpatient imaging centers, throughout United States with the advanced
radiology diagnostics service. We aim for this program to become an integral part of our service offering, subject to FDA 510(k)
clearance of the multi-source Nanox.ARC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The program is intended to launch in three
categories:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Population health screening and predictive analytics for conditions such as coronary arterial disease, stroke prevention and
osteoporosis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Post-acute triage for urgent conditions such as pneumothorax, acute fractures and pneumonia (including COVID-19); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Routine peer review and quality assurance cases for conditions such as lung nodules, tumors and incidental vertebral compression
fractures.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Collaboration Agreement with SK Telecom</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June&nbsp;4, 2020, we entered into a
collaboration agreement with SK Telecom, pursuant to which we and SK&nbsp;Telecom continue to explore and engage in good faith
to develop a definitive agreement for the deployment of 2,500 Nanox Systems in South Korea and Vietnam, and we have established
a wholly-owned subsidiary in South Korea with the support of SK Telecom for the purpose of manufacturing MEMs X-ray chips for the
Nanox.ARC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Collaboration Agreements with our AI
Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2019 and 2020, we entered into collaboration
agreements with certain AI partners, including Brainomix Limited (&ldquo;Brainomix&rdquo;), CureMetrix, Inc. (&ldquo;CureMetrix&rdquo;),
IMedis AI Ltd. (&ldquo;IMedis&rdquo;) and Qure.ai Technologies Pyt. Ltd. (&ldquo;Qure.ai&rdquo;). In 2020, we entered into non-binding
agreements with Lunit Inc., (&ldquo;Lunit&rdquo;) and VUNO Inc. (&ldquo;VUNO&rdquo;). CureMetrix will support the development and
testing of our technology together with medical imaging scans, in a diagnostic advisory capacity. Brainomix, IMedis and Qure.ai
will each collaborate with us in the testing of the Nanox.ARC and the Nanox.CLOUD together with proprietary AI algorithms used
for the analysis of brain damage caused by stroke, chest and abdomen X-rays, and chest and head X-rays, respectively, in medical
imaging scans. Lunit and VUNO will each cooperate with us to jointly conduct research and development for commercializing medical
AI solutions based on digital X-ray and CT technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Collaboration Agreement with our Image-Transfer
Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We entered into a Software-as-a-Service
Agreement, dated October&nbsp;21, 2020, with DICOM Grid, Inc. d/b/a Ambra Health. Ambra is a medical data and image management
cloud software company, whose network includes thousands of imaging providers in the U.S., including seven of the top ten hospitals
and six of the top ten children&rsquo;s hospitals, as well as leading radiology practices, subspecialty groups and life sciences
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the agreement, Ambra
grants us a limited, non-exclusive, non-transferable, non-sublicensable, worldwide, royalty-free and fully paid license to use
its software for uploading, viewing, sending and archiving diagnostic imaging and reports to be integrated into the Nanox.CLOUD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term of the agreement is for one year
from the date of the agreement, and shall be automatically renewed for additional periods of the same duration, unless either party
requests termination at least sixty days prior to the end of the then-current term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Letter Agreement with A-Labs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January&nbsp;29, 2019, Nanox Gibraltar
and A-Labs Advisory &amp; Finance Ltd. (&ldquo;A-Labs&rdquo;) entered into a Letter of Engagement. On October&nbsp;18, 2019, we
entered into an Amendment to the Letter of Engagement with A-Labs, in which we replaced and succeeded Nanox Gibraltar in all matters
relating to the agreement. Under the terms of the agreement, A-Labs will provide consulting services to us in connection with various
transactions, such as a private placement or our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In October 2019, we paid A-Labs an advanced
payment of $1&nbsp;million after the signing of the amendment to the agreement, which constituted the full and final payment for
A-Labs&rsquo; services under the agreement. In addition, in connection with our initial public offering, in August 2020, we paid
A-Labs $4,750,000, representing 2.5% of the gross proceeds received from our initial public offering. The advanced payment and
any fees received under the original agreement were set off from the cash payment to A-Labs as part of our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, at the closing of our initial public
offering, we issued to A-Labs an amount of warrants to purchase 263,889 ordinary shares, representing 2.5% of all shares issued in our
initial public offering, at an exercise price equal to the price per ordinary share in such offering. At that time, A-Labs agreed not
to sell or transfer any of our ordinary shares during the one-year period commencing from the closing of our initial public offering,
which was later shortened to 180 days in order to align the lock-up period with other locked-up parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On December 28, 2020, A-Labs exercised a warrant to purchase 123,426
ordinary shares, pursuant to which A-Labs was issued 83,411 ordinary shares, and on December 31, 2020, A-Labs exercised a warrant to purchase
163,889 ordinary shares, pursuant to which A-Labs was issued 104,257 ordinary shares. In addition, A-Labs transferred a warrant to purchase
50,000 ordinary shares to a third party. On January 27, 2021, A-Labs sold 83,400 ordinary shares to a third party.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Competition</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Several large companies, such as General
Electric, Siemens, Philips, Hologic, Varian, Fuji, Toshiba and Hitachi currently dominate the medical imaging market. High regulatory,
distribution, manufacturing and service-related long-term contractual costs represent significant barriers to entry for any new
player. We expect that the existing market participants will remain key players in the future and we aim to form alliances with
several of these leading market participants, including through licensing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Over time, we anticipate that the evolution
in the industry will bring new players into the market. Digital healthcare disruptors such as cloud computing companies or leading
IT companies may enter the industry and we believe that they may become strong partners through our Subscription Model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a general matter, we view competition
on two levels:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Competing digital X-ray sources with same or better attributes; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Competing enterprises operating an MSaaS business model.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In terms of digital X-ray sources, the field
emission display technology is known and a wide range of industry leaders have used it to attempt to create an alternative, digital
source of X-ray. We are not aware of any competing company that has achieved a commercial grade, stable digital X-ray source, either
based on field emission display technology or otherwise. The most well-known attempt was the use of carbon nano tubes (&ldquo;CNT&rdquo;)
as the base material for a potential field emission-based solution. To our knowledge, there are several companies currently in
the process of developing this technology, including Carestream, XinRay Systems and Varex Imaging. Branded as a &ldquo;cold cathode,&rdquo;
CNT solutions have been proven to be unstable and, to date, no commercially available solution has been implemented after significant
investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are two main differences between our
MEMs-based X-ray source and CNT-based X-ray sources. First, carbon, which is used in CNT-based X-ray sources, is much easier to
burn than metal, which is used in our X-ray source. The carbon edges of CNT are extremely small. If these carbon edges are not
controlled precisely, so that the maximum current is below their burn temperature, they burn out. Further, the edges of CNT are
randomly positioned and cannot position nano-tubes in precise locations. Therefore, the edges burn first under high electric field
voltage and cause a chain reaction of all edges burning, which renders the CNT useless. In contrast, we believe our molybdenum
cones are a far more resistant base and our X-ray source positions metal cone edges in the precise location of the electric field
using our MEMs with negligible positioning error deviation. Second, others have tried to prevent the deterioration of the CNT-based
X-ray sources by using &ldquo;mesh&rdquo; as an electric field to extract electrons. &ldquo;Mesh&rdquo; is a grid-electrode set
a few millimeters above of CNTs. However, the distance between the metal edges and their gates is extremely large compared to our
X-ray source, and it requires 1,000 volts to extract electrons, while our X-ray source only needs 50 volts. High voltage is costly
and imprecise. Moreover, the mesh grid traps 50% of the electron emission, meaning the mesh-based solution is costly and extracts
only a small number of electrons, many of which are wasted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In terms of the MSaaS business model, we
currently seek a first-mover advantage by introducing the Subscription Model, as the main pre-requisite for this model is the low
cost of the X-ray source. However, the primary competition comes from established market participants. While in developing countries
we are experiencing keen interest, the United States and other Western regions already have major market participants that are
well entrenched in the market with strong political influence and the ability to delay deployment of our systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Security and Data Privacy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nanox System is being designed and developed
with personal privacy, data security and protection in mind as a top priority for all development parties. Medical imaging information
and other health information is highly personal and sensitive and thus regarded as a prime target for hacks and malicious theft.
As part of our normal operations, we expect to collect, process and retain personal identifying information regarding patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe we will likely be subject to
U.S. rules and regulations governing data protection, including HIPAA. See &ldquo;&mdash;Government Regulation&mdash;Healthcare
Regulatory Laws&mdash;Data Privacy and Security.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we believe we will likely be
subject to the GDPR to the extent that our business involves personal data of persons within the EEA. Data protection legislation,
including the GDPR, regulates the manner in which we may hold and communicate personal data of our employees and patients (including,
in our case, sensitive health data). We are likely to be defined as a &ldquo;Data Controller&rdquo; with respect to the personal
data of patients that we intend to collect and are therefore likely to be subject to a number of key legal obligations under the
GDPR. In addition to reflecting existing requirements that already existed under the old data protection regime, such as, among
other things, requirements to provide users with a &ldquo;fair processing notice&rdquo; if we process their data, ensure that inaccurate
data is corrected, only retain data for so long as is necessary and not transfer data outside the EEA to jurisdictions which do
not ensure an adequate level of protection of personal data without taking certain safeguards, the GDPR also implemented new, more
stringent operational and procedural requirements for our use of personal data. These include expanded prior information requirements
in light of the transparency principle to tell patients how we may use their personal data, increased controls on profiling such
persons, increased rights for patients to access, control and delete their personal data and mandatory data breach notification
requirements. In addition, there are significantly increased administrative fines of the greater of &euro;20&nbsp;million and 4%
of global turnover (as well as the right to compensation for financial or non-financial damages claimed by any individuals under
Article 82 of the GDPR). Further, following the United Kingdom&rsquo;s withdrawal from the European Economic Area and the European
Union, and the expiry of the transition period, companies have to comply with both the GDPR and the GDPR as incorporated into United
Kingdom national law, the latter regime having the ability to separately fine up to the greater of &pound;17.5 million or 4% of
global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection
law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which may expose us to
further compliance risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Separate from, and in addition to, the GDPR
requirements, certification requirements for the hosting of health data will vary by jurisdiction (and may or may not apply to
hosts of health data). As the Nanox System is projected to operate in various EEA countries, we may be required to comply with
other national healthcare regulations or regulatory requirements. For example, in France, there is a procedure as of April&nbsp;1,
2018, for hosts of health data to obtain a prior certification with the competent certification body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are dedicated to making our systems and
software both HIPAA and GDPR compliant. We intend to submit our systems to an independent external audit on a regular basis as
required by HHS. We also intend to develop our privacy protocols to comply with the GDPR. In addition, we are undertaking intendant
measures to ensure a high-level of imaging data encryption, complete separation between the imaging data and personal information
(anonymization) as well as three-factor authentication procedures during on-boarding and usage of the Nanox System. We also intend
to undertake to perform periodic Pen-Tests by external cyber security professionals and publish the results of such audits publicly
and without delay on our website and via public relations channels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Government Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nanox System and our operations will
be subject to extensive regulation by the FDA, and other federal and state authorities in the United States, as well as comparable
authorities in foreign jurisdictions. The Nanox.ARC will be subject to regulation as medical devices and radiation-emitting devices
in the United States under the FDCA, as implemented and enforced by the FDA, and under comparable regulatory schemes in foreign
jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>FDA Regulation of Medical Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA regulates the development, design, non-clinical
and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket
clearance or approval, adverse event reporting, advertising, promotion, marketing and distribution, and import and export of medical
devices to ensure that medical devices distributed within the United States are safe and effective for their intended uses or are substantially
equivalent to a predicate device and otherwise meet the requirements of the FDCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">FDA Premarket Clearance and Approval
Requirements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to certain exceptions, each medical
device commercially distributed in the United States requires either FDA clearance of a 510(k) premarket notification, or approval
of a PMA application. Under the FDCA, medical devices are classified into one of three classes&mdash;Class&nbsp;I, Class&nbsp;II
or Class&nbsp;III&mdash;depending on the degree of risk associated with each medical device and the extent of manufacturer and
regulatory control needed to ensure its safety and effectiveness. Class&nbsp;I includes devices with the lowest risk to the patient
and are those for which safety and effectiveness can be assured by adherence to the FDA&rsquo;s General Controls for medical devices,
which include compliance with the applicable portions of QSR, facility registration and product listing, reporting of adverse medical
events and truthful and non-misleading labeling, advertising and promotional materials. Class&nbsp;II devices are subject to the
FDA&rsquo;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the
device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance
documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While most Class&nbsp;I devices are exempt
from the 510(k) premarket notification requirement, manufacturers of most Class&nbsp;II devices are required to submit to the FDA
a premarket notification under Section 510(k) of the FDCA requesting permission to commercially distribute the device. The FDA&rsquo;s
permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance.
Devices deemed by the FDA to pose the greatest risks, such as life sustaining, life supporting or some implantable devices, or
devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed
device, are placed in Class&nbsp;III, requiring approval of a PMA. Some pre-amendment devices are unclassified, but are subject
to the FDA&rsquo;s premarket notification and clearance process in order to be commercially distributed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">510(k) Clearance Marketing Pathway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect the Nanox.ARC will be a Class&nbsp;II
device subject to premarket notification and clearance under section 510(k) of the FDCA. To obtain 510(k) clearance, we must submit
to the FDA a premarket notification submission demonstrating that the proposed device is &ldquo;substantially equivalent&rdquo;
to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to premarket approval,
i.e., a device that was legally marketed prior to May&nbsp;28, 1976 (pre-amendments device), and for which a PMA is not required,
a device that has been reclassified from Class&nbsp;III to Class&nbsp;II or I, or a device that was found substantially equivalent
through the 510(k) process. The FDA&rsquo;s 510(k) clearance process usually takes from three to twelve months, but often takes
longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence.
In addition, the FDA collects user fees for certain medical device submissions and annual fees and for medical device establishments.
For fiscal year 2020, the standard user fee for a 510(k) premarket notification application is $11,594.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the FDA agrees that the device is substantially
equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If
the FDA determines that the device is &ldquo;not substantially equivalent&rdquo; to a previously cleared device, the device is
automatically designated as a Class&nbsp;III device. The device sponsor must then fulfill more rigorous PMA requirements, or can
request a risk-based classification determination for the device in accordance with the &ldquo;<I>de novo</I>&rdquo; process, which
is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate
device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After a device receives 510(k) marketing
clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change
or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or <I>de
novo</I> reclassification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a
510(k), a <I>de novo</I> request or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&rsquo;s
determination. If the FDA disagrees with a manufacturer&rsquo;s determination, the FDA can require the manufacturer to cease marketing
and/or request the recall of the modified device until 510(k) marketing clearance or until PMA approval is obtained or a <I>de
novo</I> request is granted. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Over the last several years, the FDA has
proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and
a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products.
For example, in November 2018, the FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket
notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals
to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially
sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list
of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than
10&nbsp;years old. In May 2019, the FDA solicited public feedback on these proposals. The FDA requested public feedback on whether
it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were
used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may
work with Congress to implement such proposals through legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">More recently, in September 2019, the FDA
finalized guidance describing an optional &ldquo;safety and performance based&rdquo; premarket review pathway for manufacturers
of &ldquo;certain, well-understood device types&rdquo; to demonstrate substantial equivalence under the 510(k) clearance pathway
by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need,
in the case of applicable products, for manufacturers to compare the safety and performance of their medical devices to specific
predicate devices in the clearance process. The FDA maintains a list of device types appropriate for the &ldquo;safety and performance
based&rdquo; pathway and will continue to develop product-specific guidance documents that identify the performance criteria for
each such device type, as well as the testing methods recommended in the guidance documents, where feasible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">PMA Approval Pathway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Class&nbsp;III devices require PMA approval
before they can be marketed, although some pre-amendment Class&nbsp;III devices for which the FDA has not yet required a PMA are
cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process. In a PMA,
the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including
data from preclinical studies and human clinical trials. The PMA must also contain a full description of the device and its components,
a full description of the methods, facilities and controls used for manufacturing and proposed labeling. Following receipt of a
PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the
application for review, it has 180 days under the FDCA to complete its review of a PMA, although in practice, the FDA&rsquo;s review
often takes significantly longer, and can take up to several years. An advisory panel of experts from outside the FDA may be convened
to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may
or may not accept the panel&rsquo;s recommendation. In addition, the FDA will generally conduct a pre-approval inspection of the
applicant or its third-party manufacturers&rsquo; or suppliers&rsquo; manufacturing facility or facilities to ensure compliance
with the QSR. PMA devices are also subject to the payment of user fees, which for fiscal year 2020 includes a standard application
fee of $340,995 and an annual establishment registration fee of $5,236.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA will approve the new device for
commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that
there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA with post-approval
conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling,
promotion, sale and distribution and collection of long-term follow-up data from patients in the clinical study that supported
PMA approval or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form
of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data
for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow
certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of those patients.
Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the
approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain changes to an approved device, such
as changes in manufacturing facilities, methods or quality control procedures, or changes in the design performance specifications,
which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission
of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from
the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain
other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended
use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of
the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating
a reasonable assurance of safety and effectiveness. We do not expect any of our products to be marketed pursuant to a PMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Clinical Trials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Clinical trials are almost always required
to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of devices to determine
safety and effectiveness must be conducted in accordance with the FDA&rsquo;s investigational device exemption (&ldquo;IDE&rdquo;)
regulations which govern investigational device labeling, prohibit promotion of the investigational device and specify an array
of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a
&ldquo;significant risk&rdquo; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application
to the FDA, which must become effective prior to commencing human clinical trials. If the device under evaluation does not present
a significant risk to human health, then the device sponsor is not required to submit an IDE application to the FDA before initiating
human clinical trials, but must still comply with abbreviated IDE requirements when conducting such trials. A significant risk
device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted,
used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise
preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must
be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans
and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the
FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies
or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional
approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regardless of the degree of risk presented
by the medical device, clinical studies must be approved by, and conducted under the oversight of, an Institutional Review Board
(&ldquo;IRB&rdquo;) for each clinical site. The IRB is responsible for the initial and continuing review of the IDE, and may pose
additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human
clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the
FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval
for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such
as monitoring the investigation, ensuring that the investigators obtain informed consent and labeling and record-keeping requirements.
Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does
become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of
the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before
a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or
the rights, safety or welfare of human subjects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During a study, the sponsor is required
to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and
providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on
the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the
clinical study are also subject to FDA regulations and must obtain patient informed consent, rigorously follow the investigational
plan and study protocol, control the disposition of the investigational device and comply with all reporting and recordkeeping
requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time
for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Post-market Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After a device is cleared or approved for
marketing, numerous and pervasive regulatory requirements continue to apply. These include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>establishment registration and device listing with the FDA;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control,
documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>labeling regulations and FDA prohibitions against the promotion of investigational products, or the promotion of &ldquo;off-label&rdquo;
uses of cleared or approved products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>requirements related to promotional activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness
or that would constitute a major change in intended use of one of our cleared devices, or approval of certain modifications to
PMA-approved devices;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused
or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely
to cause or contribute to a death or serious injury, if the malfunction were to recur;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections
and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA
that may present a risk to health;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the FDA&rsquo;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that
is in violation of governing laws and regulations; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public
health or to provide additional safety and effectiveness data for the device.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our manufacturing processes are required
to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture,
testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished
devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history
file and complaint files. As a manufacturer, we will be subject to periodic scheduled or unscheduled inspections by the FDA. Our
failure to maintain compliance with the QSR requirements could result in the shut-down of, or restrictions on, our manufacturing
operations and the recall or seizure of our products, which would have a material adverse effect on our business. The discovery
of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing
severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician
in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or
voluntary or mandatory device recalls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA has broad regulatory compliance
and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety
of compliance or enforcement actions, which may result in any of the following sanctions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>recalls, withdrawals or administrative detention or seizure of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>operating restrictions or partial suspension or total shutdown of production;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>withdrawing 510(k) clearances or PMA approvals that have already been granted;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>refusal to grant export approvals for our products; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>criminal prosecution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Radiological Devices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We and our products will also be regulated
by the FDA under the Electronic Product Radiation Control provisions of the FDCA because the Nanox.ARC contains radiation emitting
components, and because we assemble these components during manufacturing and service activities. The Electronic Product Radiation
Control provisions require radiation-producing products to comply with certain regulations and applicable performance standards.
Manufacturers are required to certify in product labeling and reports to the FDA that their products comply with all necessary
standards as well as maintain manufacturing, testing and sales records for their products. The Electronic Product Radiation Control
provisions also require manufacturers to report product defects and affix appropriate labeling to covered products. Failure to
comply with these requirements could result in enforcement action by the FDA, which can include any of the sanctions described
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Healthcare Regulatory Laws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Within the United States, our products and
our customers will be subject to extensive regulation by a wide range of federal and state agencies that govern business practices
in the medical device industry. These laws include federal and state anti-kickback, fraud and abuse, false claims, transparency
and anti-corruption statutes and regulations. Internationally, other governments also impose regulations in connection with their
healthcare reimbursement programs and the delivery of healthcare items and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">U.S. federal healthcare fraud and abuse
laws will generally apply to our activities, among other reasons because we expect that our products will be covered under federal
healthcare programs such as Medicare and Medicaid. The Anti-Kickback Statute is particularly relevant because of its broad applicability.
Specifically, the Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing
remuneration, directly or indirectly, in exchange for, or to induce, either the referral of an individual, or the furnishing, arranging
for or recommending a good or service for which payment may be made in whole or part under federal healthcare programs, such as
the Medicare and Medicaid programs. Almost any financial interaction with a healthcare provider, patient or customer will implicate
the Anti-Kickback Statute. Statutory exceptions and regulatory safe harbors protect certain interactions if specific requirements
are met. However, only those interactions that represent fair market value exchanges generally are protected by a safe harbor or
exception. The government can exercise enforcement discretion in taking action against unprotected activities. Further, a person
or entity does not need to have actual knowledge of the Anti-Kickback Statute or specific intent to violate it in order to have
committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation
of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal
civil money penalties statute. Penalties for Anti-Kickback Statute violations may include both criminal penalties such as imprisonment
and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs.
Exclusion would mean that diagnostic tests using our products would no longer be eligible for reimbursement under federal healthcare
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many states have adopted laws similar to
the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed
by any payor, not only federal healthcare programs. Insurance companies may also bring a private cause of action for treble damages
against a manufacturer for a pattern of causing false claims to be filed under the federal Racketeer Influenced and Corrupt Organizations
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Another development affecting the healthcare
industry is the increased use of the federal Civil False Claims Act and, in particular, actions brought pursuant to the False Claims
Act&rsquo;s &ldquo;whistleblower&rdquo; or &ldquo;qui tam&rdquo; provisions. The False Claims Act imposes liability on any person
or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a
federal healthcare program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf
of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any
monetary recovery. In recent years, the number of suits brought against healthcare providers by private individuals has increased
dramatically. In addition, various states have enacted false claim laws analogous to the Civil False Claims Act, although many
of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The federal Health Insurance Portability
and Accountability Act of 1996, or HIPAA, among other things, created two new federal crimes: healthcare fraud and false statements
relating to healthcare matters. The HIPAA healthcare fraud statute prohibits, among other things, knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute
is a felony and may result in fines, imprisonment and/or exclusion from government-sponsored programs. The HIPAA false statements
statute prohibits, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making
any materially false, fictitious or fraudulent statement or representation in connection with the delivery of or payment for healthcare
benefits, items or services. A violation of this statute is a felony and may result in fines and/or imprisonment. Similar to the
federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statutes or specific intent to
violate them in order to have committed a violation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Laws and regulations have also been enacted
by the federal government and various states to regulate the sales and marketing practices of medical device and pharmaceutical
manufacturers. The laws and regulations generally limit financial interactions between manufacturers and healthcare providers,
require pharmaceutical and medical device companies to comply with voluntary compliance standards issued by industry associations
and the relevant compliance guidance promulgated by the U.S. federal government and/or require disclosure to the government and/or
public of financial interactions (so-called &ldquo;sunshine laws&rdquo;). Many of these laws and regulations contain ambiguous
requirements or require administrative guidance for implementation. Manufacturers must adopt reasonable interpretations of requirements
if there is ambiguity and those interpretations could be challenged. Given the lack of clarity in laws and their implementation,
our activities could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Coverage and Reimbursement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Over the past few years, the growth rate
of advanced imaging volumes has slowed in part due to additional patient-related cost-sharing programs and an increasing trend
of third-party payors intensifying their utilization management efforts, for example, through benefit managers who require prior
authorizations to control the growth rate of imaging services generally. We expect that these trends will continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">By way of example, in the United States,
the Protecting Access to Medicare Act of 2014 required CMS, in conjunction with medical specialty societies, to adopt AUC for certain advanced diagnostic imaging services, including MRI, CT, nuclear medicine (including
position emission tomography). Beginning in 2022, payment will be made to the furnishing professional for an applicable advanced
diagnostic imaging service only if the claim indicates that the ordering professional consulted a qualified clinical decision support
mechanism, as identified by HHS, as to whether the ordered service adheres to the applicable AUC. Applicable settings include physician
offices, hospital outpatient departments, including emergency departments, ambulatory surgical centers and independent diagnostic
testing facilities. Advanced imaging services ordered by certain physicians identified as having outlier-ordering partners will
be subject to prior authorization for applicable imaging services provided to Medicare beneficiaries. The outlier methodology used
by CMS will be subject to future notice and comment rulemaking before the prior authorization component is implemented. We cannot
predict the full impact of this project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Third-party payors may impose limits on
coverage or reimbursement for diagnostic imaging services, including denying reimbursement for tests that do not follow recommended
diagnostic procedures or can only be billed using an unlisted or miscellaneous code. To the extent our customers will depend on
third-party payors, unfavorable coding, coverage and reimbursement policies may constrict the profit margins of our provider customers,
which may force us to lower our fees to attract and retain customers. If we are required to request new billing codes that more
precisely identify and describe our imaging services, coverage is limited or reimbursement rates are inadequate, a healthcare provider
might find it financially unattractive to own our diagnostic imaging systems. It is possible that third-party payor coding, coverage
and reimbursement policies will affect the need or prices for our products in the future, which could significantly affect our
financial performance and our ability to conduct our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Healthcare Reform</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States and certain foreign
jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the
healthcare system. In March 2010, the ACA was signed into law and substantially changed the way healthcare is financed by both
governmental and private insurers in the United States. The ACA contains a number of provisions, including those governing enrollment
in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the ACA imposed, among other
things, a new federal excise tax on the sale of certain medical devices, which, through a series of legislative amendments, was
suspended, effective January&nbsp;1, 2016, and subsequently repealed altogether on December&nbsp;20, 2019, provided incentives
to programs that increase the federal government&rsquo;s comparative effectiveness research and implemented payment system reforms
including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination,
quality and efficiency of certain healthcare services through bundled payment models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since its enactment, there have been judicial
and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to
the ACA in the future. By way of example, in 2017, Congress enacted the TCJA, which eliminated the tax-based shared responsibility
payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that
is commonly referred to as the &ldquo;individual mandate.&rdquo; On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled
that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of
the TCJA, the remaining provisions of the ACA are invalid as well. On December&nbsp;18, 2019, the U.S. Court of Appeals for the
5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine
whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case. A decision
is expected during the current Supreme Court term in 2021, and the ACA remains in effect while judicial review of the decision
is pending. It is unclear how these decisions, future decisions, subsequent appeals, and other efforts to repeal and replace the
ACA will impact the ACA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other legislative changes have been proposed
and adopted in the United States since the ACA was enacted, including aggregate reductions of Medicare payments to providers of
2% per fiscal year, which has been temporarily suspended from May 1, 2020 through March 31, 2021, and reduced payments to several
types of Medicare providers. We believe the overall escalating cost of medical products and services being paid for by the government
and private health insurance has led to, and will continue to lead to, increased pressures on the healthcare and medical device
industry to reduce the costs of products and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Data Privacy and Security</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Medical device companies may be subject
to U.S. federal and state and foreign health information privacy, security and data breach notification laws, which may govern
the collection, use, disclosure and protection of health-related and other personal information. In the United States, HIPAA imposes
privacy, security and breach reporting obligations with respect to individually identifiable health information upon &ldquo;covered
entities&rdquo; (health plans, health care clearinghouses and certain health care providers), and their respective business associates,
individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a
service for or on behalf of a covered entity. HIPAA and its respective implementing regulations, including the final omnibus rule
published on January&nbsp;25, 2013, imposes specified requirements relating to the privacy, security and transmission of individually
identifiable health information. HIPAA mandates the reporting of certain breaches of health information to HHS, affected individuals
and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of
unsecured protected health information (&ldquo;PHI&rdquo;), a complaint about privacy practices or an audit by HHS, may be subject
to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if
required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance.
The Health Information Technology For Economic and Clinical Health Act also increased the civil and criminal penalties that may
be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority
to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&rsquo;s
fees and costs associated with pursuing federal civil actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even when HIPAA does not apply, according
to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers&rsquo; personal information secure
constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act,
15 U.S.C &sect; 45(a). The FTC expects a company&rsquo;s data security measures to be reasonable and appropriate in light of the
sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools
to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that
merits stronger safeguards. The FTC&rsquo;s guidance for appropriately securing consumers&rsquo; personal information is similar
to what is required by the HIPAA Security Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, certain state and non-U.S.
laws, such as the GDPR, govern the privacy and security of health information in certain circumstances, some of which are more
stringent or broader in scope than HIPAA and many of which differ from each other in significant ways and may not have the same
effect, thus complicating compliance efforts. Further, &ldquo;business associates,&rdquo; defined as independent contractors or
agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing
a service for or on behalf of a covered entity, are also subject to certain HIPAA privacy and security standards. Failure to comply
with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation.
For example, California enacted the CCPA, which went into effect January&nbsp;1,
2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights
to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private
right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach.
Although the law includes limited exceptions, including for PHI maintained by a covered entity or business associate, it may regulate
or impact our expected processing of personal information depending on the context. Further, the California Privacy Rights Act
(CPRA), recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including
additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain
uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations
and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect
on January 1, 2023, and additional compliance investment and potential business process changes may be required. In Europe, the
GDPR went into effect in May 2018 and introduces strict requirements for processing the personal data of individuals within the
EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory
enforcement of data protection requirements and potential fines for noncompliance of up to &euro;20&nbsp;million or 4% of the annual
global revenues of the noncompliant company, whichever is greater. Relatedly, following the United Kingdom&rsquo;s withdrawal from
the European Economic Area and the European Union, and the expiry of the transition period, companies have to comply with both
the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine
up to the greater of &pound;17.5 million or 4% of global turnover. The relationship between the United&nbsp;Kingdom and the European
Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred
between each jurisdiction, which exposes us to further compliance risk. The State of Israel has also implemented data protection
laws and regulations, including the Israeli Protection of Privacy Law of 1981.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Foreign Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As we plan to market and deploy our Nanox
System broadly across the globe, we will be subject to regulations applicable to medical and radiation-emitting devices in the
jurisdictions in which we operate, which regulations vary among countries. While some countries&rsquo; regulations may not impose
barriers to marketing and selling our products or only require certain notification, others may require that we obtain the clearance,
registration or approval of a specified regulatory body. Process for obtaining such clearance, registration or approvals may involve
additional testing and time. Furthermore, complying with foreign regulatory requirements can be expensive and time-consuming, and
we will need to seek for regulatory clearances or approvals in each country in which we plan to market our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, depending on the country, if
we modify our products, we may need to apply for additional regulatory clearances or approvals before we are permitted to sell
the modified product. Also, for maintaining our authorizations in a particular country, we will need to continue meeting quality
and safety standards required in such country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Finally, while regulatory clearance or approval
by the FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, registration or regulatory
clearance or approval in one country, or denial thereof, may have effects on the regulatory process in others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Legal Proceedings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In September 2020, two securities class action
complaints were filed, which were subsequently consolidated and captioned as <I>White v. Nano-X Imaging Ltd. et al</I>, Case No. 1:20-cv-04355,
filed in the United States District Court for the Eastern District of New York against us and certain current officers and a director
alleging violations of securities laws and seeking unspecified damages. On December&nbsp;7, 2020, proposed lead plaintiffs submissions
were fully briefed. We believe this lawsuit is without merit and intend to defend the case vigorously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are unable to estimate a range of loss, if
any, that could result were there to be an adverse final decision in this case. If an unfavorable outcome were to occur, it is possible
that the impact could be material to our results of operations in the period in which any such outcome becomes probable and estimable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, we may become involved in legal
proceedings arising in the ordinary course of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">C. Organizational Structure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NANO-X IMAGING LTD, an Israeli Company (&ldquo;Nanox
IL&rdquo;), was incorporated on December&nbsp;20, 2018 and commenced its operations on September&nbsp;3, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September&nbsp;19, 2019, Nanox IL established
Nanox Imaging Inc., a wholly owned subsidiary in Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September&nbsp;25, 2020, Nanox IL established
Nano-X Korean Inc., a wholly owned subsidiary in Korea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">D. Property, Plants and Equipment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located in
a leased facility in Neve Ilan, Israel. We lease approximately 550&nbsp;square meters (approximately 5,920 square feet) of office space
and warehouses. The lease expires in December&nbsp;2021, and we have the option to extend our lease for an additional 24 months so long
as we meet the terms of the original lease agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also lease approximately 620 square meters
(approximately 6,670 square feet) of office space in Neve Ilan, Israel, that may be used for offices and technical development. The lease
expires in June 2023. In November 2020, we leased an additional approximately 370 square meters (approximately 3,980 square feet) of
office space in Neve Ilan, Israel. This lease also expires in June 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Nanox Japan (predecessor) leases additional facilities
of approximately 740 square feet of lab space and approximately 190 square feet of space in a clean room at the premises of the University
of Tokyo for research and development activities. The lease automatically renews on a semi-annual basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We lease approximately 390 square meters of space
for a temporary factory and approximately 200 square meters of space for a research and development center in Korea. The lease for the
temporary factory expires in January 2022 and the lease for the research and development center expires in November 2021. In December
2020, we purchased approximately 11,889 square meters of land in Yongin, Geonggi province, on which we <FONT STYLE="font-family: Times New Roman, Times, Serif">intend
to build a manufacturing facility for approximately $6.2 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe this space will be sufficient to meet
our needs for the next 12-18 months and that suitable additional space will be available as and when needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>Unresolved Staff Comments</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_006"></A>Item 5.</TD><TD>Operating and Financial Review and Prospects</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following discussion and analysis of our financial
condition and results of operations should be read in conjunction with our audited consolidated financial statements and the related
notes included elsewhere in this annual report on Form 20-F. This discussion contains forward-looking statements based upon current expectations
that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements
as a result of various factors, including those discussed in the section titled &ldquo;Item 3. Key Information&mdash;D. Risk Factors&rdquo;
and in other parts of this annual report on Form 20-F. Our consolidated financial statements have been prepared in accordance with U.S.
GAAP. The functional currency of NANO-X IMAGING LTD is the U.S. dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. Operating Results</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Early detection saves lives&mdash;and we at Nanox
are focused on applying our proprietary medical imaging technology to make diagnostic medicine more accessible and affordable across
the globe. Our vision is to increase early detection of medical conditions that are discoverable by X-ray, which we believe is key to
increasing early treatment, improving health outcomes and, ultimately, saving lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To further our vision, we have developed a working
prototype of the Nanox.ARC, a medical imaging system incorporating our novel X-ray source, and we have developed a prototype of the Nanox.CLOUD,
a companion cloud software. If cleared, we plan to market and deploy the Nanox System broadly across the globe at a substantially lower
cost compared to currently available medical imaging systems, such as CT. We believe that, if cleared, our technology&rsquo;s relatively
low cost will enable us to increase accessibility and affordability of early-detection medical imaging systems globally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since our inception, we have devoted substantially
all of our financial resources to acquiring the base technology for our X-ray source and related know-how, conducting research and development
activities, organizing and staffing our company, developing our business plan, securing related intellectual property rights and raising
capital. We do not have any product approved for sale and have not generated any revenue from product sales. We have funded our operations
to date primarily with proceeds from the sale of our ordinary shares and warrants (after September&nbsp;3, 2019) and those of our predecessor
company (prior to September&nbsp;3, 2019). During the years ended December 31, 2020, 2019 and 2018, we received net cash proceeds of
$240.4&nbsp;million, $14.0&nbsp;million and $3.7 million, respectively, from the sales of our and our predecessor&rsquo;s ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have incurred significant operating losses
since our inception. Our ability to achieve profitability depends on the successful development and commercialization of our technology
and our products. We incurred net losses of $43.8&nbsp;million, $22.6&nbsp;million and $1.9 million for the years ended December&nbsp;31,
2020, 2019 and 2018, respectively. As of December 31, 2020 and 2019, we had an accumulated deficit of $84.4&nbsp;million and $40.6&nbsp;million,
respectively. We expect to continue to incur significant expenses for at least the next several years as we advance the Nanox System
through further development and regulatory approval. If we obtain marketing approval for the Nanox.ARC, we expect to incur significant
commercialization expenses related to product manufacturing, marketing, sales and distribution. In addition, we incur additional costs
associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we
did not incur as a private company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to jumpstart the MSaaS-based medical imaging
market by producing and deploying an initial wave of approximately 15,000 Nanox.ARC units by the end of 2024. We estimate that effectively
stimulating market interest in our Nanox System will require deploying at least 5,000 to 10,000 Nanox.ARC units. In addition, we believe
that a minimum installed base of at least 1,000 Nanox.ARC units will be required to support our business during the initial wave of deployment,
assuming we enter into at least one licensing agreement on commercially reasonable terms. We expect to incur significant expenses for
the manufacture, installation, deployment and maintenance of the Nanox System. As&nbsp;a result, we need substantial funding to support
our continuing operations and pursue our business strategy before we can generate significant revenues. Until such time as we can generate
significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other
capital sources, including collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties.
We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at
all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or
discontinue the development and commercialization of one or more of our products or delay our pursuit of potential in-licenses or acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2020, we had cash and cash equivalents of $213.5&nbsp;million.
We believe that our cash on hand and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements
for at least the next twelve months from the date of issuance of the financial statements. We have based this estimate on assumptions
that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. See &ldquo;Item 5. Operating and Financial
Review and Prospects&mdash;B. Liquidity and Capital Resources.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Asset Purchase</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were formed on December&nbsp;20, 2018. Pursuant
to the Asset Purchase Agreement, as amended on December&nbsp;3, 2019 and December&nbsp;31, 2019, substantially all of the assets of Nanox
Gibraltar, including all patents, patent applications and all other intellectual property rights, but not including the shares of Nanox
Japan (predecessor), were sold to us for an aggregate consideration of $13.3&nbsp;million, reflecting the fair market value of the transferred
assets, which was estimated to be $6.1&nbsp;million (excluding cash) based on an independent valuation report, plus the cash balance
less $200,000, which cash amount totaled $7.2&nbsp;million as of the date of the Asset Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Asset Purchase Agreement,
the consideration for the transferred assets will be paid only on the occurrence of one of the following events: (a) the closing of a
transaction involving the sale of all or substantially all of our assets; (b) the acquisition of us by, or the merger of us with, another
entity, consolidation, reorganization, recapitalization, sale, assignment or disposal by us of all or substantially all of our issued
and outstanding shares; (c) the transfer, sale, lease, grant or other disposition of or the grant of an exclusive license over all or
substantially all of our assets, including, but not limited to, intellectual property, with the same economic effect to that of a sale
and/or cessation of its business; (d)&nbsp;any other transaction, except for a financing round, following which our shareholders prior
to the closing of such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity; (e)&nbsp;the
closing of our first underwritten public offering pursuant to a registration statement under the Securities Act or the Securities Law
(or under equivalent securities law of another jurisdiction) or any other securities laws world-wide with the same effects and results;
and (f) an equity financing by us at a minimum pre-money valuation of $100.0&nbsp;million, with proceeds to us of at least $30.0&nbsp;million.
In the events of (e)&nbsp;or (f) above, we will have the option to pay the consideration in cash or by the issuance to Nanox Gibraltar
of our securities of the same series to be issued upon such event, in an amount reflecting a 25% discount on the price per share to be
determined in connection with (e) and (f) above. If we elect to pay such consideration in cash, Nanox Gibraltar will have the right,
at its sole discretion and in good faith, to reject such payment in cash, and require that we pay such consideration in the form of our
securities in such amount and with such discount described above. In connection with this, we recorded a related party liability in an
amount of $17.8&nbsp;million in its financial statements as of and for the year ended December&nbsp;31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In January 2020, our board of directors and the
board of directors and shareholders of Nanox Gibraltar approved the issuance of shares in accordance with the terms of the Asset Purchase
Agreement described above. As a result, 1,109,245 of our ordinary shares were issued to Nanox Gibraltar, representing an aggregate consideration
of approximately $17.8&nbsp;million, and we have no further obligations to Nanox Gibraltar under the Asset Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Components of Our Results of Operations</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of the date of this annual report on Form 20-F,
we have not generated any revenue from product sales or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Operating Expenses</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Research and Development Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses consist primarily
of costs incurred in connection with the research and development of our products. These expenses include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>expenses incurred in connection with the development of our products,
                                            including payments made pursuant to agreements with third parties, such as outside consultants
                                            related to process development and manufacturing activities, as well as patent registrations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>costs of components and materials, including payments made pursuant
                                            to agreements with third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>costs of laboratory supplies incurred for each program;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>facilities, depreciation and other expenses, including direct
                                            or allocated expenses for rent and maintenance of facilities, as well as insurance costs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>costs related to compliance with regulatory requirements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>employee-related expenses, including salaries, related benefits
                                            and share-based compensation expenses for employees engaged in research and development activities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recognize external development costs based
on an evaluation of the progress to completion of specific tasks using information provided to us by our suppliers and service providers.
Upfront payments, milestone payments (other than those deemed contingent consideration in a business combination) and annual maintenance
fees under license agreements are expensed in the period in which they are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development activities are central
to our business. We expect that our research and development expenses will increase substantially over the next several years as we continue
development of the Nanox System. We expect to continue to devote a substantial portion of our resources to the Nanox.ARC hardware, the
Nanox.CLOUD software and our underlying technology for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The successful development and commercialization
of our products are highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts
that will be necessary to complete the development of any of our products. This uncertainty is due to the numerous risks and uncertainties
associated with product development and commercialization, including the uncertainty of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the timing and progress of development activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to maintain our current research and development
                                            programs and to establish new ones;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the receipt of regulatory approvals from applicable regulatory
                                            authorities without the need for independent clinical trials or validation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the timing, receipt and terms of any marketing approvals from
                                            applicable regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to establish new licensing or collaboration arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the performance of our future collaborators, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>establishing commercial manufacturing capabilities or making
                                            arrangements with third-party manufacturers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>obtaining, maintaining, defending and enforcing patent claims
                                            and other intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>launching commercial sales of our products, including the Nanox.ARC
                                            hardware and Nanox.CLOUD software, whether alone or in collaboration with others; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>maintaining a continued acceptable safety profile of the products
                                            following approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any changes in the outcome of any of these variables
with respect to the development of our products could result in a significant change in the costs and timing associated with the development
of these products. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials or other testing
beyond what we currently expect, we could be required to expend significant additional financial resources and time to complete development
of our products. We may never obtain regulatory approval for any of our products and third parties may never obtain regulatory approvals
for any products containing our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Marketing, General and Administrative Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Marketing expenses consist of public relations
and general marketing expenses. General and administrative expenses consist primarily of salaries, related benefits and share-based compensation
expense for personnel in executive, finance and administrative functions. General and administrative expenses also include facilities,
depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance, as
well as professional fees for legal, patent, consulting, investor and public relations, accounting and audit services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We anticipate that our marketing, general and
administrative expenses will increase as we increase our headcount to support our continued research activities and development of our
products. We also incur accounting, audit, legal, regulatory, compliance, director and officer insurance and investor and public relations
costs associated with being a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Results of Operations</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Comparison of the year ended December 31,
2020 and 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes the results of operations
for the years ended December 31, 2020 and 2019, respectively, together with the changes in those items in dollars:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Research and development&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,210</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,717</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,493</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Marketing&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,889</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General and administrative &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,970</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating loss&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,923</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,571</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,352</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Financial (income) expenses, net&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(108</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(43,815</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(22,563</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(21,252</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Research and Development Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our research and development
expenses incurred during the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Research and Development Expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">R&amp;D - salaries and wages &#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,091</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">437</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,384</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">661</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">R&amp;D - professional services &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,647</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,450</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Other &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses increased by
$6.5 million to $9.2 million for the year ended December&nbsp;31, 2020 from $2.7 million for the year ended December 31, 2019. The increase
in research and development expenses was primarily attributable to increases in salaries and wages, share-based compensation and professional
services as we continue to expand our research and development activities relating to the Nanox System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Marketing, General and Administrative Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our marketing expenses
incurred during the periods presented:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Marketing Expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Marketing &ndash; salaries and wages&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">733</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">200</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Marketing and business development&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,460</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">739</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Share-based compensation &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">617</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,556</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Marketing expenses increased by $10.89 million
to $12.45&nbsp;million for the year ended December&nbsp;31, 2020 from $1.6 million for the year ended December 31, 2019. The increase
in marketing expenses was primarily attributable to increases in salaries and wages, share-based compensation (of which $6.1 million related
to the amendment to a certain business development agreement with two of our finders, as discussed in &ldquo;Item 4. Information on the
Company&mdash;B. Business Overview&mdash;Commercial Agreements&mdash;MSaaS Agreements&rdquo;), and professional services as we continue
to expand our business and to build management infrastructure to move toward the commercial stage of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our general and administrative
expenses incurred during the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: -0.125in; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: -0.125in; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: -0.125in; font-weight: bold">General and Administrative Expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0in">G&amp;A &ndash; salaries and wages&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,847</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">461</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0in">Share-based compensation&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,967</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0in">Executives and officers&rsquo; insurance &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,812</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">---</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0in">Management fee&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">534</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0in">G&amp;A &ndash; professional services&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,449</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,470</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0in">Legal fees&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">671</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0in">Rent and Maintenance&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">620</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0in">Depreciation and Amortization&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0in">Other&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">274</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in">Total&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,298</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses increased
by $4.0 million to $22.3&nbsp;million for the year ended December&nbsp;31, 2020 from $18.3&nbsp;million for the year ended December 31,
2019. The increase in general and administrative expenses was primarily attributable to increases in salaries and wages, executives&rsquo;
insurance and professional services as we continue to expand our business and to build management infrastructure to move toward the commercial
stage of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Comparison of the years ended December&nbsp;31,
2019 and 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes the results of operations
for the years ended December&nbsp;31, 2019 and 2018, respectively, together with the changes in those items in dollars:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating expenses</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Research and development&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,717</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">672</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,045</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Marketing&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">209</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,347</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">General and administrative &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,023</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,275</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating loss&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,571</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,904</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,667</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Financial (income) expenses, net&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(22,563</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,909</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(20,654</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Research and Development Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our research and development
expenses incurred during the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Research and Development Expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">R&amp;D - salaries and wages &#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">437</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">131</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">661</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">R&amp;D - professional services &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">519</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Other &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,717</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">672</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses increased by
$2 million to $2.7&nbsp;million for the year ended December&nbsp;31, 2019 from $0.7&nbsp;million for the year ended December 31, 2018.
The increase in research and development expenses was primarily attributable to increases in salaries and wages, share-based compensation
and professional services as we continue to expand our research and development activities relating to the Nanox System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Marketing, General and Administrative Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our marketing expenses
incurred during the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Marketing Expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Marketing &ndash; salaries and wages&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">200</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Marketing and business development&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">739</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">209</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Share-based compensation &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">209</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Marketing expenses increased by increased by $1.35
million to $1.56&nbsp;million for the year ended December&nbsp;31, 2019 from $0.21&nbsp;million for the year ended December 31, 2018.
The increase in marketing expenses was primarily attributable to increases in share-based compensation and professional services as we
continue to expand our business and to build management infrastructure to move toward the commercial stage of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our general and administrative
expenses incurred during the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">General and Administrative Expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">G&amp;A &ndash; salaries and wages&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">461</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">88</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,967</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Management fee&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">534</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">429</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">G&amp;A &ndash; professional services&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">417</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Other&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">449</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,023</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses increased
by increased by $17.3 million to $18.3 million for the year ended December&nbsp;31, 2019 from $1.0&nbsp;million for the year ended December
31, 2018. The increase in general and administrative expenses was primarily attributable to increases in share-based compensation and
professional services as we continue to expand our business and to build management infrastructure to move toward the commercial stage
of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Critical Accounting Policies and Significant
Judgments and Estimates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our consolidated financial statements are prepared
in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements
and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and
expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience,
known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate
our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or
conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While our significant accounting policies are
described in more detail in Note 2 to our audited consolidated financial statements appearing elsewhere in this annual report on Form
20-F, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation
of our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Use of Estimates in the Preparation of
Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of the consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported
amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates and such differences may
have a material impact on our consolidated financial statements. As applicable to the consolidated financial statements, the most significant
estimates relate to fair value of share-based payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Functional Currency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The U.S. dollar is the currency of the primary
economic environment in which our operations is conducted. A&nbsp;substantial portion of the operational costs are denominated in U.S.
dollars. Accordingly, our functional currency is the U.S. dollar (&ldquo;primary currency&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Foreign currency assets and liabilities are translated
into the primary currency using the exchange rates in effect on the consolidated balance sheet date. Equity accounts are translated at
historical rates, except for the change in accumulated deficit during the year, which is the result of the income statement translation
process. Expense accounts are translated using the weighted average exchange rate during the period. Currency transaction gains and losses
are presented in financial income and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Property and Equipment, Net</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Property and equipment are stated at cost, net
of accumulated depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful lives:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; width: 90%; padding-right: 5.4pt; padding-left: 0in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in">&nbsp;</P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 10%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>%</B></P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Computers and electronic equipment&#9;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">10&ndash;33</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Office furniture and lab equipment&#9;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">6-20</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Machines&#9;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">10-20</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0in">Leasehold Improvement&#9;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">10</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 0in">Land&#9;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 0in">Construction in progress &#9;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0</TD></TR>
</TABLE>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Impairment of Long-Lived Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our long-lived assets are reviewed for impairment
in accordance with ASC No. 360, &ldquo;Property, Plant and Equipment,&rdquo; whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable. The recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by such assets. If such assets are
considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds
the fair value of the assets. During the years ended December 31, 2020 and 2019, no impairment triggering events were identified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Legal and Other Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are involved in claims and other legal proceedings
that arise from time to time in the ordinary course of business. We record accruals for these types of contingencies to the extent that
we conclude their occurrence is probable and that the related liabilities are estimable. When accruing these costs, we will recognize
an accrual in the amount within a range of loss that is the best estimate within the range. When no amount within the range is a better
estimate than any other amount, we accrue for the minimum amount within the range. We record anticipated recoveries under existing insurance
contracts that are virtually certain of occurring at the gross amount that is expected to be collected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We review the adequacy of the accruals on a periodic
basis and may determine to alter our reserves at any time in the future if we believe it would be appropriate to do so. As such accruals
are based on management&rsquo;s judgment as to the probability of losses and, where applicable, actuarially determined estimates, accruals
may materially differ from actual verdicts, settlements or other agreements made with regards to such contingencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses are charged
to the statement of operations as incurred and consist primarily of personnel, materials and supplies for research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Marketing and Sales Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Marketing expenses consist primarily of marketing
campaigns and business development expenses. Marketing expenses are charged to the statement of operations, as incurred. Marketing expenses
for the years ended December&nbsp;31, 2020 and 2019, amounted to $12.45&nbsp;million and $1.6&nbsp;million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Income Tax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for income taxes in accordance with
ASC 740, &ldquo;Income Taxes&rdquo; (&ldquo;ASC 740&rdquo;). ASC 740 prescribes the use of the liability method whereby deferred tax
asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
We provide a valuation allowance, if necessary, to reduce deferred tax assets to the assets&rsquo; estimated realizable value if it is
more likely than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive
and negative evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU 2015-17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Taxes that would apply in the event of disposal
of investments in our foreign subsidiary have not been taken into account in computing the deferred income taxes, as it is our intent
and ability to hold these investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We account for uncertain tax positions in accordance
with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate
the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is
more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution
of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than
50% (cumulative probability) likely to be realized upon ultimate settlement. We accrue interest and penalties related to unrecognized
tax benefits under taxes on income (tax benefit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Share-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We measure and recognize share-based compensation
expense in our consolidated financial statements based on the grant date fair value for all share-based payment awards made to non-employees,
employees, officers and directors. We recognize the grant date fair value of the award as an expense based on the straight-line method
over the requisite service periods in our consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We estimated the grant date fair value of share
options for the years ended December 31, 2020 and 2019 using the Black-Scholes option-pricing model. Our use of the Black-Scholes option-pricing
model requires the input of highly subjective assumptions, including estimated fair value of our ordinary share price, expected share
price volatility and expected term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Estimated Fair Value of Share Price. Because our shares were
                                            not publicly traded prior to our initial public offering, we estimated the fair value of
                                            options granted to non-employees, employees, officers and directors at the date of grant
                                            using a number of objective and subjective factors consistent with the methodologies outlined
                                            in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Companies
                                            Equity Securities Issued as Compensation, and based on independent third-party valuations
                                            that we obtained on a periodic basis. Following our initial public offering, our ordinary
                                            shares are publicly traded, and therefore we currently base the value of our ordinary shares
                                            on their market price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Risk-Free Interest Rate. We base the risk-free interest rate
                                            on the implied yield on currently available U.S. treasury bonds with a remaining term equal
                                            to the expected life of our options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Dividend Yield. We base dividend yield on our historical experience
                                            and expectation of no future dividend payouts. We have historically not paid cash dividends
                                            and have no foreseeable plans to pay cash dividends in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Expected Volatility. We base expected share price volatility
                                            on the historical volatility of the ordinary shares of comparable companies that are publicly
                                            traded.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Expected Term. The expected term of options granted represents
                                            the period of time that options granted are expected to be outstanding. As we do not have
                                            sufficient historical exercise data to provide a reasonable basis upon which to estimate
                                            expected term, the expected term was determined using the simplified method, which takes
                                            into consideration the option&rsquo;s contractual life and the vesting periods.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any changes in these highly subjective assumptions
would significantly impact our share-based compensation expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Loss per Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Basic earnings per share are computed by dividing
net income (loss) attributable to our ordinary shareholders by the weighted average number of ordinary shares outstanding for each reporting
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In computing our diluted earnings per share, the
denominator for diluted earnings per share is a computation of the weighted-average number of ordinary shares and the potential dilutive
ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding include the dilutive effect of in-the-money
options using the treasury stock method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We did not take into account any dilutive instruments,
such as share-based payments, since their effect, on a fully diluted basis, is anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Fair Value Measurement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Fair value is based on the price that would be
received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants
at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair
value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">Level 1:&#9;Quoted prices (unadjusted)
in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority
to Level 1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">Level 2:&#9;Observable prices that are
based on inputs not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">Level 3:&#9;Unobservable inputs are used
when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In determining fair value, we utilize valuation
techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers
counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Deferred offering costs directly relating to our
initial public offering are capitalized. As of December 31, 2020 we did not capitalize any deferred offering costs on the consolidated
balance sheet, comparing to $1.2 million as of December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">JOBS Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The JOBS Act permits an &ldquo;emerging growth
company&rdquo; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable
to public companies until those standards would otherwise apply to private companies. We have elected to &ldquo;opt out&rdquo; of such
extended transition period and, as a result, we will comply with new or revised accounting standards as required when they are adopted
for public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Recently Issued Accounting Pronouncements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A description of recently issued accounting pronouncements
that may potentially impact our financial position and results of operations is disclosed in Note 2 to our audited consolidated financial
statements, included elsewhere in this annual report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">B. Liquidity and Capital Resources</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since our inception, we have not generated any
revenue from product sales or otherwise, and have incurred significant operating losses and negative cash flows from our operations.
We have not yet commercialized any products or technologies, and we do not expect to generate revenue from sales of any products in the
near term, if at all. We have funded our operations to date primarily with proceeds from the sale of our and our predecessor company&rsquo;s
ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Cash Flows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides information regarding
our cash flows for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Net cash used in operating activities&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">($</TD><TD STYLE="width: 9%; text-align: right">21,487</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">($</TD><TD STYLE="width: 9%; text-align: right">5,524</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">($</TD><TD STYLE="width: 9%; text-align: right">3,671</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used in investing activities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,937</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(125</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(73</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by financing activities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,991</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,861</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,684</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net change in cash and cash equivalents and restricted cash&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">205,567</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,212</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(60</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Net Cash used in Operating Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the years ended December&nbsp;31, 2020,
2019 and 2018, net cash used in operating activities was $21.5&nbsp;million, $5.5&nbsp;million and $3.7 million, respectively, resulting
from our net loss of $43.8&nbsp;million, $22.6&nbsp;million and $1.9 million, respectively, adjusted for stock-based compensation changes
of $24.8 million, non-cash charges of $0.2 million and changes in components of working capital of ($2.7)&nbsp;million for the year ended
December 31, 2020, $16.25&nbsp;million, $0.1 million and $0.75 million for the year ended December 31, 2019 and $0.1 million, $0.1 million
and ($1.9) million for the year ended December 31, 2018, respectively. The&nbsp;increase in cash used in operating activities was primarily
due to activities related to our business expansion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Net Cash used in Investing Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the years ended December&nbsp;31, 2020,
2019 and 2018, net cash used in investment activities was $13.9&nbsp;million, $0.1&nbsp;million and $0.1 million, respectively. The increase
in cash used in investing activities during the year ended December 31, 2020 was primarily due to purchases of land and equipment in
Korea, as part of the preparation for the commencement of full manufacturing activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Net Cash provided by Financing Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the years ended December&nbsp;31, 2020,
2019 and 2018, net cash provided by financing activities was $241&nbsp;million, $13.9&nbsp;million and $3.7 million, respectively, primarily
due to proceeds from the issuance of ordinary shares and warrants, net of issuance costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Funding Requirements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect our expenses to increase in connection
with our ongoing activities, particularly as we continue the research and development of the Nanox System and seek marketing approval
for this product. In addition, we incur additional costs associated with operating as a public company. Our expenses will also increase
if, and as, we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>seek regulatory approvals for any additional products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>seek to discover and develop additional products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>establish a manufacturing, sales, marketing, medical affairs
                                            and distribution infrastructure to commercialize the Nanox System for which we may obtain
                                            marketing approval and intend to commercialize on our own or jointly;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>hire additional quality control and scientific personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>expand our operational, financial and management systems and
                                            increase personnel, including personnel to support our clinical development, manufacturing
                                            and commercialization efforts and our operations as a public company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>construct <FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            manufacturing facility in South Korea for the purpose of manufacturing MEMs X-ray chips;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>maintain, expand and protect our intellectual property portfolio;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>acquire or in-license other products and technologies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that our cash on hand and cash equivalents will enable us
to fund our operating expenses and capital expenditure requirements for at least the next twelve months from the date of issuance of the
financial statements. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital
resources sooner than we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because of the numerous risks and uncertainties
associated with manufacture, research, development and commercialization of products, we are unable to estimate the exact amount of our
working capital requirements. Our&nbsp;future funding requirements will depend on, and could increase significantly as a result of, many
factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the scope, progress, results and costs of researching and developing
                                            the Nanox System;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the costs, timing and outcome of regulatory review of the Nanox.ARC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the costs of future activities, including product sales, medical
                                            affairs, marketing, manufacturing and distribution, for the Nanox System for which we receive
                                            marketing approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>commercial manufacturing, shipping, installation and deployment
                                            of the Nanox System and sufficient inventory to support commercial launch;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the revenue, if any, received from commercial sale of the Nanox
                                            System, should the Nanox.ARC receive marketing approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the cost and timing of hiring new employees to support our continued
                                            growth;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the costs of preparing, filing and prosecuting patent applications,
                                            maintaining and enforcing our intellectual property rights and defending intellectual property-related
                                            claims;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the ability to establish and maintain collaborations on favorable
                                            terms, if at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the costs incurred with respect to and the outcome of the securities
                                            class-action litigation we are currently subject to and any similar or other claims and litigation
                                            we may be subject to in the future; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the timing, receipt and amount of sales of the Nanox System,
                                            if any.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A change in any of these or other variables with
respect to the development of any of our products could significantly change the costs and timing associated with the development of
that product. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital
requirements associated with such operating plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Until such time, if ever, as we can generate substantial
product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations,
strategic partnerships or marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of
such securities could include liquidation or other preferences that adversely affect your rights as an ordinary shareholder. Debt financing
and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take
specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing
would result in increased fixed payment obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we raise funds through collaborations, strategic
partnerships or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, research programs or products or grant licenses on terms that may not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are unable to raise additional funds when
needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts, or grant rights
to develop and market products that we would otherwise prefer to develop and market ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">C. Research and Development, Patents and Licenses, etc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Research and Development Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses are charged
to the statement of operations as incurred and consist primarily of personnel, materials and supplies for research and development activities.
See &ldquo;Item 5. Operating and Financial Review and Prospects&mdash;A. Operating Results&mdash;Critical Accounting Policies and Significant
Judgments and Estimates&mdash;Research and Development Expenses.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Intellectual Property</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of February 28, 2021, we had four issued patents in the United States
and six provisional or pending U.S.&nbsp;patent applications. We also had three patents issued in Israel, two patents pending in Israel,
five pending patent applications in the European Patent Office and two pending Patent Cooperation Treaty patent applications, which are
the counterparts of our U.S. patent applications. As of January 3, 2021, we had three patents issued in each of Japan and China, two patents
pending in each of Japan and China and five pending patent applications in Korea. Our issued patents expire between the years 2032 and
2034, and are directed to various features and combinations of features of the Nanox.ARC. We also have three trademarks granted and three
trademarks pending in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to continue filing for patents on new
technologies as they are developed and to actively pursue any infringement upon our patents. We believe that our know-how and trade secrets
represent de facto barriers to potential competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">D. Trend Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a development-stage company and cannot
predict with any degree of accuracy the outcome of our research and development efforts. As such, we cannot predict with any degree of
accuracy any significant trends, uncertainties or events that are reasonably likely to have a material effect on our net loss, liquidity
or capital resources, or cause financial information to not be indicative of future operating results or financial condition. However,
to the extent possible, certain trends, uncertainties, demands, commitments and events are described in this &ldquo;Item 5. Operating
and Financial Review and Prospects.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">E. Off-Balance Sheet Arrangements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We did not have during the
periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">F. Contractual Obligations
and Commitments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table summarizes
our contractual obligations as of December&nbsp;31, 2020 and the effects that such obligations are expected to have on our liquidity
and cash flows in future periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payment due by period</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Contractual Obligations</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than 1&nbsp;year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">1-3 &nbsp;years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">3-5 &nbsp;years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>More
than</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5&nbsp;years</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Capital (Finance) Lease Obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left">Operating Lease Obligations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,558</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">588</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">970</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Purchase Obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">588</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">970</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have entered into contracts
in the normal course of business with third parties. These contracts do not contain any minimum purchase commitments and are cancelable
by us upon prior notice and, as a result, are not included in the table of contractual obligations and commitments above. Payments due
upon cancellation consist only of payments for services provided and expenses incurred, including non-cancelable obligations of our service
providers, up to the date of cancellation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">G. Safe Harbor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This annual report on Form 20-F contains forward-looking
statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and as defined in the Private
Securities Litigation Reform Act of 1995. See section titled &ldquo;Forward-Looking Statements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_007"></A>Item 6.</TD><TD>Directors, Senior Management and Employees</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. Directors and Senior Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information concerning
our executive officers and directors, including their ages, as of March 20, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 24%"><DIV STYLE="padding: 0in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Name</B></P>
</DIV></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Age</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 64%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Position</B></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><B>Executive Officers</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Ran Poliakine&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">53</TD>
    <TD>&nbsp;</TD>
    <TD>Founder, Chief Executive Officer and Chairman of the Board</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Itzhak Maayan&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">55</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>James Dara&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">51</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Operating Officer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Tal Shank&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">43</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President Corporate Development</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Ofir Koren&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">51</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Technology Officer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Tamar Aharon Cohen&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">44</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Marketing Officer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Anat Kaphan&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">51</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President Product Marketing</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Shirly Kaufman-Kirshenbaum&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">46</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President Human Resources</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><B>Non-Employee Directors</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Onn Fenig&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">46</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Floyd Katske&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">69</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Jung Ho Park&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">57</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Erez Meltzer&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">63</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Richard Stone&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">78</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Noga Kainan&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">66</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Dan Suesskind&#9;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">77</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
</TABLE>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Ran Poliakine</B>, our founder, has served as
a member of our board of directors since our inception and has served as the Chairman of the Board of Directors since the closing of our
initial public offering. Mr.&nbsp;Poliakine has served as our Chief Executive Officer since September 2019, and served as Chief Executive
Officer of Nanox Gibraltar since August 2018. Prior to that, he served as Chief Strategy Officer in Nanox Gibraltar from June 2015 to
August 2018. Mr.&nbsp;Poliakine is a serial entrepreneur and has founded numerous companies over the past two decades, including SixAI
Ltd. (&ldquo;SixAI&rdquo;) and its controlled subsidiary (51%) 634 Ai Ltd. (previously known as Musashi Ai Ltd.) (&ldquo;634 Ai&rdquo;),
Powermat Technologies Ltd., Wellsense, Inc., Wellsense Technologies Ltd., Tap Systems, Inc. and Illumigyn Ltd. (&ldquo;Illumigyn&rdquo;).
Mr.&nbsp;Poliakine is a member of the board of directors of SixAI, Powermat Technologies Ltd., 634 Ai, and CLKIM Ltd. In addition, Mr.&nbsp;Poliakine
currently serves as a member of senior management of Illumigyn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Itzhak Maayan</B> has served as our Chief Financial
Officer since November 2019. Prior to joining us, Mr.&nbsp;Maayan served in different finance leadership roles in Perrigo Company from
2007 to 2019, including Vice&nbsp;President, Financial Services and European Investor Relations, Vice President, International Finance,
and Vice&nbsp;President and Chief Financial Officer, Perrigo Israel. Prior to Perrigo Company, Mr.&nbsp;Maayan held various finance leadership
roles at Cisco Systems Israel from 2003 to 2007, Xtivia, Inc. from 1999 to 2003, Kulick &amp; Soffa from 1995 to 1999 and Elscint Ltd.
from 1993 to 1995. Mr.&nbsp;Maayan received his bachelor&rsquo;s degree in economics and accounting from Haifa University, and is a Certified
Public Accountant in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>James Dara</B> has served as our Chief Operating
Officer since January 2021. Prior to joining us, Mr.&nbsp;Dara served as President of myCharge from 2012 to 2020. Prior to myCharge,
Mr.&nbsp;Dara served as Vice President of Business Development for Powermat Technologies Ltd. from 2009 to 2014 and as Interim CEO and
Vice President of Business Development of Wellsense Technologies Ltd. from 2009 to 2015. From 2003 to 2009, Mr.&nbsp;Dara served as Chief
Sales Officer, Senior Vice President and General Manager of North America for Braintech Inc. In addition, from 1998 to 2002, Mr.&nbsp;Dara
served as a Sales Manager and Sales Engineer for ITW Shakeproof Group. Mr.&nbsp;Dara received his bachelor of science in Mechanical Engineering
from Michigan State University, and his master&rsquo;s degree in Finance from Walsh University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><B>Tal Shank</B> has served as our Vice President
of Corporate Development since September 2019. Mr.&nbsp;Shank has served as Head of Corporate Development at Illumigyn from 2017 to date.
Mr.&nbsp;Shank currently serves on the board of directors of Nanox Gibraltar. From 2016 to 2017, Mr.&nbsp;Shank was responsible for the
corporate and governance aspects of Head Start, a company supplier of services to technology portfolio companies related to Ran Poliakine.
Prior to that, Mr.&nbsp;Shank served as Deputy CEO &amp; Legal Counsel of Speech Modules Holdings Ltd. from 2014 to 2015. From 2009 to
2014, Mr.&nbsp;Shank worked at Guy, Bachar &amp; Co. Law Firm, where he started as an associate and became partner in 2011. Mr.&nbsp;Shank
has practiced corporate and securities law in Israel since 2003, and he holds an M.B.A. and a LL.M. from Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Ofir Koren </B>has served
as our Chief Technology Officer since January 2021. Prior to joining us, Mr.&nbsp;Koren served as General Manager Israel and Vice President
of Research &amp; Development and Regulatory at ReWalk Robotics from 2013 to 2021. From 2012 to 2013, Mr.&nbsp;Koren served as Research
&amp; Development Manager for ReWalk Robotics. Prior to ReWalk Robotics, Mr.&nbsp;Koren served as General Manager at RuggedCOM from 2009
to 2012. From 2007 to 2009, Mr.&nbsp;Koren served as Vice President of Research &amp; Development at Alvarion. Mr.&nbsp;Koren served
as Research &amp; Development Director at Alvarion from 2004 to 2007. Mr.&nbsp;Koren received his bachelor of science in Electrical Engineering
from Tel Aviv University, and he holds an M.B.A. from Heriot-Watt University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 20pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Tamar Aharon Cohen</B>
has served as our Chief Marketing Officer since January 2021. Prior to joining us, Ms.&nbsp;Aharon Cohen served as the Chief Executive
Officer of Tempo Beverages Cyprus Ltd from 2017 to 2021. Ms.&nbsp;Aharon Cohen served as a Marketing Manager and a Division Manager at
Tempo Beverages Ltd from 2010 to 2017. From 2006 to 2010, Ms.&nbsp;Aharon Cohen served as a Marketing Manager, for L&rsquo;Or&eacute;al
Israel. Ms.&nbsp;Aharon Cohen holds a bachelor of Law, a bachelor&rsquo;s in Management and an executive M.B.A. from Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 20pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Anat Kaphan</B> has served
as our Vice President of Product Marketing since September 2019. Prior to joining us, Ms.&nbsp;Kaphan served as Vice President of Product
and Marketing at Mazor Robotics Ltd. from 2015 to 2018, and General Manager at Essence Group from 2014 to 2015. She also served as Marketing
Director at Phillips from 2011 to 2014. Prior to that, Ms.&nbsp;Kaphan served as Business Development Director at Lumenis from 2001 to
2011 and Product Manager at Elscint Ltd. from 1991 to 2001. Ms.&nbsp;Kaphan holds an M.B.A. in International marketing from Tel Aviv
University and received her bachelor&rsquo;s degree in Economics and Accounting from Haifa University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 20pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>Shirly Kaufman-Kirshenbaum
</B>has served as our Vice President Human Resources since April 2020. Prior to joining us, Ms.&nbsp;Kaufman-Kirshenbaum served as Human
Resources Director of Israeli-American Council (IAC) from December 2017 to April 2020, and as Regional Human Resources Director and HRBP
of EMEA and Canada at ZIM Integrated Shipping Services Ltd. from September 2010 to August 2016. Ms.&nbsp;Kaufman-Kirshenbaum has her
bachelor&rsquo;s degree in Human Resources from Haifa University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Directors</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><B>Onn Fenig</B> has served as a member of our
board of directors since November 2019. Mr.&nbsp;Fenig has served as the chairman of the board of directors of &ldquo;Beit Meitar&rdquo;
Waldorf Education Association since 2018. Mr.&nbsp;Fenig is a member of the board of directors of SixAI and manages the operations
of 634 Ai. Mr.&nbsp;Fenig has served as Chief&nbsp;Executive Officer and a member of the board of directors of Rioglass Solar systems
Ltd. since 2014, and as Chief Executive Officer of Rioglass Solar Receivers BU from 2016 to 2018. Prior to that, Mr.&nbsp;Fenig co-founded
and served as a member of the board of directors of DUTYFREEBEE LTD from 2013 to 2015. From 2011 to 2014, Mr.&nbsp;Fenig served as Commercial
Director, Project Acquisition Finance at Siemens, where he managed finance and commercial matters relating to engineering procurement
and construction projects. Prior to joining Siemens, Mr.&nbsp;Fenig served as Finance Manager, Inside Sales European Markets at Cisco
Systems from 2008 to 2010, Service Fulfilment Delivery Manager at Amdocs UK from 2006 to 2008, and Systems Analyst, Cyber Security Department
at Israeli Ministry of the Prime Minister from 2001 to 2005. Mr.&nbsp;Fenig received his bachelor&rsquo;s degree in Computer Science
from the Interdisciplinary Center Herzliya in Herzliya, Israel, and holds an M.B.A. from the University of Chicago Booth School of Business
in Chicago, Illinois.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Floyd Katske</B> has served as a member of
our board of directors since February 2020. Dr.&nbsp;Katske serves on the board of directors of Floyd A. Katske, M.D., a professional
corporation, and Triurol Inc. Since 1983, Dr.&nbsp;Katske has served as President of Floyd A. Katske, M.D. and since 1999, he has served
as President of Triurol, Inc. From 2009 to 2011, Dr.&nbsp;Katske served as the President of the Santa Clarita Valley Medical Society
and from 1997 to 1999, Dr.&nbsp;Katske served as the President of the California Urologic Association. Dr.&nbsp;Katske is a member of
the Medical Board of California and has worked as a professor and as Chief of Staff, Chief of Surgery and Chief of Urology in various
hospitals. Dr.&nbsp;Katske received his bachelor&rsquo;s degree from Rutgers University, and received his medical degree from The George
Washington University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Jung Ho Park</B> has served as a member of
our board of directors since August 2020. Mr. Park has served as CEO of SK Telecom since March 2017 and Co-CEO of SK hynix since March
2021. In his role he also oversees SK ICT Family companies, which include SK broadband, 11street, ADT Caps and T map Mobility Co. He
serves on the board of directors for SK Telecom and is the Chairman of SK Group&rsquo;s ICT Committee. He previously served as the Vice
Chairman of SK Hynix. Prior to that, Mr.&nbsp;Park served as CEO of SK Holdings from 2015 to 2016, Executive Vice President of Corporate
Development Division of SK C&amp;C from 2013 to 2014, Executive Vice President of Corporate Development Division of SK Telecom from 2009
to 2014, Managing Director of Business Development of SK Communication from 2007 to 2008, Head of Tokyo office for SK Telecom beginning
in 2006, Director of Corporate Relations for the SK Group from 2004 to 2006 and President of the New York Branch Office of SK Telecom
from 1995 to 1999. Mr.&nbsp;Park received his bachelor&rsquo;s degree in Business Administration from Korea University, and received
a master&rsquo;s degree in Business Administration from George Washington University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Erez Meltzer</B> has served as a member of
our board of directors since December 2019. Mr.&nbsp;Meltzer served as the Executive Chairman of the board of directors of Hadassah Medical
and University Center from 2014 to 2020. Since 2008, Mr.&nbsp;Meltzer has served as a teaching professor at the Tel Aviv Faculty of Medicine
in the area of crisis management. Meltzer served as Executive Vice Chairman and Chief Executive Officer of Gadot Chemicals &amp; Shipping
Group from 2008 to 2013. Prior to that, he served as Chief Executive Officer of Africa-Israel Ltd from 2006 to 2008 and President and
Chief Executive Officer of Netafim Ltd from 2001 to 2006. Mr.&nbsp;Meltzer also served as Chief Executive Officer of Creo Scitex from
1996 to 2001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Richard Stone</B> has served as a member of
our board of directors since November 2019. Professor Stone has taught at Columbia University Law School since 1974, and became Professor
Emeritus in 2018. Professor Stone has taught courses in several fields of business law, specializing in federal income taxation. From
1969 to 1973, Professor Stone served in the United States Justice Department as Assistant to the Solicitor General of the United States.
Beginning in 1981, Professor Stone began providing consulting to private and public technology start-ups, primarily in the biotechnology
field. Professor Stone co-founded several biotechnology companies, including Lev Pharmaceuticals, Siga Technologies and OptMed. In 2007,
Professor Stone began working primarily with Israeli technology companies, mostly in the medical space. He is a member of the board of
directors of OptMed, Inc., Espro Information Technologies, Quality In Flow, LabStyle Innovations and Illumigyn. Professor Stone received
his bachelor&rsquo;s degree, Magna Cum Laude, from Harvard College, and his Juris Doctor degree, Magna Cum Laude, from Harvard Law School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Noga Kainan</B> has served as a member of our
board of directors since February 2021.&nbsp;Ms. Kainan established in 2008 the forum for owners, chairpersons and CEOs of the leading
companies in the Israeli economy. Ms. Kainan also serves as chairperson of the CFO Forum, which brings together the CFOs of the leading
companies in the economy, since she established it in 1997. Her public activities include membership in committees in the Israeli Prime
Minister&rsquo;s Office, member in the Board of Trustees of Bar Ilan University, the College of Management in Israel, and the council
of NGO for IDF soldiers&rsquo; welfare. Ms. Kainan heads an association that she founded to promote the integration of autistic students
in academia. Ms. Kainan served as a director of the following companies traded on the Tel Aviv Stock Exchange: Bizportal Ltd., Poalim
I.B.I &ndash; Managing &amp; Underwriting Ltd. and Analyst Provident Funds Ltd. She also served as director at Oil Refineries Ltd. before
the company was listed on the Tel Aviv Stock Exchange. She served as a representative at the International Association of Financial Executives
Institutes (IAFEI) and as Chair of the Founding Committee of the Organization of Foreign Companies traded in the U.S. Ms.&nbsp; Kainan,
co-authored &ldquo;Israel - Success Story,&rdquo; translated to English under the name: &ldquo;Israel - Island of Success.&rdquo; Ms.
Kainan has a bachelor&rsquo;s degree in art and literature from Haifa University and an M.B.A. from Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Dan Suesskind</B> has served as a member of
our board of directors since February 2021. Mr. Suesskind served as the Chief Financial Officer of Teva Pharmaceutical Industries Ltd.
(&ldquo;Teva&rdquo;) from 1977 to 2008 and as a director of Teva for several periods of time, until 2018. Mr. Suesskind also served as
a director of the following companies: Redhill Biopharma Ltd., Syneron Medical Ltd., Migdal Ltd., Ness Technologies Inc., The First International
Bank of Israel, First International Selective Investment &ndash; Portfolio Management Company LTD, Lanoptics Ltd., ESC Medical Systems
and the Hadassah Medical Center in Jerusalem. Mr. Suesskind is currently a director of Nexfar Limited - China, Israel Corporation Ltd.
and The Jerusalem Foundation. His public activities include membership in the Investment Committee of the Israeli Academy of Sciences
and Humanities, member in the Board of Trustees of The Hebrew University and the Board of Trustees of the Ben Gurion University. Mr.
Suesskind has a bachelor&rsquo;s degree in economics and political science from the Hebrew University of Jerusalem, an M.B.A. from the
University of Massachusetts, and a Certificate in Business Administration from the Hebrew University of Jerusalem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">B. Compensation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Compensation of Executive Officers and Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For so long as we qualify as a foreign private
issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement applicable
to emerging growth companies to disclose the compensation of our chief executive officer and other two most highly compensated executive
officers on an individual, rather than an aggregate, basis. The aggregate compensation, including bonuses described in more detail below
and share-based compensation, paid and by us to our executive officers and directors for the year ended December&nbsp;31, 2020 was approximately
$6.5&nbsp;million. In addition, approximately $274,000 in the aggregate was set aside or accrued to provide pension, severance, retirement
or similar benefits or expenses. The figure does not include business travel, relocation, professional and business association dues,
meals and expenses reimbursed to officers, and other benefits commonly reimbursed or paid by companies in Israel, on the same basis for
all full-time employees generally. The aggregate compensation to our executive officers and directors includes payments from Nanox Gibraltar,
including through Six-Eye Interactive Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During 2020, certain of our executive officers
received bonuses in the following gross amounts: $700,000 to Mr.&nbsp;Poliakine in recognition of his efforts in connection with our
initial public offering and certain private placement investments; $100,000 to Mr.&nbsp;Maayan in recognition of his efforts in connection
with our initial public offering; $40,911 to Mr.&nbsp;Yron in connection with his hiring as our Chief Business Officer; $139,000 to Mr.&nbsp;Shank
in recognition of his efforts in connection with our initial public offering and his contribution to our business; and $34,232 to Ms.&nbsp;Kaphan
in recognition of her efforts in connection with our initial public offering. The gross amounts were paid, less applicable taxes and
social security payments and withholdings to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We pay each of our non-employee directors who
serves on a board committee an annual retainer of $36,000, with additional annual payment for service on board committees as follows:
$7,500 (or $15,000 for the chairperson) per membership of any committee. In addition, our external directors receive a cash fee of $36,000
per year plus additional compensation for service on a committee, as discussed above, and options to purchase our ordinary shares with
an economic value at the date of grant of $580,723, vesting quarterly over a period of four years, with full acceleration upon consummation
of an M&amp;A Transaction (as defined in our 2019 Equity Incentive Plan). Effective as of October 1, 2020, we paid Dr. Floyd Katske a
cash amount of $200 per hour (not exceeding 100 hours per month) and a grant of Restricted Share Units (&ldquo;RSUs&rdquo;) in each calendar
quarter, in the amount calculated by dividing (a) two times the cash compensation paid during such quarter by (b) the fair market value
of our ordinary shares on the last trading day of such quarter for services provided to us not related to his duty as director. Effective
as of January 2, 2021, we appointed Erez Melzer as a &ldquo;Designated Director&rdquo; (as defined below) pursuant to the compensation
policy and will pay him additional compensation in such capacity, consisting of cash compensation of $80,000 per year, and $200,000 in
equity-based compensation in the form of RSUs to be granted in quarterly installments, calculated according to the fair market value
of our ordinary shares on the last trading day of such quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Directorship Agreements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into directorship agreements with
each of our directors, pursuant to which such directors will serve on our board of directors. Pursuant to these agreements, each director
was granted options under our 2019 Equity Incentive Plan in the number and terms set out under &ldquo;&mdash;Equity Incentive Plan&rdquo;
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Employment Agreements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into written employment agreements
with certain of our executive officers. These agreements provide for notice periods of varying duration for termination of the agreement
by us or by the relevant executive officer, during which time the executive officer will continue to receive base salary and benefits.
These agreements also contain customary provisions regarding non-competition, confidentiality of information and assignment of inventions.
However, the enforceability of the non-competition provisions may be limited under applicable law. See &ldquo;Item 3. Key Information&mdash;D.
Risk Factors&mdash;Risks Related to Employee Matters&mdash;Under applicable employment laws, we may not be able to enforce covenants
not to compete and therefore may be unable to prevent our competitors from benefitting from the expertise of some of our former employees&rdquo;
for a further description of the enforceability of non-competition clauses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into an employment agreement with
Ran Poliakine, our founder, director and Chief Executive Officer. Pursuant to the agreement, if the Company terminates Ran Poliakine&rsquo;s
employment and waives his obligation to perform services during the notice period of 180 days, Ran Poliakine will be entitled to receive
payments of his base salary and social benefits in lieu of notice for the waived period, up to the full notice period for an immediate
termination. The agreement provides Ran Poliakine with a gross monthly base salary equal to $40,000 which was increased to $60,000 upon
the consummation of our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Equity Incentive Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 3, 2019, we adopted the 2019 Equity
Incentive Plan and its U.S. sub-Plan (the &ldquo;2019 Equity Incentive Plan&rdquo; or &ldquo;Plan&rdquo;). The 2019 Equity Incentive
Plan is intended to afford an incentive to any of our and our affiliates&rsquo; employees, directors, officers, consultants, advisors
and any other person or entity who provides services to us, to continue as service providers, to increase their efforts on our and our
affiliates&rsquo; behalf and to promote our success, by providing such persons with opportunities to acquire a proprietary interest in
us. The U.S. sub-Plan applies to our and any of our affiliates&rsquo; employees, directors, officers, consultants, advisors and any other
person or entity who provides services to us who are subject to United States federal income tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may issue under the 2019 Equity Incentive Plan
and its U.S. sub-Plan up to 8,041,936 of our ordinary shares, subject to adjustment if particular capital changes affect our share capital
or such other number as our board of directors may determine from time to time. Ordinary shares subject to outstanding awards under the
2019 Equity Incentive Plan and its U.S. sub-Plan that subsequently expire, or are cancelled, forfeited or terminated for any reason before
being exercised will be automatically, and without any further action, returned to the share reserve under the Plan and will again be
available for grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth, as of December&nbsp;31,
2020, the total number of ordinary shares issuable upon exercise of the options granted to each of our executive officers and our non-employee
directors, the exercise price of such options, the grant date and the expiration date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date of Grant</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration Date</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Ran Poliakine&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,206,290</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: center">November 25, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: center">November 25, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Onn Fenig&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,234</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Floyd Katske&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,234</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 20, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 20, 2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Erez Meltzer&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,234</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 11, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 11, 2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Jung Ho Park&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 4, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 4, 2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Richard Stone&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,584</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Itzhak Maayan&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">161,107</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Gilad Yron<SUP>(1)</SUP>&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">26.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">October 22, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">October 22, 2030</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">James Dara&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">N/A</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">N/A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">N/A</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Anat Kaphan&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,754</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Ofir Koren&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">N/A</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">N/A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">N/A</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Yoel Raab<SUP>(2)</SUP>&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,754</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tamar Aharon Cohen&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">N/A</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">N/A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">N/A</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tal Shank&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 25, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shirly Kaufman-Kirshenbaum&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 20, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">April 20, 2030</TD></TR>
  </TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Mr. Yron ceased serving as an executive officer on February 28, 2021.
                                            As of February 28, 2021, Mr. Yron had 8,333 options that expire on May 31, 2021.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Mr.&nbsp;Raab ceased serving as an executive officer on January&nbsp;17,
                                            2021.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In January 2021, we approved the grant of options
to each of Ofir Koren, James Dara and Tamar Aharon Cohen in respect of 100,000, 100,000 and 33,000 ordinary shares, respectively. In
March 2021, our Compensation Committee and board of directors ratified and confirmed the above grants as required by the Israeli Companies
Law. All grants of options will be issued pursuant to the 2019 Equity Incentive Plan. All options held by our directors, our Chief Executive
Officer and our Chief Financial Officer will be fully accelerated upon a &ldquo;Deemed Liquidation&rdquo; as defined in the 2019 Equity
Incentive Plan and 50% of unvested options held by our other executive officers will be fully accelerated upon a &ldquo;Deemed Liquidation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For a description of our compensation policy,
see &ldquo;Item 6. Directors, Senior Management and Employees&mdash;C. Board Practices&mdash;Compensation Committee.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">C. Board Practices</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors currently consists of&thinsp;eight
directors. Our two external directors, as well as three additional directors, are qualified as independent directors under the corporate
governance standards of the Nasdaq corporate governance rules and the independence requirements of Rule&nbsp;10A-3 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under our amended and restated articles of association,
the number of directors on our board of directors will be no less than five and no more than ten. Pursuant to the Companies Law, the
board of directors must include at least two external directors who must be nominated within three months of the closing of the initial
public offering. We exceeded the three-month period. However, our shareholders approved the appointment of two external directors at
the shareholder meeting in February 2021, and as a result we are now in compliance with the Companies Law. The minimum and maximum number
of directors may be changed, at any time and from time to time, by vote of our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other than external directors, for whom special
election requirements apply under the Companies Law, as detailed below, our directors are divided into three classes with staggered three-year
terms. Each class of directors consists, as nearly as possible, of one-third of the total number of directors constituting the entire
board of directors (other than the external directors). At each annual general meeting of our shareholders, the election or re-election
of directors following the expiration of the term of office of the directors of that class of directors will be for a term of office
that expires on the third annual general meeting following such election or re-election, such that from 2021 and after, at each annual
general meeting, the term of office of only one class of directors will expire. Each director holds office until the third annual general
meeting of our shareholders and until his or her successor is duly appointed, unless the tenure of such director expires earlier pursuant
to the Companies Law or unless removed from office as described below, except that our external directors have a term of office of three
years under Israeli law (see&nbsp;&ldquo;&mdash;External Directors&mdash;Election and Dismissal of External Directors&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our directors, other than external directors,
are divided among three classes as follows: the Class&nbsp;I directors, consisting of Erez Meltzer and Richard Stone, will hold office
until our annual general meeting of shareholders to be held in 2021; the Class&nbsp;II directors, consisting of Onn Fenig and Floyd Katske,
will hold office until our annual general meeting of shareholders to be held in 2022; and the Class&nbsp;III directors, consisting of
Ran Poliakine and Jung Ho Park, will hold office until our annual general meeting of shareholders to be held in 2023. Our external directors,
Noga Kainan and Dan Suesskind, will hold office until our annual general meeting of shareholders in 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under our amended and restated articles of association,
our board of directors may appoint directors to fill vacancies on our board of directors, including if the number of directors is below
the maximum number of directors who may serve as provided in our amended and restated articles, for a term of office equal to the remaining
period of the term of office of the director(s) whose office(s) has been vacated. External directors are elected for an initial term
of three years and may be elected for up to two additional three-year terms under the circumstances described below. External directors
may be removed from office only under the limited circumstances set forth in the Companies Law. See &ldquo;&mdash;External Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under Israeli law, the chief executive officer
or a relative of the chief executive officer of a public company may not serve as the chairman of the board of directors of the company
and the chairman or a relative of the chairman may not be vested with the authority of the chief executive officer, in each case, unless
approved by a special majority of our shareholders as required under the Companies Law. The shareholders&rsquo; approval can be provided
for a period of five years following an initial public offering, and subsequently, for additional periods of up to three years. In addition,
a person who is subordinated, directly or indirectly, to the chief executive officer may not serve as the chairman of the board of directors;
the chairman of the board of directors may not be vested with authorities that are granted to persons who are subordinated to the chief
executive officer; and the chairman of the board of directors may not serve in any other position in the company or in a controlled subsidiary,
but he or she may serve as a director or chairman of a controlled subsidiary. Prior to our initial public offering, we obtained our shareholders&rsquo;
approval that Mr.&nbsp;Ran Poliakine may serve as both our chairman of the board of directors and chief executive officer for a period
of up to five years from the closing of our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, under the Companies Law, our board
of directors must determine the minimum number of directors who are required to have financial and accounting expertise. Under applicable
regulations, a director with financial and accounting expertise is a director who, by reason of his or her education, professional experience
and skill, has a high level of proficiency in and understanding of business accounting matters and financial statements. See&nbsp;&ldquo;&mdash;External
Directors&mdash;Qualifications of External Directors.&rdquo; He or she must be able to thoroughly comprehend the financial statements
of the company and initiate debate regarding the manner in which financial information is presented. In determining the number of directors
required to have such expertise, the board of directors must consider, among other things, the type and size of the company and the scope
and complexity of its operations. Our board of directors has determined that we require at least one director with the requisite financial
and accounting expertise and that Erez Meltzer has such expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no family relationships among any of
our office holders (including directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">External Directors</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Qualifications of External Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law, companies incorporated
under the laws of the State of Israel, whose shares are publicly traded, including companies with shares listed on the Nasdaq, are required
to appoint at least two external directors. Our shareholders approved the appointment of Noga Kainan and Dan Suesskind as external directors
in February 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A person may not be appointed as an external director
if the person is a relative of a controlling shareholder or if on the date of the person&rsquo;s appointment or within the preceding
two years the person or his or her relatives, partners, employers or anyone to whom that person is subordinate, whether directly or indirectly,
or entities under the person&rsquo;s control have or had any affiliation with any of&thinsp; (each an &ldquo;Affiliated Party&rdquo;):
(1) us; (2) any person or entity controlling us on the date of such appointment; (3) any relative of a controlling shareholder; or (4)
any entity controlled, on the date of such appointment or within the preceding two years, by us or by a controlling shareholder. If there
is no controlling shareholder or any shareholder holding 25% or more of voting rights in the company, a person may not be appointed as
an external director if the person has any affiliation to the chairman of the board of directors, the general manager (chief executive
officer), any shareholder holding 5% or more of the company&rsquo;s shares or voting rights or the senior financial officer as of the
date of the person&rsquo;s appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term affiliation includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>an employment relationship;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>a business or professional relationship maintained on a regular
                                            basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>control; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>service as an office holder, excluding service as a director
                                            in a private company prior to the first offering of its shares to the public if such director
                                            was appointed as a director of the private company in order to serve as an external director
                                            following the initial public offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term &ldquo;relative&rdquo; is defined as
a spouse, sibling, parent, grandparent, descendant, spouse&rsquo;s descendant, sibling and parent and the spouse of each of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A person may not serve as an external director
if that person or that person&rsquo;s relative, partner, employer, a person to whom such person is subordinate (directly or indirectly)
or any entity under the person&rsquo;s control has a business or professional relationship with any entity that has an affiliation or
other prohibited relationship with any Affiliated Party, even if such relationship is intermittent (excluding insignificant relationships).
Additionally, any person who has received compensation intermittently (excluding insignificant relationships) other than compensation
permitted under the Companies Law may not continue to serve as an external director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No person can serve as an external director if
the person&rsquo;s position or other affairs create, or may create, a conflict of interest with the person&rsquo;s responsibilities as
a director or may otherwise interfere with the person&rsquo;s ability to serve as an external director or if such a person is an employee
of the Israel Securities Authority or of an Israeli stock exchange. If at the time an external director is appointed all current members
of the board of directors, who are not controlling shareholders or relatives of controlling shareholders, are of the same gender, then
the external director to be appointed must be of the other gender. In addition, a person who is a director of a company may not be elected
as an external director of another company if, at that time, a director of the other company is acting as an external director of the
first company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Companies Law provides that an external director
must meet certain &ldquo;professional qualifications&rdquo; or have &ldquo;financial and accounting expertise&rdquo; and that at least
one external director must have &ldquo;financial and accounting expertise.&rdquo; However, if at least one of our other directors (1)
meets the independence requirements of the Exchange Act, (2) meets the standards of the Nasdaq corporate governance rules for membership
on the audit committee and (3) has &ldquo;financial and accounting expertise&rdquo; as defined in the Companies Law and applicable regulations,
then none of our external directors is required to possess financial and accounting expertise as long as they possess other requisite
professional qualifications. The determination of whether a director possesses &ldquo;financial and accounting expertise&rdquo; is made
by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The regulations promulgated under the Companies
Law define an external director with requisite professional qualifications as a director who satisfies one of the following requirements:
(1) the director holds an academic degree in either economics, business administration, accounting, law or public administration, (2)
the director either holds an academic degree in any other field or has completed another form of higher education in the company&rsquo;s
primary field of business or in an area which is relevant to his or her office as an external director in the company, or (3) the director
has at least five years of experience serving in any one of the following, or at least five years of cumulative experience serving in
two or more of the following capacities: (a) a senior business management position in a company with a substantial scope of business,
(b) a senior position in the company&rsquo;s primary field of business or (c)&nbsp;a senior position in public administration. The determination
of whether a director possesses the requisite &ldquo;professional qualifications&rdquo; is made by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Until the lapse of a two-year period from the
date that an external director of a company ceases to act in such capacity, the company in which such external director served, and its
controlling shareholder (as defined below) or any entity under control of such controlling shareholder, may not, directly or indirectly,
grant such former external director, or his or her spouse or child, any benefit, including via (i)&nbsp;the appointment of such former
director or his or her spouse or his child as an officer in the company or in an entity controlled by the company&rsquo;s controlling
shareholder, (ii)&nbsp;the employment of such person, and (iii)&nbsp;the engagement, directly or indirectly, of such person as a provider
of professional services for compensation, directly or indirectly, including via an entity under his or her control. With respect to
a relative who is not a spouse or a child, such limitations shall only apply for one year from the date such external director ceased
to be engaged in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term &ldquo;controlling shareholder&rdquo;
means a shareholder with the ability to direct the activities of the company, other than by virtue of being an office holder. A shareholder
is presumed to have &ldquo;control&rdquo; of the company and thus to be a controlling shareholder of the company if the shareholder holds
50% or more of the &ldquo;means of control&rdquo; of the company. &ldquo;Means of control&rdquo; is defined as (1) the right to vote
at a general meeting of a company or a corresponding body of another corporation; or (2) the right to appoint directors of the corporation
or its general manager. For the purpose of approving certain related-party transactions, the term also includes any shareholder that
holds 25% or more of the voting rights of the company if the company has no shareholder that owns more than 50% of its voting rights.
For the purpose of determining the holding percentage stated above, two or more shareholders who have a personal interest in a transaction
that is brought for the company&rsquo;s approval are deemed as joint holders. The term &ldquo;office holder&rdquo; is defined as a chief
executive officer (referred to in the Companies Law as a general manager), chief business manager, deputy general manager, vice general
manager, director or manager directly subordinate to the general manager or any other person assuming the responsibilities of any of
the foregoing positions, without regard to such person&rsquo;s title.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Audit Committee</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Companies Law Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law, the board of directors
of a public company must also appoint an audit committee comprised of at least three directors, including all of the external directors.
The audit committee may not include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the chairman of the board of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>a controlling shareholder or a relative of a controlling shareholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>any director employed by the company or by one of its controlling
                                            shareholders or by an entity controlled by one of its controlling shareholders (other than
                                            as a member of the board of directors);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>any director who regularly provides services to the company,
                                            to one of its controlling shareholders or to an entity controlled by one of its controlling
                                            shareholders; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>a director who derives most of his or her income from a controlling
                                            shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to the Companies Law, the majority of
the members of the audit committee, as well as the majority of members present at audit committee meetings, will be required to be &ldquo;independent&rdquo;
(as defined below) and the chairman of the audit committee will be required to be an external director. Any persons not qualified from
serving as a member of the audit committee may not be present at the audit committee meetings, unless the chairman of the audit committee
has determined that such person is required to be present at the meeting or if such person qualifies under one of the exemptions of the
Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The term &ldquo;independent director&rdquo; is
defined under the Companies Law as an external director or a director who meets the following conditions and who is appointed or classified
as such according to the Companies Law: (1) he or she meets the qualifications for being appointed as an external director, except for
(i)&nbsp;the requirement that the director be an Israeli resident (which does not apply to companies such as ours whose securities have
been offered outside of Israel or are listed outside of Israel); and (ii)&nbsp;the requirement for &ldquo;financial and accounting expertise&rdquo;
or professional qualifications, and the audit committee approves the director having met such conditions and (2) he or she has not served
as a director of the company for over nine consecutive years with any interruption of up to two years of his or her service not being
deemed a disruption to the continuity of his or her service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Nasdaq Listing Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Nasdaq corporate governance rules, we
are required to maintain an audit committee consisting of at least three independent directors, all of whom are financially literate
and one of whom has accounting or related financial management expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with U.S. law and Nasdaq requirements,
our audit committee is also responsible for the appointment, compensation and oversight of the work of our independent auditors and for
assisting our board of directors in monitoring our financial statements, the effectiveness of our internal controls and our compliance
with legal and regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our audit committee consists of Erez Meltzer,
Noga Kainan and Dan Suesskind. In accordance with the Companies Law, Noga Kainan serves as chairperson of the audit committee. Our board
of directors has determined, in its business judgment, that Noga Kainan is an audit committee financial expert as defined by the SEC
rules and has the requisite financial experience as defined by the Nasdaq corporate governance rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the members of the audit committee is
required to be &ldquo;independent&rdquo; as such term is defined in Rule&nbsp;10A-3(b)(1) under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Approval of Transactions with Related
Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The approval of the audit committee is required
to effect specified actions and transactions with office holders and controlling shareholders and their relatives, or in which they have
a personal interest. The audit committee may not approve an action or a transaction with a controlling shareholder or with an office
holder unless, among other things, at the time of approval the audit committee meets the composition requirements under the Companies
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Audit Committee Role</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors has adopted an audit committee
charter setting forth the responsibilities of the audit committee consistent with the rules of the SEC and the Nasdaq corporate governance
rules, as well as the requirements for such committee under the Companies Law, which include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>recommending the retention and termination of our independent
                                            registered public accounting firm to the board of directors in accordance with Israeli law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>recommending to the board of directors in accordance with Israeli
                                            law the appointment, compensation, retention and oversight of any accounting firm engaged
                                            for the purpose of preparing or issuing an audit report or performing other audit services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>recommending the terms of audit and non-audit services to be
                                            provided by the independent registered public accounting firm for pre-approval by our board
                                            of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>recommending the engagement or termination of the person filling
                                            the office of our internal auditor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reviewing with management and our independent directors our financial
                                            statements prior to their submission to the SEC; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>approval of certain transactions with office holders and controlling
                                            shareholders, as described below, and other related party transactions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, under the Companies Law, the role
of the audit committee includes the identification of irregularities in our business management, among other things, by consulting with
the internal auditor or our independent auditors and suggesting an appropriate course of action to the board of directors. The audit
committee is also required to adopt procedures with respect to processing of employees&rsquo; complaints in connection with deficiencies
in the management of the company, and the appropriate means of protection afforded to such employees. In addition, the audit committee
or the board of directors, as set forth in the articles of association of the company, is required to approve the yearly or periodic
work plan proposed by the internal auditor, and where the board of directors approves such work plan, to examine such work plan before
its submission to the board of directors and propose amendments thereto. The audit committee is required to assess the company&rsquo;s
internal audit system and the performance of its internal auditor. The Companies Law also requires that the audit committee assess the
scope of the work and compensation of the company&rsquo;s external auditor. In addition, the audit committee is required to determine
whether certain related party actions and transactions are &ldquo;material&rdquo; or &ldquo;extraordinary&rdquo; for the purpose of the
requisite approval procedures under the Companies Law and whether certain transactions with a controlling shareholder will be subject
to a competitive procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The audit committee charter shall state that in
fulfilling its role the committee is empowered to conduct or authorize investigations into any matters within its scope of responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Compensation Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law, public companies are
required to appoint a compensation committee in accordance with the guidelines set forth thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law, our compensation committee
must consist of at least three members. All of the external directors must serve on the committee and constitute a majority of its members.
The chairman of the compensation committee must be an external director. The remaining members are not required to be external directors,
but must be directors who would qualify to serve as members of the audit committee (as described above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The compensation committee consists of Onn Fenig,
Noga Kainan and Dan Suesskind, and assists the board of directors in determining compensation for our directors and officers. In accordance
with the Companies Law, Dan Suesskind serves as chairperson of the compensation committee. In addition, Onn Fenig replaced Erez Meltzer
on the compensation committee following the approval of Mr. Meltzer as a &ldquo;Designated Director&rdquo; at the shareholder meeting
in February 2021, since Mr. Meltzer&rsquo;s compensation disqualifies him from serving on the compensation committee under the Companies
Law. Under our compensation policy, a &ldquo;Designated Director&rdquo; is a member of the board of directors who due to his particular
stature or added value to us was designated as such by the compensation committee, board of directors and/or our shareholders, as applicable.
In accordance with our compensation policy, members of the board of directors who are determined as Designated Directors are eligible
to receive additional compensation from us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with the Companies Law, the roles
of the compensation committee are, among others, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>to recommend to the board of directors the compensation policy for
                                            directors and officers, and, once every three years, or five years from a company&rsquo;s
                                            initial public offering, to recommend to the board of directors, whether the compensation
                                            policy that had been approved should be extended for a longer period of time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>to recommend to the board of directors updates to the compensation
                                            policy, from time to time, and examine its implementation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>to decide whether to approve the terms of office and employment of
                                            directors and officers that require approval of the compensation committee; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>to decide whether the compensation terms of the chief executive officer,
                                            which were determined pursuant to the compensation policy, will be exempted from approval
                                            by the shareholders because such approval would harm the ability to engage the chief executive
                                            officer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the roles mentioned above, our
compensation committee may also make recommendations to our board of directors regarding the awarding of employee equity grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In general, under the Companies Law, a public
company must have a compensation policy approved by the board of directors after receiving and considering the recommendations of the
compensation committee. In addition, the compensation policy requires the approval of the general meeting of the shareholders. In public
companies such as our company, shareholder approval by a majority vote of the ordinary shares present and voting at a meeting of shareholders
called for such purpose is required, provided that either: (i)&nbsp;such majority includes the majority of the votes of those shareholders
who are non-controlling shareholders and do not have a personal interest in the approval of the compensation policy, who voted at the
meeting (excluding abstentions) or (ii)&nbsp;the total number of votes against the proposal among the shareholders mentioned in clause
(i)&nbsp;does exceed 2% of the voting rights in the company. Under special circumstances, the board of directors may approve the compensation
policy despite the objection of the shareholders on the condition that the compensation committee and then the board of directors decide,
on the basis of detailed arguments and after discussing again the compensation policy, that approval of the compensation policy, despite
the objection of the meeting of shareholders, is in the best interests of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">However, if a company initially offering its securities
to the public, adopts a compensation policy in advance of its initial public offering, and describes the compensation policy in the prospectus
relating to the offering, or adopts a compensation policy within nine months from the date the company becomes a public company, then
the compensation policy is deemed a validly adopted policy in accordance with the Companies Law requirements described above and will
be valid for a term of five years from the date such company becomes a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The compensation policy must be based on certain
considerations, include certain provisions and needs to reference certain matters as set forth in the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The compensation policy must serve as the basis
for decisions concerning the financial terms of employment or engagement of office holders, including exculpation, insurance, indemnification
or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain
factors, including advancement of the company&rsquo;s objectives, business plan and long-term strategy, and creation of appropriate incentives
for office holders. It must also consider, among other things, the company&rsquo;s risk management, size and the nature of its operations.
The compensation policy must furthermore consider the following additional factors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the education, skills, experience, expertise and accomplishments
                                            of the relevant office holder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the office holder&rsquo;s position, responsibilities and prior
                                            compensation agreements with him or her;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the ratio between the cost of the terms of employment of an office
                                            holder and the cost of the employment of other employees of the company, including employees
                                            employed through contractors who provide services to the company, in particular the ratio
                                            between such cost, the average and median salary of the employees of the company, as well
                                            as the impact of such disparities on the work relationships in the company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>if the terms of employment include variable components &mdash;
                                            the possibility of reducing variable components at the discretion of the board of directors
                                            and the possibility of setting a limit on the exercise value of non-cash variable equity-based
                                            components; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>if the terms of employment include severance compensation &mdash;
                                            the term of employment or office of the office holder, the terms of his or her compensation
                                            during such period, the company&rsquo;s performance during the such period, his or her individual
                                            contribution to the achievement of the company goals and the maximization of its profits
                                            and the circumstances under which the office holder is leaving the company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The compensation policy must also include, among
others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>with regard to variable components:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>with the exception of office holders who are subordinate to the
                                            chief executive officer, determining the variable components on long-term performance basis
                                            and on measurable criteria; however, the company may determine that an immaterial part of
                                            the variable components of the compensation package of an office holder shall be awarded
                                            based on non-measurable criteria, if such amount is not higher than three monthly salaries
                                            per annum while taking into account the office holder&rsquo;s contribution to the company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the ratio between variable and fixed components, as well as the
                                            limit of the values of variable components at the time of their grant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>a condition under which the office holder will return to the
                                            company, according to conditions to be set forth in the compensation policy, any amounts
                                            paid as part of his or her terms of employment, if such amounts were paid based on information
                                            later to be discovered to be wrong, and such information was than re-presented in the company&rsquo;s
                                            financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the minimum holding or vesting period of variable equity-based
                                            components, while taking into consideration long-term incentives; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>a limit to retirement grants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our compensation policy was approved by the board
of directors and the shareholders on February 9, 2021, and will be in effect for a period of five years from the date of approval. Our
compensation policy is designed to promote retention and motivation of directors and executive officers, incentivize superior individual
excellence, align the interests of our directors and executive officers with our long-term performance and provide a risk management
tool. To that end, a portion of an executive officer&rsquo;s compensation package is targeted to reflect our short and long-term goals,
as well as the executive officer&rsquo;s individual performance. On the other hand, our compensation policy includes measures designed
to reduce the executive officer&rsquo;s incentives to take excessive risks that may harm us in the long-term, such as limits on the value
of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive
officer and minimum vesting periods for equity-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our compensation policy also addresses our executive
officers&rsquo; individual characteristics (such as his or her respective position, education, scope of responsibilities and contribution
to the attainment of our goals) as the basis for compensation variation among our executive officers, and considers the internal ratios
between compensation of our executive officers and directors and other employees. Pursuant to our compensation policy, the compensation
that may be granted to an executive officer may include: base salary, annual bonuses and other cash bonuses (such as relocation, signing
and special bonuses) as well as change of control related bonuses, equity-based compensation, benefits and retirement and termination
of employment arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&rsquo;s base salary (or
to the total annual compensation in the case of the special bonus for special achievements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An annual cash bonus may be awarded to executive
officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may be granted to our
executive officers, other than our chief executive officer, will be based on performance objectives and a discretionary evaluation of
the executive officer&rsquo;s overall performance by our chief executive officer, subject to minimum thresholds. Furthermore, the performance
objectives will be recommended by our chief executive officer and approved by our compensation committee (and, if required by law, by
our board of directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The performance measurable objectives of our chief
executive officer, which will be determined annually by our compensation committee and board of directors, will include the weight to
be assigned to each achievement in the overall evaluation. A less significant portion of the chief executive officer&rsquo;s annual cash
bonus may be based on a discretionary evaluation of the chief executive officer&rsquo;s overall performance by the compensation committee
and the board of directors based on quantitative and qualitative criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The equity-based compensation under our compensation
policy for our executive officers is designed in a manner consistent with the underlying objectives in determining the base salary and
the annual cash bonus, with its main objectives being to enhance the alignment between the executive officers&rsquo; interests with our
long-term interests and those of our shareholders and to strengthen the retention and the motivation of executive officers in the long
term. Our compensation policy entitles our executive officers to compensation in the form of share options or other equity-based awards,
such as restricted share units, in accordance with our share incentive plan then in place (subject to the compensation committee&rsquo;s
approval or the approval of the board of directors). All equity-based incentives granted to executive officers shall be subject to vesting
periods in order to promote long-term retention of the awarded executive officers. The equity-based compensation may be granted from
time to time and will be individually determined and awarded according to the performance, educational background, prior business experience,
qualifications, role and the personal responsibilities of the executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, our compensation policy contains
compensation recovery provisions which allows us under certain conditions to recover bonuses paid in excess, enables our chief executive
officer to approve an immaterial change in the terms of employment of an executive officer (provided that the changes of the terms of
employment are in accordance with our compensation policy) and allows us to exculpate, indemnify and insure our executive officers and
directors, subject to certain limitations set forth thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our compensation policy also governs the compensation
of the members of our board of directors and determines that the compensation of the directors shall be in accordance with the Companies
Regulations (Rules Regarding the Compensation and Expenses of an External Director), 5760-2000, as amended by the Companies Regulations
(Relief for Public Companies Traded in Stock Exchange Outside of Israel), 5760-2000, or the compensation of directors regulations, as
such regulations may be amended from time to time, provided, however, that under special circumstances such as in the case of a professional
director, an expert director or a director who has particular stature or added value and makes a unique contribution to the Company,
such director&rsquo;s compensation may be different than the compensation of all other directors. Our directors may also be entitled
to receive equity-based compensation in the form of restricted shares, restricted share units or share options subject to an annual maximum
and to a vesting period in order to promote long-term retention of the awarded director, subject to the approval of our shareholders,
as required under the Companies Law. Furthermore, the chairman of our board of directors may be entitled to a higher base compensation
or equity-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">D. Employees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December&nbsp;31, 2020, we had 40 employees
based in Israel, six employees based in Japan and four employees based in Korea. We have never experienced any employment-related work
stoppages and believe our relationship with our employees is good. The following table sets out our total number of employees by function
for the last three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><DIV STYLE="padding: 0in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Area of Activity</B></P> </DIV></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<BR> December 31, 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<BR> December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<BR> December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 0in">General and Administrative&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">22</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0in">Research, Development and Quality Assurance&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0in">Sales and Marketing&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in">Total&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="white-space: nowrap; text-align: left"><SUP>(1)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Total does not include subcontractors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our human capital resources objectives include,
as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants.
The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based
and cash-based compensation awards, in order to increase shareholder value and the success of our company by motivating such individuals
to perform to the best of their abilities and achieve our objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">E. Share Ownership</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For information regarding the share ownership
of our directors and executive officers, see &ldquo;Item 7. Major Shareholders and Related Party Transactions&mdash;A. Major Shareholders.&rdquo;
For information regarding equity-based grants to our directors, executive officers and other employees, see &ldquo;Item 6. Directors,
Senior Management and Employees&mdash;B. Compensation&mdash;Compensation of Executive Officers and Directors&rdquo; and &ldquo;Item 6.
Directors, Senior Management and Employees&mdash;B. Compensation&mdash;Equity Incentive Plan.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="a_008"></A>Item 7.</TD><TD>Major Shareholders and Related Party Transactions</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. Major Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information with
respect to the beneficial ownership of our ordinary shares as of March 20, 2021 by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>each person or entity known by us to own beneficially more than
                                            5% of our outstanding ordinary shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>each of our directors and executive officers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>all of our directors and executive officers as a group; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>each selling shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The beneficial ownership of our ordinary shares
is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security if
that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power,
which includes the power to dispose of or to direct the disposition of the security. In determining beneficial ownership percentages,
we deem ordinary shares that a shareholder has the right to acquire, including the ordinary shares issuable pursuant to options or warrants
that are currently exercisable or exercisable within 60 days of March 20, 2021, if any, to be outstanding and to be beneficially owned
by the person with such right to acquire additional ordinary shares for the purposes of computing the percentage ownership of that person,
but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. The percentage of
ordinary shares beneficially owned prior to or after the offering is based on 47,378,183 ordinary shares outstanding as of March 20,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except where otherwise indicated, we believe,
based on information furnished to us by such owners, that the beneficial owners of the ordinary shares listed below have sole investment
and voting power with respect to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None of our shareholders have different voting
rights from other shareholders. To the best of our knowledge, we are not owned or controlled, directly or indirectly, by another corporation
or by any foreign government. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our
company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise noted below, the address for
each beneficial owner is c/o Communications Center, Neve Ilan, Israel 9085000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares Beneficially<BR> Owned After the Offering</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name of Beneficial Owner</TD><TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic">5% or greater shareholders</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Ran Poliakine(1)&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,131,513</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8.66</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Moshe Moalem(2)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,948,670</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.33</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">SK Telecom Co., Ltd and SK Telecom TMT Investment Corp.(3)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,869,909</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.28</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Yozma Group Korea(4)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,512,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.30</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">Directors and executive officers</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Ran Poliakine(1)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,131,513</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.66</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Onn Fenig(5)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,515</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Floyd Katske(6)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,573</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Erez Meltzer(7)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,088</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jung Ho Park(8)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Richard Stone(9)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">554,761</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.17</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Noga Kainan(10)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">794</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dan Suesskind&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Itzhak Maayan(11)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,554</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">James Dara&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Ofir Koren&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tamar Aharon Cohen&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Anat Kaphan(12)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,184</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Tal Shank(13)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Shirly Kaufman-Kirshenbaum(14)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left">All directors and executive officers as a group (15 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,830,856</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.09</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD>Amount represents less than 1% of outstanding ordinary shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Represents
(a) 3,958,570 ordinary shares of the Company held by Ran Poliakine as of March 20, 2021, (b) 118,750 ordinary shares of the Company held
in trust by Shay Zuckerman &amp; Co. Law Firm (&ldquo;Shay Zuckerman&rdquo;), pursuant to an Escrow Agreement, dated February&nbsp;3,
2020, between Ran Poliakine, Moshe Moalem and Shay Zuckerman, as trustee, (c) options to purchase
<FONT STYLE="background-color: white">304,193 </FONT>ordinary shares exercisable within 60 days of March 20, 2021, <FONT STYLE="background-color: white">which
have not yet been exercised and (d) a sale of 250,000 ordinary shares that is in the reporting process and not reflected in the records
of Continental Stock Transfer &amp; Trust Co</FONT>. as of March 20, 2021. The ordinary shares held by Shay Zuckerman are held in trust
for the benefit of Ran Poliakine. Ran Poliakine has voting power of all the ordinary shares held in trust by Shay Zuckerman. Pursuant
to a mediation agreement signed between the parties in October 2020, during 2021, the parties will take a number of actions, upon which
the dispositive power over these ordinary shares will pass to Ran Poliakine.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Represents
                                            3,948,670 ordinary shares held by Moshe Moalem, based solely on the Schedule 13G filed by
                                            Moshe Moalem on February 18, 2021.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Based
                                            solely on the Schedule 13G filed by SK Telecom Co., Ltd and SK Telecom TMT Investment Corp.
                                            on February 11, 2021, consisting of (a) 2,607,466 ordinary shares and (b) warrants to purchase
                                            2,262,443 ordinary shares held by SK Telecom TMT Investment Corp., a wholly owned subsidiary
                                            of SK Telecom Co., Ltd. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Based
                                            solely on the Schedule 13G filed by YOZMA GROUP KOREA Co., Ltd. on March 5, 2021, consisting
                                            of</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">(a) 887,000 ordinary shares
                                            held by Yozma Global AI Fund No.2 (&ldquo;Yozma Fund No.2&rdquo;) and (b) 1,625,000 ordinary
                                            shares held by Yozma Global AI Fund No.3 (&ldquo;Yozma Fund No.3&rdquo;). <FONT STYLE="background-color: white">Yozma
                                            Group Korea is the general partner of each of Yozma Fund No.2 and Yozma Fund No.3. Wonjae
                                            Lee is the Chief Executive Officer and controlling shareholder of Yozma Group Korea and is
                                            deemed to have voting and dispositive power over the shares held by Yozma Fund No.2 and Yozma
                                            Fund No.3. </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(5)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Represents
options to purchase 15,088 ordinary shares exercisable within 60 days of March 20, 2021, of which 12,573 have been exercised and sold.
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(6)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Represents
options to purchase 12,573 ordinary shares exercisable within 60 days of March 20, 2021, and have not yet been exercised.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(7)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Represents
options to purchase 15,088 ordinary shares exercisable within 60 days of March 20, 2021, and have not yet been exercised. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(8)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Represents
options to purchase 18,750 ordinary shares exercisable within 60 days of March 20, 2021, and have not yet been exercised.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(9)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="background-color: white">Represents
(a) 426,400 ordinary shares held by Richard Stone as of March 20, 2021 based solely on the records of Continental Stock Transfer &amp;
Trust Co., (b) options to purchase 37,719 ordinary shares exercisable within 60 days of March 20, 2021, (c) warrants to purchase 192,927
ordinary shares held by Richard Stone, (d) 66,215 ordinary shares held by </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Frostop
Securities (&ldquo;Frostop&rdquo;) </FONT><FONT STYLE="background-color: white">as of March 20, 2021, and (e) a sale of 168,500 ordinary
shares that is in the reporting process and not reflected in the records of Continental Stock Transfer &amp; Trust Co. as of March 20,
2021. Richard Stone is a minority holder of Frostop and is deemed to have sole current voting and dispositive power over the 66,215 ordinary
shares held by Frostop, and Frostop has agreed to transfer such shares to Richard Stone.</FONT></P>
<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(10)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Represents
794 ordinary shares held by I.B.L BUSINESS CONSULTING LTD. (&ldquo;I.B.L.&rdquo;). Noga Kainan is the controlling shareholder of I.B.L.
and is deemed to have voting and dispositive power of the shares held by I.B.L.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(11)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Represents
                                            options to purchase 40,554 ordinary shares exercisable within 60 days of March 20, 2021,
                                            and have not yet been exercised, which include the acceleration of 50% of Mr.&nbsp;Maayan&rsquo;s
                                            unvested options approved in January 2021.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(12)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Represents
options to purchase 22,184 ordinary shares exercisable within 60 days of March 20, 2021, and have not yet been exercised. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(13)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Represents
options to purchase 23,025 ordinary shares exercisable within 60 days of March 20, 2021, and have not yet been exercised.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(14)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Represents
options to purchase 9,099 ordinary shares exercisable within 60 days of March 20, 2021, and have not yet been exercised.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">As
of March 20, 2021, according to the records of Continental Stock Transfer &amp; Trust Co., approximately 4,853,369 of our outstanding
ordinary shares are held by 31 record holders in the United States. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">B. Related
Party Transactions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
policy is to enter into transactions with related parties on terms that, on the whole, are no more favorable, or no less favorable, than
those available from unaffiliated third parties. Based on our experience in the business sectors in which we operate and the terms of
our transactions with unaffiliated third parties, we believe that all of the transactions described below met this policy standard at
the time they occurred. The following is a description of material transactions, or series of related material transactions, since January&nbsp;1,
2020, to which we were or will be a party and in which the other parties included or will include our directors, executive officers,
holders of more than 5% of our voting securities or any member of the immediate family of any of the foregoing persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Asset
Purchase by the Company From Nanox Gibraltar</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Asset Purchase Agreement, dated as of September 3, 2019, as amended on December&nbsp;3, 2019 and December&nbsp;31, 2019, substantially
all of the assets of Nanox Gibraltar, including all patents, patent applications and all other intellectual property rights, but not
including the shares of Nanox Japan (predecessor), were sold to the Company for an aggregate consideration of $13.3&nbsp;million, reflecting
the fair market value of the transferred assets, which was estimated to be $6.1&nbsp;million (excluding cash) based on an independent
valuation report, plus the cash balance less $200,000, which totaled $7.2&nbsp;million as of the date of the Asset Purchase Agreement.
Following the Asset Purchase, substantially all the employees of Nanox Japan (predecessor) dedicated to the Company&rsquo;s business
have become employees of Nanox Imaging, Inc., our wholly owned Japanese subsidiary incorporated on September&nbsp;19, 2019, in December
2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the terms of the Asset Purchase Agreement, the consideration for the transferred assets will be paid only on the occurrence of one of
the following events: (a) the closing of a transaction involving the sale of all or substantially all of the Company&rsquo;s assets;
(b) the acquisition of the Company by, or the merger of the Company with, another entity, consolidation, reorganization, recapitalization,
sale, assignment or disposal by the Company of all or substantially all of the issued and outstanding shares of the Company; (c) the
transfer, sale, lease, grant or other disposition of or the grant of an exclusive license over all or substantially all of Company&rsquo;s
assets, including, but not limited to, intellectual property, with the same economic effect to that of a sale and/or cessation of its
business; (d)&nbsp;any other transaction, except for a financing round, following which the shareholders of the Company prior to the
closing of such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity; (e) the closing of
the first underwritten public offering of the Company pursuant to a registration statement under the Securities Act or the Securities
Law (or under equivalent securities law of another jurisdiction) or any other securities laws world-wide with the same effects and results;
(f) an equity financing of the Company at a minimum pre-money valuation of $100.0&nbsp;million, with proceeds to the Company of at least
$30.0&nbsp;million. In the events of (e) or (f) above, the Company will have the option to pay the consideration in cash or by the issuance
to Nanox Gibraltar of the Company&rsquo;s securities of the same series to be issued upon such event, in an amount reflecting a 25% discount
on the price per share to be determined in connection with (e) and (f) above. If the Company elects to pay such consideration in cash,
Nanox Gibraltar will have the right, at its sole discretion and in good faith, to reject such payment in cash, and require that the Company
pay such consideration in the form of the Company&rsquo;s securities in such amount and with such discount described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
January 2020, the board of directors of the Company and the board of directors and shareholders of Nanox Gibraltar approved the issuance
of shares in accordance with the terms of the Asset Purchase Agreement described above. As a result, 1,109,245 of the Company&rsquo;s
ordinary shares were issued to Nanox Gibraltar, representing an aggregate consideration of approximately $17.8&nbsp;million at the date
of issuance, and the Company has no further obligations to Nanox Gibraltar under the Asset Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Relationship
With SKT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&nbsp;17, 2019, Nanox
Gibraltar entered into a Strategic Share Purchase Agreement with SKT, Pureun Partners Asset Management Co., Ltd. and EBEST-PPAM Fund No.
9 (collectively, the &ldquo;SKT Entities&rdquo;), pursuant to which Nanox Gibraltar sold 2,262,443 ordinary shares to the SKT Entities
for an aggregate purchase price of approximately $5.0&nbsp;million. In connection with such transaction, Nanox Gibraltar also issued a
warrant to SKT to acquire 2,262,443 ordinary shares at an exercise price of $20.87 per share (the &ldquo;Warrant&rdquo;).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with the transactions described above, Nanox Gibraltar also entered into an investor rights agreement with the SKT Entities
(the &ldquo;Investor Rights Agreement&rdquo;). The agreement provides for the rights to nominate a member of our board of directors,
as well as certain registration rights. The rights under the Investor Rights Agreement terminated upon the closing of our initial public
offering. The SKT Entities became parties to the Registration Rights Agreement prior to the closing of our initial public offering. See
&ldquo;Item 10. Additional Information&mdash;C. Material Contracts&mdash;Registration Rights Agreements&rdquo; for detailed description
of the registration rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June&nbsp;4, 2020, we entered into a Share Purchase Agreement with SKT, pursuant to which we sold 1,250,000&nbsp;ordinary shares to SKT
for an aggregate purchase price of $20.0&nbsp;million. In connection with such agreement, we amended the Warrant to extend the exercise
period to the earlier of June&nbsp;17, 2025 or an exit event, which event does not include an initial public offering, and we amended
the Investor Rights Agreement which grants SKT the right to appoint Mr.&nbsp;Jung Ho Park (or another person designated by SKT) as a
director for a term of three years. In addition, we granted Mr.&nbsp;Park options to purchase 100,000 of our ordinary shares, vesting
in equal quarterly installments over a period of four years, at an exercise price of $16.00 per ordinary share. In the event that SKT
nominates any replacement director, any such director may receive options with the same terms, but the aggregate number of options granted
to all such directors together shall not exceed 100,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
on June&nbsp;4, 2020, we entered into a collaboration agreement with SK Telecom, pursuant to which we and SK Telecom continue to explore
and engage in good faith to develop a definitive agreement for the deployment of 2,500 Nanox Systems in South Korea and Vietnam, and
we have established a wholly-owned subsidiary in South Korea with the support of SK Telecom for the purpose of manufacturing MEMs X-ray
chips for the Nanox.ARC. The collaboration agreement will be in effect until the earlier of December&nbsp;31, 2021 or the execution of
a definitive agreement, and may be extended upon the mutual agreement of the parties. The agreement may be terminated by mutual notice
or by notice of the non-breaching party in case of a material breach of a party&rsquo;s material obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, we signed an agreement with Dr. Ilung Kim, dated December&nbsp;16, 2019, for the provision of consulting services to us. Under
the agreement, we granted Dr. Kim options to purchase 1,206,290 of our ordinary shares at an exercise price of $2.21 per ordinary share.
301,572 of the options vested as of the grant date and the remaining 904,718 options will vest in equal monthly installments over a period
of three&nbsp;years from the vesting commencement date (September&nbsp;1, 2019). All unvested options will be fully accelerated immediately
prior to the closing of Deemed Liquidation (as defined in the Equity Incentive Plan). The vested options are exercisable until the earlier
of (a) the second anniversary of termination of the engagement between us and Dr.&nbsp;Kim or (b) the tenth anniversary from the date
of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Agreements
With Directors and Officers</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following is a summary of each material contract, other than material contracts entered into in the ordinary course of business, to which
we are or have been a party, for the two years immediately preceding the date of this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Relationship
With Illumigyn Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
December&nbsp;1, 2019, Illumigyn has sub-leased approximately 165 square meters of private office space, including access to shared public
spaces, from us in Neve Ilan, Israel. Illumigyn pays approximately $12,000 per month and during the year ended December&nbsp;31, 2020,
the total payment received from Illumigyn was approximately $163,000. Mr.&nbsp;Poliakine currently serves as a member of senior management
of Illumigyn through a service provider agreement and is a significant shareholder primarily through indirect holdings, and he served
as a member of the board of directors of Illumigyn until August 2019. In addition, Mr.&nbsp;Richard Stone is a significant shareholder
in, and serves as a member of the board of directors of Illumigyn, Anat Kaphan, our Vice President of Product Marketing, also serves
as a consultant to Illumigyn and Tal Shank, our Vice President of Corporate Development, is also Head of Corporate Development of Illumigyn.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Relationship
with SixAI Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April&nbsp;16, 2020, we entered into a service
agreement (the &ldquo;Service Agreement&rdquo;) with SixAI, pursuant to which SixAI shall provide Nanox with certain software development
and mechanical engineering services. The Service Agreement is effective as of March&nbsp;1, 2020 and has been extended by mutual agreement
of the parties to March&nbsp;31, 2021. In consideration for the services provided, we will pay SixAI a monthly fee of $40,000 plus VAT.
As of December&nbsp;31, 2020, we have paid $415,350 to SixAI. Mr.&nbsp;Poliakine and Mr.&nbsp;Fenig currently serve as members of the
board of directors of SixAI and Mr.&nbsp;Poliakine is a controlling shareholder of SixAI. In addition, Mr.&nbsp;Poliakine is a director
of 634 Ai which is a controlled subsidiary (51%) of SixAI and Mr.&nbsp;Fenig manages 634 Ai operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Relationship
with Wellsense Technologies, Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
February 2020, Wellsense Technologies, Ltd. has sub-leased approximately 165 square meters of private office space, including access
to shared public spaces, from us in Neve Ilan, Israel. Wellsense Technologies, Ltd. pays approximately $7,000 per month and, during the
year ended December&nbsp;31, 2020, the total payment received from Wellsense Technologies, Ltd. was approximately $59,000. Each of Ran
Poliakine and Richard Stone is a shareholder of the parent company of Wellsense Technologies, Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Service
Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2021, the shareholders approved the entry into an agreement with Floyd Katske, effective as of October 1, 2020, whereby Floyd
Katske will assist the Chief Executive Officer and us with various tasks given his medical knowledge, expertise and experience, as may
be requested from time-to-time by our Chief Executive Officer. These tasks are in addition and unrelated to his role as a director. We
have agreed to pay Floyd Katske with respect to such services $200 per hour, (plus applicable VAT) against an invoice. The services will
be limited to 100 hours in any calendar month, according to hours approved by the Chairman. In addition, we agreed to pay Floyd Katske
cash compensation consisting of RSUs granted in each calendar quarter, in the amount calculated by dividing (i) two times the cash compensation
paid during such quarter as aforesaid by (ii) the fair market value of our ordinary shares on the last trading day of such quarter. All
tax consequences swill be borne by Floyd Katske. The agreement may be terminated by 14 days&rsquo; written notice by either party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Designated
Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
our compensation policy, we have designated Erez Meltzer as a &ldquo;Designated Director,&rdquo; effective as of January 1, 2021, due
to his stature, added value and extraordinary contribution to us, including throughout our initial public offering process and thereafter.
As a Designated Director, Erez Meltzer shall receive additional cash compensation (in addition to the annual base compensation and annual
equity compensation paid to him for service as a director) of $80,000 per year, and of $200,000 in equity-based compensation in the form
of RSUs to be granted in quarterly installments, calculated according to the fair market value of our ordinary shares on the last trading
day of such quarter.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directorship
Agreements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have entered into directorship agreements with each of our directors, pursuant to which such directors will serve on our board of directors.
Pursuant to these agreements, each director was granted options under our 2019 Equity Incentive Plan in the number and terms set out
under &ldquo;Item 6. Directors, Senior Management and Employees&mdash;B. Compensation&mdash;Equity Incentive Plan.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
Incentive Plans</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
a description of our equity incentive plans with members of our board of directors and executive officers, see &ldquo;Item 6. Directors,
Senior Management and Employees&mdash;B. Compensation&mdash;Equity Incentive Plan.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors
and Officers Insurance Policy and Indemnification Agreements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
amended and restated articles of association permit us to exculpate, indemnify and insure each of our directors and officers to the fullest
extent permitted by the Companies Law. We have obtained directors and officers insurance for each of our executive officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have entered into agreements with each of our current directors and officers exculpating them from a breach of their duty of care to
us to the fullest extent permitted by law, and undertaking to indemnify them to the fullest extent permitted by law including, with respect
to liabilities resulting from our initial public offering, to the extent that these liabilities are not covered by insurance, all subject
to limited exceptions. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to
events determined as foreseeable by the board of directors based on our current or expected activities. The maximum aggregate amount
of indemnification that we may pay to our directors and officers based on such indemnification agreement shall not exceed the greater
of (i)&nbsp;in relation to indemnity in connection with an offering to the public of our securities, the aggregate amount of proceeds
from the sale by us and/or any of our shareholders in connection with such public offering, (ii) 25% of our total shareholders&rsquo;
equity pursuant to our most recent financial statements as of the time of the actual payment of indemnification, and (iii) $50&nbsp;million
(in each case as may be increased from time to time by shareholders&rsquo; approval). Such indemnification amounts are in addition to
any insurance amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">However,
in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy
and therefore unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration
Rights Agreements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into a registration rights agreement
(the &ldquo;Registration Rights Agreement&rdquo;) that entitles holders of approximately 14,231,839 of our ordinary shares and other securities
convertible into or exchangeable for ordinary shares, including SKT and Yozma, to certain piggyback registration rights. See &ldquo;Item
10. Additional Information&mdash;C. Material Contracts&mdash;Registration Rights Agreements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">C.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interests
                                            of Experts and Counsel</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"></TD><TD STYLE="font-style: normal; text-align: justify; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
                                            applicable.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_009"></A>Item 8.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial
                                            Information</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">A.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated
                                            Financial Statements and Other Financial Information</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-style: normal; vertical-align: top; text-align: justify; font-weight: normal">
<TD STYLE="font-style: normal; width: 0; font-weight: normal"></TD><TD STYLE="font-style: normal; width: 0.75in; text-align: left; font-weight: normal"></TD><TD STYLE="font-style: normal; text-align: justify; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">See
                                                                                                                                                             &ldquo;Item 18. Financial Statements.&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
Proceedings</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-style: normal; vertical-align: top; text-align: justify; font-weight: normal">
<TD STYLE="font-style: normal; width: 0; font-weight: normal"></TD><TD STYLE="font-style: normal; width: 0.75in; text-align: left; font-weight: normal"></TD><TD STYLE="font-style: normal; text-align: justify; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif">See
                                                                                                                                                             &ldquo;Item 4. Information on the Company&mdash;B. Business Overview&mdash;Legal Proceedings.&rdquo;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend
Policy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have never declared or paid any cash dividends on our ordinary shares and we anticipate that, for the foreseeable future, we will retain
any future earnings to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay
cash dividends for at least the next several years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
distribution of dividends may also be limited by the Companies Law, which permits the distribution of dividends only out of retained
earnings or earnings derived over the two most recent fiscal years, whichever is higher, provided that there is no reasonable concern
that payment of a dividend will prevent a company from satisfying its existing and foreseeable obligations as they become due. Our amended
and restated articles of association provide that dividends will be paid at the discretion of, and upon resolution by, our board of directors,
subject to the provision of the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">B. Significant
Changes</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as disclosed elsewhere in this annual report on Form 20-F, we have not experienced any significant changes since the date of our audited
consolidated financial statements included in this annual report on Form 20-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_010"></A>Item 9.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Offer and
                                            Listing</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A. Offer
and Listing Details</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ordinary shares have been listed on the NASDAQ Global Market since August 20, 2020 under the symbol &ldquo;NNOX.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">B. Plan
of Distribution</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">C. Markets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ordinary shares have been listed on the NASDAQ Global Market since August 20, 2020 under the symbol &ldquo;NNOX.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">D. Selling
Shareholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">E. Dilution</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">F. Expenses
of the Issue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_011"></A>Item 10.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
                                            Information</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A. Share
Capital</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">B. Memorandum
and Articles of Association</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
copy of our amended and restated articles of association is attached as Exhibit 1.1 to this Annual Report.&nbsp;Our registration number
with the Israeli Registrar of Companies is 515942076. Our registration number may be changed by the Israeli Registrar of Companies to
indicate that we are a public company. The following are summaries of material provisions of our current amended and restated articles
of association that became effective immediately prior to the completion of our initial public offering in August 2020, insofar as they
relate to the material terms of our ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Objects
of Our Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
purpose as set forth in our amended and restated articles of association is to engage in any lawful activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Board
of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">See
&ldquo;Item 6. Directors, Senior Management and Employees&mdash;C. Board Practices.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Ordinary
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, we had 46,100,173 ordinary shares outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have never declared or paid any cash dividends on our ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. See &ldquo;Item
8. Financial Information&mdash;A. Consolidated Statements and Other Financial Information&mdash;Dividend Policy&rdquo; for more information
with respect to the requirements under Israeli law for the declaration and payment of dividends to our shareholders. Under the Companies
Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company
unless the company&rsquo;s articles of association provide otherwise. Our amended and restated articles of association do not require
shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Voting
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
of our ordinary shares have identical voting and other rights in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holders
of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general
meeting. In any meeting of shareholders, we will follow the quorum requirements for general meetings as set forth in our amended and
restated articles of association, instead of one-third of the issued share capital as required under the Nasdaq Marketplace Rules. Pursuant
to our amended and restated articles of association, the quorum required for our general meetings of shareholders will consist of at
least two shareholders present in person or by proxy (including by voting deed) and holding shares conferring in the aggregate at least
25% of the voting power of the Company. A meeting adjourned for lack of a quorum will generally be adjourned to the same day of the following
week at the same time and place, or to such other day, time or place as indicated by our board of directors if so specified in the notice
of the meeting. At the reconvened meeting, subject to a limited exception, any number of shareholders present in person or by proxy shall
constitute a lawful quorum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching
to the ordinary shares cast at a meeting, while a special resolution requires the affirmative vote of no less than two-thirds of the
votes attaching to the ordinary shares cast at a meeting. Both ordinary resolutions and special resolutions may also be passed by a unanimous
written resolution signed by all the shareholders of our company, as permitted by the Companies Law and our amended and restated memorandum
and articles of association. A special resolution will be required for important matters such as a change of name or making changes to
our amended and restated memorandum and articles of association. Holders of the ordinary shares may, among other things, divide or combine
their shares by ordinary resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Transfer
of Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association,
unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares
are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended
and restated articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are,
or have been, in a state of war with Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Liquidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event of our liquidation, after satisfaction of liabilities to creditors and other payments due as per applicable law, our assets
will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive
dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential
rights that may be authorized in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Calls
on Shares and Forfeiture of Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
board of directors may from time to time make calls upon shareholders for any amounts unpaid on their shares in a notice served to such
shareholders at least 14 calendar days prior to the specified time or times of payment. The shares that have been called upon and remain
unpaid are subject to forfeiture. Any amount unpaid in respect of a call shall bear interest from the date on which it is payable until
actual payment thereof, at such rate (not exceeding the then prevailing debitory rate charged by leading commercial banks in Israel),
and at such time(s) as the Board of Directors may prescribe. Upon the allotment of shares, the Board of Directors may provide for differences
among the allottees of such shares as to the amount of calls and/or the times of payment thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Redemption,
Repurchase and Surrender of Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may, subject to applicable law, issue redeemable shares and redeem the same or issue conditional securities with such conditions so as
such securities may be cancelled or revoked or may be considered to have been cancelled or revoked upon the fulfillment of such conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Modifications
of Rights of Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the Companies Law and our amended and restated articles of association, the rights attached to any class of share, such as voting, liquidation
and dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a
separate class meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in our amended and
restated articles of association, in addition to the ordinary majority vote of all classes of voting shares voting together as a single
class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Issuance
of Additional Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may, upon a resolution of the shareholders at a General Meeting, from time to time, increase our share capital by the creation of new
shares. Any such increase shall be in such amount and shall be divided into shares of such nominal amounts or without nominal amounts,
and such shares shall confer such rights and preferences, and shall be subject to such restrictions, as the resolution approving the
creation of such shares shall provide. Except to the extent otherwise provided in the resolution creating such new shares, such new shares
shall be subject to all the provisions applicable to the shares of the original capital. Without prejudice to any special rights previously
conferred upon the holders of existing shares in the Company, the Company may, from time to time, provide for shares with such preferred
or deferred rights or rights of redemption or other special rights and/or such restrictions, whether in regard to dividends, voting,
repayment of share capital or otherwise, as may be stipulated in the resolution pursuant to which such shares are created.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Access
to Corporate Records</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the Companies Law, shareholders generally have the right to review minutes of our general meetings, our shareholders register and material
shareholders register, our amended and restated articles of association, our annual audited financial statements and any document that
we are required by law to file publicly with the Israeli Registrar of Companies or the Israel Securities Authority. In addition, any
shareholder who specifies the purpose of their request may request to be provided with any document related to an action or transaction
requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe
it has not been made in good faith or if such denial is necessary to protect our interests or protect a trade secret or patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Anti-Takeover
Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&rsquo;s voting
rights or issued and outstanding share capital is required by the Companies Law to make a tender offer to all of the company&rsquo;s
shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public
Israeli company and who would as a result hold over 90% of the voting rights or issued and outstanding share capital of a certain class
of shares is required to make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all
of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and
outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal
interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by
operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of
the issued and outstanding share capital of the company or of the applicable class of shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder
accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to
determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However,
under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be
entitled to petition the Israeli court as described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the full tender offer was not accepted in accordance with the above alternatives, the acquirer may not acquire shares of the company
that will increase its holdings to more than 90% of the company&rsquo;s issued and outstanding share capital or of the applicable class
from shareholders who accepted the tender offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>General
Meetings of Shareholders and Shareholder Proposals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later
than 15 months after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders
are referred to in our amended and restated articles of association as special meetings. Our board of directors may call special meetings
whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides
that our board of directors is required to convene a special general meeting upon the written request of (i)&nbsp;any two or more of
our directors or one-quarter or more of the members of our board of directors or (ii)&nbsp;one or more shareholders holding, in the aggregate,
either (a) 5% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b) 5% or more of our outstanding
voting power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors
include a matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter
at the general meeting. Our amended and restated articles of association contain procedural guidelines and disclosure items with respect
to the submission of shareholder proposals for shareholder meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">C.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Material
                                            Contracts</FONT></TD>
</TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">FoxSemicon
Integrated Technology, Inc. Manufacturing Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May&nbsp;26, 2020, we entered into a Contract Manufacturing Agreement with FITI. Under the terms of the agreement, FITI agrees to manufacture,
package, distribute and ship, and we agree to purchase, certain products and procurement and assembly services, including a minimum of
1,000 Nanox Systems per year. We agree to provide FITI with a rolling forecast of our estimated monthly purchases, which FITI will use
to prepare its supply chain to cover the material and manufacturing needs. Subsequently, we will send purchase orders to FITI for certain
products and services. Prices for the products will be agreed by the parties at least 90 days prior to the first expected delivery date.
FITI will be entitled to order materials in accordance with an approved supplier list and on the terms that the parties agree upon on
a quarterly basis, and FITI must obtain our prior written consent if it procures materials from other suppliers. FITI may also purchase
materials from us to support orders pursuant to our requests. The parties also agree to enter into a quality agreement, which will set
forth the manufacturing standards applicable to FITI. The agreement will be in effect for three years from the date of the agreement
and is renewable for successive terms of one year unless or until either party notifies the other in writing of its intention not to
renew with 90 days&rsquo; prior notice. The agreement may be terminated by notice of the non-breaching party in case of a material breach
of a party&rsquo;s material obligations, or by either party in case of the bankruptcy or insolvency of the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Asset
Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
entered into an Asset Purchase Agreement with Nanox Gibraltar on September 3, 2019. See &ldquo;Item 4. Information on the Company&mdash;A.
History and Development of the Company&rdquo; for a description of the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Warrant
Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 20, 2021, there were 13 outstanding warrants to purchase a total of 2,838,496 ordinary shares with exercise prices ranging from
$0.01 per share to $20.87 per share. These warrants are exercisable immediately and expire on various dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The warrants were issued to certain persons in
connection with certain corporate, financing and consulting transactions. Eleven of these warrants were issued on September 2, 2019, in
the framework of the Asset Purchase Agreement. The remaining two are a warrant issued to A-Labs upon the consummation of our initial public
offering to purchase 50,000 ordinary shares with exercise price of $18, as described above under &ldquo;Item 4. Information on the Company&mdash;B.
Business Overview&mdash;Letter Agreement with A-Labs&rdquo; and the Warrant issued to SKT to purchase 2,262,443 ordinary shares with exercise
price of $20.87, as described above under &ldquo;Item 7. Major Shareholders and Related Party Transactions&mdash;B. Related Party Transactions&mdash;Relationship
With SKT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration
Rights Agreements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into the Registration Rights Agreement
with shareholders who held 14,533,835 of our ordinary shares and other securities convertible into or exchangeable for ordinary shares;
however, some of these shares may have been sold on the market, in which case the registration rights would no longer be applicable. This
amount includes the exercised warrants, as of March 20, 2021, which were entitled to piggyback registration rights (as described below)
but exclude the shares that were sold in our secondary offering in February 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Registration Rights Agreement,
and subject to the limitations specified therein, if we register our ordinary shares under the Securities Act for sale to the public,
either for our own account or for the account of other security holders or both, the holders of registrable securities are entitled to
notice of the intended registration and to include any or all of their registrable securities in the registration. The right of holders
of registrable securities to include shares in an underwritten offering is subject to the right of the underwriters to limit the number
of shares included in such offering. Holders of registrable securities are generally required to pay all expenses of registration, including
the fees and disbursements of its counsel and all underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, as of March 20, 2021, holders of warrants to purchase an aggregate of 2,282,443 ordinary shares are entitled to piggyback registration
rights under the terms of such warrants substantially similar to the registration rights described in the preceding paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">D.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exchange
                                            Controls</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of
the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of certain countries that
have been, or are considered to be, in a state of war with Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">E.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Taxation</FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Israeli
Tax Considerations and Government Programs</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>General
Corporate Tax Structure in Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Israeli
resident companies are generally subject to corporate tax, currently at the rate of 23% of a company&rsquo;s taxable income. However,
the effective tax rate payable by a company that derives income from a Benefited Enterprise, a Preferred Enterprise, or a Preferred Technological
Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli resident company are subject to tax at
the regular corporate tax rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
Israeli tax legislation, a corporation will be considered as an &ldquo;Israeli resident company&rdquo; if it meets one of the following:
(i)&nbsp;it was incorporated in Israel; or (ii)&nbsp;the control and management of its business are exercised in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Law
for the Encouragement of Industry (Taxes), 5729-1969</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax
benefits for &ldquo;Industrial Companies.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Industry Encouragement Law defines an &ldquo;Industrial Company&rdquo; as a company resident in Israel and which was incorporated in
Israel, of which 90% or more of its income in any tax year, other than income from defense loans, is derived from an &ldquo;Industrial
Enterprise&rdquo; owned by it and located in Israel or in the &ldquo;Area,&rdquo; as such terms are defined in the Israeli Income Tax
Ordinance (New Version) 1961, or the Ordinance. An &ldquo;Industrial Enterprise&rdquo; is defined as an enterprise which is held by an
Industrial Company whose principal activity in a given tax year is industrial production.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following corporate tax benefits, among others, are available to Industrial Companies:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679; </FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization
                                            over an eight-year period of the cost of purchased know-how and patents and rights to use
                                            a patent and know-how which are used for the development or advancement of the Industrial
                                            Enterprise, commencing from the tax year where the Industrial Enterprise began to use them.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
                                            limited conditions, an election to file consolidated tax returns with related Israeli Industrial
                                            Companies; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Expenses
                                            related to a public offering are deductible in equal amounts from income attributed to the
                                            Industrial Enterprise over three years commencing in the year of the offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although,
as of the date of this annual report on Form 20-F, we do not have industrial production activities, we may qualify as an Industrial Company
in the future and may be eligible for the benefits described above. However, we cannot assure that we will qualify as an Industrial Company
or that the benefits described above will be available to us, or that even if available, we shall opt to use them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tax
Benefits and Grants for Research and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Israeli
tax law allows, under certain conditions, a tax deduction for expenditures related to scientific research and development projects, including
capital expenditures, for the year in which they are incurred. Expenditures are deemed related to scientific research and development
projects, if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                            expenditures are approved by the relevant Israeli government ministry, determined by the
                                            field of research; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                            research and development is for the promotion of the company and is carried out by or on
                                            behalf of the company seeking such tax deduction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
amount of such deductible expenses is reduced by the sum of any funds received through government grants for the financing of such scientific
research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is
related to an expense invested in an asset depreciable under the general depreciation rules of the Ordinance. Expenditures not so approved
are deductible in equal amounts over three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
time to time, we may apply to the Israeli Innovation Authority (the &ldquo;IIA&rdquo;), for approval to allow a tax deduction for research
and development expenses during the year incurred. There can be no assurance that such application will be accepted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Law
for the Encouragement of Capital Investments, 5719-1959</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Law for the Encouragement of Capital Investments, 5719-1959 (the &ldquo;Investment Law&rdquo;), provides certain incentives for capital
investments in production facilities (or other eligible assets) by &ldquo;Industrial Enterprises&rdquo; (as defined under the Investment
Law). The benefits available under the Investment Law are subject to the fulfillment of conditions stipulated therein. If a company does
not meet these conditions, it may be required to refund the amount of tax benefits, as adjusted by the Israeli consumer price index,
and interest, or other monetary penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tax
Benefits Subsequent to the 2005 Amendment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
amendment to the Investment Law, which became effective as of April&nbsp;1, 2005, or the 2005 Amendment, changed certain provisions of
the Investment Law. An eligible investment program under the 2005 Amendment qualifies for benefits as a &ldquo;Benefited Enterprise.&rdquo;
Prior to the 2005 Amendment, investment programs under the Investment Law were called &ldquo;Approved Enterprises.&rdquo; The extent
of the tax benefits available under the 2005 Amendment to qualifying income of a Benefited Enterprise depend on, among other things,
the geographic location of the Benefited Enterprise in Israel. The location will also determine the period for which tax benefits are
available. Such tax benefits include an exemption from corporate tax on undistributed income for a period of between two to ten years,
depending on the geographic location of the Benefited Enterprise in Israel, and a reduced corporate tax rate of between 10% and the applicable
corporate tax rate for the remainder of the benefits period, depending on the level of foreign investment in the company in each year
during the benefits period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are not entitled to tax benefits under the 2005 Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tax
Benefits Under the 2011 Amendment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Investment Law was significantly amended as of January&nbsp;1, 2011, or the 2011 Amendment. The 2011 Amendment introduced new benefits
to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
2011 Amendment introduced new tax benefits for income generated by a &ldquo;Preferred Company&rdquo; through its &ldquo;Preferred Enterprise,&rdquo;
in accordance with the definition of such terms in the Investment Law. The definition of a Preferred Company, includes, inter alia, a
company incorporated in Israel that (1) is not wholly owned by a government entity, (2) owns a Preferred Enterprise and (3) is controlled
and managed from Israel and is subject to further conditions set forth in the Investment Law. Moreover, a Preferred Company needs to
meet certain conditions stipulated in the Investment Law such as being an industrial company (including a minimum threshold of 25% export).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to the income attributed to its Preferred Enterprise,
unless the Preferred Enterprise is located in development area &ldquo;A,&rdquo; in which case the rate will be 7.5%. Our operations are
currently not located in development area &ldquo;A.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividends
distributed from income which is attributed to a &ldquo;Preferred Enterprise&rdquo; will be subject to withholding tax at the following
rates: (i)&nbsp;Israeli resident individuals&mdash;20% and (ii)&nbsp;non-Israeli residents&mdash;20%, subject to a reduced tax rate under
the provisions of an applicable double tax treaty and subject to the receipt in advance of valid certificate from the Israeli Tax Authority,
or the ITA. If such dividends are paid to an Israeli company, no tax is required to be withheld. However, if such dividends are subsequently
distributed by such Israeli company to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may
be provided in an applicable tax treaty will apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
provisions of the 2011 Amendment do not apply to existing &ldquo;Benefited Enterprises&rdquo; or &ldquo;Approved Enterprises,&rdquo;
which will continue to be entitled to the tax benefits under the Investment Law, as in effect prior to the 2011 Amendment, unless the
company owning such enterprises had made an election to apply the provisions of the 2011 Amendment (such election cannot be later rescinded),
which is to be filed with the ITA, not later than the date prescribed for the filing of the company&rsquo;s annual Israeli tax return
for the respective year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are currently not entitled to tax benefits under the 2011 Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tax
Benefits Under the 2017 Amendment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
amendments to the Investment Law became effective in January 2017, or the 2017 Amendment. The 2017 Amendment provides new tax benefits
for two types of &ldquo;Technological Enterprises,&rdquo; as described below, and is in addition to the other existing tax benefit programs
under the Investment Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
2017 Amendment provides that a technological company satisfying certain conditions may qualify as a &ldquo;Preferred Technological Enterprise&rdquo;
and thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as &ldquo;Preferred Technological Income,&rdquo; as defined
in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technological Enterprise located in development area &ldquo;A.&rdquo;
In addition, a Preferred Technological Company will enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of
certain &ldquo;Benefited Intangible Assets&rdquo; (as defined in the Investment Law) to a related foreign company if the Benefited Intangible
Assets were acquired from a foreign company on or after January&nbsp;1, 2017, for at least NIS 200&nbsp;million, and the sale receives
prior approval from the IIA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
2017 Amendment further provides that a technological company satisfying certain conditions may qualify as a &ldquo;Special Preferred
Technological Enterprise&rdquo; and thereby enjoy a reduced corporate tax rate of 6% on &ldquo;Preferred Technological Income&rdquo;
regardless of the company&rsquo;s geographic location within Israel. In addition, a Special Preferred Technological Enterprise will enjoy
a reduced corporate tax rate of 6% on capital gain derived from the sale of certain &ldquo;Benefited Intangible Assets&rdquo; to a related
foreign company if the Benefited Intangible Assets were either developed by an Israeli company or acquired from a foreign company on
or after January&nbsp;1, 2017, and the sale received prior approval from the IIA. A Special Preferred Technological Enterprise that acquires
Benefited Intangible Assets from a foreign company for more than NIS 500&nbsp;million may be eligible for these benefits for a period
of at least ten years, subject to certain approvals as specified in the Investment Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividends
distributed by a Preferred Technological Enterprise or a Special Preferred Technological Enterprise, paid out of Preferred Technological
Income or income attributed to production are generally subject to withholding tax at the rate of 20% or such lower rate, as may be provided
in an applicable tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).
However, if such dividends are paid to an Israeli company, no tax is required to be withheld. However, if such dividends are subsequently
distributed by such Israeli company to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may
be provided in an applicable tax treaty will apply. If dividends paid out of Preferred Technological Income are distributed to a foreign
company and other conditions are met, the withholding tax rate will be 4% (or a lower rate under a tax treaty, if applicable, subject
to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are currently not entitled to tax benefits under the 2017 Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Taxation
of Our Shareholders</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital
Gains</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital
gain tax is imposed on the disposition of capital assets by an Israeli resident for tax purposes, and on the disposition of such assets
by a non-Israeli resident for tax purposes if those assets are (i)&nbsp;located in Israel; (ii)&nbsp;are shares or a right to a share
in an Israeli resident corporation, or (iii)&nbsp;represent, directly or indirectly, rights to assets located in Israel. The Ordinance
distinguishes between &ldquo;Real Capital Gain&rdquo; and the &ldquo;Inflationary Surplus.&rdquo; Real Capital Gain is the excess of
the total capital gain over Inflationary Surplus computed generally on the basis of the increase in the Israeli consumer price index
or, in certain circumstances, a foreign currency exchange rate, between the date of purchase and the date of disposition. Inflationary
Surplus is not currently subject to tax in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Real
Capital Gain accrued by individuals on the sale of our ordinary shares will be taxed at the rate of 25%. However, if the individual shareholder
is a &ldquo;Controlling Shareholder&rdquo; (i.e., a person who holds, directly or indirectly, alone or together with another, 10% or
more of one of the Israeli resident company&rsquo;s &ldquo;means of control,&rdquo; which includes, among other things, the right to
receive profits of the company, voting rights, the rights to receive proceeds upon the company&rsquo;s liquidation and the right to appoint
a director) at the time of sale or at any time during the preceding 12-month period, such capital gain will be taxed at the rate of 30%.
Furthermore, where an individual claimed real interest expenses and linkage differentials on securities, the capital gain on the sale
of the securities will taxed at a rate of 30% (exclusive of excess tax described below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Real
Capital Gain derived by corporations will be generally subject to the corporate tax rate (23% in 2018 and thereafter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Individual
and corporate shareholder dealing in securities in Israel are taxed at the tax rates applicable to business income&mdash;23% for corporations
in 2018 and thereafter and a marginal tax rate of up to 47% in 2019 for individuals, not including excess tax (described below). Notwithstanding
the foregoing, Real Capital Gain derived from the sale of our ordinary shares by a non-Israeli shareholder may be exempt under the Ordinance
from Israeli taxation provided that the following cumulative conditions are met: (i)&nbsp;the shares were purchased upon or after the
registration of the shares on the stock exchange, (ii)&nbsp;the seller does not have a permanent establishment in Israel to which the
derived capital gain is attributable, (iii)&nbsp;if the seller is a corporation, no more than 25% of its means of control are held, directly
and indirectly, by Israeli residents, and (iv)&nbsp;if the seller is a corporation, there is no Israeli resident that is entitled to
25% or more of the revenues or profits of the corporation, directly or indirectly. In addition, such exemption would not be available
to a person whose capital gains from selling or otherwise disposing of the securities are deemed to be business income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, the sale of shares may be exempt from Israeli capital gain tax under the provisions of an applicable tax treaty. For example,
the Convention between the Government of the United States and the Government of the State of Israel with respect to Taxes of Income,
as amended, or the U.S.-Israel Double Tax Treaty, exempts U.S.&nbsp;residents for the purposes of the treaty from Israeli capital gain
tax in connection with such sale, provided (i)&nbsp;the U.S.&nbsp;resident owned, directly or indirectly, less than 10% of the Israeli
resident company&rsquo;s voting power at any time within the 12-month period preceding such sale; (ii)&nbsp;the seller, being an individual,
is present in Israel for a period or periods of less than 183 days during the taxable year; and (iii)&nbsp;the capital gain from the
sale was not derived through a permanent establishment of the U.S. resident in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders
may be liable for Israeli tax on the sale of their ordinary shares and the payment of the consideration may be subject to withholding
of Israeli tax. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding
at the time of sale. For example, in transactions involving a sale of all of the shares of an Israeli resident company, in the form of
a merger or otherwise, the ITA may require from shareholders who are not liable for Israeli tax to sign declarations in forms specified
by this authority or obtain a specific exemption from the ITA to confirm their status as a non-Israeli resident, and, in the absence
of such declarations or exemptions, may require the purchaser of the shares to withhold taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
purchaser, the Israeli stockbrokers or financial institutions through which the shares are held is obligated, subject to the above mentioned
exemptions, to withhold tax on the amount of consideration paid upon the sale of the shares (or on the Real Capital Gain on the sale,
if known) at the rate of 25% in respect of an individual and 23% in respect of a corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
the sale of securities traded on a stock exchange, a detailed return, including a computation of the tax due, must be filed and an advanced
payment must be paid on January 31 and July 31 of every calendar year in respect of sales of securities made within the previous six
months. However, if all tax due was withheld according to applicable provisions of the Ordinance and regulations promulgated thereunder
the aforementioned return need not be filed and no advance payment must be paid. Capital gain is also reportable on the annual income
tax return.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividends</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have never paid cash dividends. A distribution of dividend by our company from income attributed to a Preferred Enterprise to Israeli
residents will generally be subject to withholding tax in Israel at the following tax rates: Israeli resident individuals&mdash;20%;
Israeli resident companies&mdash;0% (although, if such dividends are subsequently distributed to individuals or a non-Israeli company,
withholding tax at a rate of 20% or such lower rate as may be provided if an applicable tax treaty will apply (subject to the receipt
in advance of a valid tax certificate from the ITA allowing for a reduced tax rate)). A distribution of dividends from income, which
is not attributed to a Preferred Enterprise to an Israeli resident individual, will generally be subject to withholding tax at a rate
of 25% or 30% if the dividend recipient is a &ldquo;Controlling Shareholder&rdquo; (as defined above) at the time of distribution or
at any time during the preceding 12-month period. If the recipient of the dividend is an Israeli resident corporation, such dividend
will be exempt from income tax provided the income from which such dividend is distributed was derived or accrued within Israel (although,
if such dividends are subsequently distributed to individuals or a non-Israeli company, withholding tax at a rate of 25% or such lower
rate as may be provided if an applicable tax treaty will apply (subject to the receipt in advance of a valid tax certificate from the
ITA allowing for a reduced tax rate)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
non-Israeli resident (either individual or corporation) is generally subject to Israeli withholding tax on the receipt of dividends at
the rate of 25% (30% if the dividends recipient is a &ldquo;Controlling Shareholder&rdquo; (as defined above), at the time of distribution
or at any time during the preceding 12-month period); those rates are subject to a reduced tax rate under the provisions of an applicable
double tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate). Under the
U.S.-Israel Double Tax Treaty, the following withholding rates will apply in respect of dividends distributed by an Israeli resident
company to a U.S. resident: (i)&nbsp;if the U.S. resident is a corporation which holds during that portion of the taxable year which
precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding
voting shares of the Israeli resident paying corporation and not more than 25% of the gross income of the Israeli resident paying corporation
for such prior taxable year (if any) consists of certain type of interest or dividends&mdash;the tax rate is 12.5%, (ii)&nbsp;if both
the conditions mentioned in (i)&nbsp;above are met and the dividend is paid from an Israeli resident company&rsquo;s income which was
entitled to a reduced tax rate applicable to an Approved Enterprise, Benefited Enterprise or Preferred Enterprise&mdash;the tax rate
is 15% if a certificate for a reduced withholding tax rate would be provided in advance from the ITA and (iii)&nbsp;in all other cases,
the tax rate is 25%. The aforementioned rates under the U.S.-Israel Double Tax Treaty will not apply if the dividend income was derived
through a permanent establishment of the U.S. resident in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
non-Israeli resident who receives dividends from which tax was withheld is generally exempt from the obligation to file tax returns in
Israel with respect to such income, provided that (i)&nbsp;such income was not generated from business conducted in Israel by the taxpayer
and (ii)&nbsp;the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Excess
Tax</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Individuals
who are subject to tax in Israel (whether such individual is an Israeli resident or non-Israeli resident) are also subject to an additional
tax on annual income exceeding a certain threshold (NIS 651,600, for 2020), which amount is linked to the Israeli consumer price index,
at a rate of 3%, including, but not limited to, income derived from dividends, interest and capital gains.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign
Exchange Regulations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-residents
of Israel who hold our ordinary shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and
winding up of our affairs, repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli
income tax is generally required to have been paid or withheld on these amounts. In addition, the statutory framework for the potential
imposition of currency exchange control has not been eliminated, and may be restored at any time by administrative action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Estate
and Gift Tax</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Israeli
law presently does not impose estate tax or in general gift taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
Federal Income Tax Considerations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following discussion is a summary of U.S. federal income tax considerations generally applicable to the ownership and disposition of
our ordinary shares. This summary applies only to investors that are U.S. Holders (as defined below) that hold our ordinary shares as
&ldquo;capital assets&rdquo; (generally, property held for investment) under the U.S.&nbsp;Internal Revenue Code of 1986, as amended
(the &ldquo;Code&rdquo;). This discussion is based upon U.S. federal tax law as in effect on the date of this annual report on Form 20-F
and on U.S. Treasury regulations in effect or, in some cases, proposed, as of the date of this annual report on Form 20-F, as well as
judicial and administrative interpretations thereof available on or before such date. All of the foregoing authorities are subject to
differing interpretations or change, which change could apply retroactively and could affect the tax considerations described below.
No ruling has been sought from the Internal Revenue Service, or the IRS, with respect to any U.S. federal income tax considerations described
below, and there can be no assurance that the IRS or a court will not take a contrary position. This discussion, moreover, does not address
the U.S. federal estate, gift, alternative minimum tax considerations, the Medicare tax on certain net investment income, any withholding
or information reporting requirements, or any state, local and non-U.S. tax considerations relating to the ownership or disposition of
our ordinary shares. The following summary does not address all aspects of U.S. federal income taxation that may be important to particular
investors in light of their individual circumstances or to persons in special tax situations such as:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">banks
and other financial institutions;</FONT></TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">insurance
companies;</FONT></TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">pension
plans;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">cooperatives;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulated
investment companies;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">real
estate investment trusts;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">broker-dealers;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">traders
that elect to use a mark-to-market method of accounting;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">certain
former U.S. citizens or long-term residents;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">tax-exempt
entities (including private foundations);</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">holders
who acquire our ordinary shares pursuant to any employee share option or otherwise as compensation;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">investors
that will hold our ordinary shares as part of a straddle, hedge, conversion, constructive sale or other integrated transaction for U.S.
federal income tax purposes;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">persons
holding our ordinary shares in connection with a trade or business outside the United States;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">persons
that actually or constructively own 10% or more of our stock (by vote or value);</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">investors
that have a functional currency other than the U.S. dollar;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">partnerships
or other entities classified as partnerships for U.S. federal income tax purposes, or persons holding our ordinary shares through such
entities, all of whom may be subject to tax rules that differ significantly from those discussed below.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investors
are urged to consult their tax advisors about the application of the U.S. federal tax rules to their particular circumstances as well
as the state, local, non-U.S. and other tax consequences to them of the ownership and disposition of our ordinary shares.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>General</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
purposes of this discussion, a &ldquo;U.S. Holder&rdquo; is a beneficial owner of our ordinary shares that is, for U.S.&nbsp;federal
income tax purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">an individual
who is a citizen or resident of the United States;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">a corporation
(or other entity treated as a corporation for U.S. federal income tax purposes) created in, or organized under the law of, the United
States or any state thereof or the District of Columbia;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">an estate
the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">a trust
(A) the administration of which is subject to the primary supervision of a U.S. court and which has one or more U.S. persons who have
the authority to control all substantial decisions of the trust or (B) that has otherwise validly elected to be treated as a U.S. person
under the Code.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of our ordinary shares,
the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership.
Partnerships holding our ordinary shares and their partners are urged to consult their tax advisors regarding the ownership and disposition
of our ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Dividends</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject
to the discussion below under &ldquo;&mdash;Passive Foreign Investment Company Considerations,&rdquo; any cash distributions (including
the amount of any Israeli tax withheld) paid on our ordinary shares out of our current or accumulated earnings and profits, as determined
under U.S. federal income tax principles, will generally be includible in the gross income of a U.S. Holder as dividend income on the
day actually or constructively received by the U.S. Holder. Because we do not intend to determine our earnings and profits on the basis
of U.S. federal income tax principles, any distribution we pay will generally be treated as a &ldquo;dividend&rdquo; for U.S. federal
income tax purposes. Dividends received on our ordinary shares will not be eligible for the dividends received deduction allowed to corporations
in respect of dividends received from U.S. corporations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Individuals
and other non-corporate U.S. Holders may be subject to tax at the lower capital gains tax rate applicable to &ldquo;qualified dividend
income,&rdquo; provided that certain conditions are satisfied, including that (1) the ordinary shares on which the dividends are paid
are readily tradable on an established securities market in the United States, or we are eligible for the benefit of the U.S.-Israel
Double Tax Treaty, (2) we are neither classified as a PFIC nor treated as such with respect to a U.S. Holder (as discussed below) for
the taxable year in which the dividend is paid or the preceding taxable year, and (3) certain holding period and other requirements are
met. Our ordinary shares are listed and traded on the Nasdaq Global Market. Thus, we believe that our ordinary shares will generally
be considered to be readily tradable on an established securities market in the United States. There can be no assurance that the ordinary
shares will continue to be considered readily tradable on an established securities market in later years. U.S. Holders are urged to
consult their tax advisors regarding the availability of the lower rate for dividends paid with respect to our ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
U.S. foreign tax credit purposes, dividends paid on our ordinary shares generally will be treated as income from foreign sources and
generally will constitute passive category income. A U.S. Holder may be subject to Israeli withholding taxes on dividends paid on our
ordinary shares. See &ldquo;&mdash;Israeli Tax Considerations and Government Programs&mdash;Taxation of Our Shareholders&mdash;Dividends.&rdquo;
Depending on the U.S.&nbsp;Holder&rsquo;s particular facts and circumstances and subject to a number of complex conditions and limitations,
Israeli withholding taxes on dividends not in excess of any applicable rate under the U.S.-Israel Double Tax Treaty may be treated as
foreign taxes eligible for credit against a U.S. Holder&rsquo;s U.S. federal income tax liability. A U.S.&nbsp;Holder who does not elect
to claim a foreign tax credit for foreign tax withheld may instead claim a deduction for U.S. federal income tax purposes in respect
of such withholding, but only for a year in which such holder elects to do so for all creditable foreign income taxes. The rules governing
the foreign tax credit are complex and each U.S.&nbsp;Holder is urged to consult its tax advisor regarding the availability of the foreign
tax credit under its particular circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Sale
or Other Disposition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
U.S. Holder will generally recognize gain or loss upon the sale or other disposition of our ordinary shares in an amount equal to the
difference between the amount realized upon the disposition and the U.S. Holder&rsquo;s adjusted tax basis in such ordinary shares. Subject
to the discussion below under &ldquo;&mdash;Passive Foreign Investment Company Considerations,&rdquo; the gain or loss will generally
be capital gain or loss and individuals and other non-corporate U.S. Holders who have held the ordinary shares for more than one year
will generally be eligible for reduced tax rates. The deductibility of a capital loss may be subject to limitations. Any such gain or
loss that the U.S. Holder recognizes will generally be treated as U.S. source income or loss for foreign tax credit limitation purposes,
such that the U.S. Holder may not be able to use the foreign tax credit arising from any Israeli tax imposed on the disposition of our
ordinary shares unless such credit can be applied (subject to applicable limitations) against U.S. federal income tax due on other income
derived from foreign sources in the same income category (generally, the passive category). Each U.S. Holder is urged to consult its
tax advisor regarding the tax consequences if a foreign tax is imposed on a disposition of our ordinary shares, including the availability
of the foreign tax credit under its particular circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Passive
Foreign Investment Company Considerations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
non-U.S. corporation, such as our company, will be classified as a PFIC for U.S. federal income tax purposes for any taxable year, if
either (i) 75% or more of its gross income for such year consists of certain types of passive income or (ii) 50% or more of the value
of its assets (generally determined on the basis of a quarterly average) during such year is attributable to assets that produce or are
held for the production of passive income. For this purpose, cash and assets readily convertible into cash are generally classified as
passive assets and goodwill and other unbooked intangibles associated with active business activities may generally be classified as
non-passive assets. Passive income generally includes, among other things, dividends, interest, royalties and rents (other than certain
royalties and rents derived in the active conduct of a trade or business and not derived from a related person), and gains from the disposition
of passive assets. We will be treated as owning a proportionate share of the assets and earning a proportionate share of the income of
any other corporation in which we own, directly or indirectly, at least 25% (by value) of the stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Whether
we are, or will be, classified as a PFIC is a factual determination made annually that will depend, in part, upon the composition of
our income and assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prior
to the commercialization of our medical imaging technology, passive income could constitute more than 75% of gross income for any taxable
year. Consequently, we believe that we will technically be classified as a PFIC for the taxable year ended December&nbsp;31, 2020. Depending
upon the composition of our income and assets and the market price of our ordinary shares during 2021 and subsequent taxable years and
whether we start generating a substantial amount of active revenue, we could continue to be classified as a PFIC for 2021 and subsequent
taxable years if we are classified as a PFIC for 2020. Accordingly, U.S. Holders of our ordinary shares should be willing to assume the
risks of investing in a PFIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
because there are uncertainties in the application of the relevant rules, it is possible that the IRS may challenge our classification
of certain income or assets as non-passive, or our valuation of our goodwill and other unbooked intangibles, each of which may increase
the likelihood of us becoming classified as a PFIC for the current or subsequent taxable years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares, unless the U.S. Holder makes a
mark-to-market election (as described below), the U.S. Holder will generally be subject to special tax rules on (i)&nbsp;any excess distribution
that we make to the U.S. Holder (which generally means any distribution paid during a taxable year to a U.S. Holder that is greater than
125% of the average annual distributions paid in the three preceding taxable years or, if shorter, the U.S. Holder&rsquo;s holding period
for the ordinary shares), and (ii)&nbsp;any gain realized on the sale or other disposition of our ordinary shares. In addition, dividends
paid in respect of our ordinary shares would not be eligible for the lower tax rate described under &ldquo;&mdash;Dividends&rdquo; above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the PFIC rules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the excess
distribution or gain will be allocated ratably over the U.S. Holder&rsquo;s holding period for the ordinary shares;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the amount
allocated to the taxable year of the excess distribution, sale or other disposition and to any taxable years in the U.S. Holder&rsquo;s
holding period prior to the first taxable year in which we are classified as a PFIC (each, a &ldquo;pre-PFIC year&rdquo;), will be taxable
as ordinary income;</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the amount
allocated to each prior taxable year, other than a pre-PFIC year, will be subject to tax at the highest tax rate in effect for individuals
or corporations, as appropriate, for that year; and</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the interest
charge generally applicable to underpayments of tax will be imposed on the tax attributable to each prior taxable year, other than a
pre-PFIC year.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares, we generally will continue to
be treated as a PFIC with respect to such U.S. Holder for all succeeding years during which the holder holds our ordinary shares. However,
if we cease to meet the threshold requirements for PFIC status, provided that the U.S. Holder has not made a mark-to-market election,
as described below, such holder may avoid some of the adverse effects of the PFIC regime by making a &ldquo;deemed sale&rdquo; election
with respect to our ordinary shares held by such U.S. Holder. If such election is made, the U.S. Holder will be deemed to have sold our
ordinary shares it holds on the last day of the last taxable year in which we were classified as a PFIC at their fair market value and
any gain from such deemed sale will be taxed under the PFIC rules described above. After the deemed sale election, so long as we do not
become classified as a PFIC in a subsequent taxable year, the ordinary shares with respect to which such election was made will not be
treated as shares in a PFIC and the U.S. Holder will not be subject to the PFIC rules described above with respect to any &ldquo;excess
distribution&rdquo; received from us or any gain from an actual sale or other disposition of the ordinary shares. The rules dealing with
deemed sale elections are very complex. U.S. Holders of our ordinary shares are strongly urged to consult their tax advisors as to the
possibility and consequences of making a deemed sale election if we cease to be classified as a PFIC and such election becomes available
to such holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares and any subsidiary we own is also
classified as a PFIC, such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC
for purposes of the application of these rules. As a result, such U.S. Holder may incur liability for the deferred tax and interest charge
described above if either (1) we receive any excess distribution from, or dispose of all or part of our interest in, the lower-tier PFIC
or (2) the U.S. Holder disposes of all or part of our ordinary shares. It is possible that any subsidiary we own would be a PFIC for
the current taxable year or future taxable years. U.S. Holders are urged to consult their tax advisors regarding the application of the
PFIC rules to any subsidiary we own.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
an alternative to the foregoing rules, a U.S. Holder of &ldquo;marketable stock&rdquo; (as defined below) in a PFIC may make a mark-to-market
election with respect to such stock. If a U.S. Holder makes this election with respect to our ordinary shares, the holder will generally
(i)&nbsp;include as ordinary income for each taxable year that we are classified as a PFIC the excess, if any, of the fair market value
of the ordinary shares held at the end of the taxable year over the adjusted tax basis of such ordinary shares and (ii)&nbsp;deduct as
an ordinary loss in each such taxable year the excess, if any, of the adjusted tax basis of the ordinary shares over the fair market
value of such ordinary shares held at the end of the taxable year, but such deduction will only be allowed to the extent of the amount
previously included in income as a result of the mark-to-market election. The U.S. Holder&rsquo;s adjusted tax basis in the ordinary
shares would be adjusted to reflect any income or loss resulting from the mark-to-market election. If a U.S. Holder makes a mark-to-market
election in respect of our ordinary shares and we cease to be classified as a PFIC, the holder will not be required to take into account
the gain or loss described above during any period that we are not classified as a PFIC. If a U.S. Holder makes a mark-to-market election,
any gain such U.S. Holder recognizes upon the sale or other disposition of our ordinary shares in a year when we are classified as a
PFIC will be treated as ordinary income and any loss will be treated as ordinary loss, but such loss will only be treated as ordinary
loss to the extent of the net amount previously included in income as a result of the mark-to-market election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
mark-to-market election is available only for &ldquo;marketable stock,&rdquo; which is stock that is regularly traded on a qualified
exchange or other market, as defined in applicable U.S. Treasury regulations. Our ordinary shares are listed on the Nasdaq Global Market
and should be treated as regularly traded for purposes of the mark-to-market rules. While we anticipate that our ordinary shares will
continue to qualify as being regularly traded, no assurances may be given in this regard. If any subsidiary we own is, or becomes, classified
as a PFIC, the mark-to-market election will likely not be available with respect to the shares of such subsidiary that are treated as
owned by a U.S.&nbsp;Holder. Consequently, a U.S. Holder could be subject to the PFIC rules with respect to income of a lower-tier PFIC
the value of which had already been taken into account indirectly via mark-to-market adjustments. U.S. Holders are urged to consult their
tax advisors as to the availability and desirability of a mark-to-market election, as well as the impact of such election on interests
in any lower-tier PFIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Alternatively,
a U.S. shareholder of a PFIC may avoid the PFIC tax consequences described above in respect of its shares of PFIC stock by making a timely
&ldquo;qualified electing fund,&rdquo; or QEF, election. To comply with the requirements of a QEF election, such shareholder must receive
certain information from the PFIC. Because we do not intend to provide information necessary for U.S. Holders to make QEF elections,
such election will not be available to U.S. Holders of our ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
a U.S. Holder owns our ordinary shares during any taxable year that we are classified as a PFIC, the holder must generally file an annual
IRS Form 8621 regarding distributions received on, and any gain realized on the disposition of, our ordinary shares. U.S. Holders are
urged to consult their tax advisor regarding our PFIC status and the U.S. federal income tax consequences of owning and disposing of
our ordinary shares if we are, or become, classified as a PFIC, including the possibility of making a mark-to-market or deemed sale election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
summary of U.S. federal income tax consequences set out above is for general informational purposes only. Investors are urged to consult
their tax advisors about the application of the U.S. federal tax rules to their particular circumstances as well as the state, local,
non-U.S. and other tax consequences to them of the purchase, ownership and disposition of our ordinary shares.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">F.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividends
and Paying Agents</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">G.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Statement
by Experts</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">H.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Documents
on Display</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have previously filed with the SEC a registration statement on Form F-1 (File No. 333-240209), as amended, and a registration statement
on Form F-1 (File No. 333-252860), as amended, each with respect to our ordinary shares. As allowed by the SEC, in Item 19 of this annual
report on Form 20-F, we incorporate by reference certain information we previously filed with the SEC. This means that we can disclose
important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference
is considered to be part of this annual report on Form 20-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are subject to the periodic reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we are required
to file reports and other information with the SEC. The SEC maintains a website at www.sec.gov that contains reports and other information
regarding registrants that file electronically with the SEC. Our annual report on Form 20-F and other information submitted by us to
the SEC may be accessed through this website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements,
and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained
in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file annual, quarterly and current
reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the
Exchange Act. However, we are required to file with the SEC, within four months after the end of each fiscal year, or such applicable
time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public
accounting firm, and to submit to the SEC, on Form 6-K, unaudited quarterly financial information for the first three quarters of each
fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
maintain a corporate website at http://www.nanox.vision. In accordance with NASDAQ Stock Market Rule 5250(d), we will post this annual
report on Form 20-F on our website. Information contained on our website is not incorporated by reference into this annual report on
Form 20-F. In addition, we will provide hardcopies of our annual report on Form 20-F free of charge to shareholders upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">I.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subsidiary
Information</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_012"></A>Item 11.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Qualitative
                                            and Quantitative Disclosures About Market Risk</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
Rate Risk</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, we had cash equivalents consisting primarily of U.S. Dollar bank deposits. Our&nbsp;primary exposure to market
risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. Consequently, changes
in market interest rates would not have a material impact on our financial position or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2020, we had no debt outstanding and are therefore not exposed to interest rate risk with respect to the cost of servicing
and repaying debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Inflation-related
Risks</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not believe that the rate of inflation in Israel has had a material impact on our business to date, however, our costs in Israel will
increase if the inflation rate in Israel exceeds the devaluation of the NIS against the U.S. dollar or if the timing of such devaluation
lags behind inflation in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign
Currency Exchange Risk</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
statements of operations and cash flows could be adversely affected in the future due to changes in foreign exchange rates. We expect
to have cash and cash equivalents denominated in U.S. Dollars. As a result, changes in foreign currency exchange rates would not have
a material impact on our financial position or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_013"></A>Item 12.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Description
                                            of Securities Other than Equity Securities</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">A.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Debt
Securities</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">B.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
and Rights</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">As
of March&nbsp;20, 2021, there are 13 outstanding warrants to purchase a total of 2,838,496 of our ordinary shares with outstanding exercise
prices ranging from $0.01 per share to $20.87 per share. These warrants are exercisable immediately and expire on various dates. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
warrants were issued to certain persons in connection with certain corporate, financing and consulting transactions. Eleven of these warrants
were issued on September 2, 2019, in the framework of the Asset Purchase Agreement. The remaining two are a warrant issued to A-Labs Finance
and Advisory upon the consummation of our initial public offering to purchase 50,000 ordinary shares with as exercise price of $18, as
described above under &ldquo;</FONT>Item 4. Information on the Company&mdash;B. Business Overview&mdash;<FONT STYLE="background-color: white">Letter
Agreement with A-Labs&rdquo; and the Warrant issued to SKT to purchase 2,262,443 ordinary shares with exercise price of $20.87, as described
above under </FONT>&ldquo;Item 7. Major Shareholders and Related Party Transactions&mdash;B. Relationship With SKT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">C.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
Securities</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">D.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">American
Depositary Shares</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_014"></A>PART
II</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_015"></A>Item 13.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Defaults,
                                            Dividend Arrearages and Delinquencies</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_016"></A>Item 14.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Material
                                            Modifications to the Rights of Security Holders and Use of Proceeds</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">See
&ldquo;Item 10. Additional Information&mdash;B. Memorandum and Articles of Association&rdquo; for a description of the rights of holders
of our ordinary shares, which remain unchanged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_017"></A>Item 15.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Controls
                                            and Procedures</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Disclosure
                                            Controls and Procedures</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
management has evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our
disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this
report, and has concluded that our disclosure controls and procedures were ineffective as of December 31, 2020, due to the material weaknesses
as discussed in &ldquo;Item 3. Key Information&mdash;D. Risk Factors,&rdquo; to provide reasonable assurance that information required
to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within
the time periods specified in the applicable rules and forms, and that it is accumulated and communicated to our Management, including
our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Remediation
Plans</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have implemented measures to remediate the identified material weakness. Those remediation measures are ongoing and have included the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            have hired a corporate controller with U.S. GAAP and SEC reporting experience, an internal
                                            auditor (part-time) and a financial planning and analysis professional and are continuing
                                            to seek additional financial professionals to increase the number of qualified financial
                                            reporting personnel and to strengthen our finance department;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            are selecting and implementing a new enterprise resource planning system;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            are developing, communicating, and implementing an accounting policy manual for our financial
                                            reporting personnel for recurring transactions and period-end closing processes; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            are establishing monitoring and oversight controls for non-recurring and complex transactions
                                            to ensure the accuracy and completeness of our consolidated financial statements and related
                                            disclosures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
we believe that these efforts will improve our internal control over financial reporting, the implementation of our remediation is ongoing
and will require validation and testing of the design and operating effectiveness of our internal controls over a sustained period of
financial reporting cycles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe we are making progress toward achieving the effectiveness of our internal controls and disclosure controls. The actions that
we are taking are subject to ongoing senior management review, as well as audit committee oversight. We will not be able to conclude
whether the steps we are taking will fully remediate the material weakness in our internal control over financial reporting until we
have completed our remediation efforts and subsequent evaluation of their effectiveness. We may also conclude that additional measures
may be required to remediate the material weakness in our internal control over financial reporting, which may necessitate additional
evaluation and implementation time. We will continue to assess the effectiveness of our internal control over financial reporting and
take steps to remediate the material weakness we have identified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Management&rsquo;s
                                            Annual Report on Internal Control Over Financial Reporting</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">This
annual report does not include a report of management&rsquo;s assessment regarding internal control over financial reporting or an attestation
report of the company&rsquo;s registered public accounting firm due to a transition period established by rules of the SEC for newly
public companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Attestation
                                            Report of the Registered Public Accounting Firm</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As an &ldquo;emerging growth company,&rdquo; as
defined in the JOBS Act, we may take advantage of certain temporary exemptions from various reporting requirements, including, but not
limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act (and the
SEC rules and regulations thereunder). When these exemptions cease to apply, we expect to incur additional expenses and devote increased
management effort toward ensuring compliance with them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
                                            in Internal Control Over Financial Reporting</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
were no changes in our internal control over financial reporting during the period covered by this annual report on Form 20-F that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_018"></A>Item 16.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">[Reserved]</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit Committee
                                            Financial Expert</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Noga
Kainan, an independent director and a member of our audit committee, is an audit committee financial expert.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Code of
                                            Ethics</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have adopted a code of ethics and conduct, which is applicable to all of our directors, officers and employees. We have made our code
of ethics publicly available on our website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Principal
                                            Accountant Fees and Services</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth the aggregate fees by categories specified below in connection with certain professional services rendered
by Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, our
principal external auditors, for the periods indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit Fees<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">110,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">376,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit-Related Fees<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax Fees<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">All Other Fees<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">386,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 40%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Audit
Fees&rdquo; represents the aggregate fees billed or accrued for the interim reviews and audit of our annual financial statements. This
category also includes services that generally the independent accountant provides, such as consents and assistance with and review of
documents filed with the SEC as well as fees related to audits in connection with our initial public offering in August 2020.</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>









<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Audit-Related
                                            Fees&rdquo; represents the aggregate fees billed or accrued for assurance and related services
                                            that are reasonably related to the performance of the audit or review of our financial statements
                                            and not reported under &ldquo;Audit Fees.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Tax Fees&rdquo;
                                            represents the aggregate fees billed or accrued for professional tax services rendered by
                                            our independent registered public accounting firm for tax compliance and tax advice on actual
                                            or contemplated transactions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;All Other
                                            Fees&rdquo; represents the aggregate fees billed or accrued for services rendered by our
                                            independent registered public accounting firm other than services reported under &ldquo;Audit
                                            Fees,&rdquo; &ldquo;Audit-related Fees&rdquo; and &ldquo;Tax Fees.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit
Committee Pre-Approval Policies and Procedures</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Audit Committee has adopted a policy pursuant to which we will not engage our auditors to perform any non-audit services unless the audit
committee pre-approves the service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_019"></A>Item 16D.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Exemptions
                                            from the Listing Standards for Audit Committees</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_020"></A>Item 16E.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchases
                                            of Equity Securities by the Issuer and Affiliated Purchasers</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_021"></A>Item 16F.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
                                            in Registrant&rsquo;s Certifying Accountant</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_022"></A>Item 16G.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Corporate
                                            Governance</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a foreign private issuer, we are permitted to follow certain Israeli corporate governance practices instead of the Nasdaq corporate governance
rules, provided that we disclose which requirements we are not following and the equivalent Israeli requirement. Pursuant to the &ldquo;foreign
private issuer exemption&rdquo;:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            intend to follow Israeli corporate governance practices instead of the Nasdaq requirements
                                            with regard to, among other things, the nomination committee and director nomination procedures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            intend to comply with Israeli law, which permits a company to determine in its articles of
                                            association the number of shareholders and percentage of holdings required for a quorum at
                                            a general meeting, subject to certain minimum requirements. Our amended and restated articles
                                            of association provide that a quorum of two or more shareholders holding at least 25% of
                                            the voting rights in person or by proxy is required for commencement of business at a general
                                            shareholder meeting. The quorum set forth in our amended and restated articles of association
                                            with respect to an adjourned meeting shall, subject to a limited exception, consist of one
                                            or more shareholders present in person or by proxy (including by voting deed), regardless
                                            of the number or percentage of our outstanding shares held by them;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">with
                                            the exception of external directors and directors elected by our board of directors due to
                                            a vacancy, in accordance with the staggered nomination as described under &ldquo;Item 6.
                                            Directors, Senior Management and Employees&mdash;C. Board Practices&mdash;Board of Directors,&rdquo;
                                            we intend to elect our directors to hold office until the annual general meeting of our shareholders
                                            that occurs in the third year following his or her election and until his or her successor
                                            shall be elected and qualified. The nominations for directors, which are presented to our
                                            shareholders by our board of directors, are generally made by the board of directors itself,
                                            in accordance with the provisions of our amended and restated articles of association and
                                            the Companies Law;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            intend to adopt and approve material changes to equity incentive plans in accordance with
                                            the Companies Law, which does not impose a requirement of shareholder approval for such actions.
                                            In addition, we intend to follow Israeli corporate governance practice, which requires shareholder
                                            approval prior to an issuance of securities in connection with equity-based compensation
                                            of officers, directors, employees or consultants only under certain circumstances, in lieu
                                            of Nasdaq Marketplace Rule 5635(c);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">as
                                            opposed to making periodic reports to shareholders and proxy solicitation materials available
                                            to shareholders in the manner specified by the Nasdaq corporate governance rules, the Companies
                                            Law does not require us to distribute periodic reports directly to shareholders, and the
                                            generally accepted business practice in Israel is not to distribute such reports to shareholders
                                            but to make such reports available through a public website. We will only mail such reports
                                            to shareholders upon request. As a foreign private issuer, we are generally exempt from the
                                            SEC&rsquo;s proxy solicitation rules; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P></DIV>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            follow Israeli corporate governance practices instead of Nasdaq requirements to obtain shareholder
                                            approval for all corporate actions requiring such approval under the requirements of the
                                            Companies Law such as (i)&nbsp;transactions with directors concerning the terms of their
                                            service or indemnification, exemption and insurance for their service (or for any other position
                                            that they may hold at our company), (ii)&nbsp;extraordinary transactions with controlling
                                            shareholders, (iii)&nbsp;terms of employment or other engagement of the controlling shareholder
                                            of the company or such controlling shareholder&rsquo;s relative, (iv)&nbsp;private placements
                                            that will result in a change of control, (v)&nbsp;certain transactions, other than a public
                                            offering, involving issuances of a 20% or greater interest in us and (vi)&nbsp;certain acquisitions
                                            of the stock or assets of another company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Otherwise,
we intend to comply with the rules generally applicable to U.S. domestic companies listed on the Nasdaq. We may in the future decide
to use the foreign private issuer exemption with respect to some or all of the other Nasdaq corporate governance rules. We also intend
to comply with Israeli corporate governance requirements under the Companies Law applicable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_023"></A>Item 16H.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Mine Safety
                                            Disclosure</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_027"></A>PART
III</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_024"></A>Item 17.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial
                                            Statements</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have elected to provide financial statements pursuant to Item 18.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="a_025"></A>Item 18.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial
                                            Statements</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
consolidated financial statements of Nano-X Imaging Ltd. are included at the end of this annual report on Form 20-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 10%"><B><A NAME="a_026"></A>Item 19.</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 89%"><B>Exhibits</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">1.1*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120003529/filename5.htm">Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&rsquo;s Draft Registration Statement on Form F-1 (File No. 377-02938) filed on February&nbsp;18, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">1.2*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120018404/nt10006151x9_ex3-2.htm">Form of Amended and Restated Articles of Association of the Registrant to become effective immediately prior to the closing of the offering (incorporated by reference to Exhibit 3.2 to the Registrant&rsquo;s Registration Statement on Form F-1/A (File No. 333-240209) filed on August&nbsp;14, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">2.2<FONT STYLE="font-size: 10pt">&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f20f2020ex2-2_nanoximaging.htm">Description of Securities Registered under Section 12 of the Exchange Act</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">4.1<FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120003529/filename2.htm">Asset Purchase Agreement, dated September&nbsp;3, 2019, by and between the Registrant and Nanox Imaging PLC (incorporated by reference to Exhibit 2.1 to the Registrant&rsquo;s Draft Registration Statement on Form F-1 (File No. 377-02938) filed on February&nbsp;18, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">4.2<FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120003529/filename3.htm">Amendment to the Asset Purchase Agreement, dated December&nbsp;3, 2019, by and between the Registrant and Nanox Imaging PLC (incorporated by reference to Exhibit 2.2 to the Registrant&rsquo;s Draft Registration Statement on Form F-1 (File No. 377-02938) filed on February&nbsp;18, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">4.3<FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120003529/filename4.htm">Amendment to the Asset Purchase Agreement, dated December&nbsp;31, 2019, by and between the Registrant and Nanox Imaging PLC (incorporated by reference to Exhibit 2.3 to the Registrant&rsquo;s Draft Registration Statement on Form F-1 (File No. 377-02938) filed on February&nbsp;18, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">4.4<FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex4-2.htm">Form of warrants to purchase ordinary shares, dated September&nbsp;2, 2019, in connection with the warrants originally issued to certain investors by Nanox Imaging PLC in 2016 (incorporated by reference to Exhibit 4.2 to the Registrant&rsquo;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&nbsp;30, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">4.5<FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex4-3.htm">Form of warrants to purchase ordinary shares, dated September&nbsp;2, 2019, in connection with the warrants originally issued to certain finders by Nanox Imaging PLC in 2015 (incorporated by reference to Exhibit 4.3 to the Registrant&rsquo;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&nbsp;30, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">4.6<FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex4-4.htm">Form of warrants to purchase ordinary shares, dated September&nbsp;2, 2019, in connection with the warrants originally issued to certain finders and employee by Nanox Imaging PLC in 2014 and 2015 (incorporated by reference to Exhibit 4.4 to the Registrant&rsquo;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&nbsp;30, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">4.7<FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex4-5.htm">Form of warrants to purchase ordinary shares issued to A-Labs Finance and Advisory Ltd. (incorporated by reference to Exhibit 4.5 to the Registrant&rsquo;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&nbsp;30, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">4.8*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex4-6.htm">Warrant to purchase ordinary shares, dated September&nbsp;2, 2019, issued to SK Telecom TMT Investment Corp. (incorporated by reference to Exhibit 4.6 to the Registrant&rsquo;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&nbsp;30, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">4.9*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex4-7.htm">Amendment to Warrant to purchase ordinary shares, dated June&nbsp;4, 2020, issued to SK Telecom TMT Investment Corp. (incorporated by reference to Exhibit 4.7 to the Registrant&rsquo;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&nbsp;30, 2020 with the SEC)</A></TD></TR>
  </TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P></DIV>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; width: 10%">4.10*</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 89%"><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex10-1.htm">Contract Manufacturing Agreement, dated May&nbsp;26, 2020, by and between the Registrant and FoxSemicon Integrated Technology, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant&rsquo;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&nbsp;30, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">4.11*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120018404/nt10006151x9_ex10-2.htm">Registration Rights Agreement by and among the Registrant and the certain shareholders named therein (incorporated by reference to Exhibit 10.2 to the Registrant&rsquo;s Registration Statement on Form F-1/A (File No. 333-240209) filed on August&nbsp;14, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">4.12*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex10-3.htm">2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&rsquo;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&nbsp;30, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">4.13*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex10-4.htm">U.S. Sub-Plan (incorporated by reference to Exhibit 10.4 to the Registrant&rsquo;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&nbsp;30, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">4.14*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036120018404/nt10006151x9_ex10-5.htm">Form of Indemnification Agreement between the Registrant and each director and executive officer (incorporated by reference to Exhibit 10.5 to the Registrant&rsquo;s Registration Statement on Form F-1/A (File No. 333-240209) filed on August&nbsp;14, 2020 with the SEC)</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">8.1*</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1795251/000114036121003760/nt10018955x3_ex21-1.htm">List of subsidiaries of the Registrant</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">12.1<FONT STYLE="font-size: 10pt">&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f20f2020ex12-1_nanoximaging.htm">Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">12.2<FONT STYLE="font-size: 10pt">&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f20f2020ex12-2_nanoximaging.htm">Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">13.1&plusmn;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f20f2020ex13-1_nanoximaging.htm">Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">13.2&plusmn;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f20f2020ex13-2_nanoximaging.htm">Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">15.1&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f20f2020ex15-1_nanoximaging.htm">Consent of PricewaterhouseCoopers International Limited, an independent registered public accounting firm</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">101.INS</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Instance Document</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">101.SCH</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Taxonomy Extension Schema Document</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">101.CAL</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">101.DEF</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">101.LAB</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">101.PRE</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
  </TABLE>
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 40%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Previously filed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&dagger;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Filed herewith.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&plusmn;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Furnished
                                            herewith.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
reviewing the agreements included as exhibits to this annual report on Form 20-F, please remember they are included to provide you with
information regarding their terms and are not intended to provide any other factual or disclosure information about us or the other parties
to the agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties
have been made solely for the benefit of the other parties to the applicable agreement and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">should
                                            not in all instances be treated as categorical statements of fact, but rather as a way of
                                            allocating the risk to one of the parties if those statements prove to be inaccurate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">have
                                            been qualified by disclosures that were made to the other party in connection with the negotiation
                                            of the applicable agreement, which disclosures are not necessarily reflected in the agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">may
                                            apply standards of materiality in a way that is different from what may be viewed as material
                                            to you or other investors; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">were
                                            made only as of the date of the applicable agreement or such other date or dates as may be
                                            specified in the agreement and are subject to more recent developments.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accordingly,
these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIGNATURES</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NANO-X
IMAGING LTD hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized
the undersigned to sign this annual report on Form 20-F on its behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif">NANO-X IMAGING LTD</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="text-decoration: none; font-family: Times New Roman, Times, Serif">/s/
    Ran Poliakine</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ran Poliakine</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:
April  6, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 90%; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><B>Page</B></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#fin_001"><B>Report of Independent Registered Public Accounting Firm</B></A></TD>
    <TD STYLE="text-align: center">F-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#fin_002"><B>Consolidated Balance Sheets</B></A></TD>
    <TD STYLE="text-align: center">F-3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#fin_003"><B>Consolidated Statements of Operations</B></A></TD>
    <TD STYLE="text-align: center">F-4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#fin_004"><B>Consolidated Statements of Changes in Shareholders&rsquo; Equity (Capital Deficiency)</B></A></TD>
    <TD STYLE="text-align: center">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#fin_005"><B>Consolidated Statements of Cash Flows</B></A></TD>
    <TD STYLE="text-align: center">F-6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><A HREF="#fin_006"><B>Notes to the Consolidated Financial Statements</B></A></TD>
    <TD STYLE="text-align: center">F-7 &ndash; F-25</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 146; Options: NewSection -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="image_007.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fin_001"></A><B>Report of Independent Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">To the Board of Directors and Shareholders
of Nano-X Imaging Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B><I>Opinion on the Financial Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have audited the accompanying consolidated balance sheets of Nano-X Imaging Ltd. and its subsidiaries (the &ldquo;Company&rdquo;)
as of December 31, 2020 and 2019, and the related consolidated statements of operations, of changes in shareholders&rsquo; equity
(capital deficiency) and of cash flows </FONT><FONT STYLE="background-color: white">for each of the three years in the period ended
December 31, 2020</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">, including the related notes (collectively referred
to as the &ldquo;consolidated financial statements&rdquo;). In our opinion, the consolidated financial statements present fairly,
in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations
and its cash flows for </FONT><FONT STYLE="background-color: white">each of the three years in the period ended December 31, 2020
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">in conformity with accounting principles generally accepted in
the United States of America. </FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B><I>Basis for Opinion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">These consolidated financial statements
are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s consolidated
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">We conducted our audits of these consolidated
financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due
to error or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Our audits included performing procedures
to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe
that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">/s/ Kesselman&nbsp;&amp; Kesselman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Certified Public Accountants (Isr.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">A member firm of PricewaterhouseCoopers International
Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">April 6, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">We have served as the Company&rsquo;s auditor
since 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Kesselman&nbsp;&amp;
Kesselman, PwC Israel, 146 Derech Menachem Begin St. Tel-Aviv 6492103, Israel, P.O Box 7187 Tel-Aviv 6107120,<BR>
 Telephone: +972
-3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_002"></A>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. Dollars in thousands</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 10pt; text-indent: -10pt">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.25in; text-indent: -10pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">213,468</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,072</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Prepaid expenses and other current
    assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,325</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,564</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">TOTAL CURRENT
    ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">219,793</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,636</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">NON-CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 0.25in">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 0.25in">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">228</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 0.25in">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 0.25in">Operating lease right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">526</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Other non-current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">661</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">TOTAL NON-
    CURRENT ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,356</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,235</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">236,149</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,871</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 10pt; text-indent: -10pt">Liabilities and Shareholders&rsquo;
    Equity (Capital Deficiency)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">435</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Accrued expenses and other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Related party liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,748</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Related party accrued liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Current maturities of operating
    leases</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">519</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">140</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">TOTAL CURRENT
    LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,480</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,263</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">NON-CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Non-current operating leases</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">923</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">386</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">TOTAL NON-CURRENT
    LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">923</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">386</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,403</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,649</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">COMMITMENTS AND CONTINGENCIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt"><B>SHAREHOLDERS&rsquo;
                                         EQUITY (CAPITAL DEFICIENCY):</B>

</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 0.25in">Ordinary Shares, par value NIS 0.01 per share, 100,000,000
    and 40,000,000 shares authorized at December&nbsp;31, 2020 and 2019, respectively; 46,100,173 and 27,150,080 issued and outstanding
    at December 31, 2020 and 2019, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 0.25in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,031</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,748</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(84,416</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,601</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">TOTAL SHAREHOLDERS&rsquo;
    EQUITY (CAPITAL DEFICIENCY)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">230,746</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,778</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">TOTAL LIABILITIES
    AND SHAREHOLDERS&rsquo; EQUITY (CAPITAL DEFICIENCY)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">236,149</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,871</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of these consolidated financial statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 148 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fin_003"></A><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. Dollars in thousands</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -10pt; padding-left: 0.25in">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9,210</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,717</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">672</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 0.25in">Marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">209</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">22,268</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,298</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,023</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL OPERATING EXPENSES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,923</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">22,571</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">OPERATING LOSS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(43,923</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,571</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><B>FINANCIAL (INCOME) EXPENSES,</B> net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(108</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">NET LOSS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(43,815</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(22,563</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,909</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">BASIC AND DILUTED LOSS PER SHARE</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.23</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.90</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt"><B>THE WEIGHTED AVERAGE OF THE NUMBER OF ORDINARY SHARES</B> (in thousands)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">35,654</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">25,181</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,793</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of these consolidated financial statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 149 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="fin_004"></A><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&rsquo;
EQUITY (CAPITAL DEFICIENCY)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">paid-in capital</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. Dollars in thousands</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 40%; font-weight: bold">BALANCE AT JANUARY 1, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">20,257,434</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">41</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,814</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(16,129</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(8,274</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">CHANGES DURING 2018:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Issuance of ordinary shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,666,774</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,684</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net loss for the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,909</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,909</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">BALANCE AT DECEMBER 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,924,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,596</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,038</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,384</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">CHANGES DURING 2019:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of ordinary shares and warrants, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,762,656</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of ordinary shares to employees and non-employees upon exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">454,166</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">137</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of ordinary shares to investors upon exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional consideration with respect to an assets purchase agreement, see note 1c and note 6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,276</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,276</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 1.5pt; text-align: left">Net loss for the year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,563</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(22,563</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">BALANCE AT DECEMBER 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,150,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,748</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,601</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,778</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">CHANGES DURING 2020:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of ordinary shares and warrants, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,624,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,013</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Initial public offering of ordinary shares, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,555,556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169,136</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169,167</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of ordinary shares to employees and non-employees upon exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">997,863</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">497</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of ordinary shares to investors upon exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,662,929</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,781</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,781</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Conversion of related party liability to shareholders&rsquo; equity, see note 8a</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,109,245</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,745</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,748</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net loss for the year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(43,815</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(43,815</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">BALANCE AT DECEMBER 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">46,100,173</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">131</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">315,031</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(84,416</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">230,746</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">(*)</TD>
    <TD STYLE="text-align: left">Less than 1 thousand US dollars.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of these consolidated financial statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 150 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_005"></A>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF CASH FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. Dollars in thousands</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; width: 64%; text-align: left">Net loss for the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(43,815</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(22,563</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(1,909</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,781</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,478</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,564</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Related party prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,081</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,844</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Other non-current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(522</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(139</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(103</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">393</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(134</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Operating lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Accrued expenses and other liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,359</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">970</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21,487</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,524</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,671</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(13,937</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(125</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(73</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(13,937</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(125</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(73</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from issuance of ordinary shares and warrants, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,013</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,038</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,684</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from initial public offering of ordinary shares, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169,348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from issuance of ordinary shares upon exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Deferred offering costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(339</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">240,991</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,861</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,684</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,567</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,212</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(60</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">&nbsp;CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE YEAR</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,217</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">65</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">213,784</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,217</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Unpaid offering costs</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">858</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">issuance of ordinary shares to investor upon exercise of warrants</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">200</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Operating lease liabilities arising from obtaining operating right-of-use assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,085</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">548</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Additional consideration with respect to an assets purchase purchase agreement, see note 1c</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(10,276</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Conversion of related party liability to shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,748</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: left; text-indent: -7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in">(*)</TD>
    <TD STYLE="text-align: left">Less than 1 thousand US dollars.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: left; text-indent: -7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of these consolidated financial statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 151 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_006"></A>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
1 - GENERAL:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD STYLE="text-align: left">Nano-X Imaging Ltd, an Israeli Company (hereinafter &ldquo;the Company&rdquo; or &ldquo;Nanox IL&rdquo;
or &ldquo;the Successor Company&rdquo;), was incorporated on December 20, 2018 and commenced its operations on September 3, 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.65pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On September 19, 2019, Nanox IL
established Nanox Imaging Inc. (hereinafter &ldquo;Nanox Inc.&rdquo;), a wholly owned subsidiary in Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On September 25, 2020, Nanox IL
established Nano-X Korea Inc. (hereinafter &ldquo;Nanox Korea&rdquo;), a wholly owned subsidiary in Korea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In August 2020, the Company
completed an initial public offering (&ldquo;IPO&rdquo;) on the Nasdaq Global Select Market (the &ldquo;Nasdaq&rdquo;), in which
it issued 9,178,744 ordinary shares, at a price per share of $18.&nbsp;During August 2020 the underwriters exercised their over-allotment
option and purchased an additional 1,376,812 ordinary shares at the same price per share. The proceeds received from the IPO were
$190 million (the net proceeds were approximately $169 million after deducting underwriting commissions and other offering expenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD STYLE="text-align: left">Nanox Imaging PLC is a public limited company incorporated in Gibraltar in 2012 (hereinafter &ldquo;Nanox
PLC&rdquo; or &ldquo;the predecessor company&rdquo;). Nanox PLC developed certain technological capabilities
aimed to design and build various applications for x-ray based imaging. Nanox PLC has been a development-stage company since its
inception. Nanox PLC has a wholly owned subsidiary, Nanox Japan Inc. (hereinafter &ldquo;Nanox Japan&rdquo;). Nanox
Japan primarily provided research and development services to Nanox PLC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On September 3, 2019 (hereinafter
&ldquo;Transaction Date&rdquo;), Nanox IL signed an Assets Purchase Agreement which was later amended on December 3, 2019 and December
31, 2019 (hereinafter &ldquo;the APA&rdquo;) with Nanox PLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Under the terms of the APA,
Nanox IL purchased from Nanox PLC patents, patent applications and all other intellectual property rights, as well as all cash
of Nanox PLC (less an amount of $200 thousand), with an exclusion of certain assets as defined in the APA (hereinafter &ldquo;Acquired
Assets&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Under the terms of the APA,
Nanox IL shall pay Nanox PLC $6.127 million as consideration for the purchase of the Acquired Assets, which reflects the fair value
of the Acquired Assets (excluding cash) plus the cash balance as of the date of the APA, less $200 thousand. The purchase price
shall be due and payable upon the closing of one of the following events: (a) an M&amp;A event of Nanox IL, (b) an IPO of Nanox
IL, or (c) a qualified equity financing of Nanox IL at a minimum company pre-money valuation of $100 million, with proceeds totaling
at least $30 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In the event of an IPO or a
qualified equity financing, Nanox IL has the option to pay for the Acquired Assets in cash or by the issuance of Nanox IL shares
of the same series to be issued upon such event, in an amount reflecting a 25% discount on the per share price to be determined
in such IPO or qualified equity financing. If Nanox IL chooses to pay for the Acquired Assets in cash in any of the events described
above, then Nanox PLC has the right, at its sole discretion and in good faith, to reject such payment in cash, and require Nanox
IL to pay for the Acquired Assets by the issuance of securities of the same series to be issued upon such equity financing events,
in such amount which shall reflect a 25% discount on the per share price to be determined in such equity financing events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In November 2019, Nanox PLC
transferred to Nanox IL an amount of $7.2 million, which reflects the cash consideration under the APA. The total consideration
of the purchase of the Acquired Assets is $13.3 million. The outstanding balance of $17.8 million reflects the related
party liability of the expected future payment using the Company&rsquo;s shares, refer to note 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 152 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
1 - GENERAL </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In return to the Acquired Assets,
the Company issued to Nanox PLC 1,109,245 ordinary shares during January 2020. See also note 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD STYLE="text-align: left">As of September, 3 2019, Nanox IL and Nanox PLC had the same shareholders and, therefore, the transaction
was treated as a transaction under common control for accounting purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The financial statements of
the Company prior to the Transaction Date are the historical financial statements of Nanox PLC, which have been adjusted to reflect
the fact that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">1)</TD><TD STYLE="text-align: left">only the net assets that were transferred in the transaction according to the APA. Net assets which
were not transferred in the transaction are not reflected in these consolidated financial statements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.2pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">2)</TD><TD STYLE="text-align: left">no interests of Nanox Japan were transferred under the APA. The consolidated statements of operation
include the costs incurred for services provided by Nanox Japan to Nanox PLC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 82.6pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">3)</TD><TD STYLE="text-align: left">the consideration in the transaction (the &ldquo;Related Party Liability&rdquo;) was recorded at the
beginning of the earliest period presented against a decrease in shareholders&rsquo; equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.2pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">4)</TD><TD STYLE="text-align: left">all of the share-related information reflects the share information of Nanox IL.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>d.</B></TD><TD STYLE="text-align: left">The Company&rsquo;s solution, referred to as the Nanox System, has two integrated components &ndash;
&ldquo;Nanox.ARC&rdquo; and &ldquo;Nanox. CLOUD&rdquo;. Nanox.ARC is a medical imaging system incorporating the Company&rsquo;s novel
digital X-ray source. Nanox. CLOUD is a cloud-based system designed to provide end-to-end medical imaging services, including services
such as image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic
assistive AI systems, billing and reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In January 2020, the Company submitted
a 510(k) application for the Nanox Cart X-Ray System, which is a single-source version of the Nanox.ARC (the &ldquo;Nanox Cart X-Ray System&rdquo;)
to an accredited Review Organization under the FDA&rsquo;s 510(k) third party review program. During 2020 and the first quarter of 2021,
the Company received additional information requests and submitted its official responses. On April 1, 2021, the Company received clearance
from the FDA to market the Company's Nanox Cart X-Ray System. The Company plans to submit an additional 510(k) premarket notification
to the FDA with respect to the multi-source Nanox.ARC and the Nanox.CLOUD during 2021.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company has experienced
net losses and negative cash flows from operations since its inception. The&nbsp;Company anticipates such losses will continue
until its product candidates reach commercial profitability. In August 2020, the Company completed an IPO on Nasdaq with net proceeds
received from the IPO of approximately $<FONT STYLE="font-family: Times-Roman,serif">1</FONT>69 million .Based on the Company&rsquo;s
financing activities during the year ended December 31, 2020, the Company has sufficient funds for its plans for the next twelve
months from the issuance of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 153 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
1 - GENERAL </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>e.</B></TD><TD STYLE="text-align: left">Current Impact of COVID-19</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Following the December
2019 outbreak of Coronavirus (COVID-19) in China, it has spread into most countries across the world, including Israel, Japan
and all 50 states within the U.S. The COVID-19 pandemic is evolving, and to date has led to the implementation of various
responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The
COVID-19 pandemic has adversely impacted the Company&rsquo;s operations in various ways. For example, the Company&rsquo;s engineers are
unable to make work-related trips to Korea or Israel to test and optimize the Nanox.ARC or to begin development of x-ray chip
manufacturing in Korea. The potential business partners are unable to make on-site visits to the Company&rsquo;s facilities or
attend industry conferences and meetings to experience the Nanox.ARC, which has negatively impacted the Company&rsquo;s business
development and deployment activities. The external labs the Company works with have also been affected by COVID-19,
resulting in delays in the Company&rsquo;s timelines for obtaining regulatory approval. COVID-19 has also caused shutdowns or
disruptions of business for our manufactures and suppliers. The continued spread of COVID-19 globally could adversely impact
the Company&rsquo;s development, manufacture or deployment of the Nanox Systems, which could adversely affect the Company&rsquo;s ability
to obtain regulatory approval for and to commercialize the Nanox Systems, increase the operating expenses and have a material
adverse effect on the Company&rsquo;s financial results. (For the process with the FDA, see note 1d above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: left">Our consolidated
financial statements are prepared in accordance with generally accepted accounting principles in the United States (hereinafter
-&ldquo;U.S GAAP&rdquo;). The preparation of our consolidated financial statements and related disclosures requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses and the disclosure of contingent
assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and
various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates
and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>a.&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>Use of estimates in the preparation of financial statements</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: left; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those
estimates and such differences may have a material impact on the Company&rsquo;s consolidated financial statements. As applicable
to these consolidated financial statements, the most significant estimates relate to fair value of share-based payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 154 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>b.&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>Functional currency</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The U.S. dollar is the currency
of the primary economic environment in which the operations of the Company and its subsidiary is conducted. A substantial portion
of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar
(&ldquo;primary currency&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Foreign currency assets and liabilities
are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date. Equity accounts
are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income
statement translation process. Expense accounts are translated using the weighted average exchange rate during the period. Currency
transaction gains and losses are presented in financial income and expenses, net.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>c.</B></TD>
    <TD STYLE="text-align: left"><B>Cash and cash equivalents</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company considers as cash
equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three
months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts
of cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>d.</B></TD>
    <TD STYLE="text-align: left"><B>Restricted&nbsp;Cash</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">As of December&nbsp;31, 2020,
the Company&rsquo;s restricted cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit
is presented at cost including accrued interest. This bank deposits is used as security for credit card use and collateralizing
the Company&rsquo;s lease contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>e.</B></TD>
    <TD STYLE="text-align: left"><B>Property&nbsp;and&nbsp;equipment,&nbsp;net</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Property and equipment are stated
at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful
lives:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>%</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Computers and electronic equipment</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">10-33</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Office furniture and lab equipment</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">6-20</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Machines</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">10-20</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; text-align: left; text-indent: 0; padding-left: 0; padding-right: 0">Leasehold Improvement</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0; padding-left: 0; padding-right: 0">Land</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">N/A</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The depreciable life of leasehold
improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset
reasonably certain of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 155 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 198.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>f.</B></TD>
    <TD STYLE="text-align: left"><B>Impairment&nbsp;of&nbsp;long-lived&nbsp;assets </B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company tests long-lived
assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be
recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated
undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less
than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over
the fair value of the asset, using the expected future discounted cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"> As of December
31, 2020, 2019 and 2018, the Company did not recognize an impairment loss on its long-lived assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>g.</B></TD>
    <TD STYLE="text-align: left"><B>Severance&nbsp;pay</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Israeli labor law generally
requires severance pay be granted upon dismissal of an employee or upon termination of employment under certain other circumstances.
Pursuant to Section 14 of the Severance Compensation Act, 1963 (&ldquo;Section 14&rdquo;), all of the Company&rsquo;s employees in
Israel are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies.
Payments under Section 14 relieve the Company from any future severance payment obligation with respect to those employees and,
as such, the Company may only utilize the insurance policies for the purpose of disbursement of severance pay. As a result, the
Company does not recognize an asset nor liability for these employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In 2020, all of the Company&rsquo;s
employees in Israel are subject to Section 14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>h.</B></TD>
    <TD STYLE="text-align: left"><B>Legal&nbsp;and other&nbsp;contingencies</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Certain conditions, such as
legal proceedings, may exist as of the date the consolidated financial statements are issued that may result in a loss to the
Company, but that will only be resolved when one or more future events occur or fail to occur. In assessing loss
contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such
proceedings, the Company&rsquo;s management evaluates with its legal advisors the perceived merits of any legal proceedings
or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Such assessment
inherently involves an exercise of judgment. Legal fees are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Management applies the guidance
in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable
that a material loss would be incurred and the amount of the liability can be estimated, then the Company records an accrued expense
in the Company&rsquo;s consolidated financial statements based on its best estimate. Loss contingencies considered to be remote
by management are generally not disclosed unless material. In September 2020, securities class action complaints were filed in
the United States by certain of the Company&rsquo;s shareholders against the Company and certain of the Company&rsquo;s current
officers and directors. For additional information see note 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 156 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>i.</B></TD>
    <TD STYLE="text-align: left"><B>Research and development expenses</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; text-align: left; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Research and development expenses
are charged to the statement of operations as incurred and consist primarily of personnel, materials and supplies for research
and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>j.</B></TD>
    <TD STYLE="text-align: left"><B>Income&nbsp;tax </B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: left; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company accounts for income taxes in accordance with ASC 740, &ldquo;Income Taxes&rdquo; (&ldquo;ASC&nbsp;740&rdquo;).
ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based
on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates
and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary,
to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred
tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and
assets are classified as non-current in accordance with ASU&nbsp;2015-17.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">2)</TD><TD STYLE="text-align: left">Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not been
taken into account in computing the deferred income taxes, as it is the Company&rsquo;s intent and ability to hold these investments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left">The Company accounts for uncertain
tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax
positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight
of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position
will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure
the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement.
The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 98.7pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>k.&nbsp;&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>Share-based compensation</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company accounts for share-based
compensation under ASC 718, &ldquo;Compensation - Stock Compensation,&rdquo; which requires the measurement and recognition of
compensation expense based on estimated fair values for all share-based payment awards made to non-employees, employees, officers
and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">ASC 718 requires companies to
estimate the fair value of equity-based payment awards on the date of grant. The Company uses the Black-Scholes-Merton option-pricing
model as part of such estimation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Prior to the adoption of ASU
2018-07, warrants issued to consultants and other non-employees, as compensation for services provided to the Company, were accounted
for based upon the fair value of the warrants. The fair value of the warrants granted was measured on a final basis at the end
of the related service period and was recognized over the related service period using the straight-line method. After the adoption
of ASU 2018-07, the measurement date for non-employee awards is the date of the grant. The compensation expense for non-employees
is recognized without changes in the fair value of the award, over the requisite service period, which is the vesting period of
the respective award using the straight line. The Company adopted ASU 2018-07 as of January 1, 2019 with no impact on its consolidated
financial statements as all of the Company&rsquo;s awards were fully vested at the adoption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>l.</B></TD>
    <TD STYLE="text-align: left"><B>Loss&nbsp;per&nbsp;share</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Basic earnings per share is
computed by dividing net income (loss) attributable to holders of ordinary shares of the Company by the weighted average number
of ordinary shares outstanding for each reporting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In computing the Company&rsquo;s
diluted earnings per share, the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary
shares and the potential dilutive ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding
include the dilutive effect of in-the-money options using the treasury stock method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company did not take into account
any dilutive instruments, such as investor warrants and share-based payments, since their effect, on a fully diluted basis, is
anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>m.</B></TD>
    <TD STYLE="text-align: left"><B>Fair&nbsp;value&nbsp;measurement</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Fair value is based on the price
that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between
market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the
guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into
three broad levels, which are described as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.5in">Level 1:</TD>
    <TD STYLE="text-align: left">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Level 2: </TD>
    <TD STYLE="text-align: left">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Level 3: </TD>
    <TD STYLE="text-align: left">Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to
Level 3 inputs.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In determining fair value, the
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to
the extent possible and considers counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company&rsquo;s financial instruments
consist mainly of cash and cash equivalents, restricted cash accounts payable, accrued expenses and other liabilities. The fair
value of these financial instruments approximates their carrying values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>n.</B></TD>
    <TD STYLE="text-align: left"><B>Concentration&nbsp;of&nbsp;Credit Risks</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company&rsquo;s cash and cash
equivalents and restricted cash are invested with major banks in Israel, Korea and Japan. Generally, these investments may be redeemed
upon demand and the Company believes that the financial institutions that hold the Company&rsquo;s cash balances are financially
sound and, accordingly, bear minimal risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 158 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>o.</B></TD>
    <TD STYLE="text-align: left"><B>Offering&nbsp;Costs </B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Deferred offering costs directly
relating to the Company&rsquo;s private and initial public offering, were capitalized and offset against proceeds upon the consummation
of the private and IPO transactions in shareholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>p.</B></TD>
    <TD STYLE="text-align: left"><B>Leases</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">On January 1, 2019 the Company
adopted ASU No. 2016-02, Leases (Topic 842), The Company determines if an arrangement is a lease at inception. Balances related
to operating leases are included in operating lease right-of-use (&ldquo;ROU&rdquo;) assets, current maturities of operating leases
and Non-current operating leases in the consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">The Company also elected not
separating lease components from non-lease components and to keep leases with an initial term of 12 months or less off the balance
sheet and recognize the associated lease payments in the consolidated statements of operations on a straight-line basis over the
lease term.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">ROU assets represent the Company&rsquo;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&rsquo;s obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on
the present value of lease payments over the lease term. The Company&rsquo;s lease terms may include options to extend or terminate
the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate
implicit in the lease unless that rate cannot be readily determined. As the Company&rsquo;s leases do not provide an implicit rate,
the Company&rsquo;s uses its estimated incremental borrowing rate based on the information available at the commencement date in
determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the
lease term (see also note 5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 0.25in"><B>q.&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>Newly issued and recently adopted accounting pronouncements:</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><B><I>Accounting Pronouncements
Adopted in Current year</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on
Financial Instruments (&ldquo;the Standard&rdquo;). This guidance replaces the current incurred loss impairment methodology.
Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance
that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based
on historical experience, current conditions and reasonable and supportable forecasts. In November 2018, the FASB issued ASU
2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. ASU 2018-19 clarifies that
receivables from operating leases are accounted for using the lease guidance and not as financial instruments.</FONT> Since
the Company has no financial instruments the Standard does not impact the Company&rsquo;s consolidated financial
statements.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108.8pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 159 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
3 - PROPERTY AND EQUIPMENT, NET:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">Composition of property and equipment
grouped by major classifications is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars <BR>
in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 10pt; text-indent: -10pt">Office furniture and lab equipment</TD><TD STYLE="width: 1%; font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">820</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">325</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Computers and electronic equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Machinery</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,762</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Leasehold improvement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Land &ndash; See b below</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,297</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Prepayments on account of production line in construction - See b below</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,318</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,364</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">364</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(344</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(136</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">Total property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">228</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 18pt"><B>a.</B></TD><TD STYLE="text-align: left">Total depreciation in respect of property and equipment were approximately $208 thousand, $53 thousand
and $35 thousand for the years ended December 31, 2020, 2019 and 2018, respectively.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 18pt"><B>b.</B></TD><TD STYLE="text-align: left">In December 2020, Nanox Korea purchased a land for approximately $6.2 million upon which it intends
to build a manufacturing facility. Nanox Korea also rented a temporary fabrication plant and is in the process of preparing for
the commencement of full manufacturing activities, including purchasing certain equipment and transferring certain technology.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><FONT STYLE="text-transform: uppercase"><B>NOTE
4 - CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The following table provides a
reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheet that sum to the same total
amount as shown in the consolidated statement of cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars<BR>
 in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">213,468</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,072</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Restricted bank deposit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">316</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">145</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -11.5pt; padding-left: 11.5pt">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">213,784</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,217</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 160 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
5 - LEASES:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">As of December 31, 2020, the Company
has four operating lease agreements for its car and facilities, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During the fourth quarter of
2019, the Company entered into an office lease agreement. This agreement is through December 31, 2021 with an option by the Company
to extend the period for an additional 24 months. The monthly rent payment is approximately $13 thousand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During June 2020, the Company
entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023. The monthly rent payment
for this agreement is approximately $15 thousand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During November 2020, following
the increase of the Company&rsquo;s employees, the Company signed an additional lease agreement, for a leasing of another office
complex through June 30, 2023. The monthly rent payment for this agreement is approximately $12 thousand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During November 2020, the Company
engaged with car lease company, for leasing of 6 vehicles. This agreement is effective through June 30, 2023 and the monthly payment
for this agreement is approximately $6.5 thousand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents the
effects on the amounts relating to the Company&rsquo;s total lease costs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Year ended <BR>
December&nbsp;31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Year ended <BR>
December&nbsp;31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars<BR>
 in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">(U.S. Dollars <BR>
In thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating lease cost:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Fixed payments</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">276</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Short-term lease cost</TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">65</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">112</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total operating lease cost</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">341</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">137</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents supplemental
cash flow information related to operating leases:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Year ended <BR>
December&nbsp;31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; white-space: nowrap">Year ended <BR>
December&nbsp;31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">(U.S.&nbsp;Dollars<BR>
 in&nbsp;thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">(U.S.&nbsp;Dollars<BR>
 in&nbsp;thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating cash flows from operating leases</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">169</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">25</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Right-of-use assets obtained in exchange for lease obligations (non-cash):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating leases</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,085</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">548</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 161 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
5 - LEASES </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents supplemental
balance sheet information related to operating leases:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease right-of-use assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,359</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">526</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Current maturities of operating leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">519</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-current operating leases</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">923</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">386</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total operating lease liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,442</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">526</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right"><B>December&nbsp;31,</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right"><B>December&nbsp;31,</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted average remaining lease term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.67</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.96</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted average discount rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.83</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.6</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents maturities
of operating lease liabilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars <BR> in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; text-align: left">2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">588</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">588</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">382</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2024 and thereafter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total operating lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,558</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">116</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Present value of lease liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,442</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
6 - RELATED PARTY LIABILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">According to ASC
480, &ldquo;Distinguishing Liabilities From Equity,&rdquo; a financial instrument that embodies an unconditional obligation, or a
financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle
by issuing a variable number of its equity shares shall be classified as a liability if, at inception, the monetary value of the
obligation is based solely or predominantly on a fixed monetary amount known at inception. These liabilities are measured subsequently
at fair value with changes in fair value recognized in earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">The Company analyzed
the instrument&rsquo;s provisions and concluded that it meets the above ASC 480 criteria and therefore accounted the expected future
payment under the APA in accordance with ASC 480.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt; text-align: left; text-indent: 1.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">As of December
31, 2019, the Company recorded a Related Party Liability in an amount of $17.8 million, which represents the fair value of the
shares that have been issued to Nanox PLC, based on the last financing round of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">During January
2020, subject to entering into a share purchase agreement in the aggregate amount of at least $6 million, and a pre-money valuation
of more than $100 million, the Nanox IL&rsquo;s Board approved the issuance and allotment of 1,109,245 ordinary shares to Nanox
PLC with the purchase price of $12.00 per share, which reflects a discount of 25% from the price of the last financing round of
the Company. As a result, on January 30, 2020 the related party liability was settled into equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 162 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
7 - COMMITMENTS AND CONTINGENCIES</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; text-align: left; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD STYLE="text-align: left">In September 2020, securities class action complaints were filed in the United States by certain of
the Company&rsquo;s shareholders against the Company and certain of the Company&rsquo;s current officers and directors alleging
violations of securities laws and seeking unspecified damages. On December 7, 2020, the proposed lead plaintiffs&rsquo; submissions
were fully briefed. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. As of the
date of issuance of these financial statements, the Company is unable to estimate a range of loss, if any, that could result were
there to be an adverse final decision in these cases.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD STYLE="text-align: left">For services with SixAI Ltd. (&ldquo;SixAI&rdquo;), see Note 10d.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
8 - SHAREHOLDERS&rsquo; EQUITY:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD STYLE="text-align: left"><B>Share capital</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Each holder of the Company&rsquo;s
ordinary shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are
legally available, and declared by the Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;). Since inception, the Company
has not declared any dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><I>Issuance
of Equity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><I>Ordinary Share issuances
prior to the APA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73.5pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">During the year ended December
31, 2018, Nanox PLC entered into several agreements with third party investors, pursuant to which it raised an aggregate amount
of $3,684 thousand at a purchase price of $2.21 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On June 17, 2019, Nanox PLC
issued 2,262,443 ordinary shares to third party investors for an aggregate purchase price of approximately $5,000 thousand. Certain
investors were also granted warrants to acquire 2,262,443 of ordinary shares at an exercise price of $20.87 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73.5pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Additionally, during 2019, Nanox
PLC entered into&nbsp;several agreements with certain third-party investors, pursuant to which it raised an aggregate amount of
$4,038 thousand, net of issuance costs, at a purchase price of $2.21 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73.5pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><I>Ordinary Share issuances
after the APA</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73.5pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On December 31, 2019, the Company
issued 312,500 ordinary shares to a third-party investor for an aggregate purchase price of approximately $5 million.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">During the year 2020, the Company
issued an aggregate of 4,624,500 ordinary shares to the certain investors, at a price per share of $16.00, for an aggregate purchase
price of approximately $74 million (the net proceeds were approximately $71 million after deducting issuance costs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
August 2020, the Company completed an initial public offering (&ldquo;IPO&rdquo;) on the Nasdaq Global Market (the &ldquo;Nasdaq&rdquo;),
in which it issued 9,178,744 ordinary shares at a price per share of $18.&nbsp;During August 2020, the underwriters exercised
their over-allotment option and purchased an additional 1,376,812 ordinary shares at the same price per share. The proceeds received
from the IPO were $190 million (the net proceeds were approximately $169 million after deducting underwriting commissions and
other offering expenses).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 163 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
8 - SHAREHOLDERS&rsquo; EQUITY </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><I>Settlement
of Related Party Liability</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Pursuant to the Asset Purchase
Agreement between Nanox IL and Nanox PLC, as more fully described in the Company&rsquo;s annual financial statements, in January 2020,
the Company issued 1,109,245 ordinary shares to Nanox PLC with a purchase price of $12.00 per share, which reflected a discount
of 25% from the price of the last financing round of the Company. As a result, the related party liability was settled into shareholders&rsquo;
equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73.5pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD STYLE="text-align: left"><B>Share based compensation </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On September 3, 2019, the Company&rsquo;s
Board resolved to adopt an equity incentive plan (the &ldquo;Plan&rdquo;). Based on such Plan, each option will be exercisable for
one ordinary share of the Company and will become exercisable at such terms and during such periods, as the Board shall determine.
Pursuant to the Plan (and further increase of option pool approved by the Board), 8,041,936 ordinary shares of NIS 0.01 par value
of the Company are reserved for issuance upon the exercise of the same amount of awards to be granted to some of the Company&rsquo;s
employees, directors and consultants. As of December 31, 2020, 2,978,247 ordinary shares reserved for the equity incentive plan.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Board also approved the
Plan for the purpose of selecting the capital gains tax track, under Section 102 of the Israeli Income Tax Ordinance, for options
granted to the Company&rsquo;s Israeli employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">1)</TD><TD STYLE="text-align: left">Share-based compensation to non-employees</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: left; text-indent: -14.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left">The following table summarizes
share-based awards to non-employees for the years ended December 31, 2020 and December 31, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">share-based</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">share-based</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">payment</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">payment</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 10pt; text-indent: -10pt">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,410,406</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.89</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,592,874</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.32</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Changes during the year:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Granted</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right">1,327,957</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,271,698</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.77</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*(1,267,012</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(454,166</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -10pt">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(98,725</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.92</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,372,626</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.27</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,410,406</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.89</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Exercisable at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,191,042</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.67</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,830,809</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3.79</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: left">Out of which 1,027,151 awards were exercised on a
cashless basis.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The fair value of each granted award
is estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used for the years ended December
31, 2020 and 2019 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Dividend yield</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: center">0</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: center">0</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Expected volatility</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">57.34%-44.40%</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">41.11% - 50.59%</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Risk-free interest rate</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">0.27%-1.61%</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">1.55%-1.76%</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Contractual term (years)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">5-10</P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">0.50 &ndash; 10.00</P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 164 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
8 - SHAREHOLDERS&rsquo; EQUITY </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: left; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The expected volatility is based
on the historical volatility of comparable companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The risk-free interest rate assumption
is based on observed interest rates appropriate for the expected term of the awards granted in dollar terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The Company does not have sufficient
historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course
options granted, the expected term was determined using the simplified method, which takes into consideration the option&rsquo;s
contractual life and the vesting periods (for non-employees, the expected term is equal to the option&rsquo;s contractual life).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: left; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The following table summarizes
information concerning outstanding and exercisable awards as of December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.25pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="18" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">awards</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">award</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercisable</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">at end of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">at end of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">0.01</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">186,815</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">0.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">186,815</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">0.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">269,714</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">269,714</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.18</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,191,349</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,188,914</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">444,748</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,933</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.89</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.86</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.25pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="18" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">awards</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">awards</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercisable</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">at end of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">at end of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">0.01</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">186,815</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">186,815</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">472,606</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">472,606</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,727,028</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,163,402</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20.87</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,957</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,986</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.69</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">2)</TD><TD STYLE="text-align: left">Share-based compensation to employees, officers and directors</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: left; text-indent: -21.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">During 2020, the Company granted
to certain employees, officers and directors awards to purchase 730,734 of the Company&rsquo;s ordinary shares for an average exercise
price of $13.53.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.15pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 165 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
8 - SHAREHOLDERS&rsquo; EQUITY </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap"><B>Number of</B></TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap"><B>Weighted </B></TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap"><B>Number of</B></TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap"><B>Weighted </B></TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap"><B>share-based</B></TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap"><B>average </B></TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap"><B>share-based</B></TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap"><B>average </B></TD><TD STYLE="font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>payment awards</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>exercise price</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>payment awards</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>exercise price</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,667,267</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,667,267</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes during the year:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.8pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">730,734</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.8pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.8pt">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.8pt">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 8.8pt">Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,876</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Outstanding at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,381,125</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4.14</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,667,267</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.21</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Exercisable at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,061,778</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.80</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">450,557</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.21</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: left">The fair value of each granted
award is estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used as of December 31,
2020 and 2019 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2020</TD><TD STYLE="font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2019</TD><TD STYLE="font-weight: bold; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; white-space: nowrap">Dividend yield</TD><TD STYLE="width: 1%; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: center; white-space: nowrap">0</TD><TD STYLE="width: 1%; text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="width: 1%; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: center; white-space: nowrap">0</TD><TD STYLE="width: 1%; text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; white-space: nowrap">Expected volatility</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">45.11%-55.97%</P></TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">45.11%-55.97%</P></TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; white-space: nowrap">Risk-free interest rate</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">0.23%-1.61%</P></TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">0.23%-1.61%</P></TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; white-space: nowrap">Contractual term (years)</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">10</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">10</TD><TD STYLE="text-align: left; white-space: nowrap">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0">The expected
volatility is based on the historical volatility of comparable companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70pt; text-align: left; text-indent: -1.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0">The risk-free
interest rate assumption is based on observed interest rates appropriate for the expected term of the awards granted in dollar
terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70pt; text-align: left; text-indent: -1.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0">The Company
does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly,
as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration
the option&rsquo;s contractual life and the vesting periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70pt; text-align: left; text-indent: -1.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0">The following
table summarizes information concerning outstanding and exercisable awards as of December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="18" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">awards</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">awards</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercisable</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">at end of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">at end of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 18%; text-align: center">$2.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1,995,625</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">9.05</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1,019,695</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">9.05</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: center">$16.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">$26.56-$59.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.93</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="18" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">awards</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">awards</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercisable</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">at end of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">at end of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">contractual</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 18%; text-align: center">$2.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1,667,267</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">9.90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">450,557</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">9.90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 166 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
8 - SHAREHOLDERS&rsquo; EQUITY </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">3)</TD><TD STYLE="text-align: left">Share-based compensation expenses</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. dollars in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,384</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">661</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Marketing (*)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,145</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,967</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">115</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">24,781</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">16,245</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">115</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><B>(*)</B></TD><TD STYLE="text-align: left">On October 26, 2020, the Company entered into an amendment
to a business development agreement (&ldquo;the Agreement&rdquo;) dated February 4, 2020 with two service providers pursuant to
which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate
of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date
(subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants
granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant
to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues
from any of the Company&rsquo;s systems and the issuance of warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.75in; text-align: left"><B>NOTE 9 -</B></TD><TD STYLE="text-align: left"><B>INCOME TAX:</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD STYLE="text-align: left"><B>Basis of taxation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Current tax is calculated with
reference to the profit of the Company and its subsidiary in their respective countries of operation. Set out below are details
in respect of the significant jurisdictions where the Company and its subsidiary operates and the factors that influenced the current
and deferred taxation in those jurisdictions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><B><I>Israel</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company is taxed under the
laws of the State of Israel at a corporate tax rate of 23%. In 20<FONT STYLE="font-family: Georgia, Times, Serif">20</FONT>, the
Company was at a loss position and therefore had no corporate tax liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><B><I>Korea</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Nanox Korea is subject to a Corporate
income tax with accordance with the Korean tax law. The tax rate ranges between 10% to 25%, depending on the companies&rsquo; taxable
income. In Addition, Nanox Korea is subject to a Local income tax of 10%. In 2020, Nanox Korea was at a loss position and therefore
had no corporate tax liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 167 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
9 - INCOME TAX </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><B><I>Japan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Nanox Inc. is subject to national
corporate income tax, and enterprise tax, which, in the aggregate resulted in effective tax rate of approximately 33.59% for the
year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Under Japanese tax law and regulations,
every company is required to submit an annual tax return to tax authorities. The statute of limitations to request a correction
of prior year tax liabilities is five years from when the original tax return was filed. After filling of tax return, the tax authorities
may conduct tax inspections on an irregular basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD STYLE="text-align: left"><B>Tax assessments</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Nanox IL , Nanox Korea and Nanox
Inc. have not been assessed since inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD STYLE="text-align: left"><B>Deferred tax assets </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Nanox IL&rsquo;s deferred tax asset as
of December 31, 2020 was related to tax losses accumulated since September 3, 2019 and carryforward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">A full valuation allowance was
created against deferred tax assets arisen from the carryforward tax losses, since the realization of any future benefit from the
carryforward tax losses cannot be sufficiently assured as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The reconciling item between the
statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax benefits from
carried forward tax losses due to uncertainty of the realization of such tax benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Change in valuation allowance for
the year ended December 31, 2020 was $3,262 thousand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
10 - RELATED PARTIES - TRANSACTIONS AND BALANCES:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD STYLE="text-align: left"><B>Balances with related parties:</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">December 31,</TD><TD STYLE="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2020</TD><TD STYLE="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2019</TD><TD STYLE="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">(U.S. Dollars in thousands)</TD><TD STYLE="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0 0 4pt; width: 76%; text-align: left; text-indent: 0">Related party accrued liability</TD><TD STYLE="padding: 0 0 4pt; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">-</TD><TD STYLE="padding: 0 0 4pt; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0 0 4pt; width: 1%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">72</TD><TD STYLE="padding: 0 0 4pt; width: 1%; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0 0 4pt; text-align: left; text-indent: 0">Related party liability, refer to note 6</TD><TD STYLE="padding: 0 0 4pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">-</TD><TD STYLE="padding: 0 0 4pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0 0 4pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">17,748</TD><TD STYLE="padding: 0 0 4pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD STYLE="text-align: left"><B>Related parties transactions:</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt; text-align: left"><B>&nbsp;</B></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars in thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-bottom: 4pt">Research and development &ndash; see c and d below</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">355</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">154</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; width: 9%; text-align: right">542</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">General and administrative &ndash; See c, e and f below</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(167</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,824</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">892</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 168 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
10 - RELATED PARTIES - TRANSACTIONS AND BALANCES </B>(continued):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD STYLE="text-align: left"><B>Six-Eye Interactive agreements for services </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 76.5pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On June 1 2015, Nanox PLC entered
into a consulting agreement with Six-Eye, a company owned by Ran Poliakine, the Company&rsquo;s CEO and one of major shareholders, pursuant
to which Ran Poliakine agreed to provide services as Chief Strategy Officer and a member of the Executive Committee to Nanox PLC.
On May 1, 2017, Nanox PLC entered into a services agreement with Six-Eye for the supply of ongoing services, which include research
and development services, general and financial management (including accountancy), office management services and operational
and supply services. According to the agreement between the parties, Nanox PLC reimburses Six-Eye for its actual direct expenses
plus a 12% surplus charge. The agreements were terminated in September 2019. During the years ended December 31 2019 and 2018 the
total expenses to Six-Eye were $679 thousand and $1,434 thousand, respectively. In addition to the services provided by Six-Eye
during 2019, Six-Eye also paid directly to third-party consultants and suppliers on behalf of the Company in the amount of approximately
$1,015 thousand prior to the completion of the Company&rsquo;s equity financing.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>d.</B></TD><TD STYLE="text-align: left"><B>SixAI Ltd Service agreement</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On April 16,2020, the Company
entered into an agreement with SixAI Ltd. (hereinafter-&ldquo;SixAI&rdquo;) a company controlled by Ran Poliakine, the Company&rsquo;s
CEO for certain software development and mechanical engineering services. The service agreement is effective as of March 1, 2020
and has been extended by mutual agreement of the parties to March 31, 2021. During the year ended December 31, 2020, the Company
recorded an expense of $355 thousand. Mr. Poliakine currently serves as a member of the board of directors of SixAI and Mr. Poliakine
is a significant shareholder of SixAI.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>e.</B></TD><TD STYLE="text-align: left"><B>Illumigyn Ltd. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Illumigyn Ltd (hereinafter
&ndash; &ldquo;Illumigyn&rdquo;) is a company in which Ran Poliakine, the Company&rsquo;s CEO, is a significant shareholder primarily through
indirect holdings. Since November 1 2019, Illumigyn sub-leased in transaction approximately 1,800 square feet of private office
space, including access to shared public spaces, from the office spaces which the Company leases in Neve Ilan, Israel. Illumigyn
pays approximately $12 thousand per month. During the year ended December 31, 2020, the Company received approximately $163 thousand
in relation to the sub lease.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>f.</B></TD><TD STYLE="text-align: left"><B>Wellsese Technologies Ltd.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Wellsense
Technologies Ltd (hereinafter &ndash; &ldquo;Wellsense&rdquo;) is a company in which Ran Poliakine, the Company&rsquo;s CEO, and Richard
Stone, a member of the Company&rsquo;s board of directors, are shareholders. Since February 2020, Wellsense has sub-leased private
office space, including access to shared public spaces, from the Company in Neve Ilan, Israel. Wellsense pays approximately $7.0
thousand per month. During the year ended December 31, 2020, the Company received $59 thousand, in relation to the sub lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>g.</B></TD><TD STYLE="text-align: left">Pursuant to the Asset Purchase Agreement between Nanox IL and Nanox PLC, as of December 31, 2020,
the Company has settled the related party liability balance of $192 thousand to Nanox Japan and Nanox PLC, mainly for Fixed Assets
which were transferred to the Company as part of the APA.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 169 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NANO-X IMAGING LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.85pt; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
11 </B>- <B>LOSS PER SHARE:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD STYLE="text-align: left"><B>Basic</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Basic loss
per share is calculated by dividing the loss attributable to the Company&rsquo;s owners by the weighted average number of ordinary
shares in issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.9pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-bottom: 1.5pt">Net loss attributable to Company&rsquo;s owners</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(43,815</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(22,563</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(1,909</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">The weighted average of the number of ordinary shares (in thousands)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">35,654</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">25,181</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,793</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Basic and diluted loss per share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.23</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.90</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.8pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">For the calculation
of loss per share, the Company used the net loss attributable to Company&rsquo;s owners divided by the weighted average number
of the Company&rsquo;s ordinary shares for the years ended December 31, 2020, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD STYLE="text-align: left"><B>Diluted</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.8pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">As of December 31, 20<FONT STYLE="font-family: Georgia, Times, Serif">20</FONT>
and 201<FONT STYLE="font-family: Georgia, Times, Serif">9</FONT> the Company had 7,846,290 and 9,203,124 investor warrants and
employees and non-employees option awards, respectively. These warrants and awards were not taken into account when calculating
diluted loss per share since their effect is anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.8pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><B>NOTE
12 - SUBSEQUENT EVENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD STYLE="text-align: left">During 2021, the Company granted a total of 338,929 awards with an average exercise price of $48.59
per share to employees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD STYLE="text-align: left">In February 2021 the Company completed a secondary offering of 3,091,635 ordinary shares by certain
non-director, non-officer selling pre-IPO shareholders. An additional 845,044 shares were locked up for an additional period as
part of the agreed terms. The Company cooperated with the offering lead underwriter while each participating shareholder paid the
underwriters fees and the Company covered the legal, accounting, administrative and regulatory fees which totaled approximately
$818 thousand. The Company received no proceeds from the described above public secondary offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-style: normal; font-weight: normal">F-25</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>2
<FILENAME>f20f2020ex2-2_nanoximaging.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 2.2</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Description of securities</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">As
of December 31, 2020, NANO-X IMAGING LTD had one class of securities registered under Section 12 of the Securities Exchange Act of 1934,
as amended (the &ldquo;<B>Exchange Act</B>&rdquo;): our ordinary shares. References herein to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo;
and the &ldquo;Company&rdquo; refer to NANO-X IMAGING LTX and not to any of its subsidiaries. The following description may not contain
all of the information that is important to you, and we therefore refer you to our amended and restated articles of association (our &ldquo;<B>Articles</B>&rdquo;),
a copy of which is filed with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) as an exhibit to this annual report
on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Registration Number
and Purposes of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our registration number with
the Israeli Registrar of Companies is 515942076. Our purpose as set forth in our amended and restated articles of association is to engage
in any lawful activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Share capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our authorized share capital consists of 100,000,000
ordinary shares, par value NIS 0.01 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">All
of our outstanding ordinary shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not
have any preemptive rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Transfer of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our fully paid ordinary shares
are issued in registered form and may be freely transferred under our Articles, unless the transfer is restricted or prohibited by another
instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary
shares by non-residents of Israel is not restricted in any way by our Articles or the laws of the State of Israel, except for ownership
by nationals of some countries that are, or have been, in a state of war with Israel.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Limitation of Liability
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The liability of each shareholder
for the Company's obligations is limited to the unpaid sum, if any, owing to the Company in consideration for the issuance of the shares
held by such shareholder. If at any time the Company shall issue shares with no nominal value, the liability of the Shareholders shall
be limited to the payment of the amount which the Shareholders should have paid the Company in respect of each share in accordance with
the conditions of such issuance and was not paid to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our ordinary shares do not
have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at
a shareholders meeting have the power to elect our directors, except the External Directors (as defined in the Israel Companies Law, 5759-1999
(the &ldquo;<B>Companies Law</B>&rdquo;)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under our Articles, the number
of directors on our board of directors must be no less than five and no more than ten (in each case including at least two External Directors,
as defined in the Companies Law). Subject to the aforesaid, the number of directors shall be determined, from time to time, by a majority
of the Directors then in office; provided that no determination in respect of a decrease in the number of directors shall shorten the
term of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Other than the External Directors,
the vote required to appoint a Director is a simple majority vote. In addition, under our Articles, our board of directors may elect new
directors to fill vacancies (whether such vacancy is due to a director no longer serving or due to the number of directors serving being
less than the maximum required in our Articles), provided that the total number of directors shall not, at any time, exceed ten. Our Articles
provide that the term of a director appointed by our board of directors to fill any vacancy will be for the remaining term of office of
the director(s) whose office(s) have been vacated, or in case of a vacancy due to the number of Directors serving being less than the
maximum number stated in the Articles, the Board shall determine at the time of appointment the class pursuant to the Articles to which
the additional Director shall be assigned. Furthermore, under our Articles, our directors, other than the External Directors, are divided
into three classes with staggered three-year terms, in a way that at each Annual General Meeting the term of office of only one class
of Directors will expire. Each class of directors consists, as nearly as possible, of 1/3 of the total number of directors constituting
the entire board of directors (other than External Directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Dividend and Liquidation
Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have never declared or
paid any cash dividends on our ordinary shares and we anticipate that, for the foreseeable future, we will retain any future earnings
to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends for
at least the next several years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We may declare a dividend
to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. The distribution of dividends may also
be limited by the Companies Law, which permits the distribution of dividends only out of retained earnings or earnings derived over the
two most recent fiscal years, whichever is higher, provided that there is no reasonable concern that payment of a dividend will prevent
a company from satisfying its existing and foreseeable obligations as they become due. Our amended and restated articles of association
provide that dividends will be paid at the discretion of, and upon resolution by, our board of directors, subject to the provision of
the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In the event of our liquidation,
after satisfaction of liabilities to creditors and other payments due as per applicable law, our assets will be distributed to the holders
of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by
the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Exchange Controls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or
other payments to non-residents of Israel, except for shareholders who are subject of certain countries that have been, or are considered
to be, in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Shareholder Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under Israeli law, we are
required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after
the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred to in
our amended and restated articles of association as special meetings. Our board of directors may call special meetings whenever it sees
fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board
of directors is required to convene a special general meeting upon the written request of (i) any two or more of our directors or one-quarter
or more of the members of our board of directors or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of
our outstanding issued shares and 1% or more of our outstanding voting power or (b) 5% or more of our outstanding voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under Israeli law, one or
more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include a matter
in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the general
meeting. Our Articles contain procedural guidelines and disclosure items with respect to the submission of shareholder proposals for shareholder
meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the board of directors, which may be between four and twenty one days prior to the
meeting or between twenty right and forty days prior to the date of the meeting, depending on the type of meeting and whether written
proxies are being used. Furthermore, the Companies Law requires that resolutions regarding, among other things, the following matters
must be passed at a general meeting of our shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">amendments to our amended and restated articles
of association;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">appointment or termination of our auditors;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">election of directors (unless otherwise determined
in our amended and restated articles of association);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">approval of certain related party transactions;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">increases or reductions of our authorized share
capital;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">a merger; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">the exercise of our board of directors&rsquo;
powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required
for our proper management.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under our Articles, we are
required to give notice to our registered shareholders not less than 21 days prior to the meeting. The Companies Law requires that a notice
of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the
agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested
or related parties, or an approval of a merger, or as otherwise required under applicable law, notice must be provided at least 35 days
prior to the meeting. Under the Companies Law, shareholders of a public company are not permitted to take action by written consent in
lieu of a meeting. Under Companies Law, whenever we cannot convene or conduct a general meeting in the manner prescribed under the law
or our articles of association, the court may, upon our, shareholders&rsquo; or directors&rsquo; request, order that we convene and conduct
a general meeting in the manner the court deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">All of our ordinary shares
have identical voting and other rights in all respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><I>Quorum Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to our Articles,
holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at
a general meeting. In any meeting of shareholders, we will follow the quorum requirements for general meetings as set forth in our amended
and restated articles of association, instead of one-third of the issued share capital as required under he Nasdaq Marketplace Rules.
Pursuant to our Articles, the quorum required for our general meetings of shareholders will consist of at least two shareholders present
in person or by proxy (including by voting deed) and holding shares conferring in the aggregate at least 25% of the voting power of the
Company. A meeting adjourned for lack of a quorum will generally be adjourned to the same day of the following week at the same time and
place, or to such other day, time or place as indicated by our board of directors if so specified in the notice of the meeting. At the
reconvened meeting, subject to a limited exception, any number of shareholders present in person or by proxy shall constitute a lawful
quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><I>Vote Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our Articles provide that
all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our Articles.
Pursuant to our Articles, an amendment to our Articles regarding any change of the composition or election procedures of our directors
will require a special shareholders majority of at least two-thirds of the voting power represented at the meeting in person or by proxy
and voting thereon. Under the Companies Law, among others, each of (i) the approval of an extraordinary transaction with a controlling
shareholder and (ii) the terms of employment or other engagement of the controlling shareholder of the company or such controlling shareholder&rsquo;s
relative (even if such terms are not extraordinary) requires special approval and certain transactions with respect to remuneration of
our office holders and directors, the approval and extension of a compensation policy and certain deviations therefrom require further
approvals. Under our Articles, any change to the rights and privileges of the holders of any class of our shares requires a simple majority
at a separate meeting of the class so affected (or such other percentage of the relevant class that may be set forth in the governing
documents relevant to such class), in addition to the ordinary majority vote of all classes of shares voting together as a single class
at a shareholder meeting. Another exception to the simple majority vote requirement is a resolution for an approval of a scheme of arrangement
or reorganization, of the company pursuant to Section 350 of the Companies Law, that governs the settlement of debts and reorganization
of a company, which requires the approval of holders of 75% of the voting rights represented at the meeting, in person, by proxy or by
voting deed and voting on the resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><I>Access to Corporate
Records</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under the Companies Law, shareholders
generally have the right to review minutes of our general meetings, our shareholders register and material shareholders register, our
amended and restated articles of association, our annual audited financial statements and any document that we are required by law to
file publicly with the Israeli Registrar of Companies or the Israel Securities Authority. In addition, any shareholder who specifies the
purpose of their request may request to be provided with any document related to an action or transaction requiring shareholder approval
under the related party transaction provisions of the Companies Law. We may deny this request if we believe it has not been made in good
faith or if such denial is necessary to protect our interests or protect a trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Modification
of Class Rights</I></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under the Companies Law and
our Articles, the rights attached to any class of share, such as voting, liquidation and dividend rights, may be amended by adoption of
a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance
with the rights attached to such class of shares, as set forth in our Articles, in addition to the ordinary majority vote of all classes
of voting shares voting together as a single class.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><I>Registration Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have entered into a registration
rights agreement with shareholders who held 14,533,835 of our ordinary shares and other securities convertible into or exchangeable for
ordinary shares; however some of these shares may have been sold on the market so the registration rights are no longer applicable. This
amount includes the exercised warrants, as of March 20, 2021, which were entitled to piggyback registration rights (as described below)
but exclude the shares that were sold in our secondary offering consummated in February 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under the terms of such registration
rights agreement, and subject to the limitations specified therein, if we register our ordinary shares under the Securities Act for sale
to the public, either for our own account or for the account of other security holders or both, the holders of registrable securities
are entitled to notice of the intended registration and to include any or all of their registrable securities in the registration. The
right of holders of registrable securities to include shares in an underwritten offering is subject to the right of the underwriters to
limit the number of shares included in such offering. Holders of registrable securities are generally required to pay all expenses of
registration, including the fees and disbursements of its counsel and all underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, as of March 20,
2021, holders of warrants to purchase an aggregate of 2,282,443 ordinary shares may be entitled to piggyback registration rights under
the terms of such warrants substantially similar to the registration rights described in the preceding paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Acquisitions under
Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><I>Full Tender Offer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A person wishing to acquire
shares of an Israeli public company and who would as a result hold over 90% of the target company&rsquo;s voting right or issued and outstanding
share capital is required by the Companies Law to make a tender offer to all of the company&rsquo;s shareholders for the purchase of all
of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a
result hold over 90% of the voting right or issued and outstanding share capital of a certain class of shares is required to make a tender
offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of
that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company
or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer,
all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer
will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of
the company or of the applicable class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Upon a successful completion
of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer
or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender
offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli
court as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If the full tender offer was
not accepted in accordance with the above alternatives, the acquirer may not acquire shares of the company that will increase its holdings
to more than 90% of the company&rsquo;s issued and outstanding share capital or of the applicable class from shareholders who accepted
the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><I>Special Tender Offer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as
a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does
not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Companies Law provides
that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the
purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company
who holds more than 45% of the voting rights in the company, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to the company&rsquo;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender
offer may be consummated only if (i) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired
by the offeror and (ii) the number of shares tendered by shareholders who accept the offer exceeds the number of shares whose holders
objected to the offer (excluding the purchaser and its controlling shareholders, holders of 25% or more of the voting rights in the company
or any person having a personal interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives
and entities under such person&rsquo;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling
it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase
of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the
offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.
Shares purchased in contradiction to the tender offer rules under the Companies Law, will have no rights and will become dormant shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;<I>Merger</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
Companies Law permits merger transactions if approved by each party&rsquo;s board of directors and, unless certain requirements described
under the Companies Law are met, by a majority vote of each party&rsquo;s shares, and, in the case of the target company, a majority vote
of each class of its shares voted on the proposed merger at a shareholders meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at the
shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting in
concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors
of the other party, vote against the merger. If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder
or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority
approval that governs all extraordinary transactions with controlling shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If the transaction would have
been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain
shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights
of a company, if the court holds that the merger is fair and reasonable, taking into account the value to the parties to the merger and
the consideration offered to the shareholders of the target company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further
give instructions to secure the rights of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, a merger may
not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each
party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders
of each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Israeli tax law treats some
acquisitions, such as share for share exchanges between an Israeli company and a foreign company, less favorably than U.S. tax laws. For
example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges his ordinary shares for shares in another
corporation to taxation prior to the sale of the shares received in such share-for-share swap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Anti-Takeover Measures
under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Companies Law allows us
to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred
rights with respect to voting, distributions or other matters and shares having preemptive rights. No preferred shares are authorized
under our Articles. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending
on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders
from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred
shares will require an amendment to our Articles, which requires the prior approval of the holders of a majority of the voting power attaching
to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate and
the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law as described
above in &ldquo;&mdash;Voting Rights.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>Borrowing Powers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the Companies
Law and our Articles, our board of directors may exercise all powers and take all actions that are not required under law or under our
amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for company
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><B>Changes in Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our Articles enable us to
increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution
duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital, such as the
declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board
of directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Choice of Forum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our Articles provide that
the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving
any complaint asserting a cause of action arising under the Securities Act (the &ldquo;<B>Federal Forum Provision</B>&rdquo;). While there
can be no assurance that U.S. federal or state courts or Israeli courts will follow the holding of the Delaware Supreme Court which recently
found that such provisions are facially valid under Delaware law or determine that the Federal Forum Provision should be enforced in a
particular case, application of the Federal Forum Provision means that suits brought by our shareholders to enforce any duty or liability
created by the Securities Act must be brought in federal court and cannot be brought in state court. The Federal Forum Provision does
not apply to suits brought to enforce any duty or liability created by the Exchange Act. Section 27 of the Exchange Act creates exclusive
federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations
thereunder. Accordingly, actions by our shareholders to enforce any duty or liability created by the Exchange Act or the rules and regulations
thereunder also must be brought in federal court. Our shareholders will not be deemed to have waived our compliance with the federal securities
laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in any
of our securities shall be deemed to have notice of and consented to the Federal Forum Provision. This provision may limit a shareholder&rsquo;s
ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers or other employees, which
may discourage lawsuits against us and our directors, officers and other employees.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Establishment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We were incorporated under
the laws of the State of Israel on December 20, 2018. We are registered with the Israeli Registrar of Companies in Jerusalem.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Transfer Agent and
Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The transfer agent and registrar
for our ordinary shares is Continental Stock Transfer &amp; Trust Co.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our ordinary shares are listed
on The Nasdaq Global Market under the symbol &lsquo;&lsquo;NNOX.&rsquo;&rsquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>f20f2020ex12-1_nanoximaging.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification by Principal Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Ran Poliakine, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: left">I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd (the &ldquo;Company&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: left">The Company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>[Reserved];</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>Evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>Disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal
control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD>The Company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the
equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 6, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">/s/ Ran Poliakine</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Ran Poliakine</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>f20f2020ex12-2_nanoximaging.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification by Principal Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Itzhak Maayan, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd (the &ldquo;Company&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>The Company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>[Reserved];</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>Evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>Disclosed in this report any change in the Company&rsquo;s internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal
control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD>The Company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s board of directors (or persons performing the
equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 6, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">By:</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Itzhak Maayan</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name: Itzhak Maayan</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title: Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>f20f2020ex13-1_nanoximaging.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 13.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certification by Principal Executive Officer<BR>
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Ran Poliakine, Chief Executive Officer of Nano-X Imaging Ltd (the
&ldquo;Company&rdquo;), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the Company&rsquo;s annual report on Form 20-F for the year ended December 31, 2020 (the &ldquo;Report&rdquo;) fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company for the periods presented therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 6, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Ran Poliakine</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Ran Poliakine</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>f20f2020ex13-2_nanoximaging.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certification by Principal Financial Officer<BR>
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Itzhak Maayan, Chief Financial Officer of Nano-X Imaging Ltd (the
&ldquo;Company&rdquo;), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the Company&rsquo;s annual report on Form 20-F for the year ended December 31, 2020 (the &ldquo;Report&rdquo;) fully complies with
the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company for the periods presented therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 6, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Itzhak Maayan</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Itzhak Maayan</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>f20f2020ex15-1_nanoximaging.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS INTERNATIONAL LIMITED, AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 15.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="image_008.jpg" ALT="">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: center"><U>CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">We hereby consent to the incorporation
by reference in the Registration Statement on Form S-8 (No. 333-248322) of Nano-X Imaging Ltd. of our report dated April 6, 2021 relating
to the financial statements, which appears in this Form 20-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="width: 48%; font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal">/s/Kesselman &amp; Kesselman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal">April 6, 2021 </FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal">Certified Public Accountants (Isr.)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal">A member firm of PricewaterhouseCoopers International Limited</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal"><I>Kesselman &amp; Kesselman, PwC Israel,
146 Derech Menachem Begin St. Tel-Aviv&nbsp;6492103, </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal"><I>P.O Box 7187 Tel-Aviv 6107120 Telephone:
+972 -3- 7954555, Fax: +972 -3- 7954556, www.pwc.com/il</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I></I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 8pt">Kesselman &amp; Kesselman is a member
firm of PricewaterhouseCoopers International Limited, each member firm of which is a separate legal entity</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/ E<# 2(  A$! Q$!_\0
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M4B^7YFUL\CCK0!XS( LKJ.@8@?G3:?-S/(1_?/\ .F4""BBB@ HHHH ****
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M7(42.2B_=7/ IUO=S1 QAR8VZJ3^H]#0!8GD+K$N-JQJI3U''/X=Z6<"-6D
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MU/HVK?VCKFIBYFDG\^QG5YI#\TKD  ^V.P'2L2XO[F:6VN695EA41JV.&"C
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M_*TSA?[B?*/R%2#BSD(==QVY4]?K_GUJM'O?"J/QJ\+60S+&/G"@*S 9'TH
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M'*MJ5X95O_/9[F*5MSL<DJ>Q]1U%=K-8Q7WA&;Q%#C]['LECYY9<CD]C@X_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSZD C!^O/YUAVLKQW8<-T7'YUUGA_2'6 >(I;ZTMXK>Z2&*&9\-,1@MCZ T
M;U[HEO8MH$^J3 QW=MYCPR=4 &55N>1VKS=WGUO57=1%%NRP6-0B(@] /:N[
M^*7B&UO]5L8;&Z2Z>!&,K(0R*2>$4XY  K@HA;S3JXF%M)G/(.W].E-@:EDQ
MMG1!G8WR\UV7B#P;K2?#F6^>XC%M#(MT]L3\Q3&,_KG%<MIQL+?4K6XN]0B^
MSQR!W2(%BP!Y'H#6QX@UZY\16_B+5HY9!:[$2&%6PJ1LX4<?0?K0!YV3D8I!
M2T4@ \T44E '2Z%H=E<:3=:C?W&PH,00_P!\]R?:L:XN5+X1%P.G'%!O&%FL
M0)  QBJ= %C[9*5121M3[HQT^E:MKJ,,VF7EA<VXG+IOMWQEXW'I^%86:U?#
ME\=-UZTO!R87W?I0!E45J^(_*;7KB2%%1)-LA51@ E03C'O650([?X0_\E/T
MG_=G_P#13T4?"'_DI^D_[L__ **>BF,XBBBBD(**** "BBB@ HHHH **** "
MBBB@ HHHH *EMO\ CYC^M15+;<W,?UH 3[/-_P \G_[YH^SS?\\G_P"^:/(F
M_P">;_D:/(F_YYO^1H /L\W_ #R?_OFC[/-_SR?_ +YH\B;_ )YO^1H\B;_G
MF_Y&@#0.@WZZ$=4,(%L'P3GY@.F<>F:RZVFAUN/PT';SAIADZ;N,_3TS61YK
M'.<-DY.1G-7-)6LK$Q;=[C**?O4XW1CKDX./PH'EG'++USQGZ5!0RBGA 1Q(
MO3)SQ^%'EM@G ( R<'M0 RBE*LIPRD'W%)0 4444 %%%% !1110 4444 %%%
M% !2TE% Q:*2EH *DB4D/C^[4=2P#);)/ X^O:@!5(5."2Q!R:AJ48W8'  J
M*@ KL_!UL/M%L2VP*'NV8\!F (C7_P!"-<976:#<K'J %PV+6UM1*5'4D@+C
M_P >H YR1F$DC-PY+!Q[]ZK5JZU:_9;DY.6Z-[D=ZRJ )K4@7D!/02+_ #KT
M&<VEY\-;2VG;%U+=+\W3H'"_4\?E7G(;:P;T.:]$UFT%MX$5-JE_.5T(ZJRH
MIX_%B*8'%WHD@TZUM7&"DDA8>X(']*SJUO$4@;5&C P4'SCT<\D?K632 Z'P
M;ITNJZS-:1 _O+:1&/H",4_QO*DGC74%C.8HF6*/G/RJH _E4G@J]>ROYY8S
MAEBD_5&']:I^+HS%XLU!?^F@/Z"@"C:Q!KN1/X34FG2%-4\OM,C0G\1C^>*+
M;BX,G^R#59G\C41(/X) WY&@!\099QD$=AFKT\$MW#+"LF$MHFN0I[] V/T_
M*KFK)"MV1& /+2(CC^]DG]2*LZ)&)]9BA/2>"6$_BAQ^M &"#);Z3%*54QSR
MLH]<J!_C5/SR)!(H 8<YJU=RG^RK&V_N&1S]20/Z50H D:9VC,>%"D[C@<G\
M:W] E\S2M7LR>);&0J/="''\JYRMSPP?^)BJ'I)'+&?Q0B@##HI%^Z/I2T )
M12TE %_2[2&ZDN&N-WDP0/*P4X)(X _,BJ)1E56(P&&1]*O6+A;'41QN:)0.
M.VX9IMT-\-H,(0(OO+R>IX/T- %>&))#AG"GKS5^VMRGF7,4+S) N^0HI*H/
M4FL]4!9E;Y6'K76>&KQ(;&YLKB&18;@X9E;"N,$$8[]<_E0!R<\S3SO*_P!Y
MCFHZ4@ D Y /!I*!';_"'_DI^D_[L_\ Z*>BCX0_\E/TG_=G_P#13T4QG$44
M44A!1110 4444 %%%% !1110 4444 %%%% !4MM_Q\)]?Z5%4MM_Q\Q_6@"/
M+>IHRWJ:?]HF_P">K?G1]HF_YZM^= #,MZFC+>II_P!HF_YZM^='VB;_ )ZM
M^= &J]QK7_",K&WG?V7YG#8^7/IGKC-9/F$_> ;)R<CK6N^JZN_AH6C*YT\2
M8W[.#WQGZUD;P3\R Y.21Q^%:3Z;_,F'4 8R1N4CGDJ>WTH"*<8< XYR,8H
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MHK'H *V/#AQJUIZM+M_,8K'K6T/Y-0LG]9P/U% &3C''I13G&)''HQ'ZTV@
MI*6B@"6";RDF4@D2)MX..X-;6BV5@;=I]:N)K:R'[R-(A\\YZ%5/8>IKGZN2
M1R7,3SEOEBB7 ]L[>/I0 [5;BTNKYI;.U^SP]!&#D<5"+R981$KL$!) STSU
MQ4%)0 4444".W^$/_)3])_W9_P#T4]%'PA_Y*?I/^[/_ .BGHIC.(HHHI""B
MBB@ HHHH **** "BBB@ HHHH **** "I;8XN4^M15+;?\?,?UH /M,O]X?\
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M/+?C SDD#'.::59?O CG'-("0<@X/M2 **>)7  SD 8 /-&]2.4'3 P<<^M
M#*,T_$9S@L.F 11Y1R=K*PS@8/6@ \Q\'YB<\'-*9,Y+(I).>F*849>JD<X_
M&DH DS&3RI'/8]J J''SD9)SD=*910,?Y9.,,IR,XSTH\M\CY#R,_A3*<F[=
MA<Y/84 /D&8]W/7^E15L6EI]LT\*AWR,3D9Y!'3^?\JRI8VB<JX((.* &5KZ
M<%?9N. P5 ?</G^E9%:-DW^CP@<DW(&/PH TM39QJ<L<L8EAD8L\9X/U4^HK
M+O\ 3)+-\HWF1,,JV,''N.U69M3(U*?<Q$3-\N"?D/J/ZUIQ7B7";9MFTG[X
MQCGL?\: .4"EB%'4\"O0=<<16.A.K K%!D#WC8H<_7%<C=10+JD @Q@RJ#M/
MN*Z?Q"$_LK3/*^9ECD4X]/,//YT <3<(([B11T!X^G:HZFNL^=SUV+G\JAH
MO:1!)/J<1B )BS*V>@"\FK,Z?;_-F9<R+%YA;NS%LDGUZU:TK_0/#EW?+_Q\
MW<RVL(]A\S?KM%:%Y9-H>H6MO(R.SQJYQT&1G'ZT <M,&CA5",%^?PJO5F_E
M:6[;=@!/E51T ':JIX!H ]"\)Z3!;^"KO6[E27EN#%"IZ.H4AA^)/Z4[P9JT
M5QXCT;3F4S%;@!90Q&T#GI5WQ6R:3X.T#1(FPRP+))C^\WS']37/^ D9_'EJ
MYX$/F2MC_91C_2F!C:JV^V<^M],?Y5D5HWKAM-A/=[B5\_E6=2 *V]+ BETI
MF'W[C=^&X"JNAZ1)KFJ)8QW$-OE6=I9B=JJHR3QU^E:&J26XU&"'3G+P6P6.
M)L8W$=6_$Y- &%<*5NIE(P1(P_4U'6KXC^R'7;A[(_N9-KD9SM<@%A_WUFLJ
M@ HHHH *F%U(L'DC&TJ5_ G-0TE !1110 4444".W^$/_)3])_W9_P#T4]%'
MPA_Y*?I/^[/_ .BGHIC.(HHHI""BBB@ HHHH **** "BBB@ HHHH **** "I
M;;_CY3ZU%4]HH:X7+JN#WSSQ0 SS1_SQB_(_XTOFC_GC%^1_QH\I?^>\?Z_X
M4>4O_/>/]?\ "@ \T?\ /&+\C_C1YH_YXQ?D?\:/*7_GO'^O^%'E+_SWC_7_
M  H V)->CD\*KI7V&,,) ?.'Y_GVK%Q&3P2O/?D 5)Y2>5CSXL[O]KT^E-\I
M?^>\?Z_X54I.6XE%+8;Y3'&W#9)P!U_*F@LO0D9&*D\I?^>\?Z_X4X# Q]HC
M( P 03@?E4C(S(2.0IXP..E!\LDX!7T[U)LB(.9(P<8&"?\ "E,$1SMNH^O
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M706&I6?A_76OH8ENY8)MT23 -%M]?<^E<Q6UIR1@Z;<O&KA)3O5AD,%(.#0
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MDTIM9<$JI.!GIBH<GU-)D^II7 D:":/):-UQU..E()6&,G<,YPW.33X)'4L
MQQM)QGCI3 ZD_,@/.21P30 !HSC<I'7)4]:-JD<..F3GC\* $;'S%3SG(XH\
MML9&#QN.#G I@!C< DJ< 9)'--#,H(!(!ZBCE>.13O-+9W@-D@DD<T@#S,G+
M*K9.2<8- \MB.67GGO@4?NV/0KD\]\"@1[L;64DYXSC%, $9.-K*<@G&>E(5
M88R",C(R*0JPQD$9Y&>]*'9<@,0",'GJ*0 '900&.#U'K3O,W$EE4Y.<XQ07
MW9W*I)QSC&*/W9)QN7)XSS@4# >6Q_B7GZ@"@1EL;2ISGC/2@1EB-I5LG &>
M::58 $@@'I0 %64#((R,C(ZTE.#L,@,1D8//:E,F<[E4\ 9QC% #*N6L[NOV
M<GWC/<$'./H:K'RCG&Y>>!UXI1&21L8$YP,'!I@=9/<XMH(VVS)"0QRN&YZD
M$?7&*P-3L! WGP'=;N?E;&,>Q]Z='JMQ$N#&"&&#D=:676G="H@BP0 ?EZB@
M#+K>\02$W2S@YR2/P(%83$,Q(  )Z#M6[-:37OAZWNEP[(N&4=<*2,_D<?A2
M PT=D;<C%2.X.*F:^N'7#2GTSW-5Z* +#@O8B0G)#A3^1JQ9W$,$86X1FADR
MCA>H!'45!;+YL%PA. J^9^7_ .NIH;DV8!\N.6.3[R.,\#T/8T 07=G)9R['
MP5/*..C#_/:J];KR6[V[R1@O:N<N,9,+>I';ZCBLZ[LC;X8$%2,JP.58>QH
MELYR-*N8,\>:CD?@16CKME'%I-O<MN-QO2$^@'E!B/S-4=#T^34KIXD^ZJJS
MGVW ?UKH_$<8DTE0/NG57C'_  %!G^E '%.,':.@IM.<[G8^IIM !70Z="SZ
M79!1\TDDV/QVK_6N>KM_"UN)[W0[=ONA3,WT\S/\EH PO%T@E\7:H1T6<H/H
MH _I6+5C4+@W>I75R3DRS._YDFJ] !1110 4444 %%%% "4444".W^$/_)3]
M)_W9_P#T4]%'PA_Y*?I/^[/_ .BGHIC.(HHHI""BBB@ HHHH **** "BBB@
MHHHH **** "I8/\ 7I]:BJ6W_P"/A/K0 MF0M[;EAE1*I(]>17ICZ=:R/%-"
M\;K.S$-OQY;C)._/7TKS)5$4L;!@_(;&,?A5Y-6O(!(D5T41F8A<GY2>#^-7
M3ERO4F<>9$_BE88]:DCMW1XD&%*C@>H'MG-9+_ZN/_=_K2[?-E^>9>>K'-+,
M@C8() X '.",5+=W<I*V@)=210M$H0H3GYD!/YU&\C2'+8_ 8IIZT4@  D@
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2?"'_ )*?I/\ NS_^BGHIC/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *\ 6 # 2(  A$! Q$!_\0
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MGY@V"O'K0!K44V.1)HDEB=7C<!E93D,#T(-4;W6+>QU73M/E60S:@TBQ%1D
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MTTU_ EV0UW;6UTT<-R1QEU'4X !QC/>M.W\/Z?;7.I3)$6_M%46X1SE2JIL
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M+.YP!4<-]:7$[P0W,3S(H9HU<%@#T)% %BBBB@ HHHH **** "BBB@ HHHH
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M2,%&?3FI$=)45XV5T895E.01[4 .HHHH **** "BBB@ HHHH **** "BBB@
MHHHH HZQIXU72+FP+*HG382PR,=\BN>F\(7\=Y))8ZNZ0,R;$<MF)5Q@9!&[
M'(&[LWM6SKNL_P!D+:84,UQ+Y8S_ +I/]*JIKTSC.R.@"B?"VKH$6+6Y"H7
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M5IX?(C"HPPN2=QY^]SVQFHDT"^ET&YTF\O#,SHJ"\9F+R?,221G /;BO&/\
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M* "BBB@#RGX[_P#(L:9_U^_^R-7C&A'%U+]!7L_QX_Y%C3/^OW_V1J\7T/\
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MA-R6=BSGJQ.2:<+G'/;UKI'^#OB]^FIZ7'_N[\_J*JR? SQ/-S+J]D_L7?\
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M'E5K_P ?EO\ ]=4_F*^U1T%>!0_ ?6HYXI&U.SPCJQP6['/I7OHZ4P"BBB@
MKP;Q!_R,6H_]?#_SKWFO.]2^'%W?:G=7:ZA"JS2LX4H<C)KGQ$)22L>KE6(I
MT)R=1VNCIO!7_(H:=_US/\S6]6=H.FOI&BVUA)(LC0K@LHP#R36C6T5:*1Y]
M>2E5E);-L****HR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **BN+F"TA,US-'#$" 7D8* 2<#D^Y%2T %%9>M>(-/T"*![^1P
M;B410QQQL[NW7 4#/3FM0<C- !1445S!.\J0S1R/"VR158$HV,X/H<$407,%
MSYGD31R^6YC?8P.UAU4^A'I0!+1110 453N]3M+*\L[2XEV37CM' N"=S!=Q
M'MP*D%]:MJ#6 G0W2Q"9HL_,$)(#?3(- %BBHKFY@L[=[BYFCA@C&7DD8*JC
MW)J*QU.PU2(RV%[;W4:G!:"0. ??% %JBHKFXBL[6:YG;;%"C2.V,X4#)/Y4
MEI=0WUE!=V[[X)XUDC;&,J1D'\J )J**CN+B*TMI;B>18X8E+N[=%4#))H D
MHID,T=Q!'/"X>*10Z,.C C(-0WVH66F6QN+^[AMH1P9)G"+^9H LT54T_5=/
MU: SZ=>V]W$#@O#(' /H<5;H **** "BBB@ HHHH **0$,,@@CVI: "BBB@
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M,0JCJ2< 4BNC$A64D ' - #J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M+]O_ .!!_P * /=Z*\(_X:!OO^A?M_\ P(;_  H_X:!OO^A?M_\ P(;_  H
M]WHKP<_M!7__ $+]O_X$-_A2?\-!7_\ T+]O_P"!#?X4 >\UQDWA_5H[R\N[
M1;:"3SI91(&+-.&8,H9<?PXXZ\^E<[X?^+=UK7AWQ!J;Z1#$^E0I*L8F)$F2
M>"<<=*YW_AH#4/\ H7[;_P "&_PH [FULO%.JVR72W$MM)%*VS[0=KLN!P?E
M'&<]1Z=<4K>%];N;HW%XMO<22*R*TLWS0]E?(4991Z8KA/\ AH#4/^A?MO\
MP(;_  H_X: U#_H7[;_P(;_"D!Z#<6?BO3H"RW1EAB7YA!@LRY[+L)W]3NYZ
M]*=:6GB^>PCN'O65I%^:!RJ.J\8P=G#=<Y'Y5YY_PT!J'_0OVW_@0W^%'_#0
M&H?]"_;?^!#?X4P/3[32O$4EW<OJ5ZDD9@EBC5'PI9@N"1@< AL=^:Q[3PKX
MFM;.'3A>6QLE3]XH. [;LDXQQVP!TP?6N(_X: U#_H7[;_P(;_"C_AH#4?\
MH7[;_P "&_PH ]:UW3+O51IYBMX5DBF61I&DYBPP)QQSD CC!Z>]*$UP:TTT
MISI\A14@C<;HCD;F8D<J1VZ_GQY)_P - ZA_T+]M_P"!+?X4?\- ZA_T+UM_
MX$M_\30!Z(WA+4(=2?4K.[$=T]Q-(>1MVL?E&,<\$YSST&:A.C^(]/9%M9$W
M7$IWF%@,?*3DDJ<#(';GIWK@?^&@=0_Z%ZW_ / EO_B:7_AH&_\ ^A=@_P#
MD_\ Q- 'JEI::[+9WMGJ%P?.DCE$5S&PVKNP%X !R.>G0>]9G]B>)("&TO[#
MIL9>,/#%ALA006W;>03V(S[UY^/V@KWOX=A_\"3_ /$TH_:"N^_AV+_P)/\
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M3XIA+>QL[]HT8G\, X%0)K3*-EAI!0>B[O\ V45IW\E]:LIM+8R+C)9'.1^
MZUER>(-47AX9"/0B2@ %WK3R@KI<2L>%,V5 ]_F8?K5:XTWQ!>!X;IU6,DRD
MF1=A/' VY]CBE_MUR_[VP<@]0A;/Z@U+_P )*()O*;2YDC*%0A8^8Q/3J,4
M93^$]1E4,\T.WL!<J/TZTUO"8MT+RSVQQR0C-(?Z"GWGBV]!*V]I';[>.$#.
M/J6!Y^@%9DWBC4I1B2>4^Q?'Z "D!KKX4M L19IW,I./+C&1P.Q/]:B.C65O
M-Y;2;CR,%D0K]<9K"DU>]E5D,[[&.67<2#5;SI3QOP/;B@#<N(M-0\;V'H#E
M<5BML\YO+!\O=\N?2F$EOO,3]33DZT >J_"0/_8GBSRV*/\ 9X\,.HY:G7*W
M^3FYE;_@9IOPGF,&A>+)  2EO$<'ZM4DVN,2=UNA^CG_  IH#*E6Y)Y:4_\
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M2C*/]UOI5[_A*6*D+$P)SDJ M4I;V6]E4R9"KT7.:!G<?#!@/'6FY'42 ?\
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M]LRY)&/NN.U9J3",\,"#U&:G#Q2#*N,^A/- S8O)8KNT=Y''F =?[U8RCBG
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M_@,G^%)_PB'AO_H!:=_X#)_A6U10!B_\(AX;_P"@#IO_ (#)_A1_PB'AO_H
MZ;_X#)_A6U10!B_\(?X;_P"@#IO_ (#)_A1_PA_AK_H Z;_X#)_A6U10!B?\
M(?X:_P"@#IO_ (#)_A1_PA_AK_H Z;_X#)_A6W10!B?\(?X:_P"@#IO_ (#)
M_A1_PA_AK_H Z;_X#)_A6W10!F0>'=%MK>>W@TFRCAN %F1(%"R =F&.:K_\
M(;X9_P"@!IO_ (#)_A6W10!B?\(;X9_Z &F_^ R?X4?\(=X9_P"@!IO_ (#)
M_A6W10!B?\(=X9_Z &F_^ R?X4?\(=X9_P"@!IO_ (#)_A6W10!B?\(=X9_Z
M &F_^ R?X4?\(=X:_P"@!IO_ (#)_A6W10!B?\(=X:_Z &F_^ R?X4?\(=X:
M_P"@!IO_ (#)_A6W10!B?\(=X:_Z &F_^ R?X4?\(=X9_P"@!IO_ (#)_A6W
M10!B_P#"(^',8_L+3L?]>R_X4G_"'>&O^@!IO_@,G^%;=% &)_PA_AK_ * .
MF_\ @,G^%+_PA_AK_H Z;_X#)_A6U10!B_\ "(>&_P#H Z=_X#)_A2CPEX='
M30]._P# 9/\ "MFB@#.M= T>QN%GM-+LX)ESMDCA56&>.H%6&TZR=RSV=NS$
MY),8))JS118:;6PV.-(8Q'&BH@Z*HP!3J**!!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 9FO:[:>'=.%[>).\;2I"J
M01[W9V.% '?FJ=IXRT6ZTN]U!KB2VBL#B[2YB:.2 ]MRD9YK+^)GVC_A';+[
M)Y?VK^U+3R?-^[O\P8SCMFN=L]0O(?!7BSQ/+=(/$3#R[N#R0%M'B&U4VG.1
M@YR>N: /4T=9$5T.589!]16;<ZTEMXDL-&,+,]Y#+,)0W"[-O&/?=^E<U)=:
MUKGB35[6TUP:5#I,<.U%A1O-9X]Y=]W\'; QT/-<[I]QJ_B>Z\$W+:J;:^N=
M/O&FNX8E)(#*/E!&!GCG% 'J[SQ1RQQ/*BR2$A%9@"^!DX'>L[7O$%IX=LX;
MF[CN)1-,L$<=O'YCL[9P /PKSRWNM4UV_P#!%Q<ZDR745[>P22)$O[SR]R[L
M=BRK@_4UTOQ%CGFM= BM;C[/<-K, CFV!]C8;G!ZT ='I&JIK%HUPEG>VH#E
M-EW"8G..^#VK0KAK^7Q!!J6D^&WUX">^\Z:345M41MB!<1HO*[N<Y]!69-XD
MUVTOIO#']IQ27/\ :$-HFK-$N422,OAE^[Y@Q@=N10!Z3--%;PM-/*D42C+.
M[!0![DU1U/6+?2FL%F5W^VW*6T93!PS D$^W%><>+Y]5M=(\1^'+O5VOXUTU
M+V.Y:)!(@\P*8WP,'/4' /6NC\012P6?@^*:X:XE75+<-*RA2YVMS@<"@#M:
MYA?'>D/JILHXKYXA<?93>);,;<39QLW^N>/3-=/TKS62Y;PI8-X@\.ZI#?>'
M;F\W2V$@Y5Y),,87ZYW$G:?>@#T:.>&9I%BE1VC;:X5@2K=<'T/-25Y'#=:K
MI>KZ]#9ZKY3ZEXB6R\Z2%2(,Q*Q<>K8 4 \<"KVI:QXA\/WGB*P.N"^^Q:,+
MRW>2% \<A<CY\#!Z?E0!Z=65J^MII-[I5LT#2'4+G[.K!L;#M+9/KTKB9M?U
M[PS+=F[U$ZKOT1]119(501RJ0,#:/N?-T/I45Y:ZK!K7@NXU#Q -26ZO1(8S
M$B!6,3',97^'G&#GM0!Z+I^IV6JPR36-PL\<<K0NRYX=3AASZ&K=>9#7M=O;
M;3K>VU%;66[UZYLWF2!"1$I?  QC/'6E7Q#KL=I_8IU,?:VUQM,&IR1+N6,)
MO!*_=+GH.U 'IE4-;U:'0M&N=3N$=X;=0S*@RQY X_.N;\/76KVWCC4M"OM8
M_M&VM[**>)FB59%+,0=^T<GC\JM_$7_D0-7_ .N2_P#H:T =.K!E##H1FL/6
M/%NG:/?)8%+J\U!TWBTLH3+(%_O$#[H^M;4/^IC_ -T?RKC?!TD$/BCQ5:W6
M%U=[\S'?]Z2W*CRBOJH&1[&@#H=$UZTUZ":2WCN89('\N:&YA,<D;8S@@^Q[
M5J5ROBO6;F&?3=+TN\AMKB_O!;2W6 YMQL+XP>-Q P,^M<[K&O:]X>@\0:4N
MJB]N+2SANK:\>)0\6^384D &#ZCCI0!Z917E.HWOBO3[C7X1XE=UTBSCOD9K
M:/=*S DHW'W/E.,<\]>*U1?:YXA\77.FVVNG3+6/3;>["10HTA=\YP6'W?7\
M* /0:*\RTSQ'KGB:XTK1UU-+"5H[E[B]@B4FY\F3RQY8;(&?O&HO[>\2-8SV
M(UM&NE\1QZ8MXD"<1%>?EZ9_K0!ZE4,MU;PN$EFC1RC.$+#<5'4@=2!7"12:
M_J.KZO8Q>)'LTT-(XPS01LUPY3>9)<C[O; QT-8NDWFIZSK?@_5[G4C]HDTB
M[DDV1+M<JZY[< \?]\B@#U+3]0M-5L(;ZQF6:UF7='(N<,/QJS7F%OXTU+1=
M#T+7M4E$VF7UB\<JI$%V70RR$8'1P"N/7%5IM;\82W]KHSS7PNHM/6\N6L((
MBYDD8X4AR!L4#'')- 'H^LZ[IV@6+W>HW*1(%9E4L-SX&2%'<^U6;*_M=1ME
MN;.XCGA)QOC8,,]QD=ZY2VTL^/O MA%XDB5)6<-.L)4[]K$<$9VAL#.#[5TF
MBZ3#H>CVVFV[%HK=-BL5 )]S@ 9H OT444 %%%% !1110 4444 %%%% %6_T
MVTU.*.*\@69(I4F0$D8=3E3QZ&J=UX:T>\EOY9[%';4(EAN_F8"95Z9 /4>O
M6M:B@#SSQ/X=O+GQ#-=-X;@UF"2%([5TN?L[18'*2\CS$SSWQR*Z#POX5@T3
M1=&BNDCEU#3K9H5F7("[SEP!Z9 _*NCHH R[?P[I-JUJT-DB&TEEF@(8_(\F
M=YZ]\G\ZM7NG6FHFW-W")?LTRSQ9)^21<X;CZFK5% &=K&A:;KUJEOJ5LLR(
MV^,Y*LC>JL""#]#56/PCH,>B2:.--A-C(V]XVR2S_P!XL3NW>^<UMT4 85KX
M.T"TTV[T^/3U,%Y@7.]V9I<=-S$[CCZT>(-'GU)]%^R[ MEJ$=Q(&./D4,#C
MWY%;M% !7/IX'\.)K']J+I<0NO,\X?,VP2?WPF=N[WQ7044 9-SX8T:[M;ZV
MN+".2*^E\^X4D_/)@ -G/!X'(QTJI:^!O#EG%=1Q::O^EP^1<,\CLTJ9SAB3
MDUT-% %%M&T][M+I[5&F2W-JK-D_NCC*XZ$<"LJQ\!^&M-O8;RUTQ5G@?? Q
MD=O*/HH)P!ST'%='10!EQ>'-(A: QV2*8+E[N/YC\LKYW-UZG)K&\4^&O/TJ
M5-,TRVNA/>"ZO;25MIN>,$JY^X_ ((QTKK:* .'\$^&9M-UK4=6?2QI<4\,<
M$5JT_G2-M)+/(^3DDD <G@5O>+=*N-;\*W^FVA03SH%0N<#.X'G\JVJ* &QJ
M5C53U  K*UKPQH_B Q-J5DLLL7^KF5BDB>P92#CVS6O10!A1^#/#T6C2:2FE
MP_8Y7\UU))9G_OEL[MWOG-+;>#]!M-+N=.BT]3;W3!IP[LS2D$$;F)W'&!WK
M<HH S;C0-+NGOGGLT=KZ%8+DDG]Y&,X4\^YZ5S$W@:TU/QGJ%QJ.G[M/^Q6\
M-K(DS(P*[@R@J0<8QUZUW-% &)>>$-!OM-M+";3HUM[/_CV$3&,P^NUE((SW
MYYHL_"&@V%O';VNFQQ11W2WBJ&;B91@/UZUMT4 8>K>$-"UR^6\U"P66X"[&
M=79-Z_W6VD;A['-3VOAK1[+[)]FL4C%G"]O;X)_=QN064<]\"M6B@#,_X1[2
M?[(M]*-E&;&W9&BA.2%*MN7KZ&HM:\+:-X@DBEU*S\R6(%4E1VC<*>J[E()!
M]*V** (+*RMM.LXK.S@2"VA4+''&,!14]%% !1110 4444 %%%% !1110 44
M44 17-S%:1"69MJ%E3..[$*/U(J*+4K.:411W",YW\?[C;6_(\5!KFEQ:SH\
M]A/,\,4NW=)&<,N&!X/X5SFJ>'+,W$4:7\2W.H3Q\2("K"-#N"ITY^\1ZT =
M5?:A:Z=;^?=2A(RX0<$DL3@  <DTVUU2RO+J>V@G#S0_?7!&.<''K@\''0UD
MZIIENOATVTM^J6T>-\A@61F&-H_X'GHPYS3=-AT[38_[7.I%[-P8[?S%QY?F
M29*YZDESCGD=* .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH *S_ .V]
M.$7F-<JJ[7?Y@1PK;2?SXK0KE1X5TVT1YIKYVC@NWOVW$?+U+*?]CH<=L4 =
M2&4]"#64?$NE"%)OM#&%Y?*618G*ELXQD#UXK.\+Z(+"Q2<7T<KW$8<,B# R
M.&7U)[GOQZ4_3-'L[?4VMVOQ/<0/]J>W2-8T5F&U6VC@<*?Q)- '24444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &;KT5E-H\
MJ:C.L%H63S'8X'WQ@'/8G _&L*W\&Z66\N&_G\VS91#M; @?"L3CH2PP3G/6
MNDU*PCU.R:UE/[MG1F& 0=K!L$'L<8KG)O <#7#O#J%Q'&S[@C#?Y8P  AZC
M[N._'% &A:^'([;1%TU+QCLV-%-L7<C(VY3[@''![50U30].>&PTZ]U:Y23S
M3/#LP"\F[<[L,$=3WP!FD?P)"<I'J$\41&T!5&Y!SPK?PCDGZX/:K]SX86ZL
MM/M'O'$5HFQF" .Z]/O=5)'!]<F@"[;:_I=W*L4-XK.Q 0$$;\YP5R.1P>1Q
M48\3Z,?, OXR4"D@ Y.[&,#')Y'2J+>%IW>VF?57:XL@%M',"XC'?</XB1@=
MNE5[;P-!977VNUOYDN5V%7= P#*H7./0C.0,9R/2@#>L]7L;^=X;:8O(BAG&
MQAMR 1DD=>1QUJ]61INBR6.J75_)=+/)<A?,/DA3N"@<$'IQTK7H **** "B
MBB@ HHHH **** "BBB@ KAK?0/#][?70@U.4RR.4N$7Y3("QRN<9()&,CTKN
M:Y6Z\'O+;2@:C*TB>9]F  0('8L02.3DXY]!TH DT[P]9:3JP:'4&.8U2.WE
MPV$#%@ 3R<<X/4"F6G]B:)XEOIFU2;[5=D++',<J#G(.<<#YP!DX[51M/ TD
M]C";^Y\JX1V=8XE!1,EB!CTPV"*M6_@98 4&I2F.1#'.OE+\ZDJ< _P_=_*@
M#JDECDC#HX*D9!]J=N'J*XF_\$3I$\MG>&>4  1S #?]W(9NX&W@'U-2P> U
M6SB62_D%QL'G';N5CC'0^G8]NM '5SWEO;)(TTR((XS(^3R%'4X]*A35K&6Q
MBO8YU>WE8*K@'DEMH&.O7BL6T\&PVRWX:]FE-W#)!N91E%<Y.#WYJM;> 8;6
M[AGCU*XQ"JK&C#(&ULC///3GU/- '37&I6EI=06T\P2:<XC4@\GZ]!^-6LCU
MK+U#2)-0N;&1[PJEK(LI01CYG7H0>W?(YXJO;:!+:ZQ+J NQ*;AU:9)$X7:"
M!Y8S\I/?UH M6NO:9>W+V]O=K)*@8LH!& I /7ZU9M-0M;Y6:WF#A6VGMSDC
M^AK!;P188B:.5XYD+MYJCYBS.&SGV Q]":J3^"'::V2*_?R06,C.N2,@X*C^
M]DGGMB@#KIIX;>"2::14BC4L[,<  =34-EJ-KJ$;26TA95.T[E*D'&>A /2L
MBT\,>1IESILUT9;>52$DVXD4ERW7G@'&/QJI=^"6O[A+FZUBZ:<2>8Q0;4Z
M<+GY3QU]SQ0!U>Y3T8?G0&!Q@CFN3?P%9EV>.[FB<J%#(.0 H'ZXY^IJ*7P.
M8K.1K:\=KT*1$Z_NPA)8C&,X + X_P!D4 =E14%G;)9V<-LA)6) H+')..Y]
MZGH **** "BBB@ HHHH **** "BFLZ)]]E7/J<4WSX?^>L?_ 'T* )**C^T0
M_P#/:/\ [Z%'VB'_ )[1_P#?0H DHJ/[1!_SVC_[Z%)]H@_Y[1_]]"@"6BHO
MM$'_ #VC_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^Q1]I@_P">\?\ WV*
M):*B^TP?\]X_^^Q1]I@_Y[Q_]]B@"6BHOM,'_/>/_OL4?:8/^>\?_?8H EHJ
M+[3!_P ]X_\ OL4?:;?_ )[Q?]]B@"6BHOM5O_SWB_[[%'VF G_7Q_\ ?8H
MEHI P89!!'J*C^TP?\]H_P#OL4 2T5%]I@_Y[Q_]]BC[3!_SWC_[[% $M%1?
M:8/^>\?_ 'V*/M,'_/>/_OL4 2T5%]I@_P">\?\ WV*/M,'_ #WC_P"^Q0!+
M147VF#_GO'_WV*/M,'_/>/\ [[% $M%1?:8/^>\?_?8H^TP?\]X_^^Q0!+14
M7VF#_GO'_P!]BC[3!_SWC_[[% $M%1?:8/\ GO'_ -]BC[3!_P ]X_\ OL4
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M4 ?.Z^(+/O(X^J&IUUNPD&UIXS[-Q_.OH#_A7WA'_H7K#_OT*/\ A7OA _\
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MC"%EZ$BKM;QV1Y=5ISDUW84444R HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #5 80# 2(  A$! Q$!_\0
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M_$RLCG_IS'%><=Q4]N(&8_:'D1<<&-0QS^)%6D6=Z/C1XT_Y^[3_ ,!5I?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!6U#_D&W7_ %R;^5>5_'< ^#=(!Z&[7_T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"MJ'_ "#KG_KDW\J\J^/'_(F:3_U]K_Z :]5U#_D'7/\
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MFIW,406%B\QP /[QKN?#PE_LJ)Y\>:XRV.F?:G**0(UJ***S&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-]VO,]<U7R]1N
M8D."'(->F-TKP[Q'<[?$.H+GI,PK2F)EJTN6N-4MHUSEI  *]AM(1!;)&/X0
M!7@GA;4C/X\TNV ^03<Y[\&OH%>@JJL7&U^HHRN+1116)04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2@(SUSBESH?)+L:5%1Q7$,Q81R*Q7J >1]:DJB HHHH **** "BBB@ HHHH
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M&UP"<6L__?%=&-NN7D70QP7*U+G?4]975/+W>9(5&!@XXYK3M+\/@;\FO/\
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M^Q_A1_9]E_SZ6_\ W['^%6** *KZ982J%DL;9P.@:)3C]*C_ +%TK_H&6?\
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M /S>M #J*:V[ V^O/TI3NW+CIWH 6BFN2 ,>HS0=VY<=.] #J*;\V_\ V<4
M,'.3E3T]J '44U0P)R<C/%)AED]5;]* 'T4Q4P"I.5/0&CRQLV,2P]Z '9 (
M&>30652 3C/2FF,%0K9.._>G%05P1D>] "&10^TG![9[TWS.VW#=@>]*L8 (
M)RO8'G%/H BWNQPJX8=0W^-+\[<@E".QY%244 5RCYP01GTY'Y5((E&,9'J.
MU244 -5%7. !GK3@,=*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I C0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%Y]9D%]#JZ2'R9%6"9XA'YB[>>.^#U/?/% '04444 %4]7LFU+1KVQ1Q&US
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M!;J[6RAE&4Y^<D$]>PS46AR^*(=5MY[NQE47UP#> 0A>!$JAB<D* 1R._8T
M1'X=7PC=_M]J]Q+&(Y&:-U"D(JB10I'SC:0/8FM"S\%QV6LZ;<2WL3O%(9S&
MQ;=+(/,^<9/4"11_P&H7F\76>MW2PK/-:RWI:W#0JRE2R@JS9RB!<D'US]"S
M6++Q*/%MUJ-BTS0P(S6R-&KH3Y:909/&X@@_2@#OJ*YKPM>>(KJXOQKD B56
M'E*(]H4Y;(!_B&-O/OU].EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;4_[0@DV_GMKH='\6:!K_&E:O:73?W$D&_\ [Y//Z4 ;%%%% !1110 4444
M%%%% !1110 445SWBSQIH_@W3Q=:I,=\F1#;QC=)*1Z#T]SQ0!T-%>$R_'O5
MYY7ET[PL'M%/WGD=CCW*K@5V'@OXPZ+XJNX]/N87TW49.(XY7#)(?16XY]B!
M0!Z-1110 4444 %%%% !1110 4444 %%%% !14%U?6EB@>[NH+="<!II @)_
M&JG_  D6A_\ 09T__P "D_QH TJ*S1XAT5B NL:>2>@%RG/ZUH@@C(.0>AH
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M-.6N2C#!4.<@'WQBL7PK\$-#T*^COM1N9-5N(VW1I(@2('L2O.X_4X]J]1H
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MVWVBY8K%O5,@9Y9@H_4B@"S15.YU.UM=.%^[DV[;,,HSG<0!^I%7* "BBB@
MHJ.>>.V@>:9PD: LS'H!4%_J=KIL,4MRY5)9!&K 9Y.<9]N* +=%1K/$ZQE9
M%Q*,Q\_>&,\?A4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 445'-((T9V.%49.* )**RTU6&0J0RA6[D_
M_6JW;W,<X)C;..M.PKEFBBBD,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"BG_(=F_Z]D_]">KU<Z='DD\9W5^-5OT5[*-!;(X\M?F;D CKQ^IK
M4_LU_P#H(WO_ 'VO_P 30!>HJC_9K_\ 01O?^^U_^)H_LU_^@C>_]]K_ /$T
M 7J*H_V:_P#T$;W_ +[7_P")H_LU_P#H(WO_ 'VO_P 30!>HK/TW3&T^2Y9K
MVXN!.^\+*05C]E^O?^E:% "$ @@]#UKEO"&J:=!#/X>6ZMA=Z9(T31HZ_,F<
MJPQ[$9]"#FN#^*GCR6#75\/VMT+:TME$E[*"<R2%24CXYQT)KR3PYXB;PUJL
M\E]IUMJ<,JGS;>Y4,K/U5P3WSW'4$T ?35OJ5GK_ (R"65S#-%I$;>:R.#^^
MD& H^B@Y]S73U\A^&[Z]N?$5U?">>.9HF=DLD D;D;1&H( VG!]@M?1GP\\6
M-XGT>XBNI8Y-1T^8V]R\?"R$=' [9';U!H ["BBB@#B=6\(ZK<Z[?:E9WZ*+
M@_NXFD=1'^[52ZD#ASM*D_W6R.15-_!_B";Y9;N)HS.LL2-?3,+51)NVC(_>
M9&!ENF.*UM4UCQ3:ZQ)9V.BQW-NQ'E762% 8<;AGMM?/U2LZ+Q5XD52TFE-*
MK)@,ME*A28KD1$$DD \%^A]J (I?"?B"X55EUB)MQ3,[7,C^9C;A/+(V_*RE
MMW4]^]4M6T?Q'IEJ&:>YN!(C1B*WN;A]T^PXG+ ;E).,)]WW%2Z6VLFZTC3K
MBQEA@M]0\T*;5R64^:3(9/NJ 2!@\]#WK0D\3>(9M3N[:PM8I52[>VS]DD(A
M4.JARV</D,W QC% %SPWIVIF#4)+J[O"FUK:SCG=E91C+,3R3\Y(5NH4"L&W
M\/>*GFFM&U-K:6".)([PW,I RKY55(VN3E<MP01D#I6BGB+Q=ND":3'<-&=L
MD?V>2+RV+%% 9CAQ]UR5_AS[50U&^\0LL=L-,=C;WJS1QK;RM]I*RN2P<DA%
M^5>#V;CB@"Y:^%?$<,+K+?\ F%HG2$M?R_Z*Q!Y&%&_.1UZ8XILOA+7WG,DV
MI1[48OYKW4A\Q]Q*OM(PA (''I5^SU_Q!+X8DO9[%8[H7"Q[A;2G9&<;G\OA
MFVY(P.N*R[[4O$^K:5-#<Z9M@EQ%L2V<.W&X2<G@' &TC(SC.10!)=>#-=NI
MY99=0#%=S0,+R0.K-%L)#8^49[8/?KFNWTV*YATRUBO'1[E(E65H\[2P')&>
M?SKB_P"V_%5G:2/;:.)$C)5+=HI"[$B1MVXGH"JC'^UC/2NH\-WU]J.C)<:C
M"L5P79<*C)N4' ;:W(R* -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M30-'E8M)I=DS%50DP*<A>@Z=!6B!@8'2@ HHHH **** "BBB@ HHHH ****
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MNKE+6TGN&RRPHSL!UX&<4 345FW.M06V@KJ[1R&%HTD"#&[#8Q_.M'</4>E
M"T5#;74%W D]O*DD3C*NIR"*E!!Z$&@!:*** "BBB@ HHHH **** &R2)#$\
MLC!412S,>@ ZFN3N_&_@_4K*:%?$.GEB#M)E PW8\UU5Q!'=6TMO*"8Y4*,
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M,1?%%H^-MPE./B:WQ_Q\I^8K9_X51X/_ .@8_P#W_?\ QI?^%4>#_P#H&O\
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MIK5\/^$M*TF_;5K6*47MQ'B5VE+ YP3QVKI=O9_,Y5?VGR.FHHHK$U"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH QKG4[*P\0^7=7,<4DUN@C1F
MP6PS9/T'<U>_M33_ /G^M?\ O\O^-2S6=M<.CS01NZ$%6902N/0T_P J/_GF
MOY4 5_[4T_\ Y_K7_O\ +_C1_:FG_P#/]:_]_E_QJQY4?_/-?RH\J/\ YYK^
M5 %?^U-/_P"?ZU_[_+_C1_:FG_\ /]:_]_E_QJQY4?\ SS7\J/*C_P">:_E0
M!1CU_2)M672HM1MI+]HC,($<%B@.,\5HU +*U%T+H6T(N NP3>6-X7TSUQ[5
M/0!YOX7-HOQ&\?7E]Y(6"6W!FFQB-/+R1D]!61K7A&PG\4S^,]'\=V&G+<$Q
M;V$<D8?9M902P!^7MU%3VBQOKWQ16:PDOXSY.ZTB8AIAY1^4$<@GVKF=2NO#
M>F?#&W;4/ =Y;6C:HP73Y[V1'#^7_K-Q&<$<8I =KX \,:)X%,]K<>([.^O-
M3,<D:.R*67!V[5+$MG)YJ;P1&D'Q(\=0PJL<7GV[;$&%R4.3BL"X72I_%GA.
M>/P/?7.;2T,&H1W$ACM5_A5L##;>Y)YKH?!O_)3O'7_76V_] -,#T&BBB@#E
M-5\$6^J7=[=M,L5U<7$4T=PL?[R$(JK@'/L3GWK$O?A_?1Z?));7D GCC?9%
M;P%5;]ULPH+$!G[MZ],=]K5(?&1UB2/3+FU&G2$;9)0-\>X<\8YVE>/7S/:L
MZ*3QQ&I/E3R!EV$2F#<LQ7EACCR@>F?F]C0!5B\&VUYI]N\VJVL<5S($2*"+
M$0D!3[@+'YOW39/J34W_  KB8PS*U]:@O%Y06.!E4X7;O;Y\ECU/J?6FZ;H_
MB.*^TRWNH9?LEM>^> C1>4J'S"2W\9?<PQCC!^M07VL^)[C7[O3]+NG>9))O
M,C41%4B5DV[,_,'VD_>X)Z4 ;NM>#[C5H;)#?PEX+80.\L&<$%3YB $!6^7'
MT-4)_AT3"$AO(,&,K)'- 61W(<&0@,/G&X8/M^5C3;'Q3%HVK23W$PU.ZDA,
M1/E_(-J*Q4<J#C=QTR*I^7XYCO+A));F2T64@-"L'F,GS;"A;C^YNR!WQ0!<
MU/PFNMQ6T,&HP,+.!;*0O$7,3(5;<G(VN< '.>"*KV_@.5)(IQ>64Z1L!Y+V
M[&&<#(\V0;_FEY^][=*+;1?$LOAN[CN)F@O;BY2:18]F]CF+<P8' ^ZW&.:;
M'8^-(X5\J=H!&I"P1I $)" CMW?(..WI0 Q?AJ8X&MH[^%(F4YD6 B7E2ICR
M&QY9SNQCKWKI=%\/_P!C:KJ=Q%)$MK=LACMXX\"/:,9R2>V.!@<=.:K>%O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $1 D0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#UUM&UIG8C
MQ5>*"20HM8./;[M)_8NM_P#0V7O_ ("0?_$UO44P,'^Q=;_Z&R]_\!(/_B:/
M[%UO_H;+W_P$@_\ B:WJ* ,'^Q=;_P"ALO?_  $@_P#B:/[%UO\ Z&R]_P#
M2#_XFMZB@#!_L76_^ALO?_ 2#_XFC^Q=;_Z&R]_\!(/_ (FMZB@#!_L76_\
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M/_B*/[#UO_H;+S_P$@_^(KH** *]C!/;6:17-V]W*N=TSHJEN?10![458HH
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MQF7.,C'"D\9^M<WX=^*NN:3H,%OJ,$5U>7EY,(+J]NR$1%/S!B 2 IP!@<T
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MUV\,D-M*TBA[57.3M8#)QD@9Z"M7PGX/MO"BWTB7EQ>WE_*);FYGVAG(Z<*
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M!FR*DD%..O..>U0M\(;&>#41>Z[JMY/J"Q+/<3LK/^[8,,<>V*]'HH P=/\
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MJ* ,'_A$=,_Y[:I_X-+C_P"+H_X1'3/^>VJ?^#2X_P#BZWJ* ,'_ (1'3/\
MGMJG_@TN/_BZ/^$1TS_GMJG_ (-+C_XNMZB@#!_X1'3/^>VJ?^#2X_\ BZ/^
M$1TS_GMJG_@TN/\ XNMZB@#!_P"$1TS_ )[:I_X-+C_XNC_A$=,_Y[:I_P"#
M2X_^+K>HH P?^$1TS_GMJG_@TN/_ (NC_A$=,_Y[:I_X-+C_ .+K>HH P?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MJ7D1GL;B$2F$R1,GFC^#((W?AUKP[P^[_#F\CT_4]!TV:_%E=3Z7K-LV[[0
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MGU.Z^T-&7FN+QGD C.44'H /I0!VB_=7Z"EHZ "BF 5+452T@"BBB@ HHHH
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M_P 71_PB.F_\]]4_\&EQ_P#%T ;U%8/_  B.F_\ /?5/_!I<?_%T?\(CIO\
MSWU3_P &EQ_\70!O45@_\(CIO_/?5/\ P:7'_P 71_PB.F_\]]4_\&EQ_P#%
MT ;U%8/_  B.F_\ /?5/_!I<?_%T?\(CIO\ SWU3_P &EQ_\70!O45@_\(CI
MO_/?5/\ P:7'_P 71_PB.F_\]]4_\&EQ_P#%T ;U%8/_  B.F_\ /?5/_!I<
M?_%T?\(CIO\ SWU3_P &EQ_\70!O45@_\(CIO_/?5/\ P:7'_P 71_PB.F_\
M]]4_\&EQ_P#%T ;U%8/_  B.F_\ /?5/_!I<?_%T?\(CIO\ SWU3_P &EQ_\
M70!O45@_\(CIO_/?5/\ P:7'_P 71_PB.F_\]]4_\&EQ_P#%T ;U%8/_  B.
MF_\ /?5/_!I<?_%T?\(CIO\ SWU3_P &EQ_\70!O45@_\(CIO_/?5/\ P:7'
M_P 71_PB.F_\]]4_\&EQ_P#%T ;U%8/_  B.F_\ /?5/_!I<?_%T?\(CIO\
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MSEL]_I734 %%%% !1110 4444 %2U%4M( HHHH **** "BBB@ HHHH ****
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MU;L>G4445J< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@#GV\*::S,QFU3)))QJ=P!_Z'2?\(EIO_/?5?_!I<?\
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M\(EIO_/QJO\ X-+C_P"+K=HH PO^$2TW_GXU7_P:7'_Q='_"):;_ ,_&J_\
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M^$1TW_GXU7_P:7'_ ,76[10!A?\ "(Z;_P _&J_^#2X_^+H_X1'3?^?C5?\
MP:7'_P 76[10!A?\(CIO_/QJO_@TN/\ XNC_ (1+3?\ GXU7_P &EQ_\76[1
M0!A?\(EIO_/QJO\ X-+C_P"+H_X1+3?^?C5?_!I<?_%UNT4 87_"):;_ ,_&
MJ_\ @TN/_BZ/^$2TW_GXU7_P:7'_ ,76[10!A?\ "):;_P _&J_^#2X_^+H_
MX1+3?^?C5?\ P:7'_P 76[10!A?\(EIO_/QJO_@TN/\ XNC_ (1+3?\ GXU7
M_P &EQ_\76[10!A?\(EIO_/QJO\ X-+C_P"+H_X1+3?^?C5?_!I<?_%UNT4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^ TO_P 31_PFOA[_ )_V_P# :7_XF@#?J6N;_P"$U\/?\_[?^ TO_P 33_\
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M_P _[?\ @/+_ /$T?\)OX>_Y_F_\!Y?_ (F@#H:*Y[_A-_#W_/\ M_X#R_\
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &, AD# 2(  A$! Q$!_\0
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MOA)FSC@9J%(<3-(2?05)(^Q<[2WL*<I)'(Q6UKF97OKJ*PL)[N4A8X4+L?0
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M<=:J7-X(1L0Y/K5I6$22SE"2Q[>M11WTIX#9%46=I!W):IPHBA]Z8$[WY7J
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MWL1')+VSU'U]*!FB1=)J)DQ(L8<'*G.1WR/6NMTK3+[6[@)-8O':LI*LEO\
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MN(]1M/$,$[B-9,%N!GZ5L63>=K,;HRN$M=S%3D?,W'/X5YO9R&6YBP!N"O@
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M=E"5W89@Z^?^)O>#_IN_\ZR]57?H]P!_SSK5U[G6;P?]-W_G6=?1R2:=*D9
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MNWQ9]%7!K+U&W=]/1)"!).X\M>[ =37=O8VEN0RVR$K_ !R')KD+N2.[\2N
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MPAJ]M&-T<2M@9 D!%:"^'=2'*QQJY_B,F<4M0.2\:>'+&'1TO856-XG 94)
M(/\ ]>O-9K"-;=L2E2P+<\]J]TE\.:G(BK<117D8;)1V #5:'AA&^;^RK*-L
M8Y530&AT.EC&D60]($_]!%6Z9$FR)$P!M4# Z"GU9(4444 %%%% !1110 G-
M-)8=!3Z*0$+/(.F/RJI-<7BG]T(V]B*T,#TIC1*U)W'H<_<ZYJ%KR]H"/456
M7Q;(W&V-6]"#71O;@@BLN\T>UN ?,@7/J*EW'H5!XFN002D1'MFKL'B6UFP'
M/DM_M<@_C6!<:$+=]T4C[/[I-9%_,+%OGM9W7^\N*7,T.R/1XKZ-USN4@]P<
MBK"RH_1A7E,&OP+_ *B8QMZ,<&K$WBB^6(+#)&&'\13DU2FNHN4]'N3>!2UL
MT1/HPKE;[Q??Z)/MU6Q_<L<":(' ^HKD#XUUFV?YIP5_V0*LWOC*ZUS3TM&M
M5D&\,[ <D#M1SH+'HUM?RWUE'=6\T2Q.,CS%(JK=:C<Q1N/[1T^-\?*6Y /Y
MUQY\C4(5V226TBC'ER'@>U8EY%/:R;)(FR?NE/F#4N8.4WKGQUKZ:K%8VUM9
MS._R[AG:Q]5/]*M?\)7XAC?9<Q6T3>@B8_UKB6E9OE?$:CNYQ@_XUM6VKJUL
M(+VZ2YY 21,[D'N>])R8[([2RU77;F,/Y4&P]&*D TZ6^\2!BT4%H0H^X3C<
M?K2Z;=!= BE#>9&A**<8R.U0?VG+Y@)QMSTK6*;5R6;^FS7<MLGVT1I<$99$
M.1^%6Y"P3*XS[UR&L7TD6L6<BR.D< )98VP6SV/M6RVL:=-;1L;R$;QG!E&1
M4\RO8+$>HZI>P6ERUL(C+$,J&'![FN ;XIZC""LWV-95)#+M/^-='JM_9QV=
MVT,\9E +1#.=W KSWQ=IT%EJD%U#$&BNHP<A,_./O5G-N^A:2-=OBUJG_+.*
MU;_@#?XU)#\4M;E8#[-:X/?8?\:XQ$E<#9;2D>T>*T+:UO N[[#,JC'SLO I
M<S[ARF_=_%778+AHTM;9L=]A_P :@_X6SXB_Y\K3_OD_XUR=[?7,]U*1;Q_>
MZCC]*K%[MOX8Q2]HQ\J.T?XL^) ,BTLOQ4_XUT_@GQCX@U_68H=0M[9+22%W
M#QJ02RD#U]Z\B241%FN@)%[*#CFO3_AL_F7]IA<+]EE8#TRX_P *J$VV)I6(
MO&WQ+U?PWXEO=.M8;<Q0HC(7C)))4$YY]ZK67Q5UBZM8YF@M4+#HT9']:B^(
M.H0Q>)]2@N8XID,:!0\>=F4'?K7#)K<=X+:W\H(T2>69/[V*J39*2.Y/Q1\2
M?VE:Q+;VC122;'"Q,6YZ$<UT.E>*?$5O UWXFGTRQ@21E\M$)D<#OC/%>7L)
M!\T;E''1E/(-9=R+G48!<&>:6]@<^?&22"O9Z(M@T>D:Q\7[T74B:1:1^2G\
M<Z'+>G&:[WP7X@N/$7AJ*_NEC6YWLDBH, $&OGQ(S'!'(S!O-_>MCVZ5W7PN
M\2_V?/)I=P24NW,D9_NN.H_'^E$I- D>U!CBE9B!Q5:&995R#FI@V<4*5T#5
MBK>W=Q:V[3+$9-O)51DXIEEK$%[:+<(<*3@Y'0^E:! 85G-$1,\4<"F(\N>G
M-1+F3W*5FA9M7BC.U2"WI2VNH23R*C(!FL.6PG6\N!+@6^ 8G'53W!KG9=8U
M71Y,+/QD@%D!S41G+FU94HJVAZ?4+I.?N2JOU3/]:\\B\=:JH&X0/]4Q5J/X
M@70_UEG"WNK$5TW1E8[!H]4R=MQ;8]XS_C32-7'>U;Z BN<B^($9_P!;8./]
MU\U=B\<Z=(0&BG3Z@&BXC2,NL+_RQA;Z5!->:T@^2U0G_=S_ %I9?$MI_9ES
M=PK*XBC+8V'G\:;X:NY[G34N;IL-*-VWG S0 1:CJA)\ZW"@#^X:G34+EAG"
M ?[IJ[=SHEK(=W;'!YJNFF1O$I5W7<,X/.*8$+:I/Y9953CUJDVO78/W(_R-
M7GT;C E)![=*HR^'Y]_[N9"/>@>@G]OW14_+$#]#2C7[L_P18^AJ Z-<A@I*
M>F1S4']GW:G;Y1)]C2'H7H]=O'/*Q ?0T\ZW=*.5C_(U26!Q@>6WITK2;0G=
M 5F ..XH#0A&NW)&=L?Y&I!K-R5R%CS]*J/I3Q7 C,\6X_45:&E72C&U3]#0
M&A&^NW:J2%BX]C6CI^H2WB;F"X YQZUD3:;>#.("1[5J:;$;:T"-&RN>6R*B
M3:'H7I)RBY.*:MVK?Q"H+E^ @4_-[53@6.<.N[9(AP17/*K-.R+48M79M@Y
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M@^\2>_TKI?BCN3X@ZDRCYG6)5_[]BN01S%=8#$!$R>>I%=#,D=/*BQ3,B.'
M[_A1'K<WA]99K73X;E[A3&_F=,$5BV%V5F E8YG.>:V2GF1LA Y&.:E:,9SF
MZ9P99553(V0JO@ >@J2WGFM+J*XA8+)$X93N/45,YVY0E?W70".J[NQ'5L^@
M7'--JZ$CZ!T75UOM.M=3MFW13+\ZCLW<5T,5PLN"#TYKYZT#Q/J.AR-%;N6M
MV/S12="?4>AKT'1?'=K=.$GS;R].>5/XU@TXO0NR9Z<K\9J%[A4;%9]M?":(
M8.<CM5;4KM(HC\V"10YNPU!#]0U&$ EI BKU-<5K6K)>@AD_=*<(#U/O46J:
MBS\9X]S5&SA$[&:7D \>]92UV-$DC>T:"*011R1(V?45:N-.M-Y!@0?04FA+
MYE[GLBDU>N1^];ZYKJI7Y3&>YDG2;1C]PCZ&JT8TM=:M]$%O/Y\N93<,,* /
MX1ZUL#[PJ5X5E3YD!(!VL1R,^E:$DTWB;3+MUL;%D=@&1D'"\=JV](N8A:QV
MZQE HP/0USMGHGA*)HS#=01SJ<R!I@"3WR#776[V7EJL$L+*.FUP:%<3+)16
MZJ#]12T @]#FBJ$1_:(3,8?-3S!_!N&?RI^!G.*YBW\)"+4C=O<NTC.6+YYZ
MY'^%=.<XXZT 1M K'.2/I35M@KEMQ.1BN6MM*UY-8-U+>NS.Q)7/R* >F/I7
M84 5HK3RI2^0?08J;=)_<'YT^B@#D/&37>_3A;K(N;E6E*]D'K6K)XIT>W<Q
MS780KU+ XK*\5W]G;>;!>W/E>< (A].M8LV@B[T-I;QE"1KO1HQRP[<^E0W9
ME6NCM(O$NBS?<U*W/U?%7(]1L9O]7=P-])!7BEUX9OX&?"H4!XRW-4FT^\B.
M/)<-_LG-'.NH*+9[\&C?HRM]#FD,,1.2BY]<5X5&NJVWSHMVH]1NK:T_Q'?1
M#9)=S*P_O,?ZU+J16XU!GKXX%%16[%[6)R<ED!S^%2UJ0%1RNJ*"Q &>YQ4E
M4]2M4O+=8W8J V<BD]@16U#5XK"PN;HHSB!"Y4?Q#V-<I:_$ZRN%W/I\R?-C
M <&M74]-1=(O(D).^%A@_2O%[1B-R^AJ-2['M2>+X)/]7:R?BU./BHGI:@?5
MJXNQ?=$A!Z@5H#ZTKA9'0GQ-<G[L,8_$TP^(KYB-HB'_  &L93Q2A\50CJK3
M5)Y;=7?:2?:K U1A]Z,?@:Q=.?-I@]F-6&:F(VK6]6Y=E"%<#-2N^*Q;*9HI
MSMQRM6Y+AV4G^5)R0TA)$59VFR=S#!%5;Z=(+2:9_N(I8X]JBDOV6X*[59!^
M=9&JZY:RZ'>21]%S'R?O-Z"IT>@]2;3KTWUHDYB:(L,A#UQ5T-M!.365ILA>
MU5^FX#C\*OE^!6,D40RS,Q))SS65.;DDX\MAG([&M @$MSWJJ^,YK%JZ+O8R
MK^66.PGWJ5!0C)Y KF_#]W(NIVL3E6^;;E1CL:Z+7'5-+GRV"1@>YKDO#[!M
M=L^1]_/Z&M*2L3)W-J'386T^ZF(.[+8]JS'L8_+DSVA!SGO72Z?:RSV$R[D"
M.6"D]<YJO>:;%:Q.T]T &0)\JD_C76GH0<_<6L:FXPO14'\J2>W0"Y&T?>0=
M*Z"+28-0ADEBNB4<@?=QTJ1_#RN9,S'$C!NG3% CEKF-1]J^7JZBK-@@^WW>
M>,8K;F\.QL7S.WSL&.!Z4BZ+'"TK+,VZ0?-[4-I 4;J2*UTY)&.T&13T]ZO6
M/CBWGOD2YCV*%*B7/]*R-4MVO-/MX8YI$ D"\ ?,17.Z;H]W<:U]CD9!"$+E
MN!WZ&HT2N/4[;4_%=FK,(G=G' ST_.IM'\>VENKK/$P8*<$$8)KF;KPEM1Y$
MGW!5XC5^363I_AS4M3B2YMU61"[*4+XZ&B+3U"S.['Q WO,?),"X_=L3R#[B
MN4O-<O;V5I[W4;HY78&557(_*K-IX7U3S9Q.H4 86,-G:>V:23PQJ]Q:;9&M
M]@.?,+$D"J=FK,:NMBE'KP2-E>6Y>3^'S!NW?4UZ!\,YQ>:O/,2FX%QA3TX%
M<%X=LTFU=HKQ%E6.!G..F<\5Z9\-(HXX=R1(N\R$D#WJ>5)IA*3DC@_B7 7^
M(6H2&10%2( 9_P!@5QDMJHA5MV7W\G!Z5ZAX^MH&\87<DC8)$>1_P$5S]QI]
MK+I\S0@N5 /#=.:;8DM#GWTEX+J)F(;Y RA>16JI8!<CYL5W5IX3C,4;&U.X
M@'DT:KX5D^P.T%LB-&-W'4BEJ-'%)HUQJDKBS0.[#+*7QQ69=Z3<6L^Q[1N.
MIY(KH=*OY-+U&*Y0D%3\P]N]=+XAUBTDT^=%D#2&,$ =L]*=Q,\XCA&#)M^Z
M,U!YLJSX4%B!TQC!K2:,PZ2';.Z1\"LI3YESD!SENF<4/41TVE:YJ^D',3R/
M& /W<K K71-XGCU #[0HMG[EG!&:XV.$20@_9"6+_P 4E*MJ6*XM(!E\Y>2I
ME33*4FCH[ZU-R/,BF#IU^4YIUG.J1>7ABPXX%0>$;I+'6_\ 2A9BTF.QP#G)
M/2O6H--LK7)@M84)ZE5%2J-RG4,;P_:/#IQFD0K)+S@]0*+M?F/K6W(,*1BL
MB[ +C)&6.!DXYK9+E5C*]V4<X8'-:,2>5%Y\I$<8YW/Q3&FLM-7( N+K_P =
M4USVH7%UJ<KAY"Q )"YP..>*YJF)47RK<I1N)J?_  A.I7LCS30)<,<O\Y0Y
MJL_A;PXP7[/J,D9(R ER*\W@A/B*:[E\J998F.\+'D!<\$TR\TJ02?O;K]X
M!B12IQVJE5LM0Y3TY/"<BX^R>(;Y/3$F?ZU.NC>*;?BW\4RGT$@S7DB6VH0?
MZJ[<#MMF(JRFJ>([7B._N\#T?=356(<K/5A-X]MN(]1L[@?[:C_"I!XC\=6Q
M_>Z99SC_ &3C^M>5)XV\3VW'VYFXZ21@U'HGCC7=&$X,XN_-;=^_);;[#TJU
M-"L>M?\ "?>(K?\ X^O##D#O&QJ1?BI&G_'UH-]%[CFN!A^+-XN/.TR)_P#<
M<BM"+XL63_\ 'QIDZ^N"&I\WF!W,/Q4\/2?ZT7<)[[HNE:$'Q#\+S]-31/\
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M0$Y)YJ1^:CBN+=G>%9XVE4'*!@2,>U)E'/M&Q%H!WG8UA7VH2:9JES+%"LK
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M0:I:O#J>D%AE1), V#@X6MDN6/*MA%[2N=,@^A_G5TMQ5+2O^09 /;^M6^U
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M,HV[@IYSUI =II?&FP<?PU<S5/3!C38/]VK9I#' C-!/!IO>@U#W @?ZU2U
M;;%_4D#]:NL<9JAJAQ;(/5UH ?H"^;XEU-5(R+9%J&\LI!=,57Y<YIOAR\6W
MU[5Y77<,(O':MEM5LGDRT1!]:UB[">IGWMQ'IVEVMK<Q[C--N9<XQZ5LO/\
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M-<!1\V,':W/_ .NNOKCOB1D>'H#NE4"Y7)C3=_"W4>E)@CR>6QMI ##.4W
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M"%(D88S^-1GP+X<*!3I_&=Q_?/\ ,??GG\:CE8[GBDL1$?F@$QCCS$7*J/\
M9'?ZFJ#J)LK&(Y%!['8P^M>\'P'X<,AD^P$,>XGD'_LU,E^'OA>;&_2U)]?-
M<'^=.P[G@;H4(&XJ>PF7^M&Z0* 58KGJOSK^5>^K\/\ PRBE1IN5/8S2'^;4
MT?#OPLKEETP D8XFD'_LU%@N>&^79(F0F>>5'4FJK6JR2MY;*&Z[3\I']*]\
M/P[\+$@G2QE>G[Y^/_'J/^%=^%MFW^S!MSDCSI.?_'J=@N?/LMI*B;I$^7L6
M'7_@0J$1%NI8 <Y.&45]%+\/_#*.633BI(Q@3R8Q]-V*;+\._"LV-VE*,?W9
M77/UP>:5@N?/:Q# 8(,=0%[^YI-@+<G*CJ?4^E?03?#;PFQ).E\GTGD_^*H_
MX5OX4P!_90P.@\Z3_P"*HL%SP*,/O!0[6]^BBM?3KO[(@*J'<@B*,. 1GK)S
MZ=J]F/PW\*%2O]E\'K^_D_\ BJ5OASX4=2&TI3QCF9^!_P!]50CQ<2))M:?!
M",?*6YBQN8]26'6L^>QA,:*L3#+EVE1M^5^G:O?$\ >&HUV)8,%QC;Y\A&/I
MNIC_  Y\*NVXZ4%/'W)I%Z?1J N?.TEG'M8Y5CN 5#P<>]$$[6$I5$C*!L[7
MC(!([AA7T5_PKSPL0,Z8&QR"TSD_GFF?\*V\)[=O]E<9S_KY.O\ WU42@I*S
M'&5G='BPU^RN(E^U6<J28QYT$F\[?<'K]#67J&F:=>VY>RU.(2H<B*93&Q]N
M>*]Y?X7^#I#EM(&?43R#^34'X7^#V7#:0&'7#3R'_P!FK-47'2+-/:)N[1X+
MKL=K9Z?;:9:A=[$37)0Y&<8QG\ZQTME/W>O;Z5](+\+/!JEBND8W=?\ 2)?_
M (JG?\*P\'@Y_L@9Z9\^3_XJJI4_9QM>XJE3GE>Q\X*DL&3$S*!SP>OUJU!<
M2/*HF"$X)#; &_.OH;_A6'A#;M_LGC_KO)_\53)?A;X-F^_I /\ VWD_^*K2
MQG<^:)H%9F(!.>],^RQA5#==V#@U]-'X6^#FSG2,Y_Z>)/\ XJD_X55X,S_R
M!^^?^/B3_P"*JHMH-#YF^PH\KA6P .]0M:.J(P&2]?4 ^%G@T?\ ,('_ '_D
M_P#BJ:WPI\%N@5M'^4=!]HE_^*JU48K(^6B""0>HXJ](ICT6,$???-?2@^$?
M@A6R-%YZ_P#'Q+_\54\_PP\(7.WS=)W;3D?OY/\ XJFZMQ6/"KV8(ML4S_Q[
MID#G%=E\*;DR^--I_P"?:0XY'IVKT63X:>$I3E]*W'&,F>3./^^JO:/X+T#0
M;W[9IMD89]A3<9G;Y3U&"3Z5B][E7TL<E\3;NUCFMK*2&UF,A\]UFU VY! P
M.!U%83SV=IX%5VLM(3[?=8V2:D[(ZIWW=2<]J] UKX=>%O$.IR:CJFFFXNG
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MAIOO6]Z>W.HW'_Q= CGG\)Z[-IEY:S!"9KFS5=\H_P!7& 7/USGBM8>'YH?
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !7 &8# 2(  A$! Q$!_\0
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M$;/5-8G^U:MJ5KX;T>ST:WU#5+G"_:-1O(K-+B^GVKYUS)))@;L  ZVBBB@
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7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !] )0# 2(  A$! Q$!_\0
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M4I=6:]!BNQ&%@N"BL-@/(Z&O<O"_@/PWX.5SHNFI#,XP\[DO(P]-QY ]A@4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>16
<FILENAME>nnox-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 06 12:29:48 EDT 2021 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:pf0="http://xbrl.sec.gov/country/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nnox="http://www.nanox.vision.com/20201231" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="nnox-20201231.xsd"/>
  <context id="c0_From1Jan2020To31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c2_AsOf31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c3_From1Jan2019To31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c4_From1Jan2018To31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c5_AsOf31Dec2017_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c6_AsOf31Dec2017_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c7_AsOf31Dec2017_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31Dec2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="c9_From1Jan2018To31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c10_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c11_From1Jan2018To31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c12_AsOf31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c13_AsOf31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c14_AsOf31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c15_AsOf31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c16_From1Jan2019To31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c17_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c18_From1Jan2019To31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c19_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c20_AsOf31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c21_AsOf31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c22_From1Jan2020To31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c24_From1Jan2020To31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c25_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c26_AsOf31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c27_AsOf31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c28_From1Aug2020To31Aug2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-01</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="c29_From1Aug2020To31Aug2020_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-01</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="c30_From1Nov2019To30Nov2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <startDate>2019-11-01</startDate>
      <endDate>2019-11-30</endDate>
    </period>
  </context>
  <context id="c31_From2Aug2020To31Aug2020_NasdaqMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nnox:NasdaqMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-02</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="c32_From1Jan2020To31Dec2020_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c33_From1Jan2020To31Dec2020_OfficeEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c34_From1Jan2020To31Dec2020_MachineryAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c35_From1Jan2020To31Dec2020_LeaseholdsAndLeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c36_From1Jan2020To31Dec2020_LandMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c37_AsOf31Dec2020_OfficeEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c38_AsOf31Dec2019_OfficeEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c39_AsOf31Dec2020_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c40_AsOf31Dec2019_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c41_AsOf31Dec2020_MachineryAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c42_AsOf31Dec2019_MachineryAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c43_AsOf31Dec2020_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c44_AsOf31Dec2019_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c45_AsOf31Dec2020_LandSeeBBelowMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">nnox:LandSeeBBelowMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c46_AsOf31Dec2019_LandSeeBBelowMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">nnox:LandSeeBBelowMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c47_AsOf31Dec2020_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">nnox:PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c48_AsOf31Dec2019_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorPropertyClassAxis">nnox:PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c49_From2Jun2020To30Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <startDate>2020-06-02</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c50_From2Nov2020To30Nov2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <startDate>2020-11-02</startDate>
      <endDate>2020-11-30</endDate>
    </period>
  </context>
  <context id="c51_From2Jan2020To31Jan2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <startDate>2020-01-02</startDate>
      <endDate>2020-01-31</endDate>
    </period>
  </context>
  <context id="c52_From1Jun2019To17Jun2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2019-06-17</endDate>
    </period>
  </context>
  <context id="c53_From1Jun2019To17Jun2019_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-06-01</startDate>
      <endDate>2019-06-17</endDate>
    </period>
  </context>
  <context id="c54_AsOf17Jun2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <instant>2019-06-17</instant>
    </period>
  </context>
  <context id="c55_From1Jan2019To31Dec2019_NanoxPLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxPLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c56_AsOf31Aug2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-08-31</instant>
    </period>
  </context>
  <context id="c57_AsOf31Jan2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <instant>2020-01-31</instant>
    </period>
  </context>
  <context id="c58_AsOf3Sep2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <instant>2019-09-03</instant>
    </period>
  </context>
  <context id="c59_From1Jan2020To31Dec2020_EquityIncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nnox:EquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c60_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c61_AsOf31Dec2020_EmployeesOfficersAndDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c62_From2Oct2020To26Oct2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
    </entity>
    <period>
      <startDate>2020-10-02</startDate>
      <endDate>2020-10-26</endDate>
    </period>
  </context>
  <context id="c63_From1Jan2020To31Dec2020_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c64_From1Jan2020To31Dec2020_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c65_From1Jan2019To31Dec2019_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c66_From1Jan2019To31Dec2019_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c67_AsOf31Dec2020_ExercisePricesOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c68_From1Jan2020To31Dec2020_ExercisePricesOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c69_AsOf31Dec2020_ExercisePricesTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c70_From1Jan2020To31Dec2020_ExercisePricesTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c71_AsOf31Dec2020_ExercisePricesThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c72_From1Jan2020To31Dec2020_ExercisePricesThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c73_AsOf31Dec2020_ExercisePricesFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c74_From1Jan2020To31Dec2020_ExercisePricesFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c75_AsOf31Dec2020_ExercisePricesFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c76_From1Jan2020To31Dec2020_ExercisePricesFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c77_AsOf31Dec2020_ExercisePricesSixMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c78_From1Jan2020To31Dec2020_ExercisePricesSixMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c79_AsOf31Dec2019_ExercisePricesOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c80_From1Jan2019To31Dec2019_ExercisePricesOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c81_AsOf31Dec2019_ExercisePricesTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c82_From1Jan2019To31Dec2019_ExercisePricesTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c83_AsOf31Dec2019_ExercisePricesThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c84_From1Jan2019To31Dec2019_ExercisePricesThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c85_AsOf31Dec2019_ExercisePricesSevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c86_From1Jan2019To31Dec2019_ExercisePricesSevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c87_AsOf31Dec2019_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c88_AsOf31Dec2018_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c89_From1Jan2020To31Dec2020_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c90_From1Jan2019To31Dec2019_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c91_AsOf31Dec2020_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c92_From1Jan2020To31Dec2020_MinimumMember_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c93_From1Jan2020To31Dec2020_MaximumMember_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c94_From1Jan2019To31Dec2019_MinimumMember_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c95_From1Jan2019To31Dec2019_MaximumMember_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c96_AsOf31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c97_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c98_AsOf31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c99_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c100_AsOf31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c101_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c102_AsOf31Dec2019_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c103_From1Jan2019To31Dec2019_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ExercisePricesOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c104_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c105_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c106_From1Jan2018To31Dec2018_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c107_From1Jan2020To31Dec2020_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c108_From1Jan2019To31Dec2019_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c109_From1Jan2018To31Dec2018_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c110_From1Jan2020To31Dec2020_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c111_From1Jan2019To31Dec2019_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c112_From1Jan2018To31Dec2018_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c113_From1Jan2020To31Dec2020_IL">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:IL</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c114_From1Jan2020To31Dec2020_MinimumMember_KR">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:KR</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c115_From1Jan2020To31Dec2020_MaximumMember_KR">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:KR</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c116_From1Jan2020To31Dec2020_KR">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:KR</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c117_From1Jan2020To31Dec2020_JP">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:JP</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c118_From15May2015To1Jun2015_RanPoliakineMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:RanPoliakineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-05-15</startDate>
      <endDate>2015-06-01</endDate>
    </period>
  </context>
  <context id="c119_AsOf1May2017_SixEyeInteractiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:SixEyeInteractiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-01</instant>
    </period>
  </context>
  <context id="c120_From1Jan2019To31Dec2019_SixEyeInteractiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:SixEyeInteractiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c121_From1Jan2020To31Dec2020_SixAILtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:SixAILtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c122_From1Jan2020To31Dec2020_WellseseTechnologiesLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:WellseseTechnologiesLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c123_AsOf31Dec2020_NanoxPLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:NanoxPLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c124_From1Jan2020To31Dec2020_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c125_From1Jan2019To31Dec2019_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c126_From1Jan2018To31Dec2018_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c127_From1Jan2020To31Dec2020_EmployeebMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:EmployeebMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c128_AsOf31Dec2019_NonEmployeeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nnox:NonEmployeeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c129_From5Jan2021To31Jan2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-05</startDate>
      <endDate>2021-01-31</endDate>
    </period>
  </context>
  <context id="c130_AsOf31Jan2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-01-31</instant>
    </period>
  </context>
  <context id="c131_From18Feb2021To28Feb2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-02-18</startDate>
      <endDate>2021-02-28</endDate>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="ilsPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:ILS</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:label="_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants-c16_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:href="#_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants-c16_From1Jan2019To31Dec2019_CommonStockMember_usd"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_0" xml:lang="en-US">Less than 1 thousand US dollars.
</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants-c16_From1Jan2019To31Dec2019_CommonStockMember_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_IncreaseDecreaseOperatingLease-c3_From1Jan2019To31Dec2019_usd" xlink:href="#_IncreaseDecreaseOperatingLease-c3_From1Jan2019To31Dec2019_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_IncreaseDecreaseOperatingLease-c3_From1Jan2019To31Dec2019_usd" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_StockIssuedDuringPeriodSharesStockOptionsExercised-c0_From1Jan2020To31Dec2020_shares" xlink:href="#_StockIssuedDuringPeriodSharesStockOptionsExercised-c0_From1Jan2020To31Dec2020_shares"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_1" xml:lang="en-US">Out of which 1,027,151 awards were exercised on a cashless basis.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_StockIssuedDuringPeriodSharesStockOptionsExercised-c0_From1Jan2020To31Dec2020_shares" xlink:to="ftnt_1" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AllocatedShareBasedCompensationExpense-c107_From1Jan2020To31Dec2020_SellingAndMarketingExpenseMember_usd" xlink:href="#_AllocatedShareBasedCompensationExpense-c107_From1Jan2020To31Dec2020_SellingAndMarketingExpenseMember_usd"/>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_2" xml:lang="en-US">On October 26, 2020, the Company entered into an amendment to a business development agreement (&quot;the Agreement&quot;) dated February 4, 2020 with two service providers pursuant to which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company&#8217;s systems and the issuance of warrants.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AllocatedShareBasedCompensationExpense-c107_From1Jan2020To31Dec2020_SellingAndMarketingExpenseMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AllocatedShareBasedCompensationExpense-c108_From1Jan2019To31Dec2019_SellingAndMarketingExpenseMember_usd" xlink:href="#_AllocatedShareBasedCompensationExpense-c108_From1Jan2019To31Dec2019_SellingAndMarketingExpenseMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AllocatedShareBasedCompensationExpense-c108_From1Jan2019To31Dec2019_SellingAndMarketingExpenseMember_usd" xlink:to="ftnt_2" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_AllocatedShareBasedCompensationExpense-c109_From1Jan2018To31Dec2018_SellingAndMarketingExpenseMember_usd" xlink:href="#_AllocatedShareBasedCompensationExpense-c109_From1Jan2018To31Dec2018_SellingAndMarketingExpenseMember_usd"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_AllocatedShareBasedCompensationExpense-c109_From1Jan2018To31Dec2018_SellingAndMarketingExpenseMember_usd" xlink:to="ftnt_2" order="1"/>
  </link:footnoteLink>
  <dei:AmendmentFlag contextRef="c0_From1Jan2020To31Dec2020">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jan2020To31Dec2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentAnnualReport contextRef="c0_From1Jan2020To31Dec2020">true</dei:DocumentAnnualReport>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jan2020To31Dec2020">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jan2020To31Dec2020">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jan2020To31Dec2020">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentShellCompanyReport contextRef="c0_From1Jan2020To31Dec2020">false</dei:DocumentShellCompanyReport>
  <dei:DocumentTransitionReport contextRef="c0_From1Jan2020To31Dec2020">false</dei:DocumentTransitionReport>
  <dei:DocumentType contextRef="c0_From1Jan2020To31Dec2020">20-F</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jan2020To31Dec2020">0001795251</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityExTransitionPeriod>
  <dei:EntityFileNumber contextRef="c0_From1Jan2020To31Dec2020">001-38024</dei:EntityFileNumber>
  <dei:EntityFilerCategory contextRef="c0_From1Jan2020To31Dec2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationStateCountryCode contextRef="c0_From1Jan2020To31Dec2020">L3</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="c0_From1Jan2020To31Dec2020">Nano-X Imaging Ltd.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityShellCompany>
  <dei:EntityVoluntaryFilers contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">46100173</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">213468000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">8072000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">6325000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">1564000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">219793000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">9636000</us-gaap:AssetsCurrent>
  <us-gaap:RestrictedCash unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">316000</us-gaap:RestrictedCash>
  <us-gaap:RestrictedCash unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">145000</us-gaap:RestrictedCash>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">14020000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">228000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DeferredOfferingCosts unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredOfferingCosts unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">1197000</us-gaap:DeferredOfferingCosts>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">1359000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">526000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">661000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">139000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AssetsNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">16356000</us-gaap:AssetsNoncurrent>
  <us-gaap:AssetsNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">2235000</us-gaap:AssetsNoncurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">236149000</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">11871000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">435000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">475000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">3526000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">1828000</us-gaap:AccruedLiabilitiesCurrent>
  <nnox:RelatedPartyLiabilities unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <nnox:RelatedPartyLiabilities unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">17748000</nnox:RelatedPartyLiabilities>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">72000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">519000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">140000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">4480000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">20263000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">923000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">386000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:LiabilitiesNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">923000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">386000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:Liabilities unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">5403000</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">20649000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c2_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">131000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">75000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="ilsPershares" contextRef="c1_AsOf31Dec2020" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="ilsPershares" contextRef="c2_AsOf31Dec2019" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">40000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">46100173</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">27150080</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">46100173</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">27150080</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">315031000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">31748000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">-84416000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">-40601000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">230746000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">-8778000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">236149000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">11871000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">9210000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">2717000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">672000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SellingAndMarketingExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">12445000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingAndMarketingExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">1556000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingAndMarketingExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">209000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">22268000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">18298000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">1023000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">43923000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">22571000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">1904000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-43923000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-22571000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-1904000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">108000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">8000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-5000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-43815000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-22563000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-1909000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">-1.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">-0.90</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c4_From1Jan2018To31Dec2018" decimals="2">-0.09</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">35654000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">25181000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">20793000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c5_AsOf31Dec2017_CommonStockMember" decimals="INF">20257434</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c5_AsOf31Dec2017_CommonStockMember" decimals="-3">41000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c6_AsOf31Dec2017_AdditionalPaidInCapitalMember" decimals="-3">7814000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c7_AsOf31Dec2017_RetainedEarningsMember" decimals="-3">-16129000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c8_AsOf31Dec2017" decimals="-3">-8274000</us-gaap:StockholdersEquity>
  <nnox:IssuanceOfOrdinarySharesReservedForFutureIssuanceShares unitRef="shares" contextRef="c9_From1Jan2018To31Dec2018_CommonStockMember" decimals="INF">1666774</nnox:IssuanceOfOrdinarySharesReservedForFutureIssuanceShares>
  <nnox:IssuanceOfOrdinaryShareReservedForFutureIssuance unitRef="usd" contextRef="c9_From1Jan2018To31Dec2018_CommonStockMember" decimals="-3">17000</nnox:IssuanceOfOrdinaryShareReservedForFutureIssuance>
  <nnox:IssuanceOfOrdinaryShareReservedForFutureIssuance unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" decimals="-3">3667000</nnox:IssuanceOfOrdinaryShareReservedForFutureIssuance>
  <nnox:IssuanceOfOrdinaryShareReservedForFutureIssuance unitRef="usd" contextRef="c11_From1Jan2018To31Dec2018_RetainedEarningsMember" xs:nil="true"/>
  <nnox:IssuanceOfOrdinaryShareReservedForFutureIssuance unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">3684000</nnox:IssuanceOfOrdinaryShareReservedForFutureIssuance>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c9_From1Jan2018To31Dec2018_CommonStockMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" decimals="-3">115000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c11_From1Jan2018To31Dec2018_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">115000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c9_From1Jan2018To31Dec2018_CommonStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c10_From1Jan2018To31Dec2018_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c11_From1Jan2018To31Dec2018_RetainedEarningsMember" decimals="-3">-1909000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c12_AsOf31Dec2018_CommonStockMember" decimals="INF">21924208</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c12_AsOf31Dec2018_CommonStockMember" decimals="-3">58000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c13_AsOf31Dec2018_AdditionalPaidInCapitalMember" decimals="-3">11596000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c14_AsOf31Dec2018_RetainedEarningsMember" decimals="-3">-18038000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c15_AsOf31Dec2018" decimals="-3">-6384000</us-gaap:StockholdersEquity>
  <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares unitRef="shares" contextRef="c16_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">4762656</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares>
  <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_CommonStockMember" decimals="-3">16000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
  <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">14022000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
  <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">14038000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c16_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">454166</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_CommonStockMember" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">136000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">137000</us-gaap:StockIssuedDuringPeriodValueOther>
  <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares unitRef="shares" contextRef="c16_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">9050</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares>
  <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants id="_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants-c16_From1Jan2019To31Dec2019_CommonStockMember_usd" unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">25000</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants>
  <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">25000</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">16245000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">16245000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6 unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6 unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">-10276000</nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6>
  <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6 unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6 unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-10276000</nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c17_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_RetainedEarningsMember" decimals="-3">-22563000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c19_AsOf31Dec2019_CommonStockMember" decimals="INF">27150080</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c19_AsOf31Dec2019_CommonStockMember" decimals="-3">75000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c20_AsOf31Dec2019_AdditionalPaidInCapitalMember" decimals="-3">31748000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c21_AsOf31Dec2019_RetainedEarningsMember" decimals="-3">-40601000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">-8778000</us-gaap:StockholdersEquity>
  <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares unitRef="shares" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">4624500</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares>
  <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="-3">14000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
  <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">70999000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
  <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">71013000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">10555556</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="-3">31000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">169136000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">169167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">997863</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">497000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">500000</us-gaap:StockIssuedDuringPeriodValueOther>
  <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares unitRef="shares" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">1662929</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares>
  <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="-3">5000</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants>
  <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">125000</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants>
  <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">130000</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">24781000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:EmployeeBenefitsAndShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">24781000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="shares" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">1109245</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">17745000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">17748000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" decimals="-3">-43815000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c25_AsOf31Dec2020_CommonStockMember" decimals="INF">46100173</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c25_AsOf31Dec2020_CommonStockMember" decimals="-3">131000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c26_AsOf31Dec2020_AdditionalPaidInCapitalMember" decimals="-3">315031000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c27_AsOf31Dec2020_RetainedEarningsMember" decimals="-3">-84416000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">230746000</us-gaap:StockholdersEquity>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">24781000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">16245000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">115000</us-gaap:ShareBasedCompensation>
  <us-gaap:Depreciation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">208000</us-gaap:Depreciation>
  <us-gaap:Depreciation unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">53000</us-gaap:Depreciation>
  <us-gaap:Depreciation unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">35000</us-gaap:Depreciation>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">4478000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">1564000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-66000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
  <nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-1081000</nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses>
  <nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">1844000</nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">522000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">139000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-103000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">393000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-134000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <nnox:IncreaseDecreaseOperatingLease unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">83000</nnox:IncreaseDecreaseOperatingLease>
  <nnox:IncreaseDecreaseOperatingLease id="_IncreaseDecreaseOperatingLease-c3_From1Jan2019To31Dec2019_usd" unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <nnox:IncreaseDecreaseOperatingLease unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">2359000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">970000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-21487000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-5524000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-3671000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">13937000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">125000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">73000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">-13937000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-125000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-73000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">71013000</nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
  <nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">14038000</nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
  <nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">3684000</nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">169348000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:ProceedsFromWarrantExercises unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">630000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">162000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:PaymentsOfFinancingCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:PaymentsOfFinancingCosts unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">339000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsOfFinancingCosts unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">240991000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">13861000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">3684000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">205567000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">8212000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">-60000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">8217000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c15_AsOf31Dec2018" decimals="-3">5000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c8_AsOf31Dec2017" decimals="-3">65000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">213784000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <nnox:UnpaidOfferingCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <nnox:UnpaidOfferingCosts unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">858000</nnox:UnpaidOfferingCosts>
  <nnox:UnpaidOfferingCosts unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <nnox:issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">200000</nnox:issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants>
  <nnox:issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <nnox:issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1085000</nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities>
  <nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">548000</nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities>
  <nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">-10276000</nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements>
  <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">17748000</nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity>
  <nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" xs:nil="true"/>
  <us-gaap:NatureOfOperations contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;b&gt;NOTE
1 - GENERAL:&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Nano-X Imaging Ltd, an Israeli Company (hereinafter &amp;#x201c;the Company&amp;#x201d; or &amp;#x201c;Nanox IL&amp;#x201d;
or &amp;#x201c;the Successor Company&amp;#x201d;), was incorporated on December 20, 2018 and commenced its operations on September 3, 2019.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;On September 19, 2019, Nanox IL
established Nanox Imaging Inc. (hereinafter &amp;#x201c;Nanox Inc.&amp;#x201d;), a wholly owned subsidiary in Japan.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;On September 25, 2020, Nanox IL
established Nano-X Korea Inc. (hereinafter &amp;#x201c;Nanox Korea&amp;#x201d;), a wholly owned subsidiary in Korea.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In August 2020, the Company
completed an initial public offering (&amp;#x201c;IPO&amp;#x201d;) on the Nasdaq Global Select Market (the &amp;#x201c;Nasdaq&amp;#x201d;), in which
it issued 9,178,744 ordinary shares, at a price per share of $18.&amp;#xa0;During August 2020 the underwriters exercised their over-allotment
option and purchased an additional 1,376,812 ordinary shares at the same price per share. The proceeds received from the IPO were
$190 million (the net proceeds were approximately $169 million after deducting underwriting commissions and other offering expenses).&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Nanox Imaging PLC is a public limited company incorporated in Gibraltar in 2012 (hereinafter &amp;#x201c;Nanox
PLC&amp;#x201d; or &amp;#x201c;the predecessor company&amp;#x201d;). Nanox PLC developed certain technological capabilities
aimed to design and build various applications for x-ray based imaging. Nanox PLC has been a development-stage company since its
inception. Nanox PLC has a wholly owned subsidiary, Nanox Japan Inc. (hereinafter &amp;#x201c;Nanox Japan&amp;#x201d;). Nanox
Japan primarily provided research and development services to Nanox PLC.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;On September 3, 2019 (hereinafter
&amp;#x201c;Transaction Date&amp;#x201d;), Nanox IL signed an Assets Purchase Agreement which was later amended on December 3, 2019 and December
31, 2019 (hereinafter &amp;#x201c;the APA&amp;#x201d;) with Nanox PLC.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Under the terms of the APA,
Nanox IL purchased from Nanox PLC patents, patent applications and all other intellectual property rights, as well as all cash
of Nanox PLC (less an amount of $200 thousand), with an exclusion of certain assets as defined in the APA (hereinafter &amp;#x201c;Acquired
Assets&amp;#x201d;).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Under the terms of the APA,
Nanox IL shall pay Nanox PLC $6.127 million as consideration for the purchase of the Acquired Assets, which reflects the fair value
of the Acquired Assets (excluding cash) plus the cash balance as of the date of the APA, less $200 thousand. The purchase price
shall be due and payable upon the closing of one of the following events: (a) an M&amp;amp;A event of Nanox IL, (b) an IPO of Nanox
IL, or (c) a qualified equity financing of Nanox IL at a minimum company pre-money valuation of $100 million, with proceeds totaling
at least $30 million.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In the event of an IPO or a
qualified equity financing, Nanox IL has the option to pay for the Acquired Assets in cash or by the issuance of Nanox IL shares
of the same series to be issued upon such event, in an amount reflecting a 25% discount on the per share price to be determined
in such IPO or qualified equity financing. If Nanox IL chooses to pay for the Acquired Assets in cash in any of the events described
above, then Nanox PLC has the right, at its sole discretion and in good faith, to reject such payment in cash, and require Nanox
IL to pay for the Acquired Assets by the issuance of securities of the same series to be issued upon such equity financing events,
in such amount which shall reflect a 25% discount on the per share price to be determined in such equity financing events.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In November 2019, Nanox PLC
transferred to Nanox IL an amount of $7.2 million, which reflects the cash consideration under the APA. The total consideration
of the purchase of the Acquired Assets is $13.3 million. The outstanding balance of $17.8 million reflects the related
party liability of the expected future payment using the Company&amp;#x2019;s shares, refer to note 6.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In return to the Acquired Assets,
the Company issued to Nanox PLC 1,109,245 ordinary shares during January 2020. See also note 6.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;As of September, 3 2019, Nanox IL and Nanox PLC had the same shareholders and, therefore, the transaction
was treated as a transaction under common control for accounting purposes.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The financial statements of
the Company prior to the Transaction Date are the historical financial statements of Nanox PLC, which have been adjusted to reflect
the fact that:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;1)&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;only the net assets that were transferred in the transaction according to the APA. Net assets which
were not transferred in the transaction are not reflected in these consolidated financial statements.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;2)&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;no interests of Nanox Japan were transferred under the APA. The consolidated statements of operation
include the costs incurred for services provided by Nanox Japan to Nanox PLC.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;3)&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;the consideration in the transaction (the &amp;#x201c;Related Party Liability&amp;#x201d;) was recorded at the
beginning of the earliest period presented against a decrease in shareholders&amp;#x2019; equity.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;4)&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;all of the share-related information reflects the share information of Nanox IL.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;d.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;The Company&amp;#x2019;s solution, referred to as the Nanox System, has two integrated components &amp;#x2013;
&amp;#x201c;Nanox.ARC&amp;#x201d; and &amp;#x201c;Nanox. CLOUD&amp;#x201d;. Nanox.ARC is a medical imaging system incorporating the Company&amp;#x2019;s novel
digital X-ray source. Nanox. CLOUD is a cloud-based system designed to provide end-to-end medical imaging services, including services
such as image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic
assistive AI systems, billing and reporting.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In January 2020, the Company submitted
a 510(k) application for the Nanox Cart X-Ray System, which is a single-source version of the Nanox.ARC (the &amp;#x201c;Nanox Cart X-Ray System&amp;#x201d;)
to an accredited Review Organization under the FDA&amp;#x2019;s 510(k) third party review program. During 2020 and the first quarter of 2021,
the Company received additional information requests and submitted its official responses. On April 1, 2021, the Company received clearance
from the FDA to market the Company&apos;s Nanox Cart X-Ray System. The Company plans to submit an additional 510(k) premarket notification
to the FDA with respect to the multi-source Nanox.ARC and the Nanox.CLOUD during 2021.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company has experienced
net losses and negative cash flows from operations since its inception. The&amp;#xa0;Company anticipates such losses will continue
until its product candidates reach commercial profitability. In August 2020, the Company completed an IPO on Nasdaq with net proceeds
received from the IPO of approximately $&lt;font style=&quot;font-family: Times-Roman,serif&quot;&gt;1&lt;/font&gt;69 million .Based on the Company&amp;#x2019;s
financing activities during the year ended December 31, 2020, the Company has sufficient funds for its plans for the next twelve
months from the issuance of these financial statements.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;e.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Current Impact of COVID-19&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Following the December
2019 outbreak of Coronavirus (COVID-19) in China, it has spread into most countries across the world, including Israel, Japan
and all 50 states within the U.S. The COVID-19 pandemic is evolving, and to date has led to the implementation of various
responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The
COVID-19 pandemic has adversely impacted the Company&amp;#x2019;s operations in various ways. For example, the Company&amp;#x2019;s engineers are
unable to make work-related trips to Korea or Israel to test and optimize the Nanox.ARC or to begin development of x-ray chip
manufacturing in Korea. The potential business partners are unable to make on-site visits to the Company&amp;#x2019;s facilities or
attend industry conferences and meetings to experience the Nanox.ARC, which has negatively impacted the Company&amp;#x2019;s business
development and deployment activities. The external labs the Company works with have also been affected by COVID-19,
resulting in delays in the Company&amp;#x2019;s timelines for obtaining regulatory approval. COVID-19 has also caused shutdowns or
disruptions of business for our manufactures and suppliers. The continued spread of COVID-19 globally could adversely impact
the Company&amp;#x2019;s development, manufacture or deployment of the Nanox Systems, which could adversely affect the Company&amp;#x2019;s ability
to obtain regulatory approval for and to commercialize the Nanox Systems, increase the operating expenses and have a material
adverse effect on the Company&amp;#x2019;s financial results. (For the process with the FDA, see note 1d above).&lt;/p&gt;&lt;br/&gt;</us-gaap:NatureOfOperations>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c28_From1Aug2020To31Aug2020_IPOMember" decimals="INF">9178744</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c28_From1Aug2020To31Aug2020_IPOMember" decimals="0">18</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c29_From1Aug2020To31Aug2020_OverAllotmentOptionMember" decimals="INF">1376812</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <nnox:InitialPublicOfferingNetProceeds unitRef="usd" contextRef="c28_From1Aug2020To31Aug2020_IPOMember" decimals="-6">190000000</nnox:InitialPublicOfferingNetProceeds>
  <us-gaap:BusinessAcquisitionNameOfAcquiredEntity contextRef="c0_From1Jan2020To31Dec2020">Nanox IL shall pay Nanox PLC $6.127 million as consideration for the purchase of the Acquired Assets, which reflects the fair value of the Acquired Assets (excluding cash) plus the cash balance as of the date of the APA, less $200 thousand. The purchase price shall be due and payable upon the closing of one of the following events: (a) an M&amp;amp;A event of Nanox IL, (b) an IPO of Nanox IL, or (c) a qualified equity financing of Nanox IL at a minimum company pre-money valuation of $100 million, with proceeds totaling at least $30 million.</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
  <nnox:CashConsiderationDescription contextRef="c30_From1Nov2019To30Nov2019">Nanox PLC transferred to Nanox IL an amount of $7.2 million, which reflects the cash consideration under the APA. The total consideration of the purchase of the Acquired Assets is $13.3 million. The outstanding balance of $17.8 million reflects the related party liability of the expected future payment using the Company&amp;#x2019;s shares, refer to note 6.</nnox:CashConsiderationDescription>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering unitRef="usd" contextRef="c31_From2Aug2020To31Aug2020_NasdaqMember_IPOMember" decimals="-6">169000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;b&gt;NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES:&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: left&quot;&gt;Our consolidated
financial statements are prepared in accordance with generally accepted accounting principles in the United States (hereinafter
-&amp;#x201c;U.S GAAP&amp;#x201d;). The preparation of our consolidated financial statements and related disclosures requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses and the disclosure of contingent
assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and
various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates
and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;a.&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Use of estimates in the preparation of financial statements&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those
estimates and such differences may have a material impact on the Company&amp;#x2019;s consolidated financial statements. As applicable
to these consolidated financial statements, the most significant estimates relate to fair value of share-based payments.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;b.&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Functional currency&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The U.S. dollar is the currency
of the primary economic environment in which the operations of the Company and its subsidiary is conducted. A substantial portion
of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar
(&amp;#x201c;primary currency&amp;#x201d;).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Foreign currency assets and liabilities
are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date. Equity accounts
are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income
statement translation process. Expense accounts are translated using the weighted average exchange rate during the period. Currency
transaction gains and losses are presented in financial income and expenses, net.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company considers as cash
equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three
months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts
of cash.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;d.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Restricted&amp;#xa0;Cash&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;As of December&amp;#xa0;31, 2020,
the Company&amp;#x2019;s restricted cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit
is presented at cost including accrued interest. This bank deposits is used as security for credit card use and collateralizing
the Company&amp;#x2019;s lease contracts.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;e.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Property&amp;#xa0;and&amp;#xa0;equipment,&amp;#xa0;net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Property and equipment are stated
at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful
lives:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;10-33&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;6-20&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;Machines&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;10-20&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 88%; text-align: left; text-indent: 0; padding-left: 0; padding-right: 0&quot;&gt;Leasehold Improvement&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: center&quot;&gt;10&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0; padding-left: 0; padding-right: 0&quot;&gt;Land&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;N/A&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The depreciable life of leasehold
improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset
reasonably certain of exercise.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;f.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Impairment&amp;#xa0;of&amp;#xa0;long-lived&amp;#xa0;assets &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company tests long-lived
assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be
recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated
undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less
than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over
the fair value of the asset, using the expected future discounted cash flows.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt; As of December
31, 2020, 2019 and 2018, the Company did not recognize an impairment loss on its long-lived assets.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;g.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Severance&amp;#xa0;pay&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Israeli labor law generally
requires severance pay be granted upon dismissal of an employee or upon termination of employment under certain other circumstances.
Pursuant to Section 14 of the Severance Compensation Act, 1963 (&amp;#x201c;Section 14&amp;#x201d;), all of the Company&amp;#x2019;s employees in
Israel are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies.
Payments under Section 14 relieve the Company from any future severance payment obligation with respect to those employees and,
as such, the Company may only utilize the insurance policies for the purpose of disbursement of severance pay. As a result, the
Company does not recognize an asset nor liability for these employees.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In 2020, all of the Company&amp;#x2019;s
employees in Israel are subject to Section 14.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;h.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Legal&amp;#xa0;and other&amp;#xa0;contingencies&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Certain conditions, such as
legal proceedings, may exist as of the date the consolidated financial statements are issued that may result in a loss to the
Company, but that will only be resolved when one or more future events occur or fail to occur. In assessing loss
contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such
proceedings, the Company&amp;#x2019;s management evaluates with its legal advisors the perceived merits of any legal proceedings
or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Such assessment
inherently involves an exercise of judgment. Legal fees are expensed as incurred.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Management applies the guidance
in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable
that a material loss would be incurred and the amount of the liability can be estimated, then the Company records an accrued expense
in the Company&amp;#x2019;s consolidated financial statements based on its best estimate. Loss contingencies considered to be remote
by management are generally not disclosed unless material. In September 2020, securities class action complaints were filed in
the United States by certain of the Company&amp;#x2019;s shareholders against the Company and certain of the Company&amp;#x2019;s current
officers and directors. For additional information see note 7.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;i.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Research and development expenses&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Research and development expenses
are charged to the statement of operations as incurred and consist primarily of personnel, materials and supplies for research
and development activities.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;j.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Income&amp;#xa0;tax &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;1)&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company accounts for income taxes in accordance with ASC 740, &amp;#x201c;Income Taxes&amp;#x201d; (&amp;#x201c;ASC&amp;#xa0;740&amp;#x201d;).
ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based
on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates
and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary,
to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred
tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and
assets are classified as non-current in accordance with ASU&amp;#xa0;2015-17.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;2)&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not been
taken into account in computing the deferred income taxes, as it is the Company&amp;#x2019;s intent and ability to hold these investments.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left&quot;&gt;The Company accounts for uncertain
tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax
positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight
of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position
will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure
the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement.
The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;k.&amp;#xa0;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Share-based compensation&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company accounts for share-based
compensation under ASC 718, &amp;#x201c;Compensation - Stock Compensation,&amp;#x201d; which requires the measurement and recognition of
compensation expense based on estimated fair values for all share-based payment awards made to non-employees, employees, officers
and directors.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;ASC 718 requires companies to
estimate the fair value of equity-based payment awards on the date of grant. The Company uses the Black-Scholes-Merton option-pricing
model as part of such estimation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Prior to the adoption of ASU
2018-07, warrants issued to consultants and other non-employees, as compensation for services provided to the Company, were accounted
for based upon the fair value of the warrants. The fair value of the warrants granted was measured on a final basis at the end
of the related service period and was recognized over the related service period using the straight-line method. After the adoption
of ASU 2018-07, the measurement date for non-employee awards is the date of the grant. The compensation expense for non-employees
is recognized without changes in the fair value of the award, over the requisite service period, which is the vesting period of
the respective award using the straight line. The Company adopted ASU 2018-07 as of January 1, 2019 with no impact on its consolidated
financial statements as all of the Company&amp;#x2019;s awards were fully vested at the adoption date.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;l.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Loss&amp;#xa0;per&amp;#xa0;share&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Basic earnings per share is
computed by dividing net income (loss) attributable to holders of ordinary shares of the Company by the weighted average number
of ordinary shares outstanding for each reporting period.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In computing the Company&amp;#x2019;s
diluted earnings per share, the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary
shares and the potential dilutive ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding
include the dilutive effect of in-the-money options using the treasury stock method.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company did not take into account
any dilutive instruments, such as investor warrants and share-based payments, since their effect, on a fully diluted basis, is
anti-dilutive.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;m.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Fair&amp;#xa0;value&amp;#xa0;measurement&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Fair value is based on the price
that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between
market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the
guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into
three broad levels, which are described as follows:&lt;/p&gt;&lt;br/&gt;&lt;table border=&quot;0&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 1in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.5in&quot;&gt;Level 1:&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Level 2: &lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Level 3: &lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to
Level 3 inputs.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In determining fair value, the
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to
the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company&amp;#x2019;s financial instruments
consist mainly of cash and cash equivalents, restricted cash accounts payable, accrued expenses and other liabilities. The fair
value of these financial instruments approximates their carrying values.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;n.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Concentration&amp;#xa0;of&amp;#xa0;Credit Risks&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company&amp;#x2019;s cash and cash
equivalents and restricted cash are invested with major banks in Israel, Korea and Japan. Generally, these investments may be redeemed
upon demand and the Company believes that the financial institutions that hold the Company&amp;#x2019;s cash balances are financially
sound and, accordingly, bear minimal risk.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;o.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Offering&amp;#xa0;Costs &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Deferred offering costs directly
relating to the Company&amp;#x2019;s private and initial public offering, were capitalized and offset against proceeds upon the consummation
of the private and IPO transactions in shareholders&amp;#x2019; equity.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;p.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left&quot;&gt;On January 1, 2019 the Company
adopted ASU No. 2016-02, Leases (Topic 842), The Company determines if an arrangement is a lease at inception. Balances related
to operating leases are included in operating lease right-of-use (&amp;#x201c;ROU&amp;#x201d;) assets, current maturities of operating leases
and Non-current operating leases in the consolidated balance sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left&quot;&gt;The Company also elected not
separating lease components from non-lease components and to keep leases with an initial term of 12 months or less off the balance
sheet and recognize the associated lease payments in the consolidated statements of operations on a straight-line basis over the
lease term.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;ROU assets represent the Company&amp;#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&amp;#x2019;s obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on
the present value of lease payments over the lease term. The Company&amp;#x2019;s lease terms may include options to extend or terminate
the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate
implicit in the lease unless that rate cannot be readily determined. As the Company&amp;#x2019;s leases do not provide an implicit rate,
the Company&amp;#x2019;s uses its estimated incremental borrowing rate based on the information available at the commencement date in
determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the
lease term (see also note 5).&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 0.75in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;q.&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Newly issued and recently adopted accounting pronouncements:&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;&lt;b&gt;&lt;i&gt;Accounting Pronouncements
Adopted in Current year&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on
Financial Instruments (&amp;#x201c;the Standard&amp;#x201d;). This guidance replaces the current incurred loss impairment methodology.
Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance
that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based
on historical experience, current conditions and reasonable and supportable forecasts. In November 2018, the FASB issued ASU
2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. ASU 2018-19 clarifies that
receivables from operating leases are accounted for using the lease guidance and not as financial instruments.&lt;/font&gt; Since
the Company has no financial instruments the Standard does not impact the Company&amp;#x2019;s consolidated financial
statements.&lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;a.&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Use of estimates in the preparation of financial statements&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those
estimates and such differences may have a material impact on the Company&amp;#x2019;s consolidated financial statements. As applicable
to these consolidated financial statements, the most significant estimates relate to fair value of share-based payments.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;b.&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Functional currency&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The U.S. dollar is the currency
of the primary economic environment in which the operations of the Company and its subsidiary is conducted. A substantial portion
of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar
(&amp;#x201c;primary currency&amp;#x201d;).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Foreign currency assets and liabilities
are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date. Equity accounts
are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income
statement translation process. Expense accounts are translated using the weighted average exchange rate during the period. Currency
transaction gains and losses are presented in financial income and expenses, net.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company considers as cash
equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three
months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts
of cash.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;d.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Restricted&amp;#xa0;Cash&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;As of December&amp;#xa0;31, 2020,
the Company&amp;#x2019;s restricted cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit
is presented at cost including accrued interest. This bank deposits is used as security for credit card use and collateralizing
the Company&amp;#x2019;s lease contracts.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;e.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Property&amp;#xa0;and&amp;#xa0;equipment,&amp;#xa0;net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Property and equipment are stated
at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful
lives:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;10-33&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;6-20&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;Machines&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;10-20&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 88%; text-align: left; text-indent: 0; padding-left: 0; padding-right: 0&quot;&gt;Leasehold Improvement&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: center&quot;&gt;10&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0; padding-left: 0; padding-right: 0&quot;&gt;Land&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;N/A&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The depreciable life of leasehold
improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset
reasonably certain of exercise.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;f.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Impairment&amp;#xa0;of&amp;#xa0;long-lived&amp;#xa0;assets &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company tests long-lived
assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be
recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated
undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less
than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over
the fair value of the asset, using the expected future discounted cash flows.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt; As of December
31, 2020, 2019 and 2018, the Company did not recognize an impairment loss on its long-lived assets.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <nnox:SeverancePayPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;g.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Severance&amp;#xa0;pay&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Israeli labor law generally
requires severance pay be granted upon dismissal of an employee or upon termination of employment under certain other circumstances.
Pursuant to Section 14 of the Severance Compensation Act, 1963 (&amp;#x201c;Section 14&amp;#x201d;), all of the Company&amp;#x2019;s employees in
Israel are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies.
Payments under Section 14 relieve the Company from any future severance payment obligation with respect to those employees and,
as such, the Company may only utilize the insurance policies for the purpose of disbursement of severance pay. As a result, the
Company does not recognize an asset nor liability for these employees.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In 2020, all of the Company&amp;#x2019;s
employees in Israel are subject to Section 14.&lt;/p&gt;</nnox:SeverancePayPolicyTextBlock>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nIPpN2lKEuYCUI09N/Lg5fLZ/Jooq7WY3vjnqJRpjb6jZqCaBUUFGxW7cfKXOabJw5eGbn/VcawsWaAshx1PaHoM/OHV30jj0wwDQLMupnstb67s8lIznxLhUJ8ajICx/w==] CSR-->
  <nnox:LegalAndOtherContingenciesPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;h.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Legal&amp;#xa0;and other&amp;#xa0;contingencies&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Certain conditions, such as
legal proceedings, may exist as of the date the consolidated financial statements are issued that may result in a loss to the
Company, but that will only be resolved when one or more future events occur or fail to occur. In assessing loss
contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such
proceedings, the Company&amp;#x2019;s management evaluates with its legal advisors the perceived merits of any legal proceedings
or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Such assessment
inherently involves an exercise of judgment. Legal fees are expensed as incurred.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Management applies the guidance
in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable
that a material loss would be incurred and the amount of the liability can be estimated, then the Company records an accrued expense
in the Company&amp;#x2019;s consolidated financial statements based on its best estimate. Loss contingencies considered to be remote
by management are generally not disclosed unless material. In September 2020, securities class action complaints were filed in
the United States by certain of the Company&amp;#x2019;s shareholders against the Company and certain of the Company&amp;#x2019;s current
officers and directors. For additional information see note 7.&lt;/p&gt;</nnox:LegalAndOtherContingenciesPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;i.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Research and development expenses&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Research and development expenses
are charged to the statement of operations as incurred and consist primarily of personnel, materials and supplies for research
and development activities.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;j.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Income&amp;#xa0;tax &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;1)&lt;/td&gt;&lt;td style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company accounts for income taxes in accordance with ASC 740, &amp;#x201c;Income Taxes&amp;#x201d; (&amp;#x201c;ASC&amp;#xa0;740&amp;#x201d;).
ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based
on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates
and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary,
to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred
tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and
assets are classified as non-current in accordance with ASU&amp;#xa0;2015-17.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;2)&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not been
taken into account in computing the deferred income taxes, as it is the Company&amp;#x2019;s intent and ability to hold these investments.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left&quot;&gt;The Company accounts for uncertain
tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax
positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight
of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position
will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure
the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement.
The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;k.&amp;#xa0;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Share-based compensation&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company accounts for share-based
compensation under ASC 718, &amp;#x201c;Compensation - Stock Compensation,&amp;#x201d; which requires the measurement and recognition of
compensation expense based on estimated fair values for all share-based payment awards made to non-employees, employees, officers
and directors.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;ASC 718 requires companies to
estimate the fair value of equity-based payment awards on the date of grant. The Company uses the Black-Scholes-Merton option-pricing
model as part of such estimation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Prior to the adoption of ASU
2018-07, warrants issued to consultants and other non-employees, as compensation for services provided to the Company, were accounted
for based upon the fair value of the warrants. The fair value of the warrants granted was measured on a final basis at the end
of the related service period and was recognized over the related service period using the straight-line method. After the adoption
of ASU 2018-07, the measurement date for non-employee awards is the date of the grant. The compensation expense for non-employees
is recognized without changes in the fair value of the award, over the requisite service period, which is the vesting period of
the respective award using the straight line. The Company adopted ASU 2018-07 as of January 1, 2019 with no impact on its consolidated
financial statements as all of the Company&amp;#x2019;s awards were fully vested at the adoption date.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;l.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Loss&amp;#xa0;per&amp;#xa0;share&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Basic earnings per share is
computed by dividing net income (loss) attributable to holders of ordinary shares of the Company by the weighted average number
of ordinary shares outstanding for each reporting period.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In computing the Company&amp;#x2019;s
diluted earnings per share, the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary
shares and the potential dilutive ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding
include the dilutive effect of in-the-money options using the treasury stock method.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company did not take into account
any dilutive instruments, such as investor warrants and share-based payments, since their effect, on a fully diluted basis, is
anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;m.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Fair&amp;#xa0;value&amp;#xa0;measurement&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Fair value is based on the price
that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between
market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the
guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into
three broad levels, which are described as follows:&lt;/p&gt;&lt;br/&gt;&lt;table border=&quot;0&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 1in&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left; width: 0.5in&quot;&gt;Level 1:&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Level 2: &lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Level 3: &lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to
Level 3 inputs.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;In determining fair value, the
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to
the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company&amp;#x2019;s financial instruments
consist mainly of cash and cash equivalents, restricted cash accounts payable, accrued expenses and other liabilities. The fair
value of these financial instruments approximates their carrying values.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;n.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Concentration&amp;#xa0;of&amp;#xa0;Credit Risks&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Company&amp;#x2019;s cash and cash
equivalents and restricted cash are invested with major banks in Israel, Korea and Japan. Generally, these investments may be redeemed
upon demand and the Company believes that the financial institutions that hold the Company&amp;#x2019;s cash balances are financially
sound and, accordingly, bear minimal risk.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <nnox:DeferredOfferingCostsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;o.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Offering&amp;#xa0;Costs &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Deferred offering costs directly
relating to the Company&amp;#x2019;s private and initial public offering, were capitalized and offset against proceeds upon the consummation
of the private and IPO transactions in shareholders&amp;#x2019; equity.&lt;/p&gt;</nnox:DeferredOfferingCostsPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;p.&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left&quot;&gt;On January 1, 2019 the Company
adopted ASU No. 2016-02, Leases (Topic 842), The Company determines if an arrangement is a lease at inception. Balances related
to operating leases are included in operating lease right-of-use (&amp;#x201c;ROU&amp;#x201d;) assets, current maturities of operating leases
and Non-current operating leases in the consolidated balance sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left&quot;&gt;The Company also elected not
separating lease components from non-lease components and to keep leases with an initial term of 12 months or less off the balance
sheet and recognize the associated lease payments in the consolidated statements of operations on a straight-line basis over the
lease term.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;ROU assets represent the Company&amp;#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&amp;#x2019;s obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on
the present value of lease payments over the lease term. The Company&amp;#x2019;s lease terms may include options to extend or terminate
the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate
implicit in the lease unless that rate cannot be readily determined. As the Company&amp;#x2019;s leases do not provide an implicit rate,
the Company&amp;#x2019;s uses its estimated incremental borrowing rate based on the information available at the commencement date in
determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the
lease term (see also note 5).&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;&lt;td style=&quot;text-align: left; width: 0.25in&quot;&gt;&lt;b&gt;q.&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Newly issued and recently adopted accounting pronouncements:&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;&lt;b&gt;&lt;i&gt;Accounting Pronouncements
Adopted in Current year&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on
Financial Instruments (&amp;#x201c;the Standard&amp;#x201d;). This guidance replaces the current incurred loss impairment methodology.
Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance
that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based
on historical experience, current conditions and reasonable and supportable forecasts. In November 2018, the FASB issued ASU
2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. ASU 2018-19 clarifies that
receivables from operating leases are accounted for using the lease guidance and not as financial instruments.&lt;/font&gt; Since
the Company has no financial instruments the Standard does not impact the Company&amp;#x2019;s consolidated financial
statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <nnox:ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;10-33&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;6-20&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;Machines&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;10-20&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 88%; text-align: left; text-indent: 0; padding-left: 0; padding-right: 0&quot;&gt;Leasehold Improvement&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: center&quot;&gt;10&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0; padding-left: 0; padding-right: 0&quot;&gt;Land&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;N/A&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</nnox:ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock>
  <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c32_From1Jan2020To31Dec2020_ComputerEquipmentMember">10-33</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
  <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c33_From1Jan2020To31Dec2020_OfficeEquipmentMember">6-20</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
  <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c34_From1Jan2020To31Dec2020_MachineryAndEquipmentMember">10-20</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
  <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c35_From1Jan2020To31Dec2020_LeaseholdsAndLeaseholdImprovementsMember">10</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
  <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c36_From1Jan2020To31Dec2020_LandMember">N/A</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;b&gt;NOTE
3 - PROPERTY AND EQUIPMENT, NET:&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;Composition of property and equipment
grouped by major classifications is as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars &lt;br/&gt;
in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Georgia, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;820&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;325&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;151&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;39&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Machinery&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,762&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Leasehold improvement&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;16&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Land &amp;#x2013; See b below&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6,297&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Prepayments on account of production line in construction - See b below&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;5,318&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;14,364&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;364&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(344&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(136&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;Total property and equipment, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;14,020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;228&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 58.5pt&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 18pt&quot;&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Total depreciation in respect of property and equipment were approximately $208 thousand, $53 thousand
and $35 thousand for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 58.5pt&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 18pt&quot;&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;In December 2020, Nanox Korea purchased a land for approximately $6.2 million upon which it intends
to build a manufacturing facility. Nanox Korea also rented a temporary fabrication plant and is in the process of preparing for
the commencement of full manufacturing activities, including purchasing certain equipment and transferring certain technology.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PaymentsForPurchaseOfOtherAssets1 unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">6200000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars &lt;br/&gt;
in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Georgia, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;820&lt;/td&gt;&lt;td style=&quot;width: 1%; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;325&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;151&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;39&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Machinery&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,762&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Leasehold improvement&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;16&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Land &amp;#x2013; See b below&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6,297&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Prepayments on account of production line in construction - See b below&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;5,318&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;14,364&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;364&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(344&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(136&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;Total property and equipment, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;14,020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;228&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c37_AsOf31Dec2020_OfficeEquipmentMember" decimals="-3">820000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c38_AsOf31Dec2019_OfficeEquipmentMember" decimals="-3">325000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c39_AsOf31Dec2020_ComputerEquipmentMember" decimals="-3">151000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c40_AsOf31Dec2019_ComputerEquipmentMember" decimals="-3">39000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c41_AsOf31Dec2020_MachineryAndEquipmentMember" decimals="-3">1762000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c42_AsOf31Dec2019_MachineryAndEquipmentMember" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c43_AsOf31Dec2020_LeaseholdImprovementsMember" decimals="-3">16000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c44_AsOf31Dec2019_LeaseholdImprovementsMember" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c45_AsOf31Dec2020_LandSeeBBelowMember" decimals="-3">6297000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c46_AsOf31Dec2019_LandSeeBBelowMember" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c47_AsOf31Dec2020_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember" decimals="-3">5318000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c48_AsOf31Dec2019_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">14364000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">364000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">344000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">136000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <nnox:CashEquivalentsAndRestrictedCashTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;font style=&quot;text-transform: uppercase&quot;&gt;&lt;b&gt;NOTE
4 - CASH, CASH EQUIVALENTS AND RESTRICTED CASH:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;The following table provides a
reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheet that sum to the same total
amount as shown in the consolidated statement of cash flows.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars&lt;br/&gt;
 in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;213,468&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;8,072&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Restricted bank deposit&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;316&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;145&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -11.5pt; padding-left: 11.5pt&quot;&gt;Total cash, cash equivalents and restricted cash shown in the statement of cash flows&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;213,784&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,217&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</nnox:CashEquivalentsAndRestrictedCashTextBlock>
  <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars&lt;br/&gt;
 in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;213,468&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;8,072&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Restricted bank deposit&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;316&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;145&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -11.5pt; padding-left: 11.5pt&quot;&gt;Total cash, cash equivalents and restricted cash shown in the statement of cash flows&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;213,784&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,217&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
  <us-gaap:RestrictedCashEquivalentsNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">316000</us-gaap:RestrictedCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashEquivalentsNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">145000</us-gaap:RestrictedCashEquivalentsNoncurrent>
  <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;b&gt;NOTE
5 - LEASES:&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;As of December 31, 2020, the Company
has four operating lease agreements for its car and facilities, as follows:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;During the fourth quarter of
2019, the Company entered into an office lease agreement. This agreement is through December 31, 2021 with an option by the Company
to extend the period for an additional 24 months. The monthly rent payment is approximately $13 thousand.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;During June 2020, the Company
entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023. The monthly rent payment
for this agreement is approximately $15 thousand.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;During November 2020, following
the increase of the Company&amp;#x2019;s employees, the Company signed an additional lease agreement, for a leasing of another office
complex through June 30, 2023. The monthly rent payment for this agreement is approximately $12 thousand.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;During November 2020, the Company
engaged with car lease company, for leasing of 6 vehicles. This agreement is effective through June 30, 2023 and the monthly payment
for this agreement is approximately $6.5 thousand.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;The table below presents the
effects on the amounts relating to the Company&amp;#x2019;s total lease costs:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;Year ended &lt;br/&gt;
December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;Year ended &lt;br/&gt;
December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars&lt;br/&gt;
 in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;(U.S. Dollars &lt;br/&gt;
In thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating lease cost:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Fixed payments&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;276&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;25&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Short-term lease cost&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;65&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;112&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Total operating lease cost&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;341&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;137&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;The table below presents supplemental
cash flow information related to operating leases:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;Year ended &lt;br/&gt;
December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;Year ended &lt;br/&gt;
December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;(U.S.&amp;#xa0;Dollars&lt;br/&gt;
 in&amp;#xa0;thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;(U.S.&amp;#xa0;Dollars&lt;br/&gt;
 in&amp;#xa0;thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right&quot;&gt;169&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right&quot;&gt;25&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Right-of-use assets obtained in exchange for lease obligations (non-cash):&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating leases&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,085&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;548&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;The table below presents supplemental
balance sheet information related to operating leases:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,359&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;526&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Current maturities of operating leases&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;519&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;140&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt&quot;&gt;Non-current operating leases&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;923&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;386&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt&quot;&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,442&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;526&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: right&quot;&gt;&lt;b&gt;December&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: right&quot;&gt;&lt;b&gt;December&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Weighted average remaining lease term&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating leases&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.67&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.96&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating leases&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.83&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.6&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left&quot;&gt;The table below presents maturities
of operating lease liabilities:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars &lt;br/&gt; in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2020&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 88%; text-align: left&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;588&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;588&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;382&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;2024 and thereafter&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Total operating lease payments&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,558&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Less: imputed interest&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;116&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,442&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
  <nnox:LeaseTermDescription contextRef="c3_From1Jan2019To31Dec2019">This agreement is through December 31, 2021 with an option by the Company to extend the period for an additional 24 months.</nnox:LeaseTermDescription>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">13000</us-gaap:LeaseAndRentalExpense>
  <nnox:LeaseTermDescription contextRef="c49_From2Jun2020To30Jun2020">During June 2020, the Company entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023.</nnox:LeaseTermDescription>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c49_From2Jun2020To30Jun2020" decimals="-3">15000</us-gaap:LeaseAndRentalExpense>
  <nnox:LeaseTermDescription contextRef="c50_From2Nov2020To30Nov2020">During November 2020, following the increase of the Company&amp;#x2019;s employees, the Company signed an additional lease agreement, for a leasing of another office complex through June 30, 2023.</nnox:LeaseTermDescription>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c50_From2Nov2020To30Nov2020" decimals="-3">12000</us-gaap:LeaseAndRentalExpense>
  <nnox:LeasesTermDescription contextRef="c50_From2Nov2020To30Nov2020">the Company engaged with car lease company, for leasing of 6 vehicles. This agreement is effective through June 30, 2023</nnox:LeasesTermDescription>
  <nnox:VehicleLeasePayments contextRef="c50_From2Nov2020To30Nov2020">$6.5</nnox:VehicleLeasePayments>
  <us-gaap:LeaseCostTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;Year ended &lt;br/&gt;
December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;Year ended &lt;br/&gt;
December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars&lt;br/&gt;
 in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;(U.S. Dollars &lt;br/&gt;
In thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Operating lease cost:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left&quot;&gt;Fixed payments&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;276&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;25&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Short-term lease cost&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;65&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;112&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Total operating lease cost&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;341&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;137&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
  <us-gaap:LeaseCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">276000</us-gaap:LeaseCost>
  <us-gaap:LeaseCost unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">25000</us-gaap:LeaseCost>
  <us-gaap:ShortTermLeaseCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">65000</us-gaap:ShortTermLeaseCost>
  <us-gaap:ShortTermLeaseCost unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">112000</us-gaap:ShortTermLeaseCost>
  <nnox:TotalOperatingLeaseCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">341000</nnox:TotalOperatingLeaseCost>
  <nnox:TotalOperatingLeaseCost unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">137000</nnox:TotalOperatingLeaseCost>
  <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;Year ended &lt;br/&gt;
December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;Year ended &lt;br/&gt;
December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;(U.S.&amp;#xa0;Dollars&lt;br/&gt;
 in&amp;#xa0;thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;(U.S.&amp;#xa0;Dollars&lt;br/&gt;
 in&amp;#xa0;thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right&quot;&gt;169&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right&quot;&gt;25&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Right-of-use assets obtained in exchange for lease obligations (non-cash):&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating leases&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,085&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;548&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
  <us-gaap:OperatingLeasePayments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">169000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeasePayments unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">25000</us-gaap:OperatingLeasePayments>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">1085000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">548000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <nnox:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,359&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;526&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Current maturities of operating leases&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;519&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;140&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt&quot;&gt;Non-current operating leases&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;923&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;386&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt&quot;&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,442&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;526&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: right&quot;&gt;&lt;b&gt;December&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: right&quot;&gt;&lt;b&gt;December&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Weighted average remaining lease term&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating leases&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.67&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.96&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: -10pt; padding-left: 10pt&quot;&gt;Operating leases&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.83&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.6&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</nnox:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock>
  <nnox:CurrentMaturitiesOfOperatingLeases unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">519000</nnox:CurrentMaturitiesOfOperatingLeases>
  <nnox:CurrentMaturitiesOfOperatingLeases unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">140000</nnox:CurrentMaturitiesOfOperatingLeases>
  <nnox:NoncurrentOperatingLeases unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">923000</nnox:NoncurrentOperatingLeases>
  <nnox:NoncurrentOperatingLeases unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">386000</nnox:NoncurrentOperatingLeases>
  <us-gaap:OperatingLeaseLiability unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">1442000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiability unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-3">526000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c1_AsOf31Dec2020">P2Y244D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2_AsOf31Dec2019">P3Y350D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent unitRef="pure" contextRef="c1_AsOf31Dec2020" decimals="4">0.0583</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent unitRef="pure" contextRef="c2_AsOf31Dec2019" decimals="3">0.056</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-weight: bold; text-align: center&quot;&gt;December&amp;#xa0;31,&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars &lt;br/&gt; in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2020&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;width: 88%; text-align: left&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;588&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;588&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;382&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;2024 and thereafter&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Total operating lease payments&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,558&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;Less: imputed interest&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;116&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,442&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">588000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">588000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">382000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears unitRef="usd" contextRef="c1_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">1558000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:ReceivableWithImputedInterestNetAmount unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">116000</us-gaap:ReceivableWithImputedInterestNetAmount>
  <nnox:RelatedPartyLiabilityTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;b&gt;NOTE
6 - RELATED PARTY LIABILITY&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in&quot;&gt;According to ASC
480, &amp;#x201c;Distinguishing Liabilities From Equity,&amp;#x201d; a financial instrument that embodies an unconditional obligation, or a
financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle
by issuing a variable number of its equity shares shall be classified as a liability if, at inception, the monetary value of the
obligation is based solely or predominantly on a fixed monetary amount known at inception. These liabilities are measured subsequently
at fair value with changes in fair value recognized in earnings.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in&quot;&gt;The Company analyzed
the instrument&amp;#x2019;s provisions and concluded that it meets the above ASC 480 criteria and therefore accounted the expected future
payment under the APA in accordance with ASC 480.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in&quot;&gt;As of December
31, 2019, the Company recorded a Related Party Liability in an amount of $17.8 million, which represents the fair value of the
shares that have been issued to Nanox PLC, based on the last financing round of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in&quot;&gt;During January
2020, subject to entering into a share purchase agreement in the aggregate amount of at least $6 million, and a pre-money valuation
of more than $100 million, the Nanox IL&amp;#x2019;s Board approved the issuance and allotment of 1,109,245 ordinary shares to Nanox
PLC with the purchase price of $12.00 per share, which reflects a discount of 25% from the price of the last financing round of
the Company. As a result, on January 30, 2020 the related party liability was settled into equity.&lt;/p&gt;&lt;br/&gt;</nnox:RelatedPartyLiabilityTextBlock>
  <us-gaap:DueToRelatedPartiesNoncurrent unitRef="usd" contextRef="c2_AsOf31Dec2019" decimals="-5">17800000</us-gaap:DueToRelatedPartiesNoncurrent>
  <nnox:PurchaseAgreementDescription contextRef="c51_From2Jan2020To31Jan2020">subject to entering into a share purchase agreement in the aggregate amount of at least $6 million, and a pre-money valuation of more than $100 million, the Nanox IL&amp;#x2019;s Board approved the issuance and allotment of 1,109,245 ordinary shares to Nanox PLC with the purchase price of $12.00 per share, which reflects a discount of 25% from the price of the last financing round of the Company. As a result, on January 30, 2020 the related party liability was settled into equity.</nnox:PurchaseAgreementDescription>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;b&gt;NOTE
7 - COMMITMENTS AND CONTINGENCIES&lt;/b&gt;:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;In September 2020, securities class action complaints were filed in the United States by certain of
the Company&amp;#x2019;s shareholders against the Company and certain of the Company&amp;#x2019;s current officers and directors alleging
violations of securities laws and seeking unspecified damages. On December 7, 2020, the proposed lead plaintiffs&amp;#x2019; submissions
were fully briefed. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. As of the
date of issuance of these financial statements, the Company is unable to estimate a range of loss, if any, that could result were
there to be an adverse final decision in these cases.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;For services with SixAI Ltd. (&amp;#x201c;SixAI&amp;#x201d;), see Note 10d.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;b&gt;NOTE
8 - SHAREHOLDERS&amp;#x2019; EQUITY:&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Each holder of the Company&amp;#x2019;s
ordinary shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are
legally available, and declared by the Company&amp;#x2019;s Board of Directors (the &amp;#x201c;Board&amp;#x201d;). Since inception, the Company
has not declared any dividends.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;&lt;i&gt;Issuance
of Equity&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;&lt;i&gt;Ordinary Share issuances
prior to the APA&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;During the year ended December
31, 2018, Nanox PLC entered into several agreements with third party investors, pursuant to which it raised an aggregate amount
of $3,684 thousand at a purchase price of $2.21 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;On June 17, 2019, Nanox PLC
issued 2,262,443 ordinary shares to third party investors for an aggregate purchase price of approximately $5,000 thousand. Certain
investors were also granted warrants to acquire 2,262,443 of ordinary shares at an exercise price of $20.87 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Additionally, during 2019, Nanox
PLC entered into&amp;#xa0;several agreements with certain third-party investors, pursuant to which it raised an aggregate amount of
$4,038 thousand, net of issuance costs, at a purchase price of $2.21 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;&lt;i&gt;Ordinary Share issuances
after the APA&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;On December 31, 2019, the Company
issued 312,500 ordinary shares to a third-party investor for an aggregate purchase price of approximately $5 million.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;During the year 2020, the Company
issued an aggregate of 4,624,500 ordinary shares to the certain investors, at a price per share of $16.00, for an aggregate purchase
price of approximately $74 million (the net proceeds were approximately $71 million after deducting issuance costs).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;In
August 2020, the Company completed an initial public offering (&amp;#x201c;IPO&amp;#x201d;) on the Nasdaq Global Market (the &amp;#x201c;Nasdaq&amp;#x201d;),
in which it issued 9,178,744 ordinary shares at a price per share of $18.&amp;#xa0;During August 2020, the underwriters exercised
their over-allotment option and purchased an additional 1,376,812 ordinary shares at the same price per share. The proceeds received
from the IPO were $190 million (the net proceeds were approximately $169 million after deducting underwriting commissions and
other offering expenses).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;&lt;i&gt;Settlement
of Related Party Liability&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Pursuant to the Asset Purchase
Agreement between Nanox IL and Nanox PLC, as more fully described in the Company&amp;#x2019;s annual financial statements, in January 2020,
the Company issued 1,109,245 ordinary shares to Nanox PLC with a purchase price of $12.00 per share, which reflected a discount
of 25% from the price of the last financing round of the Company. As a result, the related party liability was settled into shareholders&amp;#x2019;
equity.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Share based compensation &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;On September 3, 2019, the Company&amp;#x2019;s
Board resolved to adopt an equity incentive plan (the &amp;#x201c;Plan&amp;#x201d;). Based on such Plan, each option will be exercisable for
one ordinary share of the Company and will become exercisable at such terms and during such periods, as the Board shall determine.
Pursuant to the Plan (and further increase of option pool approved by the Board), 8,041,936 ordinary shares of NIS 0.01 par value
of the Company are reserved for issuance upon the exercise of the same amount of awards to be granted to some of the Company&amp;#x2019;s
employees, directors and consultants. As of December 31, 2020, 2,978,247 ordinary shares reserved for the equity incentive plan.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;The Board also approved the
Plan for the purpose of selecting the capital gains tax track, under Section 102 of the Israeli Income Tax Ordinance, for options
granted to the Company&amp;#x2019;s Israeli employees.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: left&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;1)&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Share-based compensation to non-employees&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left&quot;&gt;The following table summarizes
share-based awards to non-employees for the years ended December 31, 2020 and December 31, 2019:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;share-based&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;share-based&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;payment&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;payment&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,410,406&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.89&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,592,874&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.32&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Changes during the year:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.25in; text-indent: -10pt&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;font-family: Georgia, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;1,327,957&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;13.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,271,698&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.77&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.25in; text-indent: -10pt&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;*(1,267,012&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.94&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(454,166&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.3&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.25in; text-indent: -10pt&quot;&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.25in; text-indent: -10pt&quot;&gt;Expired&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt&quot;&gt;Cancelled&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(98,725&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.92&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;Outstanding at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,372,626&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.27&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,410,406&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1.89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;Exercisable at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,191,042&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.67&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,830,809&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3.79&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: left&quot;&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;*&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Out of which 1,027,151 awards were exercised on a
cashless basis.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left&quot;&gt;The fair value of each granted award
is estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used for the years ended December
31, 2020 and 2019 are as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0&quot;&gt;Dividend yield&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: center&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: center&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0&quot;&gt;Expected volatility&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;57.34%-44.40%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;41.11% - 50.59%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0&quot;&gt;Risk-free interest rate&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;0.27%-1.61%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;1.55%-1.76%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0&quot;&gt;Contractual term (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;5-10&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;0.50 &amp;#x2013; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left&quot;&gt;The expected volatility is based
on the historical volatility of comparable companies.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left&quot;&gt;The risk-free interest rate assumption
is based on observed interest rates appropriate for the expected term of the awards granted in dollar terms.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left&quot;&gt;The Company does not have sufficient
historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course
options granted, the expected term was determined using the simplified method, which takes into consideration the option&amp;#x2019;s
contractual life and the vesting periods (for non-employees, the expected term is equal to the option&amp;#x2019;s contractual life).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left&quot;&gt;The following table summarizes
information concerning outstanding and exercisable awards as of December 31, 2020 and 2019:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;18&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards exercisable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;award&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;outstanding&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercisable&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: right&quot;&gt;0.01&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;186,815&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;0.33&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;186,815&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;0.33&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.92&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;269,714&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;269,714&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,191,349&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.22&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,188,914&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.22&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;16.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;444,748&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.89&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;283,933&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.89&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;260,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.86&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;260,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.86&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;30.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;20,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.81&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,666&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.81&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;18&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31, 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards exercisable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;outstanding&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercisable&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: right&quot;&gt;0.01&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;186,815&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;1.33&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;186,815&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;1.33&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.92&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;472,606&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.81&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;472,606&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.81&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,727,028&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.27&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,163,402&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.27&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;20.87&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;23,957&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.69&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,986&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.69&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;2)&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Share-based compensation to employees, officers and directors&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left&quot;&gt;During 2020, the Company granted
to certain employees, officers and directors awards to purchase 730,734 of the Company&amp;#x2019;s ordinary shares for an average exercise
price of $13.53.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;share-based&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;average &lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;share-based&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;average &lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;&lt;b&gt;payment awards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;&lt;b&gt;payment awards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left&quot;&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,667,267&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,667,267&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Changes during the year:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 8.8pt&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;730,734&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;13.53&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 8.8pt&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 8.8pt&quot;&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 8.8pt&quot;&gt;Expired&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 8.8pt&quot;&gt;Cancelled&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(16,876&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Outstanding at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,381,125&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4.14&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,667,267&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Exercisable at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,061,778&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2.80&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;450,557&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: left&quot;&gt;The fair value of each granted
award is estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used as of December 31,
2020 and 2019 are as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; white-space: nowrap&quot;&gt;Dividend yield&lt;/td&gt;&lt;td style=&quot;width: 1%; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: center; white-space: nowrap&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: center; white-space: nowrap&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;Expected volatility&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;45.11%-55.97%&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;45.11%-55.97%&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;Risk-free interest rate&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;0.23%-1.61%&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;0.23%-1.61%&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;Contractual term (years)&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;10&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;10&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0&quot;&gt;The expected
volatility is based on the historical volatility of comparable companies.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0&quot;&gt;The risk-free
interest rate assumption is based on observed interest rates appropriate for the expected term of the awards granted in dollar
terms.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0&quot;&gt;The Company
does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly,
as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration
the option&amp;#x2019;s contractual life and the vesting periods.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0&quot;&gt;The following
table summarizes information concerning outstanding and exercisable awards as of December 31, 2020 and 2019:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;18&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards exercisable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;outstanding&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercisable&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: center&quot;&gt;$2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;1,995,625&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;9.05&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;1,019,695&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;9.05&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;$16.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;205,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;37,917&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;$26.56-$59.20&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;180,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4,167&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;18&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31, 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards exercisable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;outstanding&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercisable&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: center&quot;&gt;$2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;1,667,267&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;9.90&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;450,557&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;9.90&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 1in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;3)&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Share-based compensation expenses&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Year Ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2018&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. dollars in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left&quot;&gt;Research and development&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,384&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;661&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Marketing (*)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9,252&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;617&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;General and administrative&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;12,145&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;14,967&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;115&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;24,781&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;16,245&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;115&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: left&quot;&gt;
&lt;td style=&quot;width: 0&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;b&gt;(*)&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;On October 26, 2020, the Company entered into an amendment
to a business development agreement (&amp;#x201c;the Agreement&amp;#x201d;) dated February 4, 2020 with two service providers pursuant to
which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate
of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date
(subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants
granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant
to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues
from any of the Company&amp;#x2019;s systems and the issuance of warrants.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <nnox:IssuanceOfOrdinarySharesReservedForFutureIssuance unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">3684000</nnox:IssuanceOfOrdinarySharesReservedForFutureIssuance>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c15_AsOf31Dec2018" decimals="2">2.21</us-gaap:SharesIssuedPricePerShare>
  <nnox:OrdinaryShares unitRef="shares" contextRef="c52_From1Jun2019To17Jun2019" decimals="INF">2262443</nnox:OrdinaryShares>
  <us-gaap:PaymentsForProceedsFromPreviousAcquisition unitRef="usd" contextRef="c52_From1Jun2019To17Jun2019" decimals="-3">5000000</us-gaap:PaymentsForProceedsFromPreviousAcquisition>
  <nnox:OrdinaryShares unitRef="shares" contextRef="c53_From1Jun2019To17Jun2019_WarrantMember" decimals="INF">2262443</nnox:OrdinaryShares>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c54_AsOf17Jun2019" decimals="2">20.87</us-gaap:SharesIssuedPricePerShare>
  <nnox:IssuanceOfOrdinarySharesReservedForFutureIssuance unitRef="usd" contextRef="c55_From1Jan2019To31Dec2019_NanoxPLCMember" decimals="-3">4038000</nnox:IssuanceOfOrdinarySharesReservedForFutureIssuance>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c2_AsOf31Dec2019" decimals="-1">2210</us-gaap:SharesIssuedPricePerShare>
  <nnox:IssuanceOfOrdinarySharesReservedForFutureIssuance unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="0">312500</nnox:IssuanceOfOrdinarySharesReservedForFutureIssuance>
  <us-gaap:PaymentsForProceedsFromPreviousAcquisition unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-6">5000000</us-gaap:PaymentsForProceedsFromPreviousAcquisition>
  <nnox:OrdinaryShares unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">4624500</nnox:OrdinaryShares>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c1_AsOf31Dec2020" decimals="2">16.00</us-gaap:SharesIssuedPricePerShare>
  <nnox:IncreasedAnCommonStockValue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-6">74000000</nnox:IncreasedAnCommonStockValue>
  <nnox:NetProceeds unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-6">71000000</nnox:NetProceeds>
  <nnox:OrdinaryShares unitRef="shares" contextRef="c28_From1Aug2020To31Aug2020_IPOMember" decimals="INF">9178744</nnox:OrdinaryShares>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c56_AsOf31Aug2020_IPOMember" decimals="0">18</us-gaap:SharesIssuedPricePerShare>
  <nnox:IncreasedAnCommonStockValue unitRef="usd" contextRef="c28_From1Aug2020To31Aug2020_IPOMember" decimals="-6">190000000</nnox:IncreasedAnCommonStockValue>
  <nnox:OrdinaryShares unitRef="shares" contextRef="c51_From2Jan2020To31Jan2020" decimals="INF">1109245</nnox:OrdinaryShares>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c57_AsOf31Jan2020" decimals="2">12.00</us-gaap:SharesIssuedPricePerShare>
  <nnox:PercentageOfDiscountPrice unitRef="pure" contextRef="c57_AsOf31Jan2020" decimals="2">0.25</nnox:PercentageOfDiscountPrice>
  <nnox:OrdinarySharesReservedUnderTheESOP unitRef="shares" contextRef="c58_AsOf3Sep2019" decimals="INF">8041936</nnox:OrdinarySharesReservedUnderTheESOP>
  <nnox:OrdinaryStockParOrStatedValuePerShare unitRef="ilsPershares" contextRef="c58_AsOf3Sep2019" decimals="2">0.01</nnox:OrdinaryStockParOrStatedValuePerShare>
  <nnox:OrdinaryShares unitRef="shares" contextRef="c59_From1Jan2020To31Dec2020_EquityIncentivePlanMember" decimals="INF">2978247</nnox:OrdinaryShares>
  <nnox:NumberOfExercisedShares unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">1027151</nnox:NumberOfExercisedShares>
  <nnox:OrdinaryShares unitRef="shares" contextRef="c60_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember" decimals="INF">730734</nnox:OrdinaryShares>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c61_AsOf31Dec2020_EmployeesOfficersAndDirectorsMember" decimals="2">13.53</us-gaap:SharePrice>
  <nnox:DescriptionOfSharebasedCompensationExpenses contextRef="c62_From2Oct2020To26Oct2020">the Company entered into an amendment to a business development agreement (&amp;#x201c;the Agreement&amp;#x201d;) dated February 4, 2020 with two service providers pursuant to which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company&amp;#x2019;s systems and the issuance of warrants.</nnox:DescriptionOfSharebasedCompensationExpenses>
  <us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;share-based&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;share-based&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;payment&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;payment&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,410,406&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.89&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,592,874&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.32&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt; text-indent: -10pt&quot;&gt;Changes during the year:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.25in; text-indent: -10pt&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;font-family: Georgia, Times, Serif&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: right&quot;&gt;1,327,957&lt;/td&gt;&lt;td style=&quot;font-family: Times New Roman, Times, Serif; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;13.70&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,271,698&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.77&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.25in; text-indent: -10pt&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;*(1,267,012&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.94&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(454,166&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.3&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.25in; text-indent: -10pt&quot;&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.25in; text-indent: -10pt&quot;&gt;Expired&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt&quot;&gt;Cancelled&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(98,725&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.92&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;Outstanding at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,372,626&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.27&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,410,406&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1.89&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt&quot;&gt;Exercisable at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,191,042&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.67&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,830,809&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3.79&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">3410406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c2_AsOf31Dec2019" decimals="2">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c15_AsOf31Dec2018" decimals="INF">1592874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c15_AsOf31Dec2018" decimals="2">1.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">1327957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">13.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="INF">2271698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">2.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="_StockIssuedDuringPeriodSharesStockOptionsExercised-c0_From1Jan2020To31Dec2020_shares" unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">1267012</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">8.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" decimals="INF">454166</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" decimals="1">0.3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">98725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">3372626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c1_AsOf31Dec2020" decimals="2">5.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c1_AsOf31Dec2020" decimals="INF">2191042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c1_AsOf31Dec2020" decimals="2">5.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c2_AsOf31Dec2019" decimals="INF">1830809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c2_AsOf31Dec2019" decimals="2">3.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0&quot;&gt;Dividend yield&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: center&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: center&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0&quot;&gt;Expected volatility&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;57.34%-44.40%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;41.11% - 50.59%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0&quot;&gt;Risk-free interest rate&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;0.27%-1.61%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;1.55%-1.76%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0&quot;&gt;Contractual term (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;5-10&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;0.50 &amp;#x2013; 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c3_From1Jan2019To31Dec2019" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c63_From1Jan2020To31Dec2020_MinimumMember" decimals="4">0.5734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c64_From1Jan2020To31Dec2020_MaximumMember" decimals="4">0.4440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c65_From1Jan2019To31Dec2019_MinimumMember" decimals="4">0.4111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c66_From1Jan2019To31Dec2019_MaximumMember" decimals="4">0.5059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c63_From1Jan2020To31Dec2020_MinimumMember" decimals="4">0.0027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c64_From1Jan2020To31Dec2020_MaximumMember" decimals="4">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c65_From1Jan2019To31Dec2019_MinimumMember" decimals="4">0.0155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c66_From1Jan2019To31Dec2019_MaximumMember" decimals="4">0.0176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c63_From1Jan2020To31Dec2020_MinimumMember">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c64_From1Jan2020To31Dec2020_MaximumMember">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c65_From1Jan2019To31Dec2019_MinimumMember">P6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c66_From1Jan2019To31Dec2019_MaximumMember">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;18&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards exercisable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;award&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;outstanding&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercisable&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: right&quot;&gt;0.01&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;186,815&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;0.33&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;186,815&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;0.33&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.92&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;269,714&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;269,714&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,191,349&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.22&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,188,914&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.22&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;16.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;444,748&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.89&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;283,933&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.89&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;260,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.86&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;260,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.86&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;30.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;20,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.81&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,666&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.81&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;18&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31, 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards exercisable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;outstanding&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercisable&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: right&quot;&gt;0.01&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;186,815&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;1.33&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;186,815&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;1.33&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.92&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;472,606&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.81&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;472,606&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.81&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,727,028&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.27&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,163,402&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.27&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;20.87&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;23,957&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.69&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,986&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.69&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c67_AsOf31Dec2020_ExercisePricesOneMember" decimals="INF">186815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c68_From1Jan2020To31Dec2020_ExercisePricesOneMember">P120D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c68_From1Jan2020To31Dec2020_ExercisePricesOneMember" decimals="INF">186815</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c68_From1Jan2020To31Dec2020_ExercisePricesOneMember">P120D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c69_AsOf31Dec2020_ExercisePricesTwoMember" decimals="INF">269714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c70_From1Jan2020To31Dec2020_ExercisePricesTwoMember">P1Y65D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c70_From1Jan2020To31Dec2020_ExercisePricesTwoMember" decimals="INF">269714</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c70_From1Jan2020To31Dec2020_ExercisePricesTwoMember">P1Y65D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c71_AsOf31Dec2020_ExercisePricesThreeMember" decimals="INF">2191349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c72_From1Jan2020To31Dec2020_ExercisePricesThreeMember">P6Y80D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c72_From1Jan2020To31Dec2020_ExercisePricesThreeMember" decimals="INF">1188914</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c72_From1Jan2020To31Dec2020_ExercisePricesThreeMember">P6Y80D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c73_AsOf31Dec2020_ExercisePricesFourMember" decimals="INF">444748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c74_From1Jan2020To31Dec2020_ExercisePricesFourMember">P8Y324D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c74_From1Jan2020To31Dec2020_ExercisePricesFourMember" decimals="INF">283933</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c74_From1Jan2020To31Dec2020_ExercisePricesFourMember">P8Y324D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c75_AsOf31Dec2020_ExercisePricesFiveMember" decimals="INF">260000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c76_From1Jan2020To31Dec2020_ExercisePricesFiveMember">P3Y313D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c76_From1Jan2020To31Dec2020_ExercisePricesFiveMember" decimals="INF">260000</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c76_From1Jan2020To31Dec2020_ExercisePricesFiveMember">P3Y313D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c77_AsOf31Dec2020_ExercisePricesSixMember" decimals="INF">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c78_From1Jan2020To31Dec2020_ExercisePricesSixMember">P9Y295D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c78_From1Jan2020To31Dec2020_ExercisePricesSixMember" decimals="INF">1666</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c78_From1Jan2020To31Dec2020_ExercisePricesSixMember">P9Y295D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c79_AsOf31Dec2019_ExercisePricesOneMember" decimals="INF">186815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c80_From1Jan2019To31Dec2019_ExercisePricesOneMember">P1Y120D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c80_From1Jan2019To31Dec2019_ExercisePricesOneMember" decimals="INF">186815</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c80_From1Jan2019To31Dec2019_ExercisePricesOneMember">P1Y120D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c81_AsOf31Dec2019_ExercisePricesTwoMember" decimals="INF">472606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c82_From1Jan2019To31Dec2019_ExercisePricesTwoMember">P1Y295D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c82_From1Jan2019To31Dec2019_ExercisePricesTwoMember" decimals="INF">472606</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c82_From1Jan2019To31Dec2019_ExercisePricesTwoMember">P1Y295D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c83_AsOf31Dec2019_ExercisePricesThreeMember" decimals="INF">2727028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c84_From1Jan2019To31Dec2019_ExercisePricesThreeMember">P5Y98D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c84_From1Jan2019To31Dec2019_ExercisePricesThreeMember" decimals="INF">1163402</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c84_From1Jan2019To31Dec2019_ExercisePricesThreeMember">P5Y98D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c85_AsOf31Dec2019_ExercisePricesSevenMember" decimals="INF">23957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c86_From1Jan2019To31Dec2019_ExercisePricesSevenMember">P5Y251D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c86_From1Jan2019To31Dec2019_ExercisePricesSevenMember" decimals="INF">7986</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c86_From1Jan2019To31Dec2019_ExercisePricesSevenMember">P5Y251D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="c60_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;share-based&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;average &lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;share-based&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;b&gt;average &lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: center; padding-bottom: 1.5pt; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;&lt;b&gt;payment awards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;&lt;b&gt;payment awards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left&quot;&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,667,267&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,667,267&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Changes during the year:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 8.8pt&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;730,734&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;13.53&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 8.8pt&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 8.8pt&quot;&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 8.8pt&quot;&gt;Expired&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 8.8pt&quot;&gt;Cancelled&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(16,876&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Outstanding at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,381,125&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4.14&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,667,267&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;Exercisable at end of year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,061,778&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2.80&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;450,557&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2.21&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c87_AsOf31Dec2019_EmployeeStockMember" decimals="INF">1667267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices unitRef="usdPershares" contextRef="c87_AsOf31Dec2019_EmployeeStockMember" decimals="2">2.21</nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c88_AsOf31Dec2018_EmployeeStockMember" decimals="INF">1667267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices unitRef="usdPershares" contextRef="c88_AsOf31Dec2018_EmployeeStockMember" decimals="2">2.21</nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" decimals="INF">730734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" decimals="2">13.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" xs:nil="true"/>
  <nnox:StockIssuedDuringPeriodSharesStockOptionsForfeited unitRef="shares" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" xs:nil="true"/>
  <nnox:StockIssuedDuringPeriodSharesStockOptionsForfeited unitRef="shares" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod unitRef="shares" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod unitRef="shares" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" xs:nil="true"/>
  <nnox:NumberOfSharebasedPaymentAwardsCancelled unitRef="shares" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" decimals="INF">-16876</nnox:NumberOfSharebasedPaymentAwardsCancelled>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" decimals="2">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <nnox:NumberOfSharebasedPaymentAwardsCancelled unitRef="shares" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c91_AsOf31Dec2020_EmployeeStockMember" decimals="INF">2381125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices unitRef="usdPershares" contextRef="c91_AsOf31Dec2020_EmployeeStockMember" decimals="2">4.14</nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c91_AsOf31Dec2020_EmployeeStockMember" decimals="INF">1061778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c91_AsOf31Dec2020_EmployeeStockMember" decimals="2">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c87_AsOf31Dec2019_EmployeeStockMember" decimals="INF">450557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c87_AsOf31Dec2019_EmployeeStockMember" decimals="2">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c60_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;font-weight: bold; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; white-space: nowrap&quot;&gt;Dividend yield&lt;/td&gt;&lt;td style=&quot;width: 1%; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: center; white-space: nowrap&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: center; white-space: nowrap&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;Expected volatility&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;45.11%-55.97%&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;45.11%-55.97%&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;Risk-free interest rate&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;0.23%-1.61%&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center&quot;&gt;0.23%-1.61%&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;Contractual term (years)&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;10&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap&quot;&gt;10&lt;/td&gt;&lt;td style=&quot;text-align: left; white-space: nowrap&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c92_From1Jan2020To31Dec2020_MinimumMember_EmployeeStockMember" decimals="4">0.4511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c93_From1Jan2020To31Dec2020_MaximumMember_EmployeeStockMember" decimals="4">0.5597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c94_From1Jan2019To31Dec2019_MinimumMember_EmployeeStockMember" decimals="4">0.4511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c95_From1Jan2019To31Dec2019_MaximumMember_EmployeeStockMember" decimals="4">0.5597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c92_From1Jan2020To31Dec2020_MinimumMember_EmployeeStockMember" decimals="4">0.0023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c93_From1Jan2020To31Dec2020_MaximumMember_EmployeeStockMember" decimals="4">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c94_From1Jan2019To31Dec2019_MinimumMember_EmployeeStockMember" decimals="4">0.0023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c95_From1Jan2019To31Dec2019_MaximumMember_EmployeeStockMember" decimals="4">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c89_From1Jan2020To31Dec2020_EmployeeStockMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c90_From1Jan2019To31Dec2019_EmployeeStockMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c60_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;18&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards exercisable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;outstanding&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercisable&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: center&quot;&gt;$2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;1,995,625&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;9.05&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;1,019,695&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;9.05&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;$16.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;205,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;37,917&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.62&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: center&quot;&gt;$26.56-$59.20&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;180,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4,167&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;18&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;December 31, 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Awards exercisable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Number of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Weighted&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;awards&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;average&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;outstanding&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;exercisable&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;remaining&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Exercise&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;at end of&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;contractual&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;year&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;life (years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 18%; text-align: center&quot;&gt;$2.21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;1,667,267&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;9.90&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;450,557&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 17%; text-align: right&quot;&gt;9.90&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c96_AsOf31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember" decimals="INF">1995625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c97_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember">P9Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c97_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember" decimals="INF">1019695</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c97_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember">P9Y18D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c98_AsOf31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesTwoMember" decimals="INF">205000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c99_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesTwoMember">P9Y226D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c99_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesTwoMember" decimals="INF">37917</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c99_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesTwoMember">P9Y226D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c100_AsOf31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesThreeMember" decimals="INF">180500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c101_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesThreeMember">P9Y339D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c101_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesThreeMember" decimals="INF">4167</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c101_From1Jan2020To31Dec2020_EmployeesOfficersAndDirectorsMember_ExercisePricesThreeMember">P9Y339D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c102_AsOf31Dec2019_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember" decimals="INF">1667267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c103_From1Jan2019To31Dec2019_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember">P9Y328D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance unitRef="shares" contextRef="c103_From1Jan2019To31Dec2019_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember" decimals="INF">450557</nnox:AwardsOutstandingNumberOfAwardsOutstandingBalance>
  <nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears contextRef="c103_From1Jan2019To31Dec2019_EmployeesOfficersAndDirectorsMember_ExercisePricesOneMember">P9Y328D</nnox:AwardsOutstandingWeightedAverageRemainingContractualLifeyears>
  <nnox:ScheduleOfWarrantsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Year Ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2018&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. dollars in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left&quot;&gt;Research and development&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;3,384&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;661&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;Marketing (*)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9,252&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;617&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;General and administrative&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;12,145&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;14,967&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;115&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;24,781&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;16,245&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;115&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</nnox:ScheduleOfWarrantsTableTextBlock>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c104_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember" decimals="-3">3384000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c105_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember" decimals="-3">661000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c106_From1Jan2018To31Dec2018_ResearchAndDevelopmentExpenseMember" xs:nil="true"/>
  <us-gaap:AllocatedShareBasedCompensationExpense id="_AllocatedShareBasedCompensationExpense-c107_From1Jan2020To31Dec2020_SellingAndMarketingExpenseMember_usd" unitRef="usd" contextRef="c107_From1Jan2020To31Dec2020_SellingAndMarketingExpenseMember" decimals="-3">9252000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="_AllocatedShareBasedCompensationExpense-c108_From1Jan2019To31Dec2019_SellingAndMarketingExpenseMember_usd" unitRef="usd" contextRef="c108_From1Jan2019To31Dec2019_SellingAndMarketingExpenseMember" decimals="-3">617000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="_AllocatedShareBasedCompensationExpense-c109_From1Jan2018To31Dec2018_SellingAndMarketingExpenseMember_usd" unitRef="usd" contextRef="c109_From1Jan2018To31Dec2018_SellingAndMarketingExpenseMember" xs:nil="true"/>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c110_From1Jan2020To31Dec2020_SellingGeneralAndAdministrativeExpensesMember" decimals="-3">12145000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c111_From1Jan2019To31Dec2019_SellingGeneralAndAdministrativeExpensesMember" decimals="-3">14967000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c112_From1Jan2018To31Dec2018_SellingGeneralAndAdministrativeExpensesMember" decimals="-3">115000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">24781000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">16245000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">115000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: left&quot;&gt;
&lt;td style=&quot;width: 0.75in; text-align: left&quot;&gt;&lt;b&gt;NOTE 9 -&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;INCOME TAX:&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Basis of taxation&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;Current tax is calculated with
reference to the profit of the Company and its subsidiary in their respective countries of operation. Set out below are details
in respect of the significant jurisdictions where the Company and its subsidiary operates and the factors that influenced the current
and deferred taxation in those jurisdictions:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;&lt;b&gt;&lt;i&gt;Israel&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;The Company is taxed under the
laws of the State of Israel at a corporate tax rate of 23%. In 20&lt;font style=&quot;font-family: Georgia, Times, Serif&quot;&gt;20&lt;/font&gt;, the
Company was at a loss position and therefore had no corporate tax liability.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;&lt;b&gt;&lt;i&gt;Korea&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;Nanox Korea is subject to a Corporate
income tax with accordance with the Korean tax law. The tax rate ranges between 10% to 25%, depending on the companies&amp;#x2019; taxable
income. In Addition, Nanox Korea is subject to a Local income tax of 10%. In 2020, Nanox Korea was at a loss position and therefore
had no corporate tax liability.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;&lt;b&gt;&lt;i&gt;Japan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;Nanox Inc. is subject to national
corporate income tax, and enterprise tax, which, in the aggregate resulted in effective tax rate of approximately 33.59% for the
year ended December 31, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;Under Japanese tax law and regulations,
every company is required to submit an annual tax return to tax authorities. The statute of limitations to request a correction
of prior year tax liabilities is five years from when the original tax return was filed. After filling of tax return, the tax authorities
may conduct tax inspections on an irregular basis.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Tax assessments&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;Nanox IL , Nanox Korea and Nanox
Inc. have not been assessed since inception.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Deferred tax assets &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;Nanox IL&amp;#x2019;s deferred tax asset as
of December 31, 2020 was related to tax losses accumulated since September 3, 2019 and carryforward.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;A full valuation allowance was
created against deferred tax assets arisen from the carryforward tax losses, since the realization of any future benefit from the
carryforward tax losses cannot be sufficiently assured as of December 31, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;The reconciling item between the
statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax benefits from
carried forward tax losses due to uncertainty of the realization of such tax benefits.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left&quot;&gt;Change in valuation allowance for
the year ended December 31, 2020 was $3,262 thousand.&lt;/p&gt;&lt;br/&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c113_From1Jan2020To31Dec2020_IL" decimals="2">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c114_From1Jan2020To31Dec2020_MinimumMember_KR" decimals="2">0.10</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c115_From1Jan2020To31Dec2020_MaximumMember_KR" decimals="2">0.25</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes unitRef="pure" contextRef="c116_From1Jan2020To31Dec2020_KR" decimals="2">0.10</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c117_From1Jan2020To31Dec2020_JP" decimals="4">0.3359</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">3262000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;b&gt;NOTE
10 - RELATED PARTIES - TRANSACTIONS AND BALANCES:&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Balances with related parties:&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;(U.S. Dollars in thousands)&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding: 0 0 4pt; width: 76%; text-align: left; text-indent: 0&quot;&gt;Related party accrued liability&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; width: 1%; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;72&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; width: 1%; text-align: left; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding: 0 0 4pt; text-align: left; text-indent: 0&quot;&gt;Related party liability, refer to note 6&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; text-align: left; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;17,748&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; text-align: left; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Related parties transactions:&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2018&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left; padding-bottom: 4pt&quot;&gt;Research and development &amp;#x2013; see c and d below&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right&quot;&gt;355&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right&quot;&gt;154&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right&quot;&gt;542&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;General and administrative &amp;#x2013; See c, e and f below&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(167&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5,824&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;892&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Six-Eye Interactive agreements for services &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;On June 1 2015, Nanox PLC entered
into a consulting agreement with Six-Eye, a company owned by Ran Poliakine, the Company&amp;#x2019;s CEO and one of major shareholders, pursuant
to which Ran Poliakine agreed to provide services as Chief Strategy Officer and a member of the Executive Committee to Nanox PLC.
On May 1, 2017, Nanox PLC entered into a services agreement with Six-Eye for the supply of ongoing services, which include research
and development services, general and financial management (including accountancy), office management services and operational
and supply services. According to the agreement between the parties, Nanox PLC reimburses Six-Eye for its actual direct expenses
plus a 12% surplus charge. The agreements were terminated in September 2019. During the years ended December 31 2019 and 2018 the
total expenses to Six-Eye were $679 thousand and $1,434 thousand, respectively. In addition to the services provided by Six-Eye
during 2019, Six-Eye also paid directly to third-party consultants and suppliers on behalf of the Company in the amount of approximately
$1,015 thousand prior to the completion of the Company&amp;#x2019;s equity financing.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;d.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;SixAI Ltd Service agreement&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;On April 16,2020, the Company
entered into an agreement with SixAI Ltd. (hereinafter-&amp;#x201c;SixAI&amp;#x201d;) a company controlled by Ran Poliakine, the Company&amp;#x2019;s
CEO for certain software development and mechanical engineering services. The service agreement is effective as of March 1, 2020
and has been extended by mutual agreement of the parties to March 31, 2021. During the year ended December 31, 2020, the Company
recorded an expense of $355 thousand. Mr. Poliakine currently serves as a member of the board of directors of SixAI and Mr. Poliakine
is a significant shareholder of SixAI.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;e.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Illumigyn Ltd. &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Illumigyn Ltd (hereinafter
&amp;#x2013; &amp;#x201c;Illumigyn&amp;#x201d;) is a company in which Ran Poliakine, the Company&amp;#x2019;s CEO, is a significant shareholder primarily through
indirect holdings. Since November 1 2019, Illumigyn sub-leased in transaction approximately 1,800 square feet of private office
space, including access to shared public spaces, from the office spaces which the Company leases in Neve Ilan, Israel. Illumigyn
pays approximately $12 thousand per month. During the year ended December 31, 2020, the Company received approximately $163 thousand
in relation to the sub lease.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;f.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Wellsese Technologies Ltd.&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Wellsense
Technologies Ltd (hereinafter &amp;#x2013; &amp;#x201c;Wellsense&amp;#x201d;) is a company in which Ran Poliakine, the Company&amp;#x2019;s CEO, and Richard
Stone, a member of the Company&amp;#x2019;s board of directors, are shareholders. Since February 2020, Wellsense has sub-leased private
office space, including access to shared public spaces, from the Company in Neve Ilan, Israel. Wellsense pays approximately $7.0
thousand per month. During the year ended December 31, 2020, the Company received $59 thousand, in relation to the sub lease.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;g.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;Pursuant to the Asset Purchase Agreement between Nanox IL and Nanox PLC, as of December 31, 2020,
the Company has settled the related party liability balance of $192 thousand to Nanox Japan and Nanox PLC, mainly for Fixed Assets
which were transferred to the Company as part of the APA.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <nnox:ExecutiveEmploymentAgreementDescription contextRef="c118_From15May2015To1Jun2015_RanPoliakineMember">On June 1 2015, Nanox PLC entered into a consulting agreement with Six-Eye, a company owned by Ran Poliakine, the Company&amp;#x2019;s CEO and one of major shareholders, pursuant to which Ran Poliakine agreed to provide services as Chief Strategy Officer and a member of the Executive Committee to Nanox PLC.</nnox:ExecutiveEmploymentAgreementDescription>
  <nnox:SurplusChargePercentage unitRef="pure" contextRef="c119_AsOf1May2017_SixEyeInteractiveMember" decimals="2">0.12</nnox:SurplusChargePercentage>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty unitRef="usd" contextRef="c120_From1Jan2019To31Dec2019_SixEyeInteractiveMember" decimals="-3">679000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTaxExpenseDueToAffiliatesDeferred unitRef="usd" contextRef="c4_From1Jan2018To31Dec2018" decimals="-3">1434000</us-gaap:RelatedPartyTaxExpenseDueToAffiliatesDeferred>
  <us-gaap:ProfessionalFees unitRef="usd" contextRef="c3_From1Jan2019To31Dec2019" decimals="-3">1015000</us-gaap:ProfessionalFees>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty unitRef="usd" contextRef="c121_From1Jan2020To31Dec2020_SixAILtdMember" decimals="-3">355000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <nnox:OfficeSpaceDescription contextRef="c0_From1Jan2020To31Dec2020">Since November 1 2019, Illumigyn sub-leased in transaction approximately 1,800 square feet of private office space, including access to shared public spaces, from the office spaces which the Company leases in Neve Ilan, Israel.</nnox:OfficeSpaceDescription>
  <us-gaap:PaymentsForRent unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-3">12000</us-gaap:PaymentsForRent>
  <us-gaap:LoansAndLeasesReceivableRelatedParties unitRef="usd" contextRef="c1_AsOf31Dec2020" decimals="-3">163000</us-gaap:LoansAndLeasesReceivableRelatedParties>
  <us-gaap:RelatedPartyCosts unitRef="usd" contextRef="c122_From1Jan2020To31Dec2020_WellseseTechnologiesLtdMember" decimals="-2">7000</us-gaap:RelatedPartyCosts>
  <us-gaap:SubleaseIncome unitRef="usd" contextRef="c122_From1Jan2020To31Dec2020_WellseseTechnologiesLtdMember" decimals="-3">59000</us-gaap:SubleaseIncome>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c123_AsOf31Dec2020_NanoxPLCMember" decimals="-3">192000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;(U.S. Dollars in thousands)&lt;/td&gt;&lt;td style=&quot;padding: 0 0 1.5pt; font-weight: bold; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding: 0 0 4pt; width: 76%; text-align: left; text-indent: 0&quot;&gt;Related party accrued liability&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; width: 1%; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;72&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; width: 1%; text-align: left; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding: 0 0 4pt; text-align: left; text-indent: 0&quot;&gt;Related party liability, refer to note 6&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; text-align: left; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0&quot;&gt;17,748&lt;/td&gt;&lt;td style=&quot;padding: 0 0 4pt; text-align: left; text-indent: 0&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
  <nnox:ScheduleOfRelatedPartiesTransactionsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2018&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;(U.S. Dollars in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left; padding-bottom: 4pt&quot;&gt;Research and development &amp;#x2013; see c and d below&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right&quot;&gt;355&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right&quot;&gt;154&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; width: 9%; text-align: right&quot;&gt;542&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;General and administrative &amp;#x2013; See c, e and f below&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(167&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5,824&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;892&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</nnox:ScheduleOfRelatedPartiesTransactionsTableTextBlock>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" contextRef="c104_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember" decimals="-3">355000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" contextRef="c105_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember" decimals="-3">154000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" contextRef="c106_From1Jan2018To31Dec2018_ResearchAndDevelopmentExpenseMember" decimals="-3">542000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" contextRef="c124_From1Jan2020To31Dec2020_GeneralAndAdministrativeExpenseMember" decimals="-3">-167000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" contextRef="c125_From1Jan2019To31Dec2019_GeneralAndAdministrativeExpenseMember" decimals="-3">5824000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" contextRef="c126_From1Jan2018To31Dec2018_GeneralAndAdministrativeExpenseMember" decimals="-3">892000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:EarningsPerShareTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;b&gt;NOTE
11 &lt;/b&gt;- &lt;b&gt;LOSS PER SHARE:&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Basic&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;Basic loss
per share is calculated by dividing the loss attributable to the Company&amp;#x2019;s owners by the weighted average number of ordinary
shares in issue.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2018&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left; padding-bottom: 1.5pt&quot;&gt;Net loss attributable to Company&amp;#x2019;s owners&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: right&quot;&gt;(43,815&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: right&quot;&gt;(22,563&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: right&quot;&gt;(1,909&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;The weighted average of the number of ordinary shares (in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;35,654&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;25,181&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;20,793&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-weight: bold; text-align: left; padding-bottom: 4pt&quot;&gt;Basic and diluted loss per share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(1.23&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.90&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.09&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;For the calculation
of loss per share, the Company used the net loss attributable to Company&amp;#x2019;s owners divided by the weighted average number
of the Company&amp;#x2019;s ordinary shares for the years ended December 31, 2020, 2019 and 2018.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;b&gt;Diluted&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left&quot;&gt;As of December 31, 20&lt;font style=&quot;font-family: Georgia, Times, Serif&quot;&gt;20&lt;/font&gt;
and 201&lt;font style=&quot;font-family: Georgia, Times, Serif&quot;&gt;9&lt;/font&gt; the Company had 7,846,290 and 9,203,124 investor warrants and
employees and non-employees option awards, respectively. These warrants and awards were not taken into account when calculating
diluted loss per share since their effect is anti-dilutive.&lt;/p&gt;&lt;br/&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ProceedsFromIssuanceOfWarrants unitRef="usd" contextRef="c127_From1Jan2020To31Dec2020_EmployeebMember" decimals="0">7846290</us-gaap:ProceedsFromIssuanceOfWarrants>
  <nnox:WarrantsOptionAwardsOutstanding unitRef="shares" contextRef="c128_AsOf31Dec2019_NonEmployeeMember" decimals="INF">9203124</nnox:WarrantsOptionAwardsOutstanding>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;10&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Year ended December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2018&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 64%; text-align: left; padding-bottom: 1.5pt&quot;&gt;Net loss attributable to Company&amp;#x2019;s owners&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: right&quot;&gt;(43,815&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: right&quot;&gt;(22,563&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; width: 9%; text-align: right&quot;&gt;(1,909&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt&quot;&gt;The weighted average of the number of ordinary shares (in thousands)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;35,654&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;25,181&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;20,793&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-weight: bold; text-align: left; padding-bottom: 4pt&quot;&gt;Basic and diluted loss per share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(1.23&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.90&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;(0.09&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left&quot;&gt;&lt;b&gt;NOTE
12 - SUBSEQUENT EVENTS:&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;During 2021, the Company granted a total of 338,929 awards with an average exercise price of $48.59
per share to employees.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;tr style=&quot;vertical-align: top&quot;&gt;
&lt;td style=&quot;width: 0.75in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in&quot;&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;In February 2021 the Company completed a secondary offering of 3,091,635 ordinary shares by certain
non-director, non-officer selling pre-IPO shareholders. An additional 845,044 shares were locked up for an additional period as
part of the agreed terms. The Company cooperated with the offering lead underwriter while each participating shareholder paid the
underwriters fees and the Company covered the legal, accounting, administrative and regulatory fees which totaled approximately
$818 thousand. The Company received no proceeds from the described above public secondary offering.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod unitRef="shares" contextRef="c129_From5Jan2021To31Jan2021_SubsequentEventMember" decimals="INF">338929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c130_AsOf31Jan2021_SubsequentEventMember" decimals="2">48.59</us-gaap:SaleOfStockPricePerShare>
  <nnox:IssuanceAndAllotmentShares unitRef="shares" contextRef="c131_From18Feb2021To28Feb2021_SubsequentEventMember" decimals="INF">3091635</nnox:IssuanceAndAllotmentShares>
  <nnox:ShareBasedCompensationGrantedForService unitRef="shares" contextRef="c131_From18Feb2021To28Feb2021_SubsequentEventMember" decimals="INF">845044</nnox:ShareBasedCompensationGrantedForService>
  <us-gaap:AdministrativeFeesExpense unitRef="usd" contextRef="c131_From18Feb2021To28Feb2021_SubsequentEventMember" decimals="-3">818000</us-gaap:AdministrativeFeesExpense>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>nnox-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 06 12:29:48 EDT 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://www.nanox.vision.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nnox="http://www.nanox.vision.com/20201231" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="nnox-20201231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nnox-20201231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nnox-20201231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nnox-20201231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet" id="nnox_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals" id="nnox_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement" id="nnox_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ShareholdersEquityType2or3" id="nnox_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statement of Changes in Shareholders&#8217; Equity (capital Deficiency)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ConsolidatedCashFlow" id="nnox_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/General" id="nnox_r_General">
        <link:definition>006 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SignificantAccountingPolicies" id="nnox_r_SignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNet" id="nnox_r_PropertyandEquipmentNet">
        <link:definition>008 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash" id="nnox_r_CashCashEquivalentsandRestrictedCash">
        <link:definition>009 - Disclosure - Cash, Cash Equivalents and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/Leases" id="nnox_r_Leases">
        <link:definition>010 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/RelatedPartyLiability" id="nnox_r_RelatedPartyLiability">
        <link:definition>011 - Disclosure - Related Party Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/CommitmentsandContingencies" id="nnox_r_CommitmentsandContingencies">
        <link:definition>012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ShareholdersEquity" id="nnox_r_ShareholdersEquity">
        <link:definition>013 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/IncomeTax" id="nnox_r_IncomeTax">
        <link:definition>014 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalances" id="nnox_r_RelatedPartiesTransactionsandBalances">
        <link:definition>015 - Disclosure - Related Parties - Transactions and Balances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LossPerShare" id="nnox_r_LossPerShare">
        <link:definition>016 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SubsequentEvents" id="nnox_r_SubsequentEvents">
        <link:definition>017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/AccountingPoliciesByPolicy" id="nnox_r_AccountingPoliciesByPolicy">
        <link:definition>018 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables" id="nnox_r_SignificantAccountingPoliciesTables">
        <link:definition>019 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetTables" id="nnox_r_PropertyandEquipmentNetTables">
        <link:definition>020 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables" id="nnox_r_CashCashEquivalentsandRestrictedCashTables">
        <link:definition>021 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LeasesTables" id="nnox_r_LeasesTables">
        <link:definition>022 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ShareholdersEquityTables" id="nnox_r_ShareholdersEquityTables">
        <link:definition>023 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesTables" id="nnox_r_RelatedPartiesTransactionsandBalancesTables">
        <link:definition>024 - Disclosure - Related Parties - Transactions and Balances (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LossPerShareTables" id="nnox_r_LossPerShareTables">
        <link:definition>025 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/GeneralDetails" id="nnox_r_GeneralDetails">
        <link:definition>026 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails" id="nnox_r_SignificantAccountingPoliciesDetails">
        <link:definition>027 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable" id="nnox_r_ScheduleofpropertyandequipmentTable">
        <link:definition>028 - Disclosure - Significant Accounting Policies (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails" id="nnox_r_PropertyandEquipmentNetDetails">
        <link:definition>029 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0" id="nnox_r_ScheduleofpropertyandequipmentTable0">
        <link:definition>030 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable" id="nnox_r_ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable">
        <link:definition>031 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LeasesDetails" id="nnox_r_LeasesDetails">
        <link:definition>032 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable" id="nnox_r_ScheduleofcompanystotalleasecostsTable">
        <link:definition>033 - Disclosure - Leases (Details) - Schedule of company's total lease costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable" id="nnox_r_ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable">
        <link:definition>034 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable" id="nnox_r_ScheduleofsupplementalbalancesheetinformationTable">
        <link:definition>035 - Disclosure - Leases (Details) - Schedule of supplemental balance sheet information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable" id="nnox_r_ScheduleofmaturitiesofoperatingleaseliabilitiesTable">
        <link:definition>036 - Disclosure - Leases (Details) - Schedule of maturities of operating lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/RelatedPartyLiabilityDetails" id="nnox_r_RelatedPartyLiabilityDetails">
        <link:definition>037 - Disclosure - Related Party Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nIPpN2lKEuYCUI09N/Lg5fLZ/Jooq7WY3vjnqJRpjb6jZqCaBUUFGxW7cfKXOabJw5eGbn/VcawsWaAshx1PaHoM/OHV30jj0wwDQLMupnstLNtT+LPrWxgK6qr3JCLuWA==] CSR-->
      <link:roleType roleURI="http://www.nanox.vision.com/role/ShareholdersEquityDetails" id="nnox_r_ShareholdersEquityDetails">
        <link:definition>038 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedpaymentstononemployeesTable" id="nnox_r_ScheduleofsharebasedpaymentstononemployeesTable">
        <link:definition>039 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based payments to non-employees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" id="nnox_r_ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable">
        <link:definition>040 - Disclosure - Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable" id="nnox_r_ScheduleofinformationconcerningoutstandingandexercisableawardsTable">
        <link:definition>041 - Disclosure - Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable" id="nnox_r_ScheduleofsharedbasedpaymentstoemployeesTable">
        <link:definition>042 - Disclosure - Shareholders' Equity (Details) - Schedule of shared - based payments to employees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofBlackScholesoptionpricingmodelTable" id="nnox_r_ScheduleofBlackScholesoptionpricingmodelTable">
        <link:definition>043 - Disclosure - Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable0" id="nnox_r_ScheduleofinformationconcerningoutstandingandexercisableawardsTable0">
        <link:definition>044 - Disclosure - Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationTable" id="nnox_r_ScheduleofsharebasedcompensationTable">
        <link:definition>045 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/IncomeTaxDetails" id="nnox_r_IncomeTaxDetails">
        <link:definition>046 - Disclosure - Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesDetails" id="nnox_r_RelatedPartiesTransactionsandBalancesDetails">
        <link:definition>047 - Disclosure - Related Parties - Transactions and Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofbalanceswithrelatedpartiesTable" id="nnox_r_ScheduleofbalanceswithrelatedpartiesTable">
        <link:definition>048 - Disclosure - Related Parties - Transactions and Balances (Details) - Schedule of balances with related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable" id="nnox_r_ScheduleofrelatedpartiestransactionsTable">
        <link:definition>049 - Disclosure - Related Parties - Transactions and Balances (Details) - Schedule of related parties transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LossPerShareDetails" id="nnox_r_LossPerShareDetails">
        <link:definition>050 - Disclosure - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable" id="nnox_r_ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable">
        <link:definition>051 - Disclosure - Loss Per Share (Details) - Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SubsequentEventsDetails" id="nnox_r_SubsequentEventsDetails">
        <link:definition>052 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="CashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="ScheduleOfCompanysTotalLeaseCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract"/>
  <xs:element name="ScheduleOfSupplementalBalanceSheetInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract"/>
  <xs:element name="RelatedPartyLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RelatedPartyLiabilityAbstract"/>
  <xs:element name="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract"/>
  <xs:element name="ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract"/>
  <xs:element name="ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract"/>
  <xs:element name="ScheduleOfSharedBasedPaymentsToEmployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract"/>
  <xs:element name="ScheduleOfBlackScholesOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfBlackScholesOptionPricingModelAbstract"/>
  <xs:element name="ScheduleOfShareBasedCompensationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfShareBasedCompensationAbstract"/>
  <xs:element name="ScheduleOfBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfRelatedPartiesTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfRelatedPartiesTransactionsAbstract"/>
  <xs:element name="ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract"/>
  <xs:element name="OperatingLeaseCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OperatingLeaseCostAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract"/>
  <xs:element name="OperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OperatingLeasesAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_WeightedAverageDiscountRateAbstract"/>
  <xs:element name="ChangesDuringTheYearAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ChangesDuringTheYearAbstract"/>
  <xs:element name="ChangesDuringTheYearAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ChangesDuringTheYearAbstract0"/>
  <xs:element name="RelatedPartyLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_RelatedPartyLiabilities"/>
  <xs:element name="IssuanceOfOrdinaryShareReservedForFutureIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance"/>
  <xs:element name="IssuanceOfOrdinarySharesReservedForFutureIssuanceShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares"/>
  <xs:element name="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
  <xs:element name="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares"/>
  <xs:element name="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants"/>
  <xs:element name="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares"/>
  <xs:element name="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6"/>
  <xs:element name="IncreaseDecreaseRelatedPartyPrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses"/>
  <xs:element name="IncreaseDecreaseOperatingLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncreaseDecreaseOperatingLease"/>
  <xs:element name="ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
  <xs:element name="UnpaidOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_UnpaidOfferingCosts"/>
  <xs:element name="issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants"/>
  <xs:element name="RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities"/>
  <xs:element name="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements"/>
  <xs:element name="ConversionOfRelatedPartyLiabilityToShareholdersEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity"/>
  <xs:element name="CashEquivalentsAndRestrictedCashTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CashEquivalentsAndRestrictedCashTextBlock"/>
  <xs:element name="RelatedPartyLiabilityTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RelatedPartyLiabilityTextBlock"/>
  <xs:element name="SeverancePayPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SeverancePayPolicyTextBlock"/>
  <xs:element name="LegalAndOtherContingenciesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_LegalAndOtherContingenciesPolicyTextBlock"/>
  <xs:element name="DeferredOfferingCostsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DeferredOfferingCostsPolicyTextBlock"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock"/>
  <xs:element name="ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
  <xs:element name="ScheduleOfWarrantsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfWarrantsTableTextBlock"/>
  <xs:element name="ShareholdersEquityTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityTablesTable"/>
  <xs:element name="ShareholdersEquityTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityTablesLineItems"/>
  <xs:element name="ScheduleOfRelatedPartiesTransactionsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
  <xs:element name="PropertyPlantAndEquipmentSalvageValuePercentageDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription"/>
  <xs:element name="MajorPropertyClass_Domain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_MajorPropertyClass_Domain"/>
  <xs:element name="TotalOperatingLeaseCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_TotalOperatingLeaseCost"/>
  <xs:element name="CurrentMaturitiesOfOperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_CurrentMaturitiesOfOperatingLeases"/>
  <xs:element name="NoncurrentOperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_NoncurrentOperatingLeases"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems"/>
  <xs:element name="AwardsOutstandingNumberOfAwardsOutstandingBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
  <xs:element name="AwardsOutstandingWeightedAverageRemainingContractualLifeyears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockOptionsForfeited" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited"/>
  <xs:element name="NumberOfSharebasedPaymentAwardsCancelled" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NumberOfSharebasedPaymentAwardsCancelled"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofsharebasedcompensationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems"/>
  <xs:element name="RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable"/>
  <xs:element name="RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems"/>
  <xs:element name="GeneralDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_GeneralDetailsTable"/>
  <xs:element name="GeneralDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_GeneralDetailsLineItems"/>
  <xs:element name="InitialPublicOfferingNetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_InitialPublicOfferingNetProceeds"/>
  <xs:element name="CashConsiderationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CashConsiderationDescription"/>
  <xs:element name="LeaseTermDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_LeaseTermDescription"/>
  <xs:element name="LeasesTermDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_LeasesTermDescription"/>
  <xs:element name="VehicleLeasePayments" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_VehicleLeasePayments"/>
  <xs:element name="PurchaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_PurchaseAgreementDescription"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="IssuanceOfOrdinarySharesReservedForFutureIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance"/>
  <xs:element name="OrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OrdinaryShares"/>
  <xs:element name="IncreasedAnCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncreasedAnCommonStockValue"/>
  <xs:element name="NetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_NetProceeds"/>
  <xs:element name="PercentageOfDiscountPrice" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_PercentageOfDiscountPrice"/>
  <xs:element name="OrdinarySharesReservedUnderTheESOP" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_OrdinarySharesReservedUnderTheESOP"/>
  <xs:element name="OrdinaryStockParOrStatedValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_OrdinaryStockParOrStatedValuePerShare"/>
  <xs:element name="NumberOfExercisedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NumberOfExercisedShares"/>
  <xs:element name="DescriptionOfSharebasedCompensationExpenses" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DescriptionOfSharebasedCompensationExpenses"/>
  <xs:element name="IncomeTaxDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_IncomeTaxDetailsTable"/>
  <xs:element name="IncomeTaxDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncomeTaxDetailsLineItems"/>
  <xs:element name="RelatedPartiesTransactionsandBalancesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_RelatedPartiesTransactionsandBalancesDetailsTable"/>
  <xs:element name="RelatedPartiesTransactionsandBalancesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems"/>
  <xs:element name="ExecutiveEmploymentAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ExecutiveEmploymentAgreementDescription"/>
  <xs:element name="SurplusChargePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_SurplusChargePercentage"/>
  <xs:element name="OfficeSpaceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OfficeSpaceDescription"/>
  <xs:element name="LossPerShareDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_LossPerShareDetailsTable"/>
  <xs:element name="LossPerShareDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_LossPerShareDetailsLineItems"/>
  <xs:element name="WarrantsOptionAwardsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_WarrantsOptionAwardsOutstanding"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SubsequentEventsDetailsLineItems"/>
  <xs:element name="IssuanceAndAllotmentShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceAndAllotmentShares"/>
  <xs:element name="ShareBasedCompensationGrantedForService" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareBasedCompensationGrantedForService"/>
  <xs:element name="EmployeebMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_EmployeebMember"/>
  <xs:element name="EmployeesOfficersAndDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_EmployeesOfficersAndDirectorsMember"/>
  <xs:element name="EquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_EquityIncentivePlanMember"/>
  <xs:element name="ExercisePricesFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ExercisePricesFiveMember"/>
  <xs:element name="ExercisePricesFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ExercisePricesFourMember"/>
  <xs:element name="ExercisePricesOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ExercisePricesOneMember"/>
  <xs:element name="ExercisePricesSevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ExercisePricesSevenMember"/>
  <xs:element name="ExercisePricesSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ExercisePricesSixMember"/>
  <xs:element name="ExercisePricesThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ExercisePricesThreeMember"/>
  <xs:element name="ExercisePricesTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ExercisePricesTwoMember"/>
  <xs:element name="LandSeeBBelowMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_LandSeeBBelowMember"/>
  <xs:element name="NanoxPLCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NanoxPLCMember"/>
  <xs:element name="NasdaqMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NasdaqMember"/>
  <xs:element name="NonEmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NonEmployeeMember"/>
  <xs:element name="PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember"/>
  <xs:element name="RanPoliakineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RanPoliakineMember"/>
  <xs:element name="SixAILtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SixAILtdMember"/>
  <xs:element name="SixEyeInteractiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SixEyeInteractiveMember"/>
  <xs:element name="WellseseTechnologiesLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_WellseseTechnologiesLtdMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>nnox-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 06 12:29:48 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedBalanceSheet" roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedIncomeStatement" roleURI="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedCashFlow" roleURI="http://www.nanox.vision.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable" roleURI="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofcompanystotalleasecostsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DeferredOfferingCosts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilities" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="nnox_RelatedPartyLiabilities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nIPpN2lKEuYCUI09N/Lg5fLZ/Jooq7WY3vjnqJRpjb6jZqCaBUUFGxW7cfKXOabJw5eGbn/VcawsWaAshx1PaHoM/OHV30jj0wwDQLMupnstb3f6yonD+k38579JCQQH7w==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseOperatingLease" xlink:href="nnox-20201231.xsd#nnox_IncreaseDecreaseOperatingLease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nnox_IncreaseDecreaseOperatingLease" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:href="nnox-20201231.xsd#nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20201231.xsd#nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable">
    <loc xlink:type="locator" xlink:label="nnox_TotalOperatingLeaseCost" xlink:href="nnox-20201231.xsd#nnox_TotalOperatingLeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nnox_TotalOperatingLeaseCost" xlink:to="us-gaap_LeaseCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nnox_TotalOperatingLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>nnox-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 06 12:29:48 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedBalanceSheet" roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedIncomeStatement" roleURI="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ShareholdersEquityType2or3" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedCashFlow" roleURI="http://www.nanox.vision.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_General" roleURI="http://www.nanox.vision.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_SignificantAccountingPolicies" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_PropertyandEquipmentNet" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_CashCashEquivalentsandRestrictedCash" roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_Leases" roleURI="http://www.nanox.vision.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_RelatedPartyLiability" roleURI="http://www.nanox.vision.com/role/RelatedPartyLiability"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_CommitmentsandContingencies" roleURI="http://www.nanox.vision.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ShareholdersEquity" roleURI="http://www.nanox.vision.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_IncomeTax" roleURI="http://www.nanox.vision.com/role/IncomeTax"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_RelatedPartiesTransactionsandBalances" roleURI="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalances"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_LossPerShare" roleURI="http://www.nanox.vision.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_SubsequentEvents" roleURI="http://www.nanox.vision.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_AccountingPoliciesByPolicy" roleURI="http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_SignificantAccountingPoliciesTables" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_PropertyandEquipmentNetTables" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_LeasesTables" roleURI="http://www.nanox.vision.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ShareholdersEquityTables" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_RelatedPartiesTransactionsandBalancesTables" roleURI="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_LossPerShareTables" roleURI="http://www.nanox.vision.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofpropertyandequipmentTable" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofpropertyandequipmentTable0" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable" roleURI="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofcompanystotalleasecostsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofsupplementalbalancesheetinformationTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofmaturitiesofoperatingleaseliabilitiesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofsharebasedpaymentstononemployeesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedpaymentstononemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofinformationconcerningoutstandingandexercisableawardsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofsharedbasedpaymentstoemployeesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofBlackScholesoptionpricingmodelTable" roleURI="http://www.nanox.vision.com/role/ScheduleofBlackScholesoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofinformationconcerningoutstandingandexercisableawardsTable0" roleURI="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofsharebasedcompensationTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofbalanceswithrelatedpartiesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofbalanceswithrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofrelatedpartiestransactionsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable" roleURI="http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_GeneralDetails" roleURI="http://www.nanox.vision.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_SignificantAccountingPoliciesDetails" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_PropertyandEquipmentNetDetails" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_LeasesDetails" roleURI="http://www.nanox.vision.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_RelatedPartyLiabilityDetails" roleURI="http://www.nanox.vision.com/role/RelatedPartyLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ShareholdersEquityDetails" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_IncomeTaxDetails" roleURI="http://www.nanox.vision.com/role/IncomeTaxDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_RelatedPartiesTransactionsandBalancesDetails" roleURI="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_LossPerShareDetails" roleURI="http://www.nanox.vision.com/role/LossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_SubsequentEventsDetails" roleURI="http://www.nanox.vision.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#DocumentAndEntityInformation" roleURI="http://www.nanox.vision.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilities" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="nnox_RelatedPartyLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" xlink:href="nnox-20201231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:href="nnox-20201231.xsd#nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseOperatingLease" xlink:href="nnox-20201231.xsd#nnox_IncreaseDecreaseOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="nnox_IncreaseDecreaseOperatingLease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20201231.xsd#nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_UnpaidOfferingCosts" xlink:href="nnox-20201231.xsd#nnox_UnpaidOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_UnpaidOfferingCosts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:href="nnox-20201231.xsd#nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:href="nnox-20201231.xsd#nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:href="nnox-20201231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:href="nnox-20201231.xsd#nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash">
    <loc xlink:type="locator" xlink:label="nnox_CashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20201231.xsd#nnox_CashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_CashEquivalentsAndRestrictedCashTextBlock" xlink:href="nnox-20201231.xsd#nnox_CashEquivalentsAndRestrictedCashTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CashEquivalentsAndRestrictedCashAbstract" xlink:to="nnox_CashEquivalentsAndRestrictedCashTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartyLiability">
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilityAbstract" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilityTextBlock" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilityTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartyLiabilityAbstract" xlink:to="nnox_RelatedPartyLiabilityTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/IncomeTax">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalances">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_SeverancePayPolicyTextBlock" xlink:href="nnox-20201231.xsd#nnox_SeverancePayPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nnox_SeverancePayPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LegalAndOtherContingenciesPolicyTextBlock" xlink:href="nnox-20201231.xsd#nnox_LegalAndOtherContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nnox_LegalAndOtherContingenciesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredOfferingCostsPolicyTextBlock" xlink:href="nnox-20201231.xsd#nnox_DeferredOfferingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nnox_DeferredOfferingCostsPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables">
    <loc xlink:type="locator" xlink:label="nnox_CashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20201231.xsd#nnox_CashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityTablesLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityTablesTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="nnox_ShareholdersEquityTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityTablesTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_EmployeesOfficersAndDirectorsMember" xlink:href="nnox-20201231.xsd#nnox_EmployeesOfficersAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nnox_EmployeesOfficersAndDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfWarrantsTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfWarrantsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="nnox_ScheduleOfWarrantsTableTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:href="nnox-20201231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:href="nnox-20201231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:href="nnox-20201231.xsd#nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorPropertyClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorPropertyClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_MajorPropertyClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_MajorPropertyClass_Domain" xlink:href="nnox-20201231.xsd#nnox_MajorPropertyClass_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="nnox_MajorPropertyClass_Domain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_MajorPropertyClass_Domain_0" xlink:href="nnox-20201231.xsd#nnox_MajorPropertyClass_Domain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="nnox_MajorPropertyClass_Domain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_MajorPropertyClass_Domain" xlink:to="us-gaap_OfficeEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_MajorPropertyClass_Domain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_MajorPropertyClass_Domain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_MajorPropertyClass_Domain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LandSeeBBelowMember" xlink:href="nnox-20201231.xsd#nnox_LandSeeBBelowMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_MajorPropertyClass_Domain" xlink:to="nnox_LandSeeBBelowMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember" xlink:href="nnox-20201231.xsd#nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_MajorPropertyClass_Domain" xlink:to="nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfCompanysTotalLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_OperatingLeaseCostAbstract" xlink:href="nnox-20201231.xsd#nnox_OperatingLeaseCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:to="nnox_OperatingLeaseCostAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OperatingLeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OperatingLeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_TotalOperatingLeaseCost" xlink:href="nnox-20201231.xsd#nnox_TotalOperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:to="nnox_TotalOperatingLeaseCost" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="nnox-20201231.xsd#nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:href="nnox-20201231.xsd#nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_OperatingLeasesAbstract" xlink:href="nnox-20201231.xsd#nnox_OperatingLeasesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="nnox_OperatingLeasesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_CurrentMaturitiesOfOperatingLeases" xlink:href="nnox-20201231.xsd#nnox_CurrentMaturitiesOfOperatingLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OperatingLeasesAbstract" xlink:to="nnox_CurrentMaturitiesOfOperatingLeases" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NoncurrentOperatingLeases" xlink:href="nnox-20201231.xsd#nnox_NoncurrentOperatingLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OperatingLeasesAbstract" xlink:to="nnox_NoncurrentOperatingLeases" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_WeightedAverageRemainingLeaseTermAbstract" xlink:href="nnox-20201231.xsd#nnox_WeightedAverageRemainingLeaseTermAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="nnox_WeightedAverageRemainingLeaseTermAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_WeightedAverageDiscountRateAbstract" xlink:href="nnox-20201231.xsd#nnox_WeightedAverageDiscountRateAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="nnox_WeightedAverageDiscountRateAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeaseLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nIPpN2lKEuYCUI09N/Lg5fLZ/Jooq7WY3vjnqJRpjb6jZqCaBUUFGxW7cfKXOabJw5eGbn/VcawsWaAshx1PaHoM/OHV30jj0wwDQLMupnstPpDNWchKWan+0vzXG7i1cg==] CSR-->
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharebasedpaymentstononemployeesTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesOneMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ExercisePricesOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesTwoMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ExercisePricesTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesThreeMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ExercisePricesThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesFourMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ExercisePricesFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesFiveMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ExercisePricesFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesSixMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ExercisePricesSixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesSevenMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ExercisePricesSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:href="nnox-20201231.xsd#nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ChangesDuringTheYearAbstract0" xlink:href="nnox-20201231.xsd#nnox_ChangesDuringTheYearAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_ChangesDuringTheYearAbstract0" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited" xlink:href="nnox-20201231.xsd#nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NumberOfSharebasedPaymentAwardsCancelled" xlink:href="nnox-20201231.xsd#nnox_NumberOfSharebasedPaymentAwardsCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="nnox_NumberOfSharebasedPaymentAwardsCancelled" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofBlackScholesoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_EmployeesOfficersAndDirectorsMember" xlink:href="nnox-20201231.xsd#nnox_EmployeesOfficersAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nnox_EmployeesOfficersAndDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesOneMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ExercisePricesOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesTwoMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ExercisePricesTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesThreeMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ExercisePricesThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationTable">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofbalanceswithrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilities" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="nnox_RelatedPartyLiabilities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable">
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems" xlink:to="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="nnox_GeneralDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_GeneralDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_GeneralDetailsTable" xlink:href="nnox-20201231.xsd#nnox_GeneralDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="nnox_GeneralDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_GeneralDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NasdaqMember" xlink:href="nnox-20201231.xsd#nnox_NasdaqMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="nnox_NasdaqMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_InitialPublicOfferingNetProceeds" xlink:href="nnox-20201231.xsd#nnox_InitialPublicOfferingNetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="nnox_InitialPublicOfferingNetProceeds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_CashConsiderationDescription" xlink:href="nnox-20201231.xsd#nnox_CashConsiderationDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="nnox_CashConsiderationDescription" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_LeaseTermDescription" xlink:href="nnox-20201231.xsd#nnox_LeaseTermDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="nnox_LeaseTermDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeaseAndRentalExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LeasesTermDescription" xlink:href="nnox-20201231.xsd#nnox_LeasesTermDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="nnox_LeasesTermDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_VehicleLeasePayments" xlink:href="nnox-20201231.xsd#nnox_VehicleLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="nnox_VehicleLeasePayments" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartyLiabilityDetails">
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilityAbstract" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartyLiabilityAbstract" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PurchaseAgreementDescription" xlink:href="nnox-20201231.xsd#nnox_PurchaseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartyLiabilityAbstract" xlink:to="nnox_PurchaseAgreementDescription" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_EquityIncentivePlanMember" xlink:href="nnox-20201231.xsd#nnox_EquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nnox_EquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxPLCMember" xlink:href="nnox-20201231.xsd#nnox_NanoxPLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_NanoxPLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_EmployeesOfficersAndDirectorsMember" xlink:href="nnox-20201231.xsd#nnox_EmployeesOfficersAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nnox_EmployeesOfficersAndDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OrdinaryShares" xlink:href="nnox-20201231.xsd#nnox_OrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_OrdinaryShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromPreviousAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreasedAnCommonStockValue" xlink:href="nnox-20201231.xsd#nnox_IncreasedAnCommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_IncreasedAnCommonStockValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NetProceeds" xlink:href="nnox-20201231.xsd#nnox_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_NetProceeds" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PercentageOfDiscountPrice" xlink:href="nnox-20201231.xsd#nnox_PercentageOfDiscountPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_PercentageOfDiscountPrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OrdinarySharesReservedUnderTheESOP" xlink:href="nnox-20201231.xsd#nnox_OrdinarySharesReservedUnderTheESOP"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_OrdinarySharesReservedUnderTheESOP" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OrdinaryStockParOrStatedValuePerShare" xlink:href="nnox-20201231.xsd#nnox_OrdinaryStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_OrdinaryStockParOrStatedValuePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NumberOfExercisedShares" xlink:href="nnox-20201231.xsd#nnox_NumberOfExercisedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_NumberOfExercisedShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DescriptionOfSharebasedCompensationExpenses" xlink:href="nnox-20201231.xsd#nnox_DescriptionOfSharebasedCompensationExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_DescriptionOfSharebasedCompensationExpenses" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/IncomeTaxDetails">
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_IncomeTaxDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsTable" xlink:href="nnox-20201231.xsd#nnox_IncomeTaxDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="nnox_IncomeTaxDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_IncomeTaxDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_IncomeTaxDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KR" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KR" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesDetails">
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsTable" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="nnox_RelatedPartiesTransactionsandBalancesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_SixEyeInteractiveMember" xlink:href="nnox-20201231.xsd#nnox_SixEyeInteractiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nnox_SixEyeInteractiveMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_SixAILtdMember" xlink:href="nnox-20201231.xsd#nnox_SixAILtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nnox_SixAILtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_WellseseTechnologiesLtdMember" xlink:href="nnox-20201231.xsd#nnox_WellseseTechnologiesLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nnox_WellseseTechnologiesLtdMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxPLCMember" xlink:href="nnox-20201231.xsd#nnox_NanoxPLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nnox_NanoxPLCMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RanPoliakineMember" xlink:href="nnox-20201231.xsd#nnox_RanPoliakineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nnox_RanPoliakineMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ExecutiveEmploymentAgreementDescription" xlink:href="nnox-20201231.xsd#nnox_ExecutiveEmploymentAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="nnox_ExecutiveEmploymentAgreementDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_SurplusChargePercentage" xlink:href="nnox-20201231.xsd#nnox_SurplusChargePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="nnox_SurplusChargePercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_ProfessionalFees" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OfficeSpaceDescription" xlink:href="nnox-20201231.xsd#nnox_OfficeSpaceDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="nnox_OfficeSpaceDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_PaymentsForRent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_RelatedPartyCosts" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_SubleaseIncome" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShareDetails">
    <loc xlink:type="locator" xlink:label="nnox_LossPerShareDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_LossPerShareDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_LossPerShareDetailsTable" xlink:href="nnox-20201231.xsd#nnox_LossPerShareDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_LossPerShareDetailsLineItems" xlink:to="nnox_LossPerShareDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_LossPerShareDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_EmployeebMember" xlink:href="nnox-20201231.xsd#nnox_EmployeebMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nnox_EmployeebMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NonEmployeeMember" xlink:href="nnox-20201231.xsd#nnox_NonEmployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nnox_NonEmployeeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_LossPerShareDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_WarrantsOptionAwardsOutstanding" xlink:href="nnox-20201231.xsd#nnox_WarrantsOptionAwardsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_LossPerShareDetailsLineItems" xlink:to="nnox_WarrantsOptionAwardsOutstanding" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="nnox_SubsequentEventsDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_SubsequentEventsDetailsTable" xlink:href="nnox-20201231.xsd#nnox_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="nnox_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceAndAllotmentShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceAndAllotmentShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="nnox_IssuanceAndAllotmentShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareBasedCompensationGrantedForService" xlink:href="nnox-20201231.xsd#nnox_ShareBasedCompensationGrantedForService"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="nnox_ShareBasedCompensationGrantedForService" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdministrativeFeesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdministrativeFeesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_AdministrativeFeesExpense" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="22" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>nnox-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 06 12:29:48 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NON- CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">TOTAL OPERATING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss attributable to Company&#8217;s owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE YEAR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of property and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="nnox_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorPropertyClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorPropertyClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorPropertyClassAxis_lbl" xml:lang="en-US">Major Property Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MajorPropertyClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20201231.xsd#nnox_CashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Cash Equivalents And Restricted Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashEquivalentsAndRestrictedCashAbstract" xlink:to="nnox_CashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Schedule of reconciliation of cash, cash equivalents and restricted cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfCompanysTotalLeaseCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract_lbl" xml:lang="en-US">Schedule of company&apos;s total lease costs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:to="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TotalOperatingLeaseCost" xlink:href="nnox-20201231.xsd#nnox_TotalOperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="nnox_TotalOperatingLeaseCost_lbl" xml:lang="en-US">Total operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalOperatingLeaseCost" xlink:to="nnox_TotalOperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to operating leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract_lbl" xml:lang="en-US">Schedule of supplemental balance sheet information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of maturities of operating lease liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilityAbstract" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartyLiabilityAbstract_lbl" xml:lang="en-US">Related Party Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartyLiabilityAbstract" xlink:to="nnox_RelatedPartyLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract_lbl" xml:lang="en-US">Schedule of share-based payments to non-employees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of share-based payment awards, Outstanding at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of share-based payment awards, Outstanding at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Awards outstanding, Number of awards outstanding balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price, Outstanding at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract_lbl" xml:lang="en-US">Schedule of options valued using a Black-Scholes pricing model with assumptions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract" xlink:to="nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract_lbl" xml:lang="en-US">Schedule of information concerning outstanding and exercisable awards [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" xlink:to="nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract_lbl" xml:lang="en-US">Schedule of shared - based payments to employees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract" xlink:to="nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:href="nnox-20201231.xsd#nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:to="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl0" xml:lang="en-US">Weighted average exercise price, Outstanding at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:to="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer&apos;s Equity, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfBlackScholesOptionPricingModelAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfBlackScholesOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfBlackScholesOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule of Black-Scholes option-pricing model [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfBlackScholesOptionPricingModelAbstract" xlink:to="nnox_ScheduleOfBlackScholesOptionPricingModelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfShareBasedCompensationAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfShareBasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfShareBasedCompensationAbstract_lbl" xml:lang="en-US">Schedule of share-based compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfShareBasedCompensationAbstract" xlink:to="nnox_ScheduleOfShareBasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of balances with related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="nnox_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfRelatedPartiesTransactionsAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfRelatedPartiesTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfRelatedPartiesTransactionsAbstract_lbl" xml:lang="en-US">Schedule of related parties transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfRelatedPartiesTransactionsAbstract" xlink:to="nnox_ScheduleOfRelatedPartiesTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract_lbl" xml:lang="en-US">Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity (Capital Deficiency)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilities" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RelatedPartyLiabilities_lbl" xml:lang="en-US">Related party liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartyLiabilities" xlink:to="nnox_RelatedPartyLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nnox_RelatedPartyLiabilities_lbl0" xml:lang="en-US">Related party liability, refer to note 6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartyLiabilities" xlink:to="nnox_RelatedPartyLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Related party accrued liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary Shares, par value NIS 0.01 per share, 100,000,000 and 40,000,000 shares authorized at December 31, 2020 and 2019, respectively; 46,100,173 and 27,150,080 issued and outstanding at December 31, 2020 and 2019, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Basic and diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">THE WEIGHTED AVERAGE OF THE NUMBER OF ORDINARY SHARES (in thousands) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">The weighted average of the number of ordinary shares (in thousands)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">CHANGES DURING 2018:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl0" xml:lang="en-US">CHANGES DURING 2019:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1" xml:lang="en-US">CHANGES DURING 2020:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance_lbl" xml:lang="en-US">Issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance" xlink:to="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares_lbl" xml:lang="en-US">Issuance of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares" xlink:to="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of ordinary shares and warrants, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of ordinary shares and warrants, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of ordinary shares to employees and non-employees upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of ordinary shares to investors upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl" xml:lang="en-US">Issuance of ordinary shares to investors upon exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" xlink:href="nnox-20201231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6_lbl" xml:lang="en-US">Additional consideration with respect to an assets purchase agreement, see note 1c and note 6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Initial public offering of ordinary shares, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Ordinary shares, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Initial public offering of ordinary shares, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Ordinary shares, issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of related party liability to shareholders&#8217; equity, see note 8a</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of related party liability to shareholders&#8217; equity, see note 8a (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseOperatingLease" xlink:href="nnox-20201231.xsd#nnox_IncreaseDecreaseOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IncreaseDecreaseOperatingLease_lbl" xml:lang="en-US">Operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseOperatingLease" xlink:to="nnox_IncreaseDecreaseOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20201231.xsd#nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from issuance of ordinary shares and warrants, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:to="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from initial public offering of ordinary shares, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Initial public offering net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1" xml:lang="en-US">Net proceeds from IPO (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from issuance of ordinary shares upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_UnpaidOfferingCosts" xlink:href="nnox-20201231.xsd#nnox_UnpaidOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_UnpaidOfferingCosts_lbl" xml:lang="en-US">Unpaid offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_UnpaidOfferingCosts" xlink:to="nnox_UnpaidOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:href="nnox-20201231.xsd#nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl" xml:lang="en-US">issuance of ordinary shares to investor upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:to="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:href="nnox-20201231.xsd#nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liabilities arising from obtaining operating right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:to="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:href="nnox-20201231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl" xml:lang="en-US">Additional consideration with respect to an assets purchase purchase agreement, see note 1c</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:href="nnox-20201231.xsd#nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl" xml:lang="en-US">Conversion of related party liability to shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:to="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL (INCOME) EXPENSES, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:href="nnox-20201231.xsd#nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl" xml:lang="en-US">Related party prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:to="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">GENERAL:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:to="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:href="nnox-20201231.xsd#nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl" xml:lang="en-US">Property and equipment, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:to="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CashEquivalentsAndRestrictedCashTextBlock" xlink:href="nnox-20201231.xsd#nnox_CashEquivalentsAndRestrictedCashTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashEquivalentsAndRestrictedCashTextBlock" xlink:to="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl" xml:lang="en-US">Restricted bank deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of the compnay&apos;s total lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OperatingLeaseCostAbstract" xlink:href="nnox-20201231.xsd#nnox_OperatingLeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OperatingLeaseCostAbstract_lbl" xml:lang="en-US">Operating lease cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OperatingLeaseCostAbstract" xlink:to="nnox_OperatingLeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Fixed payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="nnox-20201231.xsd#nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:href="nnox-20201231.xsd#nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations (non-cash):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:to="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental balance sheet information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:to="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OperatingLeasesAbstract" xlink:href="nnox-20201231.xsd#nnox_OperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OperatingLeasesAbstract_lbl" xml:lang="en-US">Operating leases:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OperatingLeasesAbstract" xlink:to="nnox_OperatingLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CurrentMaturitiesOfOperatingLeases" xlink:href="nnox-20201231.xsd#nnox_CurrentMaturitiesOfOperatingLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_CurrentMaturitiesOfOperatingLeases_lbl" xml:lang="en-US">Current maturities of operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CurrentMaturitiesOfOperatingLeases" xlink:to="nnox_CurrentMaturitiesOfOperatingLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NoncurrentOperatingLeases" xlink:href="nnox-20201231.xsd#nnox_NoncurrentOperatingLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NoncurrentOperatingLeases_lbl" xml:lang="en-US">Non-current operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NoncurrentOperatingLeases" xlink:to="nnox_NoncurrentOperatingLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_WeightedAverageRemainingLeaseTermAbstract" xlink:href="nnox-20201231.xsd#nnox_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WeightedAverageRemainingLeaseTermAbstract" xlink:to="nnox_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_WeightedAverageDiscountRateAbstract" xlink:href="nnox-20201231.xsd#nnox_WeightedAverageDiscountRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_WeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WeightedAverageDiscountRateAbstract" xlink:to="nnox_WeightedAverageDiscountRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_lbl" xml:lang="en-US">2024 and thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total operating lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilityTextBlock" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilityTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RelatedPartyLiabilityTextBlock_lbl" xml:lang="en-US">RELATED PARTY LIABILITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartyLiabilityTextBlock" xlink:to="nnox_RelatedPartyLiabilityTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of share-based payments to non-employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ChangesDuringTheYearAbstract" xlink:href="nnox-20201231.xsd#nnox_ChangesDuringTheYearAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ChangesDuringTheYearAbstract_lbl" xml:lang="en-US">Changes during the year:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="nnox_ChangesDuringTheYearAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of share-based payment awards, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of share-based payment awards, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of share-based payment awards, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of share-based payment awards, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price. Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of share-based payment awards, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Black-Scholes option-pricing model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Contractual term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of information concerning outstanding and exercisable awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Awards outstanding, Weighted average remaining contractual life (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance_lbl" xml:lang="en-US">Awards exercisable, Number of awards outstanding balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance" xlink:to="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears_lbl" xml:lang="en-US">Awards exercisable, Weighted average remaining contractual life (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears" xlink:to="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of shared - based payments to employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ChangesDuringTheYearAbstract0" xlink:href="nnox-20201231.xsd#nnox_ChangesDuringTheYearAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ChangesDuringTheYearAbstract0_lbl" xml:lang="en-US">Changes during the year:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="nnox_ChangesDuringTheYearAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of share-based payment awards, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Number of share-based payment awards, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited" xlink:href="nnox-20201231.xsd#nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited_lbl" xml:lang="en-US">Number of share-based payment awards, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited" xlink:to="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NumberOfSharebasedPaymentAwardsCancelled" xlink:href="nnox-20201231.xsd#nnox_NumberOfSharebasedPaymentAwardsCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NumberOfSharebasedPaymentAwardsCancelled_lbl" xml:lang="en-US">Number of share-based payment awards, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NumberOfSharebasedPaymentAwardsCancelled" xlink:to="nnox_NumberOfSharebasedPaymentAwardsCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Contractual term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfWarrantsTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfWarrantsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfWarrantsTableTextBlock_lbl" xml:lang="en-US">Schedule of share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfWarrantsTableTextBlock" xlink:to="nnox_ScheduleOfWarrantsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES - TRANSACTIONS AND BALANCES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of balances with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of related parties transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock" xlink:to="nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related parties transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of share-based payment awards, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers and electronic equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office furniture and lab equipment	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machines [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvement	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LandSeeBBelowMember" xlink:href="nnox-20201231.xsd#nnox_LandSeeBBelowMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LandSeeBBelowMember_lbl" xml:lang="en-US">Land &#8211; See b below [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LandSeeBBelowMember" xlink:to="nnox_LandSeeBBelowMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember" xlink:href="nnox-20201231.xsd#nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember_lbl" xml:lang="en-US">Prepayments on account of production line in construction - See b below [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember" xlink:to="nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesOneMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ExercisePricesOneMember_lbl" xml:lang="en-US">0.01 Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesOneMember" xlink:to="nnox_ExercisePricesOneMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nnox_ExercisePricesOneMember_lbl0" xml:lang="en-US">Exercise Prices One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesOneMember" xlink:to="nnox_ExercisePricesOneMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesTwoMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ExercisePricesTwoMember_lbl" xml:lang="en-US">1.92 Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesTwoMember" xlink:to="nnox_ExercisePricesTwoMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nnox_ExercisePricesTwoMember_lbl0" xml:lang="en-US">Exercise Prices Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesTwoMember" xlink:to="nnox_ExercisePricesTwoMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesThreeMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ExercisePricesThreeMember_lbl" xml:lang="en-US">2.21 Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesThreeMember" xlink:to="nnox_ExercisePricesThreeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nnox_ExercisePricesThreeMember_lbl0" xml:lang="en-US">Exercise Prices Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesThreeMember" xlink:to="nnox_ExercisePricesThreeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesFourMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ExercisePricesFourMember_lbl" xml:lang="en-US">16.00 Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesFourMember" xlink:to="nnox_ExercisePricesFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesFiveMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ExercisePricesFiveMember_lbl" xml:lang="en-US">18.00 Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesFiveMember" xlink:to="nnox_ExercisePricesFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesSixMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ExercisePricesSixMember_lbl" xml:lang="en-US">30.93 Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesSixMember" xlink:to="nnox_ExercisePricesSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ExercisePricesSevenMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesSevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ExercisePricesSevenMember_lbl" xml:lang="en-US">20.87 Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesSevenMember" xlink:to="nnox_ExercisePricesSevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_EmployeesOfficersAndDirectorsMember" xlink:href="nnox-20201231.xsd#nnox_EmployeesOfficersAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_EmployeesOfficersAndDirectorsMember_lbl" xml:lang="en-US">Employees, Officers and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmployeesOfficersAndDirectorsMember" xlink:to="nnox_EmployeesOfficersAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and development &#8211; see c and d below [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Marketing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">General and Administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative &#8211; See c, e and f below [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_InitialPublicOfferingNetProceeds" xlink:href="nnox-20201231.xsd#nnox_InitialPublicOfferingNetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_InitialPublicOfferingNetProceeds_lbl" xml:lang="en-US">Initial public offering including the options granted to underwriters proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_InitialPublicOfferingNetProceeds" xlink:to="nnox_InitialPublicOfferingNetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl" xml:lang="en-US">Acquired assets, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CashConsiderationDescription" xlink:href="nnox-20201231.xsd#nnox_CashConsiderationDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_CashConsiderationDescription_lbl" xml:lang="en-US">Cash consideration, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashConsiderationDescription" xlink:to="nnox_CashConsiderationDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl" xml:lang="en-US">Purchase of land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LeaseTermDescription" xlink:href="nnox-20201231.xsd#nnox_LeaseTermDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LeaseTermDescription_lbl" xml:lang="en-US">Rent payment agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeaseTermDescription" xlink:to="nnox_LeaseTermDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LeasesTermDescription" xlink:href="nnox-20201231.xsd#nnox_LeasesTermDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LeasesTermDescription_lbl" xml:lang="en-US">Vehicles lease, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeasesTermDescription" xlink:to="nnox_LeasesTermDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_VehicleLeasePayments" xlink:href="nnox-20201231.xsd#nnox_VehicleLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_VehicleLeasePayments_lbl" xml:lang="en-US">Vehicle lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_VehicleLeasePayments" xlink:to="nnox_VehicleLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Related party liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PurchaseAgreementDescription" xlink:href="nnox-20201231.xsd#nnox_PurchaseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PurchaseAgreementDescription_lbl" xml:lang="en-US">Purchase agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseAgreementDescription" xlink:to="nnox_PurchaseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance_lbl" xml:lang="en-US">Aggregate amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance" xlink:to="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OrdinaryShares" xlink:href="nnox-20201231.xsd#nnox_OrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OrdinaryShares_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinaryShares" xlink:to="nnox_OrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromPreviousAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl" xml:lang="en-US">Aggregate purchase price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreasedAnCommonStockValue" xlink:href="nnox-20201231.xsd#nnox_IncreasedAnCommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IncreasedAnCommonStockValue_lbl" xml:lang="en-US">Aggregate purchase price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreasedAnCommonStockValue" xlink:to="nnox_IncreasedAnCommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NetProceeds" xlink:href="nnox-20201231.xsd#nnox_NetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NetProceeds_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NetProceeds" xlink:to="nnox_NetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PercentageOfDiscountPrice" xlink:href="nnox-20201231.xsd#nnox_PercentageOfDiscountPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PercentageOfDiscountPrice_lbl" xml:lang="en-US">Percentage of discount price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PercentageOfDiscountPrice" xlink:to="nnox_PercentageOfDiscountPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OrdinarySharesReservedUnderTheESOP" xlink:href="nnox-20201231.xsd#nnox_OrdinarySharesReservedUnderTheESOP"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OrdinarySharesReservedUnderTheESOP_lbl" xml:lang="en-US">Ordinary shares reserved under the ESOP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinarySharesReservedUnderTheESOP" xlink:to="nnox_OrdinarySharesReservedUnderTheESOP_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OrdinaryStockParOrStatedValuePerShare" xlink:href="nnox-20201231.xsd#nnox_OrdinaryStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OrdinaryStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Price per share (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinaryStockParOrStatedValuePerShare" xlink:to="nnox_OrdinaryStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NumberOfExercisedShares" xlink:href="nnox-20201231.xsd#nnox_NumberOfExercisedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NumberOfExercisedShares_lbl" xml:lang="en-US">Number of exercised shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NumberOfExercisedShares" xlink:to="nnox_NumberOfExercisedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DescriptionOfSharebasedCompensationExpenses" xlink:href="nnox-20201231.xsd#nnox_DescriptionOfSharebasedCompensationExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DescriptionOfSharebasedCompensationExpenses_lbl" xml:lang="en-US">Description of share-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DescriptionOfSharebasedCompensationExpenses" xlink:to="nnox_DescriptionOfSharebasedCompensationExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Local income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Change in valuation allowance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ExecutiveEmploymentAgreementDescription" xlink:href="nnox-20201231.xsd#nnox_ExecutiveEmploymentAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ExecutiveEmploymentAgreementDescription_lbl" xml:lang="en-US">Executive employment agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExecutiveEmploymentAgreementDescription" xlink:to="nnox_ExecutiveEmploymentAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SurplusChargePercentage" xlink:href="nnox-20201231.xsd#nnox_SurplusChargePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SurplusChargePercentage_lbl" xml:lang="en-US">Surplus charge percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SurplusChargePercentage" xlink:to="nnox_SurplusChargePercentage_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nIPpN2lKEuYCUI09N/Lg5fLZ/Jooq7WY3vjnqJRpjb6jZqCaBUUFGxW7cfKXOabJw5eGbn/VcawsWaAshx1PaHoM/OHV30jj0wwDQLMupnstW81p0yGdPnQUAAVZGAP/2w==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_lbl" xml:lang="en-US">Related Party Tax Expense, Due to Affiliates, Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:to="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Consultants fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OfficeSpaceDescription" xlink:href="nnox-20201231.xsd#nnox_OfficeSpaceDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OfficeSpaceDescription_lbl" xml:lang="en-US">Office space, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OfficeSpaceDescription" xlink:to="nnox_OfficeSpaceDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Monthly rent payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl" xml:lang="en-US">Lease received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyCosts_lbl" xml:lang="en-US">Wellsense paid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyCosts" xlink:to="us-gaap_RelatedPartyCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sub lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Related party liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Warrants option awards outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_WarrantsOptionAwardsOutstanding" xlink:href="nnox-20201231.xsd#nnox_WarrantsOptionAwardsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_WarrantsOptionAwardsOutstanding_lbl" xml:lang="en-US">Warrants option awards outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WarrantsOptionAwardsOutstanding" xlink:to="nnox_WarrantsOptionAwardsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Average exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceAndAllotmentShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceAndAllotmentShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceAndAllotmentShares_lbl" xml:lang="en-US">Issuance and allotment shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceAndAllotmentShares" xlink:to="nnox_IssuanceAndAllotmentShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareBasedCompensationGrantedForService" xlink:href="nnox-20201231.xsd#nnox_ShareBasedCompensationGrantedForService"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ShareBasedCompensationGrantedForService_lbl" xml:lang="en-US">Additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareBasedCompensationGrantedForService" xlink:to="nnox_ShareBasedCompensationGrantedForService_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdministrativeFeesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdministrativeFeesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xml:lang="en-US">Administrative and regulatory fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates in the preparation of financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SeverancePayPolicyTextBlock" xlink:href="nnox-20201231.xsd#nnox_SeverancePayPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SeverancePayPolicyTextBlock" xlink:to="nnox_SeverancePayPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LegalAndOtherContingenciesPolicyTextBlock" xlink:href="nnox-20201231.xsd#nnox_LegalAndOtherContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LegalAndOtherContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Legal and other contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LegalAndOtherContingenciesPolicyTextBlock" xlink:to="nnox_LegalAndOtherContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration&#160;of&#160;Credit Risks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredOfferingCostsPolicyTextBlock" xlink:href="nnox-20201231.xsd#nnox_DeferredOfferingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredOfferingCostsPolicyTextBlock" xlink:to="nnox_DeferredOfferingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Newly issued and recently adopted accounting pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NasdaqMember" xlink:href="nnox-20201231.xsd#nnox_NasdaqMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NasdaqMember_lbl" xml:lang="en-US">Nasdaq [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NasdaqMember" xlink:to="nnox_NasdaqMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxPLCMember" xlink:href="nnox-20201231.xsd#nnox_NanoxPLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NanoxPLCMember_lbl" xml:lang="en-US">Nanox PLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NanoxPLCMember" xlink:to="nnox_NanoxPLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_EquityIncentivePlanMember" xlink:href="nnox-20201231.xsd#nnox_EquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_EquityIncentivePlanMember_lbl" xml:lang="en-US">Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EquityIncentivePlanMember" xlink:to="nnox_EquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IL_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl"/>
    <loc xlink:type="locator" xlink:label="country_KR" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_KR_lbl" xml:lang="en-US">Korea [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KR" xlink:to="country_KR_lbl"/>
    <loc xlink:type="locator" xlink:label="country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_JP_lbl" xml:lang="en-US">Japan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RanPoliakineMember" xlink:href="nnox-20201231.xsd#nnox_RanPoliakineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RanPoliakineMember_lbl" xml:lang="en-US">Ran Poliakine [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RanPoliakineMember" xlink:to="nnox_RanPoliakineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SixEyeInteractiveMember" xlink:href="nnox-20201231.xsd#nnox_SixEyeInteractiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SixEyeInteractiveMember_lbl" xml:lang="en-US">Six -Eye Interactive [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SixEyeInteractiveMember" xlink:to="nnox_SixEyeInteractiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SixAILtdMember" xlink:href="nnox-20201231.xsd#nnox_SixAILtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SixAILtdMember_lbl" xml:lang="en-US">SixAI Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SixAILtdMember" xlink:to="nnox_SixAILtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_WellseseTechnologiesLtdMember" xlink:href="nnox-20201231.xsd#nnox_WellseseTechnologiesLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_WellseseTechnologiesLtdMember_lbl" xml:lang="en-US">Wellsese Technologies Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WellseseTechnologiesLtdMember" xlink:to="nnox_WellseseTechnologiesLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_EmployeebMember" xlink:href="nnox-20201231.xsd#nnox_EmployeebMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_EmployeebMember_lbl" xml:lang="en-US">Employeeb[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmployeebMember" xlink:to="nnox_EmployeebMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NonEmployeeMember" xlink:href="nnox-20201231.xsd#nnox_NonEmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NonEmployeeMember_lbl" xml:lang="en-US">Non Employee[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NonEmployeeMember" xlink:to="nnox_NonEmployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityTablesTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityTablesTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityTablesTable" xlink:to="nnox_ShareholdersEquityTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityTablesLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityTablesLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="nnox_ShareholdersEquityTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:href="nnox-20201231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of property and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:href="nnox-20201231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_MajorPropertyClass_Domain" xlink:href="nnox-20201231.xsd#nnox_MajorPropertyClass_Domain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_MajorPropertyClass_Domain_lbl" xml:lang="en-US">MajorPropertyClass_ [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_MajorPropertyClass_Domain" xlink:to="nnox_MajorPropertyClass_Domain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:to="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed to Issuer&apos;s Equity, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of shared - based payments to employees [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:to="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of shared - based payments to employees [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of Black-Scholes option-pricing model [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" xlink:to="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of Black-Scholes option-pricing model [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of share-based compensation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable" xlink:to="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of share-based compensation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable_lbl" xml:lang="en-US">Related Parties - Transactions and Balances (Details) - Schedule of related parties transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable" xlink:to="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems_lbl" xml:lang="en-US">Related Parties - Transactions and Balances (Details) - Schedule of related parties transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems" xlink:to="nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_GeneralDetailsTable" xlink:href="nnox-20201231.xsd#nnox_GeneralDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_GeneralDetailsTable_lbl" xml:lang="en-US">General (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_GeneralDetailsTable" xlink:to="nnox_GeneralDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_GeneralDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_GeneralDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_GeneralDetailsLineItems_lbl" xml:lang="en-US">General (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="nnox_GeneralDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsTable" xlink:to="nnox_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_ShareholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsTable" xlink:href="nnox-20201231.xsd#nnox_IncomeTaxDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncomeTaxDetailsTable_lbl" xml:lang="en-US">Income Tax (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncomeTaxDetailsTable" xlink:to="nnox_IncomeTaxDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_IncomeTaxDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncomeTaxDetailsLineItems_lbl" xml:lang="en-US">Income Tax (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="nnox_IncomeTaxDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsTable" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsTable_lbl" xml:lang="en-US">Related Parties - Transactions and Balances (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsTable" xlink:to="nnox_RelatedPartiesTransactionsandBalancesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems_lbl" xml:lang="en-US">Related Parties - Transactions and Balances (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LossPerShareDetailsTable" xlink:href="nnox-20201231.xsd#nnox_LossPerShareDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LossPerShareDetailsTable_lbl" xml:lang="en-US">Loss Per Share (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LossPerShareDetailsTable" xlink:to="nnox_LossPerShareDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LossPerShareDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_LossPerShareDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LossPerShareDetailsLineItems_lbl" xml:lang="en-US">Loss Per Share (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LossPerShareDetailsLineItems" xlink:to="nnox_LossPerShareDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SubsequentEventsDetailsTable" xlink:href="nnox-20201231.xsd#nnox_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SubsequentEventsDetailsTable" xlink:to="nnox_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SubsequentEventsDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="nnox_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl0" xml:lang="en-US">Additional consideration with respect to an assets purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl0" xml:lang="en-US">The entire disclosure for cash equivalent and restricted cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashEquivalentsAndRestrictedCashTextBlock" xlink:to="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl0" xml:lang="en-US">Conversion of related party liability to shareholders&#8217; equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:to="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ExecutiveEmploymentAgreementDescription_lbl0" xml:lang="en-US">Executive employment agreement, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExecutiveEmploymentAgreementDescription" xlink:to="nnox_ExecutiveEmploymentAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IncreaseDecreaseOperatingLease_lbl0" xml:lang="en-US">Operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseOperatingLease" xlink:to="nnox_IncreaseDecreaseOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl0" xml:lang="en-US">Related party prepaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:to="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IncreasedAnCommonStockValue_lbl0" xml:lang="en-US">Increased an common stock value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreasedAnCommonStockValue" xlink:to="nnox_IncreasedAnCommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_InitialPublicOfferingNetProceeds_lbl0" xml:lang="en-US">Initial public offering net proceeds .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_InitialPublicOfferingNetProceeds" xlink:to="nnox_InitialPublicOfferingNetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceAndAllotmentShares_lbl0" xml:lang="en-US">Issuance and allotment shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceAndAllotmentShares" xlink:to="nnox_IssuanceAndAllotmentShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance_lbl0" xml:lang="en-US">Amount Issuance of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance" xlink:to="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl0" xml:lang="en-US">Issuance of ordinary shares and warrants, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl0" xml:lang="en-US">Issuance of ordinary shares and warrants, net of issuance shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares_lbl0" xml:lang="en-US">Issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares" xlink:to="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl0" xml:lang="en-US">Issuance of ordinary shares to investors upon exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl0" xml:lang="en-US">Issuance of ordinary shares to investors upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_LeaseTermDescription_lbl0" xml:lang="en-US">Description of lease term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeaseTermDescription" xlink:to="nnox_LeaseTermDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_LeasesTermDescription_lbl0" xml:lang="en-US">Lease agreement term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeasesTermDescription" xlink:to="nnox_LeasesTermDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_OfficeSpaceDescription_lbl0" xml:lang="en-US">Office space, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OfficeSpaceDescription" xlink:to="nnox_OfficeSpaceDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_OrdinarySharesReservedUnderTheESOP_lbl0" xml:lang="en-US">Ordinary shares reserved under the ESOP.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinarySharesReservedUnderTheESOP" xlink:to="nnox_OrdinarySharesReservedUnderTheESOP_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_OrdinaryStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Face amount or stated value per share of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinaryStockParOrStatedValuePerShare" xlink:to="nnox_OrdinaryStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl0" xml:lang="en-US">Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:to="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_PurchaseAgreementDescription_lbl0" xml:lang="en-US">Purchase agreement, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseAgreementDescription" xlink:to="nnox_PurchaseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl0" xml:lang="en-US">Recognition of operating lease right-of-use asset against operating lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:to="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Property and equipment are stated at cost, net of accumulated depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:to="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ShareBasedCompensationGrantedForService_lbl0" xml:lang="en-US">Share based compensation granted for service.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareBasedCompensationGrantedForService" xlink:to="nnox_ShareBasedCompensationGrantedForService_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_SurplusChargePercentage_lbl0" xml:lang="en-US">Surplus charge percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SurplusChargePercentage" xlink:to="nnox_SurplusChargePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_UnpaidOfferingCosts_lbl0" xml:lang="en-US">Unpaid offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_UnpaidOfferingCosts" xlink:to="nnox_UnpaidOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_VehicleLeasePayments_lbl0" xml:lang="en-US">Amount of vehicle lease expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_VehicleLeasePayments" xlink:to="nnox_VehicleLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_WarrantsOptionAwardsOutstanding_lbl0" xml:lang="en-US">Warrants option awards outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WarrantsOptionAwardsOutstanding" xlink:to="nnox_WarrantsOptionAwardsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl0" xml:lang="en-US">Issuance of ordinary shares to investor upon exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:to="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_WellseseTechnologiesLtdMember_lbl0" xml:lang="en-US">Wellsese Technologies Ltd.[Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WellseseTechnologiesLtdMember" xlink:to="nnox_WellseseTechnologiesLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareBasedCompensationGrantedForService_lbl1" xml:lang="en-US">ShareBasedCompensationGrantedForService</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareBasedCompensationGrantedForService" xlink:to="nnox_ShareBasedCompensationGrantedForService_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_WellseseTechnologiesLtdMember_lbl1" xml:lang="en-US">WellseseTechnologiesLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WellseseTechnologiesLtdMember" xlink:to="nnox_WellseseTechnologiesLtdMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_EmployeebMember_lbl0" xml:lang="en-US">EmployeebMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmployeebMember" xlink:to="nnox_EmployeebMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl1" xml:lang="en-US">ConversionOfRelatedPartyLiabilityToShareholdersEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:to="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfSupplementalBalanceSheetInformationTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:to="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LeaseTermDescription_lbl1" xml:lang="en-US">LeaseTermDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeaseTermDescription" xlink:to="nnox_LeaseTermDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SixEyeInteractiveMember_lbl0" xml:lang="en-US">SixEyeInteractiveMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SixEyeInteractiveMember" xlink:to="nnox_SixEyeInteractiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NasdaqMember_lbl0" xml:lang="en-US">NasdaqMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NasdaqMember" xlink:to="nnox_NasdaqMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NanoxPLCMember_lbl0" xml:lang="en-US">NanoxPLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NanoxPLCMember" xlink:to="nnox_NanoxPLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ExercisePricesFiveMember_lbl0" xml:lang="en-US">ExercisePricesFiveMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesFiveMember" xlink:to="nnox_ExercisePricesFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfRelatedPartiesTransactionsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock" xlink:to="nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ExercisePricesFourMember_lbl0" xml:lang="en-US">ExercisePricesFourMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesFourMember" xlink:to="nnox_ExercisePricesFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited_lbl0" xml:lang="en-US">StockIssuedDuringPeriodSharesStockOptionsForfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited" xlink:to="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl1" xml:lang="en-US">issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:to="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LandSeeBBelowMember_lbl0" xml:lang="en-US">LandSeeBBelowMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LandSeeBBelowMember" xlink:to="nnox_LandSeeBBelowMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_WeightedAverageDiscountRateAbstract_lbl0" xml:lang="en-US">WeightedAverageDiscountRateAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WeightedAverageDiscountRateAbstract" xlink:to="nnox_WeightedAverageDiscountRateAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncreaseDecreaseOperatingLease_lbl1" xml:lang="en-US">IncreaseDecreaseOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseOperatingLease" xlink:to="nnox_IncreaseDecreaseOperatingLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfWarrantsTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfWarrantsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfWarrantsTableTextBlock" xlink:to="nnox_ScheduleOfWarrantsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SeverancePayPolicyTextBlock_lbl0" xml:lang="en-US">SeverancePayPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SeverancePayPolicyTextBlock" xlink:to="nnox_SeverancePayPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartyLiabilityTextBlock_lbl0" xml:lang="en-US">RelatedPartyLiabilityTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartyLiabilityTextBlock" xlink:to="nnox_RelatedPartyLiabilityTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DescriptionOfSharebasedCompensationExpenses_lbl0" xml:lang="en-US">DescriptionOfSharebasedCompensationExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DescriptionOfSharebasedCompensationExpenses" xlink:to="nnox_DescriptionOfSharebasedCompensationExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears_lbl0" xml:lang="en-US">AwardsOutstandingWeightedAverageRemainingContractualLifeyears</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears" xlink:to="nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NumberOfSharebasedPaymentAwardsCancelled_lbl0" xml:lang="en-US">NumberOfSharebasedPaymentAwardsCancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NumberOfSharebasedPaymentAwardsCancelled" xlink:to="nnox_NumberOfSharebasedPaymentAwardsCancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance_lbl0" xml:lang="en-US">IssuanceOfOrdinarySharesReservedForFutureIssuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance" xlink:to="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:to="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ExecutiveEmploymentAgreementDescription_lbl1" xml:lang="en-US">ExecutiveEmploymentAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExecutiveEmploymentAgreementDescription" xlink:to="nnox_ExecutiveEmploymentAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ExercisePricesSixMember_lbl0" xml:lang="en-US">ExercisePricesSixMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesSixMember" xlink:to="nnox_ExercisePricesSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl1" xml:lang="en-US">RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:to="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">WeightedAverageRemainingLeaseTermAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WeightedAverageRemainingLeaseTermAbstract" xlink:to="nnox_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ExercisePricesThreeMember_lbl1" xml:lang="en-US">ExercisePricesThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesThreeMember" xlink:to="nnox_ExercisePricesThreeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PercentageOfDiscountPrice_lbl0" xml:lang="en-US">PercentageOfDiscountPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PercentageOfDiscountPrice" xlink:to="nnox_PercentageOfDiscountPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl1" xml:lang="en-US">IncreaseDecreaseRelatedPartyPrepaidExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:to="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NumberOfExercisedShares_lbl0" xml:lang="en-US">NumberOfExercisedShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NumberOfExercisedShares" xlink:to="nnox_NumberOfExercisedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:to="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OperatingLeasesAbstract_lbl0" xml:lang="en-US">OperatingLeasesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OperatingLeasesAbstract" xlink:to="nnox_OperatingLeasesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NoncurrentOperatingLeases_lbl0" xml:lang="en-US">NoncurrentOperatingLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NoncurrentOperatingLeases" xlink:to="nnox_NoncurrentOperatingLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceAndAllotmentShares_lbl1" xml:lang="en-US">IssuanceAndAllotmentShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceAndAllotmentShares" xlink:to="nnox_IssuanceAndAllotmentShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_UnpaidOfferingCosts_lbl1" xml:lang="en-US">UnpaidOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_UnpaidOfferingCosts" xlink:to="nnox_UnpaidOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncreasedAnCommonStockValue_lbl1" xml:lang="en-US">IncreasedAnCommonStockValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreasedAnCommonStockValue" xlink:to="nnox_IncreasedAnCommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember_lbl0" xml:lang="en-US">PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember" xlink:to="nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NonEmployeeMember_lbl0" xml:lang="en-US">NonEmployeeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NonEmployeeMember" xlink:to="nnox_NonEmployeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ExercisePricesTwoMember_lbl1" xml:lang="en-US">ExercisePricesTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesTwoMember" xlink:to="nnox_ExercisePricesTwoMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PurchaseAgreementDescription_lbl1" xml:lang="en-US">PurchaseAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseAgreementDescription" xlink:to="nnox_PurchaseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract_lbl0" xml:lang="en-US">RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:to="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OrdinarySharesReservedUnderTheESOP_lbl1" xml:lang="en-US">OrdinarySharesReservedUnderTheESOP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinarySharesReservedUnderTheESOP" xlink:to="nnox_OrdinarySharesReservedUnderTheESOP_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartyLiabilities_lbl1" xml:lang="en-US">RelatedPartyLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartyLiabilities" xlink:to="nnox_RelatedPartyLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_VehicleLeasePayments_lbl1" xml:lang="en-US">VehicleLeasePayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_VehicleLeasePayments" xlink:to="nnox_VehicleLeasePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ChangesDuringTheYearAbstract_lbl0" xml:lang="en-US">ChangesDuringTheYearAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="nnox_ChangesDuringTheYearAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SurplusChargePercentage_lbl1" xml:lang="en-US">SurplusChargePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SurplusChargePercentage" xlink:to="nnox_SurplusChargePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_InitialPublicOfferingNetProceeds_lbl1" xml:lang="en-US">InitialPublicOfferingNetProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_InitialPublicOfferingNetProceeds" xlink:to="nnox_InitialPublicOfferingNetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl1" xml:lang="en-US">AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ChangesDuringTheYearAbstract0_lbl0" xml:lang="en-US">ChangesDuringTheYearAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="nnox_ChangesDuringTheYearAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6_lbl0" xml:lang="en-US">AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SixAILtdMember_lbl0" xml:lang="en-US">SixAILtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SixAILtdMember" xlink:to="nnox_SixAILtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OperatingLeaseCostAbstract_lbl0" xml:lang="en-US">OperatingLeaseCostAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OperatingLeaseCostAbstract" xlink:to="nnox_OperatingLeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CurrentMaturitiesOfOperatingLeases_lbl0" xml:lang="en-US">CurrentMaturitiesOfOperatingLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CurrentMaturitiesOfOperatingLeases" xlink:to="nnox_CurrentMaturitiesOfOperatingLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OrdinaryShares_lbl0" xml:lang="en-US">OrdinaryShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinaryShares" xlink:to="nnox_OrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance_lbl0" xml:lang="en-US">AwardsOutstandingNumberOfAwardsOutstandingBalance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance" xlink:to="nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl1" xml:lang="en-US">CashEquivalentsAndRestrictedCashTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashEquivalentsAndRestrictedCashTextBlock" xlink:to="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TotalOperatingLeaseCost_lbl0" xml:lang="en-US">TotalOperatingLeaseCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalOperatingLeaseCost" xlink:to="nnox_TotalOperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LegalAndOtherContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">LegalAndOtherContingenciesPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LegalAndOtherContingenciesPolicyTextBlock" xlink:to="nnox_LegalAndOtherContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl0" xml:lang="en-US">ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:to="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_WarrantsOptionAwardsOutstanding_lbl1" xml:lang="en-US">WarrantsOptionAwardsOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WarrantsOptionAwardsOutstanding" xlink:to="nnox_WarrantsOptionAwardsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RanPoliakineMember_lbl0" xml:lang="en-US">RanPoliakineMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RanPoliakineMember" xlink:to="nnox_RanPoliakineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ExercisePricesOneMember_lbl1" xml:lang="en-US">ExercisePricesOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesOneMember" xlink:to="nnox_ExercisePricesOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NetProceeds_lbl0" xml:lang="en-US">NetProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NetProceeds" xlink:to="nnox_NetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DeferredOfferingCostsPolicyTextBlock_lbl0" xml:lang="en-US">DeferredOfferingCostsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredOfferingCostsPolicyTextBlock" xlink:to="nnox_DeferredOfferingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LeasesTermDescription_lbl1" xml:lang="en-US">LeasesTermDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeasesTermDescription" xlink:to="nnox_LeasesTermDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesReservedForFutureIssuanceShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares" xlink:to="nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance_lbl1" xml:lang="en-US">IssuanceOfOrdinaryShareReservedForFutureIssuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance" xlink:to="nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl1" xml:lang="en-US">PropertyPlantAndEquipmentSalvageValuePercentageDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:to="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OrdinaryStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">OrdinaryStockParOrStatedValuePerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinaryStockParOrStatedValuePerShare" xlink:to="nnox_OrdinaryStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_EquityIncentivePlanMember_lbl0" xml:lang="en-US">EquityIncentivePlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EquityIncentivePlanMember" xlink:to="nnox_EquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_EmployeesOfficersAndDirectorsMember_lbl0" xml:lang="en-US">EmployeesOfficersAndDirectorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmployeesOfficersAndDirectorsMember" xlink:to="nnox_EmployeesOfficersAndDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ExercisePricesSevenMember_lbl0" xml:lang="en-US">ExercisePricesSevenMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ExercisePricesSevenMember" xlink:to="nnox_ExercisePricesSevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OfficeSpaceDescription_lbl1" xml:lang="en-US">OfficeSpaceDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OfficeSpaceDescription" xlink:to="nnox_OfficeSpaceDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashConsiderationDescription_lbl0" xml:lang="en-US">CashConsiderationDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashConsiderationDescription" xlink:to="nnox_CashConsiderationDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdministrativeFeesExpense_lbl0" xml:lang="en-US">Administrative Fees Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl0" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KR_lbl0" xml:lang="en-US">KOREA, REPUBLIC OF</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KR" xlink:to="country_KR_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl0" xml:lang="en-US">Employee Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_JP_lbl0" xml:lang="en-US">JAPAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four and Five Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl2" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl1" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl0" xml:lang="en-US">ISRAEL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee Director Award Plan, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due to Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount_lbl0" xml:lang="en-US">Receivable with Imputed Interest, Net Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl2" xml:lang="en-US">Increase (Decrease) in Stockholders&apos; Equity [Roll Forward]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_lbl0" xml:lang="en-US">Related Party Tax Expense, Due to Affiliates, Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:to="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl0" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl0" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl0" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl0" xml:lang="en-US">Loans and Leases Receivable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl0" xml:lang="en-US">Payments of Financing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyCosts_lbl0" xml:lang="en-US">Related Party Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyCosts" xlink:to="us-gaap_RelatedPartyCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl0" xml:lang="en-US">Sublease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl0" xml:lang="en-US">Payments for Purchase of Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl0" xml:lang="en-US">Due to Related Parties, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl0" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl1" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl0" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl0" xml:lang="en-US">Short-term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl0" xml:lang="en-US">Payments for (Proceeds from) Previous Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>nnox-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Apr 06 12:29:48 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedBalanceSheet" roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedIncomeStatement" roleURI="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ShareholdersEquityType2or3" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ConsolidatedCashFlow" roleURI="http://www.nanox.vision.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_General" roleURI="http://www.nanox.vision.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_SignificantAccountingPolicies" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_PropertyandEquipmentNet" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_CashCashEquivalentsandRestrictedCash" roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_Leases" roleURI="http://www.nanox.vision.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_RelatedPartyLiability" roleURI="http://www.nanox.vision.com/role/RelatedPartyLiability"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_CommitmentsandContingencies" roleURI="http://www.nanox.vision.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ShareholdersEquity" roleURI="http://www.nanox.vision.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_IncomeTax" roleURI="http://www.nanox.vision.com/role/IncomeTax"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_RelatedPartiesTransactionsandBalances" roleURI="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalances"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_LossPerShare" roleURI="http://www.nanox.vision.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_SubsequentEvents" roleURI="http://www.nanox.vision.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_AccountingPoliciesByPolicy" roleURI="http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_SignificantAccountingPoliciesTables" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_PropertyandEquipmentNetTables" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_LeasesTables" roleURI="http://www.nanox.vision.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ShareholdersEquityTables" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_RelatedPartiesTransactionsandBalancesTables" roleURI="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_LossPerShareTables" roleURI="http://www.nanox.vision.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofpropertyandequipmentTable" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofpropertyandequipmentTable0" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable" roleURI="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofcompanystotalleasecostsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofsupplementalbalancesheetinformationTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofmaturitiesofoperatingleaseliabilitiesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofsharebasedpaymentstononemployeesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedpaymentstononemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofinformationconcerningoutstandingandexercisableawardsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofsharedbasedpaymentstoemployeesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofBlackScholesoptionpricingmodelTable" roleURI="http://www.nanox.vision.com/role/ScheduleofBlackScholesoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofinformationconcerningoutstandingandexercisableawardsTable0" roleURI="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable0"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofsharebasedcompensationTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofbalanceswithrelatedpartiesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofbalanceswithrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofrelatedpartiestransactionsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable" roleURI="http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_GeneralDetails" roleURI="http://www.nanox.vision.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_SignificantAccountingPoliciesDetails" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_PropertyandEquipmentNetDetails" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_LeasesDetails" roleURI="http://www.nanox.vision.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_RelatedPartyLiabilityDetails" roleURI="http://www.nanox.vision.com/role/RelatedPartyLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_ShareholdersEquityDetails" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_IncomeTaxDetails" roleURI="http://www.nanox.vision.com/role/IncomeTaxDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_RelatedPartiesTransactionsandBalancesDetails" roleURI="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_LossPerShareDetails" roleURI="http://www.nanox.vision.com/role/LossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#nnox_r_SubsequentEventsDetails" roleURI="http://www.nanox.vision.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20201231.xsd#DocumentAndEntityInformation" roleURI="http://www.nanox.vision.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyLiabilities" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="RelatedPartyLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinaryShareReservedForFutureIssuance" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinaryShareReservedForFutureIssuance" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesReservedForFutureIssuanceShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesReservedForFutureIssuanceShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" xlink:href="nnox-20201231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:href="nnox-20201231.xsd#nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="IncreaseDecreaseRelatedPartyPrepaidExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseOperatingLease" xlink:href="nnox-20201231.xsd#nnox_IncreaseDecreaseOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="IncreaseDecreaseOperatingLease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20201231.xsd#nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidOfferingCosts" xlink:href="nnox-20201231.xsd#nnox_UnpaidOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="UnpaidOfferingCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:href="nnox-20201231.xsd#nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:href="nnox-20201231.xsd#nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:href="nnox-20201231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:href="nnox-20201231.xsd#nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ConversionOfRelatedPartyLiabilityToShareholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash">
    <loc xlink:type="locator" xlink:label="CashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20201231.xsd#nnox_CashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="CashEquivalentsAndRestrictedCashTextBlock" xlink:href="nnox-20201231.xsd#nnox_CashEquivalentsAndRestrictedCashTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndRestrictedCashAbstract" xlink:to="CashEquivalentsAndRestrictedCashTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartyLiability">
    <loc xlink:type="locator" xlink:label="RelatedPartyLiabilityAbstract" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyLiabilityTextBlock" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilityTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyLiabilityAbstract" xlink:to="RelatedPartyLiabilityTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/IncomeTax">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalances">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePayPolicyTextBlock" xlink:href="nnox-20201231.xsd#nnox_SeverancePayPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SeverancePayPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LegalAndOtherContingenciesPolicyTextBlock" xlink:href="nnox-20201231.xsd#nnox_LegalAndOtherContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LegalAndOtherContingenciesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredOfferingCostsPolicyTextBlock" xlink:href="nnox-20201231.xsd#nnox_DeferredOfferingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DeferredOfferingCostsPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables">
    <loc xlink:type="locator" xlink:label="CashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20201231.xsd#nnox_CashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityTablesTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityTablesTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityTablesLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityTablesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeesOfficersAndDirectorsMember" xlink:href="nnox-20201231.xsd#nnox_EmployeesOfficersAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesOfficersAndDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesTable" xlink:to="ShareholdersEquityTablesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfWarrantsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="ScheduleOfWarrantsTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartiesTransactionsTableTextBlock" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartiesTransactionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:href="nnox-20201231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:href="nnox-20201231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:href="nnox-20201231.xsd#nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="PropertyPlantAndEquipmentSalvageValuePercentageDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MajorPropertyClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MajorPropertyClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_MajorPropertyClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MajorPropertyClass_Domain" xlink:href="nnox-20201231.xsd#nnox_MajorPropertyClass_Domain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="MajorPropertyClass_Domain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LandSeeBBelowMember" xlink:href="nnox-20201231.xsd#nnox_LandSeeBBelowMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="LandSeeBBelowMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember" xlink:href="nnox-20201231.xsd#nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorPropertyClassAxis" xlink:to="PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashEquivalentsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfCompanysTotalLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseCostAbstract" xlink:href="nnox-20201231.xsd#nnox_OperatingLeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:to="OperatingLeaseCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalOperatingLeaseCost" xlink:href="nnox-20201231.xsd#nnox_TotalOperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:to="TotalOperatingLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="nnox-20201231.xsd#nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:href="nnox-20201231.xsd#nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesAbstract" xlink:href="nnox-20201231.xsd#nnox_OperatingLeasesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="OperatingLeasesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentMaturitiesOfOperatingLeases" xlink:href="nnox-20201231.xsd#nnox_CurrentMaturitiesOfOperatingLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesAbstract" xlink:to="CurrentMaturitiesOfOperatingLeases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncurrentOperatingLeases" xlink:href="nnox-20201231.xsd#nnox_NoncurrentOperatingLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesAbstract" xlink:to="NoncurrentOperatingLeases" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLeaseTermAbstract" xlink:href="nnox-20201231.xsd#nnox_WeightedAverageRemainingLeaseTermAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="WeightedAverageRemainingLeaseTermAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRateAbstract" xlink:href="nnox-20201231.xsd#nnox_WeightedAverageDiscountRateAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="WeightedAverageDiscountRateAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharebasedpaymentstononemployeesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nIPpN2lKEuYCUI09N/Lg5fLZ/Jooq7WY3vjnqJRpjb6jZqCaBUUFGxW7cfKXOabJw5eGbn/VcawsWaAshx1PaHoM/OHV30jj0wwDQLMupnstSUGkjW1+gNxB1SeaVzrCGQ==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsToNonEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract" xlink:to="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:to="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesOneMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePricesOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesTwoMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePricesTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesThreeMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePricesThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesFourMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePricesFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesFiveMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePricesFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesSixMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePricesSixMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesSevenMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePricesSevenMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="AwardsOutstandingNumberOfAwardsOutstandingBalance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="AwardsOutstandingWeightedAverageRemainingContractualLifeyears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_0" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_0" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_1" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_1" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_2" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_2" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_3" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_3" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_4" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_4" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_5" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_5" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_6" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_6" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_7" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_7" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_8" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_8" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSharedBasedPaymentsToEmployeesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSharedBasedPaymentsToEmployeesAbstract" xlink:to="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_EmployeeStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:to="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:href="nnox-20201231.xsd#nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesDuringTheYearAbstract0" xlink:href="nnox-20201231.xsd#nnox_ChangesDuringTheYearAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="ChangesDuringTheYearAbstract0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract0" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockOptionsForfeited" xlink:href="nnox-20201231.xsd#nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract0" xlink:to="StockIssuedDuringPeriodSharesStockOptionsForfeited" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharebasedPaymentAwardsCancelled" xlink:href="nnox-20201231.xsd#nnox_NumberOfSharebasedPaymentAwardsCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract0" xlink:to="NumberOfSharebasedPaymentAwardsCancelled" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract0" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_0" xlink:href="nnox-20201231.xsd#nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofBlackScholesoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBlackScholesOptionPricingModelAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBlackScholesOptionPricingModelAbstract" xlink:to="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_EmployeeStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelTable" xlink:to="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesOneMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePricesOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesTwoMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePricesTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePricesThreeMember" xlink:href="nnox-20201231.xsd#nnox_ExercisePricesThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePricesThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeesOfficersAndDirectorsMember" xlink:href="nnox-20201231.xsd#nnox_EmployeesOfficersAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesOfficersAndDirectorsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="AwardsOutstandingNumberOfAwardsOutstandingBalance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="AwardsOutstandingWeightedAverageRemainingContractualLifeyears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_0" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_0" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_1" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_1" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingNumberOfAwardsOutstandingBalance_2" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingWeightedAverageRemainingContractualLifeyears_2" xlink:href="nnox-20201231.xsd#nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedCompensationAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfShareBasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofsharebasedcompensationTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationAbstract" xlink:to="ShareholdersEquityDetailsScheduleofsharebasedcompensationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharebasedcompensationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharebasedcompensationTable" xlink:to="ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofbalanceswithrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyLiabilities" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="RelatedPartyLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartiesTransactionsAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfRelatedPartiesTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartiesTransactionsAbstract" xlink:to="RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsTable" xlink:to="RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:href="nnox-20201231.xsd#nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsTable" xlink:href="nnox-20201231.xsd#nnox_GeneralDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_GeneralDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GeneralDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NasdaqMember" xlink:href="nnox-20201231.xsd#nnox_NasdaqMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="NasdaqMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="GeneralDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingNetProceeds" xlink:href="nnox-20201231.xsd#nnox_InitialPublicOfferingNetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="InitialPublicOfferingNetProceeds" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashConsiderationDescription" xlink:href="nnox-20201231.xsd#nnox_CashConsiderationDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="CashConsiderationDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="LeaseTermDescription" xlink:href="nnox-20201231.xsd#nnox_LeaseTermDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="LeaseTermDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeasesTermDescription" xlink:href="nnox-20201231.xsd#nnox_LeasesTermDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="LeasesTermDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VehicleLeasePayments" xlink:href="nnox-20201231.xsd#nnox_VehicleLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="VehicleLeasePayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartyLiabilityDetails">
    <loc xlink:type="locator" xlink:label="RelatedPartyLiabilityAbstract" xlink:href="nnox-20201231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyLiabilityAbstract" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAgreementDescription" xlink:href="nnox-20201231.xsd#nnox_PurchaseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyLiabilityAbstract" xlink:to="PurchaseAgreementDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeesOfficersAndDirectorsMember" xlink:href="nnox-20201231.xsd#nnox_EmployeesOfficersAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesOfficersAndDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EquityIncentivePlanMember" xlink:href="nnox-20201231.xsd#nnox_EquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="EquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NanoxPLCMember" xlink:href="nnox-20201231.xsd#nnox_NanoxPLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="NanoxPLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="6.0"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesReservedForFutureIssuance" xlink:href="nnox-20201231.xsd#nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IssuanceOfOrdinarySharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShares" xlink:href="nnox-20201231.xsd#nnox_OrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OrdinaryShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromPreviousAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreasedAnCommonStockValue" xlink:href="nnox-20201231.xsd#nnox_IncreasedAnCommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IncreasedAnCommonStockValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="nnox-20201231.xsd#nnox_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="NetProceeds" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfDiscountPrice" xlink:href="nnox-20201231.xsd#nnox_PercentageOfDiscountPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="PercentageOfDiscountPrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesReservedUnderTheESOP" xlink:href="nnox-20201231.xsd#nnox_OrdinarySharesReservedUnderTheESOP"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OrdinarySharesReservedUnderTheESOP" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryStockParOrStatedValuePerShare" xlink:href="nnox-20201231.xsd#nnox_OrdinaryStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OrdinaryStockParOrStatedValuePerShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfExercisedShares" xlink:href="nnox-20201231.xsd#nnox_NumberOfExercisedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="NumberOfExercisedShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfSharebasedCompensationExpenses" xlink:href="nnox-20201231.xsd#nnox_DescriptionOfSharebasedCompensationExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="DescriptionOfSharebasedCompensationExpenses" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/IncomeTaxDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxDetailsTable" xlink:href="nnox-20201231.xsd#nnox_IncomeTaxDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_IncomeTaxDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KR" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KR" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_JP" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsTable" xlink:to="IncomeTaxDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsandBalancesDetailsTable" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartiesTransactionsandBalancesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SixEyeInteractiveMember" xlink:href="nnox-20201231.xsd#nnox_SixEyeInteractiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SixEyeInteractiveMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SixAILtdMember" xlink:href="nnox-20201231.xsd#nnox_SixAILtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SixAILtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WellseseTechnologiesLtdMember" xlink:href="nnox-20201231.xsd#nnox_WellseseTechnologiesLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="WellseseTechnologiesLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NanoxPLCMember" xlink:href="nnox-20201231.xsd#nnox_NanoxPLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="NanoxPLCMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RanPoliakineMember" xlink:href="nnox-20201231.xsd#nnox_RanPoliakineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="RanPoliakineMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsTable" xlink:to="RelatedPartiesTransactionsandBalancesDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="ExecutiveEmploymentAgreementDescription" xlink:href="nnox-20201231.xsd#nnox_ExecutiveEmploymentAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="ExecutiveEmploymentAgreementDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SurplusChargePercentage" xlink:href="nnox-20201231.xsd#nnox_SurplusChargePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="SurplusChargePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_ProfessionalFees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfficeSpaceDescription" xlink:href="nnox-20201231.xsd#nnox_OfficeSpaceDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="OfficeSpaceDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_PaymentsForRent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansAndLeasesReceivableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_LoansAndLeasesReceivableRelatedParties" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_RelatedPartyCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_SubleaseIncome" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsandBalancesDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShareDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="LossPerShareDetailsTable" xlink:href="nnox-20201231.xsd#nnox_LossPerShareDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LossPerShareDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_LossPerShareDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="LossPerShareDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeebMember" xlink:href="nnox-20201231.xsd#nnox_EmployeebMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeebMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonEmployeeMember" xlink:href="nnox-20201231.xsd#nnox_NonEmployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="NonEmployeeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareDetailsTable" xlink:to="LossPerShareDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOptionAwardsOutstanding" xlink:href="nnox-20201231.xsd#nnox_WarrantsOptionAwardsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareDetailsLineItems" xlink:to="WarrantsOptionAwardsOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="nnox-20201231.xsd#nnox_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="nnox-20201231.xsd#nnox_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceAndAllotmentShares" xlink:href="nnox-20201231.xsd#nnox_IssuanceAndAllotmentShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="IssuanceAndAllotmentShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationGrantedForService" xlink:href="nnox-20201231.xsd#nnox_ShareBasedCompensationGrantedForService"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ShareBasedCompensationGrantedForService" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdministrativeFeesExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdministrativeFeesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_AdministrativeFeesExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="nnox-20201231.xsd#nnox_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308748634280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Nano-X Imaging Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">46,100,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001795251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308751100008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 213,468<span></span>
</td>
<td class="nump">$ 8,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,325<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">219,793<span></span>
</td>
<td class="nump">9,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,020<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,359<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON- CURRENT ASSETS</a></td>
<td class="nump">16,356<span></span>
</td>
<td class="nump">2,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">236,149<span></span>
</td>
<td class="nump">11,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">3,526<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartyLiabilities', window );">Related party liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party accrued liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating leases</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">4,480<span></span>
</td>
<td class="nump">20,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating leases</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL NON-CURRENT LIABILITIES</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">5,403<span></span>
</td>
<td class="nump">20,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares, par value NIS 0.01 per share, 100,000,000 and 40,000,000 shares authorized at December 31, 2020 and 2019, respectively; 46,100,173 and 27,150,080 issued and outstanding at December 31, 2020 and 2019, respectively.</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">315,031<span></span>
</td>
<td class="nump">31,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(84,416)<span></span>
</td>
<td class="num">(40,601)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL SHAREHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</a></td>
<td class="nump">230,746<span></span>
</td>
<td class="num">(8,778)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</a></td>
<td class="nump">$ 236,149<span></span>
</td>
<td class="nump">$ 11,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308769107784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in New Shekels per share)</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">46,100,173<span></span>
</td>
<td class="nump">27,150,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">46,100,173<span></span>
</td>
<td class="nump">27,150,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750904920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 9,210<span></span>
</td>
<td class="nump">$ 2,717<span></span>
</td>
<td class="nump">$ 672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Marketing</a></td>
<td class="nump">12,445<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,268<span></span>
</td>
<td class="nump">18,298<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">43,923<span></span>
</td>
<td class="nump">22,571<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(43,923)<span></span>
</td>
<td class="num">(22,571)<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL (INCOME) EXPENSES, net</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (43,815)<span></span>
</td>
<td class="num">$ (22,563)<span></span>
</td>
<td class="num">$ (1,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)</a></td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">THE WEIGHTED AVERAGE OF THE NUMBER OF ORDINARY SHARES (in thousands) (in Shares)</a></td>
<td class="nump">35,654<span></span>
</td>
<td class="nump">25,181<span></span>
</td>
<td class="nump">20,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750755208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Shareholders&#8217; Equity (capital Deficiency) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,814<span></span>
</td>
<td class="num">$ (16,129)<span></span>
</td>
<td class="num">$ (8,274)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2017</a></td>
<td class="nump">20,257,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance', window );">Issuance of ordinary shares</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,667<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares', window );">Issuance of ordinary shares (in Shares)</a></td>
<td class="nump">1,666,774<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">115<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,909)<span></span>
</td>
<td class="num">(1,909)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,596<span></span>
</td>
<td class="num">(18,038)<span></span>
</td>
<td class="num">(6,384)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="nump">21,924,208<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts', window );">Issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,022<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares', window );">Issuance of ordinary shares and warrants, net of issuance costs (in Shares)</a></td>
<td class="nump">4,762,656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of ordinary shares to employees and non-employees upon exercise of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">136<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares)</a></td>
<td class="nump">454,166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants', window );">Issuance of ordinary shares to investors upon exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">25<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares', window );">Issuance of ordinary shares to investors upon exercise of warrants (in Shares)</a></td>
<td class="nump">9,050<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,245<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6', window );">Additional consideration with respect to an assets purchase agreement, see note 1c and note 6</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,276)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(22,563)<span></span>
</td>
<td class="num">(22,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31,748<span></span>
</td>
<td class="num">(40,601)<span></span>
</td>
<td class="num">(8,778)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">27,150,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts', window );">Issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">70,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">71,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares', window );">Issuance of ordinary shares and warrants, net of issuance costs (in Shares)</a></td>
<td class="nump">4,624,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering of ordinary shares, net of offering costs</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">169,136<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">169,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering of ordinary shares, net of offering costs (in Shares)</a></td>
<td class="nump">10,555,556<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of ordinary shares to employees and non-employees upon exercise of warrants</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">497<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares)</a></td>
<td class="nump">997,863<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants', window );">Issuance of ordinary shares to investors upon exercise of warrants</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">125<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares', window );">Issuance of ordinary shares to investors upon exercise of warrants (in Shares)</a></td>
<td class="nump">1,662,929<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24,781<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of related party liability to shareholders&#8217; equity, see note 8a</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,745<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of related party liability to shareholders&#8217; equity, see note 8a (in Shares)</a></td>
<td class="nump">1,109,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(43,815)<span></span>
</td>
<td class="num">(43,815)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 315,031<span></span>
</td>
<td class="num">$ (84,416)<span></span>
</td>
<td class="nump">$ 230,746<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">46,100,173<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than 1 thousand US dollars.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Issuance of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinaryShareReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and warrants, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and warrants, net of issuance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesReservedForFutureIssuanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares to investors upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares to investors upon exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750855048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="num">$ (43,815)<span></span>
</td>
<td class="num">$ (22,563)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">24,781<span></span>
</td>
<td class="nump">16,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,478)<span></span>
</td>
<td class="num">(1,564)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses', window );">Related party prepaid expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,081<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(522)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncreaseDecreaseOperatingLease', window );">Operating lease</a></td>
<td class="nump">83<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">2,359<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,487)<span></span>
</td>
<td class="num">(5,524)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(13,937)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(13,937)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts', window );">Proceeds from issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="nump">71,013<span></span>
</td>
<td class="nump">14,038<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering of ordinary shares, net of issuance costs</a></td>
<td class="nump">169,348<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of ordinary shares upon exercise of warrants</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">240,991<span></span>
</td>
<td class="nump">13,861<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,684<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">205,567<span></span>
</td>
<td class="nump">8,212<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE YEAR</a></td>
<td class="nump">8,217<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR</a></td>
<td class="nump">213,784<span></span>
</td>
<td class="nump">8,217<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_UnpaidOfferingCosts', window );">Unpaid offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants', window );">issuance of ordinary shares to investor upon exercise of warrants</a></td>
<td class="nump">200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities', window );">Operating lease liabilities arising from obtaining operating right-of-use assets</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements', window );">Additional consideration with respect to an assets purchase purchase agreement, see note 1c</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(10,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity', window );">Conversion of related party liability to shareholders&#8217; equity</a></td>
<td class="nump">$ 17,748<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than 1 thousand US dollars.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional consideration with respect to an assets purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of related party liability to shareholders&#8217; equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IncreaseDecreaseOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IncreaseDecreaseOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognition of operating lease right-of-use asset against operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_UnpaidOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_UnpaidOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares to investor upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308761088744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">GENERAL:</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><b>NOTE
1 - GENERAL:</b></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>a.</b></td><td style="text-align: left">Nano-X Imaging Ltd, an Israeli Company (hereinafter &#x201c;the Company&#x201d; or &#x201c;Nanox IL&#x201d;
or &#x201c;the Successor Company&#x201d;), was incorporated on December 20, 2018 and commenced its operations on September 3, 2019.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On September 19, 2019, Nanox IL
established Nanox Imaging Inc. (hereinafter &#x201c;Nanox Inc.&#x201d;), a wholly owned subsidiary in Japan.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On September 25, 2020, Nanox IL
established Nano-X Korea Inc. (hereinafter &#x201c;Nanox Korea&#x201d;), a wholly owned subsidiary in Korea.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In August 2020, the Company
completed an initial public offering (&#x201c;IPO&#x201d;) on the Nasdaq Global Select Market (the &#x201c;Nasdaq&#x201d;), in which
it issued 9,178,744 ordinary shares, at a price per share of $18.&#xa0;During August 2020 the underwriters exercised their over-allotment
option and purchased an additional 1,376,812 ordinary shares at the same price per share. The proceeds received from the IPO were
$190 million (the net proceeds were approximately $169 million after deducting underwriting commissions and other offering expenses).</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>b.</b></td><td style="text-align: left">Nanox Imaging PLC is a public limited company incorporated in Gibraltar in 2012 (hereinafter &#x201c;Nanox
PLC&#x201d; or &#x201c;the predecessor company&#x201d;). Nanox PLC developed certain technological capabilities
aimed to design and build various applications for x-ray based imaging. Nanox PLC has been a development-stage company since its
inception. Nanox PLC has a wholly owned subsidiary, Nanox Japan Inc. (hereinafter &#x201c;Nanox Japan&#x201d;). Nanox
Japan primarily provided research and development services to Nanox PLC.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On September 3, 2019 (hereinafter
&#x201c;Transaction Date&#x201d;), Nanox IL signed an Assets Purchase Agreement which was later amended on December 3, 2019 and December
31, 2019 (hereinafter &#x201c;the APA&#x201d;) with Nanox PLC.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Under the terms of the APA,
Nanox IL purchased from Nanox PLC patents, patent applications and all other intellectual property rights, as well as all cash
of Nanox PLC (less an amount of $200 thousand), with an exclusion of certain assets as defined in the APA (hereinafter &#x201c;Acquired
Assets&#x201d;).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Under the terms of the APA,
Nanox IL shall pay Nanox PLC $6.127 million as consideration for the purchase of the Acquired Assets, which reflects the fair value
of the Acquired Assets (excluding cash) plus the cash balance as of the date of the APA, less $200 thousand. The purchase price
shall be due and payable upon the closing of one of the following events: (a) an M&amp;A event of Nanox IL, (b) an IPO of Nanox
IL, or (c) a qualified equity financing of Nanox IL at a minimum company pre-money valuation of $100 million, with proceeds totaling
at least $30 million.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In the event of an IPO or a
qualified equity financing, Nanox IL has the option to pay for the Acquired Assets in cash or by the issuance of Nanox IL shares
of the same series to be issued upon such event, in an amount reflecting a 25% discount on the per share price to be determined
in such IPO or qualified equity financing. If Nanox IL chooses to pay for the Acquired Assets in cash in any of the events described
above, then Nanox PLC has the right, at its sole discretion and in good faith, to reject such payment in cash, and require Nanox
IL to pay for the Acquired Assets by the issuance of securities of the same series to be issued upon such equity financing events,
in such amount which shall reflect a 25% discount on the per share price to be determined in such equity financing events.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In November 2019, Nanox PLC
transferred to Nanox IL an amount of $7.2 million, which reflects the cash consideration under the APA. The total consideration
of the purchase of the Acquired Assets is $13.3 million. The outstanding balance of $17.8 million reflects the related
party liability of the expected future payment using the Company&#x2019;s shares, refer to note 6.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In return to the Acquired Assets,
the Company issued to Nanox PLC 1,109,245 ordinary shares during January 2020. See also note 6.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>c.</b></td><td style="text-align: left">As of September, 3 2019, Nanox IL and Nanox PLC had the same shareholders and, therefore, the transaction
was treated as a transaction under common control for accounting purposes.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The financial statements of
the Company prior to the Transaction Date are the historical financial statements of Nanox PLC, which have been adjusted to reflect
the fact that:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">1)</td><td style="text-align: left">only the net assets that were transferred in the transaction according to the APA. Net assets which
were not transferred in the transaction are not reflected in these consolidated financial statements.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">2)</td><td style="text-align: left">no interests of Nanox Japan were transferred under the APA. The consolidated statements of operation
include the costs incurred for services provided by Nanox Japan to Nanox PLC.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">3)</td><td style="text-align: left">the consideration in the transaction (the &#x201c;Related Party Liability&#x201d;) was recorded at the
beginning of the earliest period presented against a decrease in shareholders&#x2019; equity.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">4)</td><td style="text-align: left">all of the share-related information reflects the share information of Nanox IL.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>d.</b></td><td style="text-align: left">The Company&#x2019;s solution, referred to as the Nanox System, has two integrated components &#x2013;
&#x201c;Nanox.ARC&#x201d; and &#x201c;Nanox. CLOUD&#x201d;. Nanox.ARC is a medical imaging system incorporating the Company&#x2019;s novel
digital X-ray source. Nanox. CLOUD is a cloud-based system designed to provide end-to-end medical imaging services, including services
such as image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic
assistive AI systems, billing and reporting.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In January 2020, the Company submitted
a 510(k) application for the Nanox Cart X-Ray System, which is a single-source version of the Nanox.ARC (the &#x201c;Nanox Cart X-Ray System&#x201d;)
to an accredited Review Organization under the FDA&#x2019;s 510(k) third party review program. During 2020 and the first quarter of 2021,
the Company received additional information requests and submitted its official responses. On April 1, 2021, the Company received clearance
from the FDA to market the Company's Nanox Cart X-Ray System. The Company plans to submit an additional 510(k) premarket notification
to the FDA with respect to the multi-source Nanox.ARC and the Nanox.CLOUD during 2021.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company has experienced
net losses and negative cash flows from operations since its inception. The&#xa0;Company anticipates such losses will continue
until its product candidates reach commercial profitability. In August 2020, the Company completed an IPO on Nasdaq with net proceeds
received from the IPO of approximately $<font style="font-family: Times-Roman,serif">1</font>69 million .Based on the Company&#x2019;s
financing activities during the year ended December 31, 2020, the Company has sufficient funds for its plans for the next twelve
months from the issuance of these financial statements.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>e.</b></td><td style="text-align: left">Current Impact of COVID-19</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Following the December
2019 outbreak of Coronavirus (COVID-19) in China, it has spread into most countries across the world, including Israel, Japan
and all 50 states within the U.S. The COVID-19 pandemic is evolving, and to date has led to the implementation of various
responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The
COVID-19 pandemic has adversely impacted the Company&#x2019;s operations in various ways. For example, the Company&#x2019;s engineers are
unable to make work-related trips to Korea or Israel to test and optimize the Nanox.ARC or to begin development of x-ray chip
manufacturing in Korea. The potential business partners are unable to make on-site visits to the Company&#x2019;s facilities or
attend industry conferences and meetings to experience the Nanox.ARC, which has negatively impacted the Company&#x2019;s business
development and deployment activities. The external labs the Company works with have also been affected by COVID-19,
resulting in delays in the Company&#x2019;s timelines for obtaining regulatory approval. COVID-19 has also caused shutdowns or
disruptions of business for our manufactures and suppliers. The continued spread of COVID-19 globally could adversely impact
the Company&#x2019;s development, manufacture or deployment of the Nanox Systems, which could adversely affect the Company&#x2019;s ability
to obtain regulatory approval for and to commercialize the Nanox Systems, increase the operating expenses and have a material
adverse effect on the Company&#x2019;s financial results. (For the process with the FDA, see note 1d above).</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308761985944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><b>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES:</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: left">Our consolidated
financial statements are prepared in accordance with generally accepted accounting principles in the United States (hereinafter
-&#x201c;U.S GAAP&#x201d;). The preparation of our consolidated financial statements and related disclosures requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses and the disclosure of contingent
assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and
various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates
and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>a.&#xa0;</b></td>
    <td style="text-align: left"><b>Use of estimates in the preparation of financial statements</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those
estimates and such differences may have a material impact on the Company&#x2019;s consolidated financial statements. As applicable
to these consolidated financial statements, the most significant estimates relate to fair value of share-based payments.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>b.&#xa0;</b></td>
    <td style="text-align: left"><b>Functional currency</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The U.S. dollar is the currency
of the primary economic environment in which the operations of the Company and its subsidiary is conducted. A substantial portion
of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar
(&#x201c;primary currency&#x201d;).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Foreign currency assets and liabilities
are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date. Equity accounts
are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income
statement translation process. Expense accounts are translated using the weighted average exchange rate during the period. Currency
transaction gains and losses are presented in financial income and expenses, net.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>c.</b></td>
    <td style="text-align: left"><b>Cash and cash equivalents</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company considers as cash
equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three
months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts
of cash.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>d.</b></td>
    <td style="text-align: left"><b>Restricted&#xa0;Cash</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">As of December&#xa0;31, 2020,
the Company&#x2019;s restricted cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit
is presented at cost including accrued interest. This bank deposits is used as security for credit card use and collateralizing
the Company&#x2019;s lease contracts.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>e.</b></td>
    <td style="text-align: left"><b>Property&#xa0;and&#xa0;equipment,&#xa0;net</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Property and equipment are stated
at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful
lives:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Computers and electronic equipment</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">10-33</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Office furniture and lab equipment</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">6-20</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Machines</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">10-20</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left; text-indent: 0; padding-left: 0; padding-right: 0">Leasehold Improvement</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: center">&#xa0;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0; padding-left: 0; padding-right: 0">Land</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td><td style="text-align: center">N/A</td><td style="text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The depreciable life of leasehold
improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset
reasonably certain of exercise.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>f.</b></td>
    <td style="text-align: left"><b>Impairment&#xa0;of&#xa0;long-lived&#xa0;assets </b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company tests long-lived
assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be
recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated
undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less
than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over
the fair value of the asset, using the expected future discounted cash flows.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"> As of December
31, 2020, 2019 and 2018, the Company did not recognize an impairment loss on its long-lived assets.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>g.</b></td>
    <td style="text-align: left"><b>Severance&#xa0;pay</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Israeli labor law generally
requires severance pay be granted upon dismissal of an employee or upon termination of employment under certain other circumstances.
Pursuant to Section 14 of the Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), all of the Company&#x2019;s employees in
Israel are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies.
Payments under Section 14 relieve the Company from any future severance payment obligation with respect to those employees and,
as such, the Company may only utilize the insurance policies for the purpose of disbursement of severance pay. As a result, the
Company does not recognize an asset nor liability for these employees.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In 2020, all of the Company&#x2019;s
employees in Israel are subject to Section 14.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>h.</b></td>
    <td style="text-align: left"><b>Legal&#xa0;and other&#xa0;contingencies</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Certain conditions, such as
legal proceedings, may exist as of the date the consolidated financial statements are issued that may result in a loss to the
Company, but that will only be resolved when one or more future events occur or fail to occur. In assessing loss
contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such
proceedings, the Company&#x2019;s management evaluates with its legal advisors the perceived merits of any legal proceedings
or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Such assessment
inherently involves an exercise of judgment. Legal fees are expensed as incurred.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Management applies the guidance
in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable
that a material loss would be incurred and the amount of the liability can be estimated, then the Company records an accrued expense
in the Company&#x2019;s consolidated financial statements based on its best estimate. Loss contingencies considered to be remote
by management are generally not disclosed unless material. In September 2020, securities class action complaints were filed in
the United States by certain of the Company&#x2019;s shareholders against the Company and certain of the Company&#x2019;s current
officers and directors. For additional information see note 7.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>i.</b></td>
    <td style="text-align: left"><b>Research and development expenses</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Research and development expenses
are charged to the statement of operations as incurred and consist primarily of personnel, materials and supplies for research
and development activities.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>j.</b></td>
    <td style="text-align: left"><b>Income&#xa0;tax </b></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">1)</td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC&#xa0;740&#x201d;).
ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based
on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates
and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary,
to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred
tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and
assets are classified as non-current in accordance with ASU&#xa0;2015-17.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">2)</td><td style="text-align: left">Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not been
taken into account in computing the deferred income taxes, as it is the Company&#x2019;s intent and ability to hold these investments.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left">The Company accounts for uncertain
tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax
positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight
of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position
will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure
the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement.
The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>k.&#xa0;&#xa0;</b></td>
    <td style="text-align: left"><b>Share-based compensation</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company accounts for share-based
compensation under ASC 718, &#x201c;Compensation - Stock Compensation,&#x201d; which requires the measurement and recognition of
compensation expense based on estimated fair values for all share-based payment awards made to non-employees, employees, officers
and directors.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">ASC 718 requires companies to
estimate the fair value of equity-based payment awards on the date of grant. The Company uses the Black-Scholes-Merton option-pricing
model as part of such estimation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Prior to the adoption of ASU
2018-07, warrants issued to consultants and other non-employees, as compensation for services provided to the Company, were accounted
for based upon the fair value of the warrants. The fair value of the warrants granted was measured on a final basis at the end
of the related service period and was recognized over the related service period using the straight-line method. After the adoption
of ASU 2018-07, the measurement date for non-employee awards is the date of the grant. The compensation expense for non-employees
is recognized without changes in the fair value of the award, over the requisite service period, which is the vesting period of
the respective award using the straight line. The Company adopted ASU 2018-07 as of January 1, 2019 with no impact on its consolidated
financial statements as all of the Company&#x2019;s awards were fully vested at the adoption date.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>l.</b></td>
    <td style="text-align: left"><b>Loss&#xa0;per&#xa0;share</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Basic earnings per share is
computed by dividing net income (loss) attributable to holders of ordinary shares of the Company by the weighted average number
of ordinary shares outstanding for each reporting period.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In computing the Company&#x2019;s
diluted earnings per share, the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary
shares and the potential dilutive ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding
include the dilutive effect of in-the-money options using the treasury stock method.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company did not take into account
any dilutive instruments, such as investor warrants and share-based payments, since their effect, on a fully diluted basis, is
anti-dilutive.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>m.</b></td>
    <td style="text-align: left"><b>Fair&#xa0;value&#xa0;measurement</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Fair value is based on the price
that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between
market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the
guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into
three broad levels, which are described as follows:</p><br/><table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 1in">&#xa0;</td>
    <td style="text-align: left; width: 0.5in">Level 1:</td>
    <td style="text-align: left">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.</td></tr>
<tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td>
    <td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td style="text-align: left">Level 2: </td>
    <td style="text-align: left">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</td></tr>
<tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td>
    <td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td style="text-align: left">Level 3: </td>
    <td style="text-align: left">Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to
Level 3 inputs.</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In determining fair value, the
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to
the extent possible and considers counterparty credit risk in its assessment of fair value.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company&#x2019;s financial instruments
consist mainly of cash and cash equivalents, restricted cash accounts payable, accrued expenses and other liabilities. The fair
value of these financial instruments approximates their carrying values.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>n.</b></td>
    <td style="text-align: left"><b>Concentration&#xa0;of&#xa0;Credit Risks</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company&#x2019;s cash and cash
equivalents and restricted cash are invested with major banks in Israel, Korea and Japan. Generally, these investments may be redeemed
upon demand and the Company believes that the financial institutions that hold the Company&#x2019;s cash balances are financially
sound and, accordingly, bear minimal risk.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>o.</b></td>
    <td style="text-align: left"><b>Offering&#xa0;Costs </b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Deferred offering costs directly
relating to the Company&#x2019;s private and initial public offering, were capitalized and offset against proceeds upon the consummation
of the private and IPO transactions in shareholders&#x2019; equity.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>p.</b></td>
    <td style="text-align: left"><b>Leases</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">On January 1, 2019 the Company
adopted ASU No. 2016-02, Leases (Topic 842), The Company determines if an arrangement is a lease at inception. Balances related
to operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current maturities of operating leases
and Non-current operating leases in the consolidated balance sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">The Company also elected not
separating lease components from non-lease components and to keep leases with an initial term of 12 months or less off the balance
sheet and recognize the associated lease payments in the consolidated statements of operations on a straight-line basis over the
lease term.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">ROU assets represent the Company&#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on
the present value of lease payments over the lease term. The Company&#x2019;s lease terms may include options to extend or terminate
the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate
implicit in the lease unless that rate cannot be readily determined. As the Company&#x2019;s leases do not provide an implicit rate,
the Company&#x2019;s uses its estimated incremental borrowing rate based on the information available at the commencement date in
determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the
lease term (see also note 5).</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.75in">&#xa0;</td>
    <td style="text-align: left; width: 0.25in"><b>q.&#xa0;</b></td>
    <td style="text-align: left"><b>Newly issued and recently adopted accounting pronouncements:</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><b><i>Accounting Pronouncements
Adopted in Current year</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on
Financial Instruments (&#x201c;the Standard&#x201d;). This guidance replaces the current incurred loss impairment methodology.
Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance
that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based
on historical experience, current conditions and reasonable and supportable forecasts. In November 2018, the FASB issued ASU
2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. ASU 2018-19 clarifies that
receivables from operating leases are accounted for using the lease guidance and not as financial instruments.</font> Since
the Company has no financial instruments the Standard does not impact the Company&#x2019;s consolidated financial
statements.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308756762920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><b>NOTE
3 - PROPERTY AND EQUIPMENT, NET:</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">Composition of property and equipment
grouped by major classifications is as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars <br/>
in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 10pt; text-indent: -10pt">Office furniture and lab equipment</td><td style="width: 1%; font-family: Georgia, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">820</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">325</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Computers and electronic equipment</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">151</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">39</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Machinery</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,762</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Leasehold improvement</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">16</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Land &#x2013; See b below</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6,297</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Prepayments on account of production line in construction - See b below</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">14,364</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">364</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(136</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">Total property and equipment, net</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,020</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">228</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 58.5pt"></td><td style="width: 18pt"><b>a.</b></td><td style="text-align: left">Total depreciation in respect of property and equipment were approximately $208 thousand, $53 thousand
and $35 thousand for the years ended December 31, 2020, 2019 and 2018, respectively.</td></tr>
<tr style="vertical-align: top">
<td>&#xa0;</td><td>&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: top">
<td style="width: 58.5pt"></td><td style="width: 18pt"><b>b.</b></td><td style="text-align: left">In December 2020, Nanox Korea purchased a land for approximately $6.2 million upon which it intends
to build a manufacturing facility. Nanox Korea also rented a temporary fabrication plant and is in the process of preparing for
the commencement of full manufacturing activities, including purchasing certain equipment and transferring certain technology.</td></tr></table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308781311464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CashEquivalentsAndRestrictedCashAbstract', window );"><strong>Cash Equivalents And Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CashEquivalentsAndRestrictedCashTextBlock', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><font style="text-transform: uppercase"><b>NOTE
4 - CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The following table provides a
reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheet that sum to the same total
amount as shown in the consolidated statement of cash flows.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars<br/>
 in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">213,468</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">8,072</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted bank deposit</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">316</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -11.5pt; padding-left: 11.5pt">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">213,784</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">8,217</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CashEquivalentsAndRestrictedCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash equivalent and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CashEquivalentsAndRestrictedCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308756646744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><b>NOTE
5 - LEASES:</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">As of December 31, 2020, the Company
has four operating lease agreements for its car and facilities, as follows:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During the fourth quarter of
2019, the Company entered into an office lease agreement. This agreement is through December 31, 2021 with an option by the Company
to extend the period for an additional 24 months. The monthly rent payment is approximately $13 thousand.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During June 2020, the Company
entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023. The monthly rent payment
for this agreement is approximately $15 thousand.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During November 2020, following
the increase of the Company&#x2019;s employees, the Company signed an additional lease agreement, for a leasing of another office
complex through June 30, 2023. The monthly rent payment for this agreement is approximately $12 thousand.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During November 2020, the Company
engaged with car lease company, for leasing of 6 vehicles. This agreement is effective through June 30, 2023 and the monthly payment
for this agreement is approximately $6.5 thousand.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents the
effects on the amounts relating to the Company&#x2019;s total lease costs:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Year ended <br/>
December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Year ended <br/>
December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars<br/>
 in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">(U.S. Dollars <br/>
In thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease cost:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Fixed payments</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">276</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">25</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease cost</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">65</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease cost</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">341</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">137</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents supplemental
cash flow information related to operating leases:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Year ended <br/>
December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; white-space: nowrap">Year ended <br/>
December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">(U.S.&#xa0;Dollars<br/>
 in&#xa0;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">(U.S.&#xa0;Dollars<br/>
 in&#xa0;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">169</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">25</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Right-of-use assets obtained in exchange for lease obligations (non-cash):</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,085</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">548</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents supplemental
balance sheet information related to operating leases:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease right-of-use assets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,359</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">526</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current maturities of operating leases</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">519</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">140</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-current operating leases</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">923</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">386</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,442</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">526</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td style="font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; text-align: right"><b>December&#xa0;31,</b></td><td style="font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td style="font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; text-align: right"><b>December&#xa0;31,</b></td><td style="font-weight: bold; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted average remaining lease term</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.67</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.96</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted average discount rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.83</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.6</td><td style="text-align: left">%</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents maturities
of operating lease liabilities:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars <br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: left">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2020</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">588</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">588</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">382</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024 and thereafter</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total operating lease payments</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,558</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,442</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308756796360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartyLiabilityAbstract', window );"><strong>Related Party Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartyLiabilityTextBlock', window );">RELATED PARTY LIABILITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><b>NOTE
6 - RELATED PARTY LIABILITY</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">According to ASC
480, &#x201c;Distinguishing Liabilities From Equity,&#x201d; a financial instrument that embodies an unconditional obligation, or a
financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle
by issuing a variable number of its equity shares shall be classified as a liability if, at inception, the monetary value of the
obligation is based solely or predominantly on a fixed monetary amount known at inception. These liabilities are measured subsequently
at fair value with changes in fair value recognized in earnings.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">The Company analyzed
the instrument&#x2019;s provisions and concluded that it meets the above ASC 480 criteria and therefore accounted the expected future
payment under the APA in accordance with ASC 480.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">As of December
31, 2019, the Company recorded a Related Party Liability in an amount of $17.8 million, which represents the fair value of the
shares that have been issued to Nanox PLC, based on the last financing round of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">During January
2020, subject to entering into a share purchase agreement in the aggregate amount of at least $6 million, and a pre-money valuation
of more than $100 million, the Nanox IL&#x2019;s Board approved the issuance and allotment of 1,109,245 ordinary shares to Nanox
PLC with the purchase price of $12.00 per share, which reflects a discount of 25% from the price of the last financing round of
the Company. As a result, on January 30, 2020 the related party liability was settled into equity.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartyLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartyLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartyLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartyLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308761252056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><b>NOTE
7 - COMMITMENTS AND CONTINGENCIES</b>:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>a.</b></td><td style="text-align: left">In September 2020, securities class action complaints were filed in the United States by certain of
the Company&#x2019;s shareholders against the Company and certain of the Company&#x2019;s current officers and directors alleging
violations of securities laws and seeking unspecified damages. On December 7, 2020, the proposed lead plaintiffs&#x2019; submissions
were fully briefed. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. As of the
date of issuance of these financial statements, the Company is unable to estimate a range of loss, if any, that could result were
there to be an adverse final decision in these cases.</td></tr>
<tr style="vertical-align: top">
<td>&#xa0;</td><td>&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>b.</b></td><td style="text-align: left">For services with SixAI Ltd. (&#x201c;SixAI&#x201d;), see Note 10d.</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308762198712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><b>NOTE
8 - SHAREHOLDERS&#x2019; EQUITY:</b></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>a.</b></td><td style="text-align: left"><b>Share capital</b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Each holder of the Company&#x2019;s
ordinary shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are
legally available, and declared by the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;). Since inception, the Company
has not declared any dividends.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><i>Issuance
of Equity</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><i>Ordinary Share issuances
prior to the APA</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">During the year ended December
31, 2018, Nanox PLC entered into several agreements with third party investors, pursuant to which it raised an aggregate amount
of $3,684 thousand at a purchase price of $2.21 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On June 17, 2019, Nanox PLC
issued 2,262,443 ordinary shares to third party investors for an aggregate purchase price of approximately $5,000 thousand. Certain
investors were also granted warrants to acquire 2,262,443 of ordinary shares at an exercise price of $20.87 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Additionally, during 2019, Nanox
PLC entered into&#xa0;several agreements with certain third-party investors, pursuant to which it raised an aggregate amount of
$4,038 thousand, net of issuance costs, at a purchase price of $2.21 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><i>Ordinary Share issuances
after the APA</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On December 31, 2019, the Company
issued 312,500 ordinary shares to a third-party investor for an aggregate purchase price of approximately $5 million.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">During the year 2020, the Company
issued an aggregate of 4,624,500 ordinary shares to the certain investors, at a price per share of $16.00, for an aggregate purchase
price of approximately $74 million (the net proceeds were approximately $71 million after deducting issuance costs).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
August 2020, the Company completed an initial public offering (&#x201c;IPO&#x201d;) on the Nasdaq Global Market (the &#x201c;Nasdaq&#x201d;),
in which it issued 9,178,744 ordinary shares at a price per share of $18.&#xa0;During August 2020, the underwriters exercised
their over-allotment option and purchased an additional 1,376,812 ordinary shares at the same price per share. The proceeds received
from the IPO were $190 million (the net proceeds were approximately $169 million after deducting underwriting commissions and
other offering expenses).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><i>Settlement
of Related Party Liability</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Pursuant to the Asset Purchase
Agreement between Nanox IL and Nanox PLC, as more fully described in the Company&#x2019;s annual financial statements, in January 2020,
the Company issued 1,109,245 ordinary shares to Nanox PLC with a purchase price of $12.00 per share, which reflected a discount
of 25% from the price of the last financing round of the Company. As a result, the related party liability was settled into shareholders&#x2019;
equity.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>b.</b></td><td style="text-align: left"><b>Share based compensation </b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On September 3, 2019, the Company&#x2019;s
Board resolved to adopt an equity incentive plan (the &#x201c;Plan&#x201d;). Based on such Plan, each option will be exercisable for
one ordinary share of the Company and will become exercisable at such terms and during such periods, as the Board shall determine.
Pursuant to the Plan (and further increase of option pool approved by the Board), 8,041,936 ordinary shares of NIS 0.01 par value
of the Company are reserved for issuance upon the exercise of the same amount of awards to be granted to some of the Company&#x2019;s
employees, directors and consultants. As of December 31, 2020, 2,978,247 ordinary shares reserved for the equity incentive plan.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Board also approved the
Plan for the purpose of selecting the capital gains tax track, under Section 102 of the Israeli Income Tax Ordinance, for options
granted to the Company&#x2019;s Israeli employees.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 1in"></td><td style="width: 0.25in; text-align: left">1)</td><td style="text-align: left">Share-based compensation to non-employees</td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left">The following table summarizes
share-based awards to non-employees for the years ended December 31, 2020 and December 31, 2019:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">payment</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">payment</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 10pt; text-indent: -10pt">Outstanding at beginning of year</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">3,410,406</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.89</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,592,874</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.32</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Changes during the year:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt">Granted</td><td style="font-family: Georgia, Times, Serif">&#xa0;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,327,957</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">13.70</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,271,698</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.77</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">*(1,267,012</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.94</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(454,166</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.3</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt">Forfeited</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt">Expired</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(98,725</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,372,626</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5.27</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,410,406</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.89</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,191,042</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5.67</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,830,809</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.79</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: left">Out of which 1,027,151 awards were exercised on a
cashless basis.</td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The fair value of each granted award
is estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used for the years ended December
31, 2020 and 2019 are as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0; text-indent: 0">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Dividend yield</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: center">0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: center">0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Expected volatility</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">57.34%-44.40%</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">41.11% - 50.59%</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Risk-free interest rate</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">0.27%-1.61%</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">1.55%-1.76%</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Contractual term (years)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">5-10</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">0.50 &#x2013; 10.00</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The expected volatility is based
on the historical volatility of comparable companies.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The risk-free interest rate assumption
is based on observed interest rates appropriate for the expected term of the awards granted in dollar terms.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The Company does not have sufficient
historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course
options granted, the expected term was determined using the simplified method, which takes into consideration the option&#x2019;s
contractual life and the vesting periods (for non-employees, the expected term is equal to the option&#x2019;s contractual life).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The following table summarizes
information concerning outstanding and exercisable awards as of December 31, 2020 and 2019:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">award</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">0.33</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">0.33</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">1.92</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">269,714</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.18</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">269,714</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.18</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">2.21</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,191,349</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.22</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,188,914</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.22</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">16.00</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">444,748</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.89</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">283,933</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.89</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">18.00</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">260,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.86</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">260,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.86</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">30.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.81</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,666</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.81</td><td style="text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">1.33</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">1.33</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">1.92</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">472,606</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.81</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">472,606</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.81</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">2.21</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,727,028</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.27</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,163,402</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.27</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">20.87</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">23,957</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.69</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,986</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.69</td><td style="text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">2)</td><td style="text-align: left">Share-based compensation to employees, officers and directors</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">During 2020, the Company granted
to certain employees, officers and directors awards to purchase 730,734 of the Company&#x2019;s ordinary shares for an average exercise
price of $13.53.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>Number of</b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>Weighted </b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>Number of</b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>Weighted </b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>share-based</b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>average </b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>share-based</b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>average </b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>payment awards</b></p></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>exercise price</b></p></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>payment awards</b></p></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>exercise price</b></p></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,667,267</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.21</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,667,267</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.21</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes during the year:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 8.8pt">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">730,734</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.53</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 8.8pt">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 8.8pt">Forfeited</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 8.8pt">Expired</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 8.8pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,876</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,381,125</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4.14</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,667,267</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2.21</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,061,778</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.80</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">450,557</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2.21</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: left">The fair value of each granted
award is estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used as of December 31,
2020 and 2019 are as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="font-weight: bold; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2019</td><td style="font-weight: bold; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; white-space: nowrap">Dividend yield</td><td style="width: 1%; white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: center; white-space: nowrap">0</td><td style="width: 1%; text-align: left; white-space: nowrap">&#xa0;</td><td style="width: 1%; white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: center; white-space: nowrap">0</td><td style="width: 1%; text-align: left; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; white-space: nowrap">Expected volatility</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">45.11%-55.97%</p></td><td style="text-align: left; white-space: nowrap">&#xa0;</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">45.11%-55.97%</p></td><td style="text-align: left; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; white-space: nowrap">Risk-free interest rate</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">0.23%-1.61%</p></td><td style="text-align: left; white-space: nowrap">&#xa0;</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">0.23%-1.61%</p></td><td style="text-align: left; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; white-space: nowrap">Contractual term (years)</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">10</td><td style="text-align: left; white-space: nowrap">&#xa0;</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">10</td><td style="text-align: left; white-space: nowrap">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0">The expected
volatility is based on the historical volatility of comparable companies.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0">The risk-free
interest rate assumption is based on observed interest rates appropriate for the expected term of the awards granted in dollar
terms.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0">The Company
does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly,
as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration
the option&#x2019;s contractual life and the vesting periods.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0">The following
table summarizes information concerning outstanding and exercisable awards as of December 31, 2020 and 2019:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"></td><td style="width: 18%; text-align: center">$2.21</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">1,995,625</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">9.05</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">1,019,695</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">9.05</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left"></td><td style="text-align: center">$16.00</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">205,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.62</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">37,917</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.62</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: center">$26.56-$59.20</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">180,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.93</td><td style="text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"></td><td style="width: 18%; text-align: center">$2.21</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">1,667,267</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">9.90</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">450,557</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">9.90</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">3)</td><td style="text-align: left">Share-based compensation expenses</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">3,384</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">661</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Marketing (*)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9,252</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">617</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,145</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">24,781</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">16,245</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">115</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><b>(*)</b></td><td style="text-align: left">On October 26, 2020, the Company entered into an amendment
to a business development agreement (&#x201c;the Agreement&#x201d;) dated February 4, 2020 with two service providers pursuant to
which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate
of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date
(subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants
granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant
to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues
from any of the Company&#x2019;s systems and the issuance of warrants.</td>
</tr></table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308761991176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in; text-align: left"><b>NOTE 9 -</b></td><td style="text-align: left"><b>INCOME TAX:</b></td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>a.</b></td><td style="text-align: left"><b>Basis of taxation</b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Current tax is calculated with
reference to the profit of the Company and its subsidiary in their respective countries of operation. Set out below are details
in respect of the significant jurisdictions where the Company and its subsidiary operates and the factors that influenced the current
and deferred taxation in those jurisdictions:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><b><i>Israel</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company is taxed under the
laws of the State of Israel at a corporate tax rate of 23%. In 20<font style="font-family: Georgia, Times, Serif">20</font>, the
Company was at a loss position and therefore had no corporate tax liability.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><b><i>Korea</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Nanox Korea is subject to a Corporate
income tax with accordance with the Korean tax law. The tax rate ranges between 10% to 25%, depending on the companies&#x2019; taxable
income. In Addition, Nanox Korea is subject to a Local income tax of 10%. In 2020, Nanox Korea was at a loss position and therefore
had no corporate tax liability.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><b><i>Japan</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Nanox Inc. is subject to national
corporate income tax, and enterprise tax, which, in the aggregate resulted in effective tax rate of approximately 33.59% for the
year ended December 31, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Under Japanese tax law and regulations,
every company is required to submit an annual tax return to tax authorities. The statute of limitations to request a correction
of prior year tax liabilities is five years from when the original tax return was filed. After filling of tax return, the tax authorities
may conduct tax inspections on an irregular basis.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>b.</b></td><td style="text-align: left"><b>Tax assessments</b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Nanox IL , Nanox Korea and Nanox
Inc. have not been assessed since inception.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>c.</b></td><td style="text-align: left"><b>Deferred tax assets </b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Nanox IL&#x2019;s deferred tax asset as
of December 31, 2020 was related to tax losses accumulated since September 3, 2019 and carryforward.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">A full valuation allowance was
created against deferred tax assets arisen from the carryforward tax losses, since the realization of any future benefit from the
carryforward tax losses cannot be sufficiently assured as of December 31, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The reconciling item between the
statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax benefits from
carried forward tax losses due to uncertainty of the realization of such tax benefits.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Change in valuation allowance for
the year ended December 31, 2020 was $3,262 thousand.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308756511768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Transactions and Balances<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES - TRANSACTIONS AND BALANCES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><b>NOTE
10 - RELATED PARTIES - TRANSACTIONS AND BALANCES:</b></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>a.</b></td><td style="text-align: left"><b>Balances with related parties:</b></td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">December 31,</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2020</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2019</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">(U.S. Dollars in thousands)</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 4pt; width: 76%; text-align: left; text-indent: 0">Related party accrued liability</td><td style="padding: 0 0 4pt; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-indent: 0">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">-</td><td style="padding: 0 0 4pt; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: 0">&#xa0;</td><td style="padding: 0 0 4pt; width: 1%; text-indent: 0">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">72</td><td style="padding: 0 0 4pt; width: 1%; text-align: left; text-indent: 0">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding: 0 0 4pt; text-align: left; text-indent: 0">Related party liability, refer to note 6</td><td style="padding: 0 0 4pt; text-indent: 0">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">-</td><td style="padding: 0 0 4pt; text-align: left; text-indent: 0">&#xa0;</td><td style="padding: 0 0 4pt; text-indent: 0">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">17,748</td><td style="padding: 0 0 4pt; text-align: left; text-indent: 0">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>b.</b></td><td style="text-align: left"><b>Related parties transactions:</b></td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Research and development &#x2013; see c and d below</td><td style="width: 1%; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">355</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">154</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">542</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">General and administrative &#x2013; See c, e and f below</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">(167</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5,824</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">892</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>c.</b></td><td style="text-align: left"><b>Six-Eye Interactive agreements for services </b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On June 1 2015, Nanox PLC entered
into a consulting agreement with Six-Eye, a company owned by Ran Poliakine, the Company&#x2019;s CEO and one of major shareholders, pursuant
to which Ran Poliakine agreed to provide services as Chief Strategy Officer and a member of the Executive Committee to Nanox PLC.
On May 1, 2017, Nanox PLC entered into a services agreement with Six-Eye for the supply of ongoing services, which include research
and development services, general and financial management (including accountancy), office management services and operational
and supply services. According to the agreement between the parties, Nanox PLC reimburses Six-Eye for its actual direct expenses
plus a 12% surplus charge. The agreements were terminated in September 2019. During the years ended December 31 2019 and 2018 the
total expenses to Six-Eye were $679 thousand and $1,434 thousand, respectively. In addition to the services provided by Six-Eye
during 2019, Six-Eye also paid directly to third-party consultants and suppliers on behalf of the Company in the amount of approximately
$1,015 thousand prior to the completion of the Company&#x2019;s equity financing.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>d.</b></td><td style="text-align: left"><b>SixAI Ltd Service agreement</b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">On April 16,2020, the Company
entered into an agreement with SixAI Ltd. (hereinafter-&#x201c;SixAI&#x201d;) a company controlled by Ran Poliakine, the Company&#x2019;s
CEO for certain software development and mechanical engineering services. The service agreement is effective as of March 1, 2020
and has been extended by mutual agreement of the parties to March 31, 2021. During the year ended December 31, 2020, the Company
recorded an expense of $355 thousand. Mr. Poliakine currently serves as a member of the board of directors of SixAI and Mr. Poliakine
is a significant shareholder of SixAI.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>e.</b></td><td style="text-align: left"><b>Illumigyn Ltd. </b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Illumigyn Ltd (hereinafter
&#x2013; &#x201c;Illumigyn&#x201d;) is a company in which Ran Poliakine, the Company&#x2019;s CEO, is a significant shareholder primarily through
indirect holdings. Since November 1 2019, Illumigyn sub-leased in transaction approximately 1,800 square feet of private office
space, including access to shared public spaces, from the office spaces which the Company leases in Neve Ilan, Israel. Illumigyn
pays approximately $12 thousand per month. During the year ended December 31, 2020, the Company received approximately $163 thousand
in relation to the sub lease.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>f.</b></td><td style="text-align: left"><b>Wellsese Technologies Ltd.</b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Wellsense
Technologies Ltd (hereinafter &#x2013; &#x201c;Wellsense&#x201d;) is a company in which Ran Poliakine, the Company&#x2019;s CEO, and Richard
Stone, a member of the Company&#x2019;s board of directors, are shareholders. Since February 2020, Wellsense has sub-leased private
office space, including access to shared public spaces, from the Company in Neve Ilan, Israel. Wellsense pays approximately $7.0
thousand per month. During the year ended December 31, 2020, the Company received $59 thousand, in relation to the sub lease.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>g.</b></td><td style="text-align: left">Pursuant to the Asset Purchase Agreement between Nanox IL and Nanox PLC, as of December 31, 2020,
the Company has settled the related party liability balance of $192 thousand to Nanox Japan and Nanox PLC, mainly for Fixed Assets
which were transferred to the Company as part of the APA.</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308761292344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><b>NOTE
11 </b>- <b>LOSS PER SHARE:</b></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>a.</b></td><td style="text-align: left"><b>Basic</b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Basic loss
per share is calculated by dividing the loss attributable to the Company&#x2019;s owners by the weighted average number of ordinary
shares in issue.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Net loss attributable to Company&#x2019;s owners</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(43,815</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(22,563</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(1,909</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">The weighted average of the number of ordinary shares (in thousands)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">35,654</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">25,181</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">20,793</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Basic and diluted loss per share</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1.23</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.90</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.09</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">For the calculation
of loss per share, the Company used the net loss attributable to Company&#x2019;s owners divided by the weighted average number
of the Company&#x2019;s ordinary shares for the years ended December 31, 2020, 2019 and 2018.</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>b.</b></td><td style="text-align: left"><b>Diluted</b></td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">As of December 31, 20<font style="font-family: Georgia, Times, Serif">20</font>
and 201<font style="font-family: Georgia, Times, Serif">9</font> the Company had 7,846,290 and 9,203,124 investor warrants and
employees and non-employees option awards, respectively. These warrants and awards were not taken into account when calculating
diluted loss per share since their effect is anti-dilutive.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308756511768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0in; text-align: left"><b>NOTE
12 - SUBSEQUENT EVENTS:</b></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>a.</b></td><td style="text-align: left">During 2021, the Company granted a total of 338,929 awards with an average exercise price of $48.59
per share to employees.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><b>b.</b></td><td style="text-align: left">In February 2021 the Company completed a secondary offering of 3,091,635 ordinary shares by certain
non-director, non-officer selling pre-IPO shareholders. An additional 845,044 shares were locked up for an additional period as
part of the agreed terms. The Company cooperated with the offering lead underwriter while each participating shareholder paid the
underwriters fees and the Company covered the legal, accounting, administrative and regulatory fees which totaled approximately
$818 thousand. The Company received no proceeds from the described above public secondary offering.</td></tr></table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750782936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>a.&#xa0;</b></td>
    <td style="text-align: left"><b>Use of estimates in the preparation of financial statements</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those
estimates and such differences may have a material impact on the Company&#x2019;s consolidated financial statements. As applicable
to these consolidated financial statements, the most significant estimates relate to fair value of share-based payments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>b.&#xa0;</b></td>
    <td style="text-align: left"><b>Functional currency</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The U.S. dollar is the currency
of the primary economic environment in which the operations of the Company and its subsidiary is conducted. A substantial portion
of the operational costs are denominated in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar
(&#x201c;primary currency&#x201d;).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Foreign currency assets and liabilities
are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date. Equity accounts
are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income
statement translation process. Expense accounts are translated using the weighted average exchange rate during the period. Currency
transaction gains and losses are presented in financial income and expenses, net.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>c.</b></td>
    <td style="text-align: left"><b>Cash and cash equivalents</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company considers as cash
equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three
months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts
of cash.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>d.</b></td>
    <td style="text-align: left"><b>Restricted&#xa0;Cash</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">As of December&#xa0;31, 2020,
the Company&#x2019;s restricted cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit
is presented at cost including accrued interest. This bank deposits is used as security for credit card use and collateralizing
the Company&#x2019;s lease contracts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>e.</b></td>
    <td style="text-align: left"><b>Property&#xa0;and&#xa0;equipment,&#xa0;net</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Property and equipment are stated
at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful
lives:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Computers and electronic equipment</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">10-33</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Office furniture and lab equipment</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">6-20</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Machines</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">10-20</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left; text-indent: 0; padding-left: 0; padding-right: 0">Leasehold Improvement</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: center">&#xa0;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0; padding-left: 0; padding-right: 0">Land</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td><td style="text-align: center">N/A</td><td style="text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The depreciable life of leasehold
improvements is limited by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset
reasonably certain of exercise.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>f.</b></td>
    <td style="text-align: left"><b>Impairment&#xa0;of&#xa0;long-lived&#xa0;assets </b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company tests long-lived
assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be
recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset to the estimated
undiscounted future cash flows expected to be generated by the asset. If the sum of the expected undiscounted cash flow is less
than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount over
the fair value of the asset, using the expected future discounted cash flows.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"> As of December
31, 2020, 2019 and 2018, the Company did not recognize an impairment loss on its long-lived assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>g.</b></td>
    <td style="text-align: left"><b>Severance&#xa0;pay</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Israeli labor law generally
requires severance pay be granted upon dismissal of an employee or upon termination of employment under certain other circumstances.
Pursuant to Section 14 of the Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), all of the Company&#x2019;s employees in
Israel are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies.
Payments under Section 14 relieve the Company from any future severance payment obligation with respect to those employees and,
as such, the Company may only utilize the insurance policies for the purpose of disbursement of severance pay. As a result, the
Company does not recognize an asset nor liability for these employees.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In 2020, all of the Company&#x2019;s
employees in Israel are subject to Section 14.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LegalAndOtherContingenciesPolicyTextBlock', window );">Legal and other contingencies</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>h.</b></td>
    <td style="text-align: left"><b>Legal&#xa0;and other&#xa0;contingencies</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Certain conditions, such as
legal proceedings, may exist as of the date the consolidated financial statements are issued that may result in a loss to the
Company, but that will only be resolved when one or more future events occur or fail to occur. In assessing loss
contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such
proceedings, the Company&#x2019;s management evaluates with its legal advisors the perceived merits of any legal proceedings
or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. Such assessment
inherently involves an exercise of judgment. Legal fees are expensed as incurred.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Management applies the guidance
in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable
that a material loss would be incurred and the amount of the liability can be estimated, then the Company records an accrued expense
in the Company&#x2019;s consolidated financial statements based on its best estimate. Loss contingencies considered to be remote
by management are generally not disclosed unless material. In September 2020, securities class action complaints were filed in
the United States by certain of the Company&#x2019;s shareholders against the Company and certain of the Company&#x2019;s current
officers and directors. For additional information see note 7.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>i.</b></td>
    <td style="text-align: left"><b>Research and development expenses</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Research and development expenses
are charged to the statement of operations as incurred and consist primarily of personnel, materials and supplies for research
and development activities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income tax</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>j.</b></td>
    <td style="text-align: left"><b>Income&#xa0;tax </b></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">1)</td><td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC&#xa0;740&#x201d;).
ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based
on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates
and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary,
to reduce deferred tax assets to their estimated realizable value if it is more likely than not that a portion or all of the deferred
tax assets will not be realized, based on the weight of available positive and negative evidence. Deferred tax liabilities and
assets are classified as non-current in accordance with ASU&#xa0;2015-17.</td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"></td><td style="width: 0.25in">2)</td><td style="text-align: left">Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not been
taken into account in computing the deferred income taxes, as it is the Company&#x2019;s intent and ability to hold these investments.</td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left">The Company accounts for uncertain
tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax
positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight
of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position
will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure
the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement.
The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>k.&#xa0;&#xa0;</b></td>
    <td style="text-align: left"><b>Share-based compensation</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company accounts for share-based
compensation under ASC 718, &#x201c;Compensation - Stock Compensation,&#x201d; which requires the measurement and recognition of
compensation expense based on estimated fair values for all share-based payment awards made to non-employees, employees, officers
and directors.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">ASC 718 requires companies to
estimate the fair value of equity-based payment awards on the date of grant. The Company uses the Black-Scholes-Merton option-pricing
model as part of such estimation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Prior to the adoption of ASU
2018-07, warrants issued to consultants and other non-employees, as compensation for services provided to the Company, were accounted
for based upon the fair value of the warrants. The fair value of the warrants granted was measured on a final basis at the end
of the related service period and was recognized over the related service period using the straight-line method. After the adoption
of ASU 2018-07, the measurement date for non-employee awards is the date of the grant. The compensation expense for non-employees
is recognized without changes in the fair value of the award, over the requisite service period, which is the vesting period of
the respective award using the straight line. The Company adopted ASU 2018-07 as of January 1, 2019 with no impact on its consolidated
financial statements as all of the Company&#x2019;s awards were fully vested at the adoption date.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>l.</b></td>
    <td style="text-align: left"><b>Loss&#xa0;per&#xa0;share</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Basic earnings per share is
computed by dividing net income (loss) attributable to holders of ordinary shares of the Company by the weighted average number
of ordinary shares outstanding for each reporting period.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In computing the Company&#x2019;s
diluted earnings per share, the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary
shares and the potential dilutive ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding
include the dilutive effect of in-the-money options using the treasury stock method.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company did not take into account
any dilutive instruments, such as investor warrants and share-based payments, since their effect, on a fully diluted basis, is
anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>m.</b></td>
    <td style="text-align: left"><b>Fair&#xa0;value&#xa0;measurement</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Fair value is based on the price
that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between
market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the
guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into
three broad levels, which are described as follows:</p><br/><table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 1in">&#xa0;</td>
    <td style="text-align: left; width: 0.5in">Level 1:</td>
    <td style="text-align: left">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.</td></tr>
<tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td>
    <td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td style="text-align: left">Level 2: </td>
    <td style="text-align: left">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</td></tr>
<tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td>
    <td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td style="text-align: left">Level 3: </td>
    <td style="text-align: left">Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to
Level 3 inputs.</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">In determining fair value, the
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to
the extent possible and considers counterparty credit risk in its assessment of fair value.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company&#x2019;s financial instruments
consist mainly of cash and cash equivalents, restricted cash accounts payable, accrued expenses and other liabilities. The fair
value of these financial instruments approximates their carrying values.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration&#160;of&#160;Credit Risks</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>n.</b></td>
    <td style="text-align: left"><b>Concentration&#xa0;of&#xa0;Credit Risks</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and restricted cash.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">The Company&#x2019;s cash and cash
equivalents and restricted cash are invested with major banks in Israel, Korea and Japan. Generally, these investments may be redeemed
upon demand and the Company believes that the financial institutions that hold the Company&#x2019;s cash balances are financially
sound and, accordingly, bear minimal risk.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredOfferingCostsPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>o.</b></td>
    <td style="text-align: left"><b>Offering&#xa0;Costs </b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Deferred offering costs directly
relating to the Company&#x2019;s private and initial public offering, were capitalized and offset against proceeds upon the consummation
of the private and IPO transactions in shareholders&#x2019; equity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>p.</b></td>
    <td style="text-align: left"><b>Leases</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">On January 1, 2019 the Company
adopted ASU No. 2016-02, Leases (Topic 842), The Company determines if an arrangement is a lease at inception. Balances related
to operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current maturities of operating leases
and Non-current operating leases in the consolidated balance sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">The Company also elected not
separating lease components from non-lease components and to keep leases with an initial term of 12 months or less off the balance
sheet and recognize the associated lease payments in the consolidated statements of operations on a straight-line basis over the
lease term.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">ROU assets represent the Company&#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized as of the commencement date based on
the present value of lease payments over the lease term. The Company&#x2019;s lease terms may include options to extend or terminate
the lease when it is reasonably certain that the Company will exercise that option. The discount rate for the lease is the rate
implicit in the lease unless that rate cannot be readily determined. As the Company&#x2019;s leases do not provide an implicit rate,
the Company&#x2019;s uses its estimated incremental borrowing rate based on the information available at the commencement date in
determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the
lease term (see also note 5).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly issued and recently adopted accounting pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"><td style="text-align: left; width: 0.25in"><b>q.&#xa0;</b></td>
    <td style="text-align: left"><b>Newly issued and recently adopted accounting pronouncements:</b></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><b><i>Accounting Pronouncements
Adopted in Current year</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) - Measurement of Credit Losses on
Financial Instruments (&#x201c;the Standard&#x201d;). This guidance replaces the current incurred loss impairment methodology.
Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance
that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based
on historical experience, current conditions and reasonable and supportable forecasts. In November 2018, the FASB issued ASU
2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. ASU 2018-19 clarifies that
receivables from operating leases are accounted for using the lease guidance and not as financial instruments.</font> Since
the Company has no financial instruments the Standard does not impact the Company&#x2019;s consolidated financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LegalAndOtherContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LegalAndOtherContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308761108872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Computers and electronic equipment</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">10-33</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Office furniture and lab equipment</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">6-20</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-right: 0; padding-left: 0; text-indent: 0">Machines</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">10-20</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left; text-indent: 0; padding-left: 0; padding-right: 0">Leasehold Improvement</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: center">&#xa0;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0; padding-left: 0; padding-right: 0">Land</td><td>&#xa0;</td>
    <td style="text-align: center">&#xa0;</td><td style="text-align: center">N/A</td><td style="text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Property and equipment are stated at cost, net of accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308766608328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars <br/>
in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 10pt; text-indent: -10pt">Office furniture and lab equipment</td><td style="width: 1%; font-family: Georgia, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right">820</td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">325</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Computers and electronic equipment</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">151</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">39</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Machinery</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,762</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Leasehold improvement</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">16</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Land &#x2013; See b below</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6,297</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Prepayments on account of production line in construction - See b below</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">14,364</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">364</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(136</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">Total property and equipment, net</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,020</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">228</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308756568664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CashEquivalentsAndRestrictedCashAbstract', window );"><strong>Cash Equivalents And Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of reconciliation of cash, cash equivalents and restricted cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#xa0;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars<br/>
 in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">213,468</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">8,072</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted bank deposit</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">316</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">145</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -11.5pt; padding-left: 11.5pt">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">213,784</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">8,217</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308756681704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of the compnay's total lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Year ended <br/>
December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Year ended <br/>
December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: right">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars<br/>
 in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">(U.S. Dollars <br/>
In thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease cost:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Fixed payments</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">276</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">25</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease cost</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right">65</td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease cost</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">341</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">137</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information related to operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Year ended <br/>
December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; white-space: nowrap">Year ended <br/>
December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">(U.S.&#xa0;Dollars<br/>
 in&#xa0;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">(U.S.&#xa0;Dollars<br/>
 in&#xa0;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">169</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">25</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Right-of-use assets obtained in exchange for lease obligations (non-cash):</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,085</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">548</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock', window );">Schedule of supplemental balance sheet information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease right-of-use assets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,359</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">526</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current maturities of operating leases</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">519</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">140</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-current operating leases</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">923</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">386</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,442</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">526</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td style="font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; text-align: right"><b>December&#xa0;31,</b></td><td style="font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td style="font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; text-align: right"><b>December&#xa0;31,</b></td><td style="font-weight: bold; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted average remaining lease term</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.67</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.96</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted average discount rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.83</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.6</td><td style="text-align: left">%</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December&#xa0;31,</td><td style="white-space: nowrap; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars <br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: left">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2020</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">588</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">588</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">382</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024 and thereafter</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total operating lease payments</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,558</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,442</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750812712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityTablesLineItems', window );"><strong>Shareholders' Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock', window );">Schedule of share-based payments to non-employees</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">payment</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">payment</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 10pt; text-indent: -10pt">Outstanding at beginning of year</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">3,410,406</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.89</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,592,874</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.32</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Changes during the year:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt">Granted</td><td style="font-family: Georgia, Times, Serif">&#xa0;</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">1,327,957</td><td style="font-family: Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">13.70</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,271,698</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.77</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">*(1,267,012</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.94</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(454,166</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.3</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt">Forfeited</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in; text-indent: -10pt">Expired</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -10pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(98,725</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,372,626</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5.27</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,410,406</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.89</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,191,042</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5.67</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,830,809</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.79</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes option-pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0; text-indent: 0">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Dividend yield</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: center">0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: center">0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Expected volatility</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">57.34%-44.40%</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">41.11% - 50.59%</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Risk-free interest rate</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">0.27%-1.61%</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">1.55%-1.76%</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Contractual term (years)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">5-10</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">0.50 &#x2013; 10.00</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of information concerning outstanding and exercisable awards</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">award</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">0.33</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">0.33</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">1.92</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">269,714</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.18</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">269,714</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.18</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">2.21</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,191,349</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.22</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,188,914</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.22</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">16.00</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">444,748</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.89</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">283,933</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.89</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">18.00</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">260,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.86</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">260,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.86</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">30.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.81</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,666</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.81</td><td style="text-align: left">&#xa0;</td></tr>
</table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">1.33</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">1.33</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">1.92</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">472,606</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.81</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">472,606</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.81</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">2.21</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,727,028</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.27</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,163,402</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.27</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">20.87</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">23,957</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.69</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,986</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.69</td><td style="text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfWarrantsTableTextBlock', window );">Schedule of share-based compensation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">3,384</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">661</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Marketing (*)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9,252</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">617</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,145</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">115</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">24,781</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">16,245</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">115</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember', window );">Employees, Officers and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityTablesLineItems', window );"><strong>Shareholders' Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes option-pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="font-weight: bold; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2019</td><td style="font-weight: bold; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; white-space: nowrap">Dividend yield</td><td style="width: 1%; white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: center; white-space: nowrap">0</td><td style="width: 1%; text-align: left; white-space: nowrap">&#xa0;</td><td style="width: 1%; white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: center; white-space: nowrap">0</td><td style="width: 1%; text-align: left; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; white-space: nowrap">Expected volatility</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">45.11%-55.97%</p></td><td style="text-align: left; white-space: nowrap">&#xa0;</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">45.11%-55.97%</p></td><td style="text-align: left; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; white-space: nowrap">Risk-free interest rate</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">0.23%-1.61%</p></td><td style="text-align: left; white-space: nowrap">&#xa0;</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">0.23%-1.61%</p></td><td style="text-align: left; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; white-space: nowrap">Contractual term (years)</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">10</td><td style="text-align: left; white-space: nowrap">&#xa0;</td><td style="white-space: nowrap">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap">10</td><td style="text-align: left; white-space: nowrap">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of information concerning outstanding and exercisable awards</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"></td><td style="width: 18%; text-align: center">$2.21</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">1,995,625</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">9.05</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">1,019,695</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">9.05</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left"></td><td style="text-align: center">$16.00</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">205,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.62</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">37,917</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.62</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: center">$26.56-$59.20</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">180,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.93</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.93</td><td style="text-align: left">&#xa0;</td></tr>
</table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"></td><td style="width: 18%; text-align: center">$2.21</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">1,667,267</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">9.90</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">450,557</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 17%; text-align: right">9.90</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of shared - based payments to employees</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>Number of</b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>Weighted </b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>Number of</b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>Weighted </b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>share-based</b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>average </b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>share-based</b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; text-align: center; white-space: nowrap"><b>average </b></td><td style="font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>payment awards</b></p></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>exercise price</b></p></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>payment awards</b></p></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>exercise price</b></p></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center; white-space: nowrap">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,667,267</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.21</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,667,267</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.21</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes during the year:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 8.8pt">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">730,734</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.53</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 8.8pt">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 8.8pt">Forfeited</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 8.8pt">Expired</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 8.8pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,876</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,381,125</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4.14</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,667,267</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2.21</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,061,778</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.80</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">450,557</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2.21</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock awards granted to nonemployee directors that were outstanding at the beginning and end of the year, and the number of awards that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308752419336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Transactions and Balances (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of balances with related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">December 31,</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2020</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2019</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">(U.S. Dollars in thousands)</td><td style="padding: 0 0 1.5pt; font-weight: bold; text-indent: 0">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 4pt; width: 76%; text-align: left; text-indent: 0">Related party accrued liability</td><td style="padding: 0 0 4pt; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-indent: 0">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; font-family: Arial, Helvetica, Sans-Serif; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">-</td><td style="padding: 0 0 4pt; width: 1%; font-family: Arial, Helvetica, Sans-Serif; text-align: left; text-indent: 0">&#xa0;</td><td style="padding: 0 0 4pt; width: 1%; text-indent: 0">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">72</td><td style="padding: 0 0 4pt; width: 1%; text-align: left; text-indent: 0">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding: 0 0 4pt; text-align: left; text-indent: 0">Related party liability, refer to note 6</td><td style="padding: 0 0 4pt; text-indent: 0">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">-</td><td style="padding: 0 0 4pt; text-align: left; text-indent: 0">&#xa0;</td><td style="padding: 0 0 4pt; text-indent: 0">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">17,748</td><td style="padding: 0 0 4pt; text-align: left; text-indent: 0">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock', window );">Schedule of related parties transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Research and development &#x2013; see c and d below</td><td style="width: 1%; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">355</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">154</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">542</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">General and administrative &#x2013; See c, e and f below</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">(167</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5,824</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">892</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfRelatedPartiesTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308761048328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Net loss attributable to Company&#x2019;s owners</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(43,815</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(22,563</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">(1,909</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">The weighted average of the number of ordinary shares (in thousands)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">35,654</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">25,181</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">20,793</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Basic and diluted loss per share</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1.23</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.90</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.09</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750615976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Ordinary shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,167,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial public offering net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,348,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Acquired assets, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nanox IL shall pay Nanox PLC $6.127 million as consideration for the purchase of the Acquired Assets, which reflects the fair value of the Acquired Assets (excluding cash) plus the cash balance as of the date of the APA, less $200 thousand. The purchase price shall be due and payable upon the closing of one of the following events: (a) an M&amp;A event of Nanox IL, (b) an IPO of Nanox IL, or (c) a qualified equity financing of Nanox IL at a minimum company pre-money valuation of $100 million, with proceeds totaling at least $30 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CashConsiderationDescription', window );">Cash consideration, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nanox PLC transferred to Nanox IL an amount of $7.2 million, which reflects the cash consideration under the APA. The total consideration of the purchase of the Acquired Assets is $13.3 million. The outstanding balance of $17.8 million reflects the related party liability of the expected future payment using the Company&#x2019;s shares, refer to note 6.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares, issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,178,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Ordinary shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_InitialPublicOfferingNetProceeds', window );">Initial public offering including the options granted to underwriters proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Nasdaq [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial public offering net proceeds</a></td>
<td class="nump">$ 169,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares, issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CashConsiderationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CashConsiderationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_GeneralDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_GeneralDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_InitialPublicOfferingNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering net proceeds .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_InitialPublicOfferingNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the acquired entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionNameOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nnox_NasdaqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nnox_NasdaqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750659672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and electronic equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">10-33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">6-20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machines [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">10-20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308755545000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 208<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfOtherAssets1', window );">Purchase of land</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfOtherAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid to purchase other assets as part of operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPurchaseOfOtherAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750711688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of property and equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 14,364<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(344)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">14,020<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorPropertyClassAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorPropertyClassAxis=us-gaap_ComputerEquipmentMember', window );">Computers and electronic equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorPropertyClassAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorPropertyClassAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">16<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorPropertyClassAxis=nnox_LandSeeBBelowMember', window );">Land &#8211; See b below [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">6,297<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorPropertyClassAxis=nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember', window );">Prepayments on account of production line in construction - See b below [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 5,318<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorPropertyClassAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorPropertyClassAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorPropertyClassAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorPropertyClassAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorPropertyClassAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorPropertyClassAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorPropertyClassAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorPropertyClassAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorPropertyClassAxis=nnox_LandSeeBBelowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorPropertyClassAxis=nnox_LandSeeBBelowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorPropertyClassAxis=nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorPropertyClassAxis=nnox_PrepaymentsOnAccountOfProductionLineInConstructionSeeBBelowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308769190360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Schedule of reconciliation of cash, cash equivalents and restricted cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 213,468<span></span>
</td>
<td class="nump">$ 8,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted bank deposit</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 213,784<span></span>
</td>
<td class="nump">$ 8,217<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308770106936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LeaseTermDescription', window );">Rent payment agreement, description</a></td>
<td class="text">During November 2020, following the increase of the Company&#x2019;s employees, the Company signed an additional lease agreement, for a leasing of another office complex through June 30, 2023.<span></span>
</td>
<td class="text">During June 2020, the Company entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023.<span></span>
</td>
<td class="text">This agreement is through December 31, 2021 with an option by the Company to extend the period for an additional 24 months.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LeasesTermDescription', window );">Vehicles lease, description</a></td>
<td class="text">the Company engaged with car lease company, for leasing of 6 vehicles. This agreement is effective through June 30, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_VehicleLeasePayments', window );">Vehicle lease expense</a></td>
<td class="text">$6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LeaseTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LeaseTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LeasesTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement term, description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LeasesTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_VehicleLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of vehicle lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_VehicleLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308755510712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of company's total lease costs - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OperatingLeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Fixed payments</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TotalOperatingLeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OperatingLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OperatingLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_TotalOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_TotalOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308755501864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental cash flow information related to operating leases - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations (non-cash):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308752327000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental balance sheet information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OperatingLeasesAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,359<span></span>
</td>
<td class="nump">$ 526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CurrentMaturitiesOfOperatingLeases', window );">Current maturities of operating leases</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NoncurrentOperatingLeases', window );">Non-current operating leases</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,442<span></span>
</td>
<td class="nump">$ 526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 244 days<span></span>
</td>
<td class="text">3 years 350 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">5.83%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CurrentMaturitiesOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CurrentMaturitiesOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NoncurrentOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NoncurrentOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308752327576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of operating lease liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract', window );"><strong>Schedule of maturities of operating lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2021</a></td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2022</a></td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2023</a></td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears', window );">2024 and thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">1,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestNetAmount', window );">Less: imputed interest</a></td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,442<span></span>
</td>
<td class="nump">$ 526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth and fifth fiscal years following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The receivable or note face amount less the unamortized discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308755417768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Liability (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartyLiabilityAbstract', window );"><strong>Related Party Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Related party liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">subject to entering into a share purchase agreement in the aggregate amount of at least $6 million, and a pre-money valuation of more than $100 million, the Nanox IL&#x2019;s Board approved the issuance and allotment of 1,109,245 ordinary shares to Nanox PLC with the purchase price of $12.00 per share, which reflects a discount of 25% from the price of the last financing round of the Company. As a result, on January 30, 2020 the related party liability was settled into equity.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartyLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartyLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750201016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 26, 2020</div></th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 17, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 03, 2019 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance', window );">Aggregate amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,500<span></span>
</td>
<td class="nump">$ 3,684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 20.87<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="nump">$ 2,210<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,109,245<span></span>
</td>
<td class="nump">2,262,443<span></span>
</td>
<td class="nump">4,624,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromPreviousAcquisition', window );">Aggregate purchase price (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncreasedAnCommonStockValue', window );">Aggregate purchase price (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NetProceeds', window );">Net proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from IPO (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,348,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PercentageOfDiscountPrice', window );">Percentage of discount price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OrdinarySharesReservedUnderTheESOP', window );">Ordinary shares reserved under the ESOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,041,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OrdinaryStockParOrStatedValuePerShare', window );">Price per share (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NumberOfExercisedShares', window );">Number of exercised shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,027,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DescriptionOfSharebasedCompensationExpenses', window );">Description of share-based compensation expenses</a></td>
<td class="text">the Company entered into an amendment to a business development agreement (&#x201c;the Agreement&#x201d;) dated February 4, 2020 with two service providers pursuant to which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company&#x2019;s systems and the issuance of warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxPLCMember', window );">Nanox PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance', window );">Aggregate amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,038,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,178,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncreasedAnCommonStockValue', window );">Aggregate purchase price (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,178,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nnox_EquityIncentivePlanMember', window );">Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,978,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,262,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember', window );">Employees, Officers and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DescriptionOfSharebasedCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DescriptionOfSharebasedCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IncreasedAnCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increased an common stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IncreasedAnCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NumberOfExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NumberOfExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OrdinarySharesReservedUnderTheESOP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares reserved under the ESOP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OrdinarySharesReservedUnderTheESOP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OrdinaryStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OrdinaryStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PercentageOfDiscountPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PercentageOfDiscountPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromPreviousAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromPreviousAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_NanoxPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nnox_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nnox_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750865784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of share-based payments to non-employees - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract', window );"><strong>Schedule of share-based payments to non-employees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share-based payment awards, Outstanding at beginning balance</a></td>
<td class="nump">3,410,406<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,592,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at beginning balance</a></td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share-based payment awards, Granted</a></td>
<td class="nump">1,327,957<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,271,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 13.70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of share-based payment awards, Exercised</a></td>
<td class="num">(1,267,012)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(454,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 8.94<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of share-based payment awards, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of share-based payment awards, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of share-based payment awards, Cancelled</a></td>
<td class="num">(98,725)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price. Cancelled</a></td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share-based payment awards, Outstanding at ending balance</a></td>
<td class="nump">3,372,626<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,410,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at ending balance</a></td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share-based payment awards, Exercisable</a></td>
<td class="nump">2,191,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,830,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 5.67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3.79<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Out of which 1,027,151 awards were exercised on a cashless basis.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfShareBasedPaymentsToNonEmployeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308748636200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">57.34%<span></span>
</td>
<td class="nump">41.11%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.27%<span></span>
</td>
<td class="nump">1.55%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Contractual term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">44.40%<span></span>
</td>
<td class="nump">50.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">1.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Contractual term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750042440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesOneMember', window );">0.01 Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Number of awards outstanding balance</a></td>
<td class="nump">186,815<span></span>
</td>
<td class="nump">186,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">120 days<span></span>
</td>
<td class="text">1 year 120 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance', window );">Awards exercisable, Number of awards outstanding balance</a></td>
<td class="nump">186,815<span></span>
</td>
<td class="nump">186,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears', window );">Awards exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">120 days<span></span>
</td>
<td class="text">1 year 120 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesTwoMember', window );">1.92 Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Number of awards outstanding balance</a></td>
<td class="nump">269,714<span></span>
</td>
<td class="nump">472,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">1 year 65 days<span></span>
</td>
<td class="text">1 year 295 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance', window );">Awards exercisable, Number of awards outstanding balance</a></td>
<td class="nump">269,714<span></span>
</td>
<td class="nump">472,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears', window );">Awards exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">1 year 65 days<span></span>
</td>
<td class="text">1 year 295 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesThreeMember', window );">2.21 Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Number of awards outstanding balance</a></td>
<td class="nump">2,191,349<span></span>
</td>
<td class="nump">2,727,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">6 years 80 days<span></span>
</td>
<td class="text">5 years 98 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance', window );">Awards exercisable, Number of awards outstanding balance</a></td>
<td class="nump">1,188,914<span></span>
</td>
<td class="nump">1,163,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears', window );">Awards exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">6 years 80 days<span></span>
</td>
<td class="text">5 years 98 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesFourMember', window );">16.00 Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Number of awards outstanding balance</a></td>
<td class="nump">444,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">8 years 324 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance', window );">Awards exercisable, Number of awards outstanding balance</a></td>
<td class="nump">283,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears', window );">Awards exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">8 years 324 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesFiveMember', window );">18.00 Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Number of awards outstanding balance</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 313 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance', window );">Awards exercisable, Number of awards outstanding balance</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears', window );">Awards exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">3 years 313 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesSixMember', window );">30.93 Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Number of awards outstanding balance</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 295 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance', window );">Awards exercisable, Number of awards outstanding balance</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears', window );">Awards exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 295 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesSevenMember', window );">20.87 Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Number of awards outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 251 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance', window );">Awards exercisable, Number of awards outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears', window );">Awards exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 251 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750683848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of shared - based payments to employees - Employee Stock [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of shared - based payments to employees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share-based payment awards, Outstanding at beginning balance</a></td>
<td class="nump">1,667,267<span></span>
</td>
<td class="nump">1,667,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices', window );">Weighted average exercise price, Outstanding at beginning</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ChangesDuringTheYearAbstract0', window );"><strong>Changes during the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share-based payment awards, Granted</a></td>
<td class="nump">730,734<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 13.53<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of share-based payment awards, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited', window );">Number of share-based payment awards, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of share-based payment awards, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NumberOfSharebasedPaymentAwardsCancelled', window );">Number of share-based payment awards, Cancelled</a></td>
<td class="num">(16,876)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Cancelled</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share-based payment awards, Outstanding at ending balance</a></td>
<td class="nump">2,381,125<span></span>
</td>
<td class="nump">1,667,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices', window );">Weighted average exercise price, Outstanding at ending balance</a></td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share-based payment awards, Exercisable</a></td>
<td class="nump">1,061,778<span></span>
</td>
<td class="nump">450,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ChangesDuringTheYearAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ChangesDuringTheYearAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NumberOfSharebasedPaymentAwardsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NumberOfSharebasedPaymentAwardsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750673656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model - Employee Stock [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">45.11%<span></span>
</td>
<td class="nump">45.11%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.23%<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">55.97%<span></span>
</td>
<td class="nump">55.97%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityDetailsScheduleofBlackScholesoptionpricingmodelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308751186152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards - Employees, Officers and Directors [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesOneMember', window );">Exercise Prices One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Number of awards outstanding balance</a></td>
<td class="nump">1,995,625<span></span>
</td>
<td class="nump">1,667,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 18 days<span></span>
</td>
<td class="text">9 years 328 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance', window );">Awards exercisable, Number of awards outstanding balance</a></td>
<td class="nump">1,019,695<span></span>
</td>
<td class="nump">450,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears', window );">Awards exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 18 days<span></span>
</td>
<td class="text">9 years 328 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesTwoMember', window );">Exercise Prices Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Number of awards outstanding balance</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 226 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance', window );">Awards exercisable, Number of awards outstanding balance</a></td>
<td class="nump">37,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears', window );">Awards exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 226 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesThreeMember', window );">Exercise Prices Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Awards outstanding, Number of awards outstanding balance</a></td>
<td class="nump">180,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Awards outstanding, Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 339 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance', window );">Awards exercisable, Number of awards outstanding balance</a></td>
<td class="nump">4,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears', window );">Awards exercisable, Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 339 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AwardsOutstandingNumberOfAwardsOutstandingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AwardsOutstandingWeightedAverageRemainingContractualLifeyears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ExercisePricesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308751185720">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24,781<span></span>
</td>
<td class="nump">$ 16,245<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,384<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Marketing [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,252<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and Administrative [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,145<span></span>
</td>
<td class="nump">$ 14,967<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On October 26, 2020, the Company entered into an amendment to a business development agreement ("the Agreement") dated February 4, 2020 with two service providers pursuant to which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company&#8217;s systems and the issuance of warrants.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityDetailsScheduleofsharebasedcompensationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750908232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in valuation allowance (in Dollars)</a></td>
<td class="nump">$ 3,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">Korea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Local income tax rate</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">33.59%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Korea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Korea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IncomeTaxDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IncomeTaxDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308752409480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Transactions and Balances (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems', window );"><strong>Related Parties - Transactions and Balances (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred', window );">Related Party Tax Expense, Due to Affiliates, Deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Consultants fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OfficeSpaceDescription', window );">Office space, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Since November 1 2019, Illumigyn sub-leased in transaction approximately 1,800 square feet of private office space, including access to shared public spaces, from the office spaces which the Company leases in Neve Ilan, Israel.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Monthly rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableRelatedParties', window );">Lease received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nnox_RanPoliakineMember', window );">Ran Poliakine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems', window );"><strong>Related Parties - Transactions and Balances (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ExecutiveEmploymentAgreementDescription', window );">Executive employment agreement, description</a></td>
<td class="text">On June 1 2015, Nanox PLC entered into a consulting agreement with Six-Eye, a company owned by Ran Poliakine, the Company&#x2019;s CEO and one of major shareholders, pursuant to which Ran Poliakine agreed to provide services as Chief Strategy Officer and a member of the Executive Committee to Nanox PLC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_SixEyeInteractiveMember', window );">Six -Eye Interactive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems', window );"><strong>Related Parties - Transactions and Balances (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SurplusChargePercentage', window );">Surplus charge percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Total expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_SixAILtdMember', window );">SixAI Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems', window );"><strong>Related Parties - Transactions and Balances (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Total expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_WellseseTechnologiesLtdMember', window );">Wellsese Technologies Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems', window );"><strong>Related Parties - Transactions and Balances (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Wellsense paid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sub lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_NanoxPLCMember', window );">Nanox PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems', window );"><strong>Related Parties - Transactions and Balances (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Related party liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ExecutiveEmploymentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Executive employment agreement, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ExecutiveEmploymentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OfficeSpaceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Office space, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OfficeSpaceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartiesTransactionsandBalancesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SurplusChargePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Surplus charge percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SurplusChargePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of any deferred tax-related balances due to affiliates as of the date of each statement of financial position presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nnox_RanPoliakineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nnox_RanPoliakineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_SixEyeInteractiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_SixEyeInteractiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_SixAILtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_SixAILtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_WellseseTechnologiesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_WellseseTechnologiesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_NanoxPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_NanoxPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308755474296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties - Transactions and Balances (Details) - Schedule of balances with related parties - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfBalancesWithRelatedPartiesAbstract', window );"><strong>Schedule of balances with related parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party accrued liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartyLiabilities', window );">Related party liability, refer to note 6</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfBalancesWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfBalancesWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308781290232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Transactions and Balances (Details) - Schedule of related parties transactions - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development &#8211; see c and d below [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems', window );"><strong>Related Parties - Transactions and Balances (Details) - Schedule of related parties transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related parties transactions</a></td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative &#8211; See c, e and f below [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems', window );"><strong>Related Parties - Transactions and Balances (Details) - Schedule of related parties transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related parties transactions</a></td>
<td class="num">$ (167)<span></span>
</td>
<td class="nump">$ 5,824<span></span>
</td>
<td class="nump">$ 892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartiesTransactionsandBalancesDetailsScheduleofrelatedpartiestransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308748546024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nnox_EmployeebMember', window );">Employeeb[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LossPerShareDetailsLineItems', window );"><strong>Loss Per Share (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants option awards outstanding</a></td>
<td class="nump">$ 7,846,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nnox_NonEmployeeMember', window );">Non Employee[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LossPerShareDetailsLineItems', window );"><strong>Loss Per Share (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_WarrantsOptionAwardsOutstanding', window );">Warrants option awards outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,203,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LossPerShareDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LossPerShareDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_WarrantsOptionAwardsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants option awards outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_WarrantsOptionAwardsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nnox_EmployeebMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nnox_EmployeebMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nnox_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nnox_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308762322936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract', window );"><strong>Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Company&#8217;s owners</a></td>
<td class="num">$ (43,815)<span></span>
</td>
<td class="num">$ (22,563)<span></span>
</td>
<td class="num">$ (1,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">The weighted average of the number of ordinary shares (in thousands)</a></td>
<td class="nump">35,654<span></span>
</td>
<td class="nump">25,181<span></span>
</td>
<td class="nump">20,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140308750799512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceAndAllotmentShares', window );">Issuance and allotment shares</a></td>
<td class="nump">3,091,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareBasedCompensationGrantedForService', window );">Additional shares</a></td>
<td class="nump">845,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdministrativeFeesExpense', window );">Administrative and regulatory fees (in Dollars)</a></td>
<td class="nump">$ 818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceAndAllotmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance and allotment shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceAndAllotmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareBasedCompensationGrantedForService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation granted for service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareBasedCompensationGrantedForService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdministrativeFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdministrativeFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MZ9$25K3EYE[N/D+O)[%\A>3:W<FNBTTPN&BUD74/1@4U$]V3/O1UV .$XQ.
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M/K\(U-$O?JB> S!_ F)^]OXVYMQ\-%_Z?*LN_RUR$,HDL'-#<2^'H>P\U(F
MC;W6M1W;JB>B*8.VZ=9/HDIF]+SZMU&_:+I2G&]E\TK!FAPR5C0JU6S5((]D
M6UB;'XO&639S7VZ*KIM?;-N8MU\)WG"71J?'8\J+1K88,+*7K=T'8;Q1E*\[
MWOSC7 CX[QM"V'D@%JC^G1C^#U!+ P04    " "U@(9297M.US8'  #X)@
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M?ME,Z0DT=V"H@K<U3;CS*'1Z5%L<5T^>#*1LJ1['@E2S@<D%IZ;#,WL3ZJ'
MH%?%$]F:N6UU4A;M4A8Y4_:'HIF""0$4M0"YH."1$F[*EU/-$?DZD9YII.5B
M#!.O/S<-275R%N]R%C]G+HY-:8NUB2"(>Q-!;*IJ$O9Z2)<:P]C#/64S@UB(
M;7=ZL@LX^=')V!A\HD_&,$$^\F*S/]!K,<9[]MRCT -L".>DE.(M*&F--_G3
M@)0):2833Y^S>T6X:60ZM?(]A'JU<CM_Q UOMH=MZ=NC0/B2Z1N:WAOK^V[[
M48C"(+0XWE(0=&.0RW') %VN"O9(FRA*5H[;*^N56MG0[Y2GN:C'/P5IC$"'
MFCY"-2*=VN#^7>L.YYA.,%F++.EL(0NZ*>LETCG8'#JB^8&OGO^68%I"@\]&
MM"J8O'R@:GW%C^V$$R'8]8#W_\!_C<L=G=Q0'R].Y>+,;:Q;EI82X?,Q\;"R
M#':4CI.)%W@6QUN8A*>C2;>J(_ (&A@O1+Y6\E,AY:"];O):K(1NKMQ;B*>L
M%'E&>9T\L,GE BB?5C255?U)"8@05%5YM>;I0F4;D'M.ZWV)MT!0JN8=20%,
MFSE(?0Z-%3@5H$(3,WHHTJ;V$QF<#1OLUJ#%5.CFU(/9WJWGF-R=2-$4&C@6
MH2#$/=P=ENOFKB5>>!CR]C W,:8OT7=3@CXMZ"R,8>3'_:;2Q<:^%WJP'[=!
M+HXB"QBBEJN1FZL/('UC"I .JBB"@>?%EFD8M:R*7I15C=Y"G>YZFU\W2&?8
MR$N2W@)SZG;^B%G 9 ]ZT-+(:&_?\/G$? +41SJ7^M7SP[/5O653-,"FI7J
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M^91/G#Q+^@WD^/)3VXT3N@S>J:MW'[^\CJ]C<TD;9#2 QIH3-?;(*K 0O='
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M/R1,-*"9QP\9\M-3/I:@2P0WXLW"&"JB?%H'14--NYXBM)CT(_\U"B5]R\B
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M,]("O)\[R!L_T 7M;Y=>_A=02P,$%     @ M8"&4B8KE0[_%P  6$,  !@
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M(5 [ [I?*F7W&Q?@\,\9_ %02P,$%     @ M8"&4JSCD+],!0  ( X  !D
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M>;N>6%6[;X"YLO1%X88Y?<*AY@VTGBEEUQ-VL/DHO/@74$L#!!0    ( +6
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M4N:\K7E=27X'S;C\ R9;G1&M[7FTK"A5O3&[D1.)..-Y<5?DLLH57\UD)>_
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MP/TF;*!L'3@9$G\0I3LR;XBBF=_G6R;+&A-I3-@K%U.8MDDW'S&]J(WL]NS
MHH5N@W6#&@_IQ2=.N\9;QV121(4Y9O"]H%/":]4(618HJ]JW/F"* 4_@S=1^
M8V_%!EK<E]8Z0KT67>:?FA@]VQ.CH%+5U5D_6@L_K5'+5EH8[=WF%*;X)X";
M&A!:&W>31*<>PDQJ:T/3&TI;= ?U/6:_[FZ"]-<#_4S3HJGL[5)W0J&_Z/,5
MC-SMVA2 </6-Y'OZV$+<ZZJSAO1;'<R*;S+QL,&NEBV*2963!@45KINBJJ@!
M1C20#)W(]YS(2_@Q]]U1AEH29X$S F*CCC!@+V>BNH$N\TT(^IA]9\T/!!&D
M3A:GW _=U*/=2>H[238"A<!-4W;9@13^S8F/K4OJ>( ;IWSD9A$_B>+(\9,$
M[6,D@9!]6S=361#A,_,/\Q=%,VB_)%<LJ2B<9 !608RYOIL%^N.6Q-+4'RMK
MF ; PPF/W2#=$;WCLTNCPZF!XV<^4EB J0D$=4:AYXR\#%,A<\:^X5B71IO"
MB:%0B1_[G34TSNG!&A4%P29"S4JI%!6L0IE@GXK"9D BIJM%%V6:$J-3#]5J
MK)1W""VW6%^/Y$O5F>E%B4@_X^\GJ)B4:'78GI%CT(AYG<O2K"J03.<FJ#%]
MD);VQ0W;B!OR=W.DHFRPJL>#2'AESR;X?2'+G'O<(VL:3'%7H^J;0A^G;A@]
M.HLB-_(>\<AW??\1K!E[;IP]8N\*=7LV!?@B$ !%*MH\0F0/5GQTYKL)!OMN
M'-/O-'G$7M:5/AHC4$4EC9]H.4YY?.:# S?V=,'V_2?(>P1\/NCRL<M6H0R8
M8+;$S K:(143T!V,@N8ID8E&.X[^6172&K0YP/M:Y:Q;A;RB'MO"L#%:F<P/
MR]'4OF9T'&L9;?:V_M8Y#=!C#JO @S4>,#QU136OI3E.FB'5(+5.I_ ,PL@#
M.?ND R<3E&"I L&D&L$)A2T$":T]V)1B$P 8V+GI)I\HEY.)+H<W=.@@=-+N
MRR,09H-\9@M,)X6S1UR"ACU@R0=.KPID_V):H',NVUF==V"V%;=T:D@PDLHW
M9&ALX<$LLV)?^"<##P(QJ5V=QM$>F5:R.(J?D#$V:LX^9BEH/VIOK/>LQK=7
M.W4_5_N*REQL$/N8C3V\2>K#W >.-W"A<0RQ'ZSTL?R8[7QC%V;JD+KM&BSP
MA46O8\/6.]WL*]UPA4;2Y8S9QZVEZ'O[HC+(U$,][NVUYQ,ZHVNS=HEAIX<=
M&T#JCVAO'%-A"C<:[-B4G"#)G-2/T/!'&PU&Q2_P;>4(HXPG;A#05FTT<C(,
MHB91H3,5'D61DT8CE$24X& 4 BF'ND$C1C0B2#Q]>ABZHV2C@1&AYV8A;*7[
M,G<$OIT$)95^;ML32?F_;4_U!S'HFP<,Z@\-Z@\,&A%$ ";P28W#QMJ@*6J[
M%XP,BH!!$R )+]!-&J2/68-0(R*@A8P#'(T2_9,%#P/@01:I*1M+N]]8[SY>
M=:>TVR==-E<R2F_V2._SU-:XN3\42 %LTC ZL"7:V<ET9X'6_CTD'9PMA&X<
MNG\X-"TV/+X_X7KHZ^?1-(5=2@B76V?9[O@\FN[T?\RUXBP [H!C!X%_$TCV
MX>6I =B:J<_ Y, )1_!JP.IC'KF4SGHAM @/P&3@WL1WTM1 _Q'R6NPY<6PF
M?@;@FE3"OP[ W2V#['>&M%%,(/8LCMTL?;39>@C0AAV@'?P^#&@!9_U-^,KV
MP%?^.\!7=@B^\J\"7]DN?&6'X"O_:O"5[86O_*O"5_8%@/(0?-W"F6P;9_+_
M+9SY1\$EFT#3UHDLBYT$.3=SO9CRJ)\Y26::S%R\04FQ17A)P$.@"C_5OT$C
M<>/D[#C.7*C8'WGZPB\C4$AG*ZG^^7\,!/<JO*MIT,VZ3E&#A0^ M.Y2R>"9
MRP=PBWXLP4Y^<M^[-HDI<P%D;K3!R3NI0 2Q;5Z1W,FR7FCT$:("8X.0H%0S
M<^>HKRF_.>69$\0!3V#X,_:=K,QE/+V$R)%("GH1I$^/?>PZ(KA1Y&1T6N7'
M+,#^@O8%B;XFHAXB=U7Q*R!!XCU(G#VH<N/VGW >^,OU/9J^Z!Y3XJ(CK"'W
M_>. _F)57Z9UO?T5:ZY+_+=RW.C;K<AF"/-F9$6/#9H[C<E,RH;Z!N\(F,V*
M UX7HMB^_Z[D&;+X&M81'HT&3S#XHEPJ_O/%!ZU$>YMF-NGSC9<7/3P>TJ=+
MBB0VNZXO?H6!;>+ZKM?>R*%0D!]UV5F:.$%E7TEYJX8' 3-[=Z&5QT[4<OP/
M5!7SZD '&$&H_F!QL#Q42!>EIWMNWSK]85, *<P%L75SS7'BKB_CN^+=Z::[
M S"59-=B*T'WPKR[M*)KIH506'A!5R#D+/I.J5TV<F<SU%O87/]@Y;FXUQ=F
MW<.MSA]8=V';>UZWF'X^6;3 ,^;" U54%[ *=&:BG&YM<^BZ=5(N\T[7#24W
MHUT8C>YF*+?IJT_+= /'KY;(![J3Y#RP<5+WJI7V1HZ^]Q=8=&ALM>GN>\MW
M/G@F.9?-C7X,2C5^6;7FQ63?V[\WO3#/+-?#S6-5Y)(;N@8JY113/3>-CXR(
M7:.M%_K1Y;ANVWJN?\XD?+.A ?@^K>NV:] "_2O<Y_\"4$L#!!0    ( +6
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MS06N%.BV:9AZ76 M]U,_\0\+SWQ;&;L0S28[ML4UFM]W*T6SZ,A2\@:%YE*
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MR)@1EO1%!4E**WZ?$A/M_9'<"CEM4OV&3T,E1>/H!$!^;8#G)6HRZ@1Z+OF
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M'QR^2]RYHSWX3%;&//K#MV(2)5X0*LS)(PC^/.,5*N6!6,;3'C-J*7W@\?Z
M_B7DSKFLA,,KHW[(@LI)-(J@P+78*KHSNZ^XS^?<X^5&N;#"KO$=]B/(MXY,
MM0]F!974S5>\[.MP%#!*/@C(]@%9T-T0!977@L1T;,T.K/=F-+\)J89H%B>U
M?Y0E6;Z5'$?3*^'*+O@5;IZV\EDHU.1 Z +NT)&5.6'1W)_=BY5"]VD<$Q/[
M\#C?D\P;DNP#DC2#6Z.I='"C"RS> L2LN)6='63/LY.(UYCWH)]V(4NRY 1>
MORU#/^#U3Y3A30%F[Q3@YVS%!OZ/?IU@'+2,@\ X^(!QR>U5;!6"6?//G1N=
M2R5%^%/9DH=G\2O@7\]B7U7Y^_=>XR2S;_-+5XL<)Q'WL4/[C)$O*%8KM+ZH
M'5]4KFSZN7/VT%OVX-HH):SKA"IX#?\(R])^=W Q@E$W&6:=H\*MA'[D+JF-
MD\38%Y .SCOWAH3ZCQS!E6:G06J@$L&1(.2Y0(="P9I'2Z-A.!JPABP=PGM/
M%!_U285V$Z:!@]QL-34MTUK;@3-K^NS5O9E6M\)NI':@<,VA26]X'H%M)D!S
M(%.'KEL9XAX.VY*')EKOP/=K8^AP\ 3M&)[^ 5!+ P04    " "U@(92NV"H
MSOP#  #>"@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RM5MN.VS80
M??=7# 0$S0*[EB59\@6V@;TT:(&D661S05'T@9;&%A%*5$EJO?OW'5*V5HEM
M85'TQ2(ESIF9<X;C6>RD^JYS1 -/A2CUTLN-J>:^K],<"Z:'LL*2OFRD*IBA
MK=KZNE+(,F=4"#\<C1*_8+ST5@OW[EZM%K(V@I=XKT#71<'4\PT*N5MZ@7=X
M\8EO<V-?^*M%Q;;X@.9+=:]HY[<H&2^PU%R6H'"S]*Z#^<W$GG<'OG+<Z<X:
M;"9K*;_;S>_9TAO9@%!@:BP"H\<CWJ(0%HC"^&>/Z;4NK6%W?4!_YW*G7-9,
MXZT4WWAF\J4W]2###:N%^21WO^$^G]CBI5)H]PN[YNPD]B"MM9'%WI@B*'C9
M/-G3GH>.P71TQB#<&X0N[L:1B_*.&;9:*+D#94\3FEVX5)TU!<=+*\J#4?25
MDYU9O4=*2</;SVPM4%\L?$.@]I.?[@%N&H#P#$ 0P@=9FES#KV6&V8\ /D73
MAA0>0KH)>Q'O,!U"%%Q". I'/7A1FV+D\*+^%/^Z7FNCJ K^[L$<MYACASD^
M@_E ER.K!8+<@,D14EE4)7O^18.1A@D0UB>]U4:?HK07W-[#N:Y8BDN/+II&
M]8C>ZD]D"M!2#"_+@:6(> IF@[=?A@]#N)-",$5Z=G>#CQ4J9GBY[<0U'[SC
M3P16L6>Z8T9#.$D@C </N53FRJ J.H<AB2$(PL%GEYP\ 0?1.( @FD /N7%+
M;OQJ<G5=50)MA.0X93J'#?41X&73CYK6()BA3(S\.;*3W/?Z_O^YO[4Q5XQG
M0!$#*V1MR>9E*FJ+QTM7/P6%6RN7I\VZX55PMN:"&XYZWM&P94'#1LGB*&D(
MDIE5TC78*[FYJ@F+:8WD5ZX-->K&+SZE.2NWZ )K/,JUX%O'*J51RO+*^KJ8
M_UQ Y.)R-(TA'D_[]$Y:O9/_IO>:"5:F",W?4T?S4[KV^Z"F@L4:E6LLW<U9
M&9TRLM:LS/0%]'P[8N>(+U GI @NHW@&<9@,;FNEK/"46ZV<W):)(UGC8 ;!
M>#3XP^JR-SDZ- LCB*;)F9O:J2CR/QZ'SO]KN/GF_MZH<-@C05+14+%2);U
MVXYQ7"?A,)E -)PEQP 9UZF]#$ 6>&P9#Z<1O*%' F]Z:FS2UMCDU376RW.7
MHU-EUNOF=/LXHO3'2FM8OK*/ .+IU"["P\*J&=K%&*C8;*^@T6M#9)/!:8W;
MAAY<QO%T\!ZUG@,OJMJX:T^F2.TZ")+!O8V0!'ADHL:3;6=?)*?X]SLS1X%J
MZR8K#4[29OQHW[;#VW4SL[P<;R:_#TQM.74<@1LR'0WMK*2:::K9&%FY"68M
M#<U#;IG3 (K*'J#O&RG-86,=M"/MZE]02P,$%     @ M8"&4K,XZ[B/!@
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M;;N0KIHY_&/>;+-;IC=<&A"X)M>H?S$,0#<;HE&LVOJI7"E+,^[%@I8J:F=
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MO]5 KG6.(6WSE-R[H;JV;E:R#O8*T)@&HZ#?KZ^'=*^]I/]/49Z51,^*X.B
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M&NDS)LJYLEPHGA6CV9HK/>@5CY&>Q4$8 ?T^Y%P]+,RT5T_W\_\ 4$L#!!0
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MR>TWZ/Q,+5\NN79/LNUR X_DC499=6"CH&*B?=.7K@X#0)@< $0=(-H'3 X
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M>*^VGZ%)*++QEDJ:ZI=M&U_/8<O2H,H:,"G(1%Y_^7-3B!V WSL "!I \%Y
MV #"*M%:6976+4<>C[7:,FV]*9H=5+6IT)2-R.TVSE'3JB <QG= -3#L_!:0
M"VDNV$<VIZ.2E!*86A$3EEJ@(!>RZ/!HCB)?,VEA3 J^$+)>_L@>Y[?L_.R"
MG3&1LX=4E8;GB1F[2#(MF;ML)-W4DH(#DFYA><E"_P,+O,#K@$_?#?>'?\)=
M*DY;H:"M4%#%"P_$^[]R_+A>&-1T2'\>D1"V$L)*0N^ A .%N#F*L@U@9 J^
MA(E#-]R WH 3LR-R>JV<WBDY?I><&A55*-L^-G$T&(S=30=5U%)%IZB"+JKH
M_53]EJI_BBKLHNKO486#H)OJJJ6Z.D758W0Y&*9 O7>%H+N8CP;Y]^T=M.H&
M1]4]*.1R[W 7_(6Z-W;>Y\%>B?PH.K =PU;%\*B*.S!FQ$16E @)=12J$1CL
M8A_NL_O];G+?>VN+WE'ZF2UICFS#95E=_;TKWMG8ZJ#]72V]WMMI:?K7OE<4
M_*W8W>GI]D']RO5:Y(9TK CE75Y1PKI^HVH#55&U^85">C2J84KO.FCK0.LK
MI?#5L"]'^T\A_@U02P,$%     @ M8"&4B>Z/>!& P  3P<  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&ULE55M;]LV$/XK!]4M6L"U7FRW26L;2)P.
MZY ,1H)N'X9^.$MGBRU%*B1E)_]^1\I2L\UQL2\V7^YYGKO3W7&VU^:[+8D<
M/%12V7E4.E=_B&.;EU2A'>F:%-]LM*G0\=9L8UL;PB* *AEG2?(NKE"H:#$+
M9RNSF.G&2:%H9< V587F\9*DWL^C-.H.;L6V=/X@7LQJW-(=N2_URO N[ED*
M49&R0BLPM)E'%^F'Y=3;!X,_!.WMDS7X2-9:?_>;S\4\2KQ#)"EWG@'Y;T=+
MDM(3L1OW!\ZHE_3 I^N._9<0.\>R1DM++?\4A2OGT5D$!6VPD>Y6[W^E0SS!
MP5Q+&WYAW]I.V3AOK-/5 <P>5$*U__APR,,3P%GR#" [ +)_ =+),X#Q 3 .
M@;:>A;"NT.%B9O0>C+=F-K\(N0EHCD8H_Q7OG.%;P3BWN"6)C@I8H7&/<"UP
M+:3@U>LK<BBD?0-OX<O=%;P>O($!" 4W0DK.OYW%CN4]29P?I"Y;J>P9J11N
MM'*EA4^JH.*?^)C=[GW/.M\OLY.$OZ$:P3@=0I9DR1%_EJ?A5Y1W\/3\A#OC
M/I7CP#?^GZG\ZV)MG>%Z_7I"9-*+3(+(Y"<B=1"1G<BQZ%NB\T#DFWFW2-^/
MSF;Q[HC\M)>?GI1?-28ON6L MX:(N]D-N6EL;D3MN_)849PFM,WZ&W<T. U,
M1D:H+5<9[Q!LB8:@_H^BKT)7^@,^V7(V "O=\+G> #J0A-;!X!UW2ZC4(: J
MF(Z'W-M**WJ$'<H&PQ!A1*59Q)6H8) FR0^05_@=E7Z S]>OL*H_OGCP=?+1
MPJ5&PX1U;?2.OX0W%-8VJ')JI:34+CC*].DP3<Z'V60*VA1"\:!LX[(^XI9_
M=;WDIG=E8.K#K8U@/F88I-F(':O)M,@A[$N1EWZ$^EEH.;1"V+S+0#9]"1NC
MJY:M(_$;Z?.R81]4[K-L&%%T=TM=U:@>1W#A^=@]GH)#X QQCS7>Z7'2MEFP
M-L>+$/9HP9)SDN_"1Z3[AL]'Q^H^?C*S*C+;,,HMA#C:\=6?]J_%11B2\0_S
M]JFY0;,5RO*7WS T&;WGDC/M^&XW3M=A JZUXWD:EB6_>&2\ =]OM';=Q@OT
M;^CB;U!+ P04    " "U@(922/E[$*('  "('@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6R]66MSH[@2_2LJ[]S=3%7&!H$-SJLJB>V9;.U,4IM]
M?-BZ'V20;3: 6$G82=7^^-L2V("-%69W;CXDYJ$^?734M+KA8L/XDUA1*M%S
M$J?BLK>2,CL;#$2PH@D1?9;1%.XL&$^(A%.^'(B,4Q)JHR0>8,L:#1(2I;VK
M"WWM@5]=L%S&44H?.!)YDA#^<D-CMKGLV;WMA9^CY4JJ"X.KBXPLZ2.5OV8/
M',X&.Y0P2F@J(I8B3A>7O6O[[,[QE($>\5M$-Z)VC-14YHP]J9.[\+)G*48T
MIH%4$ 1^UO26QK%" AY_E:"]G4]E6#_>HL_TY&$R<R+H+8M_CT*YNNSY/132
M!<EC^3/;?*+EA(8*+V"QT/_1IA@[ H]!+B1+2F,X3Z*T^"7/I1 U ]\Z8H!+
M [QG ,JT&SBE@;-O<,R#6QJX73T,2X-A5X-1:3#:-SBFDE<:>%T-_-+ [SKI
M<6DPUN%0K)]>_ F1Y.J"LPWB:C2@J0,=0=H:UCQ*5; _2@YW(["35X\KPNF*
MQ2'EX@<T_2N/Y LZF5!)HEB\OQA(\*%&#H(2[Z; PT?P;/29I7(ET#0-:=AB
M/WO%'AL !C"YW0SQ=H8WV(AX'\@^PJ-3A"ULM1"Z-9M?Y\L^<NS"_-?'"3IY
M]_X=&B"AA!/%_Q;4B1GU1Y)6J!W@IJ_ Y0!G>PK.'G<G.3.C3FCP3Z;^L3-J
M"]<6O$_=\?PN>'=FO$>:]9'E%/R^_\YW1OC<..E&5#J[Y\[17IQ_]-RA/WZ"
M\>A.TD3\U^#-W7ESM3?W6! OEYPNB:2()"Q/)3J)4C1A<4PX./L;O6M;Q@)R
MI"'5GKF^<FP\M. 96M=7IV78R'>MVK@&Y>&.\M!(^2'GP0IV,93Q**!UPBBC
MO%@.3=VTU)/A 3D;-_E/BR%^;0BV^K[7'#5K 1HUAWP\'(*QO:]6B[<^MMNE
M&NVD&AFENN=AE$*E8M"A !C6Z=O6&+O#/3$.QV$\PJ[K[,EQ.,Z%8<-CB^[M
M9N)UC-/LZ/(?B]>I=Z _\+&L_8#]^/JX!G=_Q]W_OW&?^0></-=$:KPC-3:2
M^@+E<L990&DH.A$9'RRL9YN(V%95:%C=J2PX2]#=PWTG3B5P\^$;.ZY_N+9F
M#JIS.!,9">AE#UH#0?F:]JY0VY[S#8":.M4*,MN<^"@/:"JATT!L@<)(!#IC
MZUAJ>[1?@</#OF7]Q\0,5\SPU^095$X\1#F4:AS)%473Q_N'MBVW1*['E6^Y
M]M@9'0FK:A^U';-<^AG;;0DZH+Y C_6XHD\TWMLL]K?S5JJ%/Z]&U>I;1U*T
M7>W MGD+_I(G<Z "2TJ?884C ;H=+\Q*L$;"MK!G#X_QJ+95V[RO3J@(>)3I
M3A/(: H?5+L8HH ET$,+HN_19W7<RN[F%1<J$&X!BZ0O""*9<L".4LD0@>86
M&N40_B12YVB>"S 6 OK3-33>F;Y#()%2?73R/4FR\^^>H10+SA7L]?96=2,\
M?X]"2+LAFM$YSU5\ND7)"JV47"&Y84C%J0X3SM:1*KE4CA8Y*6AL5E&P0G76
M&8E"S7:7TUE*/TCH\N'6BZ8&VKV#% UF+!<D#5$6YP+]=OT+4B>1$#DP G"
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MLSB1+-/?Q.9,2I;HPQ6%SHFK 7!_P9C<GB@'NX_/5_\#4$L#!!0    ( +6
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MF5!6W@.5'4'SXBIE286@:=&,@,@/=K5 SJ\H%:\=Y:"^C9O]!U!+ P04
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M:/3/<+];(:=1K'W#\C7^T]H__M03H#L%3#Y5R&L6\II67O.47?)"(D@BM"%
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M?N__Z/Q>?P?R"_O:VNC]9QD_#_K!7EFT2$7L;*\N#A/X[X7!MHY'=M"W/[!
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MJ9Y,01@#?;_@7.TV)D ]ZX[^ %!+ P04    " "U@(92.%=TWE$%  #Y$@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6S%6-MNVS@0_96!]X(62&-1
MOB5M8B!Q'&P621LTZ?:AV =:&EO<4J*6I'SY^QU2MN4VLNR'!?)B2Q3/S'!N
MA^3%0NGO)D&TL$QE9BY;B;7Y^W;;1 FFW)RJ'#/Z,E4ZY99>]:QM<HT\]J!4
MML,@Z+=3+K+6\,*//>KAA2JL%!D^:C!%FG*]ND:I%I<MUMH,?!:SQ+J!]O B
MYS-\0OLE?]3TUMY*B46*F1$J XW3R]85>W\;]AS S_A+X,+L/(-;RD2I[^[E
M+KYL!<XBE!A9)X+3WQQ'**631';\NQ;:VNITP-WGC?1;OWA:S(0;'"GY5<0V
MN6R=M2#&*2^D_:P6?^!Z0=[ 2$GC?V%1SNT/6A 5QJIT#28+4I&5_WRY=L0.
MX"S8 PC7@/!80&<-Z/P$8-T]@.X:T#T6T%L#>C\#.GL _36@[WU?.LM[^H9;
M/KS0:@':S29I[L&'RZ/)P2)SF?5D-7T5A+/#SRBYQ1@>N;8"#;R#9\TSPWW<
M#? LAFLN>1;1MS<W:+F0YBW-^O)T V]^?7O1MF2$$]6.U@JO2X7A'H4,'E1F
M$P/C+,:X!C\Z@ \;!+1I]5L7A!L77(>-$O\LLE,(V F$ >O5&=0,O\'H%#H>
M'@8U\)NCX>R\!CX^'GY6 []MAC_PU6;I@P97=K;9U/'B.O]K-GV[)S%P9S$U
M?S<8T=T:T?5&=(\P8@7/? GC)35B@R=P4R!8!5?3J9"")AD:PBEJ79N)XU)/
MW^MQ+7H^9-U.-P@HS/,: WM; WN-!H[(%]3X>&8-3!%-7=+T7JJF[-RKNK]5
MW6]4_8E6'B&8G$?DCAA-I$7N@E.7]\VBG@2%$3ZJ.:83U,!\ I_ G91%*F:K
MC,AJ\DXB=?T81 :V2@3@>:[54A OH%P!.SD+ J*4@FMT_K"@II!K,:?/]+AK
M,*F412RR&3$2Y9!QP30)X6+(BXD443F1PCK5*@6;_"C P"(14>+'1RK->;8"
M;Z%Q%G[$.64A92<MPFB.\K0A&0=;AP\:O>1[%2U28V8AYRL^D5CGZ\'+>(=[
MHWVV57[6J/S>K8U41TCL7=MK2WQO5VV_LU?O^5;O>7,%\@P>%578=U?8WQY\
MAC25-@LJN@I>K\.P'=9DC2L<+S$JW)X(,,VE6J4NO'RF$=W3H<JZ/B#]4P9$
M2EC65.\$/O),+>'Q?@0D'+4O*,I\#E'927Q!;)33!L(F\"26[\8K*ADWJ<QT
MM<@(.5G!#^$YV:V&WWF:?_AEZ2KY@X'1^)-WJ,I<&=&NXQ^ERW)+E(Q14YGE
MA38%-3)7B&5M_1A[;U7LOE+%ST5,A8AZ+EQT."E(!$Z!5DXAG:V@;$[:Z^20
MEGV%%#L#*X>3J:FP%GTGWWJFJ5996(4U/-#3EN#<!G?.S^6N]ZC\K0B2O2)#
MLHHB63-'/A4ZEX6!B*(Y0\A11Y0Z=)2HVT(<D,7"TR#XK<FLBAA9,S,^*\LE
M8$G7M;S(7A)C?W"^MV.QBAC9(3I;7MW!O8V/BG?5_MG@%>-=$0%K9H*#CAVQ
MEU30Z>W?<+"*"U@S&7RE4R/I1'C&*,F45#/G!W+TZ3&>#BMF"%^1&<**&<+F
MWETNE[Q,;"^HCZ6JR&SMJ8*]</A@K[O#JH6%!UI8,2GW-+4ZPQ<Z>_N+)ZRZ
M6MAI5%H1U#$AK;I4V'W%D%9=*6SN2ALS<G^@(&J;T.G!KFH=7+-O/Z_9R+5W
M3NPI4@MV=RO4CEVRE"?7[>CV_N;*WUK\-#YB[\?E+4PEIKP4>J#.+LA+$J<D
M,C@=D&FZO&<I7ZS*_;W 1%FK4O^8("=>=Q/H^U0INWEQ"K:W7</_ %!+ P04
M    " "U@(92,!(7!5,"  #$!0  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6R55%%OVC 0_BN6U8=6ZD@(*715B%1 T_8P"4&[/4Q[,,E!K#IV9CND
M_?<[.VG$-LKH"_'9]WV^[S-W2:/TDRD +'DNA3136EA;W06!R0HHF1FH"B2>
M;)4NF<50[P)3:6"Y!Y4BB,)P')2,2YHF?F^ITT355G )2TU,799,O\Q J&9*
MA_1U8\5WA74;09I4; =KL(_54F,4]"PY+T$:KB31L)W2^^'=/';Y/N$;A\8<
MK(E3LE'JR05?\BD-74$@(+..@>%G#W,0PA%A&;\Z3MI?Z8"'ZU?V3UX[:MDP
M W,EOO/<%E-Z2TD.6U8+NU+-9^CTW#B^3 GC?TG3Y8:49+6QJNS 6$')9?ME
MSYT/!X!A_ 8@Z@#1N8!1!QAYH6UE7M:"698F6C5$NVQD<POOC4>C&B[=*ZZM
MQE...)NN0# +.5DR;3D8\H$\:"8-\R8;PF1.9DPPF>'9Y0(LX\)<8=8:_TYY
M+8"H+=K8)33<%OBT+6/5,SZN%^3RXHI<$"[)0Z%J@[0F"2S6[ZH(LJ[665MK
M]$:M"\@&9#2\)E$8A4?@\[/APX]_P@-TK;<NZJV+/-_H#;[S+?AQOS%6HZ<_
M3UP[ZJ\=^6OC_[R8(W_!-LATC9'@;,,%MR_';#U)Z.;$G:E8!E.*@\" W@--
MR3%_6YZQYW'C89].HB38'Q$3]V+B=XCI15R[ 0&:6$6DLD#&QU2=9'Z'JO@?
M5</))+[]2UAPT&-NOGUE>L>Q0P1L$1<.)C>4Z'9FM(%5E6^[C;+8Q'Y9X)@%
M[1+P?*M061>X3NX'=_H;4$L#!!0    ( +6 AE+82Y)XV (  +0(   9
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;-566V_:,!3^*T=9-;52VY"00-H!
M4BF[5%HE5-KM8=J#20[$JF-GMH'NW\]V0D:AL#Y,FO:2^'*^[UP^QR>]E9"/
M*D?4\%0PKOI>KG5YZ?LJS;$@ZER4R,W.3,B":#.5<U^5$DGF0 7SPU:KXQ>$
M<F_0<VMC.>B)A6:4XUB"6A0%D3^'R,2J[P7>>N&.SG-M%_Q!KR1SG*!^*,?2
MS/R&):,%<D4%!XFSOG<57(X2:^\,OE!<J8TQV$RF0CS:R4W6]UHV(&28:LM
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MLFL3Q-%SF]&N31R%C<VS5#I-*IV#J7Q$CI(P5V.2F4N"*I.-O4\;Z2=6^E-
M9S-[O?K=)H3N?Z%^TL2;_%7UDQW5SH).=TO^7:,X";?UWS5*+K;U]S?N\P+E
MW/5%!:E8<%W=;LUJTWJO7,?96A^:EEQUT-\T53^_)7).35T9S@QEZ[QKSJ6L
M>F0UT:)T76,JM.E!;IB;WPJ4UL#LSX30ZXEUT/RH#'X!4$L#!!0    ( +6
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M^&5IWP30+L#NKY3"K>$2=*],]@I02P,$%     @ M8"&4@-:_>L5 P  ?0@
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MH %#HJ@Z!_?.HW!S3H7;WU_&OP%02P,$%     @ M8"&4I>*NQS     $P(
M  L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2
M!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4
M+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(
M2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/I
MKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "U@(92T]@!
M$1X$  "A(@  #P   'AL+W=O<FMB;V]K+GAM;,6:VV[;.!! ?X70RZ9 MK8N
M=MJ@+K";]!(@:(TXZ&M!2V.+*$6Z))4T_?J2TFI+I>J@+Q,_V:1DZFC(X2$E
MO[K7YLM6ZR_L6R.5726U<X?SV<R6-33</M<'4/[(3IN&.U\T^YD]&."5K0%<
M(V?9?+Z<-5RHY/6KH:VUF<4%[:!T0BM?&2H^";BW/X^'(KL35FR%%.YAE73?
M)22L$4HTXCM4JV2>,%OK^_?:B.]:.2XWI=%2KI*T/_ )C!/E+]6; 'G+M[:K
M<7Q[PSW(*EG.?8,[8:SKSNC:YY[Q#OS)?:EU^JV0#LPE=_#.Z/8@U#XTX^]B
M%MU&%X?ALP_BN?F3,.K=3I1PJ<NV >7Z.!J0 5#96AQLPA1O8)4,I[!_5,7>
M*.>#Q*Y4WY0_-]RIO_15U=^U\[A1#,VY\ ?,5=6!TT%>^+*6HO)7K]B_7')5
M NN":R/ # ',C@;(3M8\@LP1R/P)(3<!(OS ,KUC'P]@(L@"@2R. 1D8+VJN
M]A'D H%<'"V2%]S6$>02@5S20KX#!8;+".8,@3FCA=F(O1+^7!YFFK+4K9]I
MU)ZM?11+ 7$6OT @7]!">IGX// 3( ]SX==6',(/3MD'<!'@2P3P)?&X\X/K
MM!MB'=X=E]VP"[@W8&/(=([-UG-:S&O@=M2G*>H.8GG<A$J?IVL>NO9:\'XI
M$.-AYDC)U=$TPC7_=Z2?6T)J@'J4%REFCI18'9N:&ZBUK,#8O[JQ-PX@)HR4
MV!A7JM0-L%O^+2;"[) 2ZR$><;X3V=_LUG!E>;=.M2S&Q/R0$@OB6EO+UF!8
MU[LQ%2:*E-H4[=;"US9(_\U=R(H8#)-#2FR'"6V=LNU#7W@8]2JFB)38$:AI
M/V?Q>AES1$;L",2U[.0V7C%GF#PRZIT'9MQQ--'M![%$>N.&P/GKVF<Q%J:-
M[ C:F(3$_)$1^P.=K<==C$DE(Y;*>+:>C"(FD^QI=AOLY!(<%W(,AODD.^;.
MXW,>8V)VR8ZW]P@QC3$QNV3$=D$Q1\F28W;)B>V"3]MQI^>877)BNPS3]D3.
MY)A.\B?2R<#EY\2-;[9J)81G'#$F^CR+6"\HYG@P8H+)B06#8XX&(R:8G%HP
M*&818V*BR8E%\YOM_, =8V+:R:FU,[GTF4ITS#HYL75PRE&B8];)J?<T&.8H
MT0O,.@6Q=7#,.-$+S#H%L75PS#C1"TQ"!;&$<,Q%C(E)J#C*'F? 7,:8Z&L5
M8@GAF&<Q)B:A@EA"/Q_F34Z6!6:>X@G-\^M&<93>F'D*8O/@F*/TQM13$*L'
MQQRE-Z:>@E@]C[?=$X-R@3EG0?VNY3=\_ZW>8DS,.0MJYSQ^JCL=2<PWB\XW
ML^$O$17LA(+J@V_>^OJ2RW)M6/CH7^D4B_ 8=M=*>>'K/JIKS:OA'Q;#OT->
M_P!02P,$%     @ M8"&4HHQ=E_/ 0  ,Q\  !H   !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<\W9RVK"0!B&X5N17(#C?X@]H%UUTVWQ!H(=#WA(R$RI
MWGU%%_8+7713YEN%2<B?%P(/83)[C_LF;]MCVFR[-#H=]L<TKS8Y=\\AI.4F
M'IHT;KMXO%Q9M?VAR9=EOPY=L]PUZQAT,IF&_N>,ZF7V<^9H<>[B7R:VJ]5V
M&5_;Y><A'O,O@\-7V^_2)L9<C19-OXYY7H73_GXZA>M!QI?)U>CM8U[U;Q]2
MA=)!"D%:/L@@R,H'.01Y^: :@NKR05,(FI8/>H"@A_)!CQ#T6#[H"8*>R@?)
M!&6<$"0-L";06I!K(?!:$&PA$%N0;"$P6Q!M(5!;D&TA<%L0;B&06Y!N(;!;
M$&\AT%M1;R706U%O)=!;!Q_;!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z
M*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>MM@LX1 ;T.]C4!O0[V-0&]#O8U
M;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O'VQV$^CMJ+<3
MZ.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H7:/>-8'>->I=$^A=H][U?^J=\GD?T[WG
MML;G_R?5^7)OO#_^NKR='+R7*\X!_I&_? -02P,$%     @ M8"&4C+A@>''
M 0  $A\  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=G);L(P% 707T'95L1X
M@ X"-FVW+8O^@)L\("*)+=M0^/LZ89!:T:B(2KV;1(GM=U]LZ6PR?MM9\KUM
M5=9^DBQ#L ^,^6Q)E?:IL53'D;EQE0[QT2V8U=E*+XB)P6#$,E,'JD,_-#62
MZ?B)YGI=AM[S-K[VA:DGB:/2)[W'_<0F:Y)H:\LBTR&.LTV=?TOI'Q+2N+*=
MXY>%]3=Q0L+.)C0C/P<<UKUNR+DBI]Y,N_"BJSB+;4OFPZXDGW:7.-.CF<^+
MC'*3K:NX)/76D<[]DBA49;HO>M.='.(.T_[*K\YORW0%QIDS9ZR/)^;H\KCC
MD32K^S86(A>*[D\\)<;25W\?-:>=4_[+[+B]'\:MVO/PK+U=O\=?S_A4_\(^
M!$@?$J0/!=+'$*2/$4@?MR!]W('T<0_2!Q^@-((B*D<AE:.8RE%0Y2BJ<A16
M.8JK' 56CB*K0)%5H,@J4&05*+(*%%D%BJP"15:!(JM D56@R"I19)4HLDH4
M626*K!)%5HDBJT215:+(*E%DE2BR*A19%8JL"D56A2*K0I%5H<BJ4&15*+(J
M%%D5BJQ#%%F'*+(._U/6=V-6?_V7MKFGE2[J8SYK?X5//P%02P$"% ,4
M" "U@(92!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( +6 AE)'*NEW[P   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +6 AE*97)PC
M$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ M8"&4L$W<G4S!   RQ   !@              ("!#@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +6 AE(@K.5+
MY@4  ) 7   8              " @7<,  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " "U@(92=K(>I(0"  "S!@  &
M@(&3$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ M8"&
M4N(&I/#@ P  6@P  !@              ("!314  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( +6 AE)E>T[7-@<  /@F   8
M      " @6,9  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" "U@(92OI]"6+X'  !^(0  &               @('/(   >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ M8"&4N?XP"%W#@  QR0  !@
M             ("!PR@  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( +6 AE(F*Y4._Q<  %A#   8              " @7 W  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "U@(921:E>J1<$  !]
M"   &               @(&E3P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ M8"&4LDGQCCK @  ?P8  !D              ("!\E,
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "U@(92K..0
MOTP%   @#@  &0              @($45P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( +6 AE*P#G(<X00  'L*   9
M  " @9=<  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
MM8"&4MT^JR^A P  ?0<  !D              ("!KV$  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " "U@(92TSXOK)0.  "1*P  &0
M            @(&'90  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( +6 AE+R_"$DH04  .8,   9              " @5)T  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ M8"&4GR/R"JV!P
M,1,  !D              ("!*GH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " "U@(92UUZ%V"<#   ?!P  &0              @($7
M@@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( +6 AE+]
MI>-?=@,  "@'   9              " @76%  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ M8"&4E'#!;DA&   DT@  !D
M     ("!(HD  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +6 AE*S..NXCP8  !P6   9              "
M@1VN  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ M8"&
M4DDP>ZO= @  H 8  !D              ("!X[0  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " "U@(92B=P#0[D"  "R!0  &0
M        @('WMP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( +6 AE('/FY]7 4  .@1   9              " @>>Z  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ M8"&4@[ =5G5 @  J0L
M !D              ("!>L   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " "U@(92'A@AAV@"   <!@  &0              @(&&PP
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( +6 AE*NT5#8
MQ ,  .D/   9              " @27&  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ M8"&4A ^SR>C @  K@<  !D
M ("!(,H  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "U
M@(92B)[F\X\#   B"@  &0              @('ZS   >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( +6 AE( HGU8>P(  %D&   9
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M970S-RYX;6Q02P$"% ,4    " "U@(922/E[$*('  "('@  &0
M    @('VWP  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M +6 AE+R#-UK; 0  ,$3   9              " @<_G  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ M8"&4BE';+0[ P  L0P  !D
M             ("!<NP  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " "U@(92WJ&Q5"0%  " (   &0              @('D[P  >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( +6 AE+BJ;D%'@0
M )D3   9              " @3_U  !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ M8"&4@;!-:4- P  =0L  !D              ("!
ME/D  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "U@(92
M%$-!<<T#  !+$   &0              @('8_   >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( +6 AE+9?&83) 4  %P0   9
M      " @=P  0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ M8"&4O,4)C'F @  ]PH  !D              ("!-P8! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "U@(92.%=TWE$%  #Y$@
M&0              @(%4"0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( +6 AE(P$A<%4P(  ,0%   9              " @=P. 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ M8"&4MA+DGC8
M @  M @  !D              ("!9A$! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    " "U@(92]Y))7U\"  !Q!@  &0
M@(%U% $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( +6
MAE(#6OWK%0,  'T(   9              " @0L7 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ M8"&4DVZBYVI @  I08  !D
M         ("!5QH! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
M    " "U@(92ZC\I-"<#  ",$0  #0              @ $W'0$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( +6 AE*7BKL<P    !,"   +
M  "  8D@ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +6 AE+3V $1'@0  *$B
M   /              "  7(A 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "U@(92BC%V7\\!   S'P  &@              @ &])0$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "U@(92,N&!X<<!   2'P
M$P              @ '$)P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
../  \ %L0  "\*0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>132</ContextCount>
  <ElementCount>310</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statement of Changes in Shareholders??? Equity (capital Deficiency)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statement of Changes in Shareholders??? Equity (capital Deficiency)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Cash, Cash Equivalents and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Related Party Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/RelatedPartyLiability</Role>
      <ShortName>Related Party Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Related Parties - Transactions and Balances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalances</Role>
      <ShortName>Related Parties - Transactions and Balances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Related Parties - Transactions and Balances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesTables</Role>
      <ShortName>Related Parties - Transactions and Balances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalances</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/General</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Significant Accounting Policies (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Leases (Details) - Schedule of company's total lease costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable</Role>
      <ShortName>Leases (Details) - Schedule of company's total lease costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental cash flow information related to operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LeasesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Leases (Details) - Schedule of supplemental balance sheet information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental balance sheet information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LeasesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Leases (Details) - Schedule of maturities of operating lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of operating lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LeasesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Related Party Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/RelatedPartyLiabilityDetails</Role>
      <ShortName>Related Party Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/RelatedPartyLiability</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based payments to non-employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofsharebasedpaymentstononemployeesTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of share-based payments to non-employees</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Shareholders' Equity (Details) - Schedule of shared - based payments to employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of shared - based payments to employees</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofBlackScholesoptionpricingmodelTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of Black-Scholes option-pricing model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable0</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of share-based compensation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/IncomeTaxDetails</Role>
      <ShortName>Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/IncomeTax</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - Related Parties - Transactions and Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesDetails</Role>
      <ShortName>Related Parties - Transactions and Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>048 - Disclosure - Related Parties - Transactions and Balances (Details) - Schedule of balances with related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofbalanceswithrelatedpartiesTable</Role>
      <ShortName>Related Parties - Transactions and Balances (Details) - Schedule of balances with related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>049 - Disclosure - Related Parties - Transactions and Balances (Details) - Schedule of related parties transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable</Role>
      <ShortName>Related Parties - Transactions and Balances (Details) - Schedule of related parties transactions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/RelatedPartiesTransactionsandBalancesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>050 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LossPerShareTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>051 - Disclosure - Loss Per Share (Details) - Schedule of basic loss per share is calculated by dividing the loss attributable to the company???s owners</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable</Role>
      <ShortName>Loss Per Share (Details) - Schedule of basic loss per share is calculated by dividing the loss attributable to the company???s owners</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LossPerShareTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="nnox-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>052 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SubsequentEvents</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nnox-20201231.xml</File>
    <File>nnox-20201231.xsd</File>
    <File>nnox-20201231_cal.xml</File>
    <File>nnox-20201231_def.xml</File>
    <File>nnox-20201231_lab.xml</File>
    <File>nnox-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001213900-21-020392-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-020392-xbrl.zip
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M%RZ HQWY)')SK01D!L6!)<Z7>GW1](;>.FVTN[T9/XS%/4$_&VZ$?T57T#%
M"[K<"1;CX25[-[;HWS K\&^<D\B-KX$-K9-UAZ.<5]6)I0AH)>Z'SY'R@=/@
M^5P/::%R7P3$X&4O]!D=1[K+JY]S 6)2=S<*[/F>0TK$X&75R&\@,Z:H-/?\
M8HV"2N@&$( @KT(1[094:]F#!ZK&\^4IS5ZP-51&^,'8QC0>\M@4O3DFDA39
M8^.!"<>+]6<4A/QX2Q7(H1C!8K" $;[[>Y[6.8=57_NDZF]6/9:>ZW S"9W2
MXLJ,5.)^:56)B]NS>I+PP/BD(:7L1XU\E;PI#@[ D<3W@;Q>^$[QF.">^*&
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MB\_77S^H#XJX)'Z?AY\GS**K@ BV:@$!J(2?Y_HM7.^!.41 R[['3M7:ORB
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M5%<<,.Y,/HBJYS"4I2227'G'^$R_V6HW-+Y9[?6=-X7C=M)MOVFD,E#BDJ$
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MAIO=9FI0#R^L%EW=DNYMWJ)8BJCL^$@1UB2];08*3,1([DBT3(/&#4T3W[>
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M:OVW,?TWV83^0THF*H\LSN17Q3I>,ZZ]S:Z[B>EL!^D(%EXRE92].$6/#\1
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M>$?FK:OY:O?>_U5?_VH/6.T!JSU@M0>L%H&U!ZSV@-4>L-H#5GO #L$M4WO
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M,7(?2&^QI+0*>C,5>TNU7'D^31CYD.<-UEZ5?V=)W9_PWM"\R2+_XH<ZN1E
MS8W1.QJ/;[ O^FGG/60]:FK+>Q!/' Y-?BZ-7PZ?.!Q(Y7YG>WF++\,W7HZ[
M&8MN,QP6>,!_I,>&'S8<++EG18@(0E>$2*,%!!4]TUJ(A1W8$:YJ>>,X#Z"F
MX]3T%*NNL*VJU(,#K4L>;_%_4_1P,@M HC\2R2%+W; V;T!L/%G,$CLV0TP8
MGAWSK6=6;)0QB6KEIM8;973!JUYNVQDQVYMF/.J;\\AQ\% 2SW>A17G5HCN6
MP=QP9]BE0P+E2H0H"U'F1<%V[[X?]B89H<'T[7_J@C0.>Z6O^6W\MF_W:%'B
MH=57T6&Q04;&'^N$C.O%UHS9?15HZO<+^$)J2=U0G6Y:J6;OM#4=\C#0M"AH
M"5U>!\H!H'VUK2 9H#IB3;7^!J+4#<X/A2*#+OW)*#\4R>6=N6H7,XBA#@;:
MG@K2:*&E=# L&209:J/<H*1#$AH6%\RNN T=#NNYK>I^ IW?:-^TP>!3&AS9
MZ^]E6E'PMFEV?M/_UA\J#8'W*3#*;L$FNR$.^KXV#%[Y#LDO;8.WYTI/&4[Z
M.2%/V+H8YXO"OD<Z^PSVT6&@QYNM[TX97TMXH!]?12UOQ;6\Q8T04:/+>WUI
M>Z&-UFL>&ZP;;:I][\ER,WU.9+M5=UPP/*?W)YMMU>[.H2,N0SWD$__&WO%G
MM3F3JG<D!6;,9+*WR FHGC'4J9,%8).,'E'-%X U<7YVTW Y.S^9?.$\H2!&
M[5V7)6?4[D\R\K(;HW9CV?Y;EA-P:2"!'8+-TQVB+]""*6Z0Y'@M=;92).-&
MJZ%.I,E3FES'D3HN.:?9UM@!5N7AL$Z%V8U#C*ZG#Y*Q7/D>;:8+AY@4G<I9
M=^I?RZ=857FO]RIWDC,:Q-^ (*"7]%DW?9(X$*,858Z[@*C!0JVXLD^>+%K8
MG[PW#N!^]N$[Y _#,I;^,FPD^LDG865YD9#3#_>#99B_OO4<G[S]>=L5GG/C
M*^O^Q<:1< <%2B>3/2&F''OO:S2[[^M/#B'M ;_>/2N,MV>1S[;O'(H!6-#E
M,%AO7EIX<(4+:_[9>"[!AUT!+@/$(6%:,%S*4&Z[/RZ9$>,9M<"_#>_IBID
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M I[LF,GL4UM^!GK;;;1N('Q361U/Y/%@D'B;)8O4I+>Y" )!WT&=AOM?:,Z
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M/*LRLT3H O9#12'B#()5-Q;UN'0 K]RJJB*WGM-?MXNB;AU0E?BDX5*%#!R
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M:*RS$RL^_-OP54K[$.CV#N8.^6LE_J'"P3GQ#Y;]C5F1E_+K++J:Q;YBI1.
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M8'FH2-]@70?VE]Q*O:>"Q '7_Z1:GW*:N"0\CY1(0 .T4?"&E2DJ!&S*U^#
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M7F?[R55I+^UR##DJ=JC#_'W>!3MJ9\=PD.%GK8$=96[EFIJ<IG=VCFO@.]3
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M_)>_16Y3+)]S;-,L=J52B<%[%55G4+DMN?;">V&-^C;7!9[+)<$:<A0_T'1
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M.-^=)O)-,W1*696ABA8>$3H _7%[<R'6/JSI'G(Q<FR+VHP3PZ'#>3B#D.@
MVXI(_]/_DUMH#2"!L.[^#T3]$.,U)"+&3 OYG6X'Q T!UA)^W\Q7!Z#0>(BA
MU7<_L-]Y^8T;B(L(JV9%)%]1_-D<*W*5$VXT,^PHC*@=\NG/@>&3;IC!P";0
ML!+;\G4D7.RH<Q&\RC;]]Q*VUCPMX^D%<1/G<-7-7#[FRWTHDI9AWKZ(>:L7
M&* )Z'O4%R75ZL$H8=QP1J1\AAR+>/IG#Z$=+&D#'>3O9_@F*%88!AFFO5%B
M&N59;V:X4XB![8+TU_[GOW_MM __%T1?!:],P[,#PP'$M;=-FTQ)EO7(5!V9
M/0//SAWTQ!V2JP)EHR3#UP/UP4@;!;35>C!*>!7-H9T,>Y)G,NWXEC#AU,:F
M@W#H0Y!,R)WR/J\[?:T![:EK$UUBN$'7-%'H!K8['1!9)MHEZX2(2TI<C\,\
M?U*M@75S(&FO'BMBM@VB><C2<"UJ&CRJ;JYSSCZO3"E1&6[]FN=6TA0@;8%5
M8[\ TEP]PF0FB!@ ^H=VVZ/A4+M >O$&XL"WS=CJ9$V22@6QW_$NST!:YY?(
M%J6:9>Q<-\S>U_R4\/,2DEE[5C7&CX0\:;?R/(EJU9I.W-TWT*%>%9F.!LM+
MVQC;#G&$,[U?7D+,C':>&7$C@+4"5LW4SK70N9[/[6 >*RCB U,33N8D><]!
M5$[BV+4[!4VV;HRIKTQS98.IYA=_MBN9Y<I=A?9^P;%+M?*W>-Y:JN-JOB1\
MB4)!(V.18<?ZJ=BW;K_)LR"J"4C5NN-5;0M1'FRYUC!9X(QHEC@@BGFV1E!#
MIM0.1-:'M$N>I)MF>BYIO+9((M\,83R /M-!60\M_4+&GD(P@=8&I'JDW&HC
M(S0RX1C#AY!0?/9(C736Q.1?BKVT8M1@51]$#=2S%0D[BJ&:DR7[E;7]@F)B
M%A5"!27!G%]H4DS4&GB5/"R+6]><4XW,C8RQ4R4^%Y>7!;;;A<"!)$X'7D4M
MEW.S9J8D7E?"1G%)L2O8*<08!($[,>MJWE4*X)4PLD(UB4/2*40KU,-Y-9<K
MA?5*^)AY(>-4(5P1U:[5Y,;K\26&CE=(HAR50A5"3M6,JC1S+N%=E7K2X%.G
M$/FH,(^6*,::UZ63ZC+]6'PMYUPA I*=8HN84S,FES!Q"@/#SF4,YEY)-",O
M>P*\BANH!\E6L[4R#BE5$,Z].U63*F3LK+FYXJ8Y@U;H0#3QUM,QF$R?F&[*
M,E.AO&SNW2F$4I392<O&"&C*F9>>]*U0U*JT^OR\;.!*BDK97 BQ".?HM0+>
MW9!M51VS+;$"WJ\6;MEVM-;,+F&V#TWDFK9C,Q!H8AIX1O_ 3-3%7P5%S"3J
MPI&%S=N3A ;VMPKB<&0GBY8^,5FC]&\ <XVN0;/WM491B@B5F8#L&^EL9Y\;
M%:K]L:KCG>Z;-MPE#E!@. [M1A/A (N&M+"*G'F%L%&>>;DQ&7_N;QBP#P+V
M1< ^6;M@2CS&H>=%N]@)%**I)@YZHMN._3E#Y4=!G@"A:)^3.W76(5J.#&S5
MI,REVR_$H20BDD83Z6J*!Z0 @1@1D2&PPA2)4BU%U:5H' ?]Z-[&5"^K2HRP
MNE0ZBK&N"M(1?QJP;Z<EI'80U<2 ]%;HVS0:C";9T>W$2;ZV6'54:$#F A83
MB\22L/XT_5].#X#4YVM?;I,L\C+73EA0[BP40G*<O'*AZ_=OQ#9VDLT_[ZZ^
M'/SKG[^;7KBX=P_>67\=/D[OE^[M:?CT\=!_=_BY\_5VM,3.X:/Y5\OY%#2#
M(?STU^'^MT7;O Q:?YR?=X:?FX^+D]Y]Z]$:^N,WL[?6DW5_?V>@?6,!QP?7
MD\E)YX_.\C>_,YEV!I]&-U^=P[ES^/;73X^C>W2VO/EVY80_7\R=KZ.'+S</
MY[#=.[O_]+-[,?"N.\[GL_"^=WO1>G?=O)P>3"[_:'Y"Z.'P[G[_\:O[\.G&
M^SI^^_6/AYYQ<GM[_G%Q=VA./O_>-\:?G@[@Q[';_&(:3_C.Z.+9HCTP?D-7
MS?YO7_9;7[^VGIY._^_R*O1<'%Q>!Z.?+P?^W6+Z^>V#O_^I=QG>=8^/_P5Z
MPQMZCL_N5T]+ \_<4E)+5HQ0EJZ@"F<U_T;"O3,;A6DWTL- +,]8LJT- 7*1
M"^>>@Y90XMDJU959IF+>EY"S>8^%%FXP$"!!03U7>L+1"DAMHY3E 7ELO?K1
M<$+R!!.3;YPXAOF-E" %L>?;)GDV1Q9TGNQ@9F <SJ,J(DG9ME6I]7M3B(=6
MDJ(8'X@  H80&(!A;,0@08P2,)B X@0IH+6,*<M8:BI!8XC0=TFWHC"@)X'1
M8^YH,'P!?=/&E/G&D^%;0NG:O#V);GI3")Q6DJKTI'H-#*2018'W-380@:ME
MJ9K]LG)&2-UZ26K*W)(WA?!J=>-ED8=%^R6Q7;4H%$4A;5$BA9ZV*R)14*DI
M%07%'#^.*&1-302BD;$X==3EF:T+;XUVBP;E?DLA?EM;&,WD:3W+H<LKT,7R
M^*V@ALSC*$1L-YX-I;]=ZPZE3=!E,8O"2V%>QIM"G'6]([J.3NPRPUL20957
M%">FOA&&4Z4)WO\9(=:=Z=ADE8M.JN/E1R]FHD#/RFJ)1VHAHK@1@W,*.($4
MA0>2E=0856UT*^16I=D9I/@@SJ 2UQ(+1"$0N0N!R(D 2(.JIW;JNS]*<Z%*
MWHNU^D'Q)*S<Y@^1B:XY4Z:YL4U[$WO$/Z5=2#HW!@6M\=*R'VTZ#0EFD!8R
M@L"WQV% 1V. R,,D00H]N:2^6-GO_$,27_R@$/WC"4O!"!"H@,( !&SDE ,;
M@S5>>BI!@A@0=%'A-&@: Z(O8MSQ8;P81/AK2U+Q*)#2U4A.&>FD_: 8]<L?
M#E)GSRNSZA29(0U[=EWKS W([/9B'=2(^"4L(1G$+:;QXP;2/[LT39ZU!B[^
MHU*;WC<SMZG0A]&CS+TK[#%Y:L\]Y ? +;U-AW.5"XCN [I$)FM.4(7^KY'4
M:]!'C7:GL=]^O<!6<C5%1124Z.ANC&HHDGJ;H!#?Y,/!P3"D:TX-PV,5F] )
M\*JMQKJM%:!J_5*\64FE:_*U:,>\HQW3?KLUCO3U0]6P(/=: $<.J/RN(D51
M22K0;Q^H=X+DOBHE^2!54[*Q:JA$.)1Z $/S]10]-HFC(L6">97H#Y%TQO>!
M,0S'>XF'U)\D6Y6ZJ6ULW3&=KYF$%]$E.NS>J".Z:\2=7@1P3E78'C#B4L=[
M@1_2ZV]8*=*8C:P1JV>%?FPY7-MQJ">5E,7$1A-U']*W'WT4>LE';-)\RC%0
MQ)F5MRRIN;-7NOFS5_0A5AEI\P.7VG6'W63V!/4G)>?0:-P7.Z)#J:=Z\71D
M1/=IL%3<'MVEH6-GR*"N50Z/V&$JJSRYZ"+E<\5AEA'J)UG&46ZRCIVQ+2DB
MK5'^E?2E2ZDOZ=XY,MAJ'7&URD+O3[)=>KG.0->Q*ZH!%ZB,TJ1P?2@6PTOY
MSEQ1I\&1$[I@.8BS7T;H&KEG2?J+/J1N@%G)%/2C_,$O+/7PEF8>=M/Y*(,H
M!^2*IH#<V<&LNTXYU+%O=D"-W*"D%$IOE?707R<]4(=MG?+091D/.G;65G0H
M"1<352LGJ_H/+CEB-?N1%KU(,M,"J"/YBH@5_8B5HNJEDD%T)%N"5$G6D[4X
MJE>RF0 Z4JR 5L%\\C,>=*19 :T"S2=T>26]]G>!>ZN5E9/E:;RN,II!6JB;
M6E09(?(PGL\,^VPE1<=N>AX"!6,HZZ'2Z9T^W2+ QG,4Z,1L8-C6.?*[<WIT
M%;YP32>TZ,VGI'^N2$.ASRKT)_I.)G9"A<A.W-C3&:E[BR'QPF" ^^/ L%W:
M_-G"9'>"DD^SEOMCQYXR<C#Q<_6*VNR$"E$W:1N5V"3&< =I=T&K^TCJ3N$-
MG)/.2IH807^N#WGJ4'EZ(-<"7;&EX^B&J%%MR2P%*5#=\>6]IZ$?681[:/CZ
M$"=$)XR@"RJV]*:KQ?=ARJ(E[,:R-#USY,+ \)=E%$T,!Y>2%*VA!LFK. WQ
M>,\D<RD[V&U\AR(6\>Z"S.GIU_N3OD_\%$(*<V)N((;^(Z3V[#P,0NK51.5V
M0/Z:HSGZ+3C>AOS*I&S0+YC;6O0Z)^WLV8:=L^-ND"+?I#>ZKG5G^&1J$.!K
M2 Q[4HXM.CRGJ&P[5#8CB&>[-FI->X%10<]?0>:U.D(7[B/$ ?+QK8?<.&1&
MBB7?>HEB(R=*X!5LW*CV$J1* 6]<=2V+)5T93H_, VP+1D"C* SVH!F,4->-
MIA*#T"<S"#*QF/J0M3&$\!H%L&T2.:8_WFILNG9,J%"5NV00D.JG,/HW[30,
M?.B12>S9@@;U=N+J/-](K$ &5VWGVLC.T306%PEP@:X9^,B$T,+G/IIK9]2W
M[)7M:1-TW*U+1:H_F4 ZB]#>ORF#R[?5ME1_OSQ3O3%-@@FAB:91%G ^3X#%
MM= DC.-:W:E!YWC<7 *=^VV'5/(%;BM[IW7W;4F9*'B$B-SZF/&E-)-CA,HN
M[M:WJS8C2+2.($KY&\%%<.(@\UO2)2YRW7!^%"3/O[//K(Z71W%YGVE&I@2D
M:*T8TB KD;2!$5\QJQMM(H1\W7<)IX9#V-T/9M G8X"J3NC2BUKTI%(=+T]0
M3R%Q0XBRR+@C>A*K!%6>\U2:C.[#84#'0C>@K3+WLVN:X3Q:*CZ%G@]->WWZ
MB&Y=\US4J6Q"4$A6U;S/JE.@D%R1^*R:T\Z!*6 \Y^;.>,OQ=UY0LH*C&:GI
MF^$87N1H% +E<Y!3[=)VV1?R,;T?D> BA:B6U<;/(M)<:)6!BUP8A;O[E*Z0
MTTCB=T02UX9NW;Y.@VB'Q(B#>JSBP#&B?==)[:'A/!I3R/*[!X2=U/I,X2G$
MIF][$6EJ7?2,(VX+\#P9NC*^(C]IM^<8&/]YBFA"2D[)6.SA]Q4)/C:1/F7;
MN8K)=1H'8WF(A7DD(7&]W8"_'4?GY L%\%Q_X!JY9E3]Y=#+QRPRB+P[!79X
MIKE&MO+YJ14Z8<_Y>9VL[/>A4Q#-9GM]4EN!KL/Y&/ID IQ_$<_\-%BRKXZY
M OV\;% :/:*4A89S:4_@$AI^3GX2PGYT;U2B8#N%IW0H^HM2:BH4/6>?O2S=
MI$J+.)I0W(Y%8RY35NYD6=@$RP0^WO[)%_MD=93N:EL[(]1U]I+-+ANY(EOU
MYO>@E-_7 8U)$/, K2B?>,#HBY:6V<OX4^?(GT "W]) UV\ 6N17))9BN#HY
M.]W5N$>MA>-H0;DRU"W]**7;#%Z4#E>A:#L=+O["R]+AJK14B B7VPG>T?8O
M2K9$E%19%%!L^&6)DHP&A6P Z7'J%8YNUD>PGH= M=-<=O)!C>3P^4CC:KB/
MT"6>EA,WJIUTE<%3I$4COO* B1/"[< VG$$X=FPSR7NXAD&23JMQD%D*G6]-
MV"EQZ0P]O59%A/!X)F"UV58O6DIAB20RBB-K2D@!%U=+?($SVW0@JY6<CJ,!
M%:6P1.PHI*GJQ14A/.XR,\\1T\XP29!N,@?3R& I8.2.K\H;776V9)5IX79+
MM@$-@C Y0((MH_&V)JOK]M"<\(?%IE@"@,ZL$Z#FT_HR'*R<+U5N'E:Y&?U)
M<B &"Z/FXL6TT/<-%_.1\?E2/OQN7:*@1C-X-NP/MAY16].E@%&N':B0DOE?
MWX_2=I,T&];FCX_TJ\$4#*\X\)O$]2UMM"$/&3]Y?N7-I./8Z060\OVZ/\09
MJX)6L"TW<XFC=BY9.4!5<C3ROOC0=A06TXYUU<&KG \D;4HCGF\&6S0_))K,
M))]]A-'!KVQY3<^IHBI2P2)$Z'M.B'M$LTU36:D_W-7AX1*=(SF9$%=H2*\;
MT8M+'& "4DKN%M1.\W Q<A5,20V-](@0G?!4PW@W4)1S4,B\^O'NM0P@-Z94
M?D6==I(HQ"E,A"BOJ)%02A'*SZOJNE;7<5# MB#H,FD0@*N8%O:1BC:+)PW)
MK-'6(A=5%2F?><F1\^,K2&=7&NSSR",2.E!)LE]D^7QZ&,"I[4.3'IRE'44B
ME$(J67B73#G((^*"T?T^^M#&Q29Q?%-)@^>DHCX$\: )QE"V"@I]7:E90U.E
MIN_JRIHU,IY;D2U/SYS0:-QPL:F/FZ&]T)6>%3(UWHQF9"ZI*2UI;.J\&3TA
M7>E9(>-F0Q!W?0CAR0ETT),V5)2A$H2QZ27,@\N>-O!S@$3(L64\:(0[!4<0
M24C=#*8/]@(FX5YPF.PBZ;OQIG-V8HL5FJM$4GJ!%<$=/=%OC&Q/@_ F#<.E
M6_"-;[9&3D$)*/X)"8ONQ65@:8,]!T@0/+479TO"N0!22#JYRSQD_,LJ'#(;
MIEEMYLQ%#IK:$.O$$C$^/H=.D1FRJ+AKG9&9$)T2:7B)J1)*RKKW34)A=$LV
M(_G_ 5!+ P04    " "U@(92 F)"=XH)  !E8@  %0   &YN;W@M,C R,#$R
M,S%?8V%L+GAM;.U=;5/;NA+^?GZ%;\Z7>Z<3G)=""@,]$T)H0P-)DU!*SYSI
M*+9,#+84)#DO_?5'<EZ($]MQ' N;._W0*36RGM6SJ]6NM')/_YK8EC*"A)H8
MG>6*!X6< I&&=1,]G.5NN_EJM]9HY/[ZJ"A_G/XGGU<^000)8%!7^E.EANUA
M5S.5'@&(&IC8RG^9_3\EKPP8&YZHZG@\/M!X&ZJ9!%+L$ U2\4#)YWF'BRYK
M!(H.3Y2> Y7JD"B%(Z58.BD=G[S_H-0O>DJI4"K.7OGCU#+14Q]0J'"Y$3W+
MK2!-^L0ZP.1!+14*9771,#=K>3(1#SSMQV6W=?'X^%AU?[ML2DV_AKS;HOK]
MNMG5!M &>1-1!I F *AY0MV'3:P!YC*Y52XEL(7X5W[1+"\>Y8NE?+EX,*%Z
M;L:;HIP2;,$.-!17\A,V'<*S'#7MH24$<I\-"#3.<@CA">^D5"B69EW\*9[\
M)#]K&%%LF;K@_AQ88BC= 80LIXBN;SL-SR 0X&\=C$QA)T*%JFBD!O:ARI&S
MP4W3AEW&?[8ABBWJ>C<S:9,7MP;HX-+"X[AR+M_G B8BG#!=W;$@-@C4,-),
MRW3M%1L:AQ)_X+-CCH#%6:$ Z7S6,F)J7!3QNQ[H"Z3H8TD"+DG=O,@CO!)
M4\HP Y8%^433,&5TCQ&&]B@&(4:@ 4MS+)>#)I?7,Q(X81#I4%^,1?2_SQ3\
M.&.-HUI8\R!9PDMAL@"R0!]:9SF'YA\ &/ZL4@H9K3F$N#-LE=BY,*Z[,@#M
MNSYK_IXJ"%>AQ>CBB:N"?*$X=UU_^@.\Z'=G2<7TJ")WEM1?[*C*:H"0*5_
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MY2AKBZ);UP(?A-.P-8_$74'X_M'VF*P!"+.]\L.86+/,Y5AE]RKU930!A?'
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M(;P24EQ[CM;("V@-388<)J11A]!@-*-142N5875L@WF)ND?T#HQQ?K#"KZA
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MXQ,B=A YHS5&.4=WB"PQQTQBH%*GNS@TXV\C;<YZ"::!]!TOZT<C-2_A]Y\
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MQ$RB#[880A-$&D@H*_%#E?0T"WF4Q(L@=/]"SD<?8R\D)9/AK%$I"$E=HT+
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M@QZ*6\3B2BZ"NGNRZFDP\OW$\M)KH,:#H 1V2&= F1\YY^O:7"BSOKC/M N
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MTR].?@=@["=!&-_][7<?;HX7-V>KU>_^[W\#\+_^^K^/C\$[&,/4RV$ ;E_
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M1$U*6->4(!'.QD[#>H_OAY!>7#[O89Q-8P7V%[&OJWHP")73>K.\7FQ75^_
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M"6#^X!RY2 ]A_E $><X2DND 8YSG4/OI4X9E] "P>WNL!1LOFE[/0:*,K5E
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M,C7GLMJD*EN9-265B&5>MV#ID=02W'*+>!I3'J_<M6PVY^8!P4N>*#X'Z'M
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MK[R'\=129UH7>J@-@EA&ZF\!_MBU#\-F2EL@&.@-42+-FYS1I* UJ1.%T81
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MB2SF"<6G@? @=U6]-O$$$M0I4^Q>C.2%BIDZ*6%7*)Z%3'$*%"N3P%BZ%D%
M"DQZT<8+@U5<I(--DE_ 6<J%3'%@X2475%\#_#CS&%E4/AW@V$>5<*^53R#
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M 2F>PS*3EP6*@B)[;J!"1/,75)T(R,4!U\5ZCVR&A\-#F2-P?H!GTSVFTH3
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M!.A? '_3EP@' L%B15,">@@9Y.C?Y$B(L")Z!Y.[U-O?ASZRD=1XKY3'S5_
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M,HSA"IV0:O6\Y;-,<"N@+3,5- /D!L\!R"0.;XF4F2:5GS9)1J]TMD6#IW-
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M<"=CF5'-Y)&AT3NAIEO=FO,\&0K.=N%<CKG)17.R+3F6WWWCX:<X) OHRGM
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MZ[JXRSU+5?K9L9:R-/^E<'+%UW-E#,#EA5P/V":U.9A8S,TBS;SB[LL=Q0.
M/&;"@;K^JR:%<\#%(:V"+?.X5B>3#2U7WR5A#R;=)S2B1XH$G%&M>Y8$LK<%
MK;'(HL*C09*"8@: IW!EBBMBR+Y@4R"*96>;MAY0?'Q#/Y[?NQLF$JS=(L#6
M^FN;9H:X9#^T<N'="WX3<K:<]W&S>'*4K<G/(?WOJNQ7G2%WU+N-('X'Y_OI
M 0:='GF<R!*9!7Q6SO<Y#AB44X)B3OJ<D,X*V%T#W82=#$C!"4@9$]4"[XF]
MXCTK6%[T(_>65Q/8GN75Q\3B_NFZEP;N-B?R.@/W6LNQ9KG45O-H6TF]W*AH
MX\L_>/LD^TN9Z[S(\S2\/>1$0>4)OE9JO>9WE?G:0HL99>0@;S?HS;FQRC3N
M);AW@9G"/<6,+OY8.&M<\O%)-H=KC**D=ARTJFH53I1*>DEUQ=#(+)E=H-$
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MP$'>O1LOK"A*ENDG+1;<%JD&RU38(L3HH]#'% 1)3-Y&R",2.>$>4&B[$:'
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M[:*4[ZWC_*O!UP_C*2;%>L9!;3X5D9YFZ*YG^'^QMS4FV1$Z9,E&9/(F(B-
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M)S!-DM!>8),WFH>(LN06H:L@1L<D;93\X5<A+P$89;_]0FC^YHH"$)M[+J4
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M:SSQ&%HAA'@-E12G:B":1D!S%Z'+<*@39")LK]><M!!.B_AQ$%N>N;[&.Z<
M_VAE^9N($N216)Q-1@#MBF/4#OYQ!G9*UYGWS.54^3:>[4W0)+=FN9LC 25%
M5\WG9G>'(-/)!JAC 6#E;+L^U-I"YA2XD<ALL^HQFTT;[EBTP+?@*0J76B7#
MP&+J+BDG)19[3*7ATZV_3[Z07>-]:RPU4<6P<1G00B)].:NC0EMJ<CF?><&]
MNVM)'::U\W$0Y,OW=N,+6A6Z%OMAY]W/"[VPLZ+]:5#FN^IIWQ:;PK8A:":6
MZYP'X6A)'DRB"]_V$BRL"W^Z* XHO9Z56D!S!X'5#$-IC<C\A@12"+)A85AO
MJ-O'-DVHM,ZL7YR6VQL'DYDX#^2V*65=<=AIP@FB?=JN9Q\C-(HB%$?7=['E
M^F2%9P_VPO+G"*^>TGE]Y[GSM%7N5>!+AS)!$#TJTP##>D!73"D86%X$<PV<
M\0):@H0MR#%R8X+<?Z7 81NY/(:>*$5O\BYK[D:&G+B5(2=@GB-GD@J E]@$
M6<$C;./*"CFFQHVSH#CVHT5]=;LJ.UJ_]U5%V(.(DH1;M<<N=6&V39\=IP\U
MV3@=ES3#KRQ+['+5#*:O(A+A@*F8TNXE344H_*\-O44*2*-FQ29;,'3H)M:Y
M@(,\PAIY:*11^V=$C#!R1MB"6G-T@TB!5TX<"2E+^1WBT,R^4RF*4()98(4]
M[;=I(]7'^O>O  VF-K;T#N!O9A%.FWK;K-!&QH62>-F-Q9N$)[;%F7",Y_C
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M-(?9MD1VM*B@/!6&+I+RJJ3 X%YT8V^C_OE:AFO3Y%8P&&7L6+#JK0 PN+M
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M;H<DR=09^>-@N0Q\>M&BA?5B)U[-]T,05.WZX8I;Y=Q:R<X!E28!/><XJS$
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M2P$"% ,4    " "U@(92+AG@NML4  "OYP  $0              @ $(S0
M;FYO>"TR,#(P,3(S,2YX<V102P$"% ,4    " "U@(92 F)"=XH)  !E8@
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E,#(P,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  /'; 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
